<SEC-DOCUMENT>0000719135-20-000057.txt : 20200810
<SEC-HEADER>0000719135-20-000057.hdr.sgml : 20200810
<ACCEPTANCE-DATETIME>20200810090104
ACCESSION NUMBER:		0000719135-20-000057
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		56
CONFORMED PERIOD OF REPORT:	20200630
FILED AS OF DATE:		20200810
DATE AS OF CHANGE:		20200810

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Apyx Medical Corp
		CENTRAL INDEX KEY:			0000719135
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				112644611
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-31885
		FILM NUMBER:		201087363

	BUSINESS ADDRESS:	
		STREET 1:		5115 ULMERTON ROAD
		CITY:			CLEARWATER
		STATE:			FL
		ZIP:			33760
		BUSINESS PHONE:		7273842323

	MAIL ADDRESS:	
		STREET 1:		5115 ULMERTON ROAD
		CITY:			CLEARWATER
		STATE:			FL
		ZIP:			33760

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BOVIE MEDICAL Corp
		DATE OF NAME CHANGE:	20150319

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BOVIE MEDICAL CORP
		DATE OF NAME CHANGE:	19990216

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AN CON GENETICS INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>a2020q210-q.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:5938bea0bd4244ad8a21da05eb6f3c06,x:ad4e8c9d90ac4d1590b7f78bd1bcb3b2-->
<!-- Document created using Wdesk  -->
<!-- Copyright 2020 Workiva -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:sheci="http://fasb.org/stm/sheci/2020-01-31" xmlns:sic-ent-all="http://xbrl.sec.gov/sic-ent-all/2020-01-31" xmlns:country-ent-all="http://xbrl.sec.gov/country-ent-all/2020-01-31" xmlns:othliab="http://fasb.org/dis/othliab/2020-01-31" xmlns:scf-indira="http://fasb.org/stm/scf-indira/2020-01-31" xmlns:scf-sd="http://fasb.org/stm/scf-sd/2020-01-31" xmlns:apyx="http://apyxmedical.com/20200630" xmlns:equity="http://fasb.org/dis/equity/2020-01-31" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:ides="http://fasb.org/dis/ides/2020-01-31" xmlns:fs-bt="http://fasb.org/dis/fs-bt/2020-01-31" xmlns:crcpb="http://fasb.org/dis/crcpb/2020-01-31" xmlns:sfp-ucreo="http://fasb.org/stm/sfp-ucreo/2020-01-31" xmlns:country-std="http://xbrl.sec.gov/country-std/2020-01-31" xmlns:ei="http://fasb.org/dis/ei/2020-01-31" xmlns:ocpfs="http://fasb.org/dis/ocpfs/2020-01-31" xmlns:stpr-std="http://xbrl.sec.gov/stpr-std-std-std/2018-01-31" xmlns:cecl="http://fasb.org/dis/cecl/2020-01-31" xmlns:bsoff="http://fasb.org/dis/bsoff/2020-01-31" xmlns:srt-all="http://fasb.org/srt-all/2020-01-31" xmlns:stpr-all="http://xbrl.sec.gov/stpr-all-all-all/2018-01-31" xmlns:otherexp="http://fasb.org/dis/otherexp/2020-01-31" xmlns:scf-dbo="http://fasb.org/stm/scf-dbo/2020-01-31" xmlns:reorg="http://fasb.org/dis/reorg/2020-01-31" xmlns:dccpoa="http://fasb.org/dis/dccpoa/2020-01-31" xmlns:se="http://fasb.org/dis/se/2020-01-31" xmlns:sic-all="http://xbrl.sec.gov/sic-all/2020-01-31" xmlns:hco="http://fasb.org/dis/hco/2020-01-31" xmlns:soi="http://fasb.org/stm/soi/2020-01-31" xmlns:sec-mort="http://fasb.org/dis/sec-mort/2020-01-31" xmlns:schedoi-iiaa="http://fasb.org/dis/schedoi-iiaa/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:debt="http://fasb.org/dis/debt/2020-01-31" xmlns:spc="http://fasb.org/stm/spc/2020-01-31" xmlns:ts="http://fasb.org/dis/ts/2020-01-31" xmlns:naics-ent-std="http://xbrl.sec.gov/naics-ent-std/2017-01-31" xmlns:rd="http://fasb.org/dis/rd/2020-01-31" xmlns:sr="http://fasb.org/dis/sr/2020-01-31" xmlns:stpr-ent-all="http://xbrl.sec.gov/stpr-ent-all-all-all/2018-01-31" xmlns:stpr-ent-std="http://xbrl.sec.gov/stpr-ent-std-std-std/2018-01-31" xmlns:edco="http://fasb.org/dis/edco/2020-01-31" xmlns:guar="http://fasb.org/dis/guar/2020-01-31" xmlns:te="http://fasb.org/dis/te/2020-01-31" xmlns:fs-ins="http://fasb.org/dis/fs-ins/2020-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:naics-all="http://xbrl.sec.gov/naics-all/2017-01-31" xmlns:ni="http://fasb.org/dis/ni/2020-01-31" xmlns:dr="http://fasb.org/dis/dr/2020-01-31" xmlns:schedoi-otsh="http://fasb.org/dis/schedoi-otsh/2020-01-31" xmlns:dei-all="http://xbrl.sec.gov/dei-all/2020-01-31" xmlns:exch-ent-all="http://xbrl.sec.gov/exch-ent-all/2020-01-31" xmlns:naics-std="http://xbrl.sec.gov/naics-std/2017-01-31" xmlns:us-arcroles="http://fasb.org/us-arcroles/2020-01-31" xmlns:soi-indira="http://fasb.org/stm/soi-indira/2020-01-31" xmlns:deprecated1="http://www.xbrl.org/2009/role/deprecated" xmlns:fs-mort="http://fasb.org/dis/fs-mort/2020-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:soi-ins="http://fasb.org/stm/soi-ins/2020-01-31" xmlns:iago="http://fasb.org/dis/iago/2020-01-31" xmlns:sfp-dbo="http://fasb.org/stm/sfp-dbo/2020-01-31" xmlns:con="http://fasb.org/dis/con/2020-01-31" xmlns:leas="http://fasb.org/dis/leas/2020-01-31" xmlns:com="http://fasb.org/stm/com/2020-01-31" xmlns:srt-roles="http://fasb.org/srt-roles/2020-01-31" xmlns:inv="http://fasb.org/dis/inv/2020-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:fs-interest="http://fasb.org/dis/fs-interest/2020-01-31" xmlns:exch-all="http://xbrl.sec.gov/exch-all/2020-01-31" xmlns:sic-ent-std="http://xbrl.sec.gov/sic-ent-std/2020-01-31" xmlns:oi="http://fasb.org/dis/oi/2020-01-31" xmlns:fs-fhlb="http://fasb.org/dis/fs-fhlb/2020-01-31" xmlns:ctbl="http://fasb.org/dis/ctbl/2020-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:country-all="http://xbrl.sec.gov/country-all/2020-01-31" xmlns:cn-part="http://fasb.org/cn-part/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:schedoi-fednote="http://fasb.org/dis/schedoi-fednote/2020-01-31" xmlns:srt-std="http://fasb.org/srt-std/2020-01-31" xmlns:crcgen="http://fasb.org/dis/crcgen/2020-01-31" xmlns:re="http://fasb.org/dis/re/2020-01-31" xmlns:ir="http://fasb.org/dis/ir/2020-01-31" xmlns:inctax="http://fasb.org/dis/inctax/2020-01-31" xmlns:soc="http://fasb.org/stm/soc/2020-01-31" xmlns:sec-cndfir="http://fasb.org/dis/sec-cndfir/2020-01-31" xmlns:us-gaap-all="http://fasb.org/us-gaap-all/2020-01-31" xmlns:sic-std="http://xbrl.sec.gov/sic-std/2020-01-31" xmlns:exch-std="http://xbrl.sec.gov/exch-std/2020-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:sec-sum="http://fasb.org/dis/sec-sum/2020-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:scf-sbo="http://fasb.org/stm/scf-sbo/2020-01-31" xmlns:regop="http://fasb.org/dis/regop/2020-01-31" xmlns:schedoi-shorthold="http://fasb.org/dis/schedoi-shorthold/2020-01-31" xmlns:ero="http://fasb.org/dis/ero/2020-01-31" xmlns:us-gaap-std="http://fasb.org/us-gaap-std/2020-01-31" xmlns:currency-ent-std="http://xbrl.sec.gov/currency-ent-std/2020-01-31" xmlns:schedoi-hold="http://fasb.org/dis/schedoi-hold/2020-01-31" xmlns:scf-re="http://fasb.org/stm/scf-re/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:invco="http://fasb.org/dis/invco/2020-01-31" xmlns:sec-vq="http://fasb.org/dis/sec-vq/2020-01-31" xmlns:soi-int="http://fasb.org/stm/soi-int/2020-01-31" xmlns:emjv="http://fasb.org/dis/emjv/2020-01-31" xmlns:rpd="http://fasb.org/dis/rpd/2020-01-31" xmlns:sfp-clreo="http://fasb.org/stm/sfp-clreo/2020-01-31" xmlns:soi-sbi="http://fasb.org/stm/soi-sbi/2020-01-31" xmlns:aro="http://fasb.org/dis/aro/2020-01-31" xmlns:sec-suppc="http://fasb.org/dis/sec-suppc/2020-01-31" xmlns:rlnro="http://fasb.org/dis/rlnro/2020-01-31" xmlns:pay="http://fasb.org/dis/pay/2020-01-31" xmlns:soi-re="http://fasb.org/stm/soi-re/2020-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:reference="http://www.xbrl.org/2009/role/reference" xmlns:soi-egm="http://fasb.org/stm/soi-egm/2020-01-31" xmlns:sec-reins="http://fasb.org/dis/sec-reins/2020-01-31" xmlns:soi-reit="http://fasb.org/stm/soi-reit/2020-01-31" xmlns:schedoi-sumhold="http://fasb.org/dis/schedoi-sumhold/2020-01-31" xmlns:eps="http://fasb.org/dis/eps/2020-01-31" xmlns:fifvd="http://fasb.org/dis/fifvd/2020-01-31" xmlns:sec-supins="http://fasb.org/dis/sec-supins/2020-01-31" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:naics-ent-all="http://xbrl.sec.gov/naics-ent-all/2017-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:crcrb="http://fasb.org/dis/crcrb/2020-01-31" xmlns:dei-ent-std="http://xbrl.sec.gov/dei-ent-std/2020-01-31" xmlns:bc="http://fasb.org/dis/bc/2020-01-31" xmlns:currency-std="http://xbrl.sec.gov/currency-std/2020-01-31" xmlns:lea="http://fasb.org/dis/lea/2020-01-31" xmlns:disops="http://fasb.org/dis/disops/2020-01-31" xmlns:scf-inv="http://fasb.org/stm/scf-inv/2020-01-31" xmlns:us-gaap-entryPoint-all="http://fasb.org/us-gaap-entryPoint-all/2020-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:crcsbp="http://fasb.org/dis/crcsbp/2020-01-31" xmlns:nt="http://fasb.org/dis/nt/2020-01-31" xmlns:fs-insa="http://fasb.org/dis/fs-insa/2020-01-31" xmlns:schedoi-oocw="http://fasb.org/dis/schedoi-oocw/2020-01-31" xmlns:cce="http://fasb.org/dis/cce/2020-01-31" xmlns:us-gaap-ent-std="http://fasb.org/us-gaap-ent-std/2020-01-31" xmlns:ceclcalc3l="http://fasb.org/dis/ceclcalc3l/2020-01-31" xmlns:sfp-cls="http://fasb.org/stm/sfp-cls/2020-01-31" xmlns:acec="http://fasb.org/dis/acec/2020-01-31" xmlns:sfp-ibo="http://fasb.org/stm/sfp-ibo/2020-01-31" xmlns:dei-ent-all="http://xbrl.sec.gov/dei-ent-all/2020-01-31" xmlns:sfp-sbo="http://fasb.org/stm/sfp-sbo/2020-01-31" xmlns:scf-indir="http://fasb.org/stm/scf-indir/2020-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ceclcalc2="http://fasb.org/dis/ceclcalc2/2020-01-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:country-ent-std="http://xbrl.sec.gov/country-ent-std/2020-01-31" xmlns:scf-dir="http://fasb.org/stm/scf-dir/2020-01-31" xmlns:dei-std="http://xbrl.sec.gov/dei-std/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:cc="http://fasb.org/dis/cc/2020-01-31" xmlns:rcc="http://fasb.org/dis/rcc/2020-01-31" xmlns:exch-ent-std="http://xbrl.sec.gov/exch-ent-std/2020-01-31" xmlns:ru="http://fasb.org/dis/ru/2020-01-31" xmlns:currency-all="http://xbrl.sec.gov/currency-all/2020-01-31" xmlns:foct="http://fasb.org/dis/foct/2020-01-31" xmlns:sec-re="http://fasb.org/dis/sec-re/2020-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:currency-ent-all="http://xbrl.sec.gov/currency-ent-all/2020-01-31" xmlns:fs-bd="http://fasb.org/dis/fs-bd/2020-01-31" xmlns:diha="http://fasb.org/dis/diha/2020-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:ap="http://fasb.org/dis/ap/2020-01-31" xmlns:ppe="http://fasb.org/dis/ppe/2020-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:eui="http://fasb.org/dis/eui/2020-01-31" xmlns:iaoi="http://fasb.org/dis/iaoi/2020-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
	<head>
		<meta http-equiv="Content-Type" content="text/html" />
		<title>Document</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div style="display:none"><ix:header><ix:hidden><ix:nonFraction decimals="-3" unitRef="usd" contextRef="FI2019Q4" name="apyx:ProvisionForObsolescenceInventory" id="Fact-5ECD63DD2118AF18390B4985F0B07CC2-wk-Fact-5ECD63DD2118AF18390B4985F0B07CC2">392000</ix:nonFraction><ix:nonFraction decimals="-3" unitRef="usd" contextRef="FI2020Q2" name="apyx:ProvisionForObsolescenceInventory" id="Fact-9B3CE0C950A00936F6194985F0AD89C3-wk-Fact-9B3CE0C950A00936F6194985F0AD89C3">685000</ix:nonFraction><ix:nonNumeric contextRef="FD2020Q2YTD" name="dei:AmendmentFlag" id="Fact-F0C70F9764034FC3DC504985F0DA06A1-wk-Fact-F0C70F9764034FC3DC504985F0DA06A1" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q2YTD" name="dei:CurrentFiscalYearEndDate" id="Fact-90E209854C62197BAEC44985F0DAD91F-wk-Fact-90E209854C62197BAEC44985F0DAD91F">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q2YTD" name="dei:DocumentFiscalPeriodFocus" id="Fact-8B1E51C3236E8F6E661E4985F0DCC3AC-wk-Fact-8B1E51C3236E8F6E661E4985F0DCC3AC">Q2</ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q2YTD" name="dei:DocumentFiscalYearFocus" id="Fact-46F5AE107DEB829B9E884985F0DC91E8-wk-Fact-46F5AE107DEB829B9E884985F0DC91E8">2020</ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q2YTD" name="dei:EntityCentralIndexKey" id="Fact-822DAC247BDEA6259BD14985F0DB5E1A-wk-Fact-822DAC247BDEA6259BD14985F0DB5E1A">0000719135</ix:nonNumeric><ix:nonFraction decimals="-3" unitRef="usd" contextRef="FI2019Q4" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" id="Fact-51DAD60546736DEB66984985F0AC4190-wk-Fact-51DAD60546736DEB66984985F0AC4190">4403000</ix:nonFraction><ix:nonFraction decimals="-3" unitRef="usd" contextRef="FI2020Q2" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" id="Fact-11CA0366799B816F17A94985F0B687C7-wk-Fact-11CA0366799B816F17A94985F0B687C7">4702000</ix:nonFraction><ix:nonFraction decimals="-3" unitRef="usd" contextRef="FI2019Q4" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" id="Fact-7460CD3B49194A842FB44985F0AFC046-wk-Fact-7460CD3B49194A842FB44985F0AFC046">273000</ix:nonFraction><ix:nonFraction decimals="-3" unitRef="usd" contextRef="FI2020Q2" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" id="Fact-19EF9DA7BC975CD2C3D24985F0ADCC3E-wk-Fact-19EF9DA7BC975CD2C3D24985F0ADCC3E">760000</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2019Q4" name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact-82790553536200EE48FA4985F0ADC041-wk-Fact-82790553536200EE48FA4985F0ADC041">0.001</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2020Q2" name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact-BF1E05C099789CF9865C4985F0ABECD2-wk-Fact-BF1E05C099789CF9865C4985F0ABECD2">0.001</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2019Q4" name="us-gaap:CommonStockSharesAuthorized" id="Fact-62775AC1D1638F990FF34985F0AF631A-wk-Fact-62775AC1D1638F990FF34985F0AF631A">75000000</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2020Q2" name="us-gaap:CommonStockSharesAuthorized" id="Fact-589B2297F1386F1DA1824985F0AF8C4D-wk-Fact-589B2297F1386F1DA1824985F0AF8C4D">75000000</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2019Q4" name="us-gaap:CommonStockSharesIssued" id="Fact-AE28C33B6FC7C733F3004985F0B7199F-wk-Fact-AE28C33B6FC7C733F3004985F0B7199F">34312257</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2020Q2" name="us-gaap:CommonStockSharesIssued" id="Fact-5C868BB1E9A90A464D4C4985F0AD5E5F-wk-Fact-5C868BB1E9A90A464D4C4985F0AD5E5F">34201895</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2019Q4" name="us-gaap:CommonStockSharesOutstanding" id="Fact-259C5ED017F87704646F4985F0B6ECEB-wk-Fact-259C5ED017F87704646F4985F0B6ECEB">34169952</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2020Q2" name="us-gaap:CommonStockSharesOutstanding" id="Fact-DF7CB262F9E35028F74F4985F0AC0FAD-wk-Fact-DF7CB262F9E35028F74F4985F0AC0FAD">34201895</ix:nonFraction><ix:nonFraction decimals="-3" unitRef="usd" contextRef="FD2020Q2YTD" name="us-gaap:InventoryWriteDown" id="Fact-A4241150829A98825E5DA6ABE23C29F1-wk-Fact-A4241150829A98825E5DA6ABE23C29F1">400000</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:href="apyx-20200630.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="FD2020Q2YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2020Q3Aug6">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-08-06</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_OptionOnSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:OptionOnSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_OptionOnSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:OptionOnSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_OptionOnSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:OptionOnSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_OptionOnSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:OptionOnSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2020Q3July2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_CorporateJointVentureMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-07-01</xbrli:startDate>
			<xbrli:endDate>2020-07-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_us-gaap_UnfavorableRegulatoryActionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:UnfavorableRegulatoryActionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_CorporateJointVentureMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_RelatedPartyTransactionAxis_apyx_BulgariaManufacturingPlantPurchaseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">apyx:BulgariaManufacturingPlantPurchaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_CoVenturerMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CoVenturerMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_CoVenturerMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CoVenturerMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_RelatedPartyTransactionAxis_apyx_BulgariaManufacturingPlantPurchaseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">apyx:BulgariaManufacturingPlantPurchaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_AdvancedEnergyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">apyx:AdvancedEnergyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_OEMMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">apyx:OEMMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_AdvancedEnergyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">apyx:AdvancedEnergyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_OEMMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">apyx:OEMMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_AdvancedEnergyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">apyx:AdvancedEnergyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_OEMMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">apyx:OEMMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_OEMMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">apyx:OEMMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_AdvancedEnergyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">apyx:AdvancedEnergyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-01</xbrli:startDate>
			<xbrli:endDate>2020-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:unit id="usdPerShare">
		<xbrli:divide>
			<xbrli:unitNumerator>
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unitNumerator>
			<xbrli:unitDenominator>
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unitDenominator>
		</xbrli:divide>
	</xbrli:unit><xbrli:unit id="usd">
		<xbrli:measure>iso4217:USD</xbrli:measure>
	</xbrli:unit><xbrli:unit id="segment">
		<xbrli:measure>apyx:segment</xbrli:measure>
	</xbrli:unit><xbrli:unit id="number">
		<xbrli:measure>xbrli:pure</xbrli:measure>
	</xbrli:unit><xbrli:unit id="shares">
		<xbrli:measure>xbrli:shares</xbrli:measure>
	</xbrli:unit></ix:resources></ix:header></div><div><a id="sC367A18F86E458349684D7FE62A3AC1E"></a></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:2px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:2px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:2px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:22pt;"><span style="font-family:inherit;font-size:22pt;font-weight:bold;">UNITED STATES</span></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:22pt;"><span style="font-family:inherit;font-size:22pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;font-weight:bold;">Washington, D.C. 20549</span></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:22pt;"><span style="font-family:inherit;font-size:22pt;font-weight:bold;">FORM </span><span><ix:nonNumeric id="d5109e580-wk-Fact-9179CEA2955ADBF12F297728FE672348" name="dei:DocumentType" contextRef="FD2020Q2YTD"><span style="font-size:22pt;font-weight:bold;">10-Q</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:22pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:2%;"></td><td style="width:49%;"></td><td style="width:49%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:4px;text-align:center;font-size:9.5pt;"><span style="font-family:Arial Unicode MS;font-size:9.5pt;"><span><ix:nonNumeric id="d5109e598-wk-Fact-4B27118DD5942D0825EFC48E2CB8787E" name="dei:DocumentQuarterlyReport" contextRef="FD2020Q2YTD" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></span></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:4px;text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:4px;text-align:right;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">For the quarterly period ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span><span style="white-space:nowrap"><ix:nonNumeric id="d5109e624-wk-Fact-2145A9DEF0A353987D99C92B0FD78AFE" name="dei:DocumentPeriodEndDate" contextRef="FD2020Q2YTD" format="ixt:datemonthdayyearen">June 30, 2020</ix:nonNumeric></span></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">or</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:4px;text-align:center;font-size:9.5pt;"><span style="font-family:Arial Unicode MS;font-size:9.5pt;"><span><ix:nonNumeric id="d5109e678-wk-Fact-9EF261A72565E3AEF6F4C48E5DE5D739" name="dei:DocumentTransitionReport" contextRef="FD2020Q2YTD" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;font-weight:bold;">For the transition period from _____ to _____</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Commission File Number: </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d5109e720-wk-Fact-204720997DD4E56C574FC4900F74AA45" name="dei:EntityFileNumber" contextRef="FD2020Q2YTD">0-12183<br/></ix:nonNumeric></span></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:24pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;"><img src="apyxmedicallogotagline.jpg" alt="apyxmedicallogotagline.jpg" style="height:145px;width:223px;"></img></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:24pt;"><span style="font-family:inherit;font-size:24pt;font-weight:bold;"><span><ix:nonNumeric id="d5109e738-wk-Fact-122175ACAF03BC281D8AC969D865ADDD" name="dei:EntityRegistrantName" contextRef="FD2020Q2YTD">APYX MEDICAL CORPORATION</ix:nonNumeric></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Exact name of registrant as specified in its charter)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:35%;"></td><td style="width:30%;"></td><td style="width:35%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d5109e759-wk-Fact-CC8F16BD50B8227254B6772888AA314D" name="dei:EntityIncorporationStateCountryCode" contextRef="FD2020Q2YTD" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d5109e769-wk-Fact-2F5C3F8A156F81099C9F7728BFB8D572" name="dei:EntityTaxIdentificationNumber" contextRef="FD2020Q2YTD">11-2644611</ix:nonNumeric></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(State or other jurisdiction of</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">incorporation or organization)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(I.R.S. Employer</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Identification No.)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><span><ix:nonNumeric id="d5109e794-wk-Fact-8F688F6E988D36978E6D7724B8E2B94A" name="dei:EntityAddressAddressLine1" contextRef="FD2020Q2YTD"><span style="font-weight:bold;">5115 Ulmerton Road,</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span><span><ix:nonNumeric id="d5109e799-wk-Fact-7BDA3497E63364457B537724FAAF6AAE" name="dei:EntityAddressCityOrTown" contextRef="FD2020Q2YTD"><span style="font-weight:bold;">Clearwater</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">, </span><span><ix:nonNumeric id="d5109e804-wk-Fact-0E96182F7336F330688677253CC99136" name="dei:EntityAddressStateOrProvince" contextRef="FD2020Q2YTD"><span style="font-weight:bold;">FL</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span><span><ix:nonNumeric id="d5109e809-wk-Fact-7CD6D30472B4611A0D8C7725844E6658" name="dei:EntityAddressPostalZipCode" contextRef="FD2020Q2YTD"><span style="font-weight:bold;">33760</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Address of principal executive offices, zip code)</span></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(</span><span><ix:nonNumeric id="d5109e820-wk-Fact-0D00A11A229F28C2FC597725D4E88365" name="dei:CityAreaCode" contextRef="FD2020Q2YTD"><span style="font-weight:bold;">727</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">) </span><span><ix:nonNumeric id="d5109e825-wk-Fact-9E63D00C81C464B797387726143FF4E4" name="dei:LocalPhoneNumber" contextRef="FD2020Q2YTD"><span style="font-weight:bold;">384-2323</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Registrant&#8217;s telephone number)</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Securities Registered Pursuant to Section 12 (b) of the Act:</span></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:36%;"></td><td style="width:26%;"></td><td style="width:38%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Title of each class</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Trading symbol(s)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Name of each exchange on which registered</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d5109e866-wk-Fact-AE1794C98241BCE73EC977267EBB41DD" name="dei:Security12bTitle" contextRef="FD2020Q2YTD">Common Stock</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d5109e871-wk-Fact-68364D9D96A01005D0077726C570AAAF" name="dei:TradingSymbol" contextRef="FD2020Q2YTD">APYX</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d5109e876-wk-Fact-A8933179D8AD0AAD8F0F772732FF3B1E" name="dei:SecurityExchangeName" contextRef="FD2020Q2YTD" format="ixt-sec:exchnameen">Nasdaq Stock Market, LLC</ix:nonNumeric></span></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Indicate by check mark whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. </span><span><ix:nonNumeric id="d5109e883-wk-Fact-5CC8D06DA321AB9105C2772AEC1580D3" name="dei:EntityCurrentReportingStatus" contextRef="FD2020Q2YTD"><span style="font-size:9.5pt;">Yes</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:9.5pt;">: </span><span style="font-family:Arial Unicode MS;font-size:9.5pt;">&#9746;</span><span style="font-family:inherit;font-size:9.5pt;"> No </span><span style="font-family:Arial Unicode MS;font-size:9.5pt;">&#9744;</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). </span><span><ix:nonNumeric id="d5109e897-wk-Fact-1AB592FFE6DC253CE9DD772B59D2A0B1" name="dei:EntityInteractiveDataCurrent" contextRef="FD2020Q2YTD"><span style="font-size:9.5pt;">Yes</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:9.5pt;">: </span><span style="font-family:Arial Unicode MS;font-size:9.5pt;">&#9746;</span><span style="font-family:inherit;font-size:9.5pt;"> No </span><span style="font-family:Arial Unicode MS;font-size:9.5pt;">&#9744;</span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer&#8221;, &#8220;accelerated filer&#8221;, &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="line-height:120%;padding-bottom:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:22%;"></td><td style="width:3%;"></td><td style="width:49%;"></td><td style="width:23%;"></td><td style="width:3%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Large accelerated filer</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:4px;text-align:left;font-size:9.5pt;"><span style="font-family:Arial Unicode MS;font-size:9.5pt;">&#9744;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonNumeric id="d5109e941-wk-Fact-593FAF9851A22EA1778F772BC3724D9D" name="dei:EntityFilerCategory" contextRef="FD2020Q2YTD" format="ixt-sec:entityfilercategoryen">Accelerated filer</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Arial Unicode MS;font-size:9.5pt;">&#9746;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Non-accelerated filer</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:4px;text-align:left;font-size:9.5pt;"><span style="font-family:Arial Unicode MS;font-size:9.5pt;">&#9744;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Smaller reporting company</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Arial Unicode MS;font-size:9.5pt;"><span><ix:nonNumeric id="d5109e972-wk-Fact-3890BFBD93B5954A977377237B9827A6" name="dei:EntitySmallBusiness" contextRef="FD2020Q2YTD" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Emerging growth company</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:4px;text-align:left;font-size:9.5pt;"><span style="font-family:Arial Unicode MS;font-size:9.5pt;"><span><ix:nonNumeric id="d5109e998-wk-Fact-F65ADC9CC0A11BD45E277723AE6C90C1" name="dei:EntityEmergingGrowthCompany" contextRef="FD2020Q2YTD" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></span></div></td></tr><tr><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:4px;text-align:left;font-size:9.5pt;"><span style="font-family:Arial Unicode MS;font-size:9.5pt;">&#9744;</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes: </span><span><ix:nonNumeric id="d5109e1029-wk-Fact-B13D68557E584DD4C0597723EE507E18" name="dei:EntityShellCompany" contextRef="FD2020Q2YTD" format="ixt-sec:boolballotbox"><span style="font-family:Arial Unicode MS;font-size:9.5pt;">&#9744;</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:9.5pt;"> No </span><span style="font-family:Arial Unicode MS;font-size:9.5pt;">&#9746;</span></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:9.5pt;"><span style="font-family:inherit;font-size:9.5pt;">As of August 6, 2020, </span><span style="font-family:inherit;font-size:9.5pt;"><span><ix:nonFraction id="d5109e1041-wk-Fact-88ED02F3F8152B3C62C6C63A082BDFE1" name="dei:EntityCommonStockSharesOutstanding" contextRef="I2020Q3Aug6" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">34,216,349</ix:nonFraction></span></span><span style="font-family:inherit;font-size:9.5pt;"> shares of the registrant&#8217;s $0.001 par value common stock were outstanding.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:2px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:2px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:2px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div><br/></div><hr style="page-break-after:always"></hr><div><a id="sA7A87A31B84252D8947A62684F78F8EC"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sA7A87A31B84252D8947A62684F78F8EC"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">APYX MEDICAL CORPORATION</span></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">INDEX TO QUARTERLY REPORT ON FORM 10-Q</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">For the quarterly period ended June 30, 2020</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:83%;"></td><td style="width:1%;"></td><td style="width:7%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Page</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Part I.</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:none;" href="#sC72D0123AC485DE3BE1A28E0964A5F2E"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:none;">Financial Information</span></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:none;" href="#sC72D0123AC485DE3BE1A28E0964A5F2E">3</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Item 1.</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:none;" href="#s42D615A966245E1C87164543AC1669A1"><span style="font-family:inherit;font-size:10pt;text-decoration:none;">Financial Statements</span></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:none;" href="#s42D615A966245E1C87164543AC1669A1">3</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:none;" href="#s26D22FABFAD651E2A0AB173C823C1B0E"><span style="font-family:inherit;font-size:10pt;text-decoration:none;">Consolidated Balance Sheets at </span></a><span style="font-family:inherit;font-size:10pt;color:#0000ff;">June 30, 2020 and December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:none;" href="#s26D22FABFAD651E2A0AB173C823C1B0E">3</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:none;" href="#sB3DF17931D7052AB8CE5A08FF927B06C"><span style="font-family:inherit;font-size:10pt;text-decoration:none;">Consolidated Statements of Operations for the three </span></a><span style="font-family:inherit;font-size:10pt;color:#0000ff;">and six months ended June 30, 2020 and 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:none;" href="#sB3DF17931D7052AB8CE5A08FF927B06C">4</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:none;" href="#sF3025368D96A5C94A9846DA70F05B4AD"><span style="font-family:inherit;font-size:10pt;text-decoration:none;">Consolidated Statements of Changes in Stockholders&#8217; Equity for the </span></a><span style="font-family:inherit;font-size:10pt;color:#0000ff;">three and six months ended June 30, 2020 and 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:none;" href="#sF3025368D96A5C94A9846DA70F05B4AD">5</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;color:#0000ff;">Consolidated Statements of Cash Flows for the six months ended June 30, 2020 and 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:none;" href="#s87580BA80EE659D9B2D6A2B6258FEAF0">6</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:none;" href="#sB7616497120C5862851296A219DAFEFA"><span style="font-family:inherit;font-size:10pt;text-decoration:none;">Notes to Consolidated Financial Statements</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:none;" href="#sB7616497120C5862851296A219DAFEFA">7</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Item 2.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:none;" href="#s79E011603C6C5FF4BE87BBAED45DB4F3"><span style="font-family:inherit;font-size:10pt;text-decoration:none;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:none;" href="#s79E011603C6C5FF4BE87BBAED45DB4F3">18</a></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Item 3.</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:none;" href="#s6B0C2323530157A6A742A6FE2CD40917"><span style="font-family:inherit;font-size:10pt;text-decoration:none;">Quantitative and Qualitative Disclosures about Market Risk</span></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:none;" href="#s6B0C2323530157A6A742A6FE2CD40917">26</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Item 4.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:none;" href="#sB7011A169FB3573E8FAE1DA29297E3AA"><span style="font-family:inherit;font-size:10pt;text-decoration:none;">Controls and Procedures</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:none;" href="#sB7011A169FB3573E8FAE1DA29297E3AA">26</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Part II.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:none;" href="#s3EDA95720B1F51768BE1BC7B5683AF29"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:none;">Other Information</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:none;" href="#s3EDA95720B1F51768BE1BC7B5683AF29">28</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Item 1.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:none;" href="#sE1B2E84895D956F8BCD8FB9E7400CFDC"><span style="font-family:inherit;font-size:10pt;text-decoration:none;">Legal Proceedings</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:none;" href="#sE1B2E84895D956F8BCD8FB9E7400CFDC">28</a></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Item 1A.</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:none;" href="#s539FA6473CF95679B8D5BDCB0796DFAD"><span style="font-family:inherit;font-size:10pt;text-decoration:none;">Risk Factors</span></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:none;" href="#s539FA6473CF95679B8D5BDCB0796DFAD">28</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Item 2.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:none;" href="#sD5F12ABC6A51575CBB678EEB360FF998"><span style="font-family:inherit;font-size:10pt;text-decoration:none;">Unregistered Sales of Equity Securities and Use of Proceeds</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:none;" href="#sD5F12ABC6A51575CBB678EEB360FF998">29</a></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Item 3.</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:none;" href="#s28C3E46F0F0E5AF189C22CE5E88E0127"><span style="font-family:inherit;font-size:10pt;text-decoration:none;">Defaults Upon Senior Securities</span></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:none;" href="#s28C3E46F0F0E5AF189C22CE5E88E0127">29</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Item 4.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:none;" href="#sA09A8DC681C35E22B2E7435FBDE342CD"><span style="font-family:inherit;font-size:10pt;text-decoration:none;">Mine Safety Disclosures</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:none;" href="#sA09A8DC681C35E22B2E7435FBDE342CD">29</a></div></td></tr></table></div></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sA7A87A31B84252D8947A62684F78F8EC"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">APYX MEDICAL CORPORATION</span></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">INDEX TO QUARTERLY REPORT ON FORM 10-Q</span></div></div><div><br/></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:83%;"></td><td style="width:1%;"></td><td style="width:7%;"></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Item 5.</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:none;" href="#s1A551E9CFA4653E39971D2E4E0876753"><span style="font-family:inherit;font-size:10pt;text-decoration:none;">Other Information</span></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:none;" href="#s1A551E9CFA4653E39971D2E4E0876753">29</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Item 6.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:none;" href="#s0FE30B1716DC51F6B9690DD2AB2D28F1"><span style="font-family:inherit;font-size:10pt;text-decoration:none;">Exhibits</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:none;" href="#s0FE30B1716DC51F6B9690DD2AB2D28F1">30</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:none;" href="#sF935F2F9B8425BD889495313897871AC"><span style="font-family:inherit;font-size:10pt;text-decoration:none;">Signatures</span></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:none;" href="#sF935F2F9B8425BD889495313897871AC">31</a></div></td></tr></table></div></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2</span></div></div><hr style="page-break-after:always"></hr><div><a id="sC72D0123AC485DE3BE1A28E0964A5F2E"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sA7A87A31B84252D8947A62684F78F8EC"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">APYX MEDICAL CORPORATION</span></div></div><div><br/></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">PART I. &#160;&#160;&#160;&#160;Financial Information</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s42D615A966245E1C87164543AC1669A1"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 1. Financial Statements</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s26D22FABFAD651E2A0AB173C823C1B0E"></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">CONSOLIDATED BALANCE SHEETS</span></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(In thousands, except share data, Unaudited)</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">June&#160;30, <br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ASSETS</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Current assets:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d33059e726-wk-Fact-02702598E6B173AB9753496B24B0061C" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">46,156</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d33059e745-wk-Fact-AF2FDE526FA8D3440A64496B24AB2685" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">58,812</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Trade accounts receivable, net of allowance of $760 and $273</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d33059e760-wk-Fact-2FA617CD8C672D75113C496B24A7320C" name="us-gaap:AccountsReceivableNetCurrent" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,306</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d33059e779-wk-Fact-1CF40BA218015A80807E496B24AF5343" name="us-gaap:AccountsReceivableNetCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,987</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax receivables</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d33059e799-wk-Fact-FE4318780EDE67A6C48C4985F0A988C1" name="us-gaap:IncomeTaxesReceivable" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,443</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d33059e818-wk-Fact-EFF263703BB25D312B834985F0AD2662" name="us-gaap:IncomeTaxesReceivable" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">426</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other receivables</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d33059e838-wk-Fact-48D81FFD93457E05087D496B24ACC76E" name="us-gaap:OtherReceivablesNetCurrent" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,671</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d33059e857-wk-Fact-80488B4F378AD38DA903496B24AB5D70" name="us-gaap:OtherReceivablesNetCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,233</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventories, net of provision for obsolescence of $685 and $392</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d33059e877-wk-Fact-2A22C0C0830CFBCD3D83496B24B26D14" name="us-gaap:InventoryNet" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,257</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d33059e896-wk-Fact-61A8AEC690F00F8AA7C1496B24A74F60" name="us-gaap:InventoryNet" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,068</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prepaid expenses and other current assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d33059e916-wk-Fact-CA59FE51CB032867F417496B24A6DE95" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,008</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d33059e935-wk-Fact-B63FC252216E8273EB2F496B24B028D0" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,207</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total current assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d33059e955-wk-Fact-4801B580ED3B3467CDAE496B24A9DA66" name="us-gaap:AssetsCurrent" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">69,841</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d33059e974-wk-Fact-1C99E09599A59806D00C496B24A1B620" name="us-gaap:AssetsCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">76,733</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment, net of accumulated depreciation and amortization of $4,702 and $4,403</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d33059e994-wk-Fact-979E84BC4453F65B4181496B24A8B0C7" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,440</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d33059e1013-wk-Fact-8797C551C22E1D8DDA41496B24A3A007" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,618</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease right-of-use assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d33059e1034-wk-Fact-7DAEE34B0C9F713CDB0A496B24A4CD42" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">295</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d33059e1053-wk-Fact-EDFAF2D6D19F5E8B2C8F4985F0B82607" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">350</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finance lease right-of-use assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d33059e1073-wk-Fact-811CF0FE9D3C195B98B0496B24A37B0E" name="us-gaap:FinanceLeaseRightOfUseAsset" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">691</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d33059e1092-wk-Fact-BF32F7AFE7C13B937D2C4985F0B6298B" name="us-gaap:FinanceLeaseRightOfUseAsset" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">653</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d33059e1112-wk-Fact-A35F4AFBAE67081420DE496B24B2A988" name="us-gaap:OtherAssetsNoncurrent" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">560</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d33059e1131-wk-Fact-57A46AB3892D183F3278496B24AC9DC7" name="us-gaap:OtherAssetsNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">391</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d33059e1156-wk-Fact-8C42496759915C5DA730496B24B2CC16" name="us-gaap:Assets" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">77,827</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d33059e1175-wk-Fact-C8CDCCA60A61246FAA19496B24A43561" name="us-gaap:Assets" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">84,745</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Current liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts payable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d33059e1318-wk-Fact-ACE7672888B76DDD62F1496B24AD0D39" name="us-gaap:AccountsPayableCurrent" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,206</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d33059e1337-wk-Fact-DC10BD8ABD9CD75E4105496B24A6570A" name="us-gaap:AccountsPayableCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,438</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued expenses and other liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d33059e1352-wk-Fact-E97C2C9BB55F7862D582496B24A591F2" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,911</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d33059e1371-wk-Fact-AFAF8A0F159C9EA96842496B24A3652D" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,396</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current portion of operating lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d33059e1391-wk-Fact-30A7CFE419C44D5FD56A496B24ABABA1" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">112</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d33059e1410-wk-Fact-A767E6C2003ED31BF5954985F0B66289" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">108</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current portion of finance lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d33059e1430-wk-Fact-A6BAFD688EEAE9B09570496B24ABBFEC" name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">266</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d33059e1449-wk-Fact-A1D67908A1CE6BC2B5D34985F0BB223B" name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">229</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Related party note payable</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d33059e1470-wk-Fact-48B2E4B51FF912FF1A474985F0B93F90" name="us-gaap:DueToRelatedPartiesCurrent" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">140</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d33059e1489-wk-Fact-78620A5CBC161809A70A4985F0BC526D" name="us-gaap:DueToRelatedPartiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">140</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d33059e1509-wk-Fact-3F3CED2C7E5A59BE718F4985F0AB87CB" name="us-gaap:LiabilitiesCurrent" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,635</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d33059e1528-wk-Fact-A56BE3898FD4F2EA730B496B24AA5332" name="us-gaap:LiabilitiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12,311</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term operating lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d33059e1548-wk-Fact-9CB200CF8683ECC7448B496B24A9D980" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">177</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d33059e1567-wk-Fact-77F78617A601E4EC5AD74985F0C33487" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">235</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term finance lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d33059e1587-wk-Fact-DB1C2CE9B6526A550E07496B24B18BDA" name="us-gaap:FinanceLeaseLiabilityNoncurrent" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">414</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d33059e1606-wk-Fact-0041F9AE7410258270F14985F0B5F358" name="us-gaap:FinanceLeaseLiabilityNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">421</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d33059e1626-wk-Fact-C29E96B20CDD29BFF7F84985F0C043A7" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">765</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d33059e1645-wk-Fact-0A4EC0F3F9C9960AFAA14985F0BDC4C6" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">519</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d33059e1665-wk-Fact-C301B47BB7E9511C02D44985F0BABF80" name="us-gaap:Liabilities" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,991</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d33059e1684-wk-Fact-041E06CD18644D34C57C4985F0B5E9FF" name="us-gaap:Liabilities" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">13,486</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">STOCKHOLDERS&#8217; EQUITY</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Common stock, $0.001 par value; 75,000,000 shares authorized; 34,201,895 issued and outstanding as of June 30, 2020, and 34,312,527 issued and 34,169,952 outstanding as of December 31, 2019</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d33059e1745-wk-Fact-6FE995DD0EB32FBB27A3496B24A7327F" name="us-gaap:CommonStockValue" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">34</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d33059e1764-wk-Fact-143AAB9DC49A689E6EB7496B24ADBF29" name="us-gaap:CommonStockValue" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">34</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additional paid-in capital</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d33059e1784-wk-Fact-4DA6BCDC6F5D7593483E496B24A9E2CA" name="us-gaap:AdditionalPaidInCapital" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">58,926</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d33059e1803-wk-Fact-FC6ADB4EE9D33680920C496B24AE25C7" name="us-gaap:AdditionalPaidInCapital" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">56,708</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Retained earnings</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d33059e1823-wk-Fact-95D49C7D8DD0C809EF8C496B24AD5EEE" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,876</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d33059e1842-wk-Fact-3BE633F8823CEAFD289B496B24AFD7D8" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">14,517</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total stockholders&#8217; equity</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d33059e1862-wk-Fact-D1C436E250D6D86CF9D04985F0B6CF81" name="us-gaap:StockholdersEquity" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">66,836</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d33059e1881-wk-Fact-C94CE513F2192AF1C5CC4985F0BF3F35" name="us-gaap:StockholdersEquity" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">71,259</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;font-weight:bold;">Total liabilities and stockholders&#8217; equity</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d33059e1907-wk-Fact-9BAAAF0EFA3532B65DFD4985F0BA58F7" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">77,827</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d33059e1926-wk-Fact-AB7967A703C16467D8F44985F0BD68F5" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">84,745</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accompanying notes are an integral part of the consolidated financial statements.</span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3</span></div></div><hr style="page-break-after:always"></hr><div><a id="sB3DF17931D7052AB8CE5A08FF927B06C"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sA7A87A31B84252D8947A62684F78F8EC"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">APYX MEDICAL CORPORATION</span></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">CONSOLIDATED STATEMENTS OF OPERATIONS</span></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(In thousands, except per share data, Unaudited)</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.635477582846%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended<br/>June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended<br/>June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d9871e772-wk-Fact-F2B9353892A9BBCB558E4985F0BD4A4E" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,296</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d9871e791-wk-Fact-C4195FF56DAD7F05326E76D0BF59C9A4" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,649</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d9871e810-wk-Fact-9BDD69852F22B2CE28FC496B254AFE05" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,293</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d9871e830-wk-Fact-D8E04E1C126201AA5E924985F0D415DA" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12,278</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Cost of sales</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d9871e845-wk-Fact-13949BD7C40D35F039794985F0A8FB45" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,202</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d9871e864-wk-Fact-FAFB259F9A77E77E137476D0BF216C98" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,975</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d9871e883-wk-Fact-E0F7CB5DA114B3BAA245496B255992CE" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,215</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d9871e903-wk-Fact-18242D1C00315F54ABF44985F0D6B253" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,041</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross profit</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d9871e923-wk-Fact-E5FB9DF13C532438C2924985F0D3EA40" name="us-gaap:GrossProfit" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,094</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d9871e942-wk-Fact-0E157A89032C104AA31F76D0BF001948" name="us-gaap:GrossProfit" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,674</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d9871e961-wk-Fact-825D69C5A173FB997681496B25529520" name="us-gaap:GrossProfit" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,078</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d9871e981-wk-Fact-3222B037426F17C447DC4985F0DC4B60" name="us-gaap:GrossProfit" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,237</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Other costs and expenses:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d9871e1083-wk-Fact-34338D3A20A868A7A2B74985F0C776EC" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">975</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d9871e1102-wk-Fact-C0692A559A325D20173A76D0BF41A126" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">888</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d9871e1121-wk-Fact-248808F42544186D5BCB496B2550D3CF" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,955</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d9871e1141-wk-Fact-25CF5287E4CB7C284DA84985F0D1A5BB" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,618</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Professional services</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d9871e1161-wk-Fact-8B14AECE3DC456392BC24985F0C38A2B" name="us-gaap:ProfessionalFees" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,658</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d9871e1180-wk-Fact-D565329A4105CC70C1A676D0BF53C8A3" name="us-gaap:ProfessionalFees" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,661</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d9871e1199-wk-Fact-DCE23DEFA4E2A4EFD2D2496B254FFA55" name="us-gaap:ProfessionalFees" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,047</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d9871e1219-wk-Fact-F8C9908017F14936F93C4985F0D5E913" name="us-gaap:ProfessionalFees" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,779</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Salaries and related costs</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d9871e1239-wk-Fact-953192D65FF7BEFC43574985F0ED8175" name="us-gaap:SalariesAndWages" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,439</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d9871e1258-wk-Fact-02B779FF99179112C63976D0BF486791" name="us-gaap:SalariesAndWages" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,510</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d9871e1277-wk-Fact-4957373C43D2ED6AA41F496B2554FD44" name="us-gaap:SalariesAndWages" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,750</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d9871e1297-wk-Fact-DF93D491AFC4F0D9336B4985F0F960CB" name="us-gaap:SalariesAndWages" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,998</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Selling, general and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d9871e1317-wk-Fact-2872712017954F8BCA474985F0B50E35" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,189</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d9871e1336-wk-Fact-9BF7D9A4E12173CA874F76D0BF4C3CE5" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,037</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d9871e1355-wk-Fact-33489C5DA4CFA2333B15496B25526A56" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,985</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d9871e1375-wk-Fact-324307BADF3204756D664985F0F8F4B1" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,994</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total other costs and expenses</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d9871e1395-wk-Fact-4A2BF40AEF11926075454985F0EF020A" name="us-gaap:OperatingExpenses" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,261</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d9871e1414-wk-Fact-A30CCF812AB2F075C19C76D0BF64EE60" name="us-gaap:OperatingExpenses" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,096</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d9871e1433-wk-Fact-00BE6571ABAFD386B4B7496B25438B98" name="us-gaap:OperatingExpenses" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">18,737</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d9871e1453-wk-Fact-A42421A70E68CDDFA7AB4985F0D55E98" name="us-gaap:OperatingExpenses" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">18,389</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;font-weight:bold;">Loss from operations</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d9871e1474-wk-Fact-6E4681D333F9B4FEF1B34985F0B9BDC1" name="us-gaap:OperatingIncomeLoss" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">6,167</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d9871e1494-wk-Fact-AC7AD5EC8AB2905C951C76D0BF2A7387" name="us-gaap:OperatingIncomeLoss" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">4,422</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d9871e1514-wk-Fact-5D65487F5B78F2E9304B496B254717EF" name="us-gaap:OperatingIncomeLoss" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">13,659</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d9871e1535-wk-Fact-7E20E27051E14A0D6F134985F0DA82C9" name="us-gaap:OperatingIncomeLoss" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">10,152</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest income</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d9871e1556-wk-Fact-C227DBBE6CA87150FAD476D0BF5F3509" name="us-gaap:InterestIncomeOperating" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d9871e1575-wk-Fact-3B8FD60B29B0E0A1762F4985F0F80D00" name="us-gaap:InterestIncomeOperating" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">403</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d9871e1594-wk-Fact-E215DB812850C07E3CFAD6178E5F048A" name="us-gaap:InterestIncomeOperating" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">223</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d9871e1613-wk-Fact-6FCD05FE238ECD6069284985F0D3ADDC" name="us-gaap:InterestIncomeOperating" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">826</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Interest expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d9871e1633-wk-Fact-4935FB2E9F22EBA81F8376D0BF5C4BBA" name="us-gaap:InterestExpense" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d9871e1653-wk-Fact-BA1C610CE519361C5AC34985F0DB0FCF" name="us-gaap:InterestExpense" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d9871e1672-wk-Fact-90E780016EE019A9EA93D6178E6C3B5B" name="us-gaap:InterestExpense" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">14</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d9871e1693-wk-Fact-9B91CCF1131A4DAF67ED4985F0D58CED" name="us-gaap:InterestExpense" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other (loss) income, net</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d9871e1713-wk-Fact-828CD9B42DC1F8EFA72276D0BF3B49AF" name="us-gaap:OtherOperatingIncomeExpenseNet" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">14</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d9871e1733-wk-Fact-397B5DCDE56513731F094985F0C6DCEF" name="us-gaap:OtherOperatingIncomeExpenseNet" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">200</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d9871e1753-wk-Fact-385DF51A61546F8417FCD6178E54A764" name="us-gaap:OtherOperatingIncomeExpenseNet" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">412</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d9871e1773-wk-Fact-D2C45063AEB20A37404A4985F0F80DE7" name="us-gaap:OtherOperatingIncomeExpenseNet" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">495</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;font-weight:bold;">Total other (loss) income, net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d9871e1794-wk-Fact-36859585850E626143FA4985F0C48B93" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">15</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d9871e1814-wk-Fact-10ED1EC62F8C075BCA9376D0BF85B4E8" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">203</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d9871e1833-wk-Fact-2643E5884A32D19DB1D8496B254FD50A" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">621</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d9871e1853-wk-Fact-BB22CF791314B745B1934985F0D7CA8B" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">331</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Loss before income taxes</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d9871e1873-wk-Fact-AEF79181B1B1150A173F4985F0C513F8" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">6,182</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d9871e1893-wk-Fact-4EFB695BDD668292AB9B76D0BEFB3E72" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">4,219</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d9871e1913-wk-Fact-76DD743D1B2F774902F4496B254CDEB5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">13,038</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d9871e1934-wk-Fact-57A2F849CC0910CEB30C4985F0D6CCCC" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">9,821</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Income tax (benefit) expense </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d9871e1955-wk-Fact-E9BF97A1F660F7AF17B476D0BF378CF0" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,492</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d9871e1975-wk-Fact-697A31017246D2D682494985F0AB7C3C" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">76</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d9871e1994-wk-Fact-D787ABABBBA24B299E50C92CFBFFA215" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">6,397</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d9871e2015-wk-Fact-281575BA2D8E389065EB4985F0D51761" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">82</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net loss</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d9871e2040-wk-Fact-397B5F09FC560A26164C4985F0BC0BD5" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">4,690</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d9871e2060-wk-Fact-BCBB336E1C78F831CB4A4985F0E0D0DA" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">4,295</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d9871e2080-wk-Fact-B864AF01CE96AE141E184985F0DABD1D" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">6,641</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d9871e2100-wk-Fact-3FF03CC6BE82BB4D951C4985F0D79FDC" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">9,903</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Earnings (loss) per Share:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic and diluted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d9871e2285-wk-Fact-41C4F6CFB4F80DCBFC6E76D0BF67B254" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" contextRef="FD2020Q2QTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.14</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d9871e2305-wk-Fact-C38EA1DCCA208B27473C4985F0BECE0E" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" contextRef="FD2019Q2QTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.13</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d9871e2325-wk-Fact-928250C9526DF248E575496B255746E3" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" contextRef="FD2020Q2YTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.19</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d9871e2346-wk-Fact-EA9116B0A8E4B9421E734985F0DBF793" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" contextRef="FD2019Q2YTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.30</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accompanying notes are an integral part of the consolidated financial statements.</span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4</span></div></div><hr style="page-break-after:always"></hr><div><a id="sF3025368D96A5C94A9846DA70F05B4AD"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sA7A87A31B84252D8947A62684F78F8EC"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">APYX MEDICAL CORPORATION</span></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY</span></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(In thousands, Unaudited)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.71150097465888%;border-collapse:collapse;text-align:left;"><tr><td colspan="19"></td></tr><tr><td style="width:43%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Three months ended June 30, 2019 and 2020</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Common Stock</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Additional Paid-In Capital</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Retained Earnings </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Total </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Par Value</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balance</span></div><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">March 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d10848e902-wk-Fact-3E61C219A196ECF715464985F0B99DEC" name="us-gaap:SharesIssued" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">33,891</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d10848e921-wk-Fact-FDD4E76B0F3912BFB0AB4985F0C4DA27" name="us-gaap:StockholdersEquity" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">34</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d10848e940-wk-Fact-0BF8CD6A14CE9DFCD96B4985F0AA1CAB" name="us-gaap:StockholdersEquity" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">54,182</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d10848e960-wk-Fact-A8DFCDC50248B35D73B54985F0A93B22" name="us-gaap:StockholdersEquity" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">28,615</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d10848e979-wk-Fact-328855CD6F52F68BA7E44985F0BD459A" name="us-gaap:StockholdersEquity" contextRef="FI2019Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">82,831</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Options exercised for cash</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d10848e994-wk-Fact-9B046A6128A2D09973154985F0A9315F" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">11</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d10848e1027-wk-Fact-A2827D4F89D14AB010AD4985F0BAE652" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">48</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d10848e1066-wk-Fact-CDAC796BA8A52078BB344985F0C83AE2" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">48</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Stock based compensation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d10848e1119-wk-Fact-6D0564721654AC4784324985F0CCECAD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">856</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d10848e1158-wk-Fact-D32DED58334CB421199C4985F0BD521B" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">856</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Shares issued on net settlement of stock options</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d10848e1178-wk-Fact-89A99B0D68E65D59610A4985F0A5A65C" name="apyx:StockSwapToAcquireOptionsShares" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">17</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d10848e1250-wk-Fact-87045BDE8CF9870114A64985F0BEAB66" name="apyx:StockSwapToAcquireOptionsAmount" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net loss</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d10848e1323-wk-Fact-44D6DCE00CC5964928674985F0C76595" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">4,295</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d10848e1343-wk-Fact-BCBB336E1C78F831CB4A4985F0E0D0DA" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">4,295</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balance </span></div><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">June 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d10848e1367-wk-Fact-FD0CC2743712FE54AA884985F0B6FF1B" name="us-gaap:SharesIssued" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">33,919</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d10848e1381-wk-Fact-B08CABE5DDD17F80178D4985F0CFDD2D" name="us-gaap:StockholdersEquity" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">34</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d10848e1405-wk-Fact-DB19878C0AE7878EAFB94985F0D07D10" name="us-gaap:StockholdersEquity" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">55,086</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d10848e1425-wk-Fact-D1B6A04F02BD1944073D4985F0A98246" name="us-gaap:StockholdersEquity" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">24,320</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d10848e1444-wk-Fact-F743A1E39A1B7B19F4614985F0A6E10C" name="us-gaap:StockholdersEquity" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">79,440</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balance</span></div><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">March 31, 2020</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d10848e1559-wk-Fact-C4D4A07964374AB6B5D276D28A687973" name="us-gaap:SharesIssued" contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">34,184</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d10848e1578-wk-Fact-E144697B57FC77E61AE276D289B87827" name="us-gaap:StockholdersEquity" contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">34</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d10848e1597-wk-Fact-25A1E9BC0F5FA10F918576D288A1AA6D" name="us-gaap:StockholdersEquity" contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">57,829</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d10848e1617-wk-Fact-550FDA73A96CE1C2ACA776D288A8ED22" name="us-gaap:StockholdersEquity" contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12,566</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d10848e1636-wk-Fact-8D158F0138178224EEC876D28951EF5D" name="us-gaap:StockholdersEquity" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">70,429</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Stock based compensation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d10848e1685-wk-Fact-1FA21E17FBD44CD237EC76D2892FC0F7" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,097</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d10848e1724-wk-Fact-1FA21E17FBD44CD237EC76D2892FC0F7" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,097</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Shares issued on net settlement of stock options </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d10848e1744-wk-Fact-A3DD9F2C5F9813A0486D76D28A596FE2" name="apyx:StockSwapToAcquireOptionsShares" contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">18</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d10848e1816-wk-Fact-A04794CA8C4E7AB7CF5476D28910ED4E" name="apyx:StockSwapToAcquireOptionsAmount" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net Loss</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d10848e1889-wk-Fact-2AA2AC602BF5E400F66776D28A4B9670" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">4,690</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d10848e1909-wk-Fact-397B5F09FC560A26164C4985F0BC0BD5" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">4,690</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balance </span></div><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">June 30, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d10848e1933-wk-Fact-0C5B0CCEF6B8E542B3344985F0BB5363" name="us-gaap:SharesIssued" contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">34,202</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d10848e1952-wk-Fact-CC3BE3E5C0AFF40A096A76D28ABCC6B9" name="us-gaap:StockholdersEquity" contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">34</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d10848e1971-wk-Fact-8EA36CF8C8C15E03580A76D288C58682" name="us-gaap:StockholdersEquity" contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">58,926</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d10848e1991-wk-Fact-84004FAEE5A39C6B528076D28978AD73" name="us-gaap:StockholdersEquity" contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,876</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d10848e2010-wk-Fact-D1C436E250D6D86CF9D04985F0B6CF81" name="us-gaap:StockholdersEquity" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">66,836</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Six months ended June 30, 2019 and 2020</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Common Stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Additional Paid-In Capital</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Retained Earnings </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Par Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balance<br/>December 31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d10848e2412-wk-Fact-5B49065ABB21BC9C5AC84985F0D04F7B" name="us-gaap:SharesIssued" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">33,705</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d10848e2431-wk-Fact-12BD79913DF0373A92204985F0B62C66" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">34</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d10848e2450-wk-Fact-F3FDB1C2D9FD18FAD6264985F0C652A0" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">52,920</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d10848e2470-wk-Fact-7D27A39B732FA0A3DA5E4985F0C6EA0B" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">34,223</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d10848e2489-wk-Fact-C26AB252431087F5B3E54985F0A79F6E" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">87,177</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Options exercised for cash</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d10848e2504-wk-Fact-7233999634B56648C7E34985F0BEC02B" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">29</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d10848e2537-wk-Fact-89EEB737D0DC1FE2D3134985F0B9BDD0" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">115</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d10848e2576-wk-Fact-3351319196A9DD693C9D4985F0D0CDE7" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">115</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Stock based compensation</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d10848e2629-wk-Fact-5776DBC247B0BA2FA5684985F0BFCE31" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,051</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d10848e2668-wk-Fact-5776DBC247B0BA2FA5684985F0BFCE31" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,051</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Shares issued on net settlement of stock options </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d10848e2689-wk-Fact-20C5308DBE475167DAFF4985F0ACDDAC" name="apyx:StockSwapToAcquireOptionsShares" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">185</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d10848e2761-wk-Fact-3500A5FE7256EE29F9E44985F0CDB105" name="apyx:StockSwapToAcquireOptionsAmount" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net loss</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d10848e2834-wk-Fact-A4BC828947F3466A81E14985F0AE9958" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">9,903</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d10848e2854-wk-Fact-3FF03CC6BE82BB4D951C4985F0D79FDC" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">9,903</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balance<br/>June 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d10848e2875-wk-Fact-FD0CC2743712FE54AA884985F0B6FF1B" name="us-gaap:SharesIssued" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">33,919</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d10848e2894-wk-Fact-B08CABE5DDD17F80178D4985F0CFDD2D" name="us-gaap:StockholdersEquity" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">34</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d10848e2913-wk-Fact-DB19878C0AE7878EAFB94985F0D07D10" name="us-gaap:StockholdersEquity" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">55,086</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d10848e2933-wk-Fact-D1B6A04F02BD1944073D4985F0A98246" name="us-gaap:StockholdersEquity" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">24,320</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d10848e2952-wk-Fact-F743A1E39A1B7B19F4614985F0A6E10C" name="us-gaap:StockholdersEquity" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">79,440</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balance<br/>December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d10848e3064-wk-Fact-232BEBACBBF823E62DA04985F0AB37AA" name="us-gaap:SharesIssued" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">34,170</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d10848e3083-wk-Fact-B3F69626EDD3937AAE7E4985F0A6C886" name="us-gaap:StockholdersEquity" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">34</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d10848e3102-wk-Fact-E61121F7B359E08730754985F0C0089D" name="us-gaap:StockholdersEquity" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">56,708</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d10848e3122-wk-Fact-1D10998B85999E32B7694985F0AD5245" name="us-gaap:StockholdersEquity" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">14,517</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d10848e3141-wk-Fact-C94CE513F2192AF1C5CC4985F0BF3F35" name="us-gaap:StockholdersEquity" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">71,259</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Options exercised for cash</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d10848e3156-wk-Fact-1A236862BE568951FC3A4985F0ACCC9C" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">10</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d10848e3189-wk-Fact-751DB13003F58B8EE3EA4985F0B7043A" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">72</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d10848e3228-wk-Fact-813D88EEBF21DD99F65C4985F0C16C19" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">72</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Stock based compensation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d10848e3281-wk-Fact-D84C0C999FFF17FBC31A4985F0BC2397" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,146</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d10848e3320-wk-Fact-F992FF3AC7F73ABDFEB34985F0C10D14" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,146</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Shares issued on net settlement of stock options </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d10848e3340-wk-Fact-3ADB7D22A67A50FCD4CF4985F0BB14A8" name="apyx:StockSwapToAcquireOptionsShares" contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">22</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d10848e3412-wk-Fact-314CA07651F3BB5E5C644985F0B7B80F" name="apyx:StockSwapToAcquireOptionsAmount" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net loss</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d10848e3485-wk-Fact-AF53225DA2AE8AD39A564985F0AFB30B" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">6,641</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d10848e3505-wk-Fact-B864AF01CE96AE141E184985F0DABD1D" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">6,641</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balance <br/>June 30, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d10848e3526-wk-Fact-0C5B0CCEF6B8E542B3344985F0BB5363" name="us-gaap:SharesIssued" contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">34,202</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d10848e3545-wk-Fact-CC3BE3E5C0AFF40A096A76D28ABCC6B9" name="us-gaap:StockholdersEquity" contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">34</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d10848e3564-wk-Fact-8EA36CF8C8C15E03580A76D288C58682" name="us-gaap:StockholdersEquity" contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">58,926</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d10848e3584-wk-Fact-84004FAEE5A39C6B528076D28978AD73" name="us-gaap:StockholdersEquity" contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,876</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d10848e3603-wk-Fact-D1C436E250D6D86CF9D04985F0B6CF81" name="us-gaap:StockholdersEquity" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">66,836</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accompanying notes are an integral part of the consolidated financial statements.</span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5</span></div></div><hr style="page-break-after:always"></hr><div><a id="s87580BA80EE659D9B2D6A2B6258FEAF0"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sA7A87A31B84252D8947A62684F78F8EC"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">APYX MEDICAL CORPORATION</span></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(In thousands, Unaudited)</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:67%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash flows from operating activities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d35337e723-wk-Fact-B864AF01CE96AE141E184985F0DABD1D" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">6,641</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d35337e743-wk-Fact-3FF03CC6BE82BB4D951C4985F0D79FDC" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">9,903</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Adjustments to reconcile net loss to net cash used in operating activities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Depreciation and amortization</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d35337e800-wk-Fact-992575F2CEB1AB0DEEB5496B24C277EF" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">439</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d35337e819-wk-Fact-F13A63F99BFE66A198A64985F0A4C26F" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">316</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Provision for inventory obsolescence</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d35337e839-wk-Fact-7EA1C67920CECB3BD6DB496B24C26BC4" name="apyx:ProvisionForInventoryObsolescence" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">413</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d35337e858-wk-Fact-D0DDAD4364C310096DA676D6FDE594B8" name="apyx:ProvisionForInventoryObsolescence" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">36</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock based compensation</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d35337e878-wk-Fact-1E13275687914D0D788C496B253616CC" name="us-gaap:ShareBasedCompensation" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,146</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d35337e897-wk-Fact-2E7E719129609A16727E4985F0F49487" name="us-gaap:ShareBasedCompensation" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,051</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unrealized gain on short term investments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d35337e917-wk-Fact-FAB15C93DB0A5A48F724496B2493DD8B" name="us-gaap:GainLossOnInvestments" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d35337e936-wk-Fact-0EA65CE40FE28EC1C44376D6FDF56060" name="us-gaap:GainLossOnInvestments" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">164</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Provision (benefit) for allowance for doubtful accounts</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d35337e957-wk-Fact-8F4864F4CB3EB1454CBB496B24C3033C" name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">486</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d35337e976-wk-Fact-774304EE0DAA49CE4F954985F0F2D670" name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">238</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Changes in operating assets and liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Trade receivables</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d35337e1039-wk-Fact-BC4AD249EAF1188B36AD496B2542C306" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,195</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d35337e1058-wk-Fact-5408E91DE3E6C91C5B984985F0D5F39C" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,333</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prepaid expenses and other assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d35337e1079-wk-Fact-A72BD588AC9DA0337B22496B24B7ABED" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,427</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d35337e1099-wk-Fact-2FAA61BB9A4F3629970E4985F0F7F436" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">879</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventories</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d35337e1120-wk-Fact-15B8A0BED265A5D464E9496B24C07A77" name="us-gaap:IncreaseDecreaseInInventories" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">571</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d35337e1140-wk-Fact-105ED17B8A2BFECC67314985F0A451DB" name="us-gaap:IncreaseDecreaseInInventories" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,015</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Accounts payable</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d35337e1161-wk-Fact-3AA6104DD8298E67C444496B24E6638D" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">232</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d35337e1181-wk-Fact-1C76EF043F7A630934174985F0F37BC0" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">218</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued and other liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d35337e1201-wk-Fact-7A7D64EA36179DD4EC2E4985F0F47C2A" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,241</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d35337e1221-wk-Fact-126C15F89FD8276A96324985F0E0DBBE" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">236</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;font-weight:bold;">Net cash used in operating activities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d35337e1241-wk-Fact-438C335908E2DA82CD49496B248CE208" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">12,433</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d35337e1261-wk-Fact-1D032740E753EC64FC974985F0D4630E" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">10,675</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash flows from investing activities</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Purchases of property and equipment</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d35337e1322-wk-Fact-CBC8069791C392261C24496B25404961" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">184</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d35337e1342-wk-Fact-00CF1C44698A482694F04985F0DD070F" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">518</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:normal;">Purchases of marketable securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d35337e1363-wk-Fact-9D2B4369737A20E3EA4D496B248AE167" name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d35337e1382-wk-Fact-B84583C5390ADC64D7A24985F0D8C6B1" name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">18,884</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Proceeds from maturities of marketable securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d35337e1403-wk-Fact-BB6F47623A5FB27666A6496B24874DF0" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d35337e1422-wk-Fact-8F6BD59B7B409AD499824985F0F417BF" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">80,726</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net cash (used in) provided by  investing activities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d35337e1442-wk-Fact-2E24ED1F3BCF54E9422F496B248891E4" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">184</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d35337e1462-wk-Fact-93D5D7391E7AA66FCC224985F0D431A8" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">61,324</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;font-weight:bold;">Cash flows from financing activities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Proceeds from stock option exercises</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d35337e1522-wk-Fact-3F887D222C35EF18CAC3496B24BF13C9" name="apyx:ProceedsFromStockOptionsExercisedAndWarrantsExercised" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">72</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d35337e1541-wk-Fact-D469B7597F923A6D541276D6FDDBC630" name="apyx:ProceedsFromStockOptionsExercisedAndWarrantsExercised" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">115</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Repayment of finance lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d35337e1561-wk-Fact-197696A34120D9B0AAD9496B24C1F8D2" name="apyx:RepaymentofFinanceLeaseLiabilities" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">120</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d35337e1581-wk-Fact-1638C4067E4E60F8C90476D6FD771C62" name="apyx:RepaymentofFinanceLeaseLiabilities" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net cash (used in) provided by financing activities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d35337e1601-wk-Fact-52EAC9B3B5DC368928E5496B2486D37B" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">48</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d35337e1621-wk-Fact-B99587E7BD2A522D2B674985F0D47137" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">115</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;font-weight:bold;">Effect of exchange rates on cash</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d35337e1641-wk-Fact-AE68C0A8E66F02745FAC496B2542B221" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d35337e1660-wk-Fact-3BE6DB0FC0EABED8061876D6FD8D9184" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net change in cash, cash equivalents and restricted cash</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d35337e1680-wk-Fact-A4FE913805A5E4D9D637496B25350F76" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">12,656</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d35337e1700-wk-Fact-D09D6500F83A53C0DE3876D6FD61D69F" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">50,764</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;font-weight:normal;">Cash, cash equivalents and restricted cash, beginning of period</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d35337e1720-wk-Fact-F4CB43850573C5B66C11496B24BF52D4" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">58,812</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d35337e1739-wk-Fact-81B8FB49E350797C61C84985F0DCDD00" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16,596</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash, cash equivalents and restricted cash, end of period</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d35337e1764-wk-Fact-0B73B5E8BFDA870FEF8D496B2538B9D1" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">46,156</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d35337e1783-wk-Fact-5A303D799F3853D3B00776D6FD9BEF5E" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">67,360</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash paid for:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d35337e1885-wk-Fact-BE89B9B63E57CECA7D7B4985F0D9484F" name="us-gaap:InterestPaidNet" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d35337e1904-wk-Fact-F400C96CB5D7A72F7E7B4985F0A5EE66" name="us-gaap:InterestPaidNet" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">14</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Taxes</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d35337e1920-wk-Fact-4B9DFAFFE5B0CDB90A73A68AF2C37A2B" name="us-gaap:IncomeTaxesPaid" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">54</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d35337e1939-wk-Fact-1F8C0FDE9102AC97F558A68AF1F9FE96" name="us-gaap:IncomeTaxesPaid" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">248</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Non cash activities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cashless exercise of stock options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d35337e2043-wk-Fact-E0D5F42D884658FD53B8496B24C2DED2" name="apyx:NonCashProceedsFromStockOptionsAndWarrantsExercised" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">49</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d35337e2062-wk-Fact-90FE643917C03B4DCD914985F0F8F6C4" name="apyx:NonCashProceedsFromStockOptionsAndWarrantsExercised" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">757</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Right-of-use assets capitalized and lease liabilities recognized upon adoption of Topic 842</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d35337e2079-wk-Fact-5A332CC05E1E4DAD02684985F0F72B68" name="apyx:LeaseAdoption" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d35337e2098-wk-Fact-9F5775762CCB1E91B50A4985F0D83E0E" name="apyx:LeaseAdoption" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">212</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Right-of-use assets capitalized and lease liabilities recognized upon lease remeasurement</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d35337e2120-wk-Fact-E8411A31B4B6BD5A73D84985F0BC8002" name="apyx:CapitalizationOfLeaseNonCash" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d35337e2139-wk-Fact-6A42B812439D45CBFCFF4985F0DE1153" name="apyx:CapitalizationOfLeaseNonCash" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">207</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Right-of-use assets capitalized and lease liabilities recognized upon execution of lease</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d35337e2161-wk-Fact-67500B84031C7D3C2739A69E7B553262" name="apyx:CapitalizationOfLeaseExecution" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">150</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d35337e2180-wk-Fact-5EA92C414819782F93B9A69E7B450CB4" name="apyx:CapitalizationOfLeaseExecution" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Transfer of other assets to fixed assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d35337e2200-wk-Fact-8C22F4C998B857AD14FFA697BF2FC1C3" name="apyx:NonCashTransferOfOtherAssetsToFixedAssets" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d35337e2219-wk-Fact-B3FD07FA5645A7A7F543A697BF41E326" name="apyx:NonCashTransferOfOtherAssetsToFixedAssets" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">42</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Transfer of inventory (to) from fixed assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d35337e2239-wk-Fact-6D8BC42F8555F2DD9E38A698550B4058" name="apyx:NonCashTransfersOfInventoryToFromFixedAssets" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">34</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d35337e2259-wk-Fact-5CF467B2D3555EFF7FF6A6985503F094" name="apyx:NonCashTransfersOfInventoryToFromFixedAssets" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">262</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accompanying notes are an integral part of the consolidated financial statements.</span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">6</span></div></div><hr style="page-break-after:always"></hr><div><a id="sB7616497120C5862851296A219DAFEFA"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sA7A87A31B84252D8947A62684F78F8EC"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">APYX MEDICAL CORPORATION</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</span></div></div><div><br/></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s0BD2108536A55FA39D33B7777F4848D7"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTE 1. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="TextSelection-BFADCCF3E0D79AE241244985F1012DB4-0-wk-Fact-8FB1C4F8F92982D444964985F0E197CE" continuedAt="TextSelection-BFADCCF3E0D79AE241244985F1012DB4-1" escape="true">BASIS OF PRESENTATION</ix:nonNumeric></span></div><ix:continuation id="TextSelection-BFADCCF3E0D79AE241244985F1012DB4-1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unless the context otherwise indicates, the terms  &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us,&#8221; &#8220;Apyx,&#8221; and similar terms refer to Apyx Medical Corporation and its consolidated subsidiaries.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are an advanced energy technology company with a passion for elevating people&#8217;s lives through innovative products in the cosmetic and surgical markets. Known for our innovative Helium Plasma Technology, Apyx is solely focused on bringing transformative solutions to the physicians and patients it serves. Our Helium Plasma Technology is marketed and sold as Renuvion&#174; in the cosmetic surgery market and J-Plasma&#174; in the hospital surgical market. Renuvion&#174; offers plastic surgeons, fascial plastic surgeons and cosmetic physicians a unique ability to provide controlled heat to the tissue to achieve their desired results. The J-Plasma&#174; system allows surgeons to operate with a high level of precision and virtually eliminating unintended tissue trauma. We also leverage our deep expertise and decades of experience in unique waveforms through original equipment manufacturing (OEM) agreements with other medical device manufacturers.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In March 2020, the World Health Organization recognized the novel strain of coronavirus ("COVID-19"), as a pandemic. This pandemic has severely restricted the level of economic activity around the world. In response, the governments of many countries, states, cities and other geographic regions have taken preventative or protective actions, such as imposing restrictions on travel and business operations and advising or requiring individuals to limit or forego their time outside of their homes. The long-term impact of the COVID-19 pandemic on our business continues to be highly uncertain and difficult to predict as the environment created by the pandemic is rapidly changing. Starting in late February, the effects of the pandemic have been material and adverse on our business. While we experienced positive indications in our business late in the second quarter, we continue to expect that the severity of the impact of the COVID-19 pandemic on our business will depend on a number of factors, including, but not limited to, the duration and severity of the pandemic and the extent and severity of the impact on our customers and suppliers, all of which are uncertain and cannot be predicted. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Most of the procedures performed using our Helium Plasma Technology are elective, and as a result many of our customers have been affected by the actions taken by various governmental authorities requiring non-essential businesses to shut down temporarily.   As these shut-downs have begun to be reversed, we have started to see an increase in demand for elective cosmetic and plastic surgery procedures, resulting in higher than expected revenues in our Advanced Energy segment.  In international markets, a greater portion of these procedures are performed in a hospital, and it is less certain when elective procedures will fully return to normal.. While we  started to experience a significant decline in sales towards the end of our first fiscal quarter, we began to see an increase in sales towards the end of our second fiscal quarter as local jurisdictions started to re-open.  However, the full extent to which the COVID-19 pandemic may materially and adversely impact the Company's future financial position, liquidity, or results of operations remains uncertain. While we began to experience an improvement in sales, domestically and internationally, towards the end of our second fiscal quarter, the pace at which this continues into the third quarter and beyond is still highly uncertain.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accompanying unaudited consolidated financial statements have been prepared based upon SEC rules that permit reduced disclosure for interim periods. For a more complete discussion of significant accounting policies and certain other information, please refer to the consolidated financial statements included in our Annual Report on Form 10-K for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">. These consolidated financial statements reflect all adjustments that are necessary for a fair presentation of results of consolidated operations and financial condition for the interim periods shown, including normal recurring accruals and other items. The results for the interim periods are not necessarily indicative of results for the full year.</span></div></ix:continuation><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">7</span></div></div><hr style="page-break-after:always"></hr><div><a id="s37FA63582AC55B1AB730127072E21E21"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sA7A87A31B84252D8947A62684F78F8EC"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">APYX MEDICAL CORPORATION</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTE 2. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:AccountingChangesTextBlock" id="TextSelection-06A2A5F253A192C1E73C4985F10129FE-0-wk-Fact-1E05AB29AC688E0D10494985F0C31EF5" continuedAt="TextSelection-06A2A5F253A192C1E73C4985F10129FE-1" escape="true">CHANGE IN ACCOUNTING POLICY</ix:nonNumeric></span></div><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="TextSelection-3A0A103D5433867674BE4985F1010EF6-0-wk-Fact-FA581FEC39334BA9C6884985F0C5FB1A" escape="true"><ix:continuation id="TextSelection-06A2A5F253A192C1E73C4985F10129FE-1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During 2019, we began granting stock option awards deeper within the organization. We do not have sufficient experience with grants to these employees and we have experienced challenges in developing reliable forfeiture estimates at the grant date. Accounting for revising the forfeiture estimates has been burdensome. Accounting Standards Codification 718, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation-Stock Compensation,</span><span style="font-family:inherit;font-size:10pt;"> prescribes two methods for accounting for forfeitures on stock option awards, either the estimation method utilized by the Company previously, or by accounting for forfeitures as they occur. On January 1, 2020 we made an accounting policy election change and began accounting for forfeitures on stock option awards using actual forfeitures. This accounting policy election change was made on a retrospective basis. However, the changes to the current and prior periods were determined to be immaterial and there have been no changes to previously reported results as a result of the change.</span></div></ix:continuation></ix:nonNumeric><div><a id="s62EB56E29CA0583BB26E613168F9FF8F"></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-weight:bold;">NOTE 3</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:DescriptionOfNewAccountingPronouncementsNotYetAdopted" id="TextSelection-A316CB898EB03E2A8CC04985F1016884-0-wk-Fact-D3610EA111BAFDD2D5C04985F0E23888" continuedAt="TextSelection-A316CB898EB03E2A8CC04985F1016884-1" escape="true">RECENT ACCOUNTING PRONOUNCEMENTS </ix:nonNumeric></span></div><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="TextSelection-499D2644D70F8E90618B4985F101DED7-0-wk-Fact-39A22F58977859F84F6E4985F0E33743" escape="true"><ix:continuation id="TextSelection-A316CB898EB03E2A8CC04985F1016884-1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2016-13, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments&#8212;Credit Losses (Topic 326).</span><span style="font-family:inherit;font-size:10pt;"> The update changes the impairment model for most financial assets and certain other instruments, including trade and other receivables, contract assets, held-to-maturity debt securities and loans, and requires entities to use a new forward-looking expected loss model that will result in the earlier recognition of allowance for losses. This update, as originally issued, was effective for annual and interim periods beginning after December 15, 2019, with early adoption permitted. In November 2019, the FASB issued ASU 2019-10, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) Effective Dates</span><span style="font-family:inherit;font-size:10pt;">, which deferred the effective dates of these standards for Smaller Reporting Companies until fiscal years beginning after December 15, 2022. The Company currently expects to continue to qualify as a Smaller Reporting Company, based upon the current SEC definition, and as a result, will be utilizing the deferred elective date. While we are in the process of determining the effects of the adoption of the standard on the consolidated financial statements,    we do not expect the impact to be material.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2017, the FASB issued ASU 2017-04,</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment</span><span style="font-family:inherit;font-size:10pt;">. The purpose of this ASU is to reduce the cost and complexity of evaluating goodwill for impairment. It eliminates the need for entities to calculate the implied fair value of goodwill by assigning the fair value of a reporting unit to all of its assets and liabilities as if that reporting unit had been acquired in a business combination. Under this ASU, an entity will perform its goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An impairment charge is recognized for the amount by which the carrying value exceeds the reporting unit&#8217;s fair value. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The Company adopted the ASU on January 1, 2020. The amendment did not have an impact on our consolidated financial condition or results of operations.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">No other new accounting pronouncement issued or effective during the fiscal year had or is expected to have a material impact on our consolidated financial statements or disclosures.</span></div></ix:continuation></ix:nonNumeric><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">8</span></div></div><hr style="page-break-after:always"></hr><div><a id="s2BEE62394FFD55DD807A8FE9D48D3AE3"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sA7A87A31B84252D8947A62684F78F8EC"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">APYX MEDICAL CORPORATION</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTE 4. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:InventoryDisclosureTextBlock" id="TextSelection-6DCE98511C840D0861734985F101684D-0-wk-Fact-C1B056981BFABC27D47B4985F0C79565" continuedAt="TextSelection-6DCE98511C840D0861734985F101684D-1" escape="true">INVENTORIES</ix:nonNumeric></span></div><ix:continuation id="TextSelection-6DCE98511C840D0861734985F101684D-1"><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:InventoryPolicyTextBlock" id="TextSelection-634C9313525AAAB8C1AD4985F1025198-0-wk-Fact-C55A14C816B3A62B85E94985F0C423E5" escape="true"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventories are stated at the lower of cost or net realizable values. Cost is determined on a first in, first out basis. Finished goods and work-in-process inventories include material, labor and overhead costs. Factory overhead costs are primarily allocated to inventory manufactured in-house based upon labor hours. </span></div></ix:nonNumeric><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="TextSelection-9B391F5B2632162E3EBA4985F102214F-0-wk-Fact-D9BEC2D3E9BF0880F7794985F0C3EE24" escape="true"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventories consisted of the following:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(In thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">June&#160;30, <br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, <br/>2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Raw materials</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5125e674-wk-Fact-3E2D532645559A8B749C496B24CF37DA" name="us-gaap:InventoryRawMaterials" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,441</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5125e693-wk-Fact-2D2531DAEB08A6687F09496B250D401C" name="us-gaap:InventoryRawMaterials" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,935</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Work in process</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5125e708-wk-Fact-3148CCA5105E5C41C952496B2519E016" name="us-gaap:InventoryWorkInProcess" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,504</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5125e727-wk-Fact-EF5E5ECEC66A0CCE9F73496B250CAFD7" name="us-gaap:InventoryWorkInProcess" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,209</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finished goods </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5125e747-wk-Fact-99AD4120FF17F9564D00496B249F06E3" name="us-gaap:InventoryFinishedGoods" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,997</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5125e766-wk-Fact-E32FC66014417BC83B49496B2511655A" name="us-gaap:InventoryFinishedGoods" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,316</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross inventories</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5125e786-wk-Fact-BBDD3C0A6C1739FA08E7496B250EEA1E" name="us-gaap:InventoryGross" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,942</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5125e805-wk-Fact-C697AFE4BB3E1300AEC2496B25167662" name="us-gaap:InventoryGross" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,460</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: provision for obsolescence</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d5125e825-wk-Fact-02807CDC34044059A489496B250FF04D" name="us-gaap:InventoryValuationReserves" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">685</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d5125e845-wk-Fact-D35541FB151A5643E09C496B2520B6BC" name="us-gaap:InventoryValuationReserves" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">392</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventories, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5125e871-wk-Fact-2A22C0C0830CFBCD3D83496B24B26D14" name="us-gaap:InventoryNet" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,257</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d5125e890-wk-Fact-61A8AEC690F00F8AA7C1496B24A74F60" name="us-gaap:InventoryNet" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,068</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the second fiscal quarter, we reassessed our forecasted product mix due to COVID-19, increased availability of our newer handpiece designs and earlier than expected completion of product registrations in some of our foreign markets.&#160; As a result, certain products were reduced to a lower carrying value, and some components were also written off as it was determined to cease further production on these models. The total associated impairment was approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d5125e906-wk-Fact-B0167297369722F645E9A6A7AA36566B" name="us-gaap:InventoryWriteDown" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">400,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> and is included in cost of sales in the accompanying consolidated statements of income for the three and six months ended June 30, 2020.</span></div></ix:continuation><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s0C16C891CA605B20957D4DF19FC5F2EA"></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTE 5. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="TextSelection-EB858DD275A14525E73B4985F102B137-0-wk-Fact-2F250F983A7F4E08B00F4985F0A74D66" continuedAt="TextSelection-EB858DD275A14525E73B4985F102B137-1" escape="true">ACCRUED EXPENSES AND OTHER CURRENT LIABILTIES</ix:nonNumeric></span></div><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" id="TextSelection-9CADB143DF4F23B35BDE4985F102B83C-0-wk-Fact-1C3A650416C6484B56BF4985F0C28C41" escape="true"><ix:continuation id="TextSelection-EB858DD275A14525E73B4985F102B137-1"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued expenses and other current liabilities consisted of the following:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:94.53125%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:63%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30, </span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued payroll</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d11708e660-wk-Fact-CEA3F133FA7396C3ECDC496B24965466" name="us-gaap:AccruedSalariesCurrent" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">726</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d11708e679-wk-Fact-676442E6E42472D06746496B2499061D" name="us-gaap:AccruedSalariesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">694</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued bonuses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d11708e699-wk-Fact-FE82ADAC8DC47986C1C5496B2497C043" name="us-gaap:AccruedBonusesCurrent" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d11708e718-wk-Fact-C030734946A1502FDAA3496B24982660" name="us-gaap:AccruedBonusesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,306</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued commissions</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d11708e738-wk-Fact-E1C8C595EB9B1F0788A5496B2495E4D2" name="us-gaap:AccruedSalesCommissionCurrent" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">531</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d11708e757-wk-Fact-DE2E48CD7F3755979B1C496B24955F3F" name="us-gaap:AccruedSalesCommissionCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">877</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued product warranties</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d11708e777-wk-Fact-D1AD6D3D4AE276AD13C7496B249653B2" name="us-gaap:ProductWarrantyAccrualClassifiedCurrent" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">439</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d11708e796-wk-Fact-4FA2049B56EFB7D8D8D4496B24980267" name="us-gaap:ProductWarrantyAccrualClassifiedCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">452</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued insurance</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d11708e816-wk-Fact-C896E8311E8F30DD69A2496B2494CEB2" name="us-gaap:AccruedInsuranceCurrent" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">626</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d11708e835-wk-Fact-129AB1E8E66E872C9DF3496B2496389F" name="us-gaap:AccruedInsuranceCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,170</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued professional fees</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d11708e855-wk-Fact-6432DF3C051ED89642D2496B249A1371" name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,043</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d11708e874-wk-Fact-50D2672B8897D23A3330496B249AA869" name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,383</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Joint and several payroll liability</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d11708e894-wk-Fact-5FD0BDC73BD953F25214496B249A882C" name="apyx:JointAndSeveralPayrollLiability" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,045</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d11708e913-wk-Fact-DE469EF781FA15DFB532496B249B7F5B" name="apyx:JointAndSeveralPayrollLiability" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,045</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Uncertain tax positions</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d11708e933-wk-Fact-2FBDD96BC4BF732480C4496B24970049" name="apyx:UncertainTaxPositionsLiability" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,573</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d11708e952-wk-Fact-D9C432933AB0C9ED1E12496B249903B5" name="apyx:UncertainTaxPositionsLiability" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,491</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other accrued expenses and current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d11708e972-wk-Fact-61B2BE49A9F0756F7D26496B249B606D" name="apyx:OtherAccruedExpensesAndLiabilitiesCurrent" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">928</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d11708e991-wk-Fact-84E6A82F917B26447F9F496B2494FE18" name="apyx:OtherAccruedExpensesAndLiabilitiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">978</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total accrued expenses and other current liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d11708e1016-wk-Fact-E97C2C9BB55F7862D582496B24A591F2" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,911</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d11708e1035-wk-Fact-AFAF8A0F159C9EA96842496B24A3652D" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,396</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation></ix:nonNumeric><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">9</span></div></div><hr style="page-break-after:always"></hr><div><a id="s9A433537B25F57749F6C5A6AD5B14CEA"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sA7A87A31B84252D8947A62684F78F8EC"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">APYX MEDICAL CORPORATION</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTE 6. &#160;&#160;&#160;&#160;EARNINGS<ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:EarningsPerShareTextBlock" id="TextSelection-BA7A558EA05BEDDED0214985F10235B3-0-wk-Fact-350D5EE60CC989A81BE24985F0AAE3B1" continuedAt="TextSelection-BA7A558EA05BEDDED0214985F10235B3-1" escape="true"> PER SHARE </ix:nonNumeric></span></div><ix:continuation id="TextSelection-BA7A558EA05BEDDED0214985F10235B3-1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We compute basic earnings per share (&#8220;basic EPS&#8221;) by dividing the net income or loss by the weighted average number of common shares outstanding for the reporting period adjusted for other units required to be included in basic EPS. Diluted earnings per share (&#8220;diluted EPS&#8221;) gives effect to all dilutive potential shares outstanding. As we are in a net loss position for all periods presented, all potential shares outstanding are anti-dilutive. <ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="TextSelection-DB283047A58D84CF12274985F1025E10-0-wk-Fact-5F77F1B8ED671F512D624985F0F37666" continuedAt="TextSelection-DB283047A58D84CF12274985F1025E10-1" escape="true">The following table provides the computation of basic and diluted earnings per share.</ix:nonNumeric></span></div><ix:continuation id="TextSelection-DB283047A58D84CF12274985F1025E10-1"><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:48%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended<br/>June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended<br/>June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in thousands, except per share data)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Numerator:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d12969e896-wk-Fact-397B5F09FC560A26164C4985F0BC0BD5" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">4,690</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d12969e916-wk-Fact-BCBB336E1C78F831CB4A4985F0E0D0DA" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">4,295</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d12969e937-wk-Fact-B864AF01CE96AE141E184985F0DABD1D" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">6,641</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d12969e957-wk-Fact-3FF03CC6BE82BB4D951C4985F0D79FDC" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">9,903</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Denominator:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average shares outstanding - basic and diluted</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12969e1154-wk-Fact-8ACC5EAA838F7814B44B76DF786A24D9" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="FD2020Q2QTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">34,186</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12969e1173-wk-Fact-A8A5B09ECAFC04922F5A76DF787FE435" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="FD2019Q2QTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">33,384</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12969e1192-wk-Fact-F5138C7D331A1C31A94C76DF785CBF13" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="FD2020Q2YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">34,181</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12969e1212-wk-Fact-50FA61C2CF58FA8149114985F0F963EB" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="FD2019Q2YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">33,363</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Earnings (loss) per share:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic and diluted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d12969e1416-wk-Fact-41C4F6CFB4F80DCBFC6E76D0BF67B254" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" contextRef="FD2020Q2QTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.14</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d12969e1436-wk-Fact-C38EA1DCCA208B27473C4985F0BECE0E" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" contextRef="FD2019Q2QTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.13</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d12969e1457-wk-Fact-928250C9526DF248E575496B255746E3" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" contextRef="FD2020Q2YTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.19</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d12969e1477-wk-Fact-EA9116B0A8E4B9421E734985F0DBF793" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" contextRef="FD2019Q2YTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.30</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Anti-dilutive instruments excluded from diluted loss per common share:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Options</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12969e1673-wk-Fact-E628052F60F327AE23294985F0D2DD5C" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2020Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_OptionOnSecuritiesMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">4,986</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12969e1692-wk-Fact-927C9DA5CF5388E49DE54985F0CC053D" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2019Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_OptionOnSecuritiesMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">1,882</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12969e1711-wk-Fact-E41FD632A584A4B64BF04985F0A376E1" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2020Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_OptionOnSecuritiesMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">4,986</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12969e1731-wk-Fact-20FE28BD1DDA0175B7FA4985F0A7954E" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2019Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_OptionOnSecuritiesMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">1,882</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation></ix:continuation><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10</span></div></div><hr style="page-break-after:always"></hr><div><a id="s789680CFCAE4555886FF9DB17CB89D85"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sA7A87A31B84252D8947A62684F78F8EC"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">APYX MEDICAL CORPORATION</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTE 7. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="TextSelection-30B24434A4B89FDC59914985F10205AD-0-wk-Fact-0B68DA5EE73474BEB89A4985F0A4EA30" continuedAt="TextSelection-30B24434A4B89FDC59914985F10205AD-1" escape="true">STOCK-BASED COMPENSATION </ix:nonNumeric></span></div><ix:continuation id="TextSelection-30B24434A4B89FDC59914985F10205AD-1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under our stock option plans, our board of directors may grant restricted stock and options to purchase common shares to our employees, officers, directors and consultants. We account for stock options in accordance with FASB ASC Topic 718, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation - Stock Compensation</span><span style="font-family:inherit;font-size:10pt;">, with stock-based compensation expense amortized over the vesting period based on the fair value on the grant date utilizing a trinomial lattice model through 2018 and the Black Scholes model for grants in 2019 and 2020, both of which include a number of estimates that affect the amount of our expense.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We recognized approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d14117e594-wk-Fact-EE18F3BEDA9343E1C21BC494595ED2D6" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">1,097,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d14117e598-wk-Fact-E1AFAE8CF762AC3A6166C494C3DC05BE" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">2,146,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">, respectively, in stock-based compensation expense during the three and </span><span style="font-family:inherit;font-size:10pt;">six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;">, as compared with </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d14117e606-wk-Fact-B7B9F290640DB342B13DC494870F9ABB" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">856,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d14117e610-wk-Fact-FA66117AF21B2F819EE7C494A70D2692" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">2,051,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">, respectively, for the three and </span><span style="font-family:inherit;font-size:10pt;">six months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="TextSelection-E75E52DD9C5A9D8E1BDF4985F102DFBC-0-wk-Fact-16CEDA277DD61396A46A4985F0F1C608" escape="true"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The status of our stock options are summarized as follows:</span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:73%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Number of options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted average exercise price</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d14117e691-wk-Fact-766EEA3C457DF38363BF4985F0CFCDF5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="FI2019Q4" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">3,966,858</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d14117e710-wk-Fact-B5C7A7DC3BD81C70B1024985F0CE72CE" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="FI2019Q4" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">4.67</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d14117e725-wk-Fact-0B63179B4A9CA7404D174985F0AA6CF0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="FD2020Q2YTD" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1,274,900</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d14117e739-wk-Fact-CF0540108C0AA11387374985F0D483C4" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="FD2020Q2YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">8.18</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercised</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d14117e759-wk-Fact-0CF4DE76482A440041DA4985F0D369F1" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="FD2020Q2YTD" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">44,381</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d14117e774-wk-Fact-D9C80AB1E3F48E10C8724985F0D652D4" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="FD2020Q2YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">3.23</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Canceled and forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d14117e794-wk-Fact-C39E2D8A1922F37C69E84985F0D0C4B5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" contextRef="FD2020Q2YTD" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">211,433</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d14117e809-wk-Fact-EBD70E122D3F036DEC2B4985F0CC7EC5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" contextRef="FD2020Q2YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">7.51</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding at June 30, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d14117e829-wk-Fact-8F0159D8A9C9F6CF038D4985F0CEDD6C" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="FI2020Q2" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">4,985,944</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d14117e848-wk-Fact-38D3971B058B8020210A4985F0A793E9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="FI2020Q2" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">5.46</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We allow stock option holders to exercise stock-based awards by surrendering  stock-based awards with a fair value of the stock-based awards exercised, referred to as net settlements. These surrenders are included in stock options exercised in the options rollforward above. For the three months ended June 30, 2020 and 2019, respectively, we received </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d14117e871-wk-Fact-1C70F173CBFFDE71D92176E57FEA5892" name="apyx:StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived" contextRef="FD2020Q2QTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">11,085</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d14117e875-wk-Fact-D69B6AEEEAE2A68C6DC776E58DCFF4D9" name="apyx:StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived" contextRef="FD2019Q2QTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">7,779</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> options as payment in the exercise of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d14117e879-wk-Fact-CC06F9EE3248C378F58176E68FC69FDF" name="apyx:StockIssuedDuringPeriodSharesStockSwaps" contextRef="FD2020Q2QTD" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">17,665</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d14117e883-wk-Fact-534CEE3E0E4A6C468D9076E69AD661FF" name="apyx:StockIssuedDuringPeriodSharesStockSwaps" contextRef="FD2019Q2QTD" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">17,221</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> options. For the six months ended June 30, 2020 and 2019, respectively, we received  </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d14117e887-wk-Fact-7A40503985C924DA7EE276E6023BB984" name="apyx:StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived" contextRef="FD2020Q2YTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">13,009</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d14117e892-wk-Fact-7ADE1B7E2CB0F492E62F76E60ECA0641" name="apyx:StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived" contextRef="FD2019Q2YTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">91,598</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> options as payment in the exercise of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d14117e896-wk-Fact-DD4FB7E4F9412A03D86776E6DA8FE3DF" name="apyx:StockIssuedDuringPeriodSharesStockSwaps" contextRef="FD2020Q2YTD" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">22,027</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d14117e900-wk-Fact-ADDD66734F1E51D7AF7976E6EDF3F1FF" name="apyx:StockIssuedDuringPeriodSharesStockSwaps" contextRef="FD2019Q2YTD" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">185,951</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> options. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Common shares required to be issued upon the exercise of stock options would be issued from our authorized and unissued shares. <ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="TextSelection-CA8A7C25A9E687D8D2104985F1023248-0-wk-Fact-EE0A3F670C645BB457454985F0EF8ED5" continuedAt="TextSelection-CA8A7C25A9E687D8D2104985F1023248-1" escape="true">We calculated the fair value of issued options utilizing a Black Scholes model with an expected life calculated via the simplified method as we do not have sufficient history to determine actual expected life.</ix:nonNumeric></span></div><ix:continuation id="TextSelection-CA8A7C25A9E687D8D2104985F1023248-1"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:54.97076023391813%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:72%;"></td><td style="width:28%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2020 Grants</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Option value</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d14117e946-wk-Fact-CF0540108C0AA11387374985F0D483C4" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="FD2020Q2YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">8.18</ix:nonFraction></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Risk-free rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d14117e957-wk-Fact-752CB4C8F6AA654C86FE4985F0CFFE91" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="FD2020Q2YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">1.7</ix:nonFraction>%</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected dividend yield</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d14117e968-wk-Fact-D9357CA47A0015AE93E74985F0D0F563" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="FD2020Q2YTD" unitRef="number" decimals="INF" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected volatility</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d14117e979-wk-Fact-008893106CFCB699FAEB4985F0CEF201" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="FD2020Q2YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">65.9</ix:nonFraction>%</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected term (in years)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d14117e990-wk-Fact-FE6E16031DE4FA33D3794985F0C99004" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="FD2020Q2YTD" format="ixt-sec:duryear">6</ix:nonNumeric></span></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation></ix:continuation><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s2E3D9828C1AA540DA156CBCA28DF7BF5"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTE 8. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:IncomeTaxDisclosureTextBlock" id="TextSelection-FF3ECC055B3B35888B864985F1036916-0-wk-Fact-580D5C1682BDCE9A9BA04985F0E48B3A" continuedAt="TextSelection-FF3ECC055B3B35888B864985F1036916-1" escape="true">INCOME TAXES </ix:nonNumeric></span></div><ix:continuation id="TextSelection-FF3ECC055B3B35888B864985F1036916-1" continuedAt="TextSelection-FF3ECC055B3B35888B864985F1036916-2"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On March 27, 2020, the U.S. government enacted the CARES Act to provide relief from COVID-19. The CARES Act includes a provision that allows companies to carryback net operating losses (NOL&#8217;s) generated in the period 2018 through 2020 to prior years. In conjunction with the disposition of the Core business in 2018, we generated a significant amount of taxable income in 2018. Subsequent to this, we generated net losses in 2019 and through the first half of 2020. For the net losses generated in 2019, we previously recorded a valuation allowance on the full value of the deferred tax assets associated with our NOL carryforwards due to realization of the NOL being improbable under then existing tax law. The CARES Act makes these assets realizable, and as of the date of the CARES Act, we have recognized an income tax benefit of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d15041e596-wk-Fact-A379DB924AFF7956090F4985F0DFDCED" name="apyx:CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">3.7</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> associated with the release of the valuation allowance on our Federal NOL carryforward related to 2019. We also recognized income tax benefits of </span></div></ix:continuation><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">11</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sA7A87A31B84252D8947A62684F78F8EC"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">APYX MEDICAL CORPORATION</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><ix:continuation id="TextSelection-FF3ECC055B3B35888B864985F1036916-2" continuedAt="TextSelection-FF3ECC055B3B35888B864985F1036916-3"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d15041e603-wk-Fact-9ED1E11CBE0C09522215C4B866E92F8A" name="apyx:CARESActIncomeTaxExpenseBenefitRelatedToCurrentPeriodNetIncomeLossBeforeIncomeTaxes" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">1.5</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d15041e607-wk-Fact-A675029181F753735F3D76EB6B0E403E" name="apyx:CARESActIncomeTaxExpenseBenefitRelatedToCurrentPeriodNetIncomeLossBeforeIncomeTaxes" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">1.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, related to our net loss before income taxes for the three and six months ended June 30, 2020, respectively. There are approximately an additional </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d15041e611-wk-Fact-8B842872D7F4E086044576EBD88B95E2" name="apyx:CARESActFederalIncomeTaxPaymentsAvailableToOffsetCurrentPeriodLosses" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> of 2018 Federal income tax payments available to offset against any other 2020 losses that may be incurred. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our income tax (benefit) expense was approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$(<ix:nonFraction id="d15041e620-wk-Fact-E9BF97A1F660F7AF17B476D0BF378CF0" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-3" scale="0" sign="-" format="ixt:numdotdecimal">1,492,000</ix:nonFraction>)</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d15041e624-wk-Fact-697A31017246D2D682494985F0AB7C3C" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">76,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> with an effective tax rate of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15041e628-wk-Fact-30D9AC085D01697A372976EDCE634D61" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="FD2020Q2QTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">24.1</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15041e632-wk-Fact-DF4B10EB2EC79FF1E13D76EDF02963C9" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="FD2019Q2QTD" unitRef="number" decimals="3" scale="-2" sign="-" format="ixt:numdotdecimal">1.8</ix:nonFraction>)%</span></span><span style="font-family:inherit;font-size:10pt;"> for the three months ended June 30, 2020 and 2019, respectively.  Our income tax (benefit) expense was approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$(<ix:nonFraction id="d15041e636-wk-Fact-8ECB3F441E3B836BA089496B25395465" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2020Q2YTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember" unitRef="usd" decimals="-3" scale="0" sign="-" format="ixt:numdotdecimal">6,397,000</ix:nonFraction>)</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d15041e641-wk-Fact-281575BA2D8E389065EB4985F0D51761" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">82,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> with an effective tax rate of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15041e645-wk-Fact-656FD7B8908EB50979B876EE8C66D1F1" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="FD2020Q2YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">49.1</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d15041e649-wk-Fact-7DDE18654DF9DC190B5776EE9818CA5A" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="FD2019Q2YTD" unitRef="number" decimals="3" scale="-2" sign="-" format="ixt:numdotdecimal">0.8</ix:nonFraction>)%</span></span><span style="font-family:inherit;font-size:10pt;"> for the six months ended June 30, 2020 and 2019, respectively. The effective rate differs from the statutory rate primarily due to the release of the valuation allowance on our net operating loss carryforward from 2019.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="TextSelection-C7DEDC9EBDE646917BCA4985F1037DCE-0-wk-Fact-8D75C7A491B70FA5C8E74985F0E40315" escape="true"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following is a roll-forward of the Company's total gross unrecognized tax benefits, not including interest and penalties, for the period ended June 30, 2020.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:75.43859649122807%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:63%;"></td><td style="width:1%;"></td><td style="width:35%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross Unrealized Tax Benefits</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at January 1, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15041e710-wk-Fact-D10A81D816CE1EA1DDC94985F0F8F8C8" name="us-gaap:UnrecognizedTaxBenefits" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,313</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additions of tax positions related to the current year</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15041e725-wk-Fact-BCE9DEAED3314334BEAF4985F0ABA01E" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additions of tax positions related to the prior year</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15041e745-wk-Fact-E4FF5D2532FA277115D64985F0A4DF2E" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Decreases for tax positions related to the prior year</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15041e765-wk-Fact-1309016AF2373952DD034985F0A59E16" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at June 30, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d15041e790-wk-Fact-149570C000DE66340C344985F0A7B708" name="us-gaap:UnrecognizedTaxBenefits" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,313</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:continuation><div style="line-height:120%;text-align:justify;font-size:10pt;"><ix:continuation id="TextSelection-FF3ECC055B3B35888B864985F1036916-3" continuedAt="TextSelection-FF3ECC055B3B35888B864985F1036916-4"><span style="font-family:inherit;font-size:10pt;">We recognize accrued interest and penalties related to unrecognized tax benefits in the provision for income taxes in our condensed consolidated financial statements. As of June 30, 2020, we had approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d15041e805-wk-Fact-566BD4B79D36005217C176EFF7C1FD73" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">260,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> in accrued interest and penalties related to unrecognized tax benefits. Included in the income tax benefit for the three months and six ended June 30, 2020, respectively are approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d15041e809-wk-Fact-B3A2534934D1D7DD9C2E76F0571D87FC" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">43,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d15041e813-wk-Fact-DE17255186B40C05F7B376F08ED9C08E" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">82,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> of interest and penalties on the Company's uncertain tax positions. If the Company were to prevail on all uncertain tax positions, the resulting impact will be material as the Company will recognize approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d15041e817-wk-Fact-62BE02B0E7D4EADEF082C497F9DFB2F2" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">1,573,000</ix:nonFraction></span></span></ix:continuation><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-FF3ECC055B3B35888B864985F1036916-4"> of tax benefits in the provision of income taxes. It is expected that all of the uncertain tax positions should be resolved by October 2022.</ix:continuation> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s8C53A56A9381592C94353C4D6D16F3C2"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTE 9. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="TextSelection-533AA3D0E29B30D261E44985F103182E-0-wk-Fact-3DC9E4BAA50E390E63704985F0ED5BFB" continuedAt="TextSelection-533AA3D0E29B30D261E44985F103182E-1" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="TextSelection-533AA3D0E29B30D261E44985F103182E-1" continuedAt="TextSelection-533AA3D0E29B30D261E44985F103182E-2"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Litigation </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The medical device industry is characterized by frequent claims and litigation, and we are and may become subject to various claims, lawsuits and proceedings in the ordinary course of our business. Such claims may include claims by current or former employees, distributors and competitors, claims concerning the marketing and promotion of our products and product liability claims.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are involved in a number of legal actions relating to the use of our Helium Plasma technology. The outcomes of these legal actions are not within our complete control and may not be known for prolonged periods of time. We believe that such claims are adequately covered by insurance; however, in the case of one of our carriers, we are in a dispute regarding the total level of coverage available. Notwithstanding the foregoing, in the opinion of management, the Company has meritorious defenses and such claims are not expected, individually or in the aggregate, to result in a material, adverse effect on our financial condition. However, in the event that damages exceed the aggregate coverage limits of our policies or if our insurance carriers disclaim coverage, we believe it is possible that costs associated with these claims could have a material adverse impact on our consolidated results of operations, financial position or cash flows.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On April 17, 2019, a complaint (the &#8220;Complaint&#8221;) was filed in the United States District Court for the Middle District of Florida, against the Company and Charles D. Goodwin, the Company&#8217;s President and Chief Executive Officer and a member of the Company&#8217;s Board of Directors, alleging certain violations of the Securities Exchange Act of 1934, as amended.&#160; On July 16, 2019, the Court appointed lead plaintiff for the putative class and approved the lead plaintiff&#8217;s selection of counsel. On September 3, 2019, lead plaintiff filed an amended complaint (the &#8220;Amended Complaint&#8221;) with the Court.&#160; </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Amended Complaint seeks class action status on behalf of all persons and entities that acquired the Company&#8217;s securities between December 21, 2018 and April 1, 2019, and alleges violations by the Company and Goodwin of Sections 10(b) and 20(a) </span></div></ix:continuation><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">12</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sA7A87A31B84252D8947A62684F78F8EC"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">APYX MEDICAL CORPORATION</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><ix:continuation id="TextSelection-533AA3D0E29B30D261E44985F103182E-2" continuedAt="TextSelection-533AA3D0E29B30D261E44985F103182E-3"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">of the Securities Exchange Act of 1934, as amended and Rule 10b-5 thereunder, primarily related to certain public statements concerning the Premarket Notification 510(k) submission made to the US Food and Drug Administration for a new indication for the Company&#8217;s J-Plasma&#174; technology for use in dermal resurfacing procedures. &#160;On October 3, 2019, defendants filed a motion to dismiss the Amended Complaint, and on March 11, 2020, the Court denied that motion.&#160; On July 10, 2020, the parties executed a settlement agreement, which is subject to Court approval. The Court preliminarily approved the settlement on July 21, 2020.&#160;The settlement agreement provides for the dismissal of the action with prejudice.&#160;At June 30, 2020,&#160;approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d14031e619-wk-Fact-3FDB21E1BD1FBEC4BE2676F93A5AB122" name="us-gaap:LossContingencyAccrualAtCarryingValue" contextRef="FI2020Q2_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_us-gaap_UnfavorableRegulatoryActionMember" unitRef="usd" decimals="INF" scale="0" format="ixt:numdotdecimal">670,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">&#160;of the&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d14031e623-wk-Fact-FE92429057FF096BEC9176F96995C9C5" name="apyx:LossContingencyAccrualTotalAccruedToDate" contextRef="FI2020Q2_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_us-gaap_UnfavorableRegulatoryActionMember" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">1,000,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> insurance&#160;deductible is unpaid and is included in accrued expenses and other current liabilities in the accompanying consolidated balance sheets. During July 2020, substantially all of the unpaid deductible was paid.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We accrue a liability in our consolidated financial statements for these actions when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is recorded. If a loss is reasonably possible, but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed in the notes to the consolidated financial statements. In most cases, significant judgment is required to estimate the amount and timing of a loss to be recorded, actual results may differ from these estimates.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Purchase Commitments</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;">, we had purchase commitments totaling approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d14031e648-wk-Fact-C2DD7AF88F4CA841C10376FA469A0B27" name="us-gaap:PurchaseObligation" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">500,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> substantially all of which is expected to be purchased within the next six months.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">China Joint Venture</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div style="line-height:120%;font-size:10pt;"><ix:continuation id="TextSelection-533AA3D0E29B30D261E44985F103182E-3" continuedAt="TextSelection-533AA3D0E29B30D261E44985F103182E-4"><span style="font-family:inherit;font-size:10pt;">In late 2019, we executed a joint venture agreement with our Chinese supplier. The agreement requires the Company to make a capital contribution into the newly formed entity of approximately&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d14031e662-wk-Fact-DE42ADD9BBFF995EC90CA6B41E8E34D3" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" contextRef="FI2019Q4_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_CorporateJointVentureMember" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">360,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">. During July 2020, we funded approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d14031e666-wk-Fact-C916F0862D482C850CE6A6BAB1C364CD" name="us-gaap:PaymentsToAcquireInterestInJointVenture" contextRef="D2020Q3July2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_CorporateJointVentureMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">150,000</ix:nonFraction></span></span></ix:continuation><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-533AA3D0E29B30D261E44985F103182E-4"> of the commitment. As of the date of these consolidated financial statements, the joint venture has not commenced principal operations.</ix:continuation> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">13</span></div></div><hr style="page-break-after:always"></hr><div><a id="s9F4E5E0B56C55219931BA7584D171E20"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sA7A87A31B84252D8947A62684F78F8EC"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">APYX MEDICAL CORPORATION</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTE 10. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="TextSelection-B3CCB92EE985A763A5864985F103897B-0-wk-Fact-D33F50D0DAB7A77C022F4985F0E34AF6" continuedAt="TextSelection-B3CCB92EE985A763A5864985F103897B-1" escape="true">RELATED PARTY TRANSACTIONS</ix:nonNumeric></span></div><ix:continuation id="TextSelection-B3CCB92EE985A763A5864985F103897B-1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Several relatives of Nikolay Shilev, Apyx Bulgaria&#8217;s Managing Director, are considered related parties. Teodora Shileva, Mr. Shilev&#8217;s spouse, is an employee of the Company working in the accounting department. Antoaneta Dimitrova Shileva-Toromanova, Mr. Shilev&#8217;s sister, is the Manager of Production and Human Resources. Svetoslav Shilev, Mr. Shilev&#8217;s son, is an engineer in the quality assurance department.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, as part of the purchase of the Bulgaria manufacturing facility, Mr. Shilev was issued a note payable for </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d14503e591-wk-Fact-63CD81000BB91E59BEAE4985F0E3CEE6" name="us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent" contextRef="FI2020Q2_us-gaap_RelatedPartyTransactionAxis_apyx_BulgariaManufacturingPlantPurchaseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">140,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> to be paid </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d14503e595-wk-Fact-378714373A6EF6AD4EBD4985F0EE59CA" name="apyx:TermOfPaymentDueNotesPayableRelatedParties" contextRef="FD2020Q2YTD_us-gaap_RelatedPartyTransactionAxis_apyx_BulgariaManufacturingPlantPurchaseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember" format="ixt-sec:duryear">5</ix:nonNumeric> years</span></span><span style="font-family:inherit;font-size:10pt;"> after the original purchase date, which is in October 2020.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The partner in our China joint venture is also a supplier of the Company. During the six months ended June 30, 2020, we made purchases from this supplier of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d14503e604-wk-Fact-74A156DC4A85BCBA97A6A6C09D975764" name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" contextRef="FD2020Q2YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_CoVenturerMember" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">850,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">. At June 30, 2020, we owed this supplier approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d14503e608-wk-Fact-70687A83995FC3D0E400A6C24FE2D711" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" contextRef="FI2020Q2_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_CoVenturerMember" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">4,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">.</span></div></ix:continuation><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s2B13722F637D58D48809F3208D9EE9E4"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTE 11. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:SegmentReportingDisclosureTextBlock" id="TextSelection-BF9988144F6B6C9877814985F103A391-0-wk-Fact-CBACE21BDCE7DCED14CD4985F0D9D706" continuedAt="TextSelection-BF9988144F6B6C9877814985F103A391-1" escape="true">GEOGRAPHIC AND SEGMENT INFORMATION </ix:nonNumeric></span></div><ix:continuation id="TextSelection-BF9988144F6B6C9877814985F103A391-1" continuedAt="TextSelection-BF9988144F6B6C9877814985F103A391-2"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating segments are aggregated into reportable segments only if they exhibit similar economic characteristics. In addition to similar economic characteristics, we also consider the following factors in determining the reportable segments: the nature of business activities, the management structure directly accountable to our chief operating decision maker for operating and administrative activities, availability of discrete financial information and information presented to the Board of Directors and investors. Asset information is not reviewed by the chief operating decision maker by segment and is not available by segment, accordingly, we have not presented a measure of assets by segment.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our reportable segments are disclosed as principally organized and managed as&#160;</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d28910e590-wk-Fact-2A098727C94D24775FD54985F0D17D08" name="us-gaap:NumberOfOperatingSegments" contextRef="FD2020Q2YTD" unitRef="segment" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">&#160;operating segments: Advanced Energy and OEM. "Corporate &amp; Other" includes certain unallocated corporate and administrative costs which were not specifically attributed to any reportable segment. The OEM segment is primarily development and manufacturing contract and product driven, all related expenses are recorded as cost of sales, therefore no segment specific operating expenses are incurred.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">14</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sA7A87A31B84252D8947A62684F78F8EC"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">APYX MEDICAL CORPORATION</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="TextSelection-B6D717FCD3B9498AA2784985F1034A94-0-wk-Fact-C02EF561DD8CB4CE10AB4985F0CF9456" continuedAt="TextSelection-B6D717FCD3B9498AA2784985F1034A94-1" escape="true"><ix:continuation id="TextSelection-BF9988144F6B6C9877814985F103A391-2" continuedAt="TextSelection-BF9988144F6B6C9877814985F103A391-3"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Summarized financial information with respect to reportable segments is as follows:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended June 30, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(In thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Advanced Energy</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">OEM</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Corporate &amp; Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d28910e807-wk-Fact-7519FBCB2DED681281A576FF7F680E99" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_AdvancedEnergyMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,867</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d28910e826-wk-Fact-F7831D26858FE62D1AC476FF81DA703E" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_OEMMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,429</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d28910e845-wk-Fact-5DD55B3BD4CEBD5B84A076FF8445DA6E" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d28910e865-wk-Fact-F2B9353892A9BBCB558E4985F0BD4A4E" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,296</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income (loss) from operations<br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d28910e962-wk-Fact-01771EC32019CF0D4CF64985F0EF9FFB" name="us-gaap:OperatingIncomeLoss" contextRef="FD2020Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_AdvancedEnergyMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">3,292</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d28910e982-wk-Fact-2F1DCC6317DDADE215CA76FFB7946DF9" name="us-gaap:OperatingIncomeLoss" contextRef="FD2020Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_OEMMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">584</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d28910e1001-wk-Fact-358A757489759927403876FFBA2B1801" name="us-gaap:OperatingIncomeLoss" contextRef="FD2020Q2QTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">3,459</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d28910e1022-wk-Fact-6E4681D333F9B4FEF1B34985F0B9BDC1" name="us-gaap:OperatingIncomeLoss" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">6,167</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest income</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d28910e1125-wk-Fact-8CFAFC52F132346BB79676FFDDCE6E62" name="us-gaap:InterestIncomeOperating" contextRef="FD2020Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_AdvancedEnergyMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d28910e1144-wk-Fact-B4C59B639A145C31ACEC76FFE0658ED6" name="us-gaap:InterestIncomeOperating" contextRef="FD2020Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_OEMMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d28910e1163-wk-Fact-A0717C0DE726A0402E1E4985F0C643DE" name="us-gaap:InterestIncomeOperating" contextRef="FD2020Q2QTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d28910e1183-wk-Fact-C227DBBE6CA87150FAD476D0BF5F3509" name="us-gaap:InterestIncomeOperating" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d28910e1203-wk-Fact-3FC0411C46D8C7DDF3107700722CFDA3" name="us-gaap:InterestExpense" contextRef="FD2020Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_AdvancedEnergyMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d28910e1222-wk-Fact-75554FA9137DF367D113770074C542EB" name="us-gaap:InterestExpense" contextRef="FD2020Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_OEMMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d28910e1241-wk-Fact-9321CA8176C640E83270770077404CB0" name="us-gaap:InterestExpense" contextRef="FD2020Q2QTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d28910e1262-wk-Fact-4935FB2E9F22EBA81F8376D0BF5C4BBA" name="us-gaap:InterestExpense" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other losses, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d28910e1283-wk-Fact-2255372453A307ABBE7577000340DF1B" name="us-gaap:OtherOperatingIncomeExpenseNet" contextRef="FD2020Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_AdvancedEnergyMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d28910e1302-wk-Fact-A2BDC8C75A2EB61DEE1F770005813029" name="us-gaap:OtherOperatingIncomeExpenseNet" contextRef="FD2020Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_OEMMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d28910e1321-wk-Fact-A088AA4D9C2335EDFBB64985F0D8EE3B" name="us-gaap:OtherOperatingIncomeExpenseNet" contextRef="FD2020Q2QTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">14</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d28910e1342-wk-Fact-828CD9B42DC1F8EFA72276D0BF3B49AF" name="us-gaap:OtherOperatingIncomeExpenseNet" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">14</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax benefit<br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d28910e1363-wk-Fact-5F333A32AF647FE0B9F2770036A7DC62" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2020Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_AdvancedEnergyMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d28910e1382-wk-Fact-67F9C3EE4C7C91B0ED927700391278E7" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2020Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_OEMMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d28910e1401-wk-Fact-DAE407B701FC8E167C134985F0ADA564" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2020Q2QTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,492</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d28910e1422-wk-Fact-E9BF97A1F660F7AF17B476D0BF378CF0" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,492</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended June 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(In thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Advanced Energy</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">OEM</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Corporate &amp; Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d28910e1637-wk-Fact-DFF395C9D97921FF84B076FE45E9EA82" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_AdvancedEnergyMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,350</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d28910e1656-wk-Fact-B16372DC5FE1DCAAEAC576FE499E3FAE" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_OEMMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,299</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d28910e1675-wk-Fact-BDB53711C3A7D637DCDA76FE4D140863" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d28910e1695-wk-Fact-C4195FF56DAD7F05326E76D0BF59C9A4" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,649</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income (loss) from operations<br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d28910e1792-wk-Fact-D72CD5490897D81688A276FE7F269069" name="us-gaap:OperatingIncomeLoss" contextRef="FD2019Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_AdvancedEnergyMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">968</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d28910e1812-wk-Fact-93F908F676EC020F4D9E76FE82DB6378" name="us-gaap:OperatingIncomeLoss" contextRef="FD2019Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_OEMMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">136</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d28910e1831-wk-Fact-C1895E6BA780B07DC74A76FE86A24E37" name="us-gaap:OperatingIncomeLoss" contextRef="FD2019Q2QTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">3,590</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d28910e1852-wk-Fact-AC7AD5EC8AB2905C951C76D0BF2A7387" name="us-gaap:OperatingIncomeLoss" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">4,422</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest income</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d28910e1955-wk-Fact-FECF995361E45CDAC81C76FEA9143826" name="us-gaap:InterestIncomeOperating" contextRef="FD2019Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_AdvancedEnergyMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d28910e1974-wk-Fact-50D501577F093A5DA80D76FEADD9DA18" name="us-gaap:InterestIncomeOperating" contextRef="FD2019Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_OEMMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d28910e1993-wk-Fact-45FA6D22069933984C0676FEB168959E" name="us-gaap:InterestIncomeOperating" contextRef="FD2019Q2QTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">403</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d28910e2013-wk-Fact-3B8FD60B29B0E0A1762F4985F0F80D00" name="us-gaap:InterestIncomeOperating" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">403</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other losses, net</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d28910e2033-wk-Fact-75375603BE1BF9AD854876FEFD374613" name="us-gaap:OtherOperatingIncomeExpenseNet" contextRef="FD2019Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_AdvancedEnergyMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d28910e2052-wk-Fact-E256B4DA4999E7D2E48376FF010FE4E7" name="us-gaap:OtherOperatingIncomeExpenseNet" contextRef="FD2019Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_OEMMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d28910e2071-wk-Fact-9D9F767282B88E76243676FF049FDEBA" name="us-gaap:OtherOperatingIncomeExpenseNet" contextRef="FD2019Q2QTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">200</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d28910e2092-wk-Fact-397B5DCDE56513731F094985F0C6DCEF" name="us-gaap:OtherOperatingIncomeExpenseNet" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">200</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax expense<br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d28910e2113-wk-Fact-4A71523D0B490544AB3976FF307B1D3D" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2019Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_AdvancedEnergyMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d28910e2132-wk-Fact-A9CDAC4DC7947C9130E376FF33F6839B" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2019Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_OEMMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d28910e2151-wk-Fact-0A9919C09E552445DA5676FF37BF6719" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2019Q2QTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">76</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d28910e2171-wk-Fact-697A31017246D2D682494985F0AB7C3C" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">76</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended June 30, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(In thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Advanced Energy</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">OEM</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Corporate &amp; Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d28910e2386-wk-Fact-90AE8793C9648BCE5B214985F0B89FE9" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_AdvancedEnergyMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,853</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d28910e2405-wk-Fact-2138248AEA74FBF678964985F0B5BA9D" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_OEMMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,440</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d28910e2424-wk-Fact-0A893C5EC4211E2BF5234985F0B0D2C6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d28910e2444-wk-Fact-9BDD69852F22B2CE28FC496B254AFE05" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,293</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income (loss) from operations</span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d28910e2543-wk-Fact-FAFCFFB24DF51871B4EA496B247A9CEE" name="us-gaap:OperatingIncomeLoss" contextRef="FD2020Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_AdvancedEnergyMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">7,276</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d28910e2563-wk-Fact-D385D8B685CA7F794D534985F0AD87C2" name="us-gaap:OperatingIncomeLoss" contextRef="FD2020Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_OEMMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">831</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d28910e2582-wk-Fact-69A7A9F22EBDFD910EFA4985F0F1183E" name="us-gaap:OperatingIncomeLoss" contextRef="FD2020Q2YTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">7,214</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d28910e2603-wk-Fact-5D65487F5B78F2E9304B496B254717EF" name="us-gaap:OperatingIncomeLoss" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">13,659</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest income</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d28910e2706-wk-Fact-FE6A090190793B291D054985F0EE2948" name="us-gaap:InterestIncomeOperating" contextRef="FD2020Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_AdvancedEnergyMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d28910e2725-wk-Fact-CCE27D3C8B11326B83F94985F0ACB9EE" name="us-gaap:InterestIncomeOperating" contextRef="FD2020Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_OEMMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d28910e2744-wk-Fact-BAE3D30E79D66CD1187F4985F0DDAB85" name="us-gaap:InterestIncomeOperating" contextRef="FD2020Q2YTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">223</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d28910e2764-wk-Fact-E215DB812850C07E3CFAD6178E5F048A" name="us-gaap:InterestIncomeOperating" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">223</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d28910e2784-wk-Fact-EFBCB7C99EE31D8F567F4985F0ED60FD" name="us-gaap:InterestExpense" contextRef="FD2020Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_AdvancedEnergyMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d28910e2803-wk-Fact-471C69656F243EB2C8704985F0AB5A70" name="us-gaap:InterestExpense" contextRef="FD2020Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_OEMMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d28910e2822-wk-Fact-541B7BA16260DDAD3AE8496B248160E4" name="us-gaap:InterestExpense" contextRef="FD2020Q2YTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">14</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d28910e2843-wk-Fact-90E780016EE019A9EA93D6178E6C3B5B" name="us-gaap:InterestExpense" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">14</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other income, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d28910e2864-wk-Fact-F7186E311A061171670D4985F0AE8C04" name="us-gaap:OtherOperatingIncomeExpenseNet" contextRef="FD2020Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_AdvancedEnergyMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d28910e2883-wk-Fact-56D3BADAB9BA2A4D63AE4985F0A958B4" name="us-gaap:OtherOperatingIncomeExpenseNet" contextRef="FD2020Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_OEMMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d28910e2902-wk-Fact-2CAF6360AB83B1F67901496B24F94508" name="us-gaap:OtherOperatingIncomeExpenseNet" contextRef="FD2020Q2YTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">412</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d28910e2922-wk-Fact-385DF51A61546F8417FCD6178E54A764" name="us-gaap:OtherOperatingIncomeExpenseNet" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">412</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax benefit</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d28910e2944-wk-Fact-605FD041AFE678778DDD4985F0F284CB" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2020Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_AdvancedEnergyMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d28910e2963-wk-Fact-48EAEB4B9D76D933914B4985F0EF35C3" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2020Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_OEMMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d28910e2982-wk-Fact-8ECB3F441E3B836BA089496B25395465" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2020Q2YTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">6,397</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d28910e3003-wk-Fact-D787ABABBBA24B299E50C92CFBFFA215" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">6,397</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation></ix:nonNumeric><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">15</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sA7A87A31B84252D8947A62684F78F8EC"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">APYX MEDICAL CORPORATION</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><ix:continuation id="TextSelection-B6D717FCD3B9498AA2784985F1034A94-1"><ix:continuation id="TextSelection-BF9988144F6B6C9877814985F103A391-3" continuedAt="TextSelection-BF9988144F6B6C9877814985F103A391-4"><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended June 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(In thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Advanced Energy</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">OEM</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Corporate &amp; Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d28910e3224-wk-Fact-CF44D983D6F51B1755564985F0A8AF1D" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_AdvancedEnergyMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,721</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d28910e3243-wk-Fact-C90F2EB637B4E9067DFB4985F0A474B6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_OEMMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,557</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d28910e3262-wk-Fact-FB4BF43C049DFA6623AF4985F0BF995D" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d28910e3282-wk-Fact-D8E04E1C126201AA5E924985F0D415DA" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12,278</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income (loss) from operations<br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d28910e3379-wk-Fact-F002544E81C2B3B6C3914985F0ACDCD1" name="us-gaap:OperatingIncomeLoss" contextRef="FD2019Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_AdvancedEnergyMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">4,296</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d28910e3399-wk-Fact-1521BB33CA335ED0149D4985F0AF6705" name="us-gaap:OperatingIncomeLoss" contextRef="FD2019Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_OEMMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">727</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d28910e3418-wk-Fact-F4DB9144B623547AD8BA4985F0BFA746" name="us-gaap:OperatingIncomeLoss" contextRef="FD2019Q2YTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">6,583</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d28910e3439-wk-Fact-7E20E27051E14A0D6F134985F0DA82C9" name="us-gaap:OperatingIncomeLoss" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">10,152</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest income</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d28910e3542-wk-Fact-6590C10A74EDBE35B1984985F0AAC649" name="us-gaap:InterestIncomeOperating" contextRef="FD2019Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_AdvancedEnergyMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d28910e3561-wk-Fact-264AA624159BA6C06AB04985F0C45E3A" name="us-gaap:InterestIncomeOperating" contextRef="FD2019Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_OEMMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d28910e3580-wk-Fact-CDF1BC73E94640511E7E4985F0BA9AE2" name="us-gaap:InterestIncomeOperating" contextRef="FD2019Q2YTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">826</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d28910e3600-wk-Fact-6FCD05FE238ECD6069284985F0D3ADDC" name="us-gaap:InterestIncomeOperating" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">826</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other losses, net</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d28910e3620-wk-Fact-8ECC999CD8F08AB4B1CC4985F0AFF543" name="us-gaap:OtherOperatingIncomeExpenseNet" contextRef="FD2019Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_AdvancedEnergyMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d28910e3639-wk-Fact-50B3C3E6D36A8B746C3F4985F0BCAE5E" name="us-gaap:OtherOperatingIncomeExpenseNet" contextRef="FD2019Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_OEMMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d28910e3658-wk-Fact-848E7FC85E1472F505E14985F0BE7857" name="us-gaap:OtherOperatingIncomeExpenseNet" contextRef="FD2019Q2YTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">495</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d28910e3679-wk-Fact-D2C45063AEB20A37404A4985F0F80DE7" name="us-gaap:OtherOperatingIncomeExpenseNet" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">495</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax expense</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d28910e3702-wk-Fact-7521982DBCFC17E8AB084985F0B735D8" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2019Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_AdvancedEnergyMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d28910e3721-wk-Fact-1E471E616082E88D83FA4985F0A62198" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2019Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_OEMMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d28910e3740-wk-Fact-63D1A137F55D80F5E2F74985F0E42D74" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2019Q2YTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">82</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d28910e3760-wk-Fact-281575BA2D8E389065EB4985F0D51761" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">82</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation></ix:continuation><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">16</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sA7A87A31B84252D8947A62684F78F8EC"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">APYX MEDICAL CORPORATION</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><ix:continuation id="TextSelection-BF9988144F6B6C9877814985F103A391-4"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">International sales represented approximately </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d28910e3793-wk-Fact-8C7E4F3B0801D2C5111A7702A3ADE38C" name="apyx:TotalRevenuePercent" contextRef="FD2020Q2QTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">21.0</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d28910e3797-wk-Fact-A0542E7839F890163FEE4985F0D1E264" name="apyx:TotalRevenuePercent" contextRef="FD2020Q2YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">24.6</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of total revenues for the three and six months ended June 30, 2020, respectively, as compared with </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d28910e3801-wk-Fact-9C1CB00C7D6D681D966B7702B0746EF4" name="apyx:TotalRevenuePercent" contextRef="FD2019Q2QTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">31.7</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d28910e3805-wk-Fact-93DF199A4285ED200C354985F0D13ED2" name="apyx:TotalRevenuePercent" contextRef="FD2019Q2YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">31.2</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of total revenues for the same prior year period. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Substantially all of these sales are denominated in U.S. dollars. <ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" id="TextSelection-9FC547D087F611E1BC484985F103B558-0-wk-Fact-05C73EA0CA4912EC4CE84985F0CEB241" continuedAt="TextSelection-9FC547D087F611E1BC484985F103B558-1" escape="true">Revenue by geographic region, based on the customer's &#8220;ship to&#8221; location on the invoice, are as follows:</ix:nonNumeric></span></div><ix:continuation id="TextSelection-9FC547D087F611E1BC484985F103B558-1"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended<br/>June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended<br/>June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(In thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Sales by Domestic and International</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Domestic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d28910e4101-wk-Fact-E41056F015EF0B1880134985F0EE8203" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,393</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d28910e4120-wk-Fact-5EA6A6F45969B745DBF84985F0EE5B3B" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,540</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d28910e4139-wk-Fact-4BF5AF72493A878B81C94985F0D361DE" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,011</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d28910e4159-wk-Fact-4AAC858E92EBC74221724985F0E6FBB1" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,450</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">International</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d28910e4174-wk-Fact-F31E009617DA147503DB4985F0EEDAE0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">903</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d28910e4193-wk-Fact-81BBCCE0FFF736295B6F4985F0E20313" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,109</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d28910e4212-wk-Fact-F3EA3792C71B4BBD16044985F0E436D6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,282</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d28910e4232-wk-Fact-71B5395672850F23CADF4985F0A9EFD6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_StatementGeographicalAxis_us-gaap_NonUsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,828</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d28910e4257-wk-Fact-F2B9353892A9BBCB558E4985F0BD4A4E" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,296</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d28910e4276-wk-Fact-C4195FF56DAD7F05326E76D0BF59C9A4" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,649</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d28910e4295-wk-Fact-9BDD69852F22B2CE28FC496B254AFE05" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,293</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d28910e4315-wk-Fact-D8E04E1C126201AA5E924985F0D415DA" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12,278</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation></ix:continuation><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">17</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sA7A87A31B84252D8947A62684F78F8EC"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">APYX MEDICAL CORPORATION</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s79E011603C6C5FF4BE87BBAED45DB4F3"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 2</span><span style="font-family:inherit;font-size:10pt;">. </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">You should read the following discussion and analysis in conjunction with our financial statements and related notes contained elsewhere in this report. This discussion contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of a variety of factors discussed in this report and those discussed in other documents we file with the SEC. In light of these risks, uncertainties and assumptions, readers are cautioned not to place undue reliance on such forward-looking statements. These forward-looking statements represent beliefs and assumptions as of the date of this report. While we may elect to update forward-looking statements and at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change. Past performance does not guarantee future results.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Executive Level Overview</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are an advanced energy technology company with a passion for elevating people&#8217;s lives through innovative products in the cosmetic and surgical markets. Known for our innovative Helium Plasma Technology, Apyx is solely focused on bringing transformative solutions to the physicians and patients it serves. Our Helium Plasma Technology is marketed and sold as Renuvion&#174; in the cosmetic surgery market and J-Plasma&#174; in the hospital surgical market. Renuvion&#174; offers plastic surgeons, fascial plastic surgeons and cosmetic physicians a unique ability to provide controlled heat to the tissue to achieve their desired results. The J-Plasma&#174; system allows surgeons to operate with a high level of precision and virtually eliminating unintended tissue trauma. We also leverage our deep expertise and decades of experience in unique waveforms through original equipment manufacturing (OEM) agreements with other medical device manufacturers.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As discussed in our Annual Report on Form 10-K for the year ended December 31, 2019, an outbreak of a novel strain of the coronavirus, COVID-19, was identified in China and has subsequently been recognized as a pandemic by the World Health Organization. The COVID-19 outbreak has severely restricted the level of economic activity around the world. In response to the COVID-19 outbreak the governments of many countries, states, cities and other geographic regions have taken preventative or protective actions, such as imposing restrictions on travel and business operations and advising or requiring individuals to limit or forego their time outside of their homes. Temporary closures of businesses have been ordered and numerous other businesses have temporarily closed voluntarily. As of the date of this filing, there are strong indications that these actions are beginning to subside as governmental bodies begin to loosen restrictions. However, given the variability in measures taken, the uncertainty among any potential resurgence of COVID-19, and patients willingness to undergo elective procedures, the related financial impact cannot be reasonably estimated at this time. As a result, there could continue to be significant adverse impacts to the results of our operations  into the third fiscal quarter and possibly beyond. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prior to the spread of COVID-19 into the US and international markets, we experienced positive year-over-year growth trends in the sale of our capital and disposable products, indicating increased utilization of our technology. Beginning in late February we began to see declines in the sale of our Helium Plasma Technology in European markets. These declines continued and also spread to the North and Latin American markets in March. Towards the end of the second quarter, we began to see improved demand for our products, primarily in the US market, however the extent of this improvement remains uncertain. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We source the components used in our products from a variety of suppliers and we have collaborative arrangements with three key foreign suppliers. At this time our suppliers have experienced no significant disruptions as a result of COVID-19. We have experienced minor delays in our procurement from these suppliers as a result of the availability of shipping from third party freight carriers. These delays have not, to date, had a significant impact on our  operations. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In response to COVID-19, we have taken action in these key areas:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Protecting the Health and Safety of our Employees: To reduce the risk to our employees and their families to potential </span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">exposure to COVID-19, we have required that all non-essential employees work remotely until further notice. We have also split the shifts of our manufacturing personnel to allow for adequate social distancing, and require all personnel to utilize personal protective equipment while on site at our facilities. We have also significantly reduced business travel and access to our facilities. </span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Maintaining Engagement of or Sales Team and Our Customers:  In addition to the initiatives we have put in place to protect health and safety for all employees, we have focused our direct sales team on remaining in close contact with their existing surgeon customers to do everything they can to provide them with support during this difficult time. With </span></div></td></tr></table><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">18</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sA7A87A31B84252D8947A62684F78F8EC"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">APYX MEDICAL CORPORATION</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">MANAGEMENT'S DISCUSSION AND ANAYLSIS OF</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">FINANCIAL CONDITION AND RESULTS OF OPERATIONS - Continued</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-left:48px;text-align:justify;"><span style="font-family:inherit;font-size:10pt;">this goal in mind, we have implemented additional training for our sales reps in order to sharpen their ability to engage with our customers virtually. In addition to engaging with existing customers via virtual methods, our reps also continue to target and reach out to prospective accounts so that they will be well-positioned when the recovery occurs and surgeons return to conducting elective cosmetic procedures. Outside the U.S., we are closely monitoring the activities of our distributor partners and helping them navigate the challenges they face as a result of the slower demand they are seeing in their respective countries.</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating Expenses: We continue to take preemptive steps to curtail spending, including implementing hiring restrictions, </span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">reducing most discretionary spending, reducing capital expenditures, and delaying certain R&amp;D projects and clinical research studies. </span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Governmental Policy: On March 27, 2020, the U.S. government enacted the CARES Act to provide relief from COVID-19. We continue to take advantage of certain provisions of the CARES Act which are applicable to us including utilizing NOL carryback provisions and the deferral of payroll taxes. We expect that utilizing these provisions will significantly help mitigate the working capital impact COVID-19 has had on our sales and operations. </span></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During 2020, we continue to drive sales in our Advanced Energy business by increasing the adoption and utilization of our generators and handpieces in the U.S. cosmetic surgery market and fulfilling demand from distributors in our international markets. Management estimates that our products have been sold in more than 50 countries. As of June 30, 2020, we had a direct sales force of 31 field-based selling professionals and a network of 4 independent sales agencies, led by 5 sales managers. This selling organization is focused on the use of Renuvion&#174; in the cosmetic surgery market. In addition, we have invested in training programs and marketing-related activities to support accelerated adoption of Renuvion&#174;.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the first two months of 2020, our plans to host new Physician Mentor Programs, or &#8220;PMPs,&#8221; and expand our presence and educational programming at industry conferences and trade shows proceeded as expected. Our events planned for March, however, were canceled due to COVID-19. In lieu of this in-person programming, our sales, marketing and field clinical teams have been very active in engaging with our customers - and prospects - around the world. We have hosted educational events virtually where we featured some of our leading clinician customers speaking on a wide range of topics, including side-by-side results comparing Renuvion&#174; to a leading competitor technology. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our virtual educational events have also included case studies to illustrate how our leading clinician customers have adopted Renuvion&#174;, their strategies for marketing and selling to new patients, and their thoughts on pricing and return on investment. We recently hosted the first installment of a planned series of webinars designed to assist our customers and prospects with opening their practices post-COVID 19.   We also engaged with clinician customers outside the U.S. including hosting multiple continuing education training sessions on J-Plasma&#174; and Renuvion&#174; with our current international distributors and conducting multiple calls with groups of international prospects interested in learning about our Renuvion&#174; technology.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating segments are aggregated into reportable segments only if they exhibit similar economic characteristics. In addition to similar economic characteristics, we also consider the following factors in determining the reportable segments: the nature of business activities, the management structure directly accountable to our chief operating decision maker for operating and administrative activities, availability of discrete financial information and information presented to the Board of Directors and investors. Asset information is not reviewed by the chief operating decision maker by segment and is not available by segment, accordingly, we have not presented a measure of assets by segment.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our reportable segments are disclosed as principally organized and managed as&#160;two&#160;operating segments: Advanced Energy and OEM. "Corporate &amp; Other" includes certain unallocated corporate and administrative costs which were not specifically attributed to any reportable segment. The OEM segment is primarily development and manufacturing contract and product driven, all related expenses are recorded as cost of sales, therefore no segment specific operating expenses are incurred.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We strongly encourage investors to visit our website: </span><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">www.apyxmedical.com</span><span style="font-family:inherit;font-size:10pt;">&#160;to view the most current news and to review our filings with the Securities and Exchange Commission.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Results of Operations</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Sales</span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">19</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sA7A87A31B84252D8947A62684F78F8EC"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">APYX MEDICAL CORPORATION</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">MANAGEMENT'S DISCUSSION AND ANAYLSIS OF</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">FINANCIAL CONDITION AND RESULTS OF OPERATIONS - Continued</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="22"></td></tr><tr><td style="width:29%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended<br/>June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended<br/>June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(In thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Change</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Change</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Sales by Reportable Segment</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Advanced Energy</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2,867</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5,350</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(46.4</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">6,853</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">9,721</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(29.5</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">OEM</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,429</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,299</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.0</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2,440</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2,557</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(4.6</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4,296</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">6,649</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(35.4</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">9,293</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">12,278</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(24.3</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;color:#cceeff;">(632,000)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Sales by Domestic and International</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Domestic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3,393</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4,540</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(25.3</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">7,011</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">8,450</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(17.0</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">International</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">903</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2,109</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(57.2</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2,282</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3,828</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(40.4</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4,296</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">6,649</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(35.4</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">9,293</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">12,278</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(24.3</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total revenue decreased by </span><span style="font-family:inherit;font-size:10pt;">(35.4)%</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">(24.3)%</span><span style="font-family:inherit;font-size:10pt;">, or approximately </span><span style="font-family:inherit;font-size:10pt;">$(2.4) million</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">$(3.0) million</span><span style="font-family:inherit;font-size:10pt;">, for the three and six months ended June 30, 2020 when compared with the three and six months ended June 30, 2019. Advanced Energy segment sales decreased </span><span style="font-family:inherit;font-size:10pt;">(46.4)%</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">(29.5)%</span><span style="font-family:inherit;font-size:10pt;">, or approximately </span><span style="font-family:inherit;font-size:10pt;">$(2.5) million</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">$(2.9) million</span><span style="font-family:inherit;font-size:10pt;">, for the three and six months ended June 30, 2020 when compared with the three and six months ended June 30, 2019. The impact of COVID-19 resulted in decreased demand for our products, both domestically and internationally in the first half of 2020 as many of our customers' businesses were ordered closed and numerous others temporarily closed voluntarily. Sales began to recover late in the second quarter as many of our customers resumed operations in a limited capacity.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">International sales represented approximately </span><span style="font-family:inherit;font-size:10pt;">21.0%</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">24.6%</span><span style="font-family:inherit;font-size:10pt;"> of total revenues for the three and six months ended June 30, 2020, respectively, as compared with </span><span style="font-family:inherit;font-size:10pt;">31.7%</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">31.2%</span><span style="font-family:inherit;font-size:10pt;"> of total revenues for the same prior year period.  Management estimates our products have been sold in more than 50 countries through local dealers coordinated by sales and marketing personnel through our facilities in Clearwater, Florida and Sofia, Bulgaria.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Gross Profit</span></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="22"></td></tr><tr><td style="width:29%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended<br/>June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended<br/>June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(In thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Change</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Change</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of sales</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2,202</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,975</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">11.5</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4,215</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4,041</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4.3</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Percentage of sales</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">51.3</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">29.7</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">45.4</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">32.9</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="22"></td></tr><tr><td style="width:29%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross profit</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2,094</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4,674</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(55.2</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5,078</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">8,237</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(38.4</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Percentage of sales</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">48.7</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">70.3</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">54.6</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">67.1</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(12.5</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;padding-top:4px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross profit for the three months ended June 30, </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;">, decreased </span><span style="font-family:inherit;font-size:10pt;">(55.2)%</span><span style="font-family:inherit;font-size:10pt;"> year-over-year, to </span><span style="font-family:inherit;font-size:10pt;">$2.1 million</span><span style="font-family:inherit;font-size:10pt;">, compared to </span><span style="font-family:inherit;font-size:10pt;">$4.7 million</span><span style="font-family:inherit;font-size:10pt;"> in the prior year. Gross margin for the three months ended June 30, </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;">, was </span><span style="font-family:inherit;font-size:10pt;">48.7%</span><span style="font-family:inherit;font-size:10pt;">, compared to </span><span style="font-family:inherit;font-size:10pt;">70.3%</span><span style="font-family:inherit;font-size:10pt;"> for the same period in 2019. Gross profit for the six months ended June 30, </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;">, decreased </span><span style="font-family:inherit;font-size:10pt;">(38.4)%</span><span style="font-family:inherit;font-size:10pt;"> year-over-year, to </span><span style="font-family:inherit;font-size:10pt;">$5.1 million</span><span style="font-family:inherit;font-size:10pt;">, compared to </span><span style="font-family:inherit;font-size:10pt;">$8.2 million</span><span style="font-family:inherit;font-size:10pt;"> in the prior year. Gross margin for the six months ended June 30, </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;">, was </span><span style="font-family:inherit;font-size:10pt;">54.6%</span><span style="font-family:inherit;font-size:10pt;">, compared to </span><span style="font-family:inherit;font-size:10pt;">67.1%</span><span style="font-family:inherit;font-size:10pt;"> for the same period in 2019. </span></div><div style="line-height:120%;padding-bottom:4px;padding-top:4px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;padding-top:4px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the second fiscal quarter, we reassessed our forecasted product mix due to COVID-19, increased availability of our newer handpiece designs, and earlier than expected completion of product registrations in some of our foreign markets.&#160; As a result, certain products were reduced to a lower carrying value, and some components were also written off as it was determined to cease further production on these models. This resulted in a decrease in gross profit of approximately $0.4 million during the three and six months ended June 30, 2020. The remaining change in gross profit margins is driven by product mix within both our Advanced Energy and OEM segments, revenue mix between our segments, geographical revenue mix, and improved product margins in our Advanced Energy segment as a result of our continued manufacturing efficiency initiatives.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">20</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sA7A87A31B84252D8947A62684F78F8EC"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">APYX MEDICAL CORPORATION</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">MANAGEMENT'S DISCUSSION AND ANAYLSIS OF</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">FINANCIAL CONDITION AND RESULTS OF OPERATIONS - Continued</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:4px;padding-top:4px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;padding-top:4px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other Costs and Expenses</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;padding-top:4px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our spending in the three and six months  ended June 30, 2020 reflected normal business activities into February and March and then a curtailment of certain costs associated with the impact of COVID-19, including restrictions on travel. While certain spending decreased in the second quarter of 2020 as a result of a reduction in revenue and activities limited by COVID-19, some of our strategic spending will continue. For example, while we have restricted new hirings, we have no plans to reduce our headcount or furlough any employees at this time. Certain costs will decline as the related underlying activities are restricted by COVID-19, including travel, trade shows and related expenses, clinical trials and in-person physician training. </span></div><div style="line-height:120%;padding-bottom:4px;padding-top:4px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Research and development</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="22"></td></tr><tr><td style="width:29%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended<br/>June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended<br/>June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(In thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Change</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Change</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and Development expense</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">975</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">888</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">9.8</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,955</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,618</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">20.8</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Percentage of sales</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">22.7</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">13.4</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">21.0</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">13.2</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development expenses increased </span><span style="font-family:inherit;font-size:10pt;">9.8%</span><span style="font-family:inherit;font-size:10pt;"> and  </span><span style="font-family:inherit;font-size:10pt;">20.8%</span><span style="font-family:inherit;font-size:10pt;"> for the three and six months ended June 30, </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;">, respectively, primarily due to spending on our two IDE clinical studies, which had applications submitted to the FDA in late 2019. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Professional services</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="22"></td></tr><tr><td style="width:29%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended<br/>June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended<br/>June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(In thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Change</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Change</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Professional services expense</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,658</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,661</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(0.2</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4,047</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3,779</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">7.1</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Percentage of sales</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">38.6</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">25.0</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">43.5</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">30.8</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Professional services expense decreased </span><span style="font-family:inherit;font-size:10pt;">(0.2)%</span><span style="font-family:inherit;font-size:10pt;"> for the three months ended June 30, </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;">, primarily attributable to decreases in physician consulting fees ($0.2 million) associated with the COVID-19 shutdown and a decrease in consulting option expense to our partner physicians ($0.3 million), as we did not grant options to our partner physicians in 2020. These decreases were partially offset by an increase in accounting and auditing fees ($0.4 million) related to recent financial statement restatements and continued efforts to remediate our internal control deficiencies and material weaknesses. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Professional services expense increased </span><span style="font-family:inherit;font-size:10pt;">7.1%</span><span style="font-family:inherit;font-size:10pt;"> for the six months ended June 30, </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;">, primarily attributable to an increase in accounting and auditing fees ($0.7 million) related to recent financial statement restatements and continued efforts to remediate our internal control deficiencies and material weaknesses. This increase was partially offset by decreases in legal expense ($0.2 million) associated with the class action lawsuit accrual in the first quarter of 2019 and a decrease in consulting option expense to our partner physicians ($0.3 million), as we did not grant options to our partner physicians in 2020.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Salaries and related costs</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="22"></td></tr><tr><td style="width:29%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended<br/>June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended<br/>June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(In thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Change</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Change</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Salaries and related expenses</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3,439</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3,510</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(2.0</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">6,750</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">6,998</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(3.5</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Percentage of sales</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">80.1</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">52.8</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">72.6</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">57.0</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">21</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sA7A87A31B84252D8947A62684F78F8EC"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">APYX MEDICAL CORPORATION</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">MANAGEMENT'S DISCUSSION AND ANAYLSIS OF</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">FINANCIAL CONDITION AND RESULTS OF OPERATIONS - Continued</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the three and six months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;">, salaries and related expenses decreased approximately </span><span style="font-family:inherit;font-size:10pt;">(2.0)%</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">(3.5)%</span><span style="font-family:inherit;font-size:10pt;">, respectively, primarily driven by a decrease in accrued bonus expense in 2020. This decrease was partially offset by higher stock option expense and an increase in average headcount for the period.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Selling, general and administrative expenses</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="22"></td></tr><tr><td style="width:29%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended<br/>June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended<br/>June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(In thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Change</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Change</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">SG&amp;A Expense</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2,189</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3,037</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(27.9</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5,985</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5,994</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(0.2</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Percentage of sales</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">51.0</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">45.7</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">64.4</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">48.8</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the three months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;">, selling, general and administrative expense decreased </span><span style="font-family:inherit;font-size:10pt;">(27.9)%</span><span style="font-family:inherit;font-size:10pt;">, primarily driven by a decrease in travel and entertainment expense ($0.5 million), a decrease in show fees and related costs ($0.2 million) and a decrease in customer samples ($0.1 million) associated with restricted travel and decreased sales activity from COVID-19. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the six months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;">, selling, general and administrative expense decreased approximately </span><span style="font-family:inherit;font-size:10pt;">(0.2)%</span><span style="font-family:inherit;font-size:10pt;">, primarily driven by a decrease in travel and entertainment expense ($0.3 million), a decrease in show fees and related costs ($0.2 million), a decrease in commission expense ($0.2 million) and a decrease in customer samples ($0.2 million) associated with restricted travel and decreased sales activity from COVID-19. These decreases were partially offset by higher bad debt expense ($0.6 million) related to increased uncertainty on the collection of our receivables  due to the economic environment resulting from COVID-19 and an increase in insurance premiums ($0.1 million) from the prior year. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other Income (Expense)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="22"></td></tr><tr><td style="width:29%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended<br/>June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended<br/>June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(In thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Change</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Change</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest income</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">7</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">403</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(98.3</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">223</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">826</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(73.0</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Percentage of sales</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">0.2</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">6.1</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2.4</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">6.7</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other income (losses), net</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(14</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(200</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(93.0</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">412</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(495</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(183.2</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Percentage of sales</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(0.3</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(3.0</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4.4</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(4.0</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total interest income decreased </span><span style="font-family:inherit;font-size:10pt;">(98.3)%</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">(73.0)%</span><span style="font-family:inherit;font-size:10pt;"> for the three and six months ended June 30, </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;">, respectively, as compared with the same periods in the prior year. This decrease is due to a lower average balance, as well as a lower yield, on our investments in U.S. Treasury Securities included in cash and cash equivalents.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other income (losses), net increased for the three and six months ended June 30, </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;">, as compared with the prior year. This increase  is primarily due to the receipt of refunds on tariffs paid in the prior year, offset by the recognition of a joint and several liability for failure to collect and remit payroll taxes related to stock option exercises in the prior year.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Income Taxes</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="22"></td></tr><tr><td style="width:29%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended<br/>June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended<br/>June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(In thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Change</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Change</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax expense (benefit)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(1,492</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">76</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(2,063.2</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(6,397</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">82</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(7,901.2</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effective tax rate</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">24.1</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(1.8</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">49.1</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(0.8</span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">22</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sA7A87A31B84252D8947A62684F78F8EC"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">APYX MEDICAL CORPORATION</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">MANAGEMENT'S DISCUSSION AND ANAYLSIS OF</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">FINANCIAL CONDITION AND RESULTS OF OPERATIONS - Continued</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our income tax (benefit) expense was approximately </span><span style="font-family:inherit;font-size:10pt;">$(1,492,000)</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">$76,000</span><span style="font-family:inherit;font-size:10pt;"> with an effective tax rate of </span><span style="font-family:inherit;font-size:10pt;">24.1%</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">(1.8)%</span><span style="font-family:inherit;font-size:10pt;"> for the three months ended June 30, 2020 and 2019, respectively.  Our income tax (benefit) expense was approximately </span><span style="font-family:inherit;font-size:10pt;">$(6,397,000)</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">$82,000</span><span style="font-family:inherit;font-size:10pt;"> with an effective tax rate of </span><span style="font-family:inherit;font-size:10pt;">49.1%</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">(0.8)%</span><span style="font-family:inherit;font-size:10pt;"> for the six months ended June 30, 2020 and 2019, respectively.  The effective rate differs from the statutory rate primarily due to the release of the valuation allowance on our net operating loss carryforward from 2019. On March 27, 2020, the U.S. government enacted the CARES Act to provide relief from COVID-19. The CARES Act includes a provision that allows companies to carryback net operating losses generated in the period 2018 through 2020 to prior years. We released the full valuation allowance of approximately $3.7M on our Federal net operating loss carryforward associated with the provisions of the CARES Act. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Liquidity and Capital Resources </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our working capital at June 30, 2020 was approximately </span><span style="font-family:inherit;font-size:10pt;">$60.2 million</span><span style="font-family:inherit;font-size:10pt;"> compared with </span><span style="font-family:inherit;font-size:10pt;">$64.4 million</span><span style="font-family:inherit;font-size:10pt;"> at December 31, 2019. The decrease in working capital from December 31, 2019 to June 30, 2020 was primarily due to the net loss incurred by the Company during the first half of 2020 partially offset by non cash activity including stock based compensation expense and our provision for allowance for doubtful accounts.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the six months ended June 30, 2020, net cash used in operating activities was approximately </span><span style="font-family:inherit;font-size:10pt;">$12.4 million</span><span style="font-family:inherit;font-size:10pt;">, which principally funded our operating loss of </span><span style="font-family:inherit;font-size:10pt;">$13.7 million</span><span style="font-family:inherit;font-size:10pt;">, compared with net cash used in operating activities of approximately </span><span style="font-family:inherit;font-size:10pt;">$10.7 million</span><span style="font-family:inherit;font-size:10pt;"> million in the same period for 2019. Utilizing the provisions of the CARES Act, we recognized an income tax benefit of approximately </span><span style="font-family:inherit;font-size:10pt;">$6.4 million</span><span style="font-family:inherit;font-size:10pt;"> in the first half of 2020, of which we expect to receive a tax refund of approximately $3.7 million by the end of 2020. We expect that utilizing the NOL carryback will significantly help mitigate the working capital impact COVID-19  has had on our sales and operations.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The CARES Act also allows us to defer the payment of payroll taxes incurred between March 27, 2020 and December 31, 2020, with half of the resulting liability due on December 31, 2021, and the remainder due on December 31, 2022. As of June 30, 2020 we deferred approximately $0.1 million in taxes utilizing this program. We expect to  defer and additional $0.3 million to $0.4 million under this program by December 31, 2020.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a result of the impact of COVID-19 on our customers, we have received multiple requests for extension on the payment of receivables. While we are committed to working with our customers to collect the receivables as expeditiously as possible, collectability of these receivables is more uncertain and we have recorded an increased allowance for doubtful accounts as a result.   A primary focus for the Company in 2020 continues to be maintaining appropriate balance sheet flexibility, including cash on hand, due to the uncertain nature and unpredictable timing of the impacts of COVID-19.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net cash used in investing activities was $0.2 million, related to investments in property and equipment. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;">, we had purchase commitments totaling approximately $0.5 million, substantially all of which is expected to be purchased within the next six months.  </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">23</span></div></div><hr style="page-break-after:always"></hr><div><a id="s4D3A6BC5B8F65C4088C6C564814A2E2D"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sA7A87A31B84252D8947A62684F78F8EC"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">APYX MEDICAL CORPORATION</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">MANAGEMENT'S DISCUSSION AND ANAYLSIS OF</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">FINANCIAL CONDITION AND RESULTS OF OPERATIONS - Continued</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Critical Accounting Estimates</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In preparing the consolidated financial statements in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP), we have adopted various accounting policies. Our most significant accounting policies are disclosed in Note 2 to the consolidated financial statements included in our Report on Form 10-K for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, filed with the Securities and Exchange Commission on March 31, 2020.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Our estimates and assumptions, including those related to inventories, intangible assets, property, plant and equipment, legal proceedings, research and development, warranty obligations, product liability, fair valued liabilities, sales returns and discounts, stock-based compensation and income taxes are updated as appropriate, which in most cases is at least quarterly. We base our estimates on historical experience, or various assumptions that are believed to be reasonable under the circumstances and the results form the basis for making judgments about the reported values of assets, liabilities, revenues and expenses. Actual results may materially differ from these estimates.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Estimates are considered to be critical if they meet both of the following criteria: (1) the estimate requires assumptions about material matters that are uncertain at the time the accounting estimates are made and (2) other materially different estimates could have been reasonably made or material changes in the estimates are reasonably likely to occur from period to period. Our critical accounting estimates include the following:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock-based Compensation</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under our stock option plans, options to purchase common shares of the Company may be granted to employees, officers and directors of the Company by the Board of Directors. We account for stock options in accordance with FASB ASC Topic 718-10, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation-Stock Compensation</span><span style="font-family:inherit;font-size:10pt;">, with compensation expense amortized over the vesting period. Options are valued using the Black-Scholes model in 2019 and 2020 and the trinomial lattice option-pricing model in prior years, both of which includes a number of estimates that affect the amount of our expense. We have determined that the most critical of these estimates are the expected life and volatility used in the calculations. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Expected life</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For employee stock-based compensation awards, we estimate the expected life of awards utilizing the SEC's simplified method. We utilize this method, as the we have not historically granted stock-based compensation awards to employees in sufficient volumes to determine a reasonable estimate of the life of awards. For awards granted to non-employees, we calculate expected life using a combination of past exercise behavior, the contractual term and expected remaining exercise behavior.  </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Volatility</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We determine the volatility by utilizing the historical volatility of our stock over the period of the awards expected life. Relevant guidance allows us to include periods in excess of the useful life if we determine that they provide a more reasonable basis for the volatility of our stock. Additionally, ASC 718-10 allows us to exclude periods from the volatility if they pertain to events or circumstances that in our judgment are specific to us and if the event or transaction is not reasonably expected to occur again during the expected term of the awards. We have not included any additional periods, nor disregarded any periods, in calculating our volatility.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Accounts Receivable Reserves</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We maintain a reserve for uncollectible accounts receivable. When evaluating the adequacy of the allowance for doubtful accounts, we analyze specific unremitted customer balances for known collectability issues,  review historical bad debt experience, customer credit worthiness and economic trends,  and we make estimates in connection with establishing the allowance for doubtful accounts, including the future impacts of current trends. Changes in estimates are reflected in the period they are made. If the financial condition of our customers deteriorates, resulting in an inability to make payments, additional allowances may be required. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">24</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sA7A87A31B84252D8947A62684F78F8EC"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">APYX MEDICAL CORPORATION</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">MANAGEMENT'S DISCUSSION AND ANAYLSIS OF</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">FINANCIAL CONDITION AND RESULTS OF OPERATIONS - Continued</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Inventory Reserves</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We maintain a reserve for excess and obsolete inventory resulting from the potential inability to sell our products at prices in excess of current carrying costs. The markets in which we operate are highly competitive, with new products and surgical procedures introduced on an ongoing basis. Such marketplace changes may cause our products to become obsolete. We make estimates regarding the future recoverability of the costs of these products and record a provision for excess and obsolete inventories based on historical experience and expected future trends. If actual product life cycles, product demand or acceptance of new product introductions are less favorable than projected by management, additional inventory write-downs may be required, which would unfavorably affect future operating results.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Litigation Contingencies</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In accordance with authoritative guidance, we record a liability in our consolidated financial statements for these actions when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible, but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed in the notes to the consolidated financial statements. In most cases, significant judgment is required to estimate the amount and timing of a loss to be recorded; actual results may differ from these estimates.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Income Taxes </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The provision for income tax expense (benefit) includes federal, foreign, state and local income taxes currently payable or receivable and those deferred because of temporary differences between the financial statement and tax bases of assets and liabilities. Deferred tax assets or liabilities are computed based on the difference between the financial statement and income tax bases of assets and liabilities using enacted marginal tax rates. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized. Deferred income tax expenses or credits are based on the changes in the asset or liability from period to period.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a result of historical losses exclusive of the sale of the Core business in 2018, and our expectation to continue to generate losses in the near future, we recorded a valuation allowance on the net deferred tax asset and do not anticipate recording an income tax benefit related to these deferred tax assets. We will reassess the realization of deferred tax assets each reporting period and will be able to reduce the valuation allowance to the extent the financial results improve and it becomes more likely than not that the deferred tax assets will be realizable. As management expects the Company to continue to generate losses in 2020 and the foreseeable future after 2020, we will continue to record a valuation allowance on the remaining deferred tax asset balance as of June 30, 2020.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We assess the financial statement impact of an uncertain tax position taken or expected to be taken on an income tax return at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized in the financial statements unless it is more likely than not of being sustained.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Inflation</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inflation has not materially impacted the operations of our Company.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Off-Balance Sheet Arrangements</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have no off-balance sheet arrangements at this time.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Recent Accounting Pronouncements</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">See Note 3 of the Notes to Consolidated Financial Statements.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">25</span></div></div><hr style="page-break-after:always"></hr><div><a id="s6B0C2323530157A6A742A6FE2CD40917"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sA7A87A31B84252D8947A62684F78F8EC"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">APYX MEDICAL CORPORATION</span></div></div><div><br/></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 3</span><span style="font-family:inherit;font-size:10pt;">. </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Quantitative and Qualitative Disclosures about Market Risk</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Not applicable.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="sB7011A169FB3573E8FAE1DA29297E3AA"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 4. Controls and Procedures</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Disclosure Controls and Procedures </span></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our management has established and maintains disclosure controls and procedures that are designed to ensure that the information required to be disclosed by us in reports that we file or submit under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms, and that such information is accumulated and communicated to management, including the Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Management carried out an evaluation, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures as of the end of the period covered by this report. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of June 30, 2020, due to the material weaknesses in our internal control over financial reporting previously identified and reported in our 2019 Annual Report on Form 10-K ("2019 Form 10-K") which, as described below, continue to exist, our disclosure controls and procedures were not effective.</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Notwithstanding such material weaknesses, which is described below in Management&#8217;s Report on Internal Control over Financial Reporting, our management has concluded that the consolidated financial statements included in this Form 10-Q present fairly, in all material respects, our financial position, results of operations and cash flows for the periods presented in conformity with GAAP.</span></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Management&#8217;s Report on Internal Control Over Financial Reporting</span></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rule 13a-15(f). The Company's internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, management carried out an evaluation of the effectiveness of the Company's internal control over financial reporting as of December 31, 2019, based on the framework set forth by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control- Integrated Framework (2013). Based on that evaluation, management concluded that, as of December 31, 2019, the Company's internal control over financial reporting was not effective as a result of the material weaknesses described below.</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The effectiveness of our internal control over financial reporting as of December 31, 2019 was audited by BDO USA LLP, an independent registered public accounting firm, as stated in their report included in  Part II, Item 8 of our most recent Form 10-K for the period ended December 31, 2019, contains an adverse opinion on the effectiveness of our internal control over financial reporting.</span></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that material misstatements of the Company's annual or interim financial statements will not be prevented or detected on a timely basis.</span></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:30px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">As of December 31, 2019 we had identified the following three material weaknesses:</span><span style="font-family:inherit;font-size:10pt;">An ineffective control environment requiring additional qualified accounting personnel with an appropriate level   of knowledge and experience with generally accepted accounting principles.  This was a deficiency from the prior year that had not been fully </span></div></td></tr></table><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">26</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sA7A87A31B84252D8947A62684F78F8EC"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">APYX MEDICAL CORPORATION</span></div></div><div><br/></div><div style="line-height:120%;padding-left:54px;text-align:justify;"><span style="font-family:inherit;font-size:10pt;">remediated. </span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Ineffective control activities due to the lack of documentation and timeliness in executing certain business process controls, specifically related to procure to pay and inventory processes and footnote reporting disclosures related to income tax accounts, primarily related to our United States operations.  This was a deficiency from the prior year that had not been fully remediated. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Ineffective control activities over financial reporting in our Bulgarian subsidiary related to the purchasing of goods and services, including the processing and payment of vendor invoices.</span></div></td></tr></table><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">  As of June 30, 2020, we continue our remediation efforts related to these deficiencies.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> Remediation Efforts to Address Material Weaknesses</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Management is committed to maintaining a strong internal control environment. In response to the identified material weaknesses, management, with the oversight of the Audit Committee of the Board of Directors, has taken actions toward the remediation of the respective material weaknesses in internal control over financial reporting as outlined below.</span></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are in the process of remediating the material weakness associated with the lack of sufficient qualified accounting personnel with an appropriate level of knowledge and experience with generally accepted accounting principles by hiring  a new Chief Financial Officer in January 2019 and, in September 2019, a new Corporate Controller with experience in internal controls and financial reporting. Both have been actively engaged in remediation efforts to address the material weaknesses to date and will continue throughout fiscal year 2020. We will continue to recruit qualified professionals with appropriate levels of knowledge and experience to assist in resolving accounting issues related to non-routine and complex transactions. We have also enhanced our policies, procedures, and controls for all key business processes. In addition, management will continue to train personnel to ensure consistent application of accounting principles and adherence to the Company&#8217;s policies, procedures, and controls. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are in the process of remediating the material weakness associated with the ineffective control activities due to the lack of documentation and timeliness in executing business process controls by enhancing our processes and  review controls associated with the processes noted above. We have reviewed current financial controls to assess if additional management review controls are necessary and will continue to work with all finance personnel to ensure the appropriate documentation criteria for the existing controls, including evidence of review, timeliness and variance thresholds. We  will continue to work with the third-party specialists we engaged to review, document, and enhance   the design of our controls, with the goal of designing and implementing controls that address the completeness and accuracy of data used in the performance of certain controls as well as the precision of management's review, but also enhance our ability to manage our business.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have enhanced, or are in the process of enhancing, certain controls over purchasing and disbursements in our Bulgarian subsidiary, including approving and validating vendor invoices received by verifying the related purchase authorization and the receipt of the goods or services.</span></div></td></tr></table><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Management believes the steps outlined above, along with the implementation of a new financial reporting system, will remediate the material weaknesses described above. The Audit Committee of the Board of Directors and management will continue to monitor the implementation of these remediation measures and the effectiveness of our internal controls over financial reporting on an ongoing basis.</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of June 30, 2020, our remediation of these deficiencies is incomplete.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Changes in Internal Control Over Financial Reporting</span></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Except as set forth above, there were no changes in our internal control over financial reporting that occurred during the three months ended June 30, 2020 that materially affected, or that are reasonably likely to materially affect our internal control over financial reporting.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">27</span></div></div><hr style="page-break-after:always"></hr><div><a id="s3EDA95720B1F51768BE1BC7B5683AF29"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sA7A87A31B84252D8947A62684F78F8EC"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">APYX MEDICAL CORPORATION</span></div></div><div><br/></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">PART II. &#160;&#160;&#160;&#160;Other Information</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="sE1B2E84895D956F8BCD8FB9E7400CFDC"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 1. Legal Proceedings</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The medical device industry is characterized by frequent claims and litigation, and we are and may become subject to various claims, lawsuits and proceedings in the ordinary course of our business. Such claims may include claims by current or former employees, distributors and competitors, claims concerning the marketing and promotion of our products and product liability claims.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are involved in a number of legal actions relating to the use of our Helium Plasma technology. The outcomes of these legal actions are not within our complete control and may not be known for prolonged periods of time. We believe that such claims are adequately covered by insurance; however, in the case of one of our carriers, we are in a dispute regarding the total level of coverage available. Notwithstanding the foregoing, in the opinion of management, the Company has meritorious defenses and such claims are not expected, individually or in the aggregate, to result in a material, adverse effect on our financial condition. However, in the event that damages exceed the aggregate coverage limits of our policies or if our insurance carriers disclaim coverage, we believe it is possible that costs associated with these claims could have a material adverse impact on our consolidated results of operations, financial position or cash flows.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On April 17, 2019, a complaint (the &#8220;Complaint&#8221;) was filed in the United States District Court for the Middle District of Florida, against the Company and Charles D. Goodwin, the Company&#8217;s President and Chief Executive Officer and a member of the Company&#8217;s Board of Directors, alleging certain violations of the Securities Exchange Act of 1934, as amended.&#160; On July 16, 2019, the Court appointed lead plaintiff for the putative class and approved the lead plaintiff&#8217;s selection of counsel. On September 3, 2019, lead plaintiff filed an amended complaint (the &#8220;Amended Complaint&#8221;) with the Court.&#160; </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Amended Complaint seeks class action status on behalf of all persons and entities that acquired the Company&#8217;s securities between December 21, 2018 and April 1, 2019, and alleges violations by the Company and Goodwin of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended and Rule 10b-5 thereunder, primarily related to certain public statements concerning the Premarket Notification 510(k) submission made to the US Food and Drug Administration for a new indication for the Company&#8217;s J-Plasma&#174; technology for use in dermal resurfacing procedures. &#160;On October 3, 2019, defendants filed a motion to dismiss the Amended Complaint, and on March 11, 2020, the Court denied that motion.&#160; On July 10, 2020, the parties executed a settlement agreement, which is subject to Court approval. The Court preliminarily approved the settlement on July 21, 2020.&#160;The settlement agreement provides for the dismissal of the action with prejudice.&#160;At June 30, 2020,&#160;approximately $670,000&#160;of the&#160;$1,000,000 insurance&#160;deductible is unpaid and is included in accrued expenses and other current liabilities in the accompanying consolidated balance sheet. During July 2020, substantially all of the unpaid deductible was paid.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We accrue a liability in our consolidated financial statements for these actions when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is recorded. If a loss is reasonably possible, but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed in the notes to the consolidated financial statements. In most cases, significant judgment is required to estimate the amount and timing of a loss to be recorded, actual results may differ from these estimates.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s539FA6473CF95679B8D5BDCB0796DFAD"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 1A. Risk factors</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There have been no material changes to the Risk Factors described in Part I, Item1A-Risk Factors in our annual report on Form10-K for the year ended December 31, 2019 other than the following:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:9px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">THE COVID-19 Pandemic has had and continues to have a material and adverse affect on our business</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our global operations expose us to risks associated with public health crises and outbreaks of epidemic, pandemic, or contagious diseases, such as the current outbreak of COVID-19. To date, COVID-19 has had, and may continue to have, a material and adverse impact on our operations. Due to these impacts and measures, we have experienced and may continue to experience significant and unpredictable reductions in the demand for our products as actions taken by governmental bodies have restricted our customers' business activities. There continues to be a significant amount of uncertainty as to when these restrictions will be lifted and when patients will choose to undergo the elective procedures provided by our customers. While many of our customers have begun to </span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">28</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sA7A87A31B84252D8947A62684F78F8EC"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">APYX MEDICAL CORPORATION</span></div></div><div><br/></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">experience positive trends in these restrictions being lifted and some patients have started elective procedures again, there is no guarantee that restrictions won't be reinstated or that patients will not choose to forgo elective procedures. In addition, our customers may delay, cancel or redirect planned capital expenditures in order to focus resources on COVID-19 or in response to continued economic disruption related to COVID-19. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a result of the COVID-19 outbreak, many businesses experienced temporary closures of facilities as a result of being considered non-essential businesses. As performers of elective procedures, these temporary closures have impacted many of our customers and materially reduced demand for our products. As a medical device company, while we have currently been exempt from these guidelines and have largely continued operations, if we continue to experience future materially reduced demand for our products, we may have to scale back our operations. In addition, if the guidelines change, we or our suppliers could be impacted, and we could be adversely affected through supply chain interruptions, manufacturing restrictions or labor restrictions. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, the COVID-19 pandemic has adversely affected, and may continue to adversely affect, the world economy and financial markets , which has resulted in a period of significant global economic slowdown  which has curtailed and delayed spending by physicians and affected demand for our products as well as increased risk of customer defaults or delays in payments. COVID-19 and the current financial, economic, and capital markets environment, and future developments in these and other areas present material uncertainty and risk with respect to our performance, financial condition, volume of business, results of operations, and cash flows. Due to the uncertain scope and duration of the pandemic, the and uncertain timing of global recovery and economic normalization, we are unable to estimate the impacts on our operations and financial results, but believe they will be material into the second quarter of 2020 and possibly beyond.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="sD5F12ABC6A51575CBB678EEB360FF998"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">None.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s28C3E46F0F0E5AF189C22CE5E88E0127"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 3. Defaults Upon Senior Securities</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">None.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="sA09A8DC681C35E22B2E7435FBDE342CD"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 4. Mine Safety Disclosures</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Not Applicable.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s1A551E9CFA4653E39971D2E4E0876753"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 5. Other Information</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">None.</span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">29</span></div></div><hr style="page-break-after:always"></hr><div><a id="s0FE30B1716DC51F6B9690DD2AB2D28F1"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sA7A87A31B84252D8947A62684F78F8EC"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">APYX MEDICAL CORPORATION</span></div></div><div><br/></div><div style="line-height:120%;text-align:justify;-sec-extract:summary;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 6. Exhibits</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:88%;"></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3.1</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:none;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/719135/000100944811000015/exhibit31.htm"><span style="font-family:inherit;font-size:10pt;text-decoration:none;">Articles of Incorporation of the Registrant (Incorporated by reference to the Registrant&#8217;s report on Form 10-K/A filed on March 31, 2011)</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3.2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:none;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/719135/000100944811000015/exhibit32.htm"><span style="font-family:inherit;font-size:10pt;text-decoration:none;">By laws of the Registrant (Incorporated by reference to the Registrant&#8217;s Annual Report on Form 10-K/A filed on March 31, 2011)</span></a></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3.3</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:none;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/719135/000071913517000064/a2017q3exhibit35.htm"><span style="font-family:inherit;font-size:10pt;text-decoration:none;">Certificate of Amendment of the Certificate of Incorporation of the Registrant (Incorporated by reference to the Registrant&#8217;s Quarterly Report on Form 10-Q filed on November 3, 2017).</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3.4</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:none;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/719135/000071913518000021/bvx_201805xex31certificate.htm"><span style="font-family:inherit;font-size:10pt;text-decoration:none;">Certificate of Elimination (Incorporated by reference to the Registrant&#8217;s Current Report on Form 8-K filed on May 3, 2018)</span></a></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3.5</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:none;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/719135/000071913518000086/0000719135-18-000086-index.htm"><span style="font-family:inherit;font-size:10pt;text-decoration:none;">Certificate of Amendment of the Certificate of Incorporation of the Registrant (Incorporated by reference to the Registrant's Current Report of Form 8-K filed on December 28, 2018)</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">31.1*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:none;color:#0000FF;-sec-extract:exhibit;" href="a2020q210-qexhibit311.htm"><span style="font-family:inherit;font-size:10pt;text-decoration:none;">Certification pursuant to Section 302 of Sarbanes-Oxley Act of 202</span></a></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">31.2*</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:none;color:#0000FF;-sec-extract:exhibit;" href="a2020q210-qexhibit312.htm"><span style="font-family:inherit;font-size:10pt;text-decoration:none;">Certification pursuant to Section 302 of Sarbanes-Oxley Act of 202</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">32.1*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:none;color:#0000FF;-sec-extract:exhibit;" href="a2020q210-qexhibit321.htm"><span style="font-family:inherit;font-size:10pt;text-decoration:none;">Certification pursuant to Section 906 of Sarbanes-Oxley Act of 202</span></a></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">32.2*</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:none;color:#0000FF;-sec-extract:exhibit;" href="a2020q210-qexhibit322.htm"><span style="font-family:inherit;font-size:10pt;text-decoration:none;">Certification pursuant to Section 906 of Sarbanes-Oxley Act of 202</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">101.INS**</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">XBRL Instance Document</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">101.SCH**</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Schema Document</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">101.CAL**</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Calculation Linkbase Document</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">101.DEF**</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Definition Linkbase Document</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">101.LAB**</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Label Linkbase Document</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">101.PRE**</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Label Presentation Document</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">* Filed herewith.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">** XBRL (Extensible Business Reporting Language) information is furnished and not filed or a part of registration&#160;statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended and otherwise is not subject to liability under these sections.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">30</span></div></div><hr style="page-break-after:always"></hr><div><a id="sF935F2F9B8425BD889495313897871AC"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sA7A87A31B84252D8947A62684F78F8EC"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">APYX MEDICAL CORPORATION</span></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURES</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:48%;"></td><td style="width:5%;"></td><td style="width:42%;"></td><td style="width:5%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Apyx Medical Corporation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Date: August&#160;10, 2020</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">By:</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">/s/ Charles D. Goodwin II</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Charles D. Goodwin II</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">President, Chief Executive Officer and Director</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Principal Executive Officer)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Date: August&#160;10, 2020</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">By:</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">/s/ Tara Semb</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Tara Semb</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Chief Financial Officer,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Treasurer and Secretary</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Principal Financial Officer)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">31</span></div></div>	</div></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>a2020q210-qexhibit311.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sF3C379C689AE517EA87CB75FF70FAF6D"></a></div><div><div style="line-height:120%;text-align:right;text-indent:57px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT 31.1</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Certificate Pursuant to Section&#160;302</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">of Sarbanes &#8211; Oxley Act of 2002</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION OF CEO</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, Charles D Goodwin II, the Registrant's Chief Executive Officer, certify that:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I have reviewed this quarterly report on Form 10-Q of Apyx Medical Corporation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, the financial statements and other financial information included in this report fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">a.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">b.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">c.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">d.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected or is reasonably likely to materially affect the registrant&#8217;s internal control over financial reporting; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">a.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">b.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal controls over financial reporting.</font></div></td></tr></table><div style="line-height:120%;text-align:left;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:48%;"></td><td style="width:5%;"></td><td style="width:34%;"></td><td style="width:13%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: August&#160;10, 2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">/s/ Charles D. Goodwin II</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Charles D. Goodwin II</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">President and Chief Executive Officer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>a2020q210-qexhibit312.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s238E9B46CC0B5A05A057D43B63864882"></a></div><div><div style="line-height:120%;text-align:right;text-indent:57px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT 31.2</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Certificate Pursuant to Section&#160;302</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">of Sarbanes &#8211; Oxley Act of 2002</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION OF CFO</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, Tara Semb, the Registrant's Chief Financial Officer, certify that:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I have reviewed this quarterly report on Form 10-Q of Apyx Medical Corporation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, the financial statements and other financial information included in this report fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">a.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">b.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">c.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">d.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected or is reasonably likely to materially affect the registrant&#8217;s internal control over financial reporting; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">a.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">b.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal controls over financial reporting.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:47%;"></td><td style="width:5%;"></td><td style="width:45%;"></td><td style="width:3%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: August&#160;10, 2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">/s/ Tara Semb</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tara Semb</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Financial Officer, Treasurer and Secretary</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;text-indent:57px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>a2020q210-qexhibit321.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sF13441C02DA55564BE844E0409F32F07"></a></div><div><div style="line-height:120%;text-align:right;text-indent:57px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT 32.1</font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Certificate Pursuant to 18 U.S.C Section 1350, as adopted pursuant to</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Section&#160;906 of Sarbanes &#8211; Oxley Act of 2002</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION OF CEO</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the quarterly report on Form 10-Q of Apyx Medical Corporation (the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">"Company"</font><font style="font-family:inherit;font-size:10pt;">) for the period ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</font><font style="font-family:inherit;font-size:10pt;">, as filed with the Securities and Exchange Commission on the date hereof (the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">"Report"</font><font style="font-family:inherit;font-size:10pt;">), the undersigned Chief Executive Officer certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes - Oxley Act of 2002, that:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:48%;"></td><td style="width:5%;"></td><td style="width:34%;"></td><td style="width:13%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: August&#160;10, 2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">/s/ Charles D. Goodwin II</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Charles D. Goodwin II</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">President and Chief Executive Officer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>a2020q210-qexhibit322.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s17D90CBA937A5B499CF92105F0AC13C4"></a></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT 32.2</font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Certificate Pursuant to 18 U.S.C Section 1350, as adopted pursuant to</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Section&#160;906 of Sarbanes &#8211; Oxley Act of 2002</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION OF CFO</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the quarterly report on Form 10-Q of Apyx Medical Corporation (the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">"Company"</font><font style="font-family:inherit;font-size:10pt;">) for the period ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</font><font style="font-family:inherit;font-size:10pt;">, as filed with the Securities and Exchange Commission on the date hereof (the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">"Report"</font><font style="font-family:inherit;font-size:10pt;">), the undersigned Chief Financial Officer certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes - Oxley Act of 2002, that:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></td></tr></table><div style="line-height:120%;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:48%;"></td><td style="width:5%;"></td><td style="width:44%;"></td><td style="width:3%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: August&#160;10, 2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">/s/ Tara Semb</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tara Semb</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Financial Officer, Treasurer and Secretary</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>apyx-20200630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://apyxmedical.com/20200630" xmlns:apyx="http://apyxmedical.com/20200630" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/srt-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2020-01-31" schemaLocation="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2020-01-31" schemaLocation="https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2020-01-31" schemaLocation="https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="apyx-20200630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="apyx-20200630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="apyx-20200630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="apyx-20200630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="AccruedExpensesAndOtherCurrentLiabilities" roleURI="http://apyxmedical.com/role/AccruedExpensesAndOtherCurrentLiabilities">
        <link:definition>2111100 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesAndOtherCurrentLiabilitiesDetails" roleURI="http://apyxmedical.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails">
        <link:definition>2411402 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesAndOtherCurrentLiabilitiesTables" roleURI="http://apyxmedical.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables">
        <link:definition>2311301 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisOfPresentation" roleURI="http://apyxmedical.com/role/BasisOfPresentation">
        <link:definition>2101100 - Disclosure - BASIS OF PRESENTATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisOfPresentationPolicies" roleURI="http://apyxmedical.com/role/BasisOfPresentationPolicies">
        <link:definition>2201201 - Disclosure - BASIS OF PRESENTATION (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ChangeInAccountingPolicy" roleURI="http://apyxmedical.com/role/ChangeInAccountingPolicy">
        <link:definition>2102100 - Disclosure - CHANGE IN ACCOUNTING POLICY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingencies" roleURI="http://apyxmedical.com/role/CommitmentsAndContingencies">
        <link:definition>2119100 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesNarrativeDetails" roleURI="http://apyxmedical.com/role/CommitmentsAndContingenciesNarrativeDetails">
        <link:definition>2419401 - Disclosure - COMMITMENTS AND CONTINGENCIES - NARRATIVE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://apyxmedical.com/role/ConsolidatedBalanceSheets">
        <link:definition>1001000 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://apyxmedical.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>1001501 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfCashFlows" roleURI="http://apyxmedical.com/role/ConsolidatedStatementsOfCashFlows">
        <link:definition>1004000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfChangesInStockholdersEquity" roleURI="http://apyxmedical.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity">
        <link:definition>1003000 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfOperations" roleURI="http://apyxmedical.com/role/ConsolidatedStatementsOfOperations">
        <link:definition>1002000 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Cover" roleURI="http://apyxmedical.com/role/Cover">
        <link:definition>0001000 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShare" roleURI="http://apyxmedical.com/role/EarningsPerShare">
        <link:definition>2113100 - Disclosure - EARNINGS PER SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareDetails" roleURI="http://apyxmedical.com/role/EarningsPerShareDetails">
        <link:definition>2413402 - Disclosure - EARNINGS PER SHARE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareTables" roleURI="http://apyxmedical.com/role/EarningsPerShareTables">
        <link:definition>2313301 - Disclosure - EARNINGS PER SHARE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeographicAndSegmentInformation" roleURI="http://apyxmedical.com/role/GeographicAndSegmentInformation">
        <link:definition>2131100 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeographicAndSegmentInformationGeographicDetails" roleURI="http://apyxmedical.com/role/GeographicAndSegmentInformationGeographicDetails">
        <link:definition>2431404 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION - GEOGRAPHIC (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeographicAndSegmentInformationNarrativeDetails" roleURI="http://apyxmedical.com/role/GeographicAndSegmentInformationNarrativeDetails">
        <link:definition>2431402 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION - NARRATIVE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeographicAndSegmentInformationReportableSegmentDetails" roleURI="http://apyxmedical.com/role/GeographicAndSegmentInformationReportableSegmentDetails">
        <link:definition>2431403 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION - REPORTABLE SEGMENT (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeographicAndSegmentInformationTables" roleURI="http://apyxmedical.com/role/GeographicAndSegmentInformationTables">
        <link:definition>2331301 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://apyxmedical.com/role/IncomeTaxes">
        <link:definition>2117100 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://apyxmedical.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>2417402 - Disclosure - INCOME TAXES - NARRATIVE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://apyxmedical.com/role/IncomeTaxesTables">
        <link:definition>2317301 - Disclosure - INCOME TAXES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesUnrecognizedTaxBenefitsRollForwardDetails" roleURI="http://apyxmedical.com/role/IncomeTaxesUnrecognizedTaxBenefitsRollForwardDetails">
        <link:definition>2417403 - Disclosure - INCOME TAXES - UNRECOGNIZED TAX BENEFITS ROLL-FORWARD (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventories" roleURI="http://apyxmedical.com/role/Inventories">
        <link:definition>2109100 - Disclosure - INVENTORIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesDetails" roleURI="http://apyxmedical.com/role/InventoriesDetails">
        <link:definition>2409402 - Disclosure - INVENTORIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesInventoriesNarrativeDetails" roleURI="http://apyxmedical.com/role/InventoriesInventoriesNarrativeDetails">
        <link:definition>2409403 - Disclosure - INVENTORIES INVENTORIES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesTables" roleURI="http://apyxmedical.com/role/InventoriesTables">
        <link:definition>2309301 - Disclosure - INVENTORIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RecentAccountingPronouncements" roleURI="http://apyxmedical.com/role/RecentAccountingPronouncements">
        <link:definition>2107100 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://apyxmedical.com/role/RelatedPartyTransactions">
        <link:definition>2120100 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsDetails" roleURI="http://apyxmedical.com/role/RelatedPartyTransactionsDetails">
        <link:definition>2420401 - Disclosure - RELATED PARTY TRANSACTIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://apyxmedical.com/role/StockBasedCompensation">
        <link:definition>2115100 - Disclosure - STOCK-BASED COMPENSATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationFairValueAssumptionsDetails" roleURI="http://apyxmedical.com/role/StockBasedCompensationFairValueAssumptionsDetails">
        <link:definition>2415404 - Disclosure - STOCK-BASED COMPENSATION - FAIR VALUE ASSUMPTIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationNarrativeDetails" roleURI="http://apyxmedical.com/role/StockBasedCompensationNarrativeDetails">
        <link:definition>2415402 - Disclosure - STOCK-BASED COMPENSATION - NARRATIVE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryOfStockOptionsDetails" roleURI="http://apyxmedical.com/role/StockBasedCompensationSummaryOfStockOptionsDetails">
        <link:definition>2415403 - Disclosure - STOCK-BASED COMPENSATION - SUMMARY OF STOCK OPTIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://apyxmedical.com/role/StockBasedCompensationTables">
        <link:definition>2315301 - Disclosure - STOCK-BASED COMPENSATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element abstract="true" id="apyx_AdvancedEnergyMember" name="AdvancedEnergyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="apyx_BulgariaManufacturingPlantPurchaseMember" name="BulgariaManufacturingPlantPurchaseMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="apyx_CARESActFederalIncomeTaxPaymentsAvailableToOffsetCurrentPeriodLosses" name="CARESActFederalIncomeTaxPaymentsAvailableToOffsetCurrentPeriodLosses" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="apyx_CARESActIncomeTaxExpenseBenefitRelatedToCurrentPeriodNetIncomeLossBeforeIncomeTaxes" name="CARESActIncomeTaxExpenseBenefitRelatedToCurrentPeriodNetIncomeLossBeforeIncomeTaxes" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="apyx_CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards" name="CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="apyx_CapitalizationOfLeaseExecution" name="CapitalizationOfLeaseExecution" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="apyx_CapitalizationOfLeaseNonCash" name="CapitalizationOfLeaseNonCash" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="apyx_JointAndSeveralPayrollLiability" name="JointAndSeveralPayrollLiability" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="apyx_LeaseAdoption" name="LeaseAdoption" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="apyx_LossContingencyAccrualTotalAccruedToDate" name="LossContingencyAccrualTotalAccruedToDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="apyx_NonCashProceedsFromStockOptionsAndWarrantsExercised" name="NonCashProceedsFromStockOptionsAndWarrantsExercised" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="apyx_NonCashTransferOfOtherAssetsToFixedAssets" name="NonCashTransferOfOtherAssetsToFixedAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="apyx_NonCashTransfersOfInventoryToFromFixedAssets" name="NonCashTransfersOfInventoryToFromFixedAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="apyx_OEMMember" name="OEMMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="apyx_OtherAccruedExpensesAndLiabilitiesCurrent" name="OtherAccruedExpensesAndLiabilitiesCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised" name="ProceedsFromStockOptionsExercisedAndWarrantsExercised" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="apyx_ProvisionForInventoryObsolescence" name="ProvisionForInventoryObsolescence" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="apyx_ProvisionForObsolescenceInventory" name="ProvisionForObsolescenceInventory" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="apyx_RepaymentofFinanceLeaseLiabilities" name="RepaymentofFinanceLeaseLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="apyx_StockIssuedDuringPeriodSharesStockSwaps" name="StockIssuedDuringPeriodSharesStockSwaps" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived" name="StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="apyx_StockSwapToAcquireOptionsAmount" name="StockSwapToAcquireOptionsAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="apyx_StockSwapToAcquireOptionsShares" name="StockSwapToAcquireOptionsShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="apyx_TermOfPaymentDueNotesPayableRelatedParties" name="TermOfPaymentDueNotesPayableRelatedParties" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="apyx_TotalRevenuePercent" name="TotalRevenuePercent" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="apyx_UncertainTaxPositionsLiability" name="UncertainTaxPositionsLiability" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>apyx-20200630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://apyxmedical.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:href="apyx-20200630.xsd#AccruedExpensesAndOtherCurrentLiabilities" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="apyx-20200630.xsd#AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:href="apyx-20200630.xsd#AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/BasisOfPresentation" xlink:href="apyx-20200630.xsd#BasisOfPresentation" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/BasisOfPresentationPolicies" xlink:href="apyx-20200630.xsd#BasisOfPresentationPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/ChangeInAccountingPolicy" xlink:href="apyx-20200630.xsd#ChangeInAccountingPolicy" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/CommitmentsAndContingencies" xlink:href="apyx-20200630.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:href="apyx-20200630.xsd#CommitmentsAndContingenciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/ConsolidatedBalanceSheets" xlink:href="apyx-20200630.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="apyx-20200630.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="apyx-20200630.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" xlink:href="apyx-20200630.xsd#ConsolidatedStatementsOfChangesInStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/ConsolidatedStatementsOfOperations" xlink:href="apyx-20200630.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/Cover" xlink:href="apyx-20200630.xsd#Cover" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/EarningsPerShare" xlink:href="apyx-20200630.xsd#EarningsPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/EarningsPerShareDetails" xlink:href="apyx-20200630.xsd#EarningsPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/EarningsPerShareTables" xlink:href="apyx-20200630.xsd#EarningsPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/GeographicAndSegmentInformation" xlink:href="apyx-20200630.xsd#GeographicAndSegmentInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/GeographicAndSegmentInformationGeographicDetails" xlink:href="apyx-20200630.xsd#GeographicAndSegmentInformationGeographicDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/GeographicAndSegmentInformationNarrativeDetails" xlink:href="apyx-20200630.xsd#GeographicAndSegmentInformationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/GeographicAndSegmentInformationReportableSegmentDetails" xlink:href="apyx-20200630.xsd#GeographicAndSegmentInformationReportableSegmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/GeographicAndSegmentInformationTables" xlink:href="apyx-20200630.xsd#GeographicAndSegmentInformationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/IncomeTaxes" xlink:href="apyx-20200630.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/IncomeTaxesNarrativeDetails" xlink:href="apyx-20200630.xsd#IncomeTaxesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/IncomeTaxesTables" xlink:href="apyx-20200630.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/IncomeTaxesUnrecognizedTaxBenefitsRollForwardDetails" xlink:href="apyx-20200630.xsd#IncomeTaxesUnrecognizedTaxBenefitsRollForwardDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/Inventories" xlink:href="apyx-20200630.xsd#Inventories" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/InventoriesDetails" xlink:href="apyx-20200630.xsd#InventoriesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/InventoriesInventoriesNarrativeDetails" xlink:href="apyx-20200630.xsd#InventoriesInventoriesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/InventoriesTables" xlink:href="apyx-20200630.xsd#InventoriesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/RecentAccountingPronouncements" xlink:href="apyx-20200630.xsd#RecentAccountingPronouncements" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/RelatedPartyTransactions" xlink:href="apyx-20200630.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/RelatedPartyTransactionsDetails" xlink:href="apyx-20200630.xsd#RelatedPartyTransactionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/StockBasedCompensation" xlink:href="apyx-20200630.xsd#StockBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/StockBasedCompensationFairValueAssumptionsDetails" xlink:href="apyx-20200630.xsd#StockBasedCompensationFairValueAssumptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/StockBasedCompensationNarrativeDetails" xlink:href="apyx-20200630.xsd#StockBasedCompensationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/StockBasedCompensationSummaryOfStockOptionsDetails" xlink:href="apyx-20200630.xsd#StockBasedCompensationSummaryOfStockOptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/StockBasedCompensationTables" xlink:href="apyx-20200630.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <link:calculationLink xlink:role="http://apyxmedical.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:type="extended" />
  <link:calculationLink xlink:role="http://apyxmedical.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_4deaf78d-f730-176a-d6c6-47d6fc92ced8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="loc_us-gaap_AccruedSalariesCurrent_999bc126-4199-eaab-72ad-fa2bffc6a064" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_4deaf78d-f730-176a-d6c6-47d6fc92ced8" xlink:to="loc_us-gaap_AccruedSalariesCurrent_999bc126-4199-eaab-72ad-fa2bffc6a064" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="loc_us-gaap_AccruedBonusesCurrent_7f869cc9-e154-1f88-3bfe-2f40174853f2" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_4deaf78d-f730-176a-d6c6-47d6fc92ced8" xlink:to="loc_us-gaap_AccruedBonusesCurrent_7f869cc9-e154-1f88-3bfe-2f40174853f2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedSalesCommissionCurrent" xlink:label="loc_us-gaap_AccruedSalesCommissionCurrent_3cca5b38-0b81-6da8-67e9-a765937199cd" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_4deaf78d-f730-176a-d6c6-47d6fc92ced8" xlink:to="loc_us-gaap_AccruedSalesCommissionCurrent_3cca5b38-0b81-6da8-67e9-a765937199cd" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:label="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent_9a5a7c16-4a2d-0587-9439-a8fa5c23e3a6" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_4deaf78d-f730-176a-d6c6-47d6fc92ced8" xlink:to="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent_9a5a7c16-4a2d-0587-9439-a8fa5c23e3a6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedInsuranceCurrent" xlink:label="loc_us-gaap_AccruedInsuranceCurrent_80098d9c-6b29-6052-d36d-506adab64bf2" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_4deaf78d-f730-176a-d6c6-47d6fc92ced8" xlink:to="loc_us-gaap_AccruedInsuranceCurrent_80098d9c-6b29-6052-d36d-506adab64bf2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_d07ae967-def7-4df5-e9cd-bcd180ad3961" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_4deaf78d-f730-176a-d6c6-47d6fc92ced8" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_d07ae967-def7-4df5-e9cd-bcd180ad3961" xlink:type="arc" />
    <link:loc xlink:href="apyx-20200630.xsd#apyx_JointAndSeveralPayrollLiability" xlink:label="loc_apyx_JointAndSeveralPayrollLiability_2107cb95-b4f4-73c2-6ca7-496b35e877fd" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_4deaf78d-f730-176a-d6c6-47d6fc92ced8" xlink:to="loc_apyx_JointAndSeveralPayrollLiability_2107cb95-b4f4-73c2-6ca7-496b35e877fd" xlink:type="arc" />
    <link:loc xlink:href="apyx-20200630.xsd#apyx_UncertainTaxPositionsLiability" xlink:label="loc_apyx_UncertainTaxPositionsLiability_d1468203-3cd1-1d15-c411-496b35d8aeef" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_4deaf78d-f730-176a-d6c6-47d6fc92ced8" xlink:to="loc_apyx_UncertainTaxPositionsLiability_d1468203-3cd1-1d15-c411-496b35d8aeef" xlink:type="arc" />
    <link:loc xlink:href="apyx-20200630.xsd#apyx_OtherAccruedExpensesAndLiabilitiesCurrent" xlink:label="loc_apyx_OtherAccruedExpensesAndLiabilitiesCurrent_12306fd2-c8c2-2e4c-f040-496b3578121d" xlink:type="locator" />
    <link:calculationArc order="9" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_4deaf78d-f730-176a-d6c6-47d6fc92ced8" xlink:to="loc_apyx_OtherAccruedExpensesAndLiabilitiesCurrent_12306fd2-c8c2-2e4c-f040-496b3578121d" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://apyxmedical.com/role/BasisOfPresentation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://apyxmedical.com/role/BasisOfPresentationPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://apyxmedical.com/role/ChangeInAccountingPolicy" xlink:type="extended" />
  <link:calculationLink xlink:role="http://apyxmedical.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://apyxmedical.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://apyxmedical.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_d88b9019-0bd3-d7de-96eb-5cd69c504c2c" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_bceb5e86-dcaf-e940-c004-d20dda9b81f2" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d88b9019-0bd3-d7de-96eb-5cd69c504c2c" xlink:to="loc_us-gaap_AssetsCurrent_bceb5e86-dcaf-e940-c004-d20dda9b81f2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_26247a2d-7bac-8834-3dc5-06c993b10b2c" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_bceb5e86-dcaf-e940-c004-d20dda9b81f2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_26247a2d-7bac-8834-3dc5-06c993b10b2c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_2107189c-f25f-5667-a3b4-dbf4394a5e32" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_bceb5e86-dcaf-e940-c004-d20dda9b81f2" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_2107189c-f25f-5667-a3b4-dbf4394a5e32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="loc_us-gaap_IncomeTaxesReceivable_932af0c4-c181-ec20-6565-1009ffd9840e" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_bceb5e86-dcaf-e940-c004-d20dda9b81f2" xlink:to="loc_us-gaap_IncomeTaxesReceivable_932af0c4-c181-ec20-6565-1009ffd9840e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_2248a5f6-a67e-f8c9-3870-0d0db6402cb8" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_bceb5e86-dcaf-e940-c004-d20dda9b81f2" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_2248a5f6-a67e-f8c9-3870-0d0db6402cb8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_aa7cc103-d668-cf3b-6875-81c99ffeac19" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_bceb5e86-dcaf-e940-c004-d20dda9b81f2" xlink:to="loc_us-gaap_InventoryNet_aa7cc103-d668-cf3b-6875-81c99ffeac19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_33b4d214-779b-2177-f7ba-19f0abb03b76" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_bceb5e86-dcaf-e940-c004-d20dda9b81f2" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_33b4d214-779b-2177-f7ba-19f0abb03b76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_bf545d72-755b-f46c-4176-2eeaac0328d1" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d88b9019-0bd3-d7de-96eb-5cd69c504c2c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_bf545d72-755b-f46c-4176-2eeaac0328d1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_fe7a6688-63e6-c3a8-34a9-6a59f12ca16e" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d88b9019-0bd3-d7de-96eb-5cd69c504c2c" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_fe7a6688-63e6-c3a8-34a9-6a59f12ca16e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_1b3c3057-5da2-541b-c72f-d6783073603c" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d88b9019-0bd3-d7de-96eb-5cd69c504c2c" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_1b3c3057-5da2-541b-c72f-d6783073603c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_17a41c51-6fe7-c037-64c3-3ef6c9692a94" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d88b9019-0bd3-d7de-96eb-5cd69c504c2c" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_17a41c51-6fe7-c037-64c3-3ef6c9692a94" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_ae7d1998-6654-2677-8e9f-f36b62210000" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_a0e4a1b3-b018-392a-9b7d-09729b37d6a1" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_ae7d1998-6654-2677-8e9f-f36b62210000" xlink:to="loc_us-gaap_Liabilities_a0e4a1b3-b018-392a-9b7d-09729b37d6a1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_723c74a6-b3c0-ab21-b11a-8bd4ce4806f0" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a0e4a1b3-b018-392a-9b7d-09729b37d6a1" xlink:to="loc_us-gaap_LiabilitiesCurrent_723c74a6-b3c0-ab21-b11a-8bd4ce4806f0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_95fe5c6d-e90e-6d2c-8e9a-8339666be1b8" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_723c74a6-b3c0-ab21-b11a-8bd4ce4806f0" xlink:to="loc_us-gaap_AccountsPayableCurrent_95fe5c6d-e90e-6d2c-8e9a-8339666be1b8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_4deaf78d-f730-176a-d6c6-47d6fc92ced8" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_723c74a6-b3c0-ab21-b11a-8bd4ce4806f0" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_4deaf78d-f730-176a-d6c6-47d6fc92ced8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_f5d89653-9412-3469-28ee-c3579ebc0767" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_723c74a6-b3c0-ab21-b11a-8bd4ce4806f0" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_f5d89653-9412-3469-28ee-c3579ebc0767" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_1b26ed2d-89b9-5574-412a-b48bbaf33fe0" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_723c74a6-b3c0-ab21-b11a-8bd4ce4806f0" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_1b26ed2d-89b9-5574-412a-b48bbaf33fe0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_cbfdef0d-4eb0-77bb-ab8b-7d8bdf053005" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_723c74a6-b3c0-ab21-b11a-8bd4ce4806f0" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_cbfdef0d-4eb0-77bb-ab8b-7d8bdf053005" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7098604a-0754-f0ec-28b7-b5aa73ca65d5" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a0e4a1b3-b018-392a-9b7d-09729b37d6a1" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7098604a-0754-f0ec-28b7-b5aa73ca65d5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_3c3e63f4-630c-b98c-78f0-49ca0fb25e96" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a0e4a1b3-b018-392a-9b7d-09729b37d6a1" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_3c3e63f4-630c-b98c-78f0-49ca0fb25e96" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_44e41183-ff71-8a5d-6bae-236dd27ab6c0" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a0e4a1b3-b018-392a-9b7d-09729b37d6a1" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_44e41183-ff71-8a5d-6bae-236dd27ab6c0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_444cfce6-fc59-0d4d-1ade-0fdec3499b08" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_ae7d1998-6654-2677-8e9f-f36b62210000" xlink:to="loc_us-gaap_StockholdersEquity_444cfce6-fc59-0d4d-1ade-0fdec3499b08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_130b8997-2f7a-8192-a853-ff9fb4629d95" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_444cfce6-fc59-0d4d-1ade-0fdec3499b08" xlink:to="loc_us-gaap_CommonStockValue_130b8997-2f7a-8192-a853-ff9fb4629d95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_26982214-e3a4-a834-1e73-cd58ba2d5ac9" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_444cfce6-fc59-0d4d-1ade-0fdec3499b08" xlink:to="loc_us-gaap_AdditionalPaidInCapital_26982214-e3a4-a834-1e73-cd58ba2d5ac9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_18ff0284-4873-6ef0-806f-4fb76051c01f" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_444cfce6-fc59-0d4d-1ade-0fdec3499b08" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_18ff0284-4873-6ef0-806f-4fb76051c01f" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://apyxmedical.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7e98a0be-51ae-18d0-54bf-b32eca8c5c1d" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0a7e00ec-a1a5-81e8-5255-8844ac6fe87f" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7e98a0be-51ae-18d0-54bf-b32eca8c5c1d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0a7e00ec-a1a5-81e8-5255-8844ac6fe87f" xlink:type="arc" />
    <link:loc xlink:href="apyx-20200630.xsd#apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised" xlink:label="loc_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised_884c1675-2eb2-57a9-d0c6-496b350d3123" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0a7e00ec-a1a5-81e8-5255-8844ac6fe87f" xlink:to="loc_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised_884c1675-2eb2-57a9-d0c6-496b350d3123" xlink:type="arc" />
    <link:loc xlink:href="apyx-20200630.xsd#apyx_RepaymentofFinanceLeaseLiabilities" xlink:label="loc_apyx_RepaymentofFinanceLeaseLiabilities_3a7c01c8-df4f-598c-d0f4-496b3621d8c3" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0a7e00ec-a1a5-81e8-5255-8844ac6fe87f" xlink:to="loc_apyx_RepaymentofFinanceLeaseLiabilities_3a7c01c8-df4f-598c-d0f4-496b3621d8c3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13d5d34e-e391-ca89-d84d-71b1e1c2a78c" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7e98a0be-51ae-18d0-54bf-b32eca8c5c1d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13d5d34e-e391-ca89-d84d-71b1e1c2a78c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_002f9190-e528-4c20-fecc-961a16ab3d50" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13d5d34e-e391-ca89-d84d-71b1e1c2a78c" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_002f9190-e528-4c20-fecc-961a16ab3d50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_fb4a1534-3ea3-3150-f601-42486b71bc63" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13d5d34e-e391-ca89-d84d-71b1e1c2a78c" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_fb4a1534-3ea3-3150-f601-42486b71bc63" xlink:type="arc" />
    <link:loc xlink:href="apyx-20200630.xsd#apyx_ProvisionForInventoryObsolescence" xlink:label="loc_apyx_ProvisionForInventoryObsolescence_70980c12-4552-76cd-6aea-496b35e06822" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13d5d34e-e391-ca89-d84d-71b1e1c2a78c" xlink:to="loc_apyx_ProvisionForInventoryObsolescence_70980c12-4552-76cd-6aea-496b35e06822" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_8e70545b-e41a-5c88-3aeb-15f273c05266" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13d5d34e-e391-ca89-d84d-71b1e1c2a78c" xlink:to="loc_us-gaap_ShareBasedCompensation_8e70545b-e41a-5c88-3aeb-15f273c05266" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnInvestments" xlink:label="loc_us-gaap_GainLossOnInvestments_455e03f5-a15c-e45e-dbed-b386cb838666" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13d5d34e-e391-ca89-d84d-71b1e1c2a78c" xlink:to="loc_us-gaap_GainLossOnInvestments_455e03f5-a15c-e45e-dbed-b386cb838666" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_62c92b83-f76e-68ff-4453-8ab3478d0029" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13d5d34e-e391-ca89-d84d-71b1e1c2a78c" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_62c92b83-f76e-68ff-4453-8ab3478d0029" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_753ca67e-e0b1-89f6-0f4c-664d01a2b0f7" xlink:type="locator" />
    <link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13d5d34e-e391-ca89-d84d-71b1e1c2a78c" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_753ca67e-e0b1-89f6-0f4c-664d01a2b0f7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_30a606b8-7e33-f76c-e640-a59fba42c06a" xlink:type="locator" />
    <link:calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13d5d34e-e391-ca89-d84d-71b1e1c2a78c" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_30a606b8-7e33-f76c-e640-a59fba42c06a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_660d037d-5031-2fde-c0d3-d2b6978292ac" xlink:type="locator" />
    <link:calculationArc order="9" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13d5d34e-e391-ca89-d84d-71b1e1c2a78c" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_660d037d-5031-2fde-c0d3-d2b6978292ac" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_1aefa3b7-6b7a-d481-5bdc-6b8b587c627e" xlink:type="locator" />
    <link:calculationArc order="10" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13d5d34e-e391-ca89-d84d-71b1e1c2a78c" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_1aefa3b7-6b7a-d481-5bdc-6b8b587c627e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_4b0bcec4-8cac-770b-1104-d9ba7647c257" xlink:type="locator" />
    <link:calculationArc order="11" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13d5d34e-e391-ca89-d84d-71b1e1c2a78c" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_4b0bcec4-8cac-770b-1104-d9ba7647c257" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2794b8a8-762d-d243-a2f5-a00d52d74432" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7e98a0be-51ae-18d0-54bf-b32eca8c5c1d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2794b8a8-762d-d243-a2f5-a00d52d74432" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ca48a49a-2cde-cf3d-6904-e8f08b6e1fbb" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2794b8a8-762d-d243-a2f5-a00d52d74432" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ca48a49a-2cde-cf3d-6904-e8f08b6e1fbb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_3d52926a-06eb-6b3a-527c-ff175422ed87" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2794b8a8-762d-d243-a2f5-a00d52d74432" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_3d52926a-06eb-6b3a-527c-ff175422ed87" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_c021636d-c733-0519-5809-dfdfd4979620" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2794b8a8-762d-d243-a2f5-a00d52d74432" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_c021636d-c733-0519-5809-dfdfd4979620" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c3fb4920-0b72-7fd0-429d-d910e936dd99" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7e98a0be-51ae-18d0-54bf-b32eca8c5c1d" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c3fb4920-0b72-7fd0-429d-d910e936dd99" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" xlink:type="extended" />
  <link:calculationLink xlink:role="http://apyxmedical.com/role/ConsolidatedStatementsOfOperations" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_da1a9111-3960-6334-38ac-32be56368293" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9ff0f538-863f-dffc-da3e-5378e55a2439" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_da1a9111-3960-6334-38ac-32be56368293" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9ff0f538-863f-dffc-da3e-5378e55a2439" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_01f4f849-ade5-f04f-1204-64d74a0c2886" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_da1a9111-3960-6334-38ac-32be56368293" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_01f4f849-ade5-f04f-1204-64d74a0c2886" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_d1241922-8a19-0b86-133e-a1933036fe7e" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_922daf79-4589-2010-458b-2bc250462d25" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_d1241922-8a19-0b86-133e-a1933036fe7e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_922daf79-4589-2010-458b-2bc250462d25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaap_ProfessionalFees_e2b46067-813f-4245-69c7-0babbeafa377" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_d1241922-8a19-0b86-133e-a1933036fe7e" xlink:to="loc_us-gaap_ProfessionalFees_e2b46067-813f-4245-69c7-0babbeafa377" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalariesAndWages" xlink:label="loc_us-gaap_SalariesAndWages_4e1cd918-563c-8f0c-9577-56ee74a25b62" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_d1241922-8a19-0b86-133e-a1933036fe7e" xlink:to="loc_us-gaap_SalariesAndWages_4e1cd918-563c-8f0c-9577-56ee74a25b62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_89404ae6-0808-876c-4ac7-0c429ea9ed38" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_d1241922-8a19-0b86-133e-a1933036fe7e" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_89404ae6-0808-876c-4ac7-0c429ea9ed38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_002f9190-e528-4c20-fecc-961a16ab3d50" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_326571dd-2089-b65a-821d-3163d8518a05" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_002f9190-e528-4c20-fecc-961a16ab3d50" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_326571dd-2089-b65a-821d-3163d8518a05" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_497f98e6-8a11-3c53-7076-ee6aaae664ce" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_326571dd-2089-b65a-821d-3163d8518a05" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_497f98e6-8a11-3c53-7076-ee6aaae664ce" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeOperating" xlink:label="loc_us-gaap_InterestIncomeOperating_26dd6f54-ff36-2514-c7c3-79c67c5774ff" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_497f98e6-8a11-3c53-7076-ee6aaae664ce" xlink:to="loc_us-gaap_InterestIncomeOperating_26dd6f54-ff36-2514-c7c3-79c67c5774ff" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_70961961-6a13-30f4-732a-8e29cef0bea0" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_497f98e6-8a11-3c53-7076-ee6aaae664ce" xlink:to="loc_us-gaap_InterestExpense_70961961-6a13-30f4-732a-8e29cef0bea0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_cab3778c-ed0a-c5c3-23e4-24869228ae7f" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_497f98e6-8a11-3c53-7076-ee6aaae664ce" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_cab3778c-ed0a-c5c3-23e4-24869228ae7f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_86cfb7da-c050-ac7c-919e-7f811affb4ae" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_326571dd-2089-b65a-821d-3163d8518a05" xlink:to="loc_us-gaap_OperatingIncomeLoss_86cfb7da-c050-ac7c-919e-7f811affb4ae" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_6a75c878-dfaf-e368-936e-ce293fe86f6f" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_002f9190-e528-4c20-fecc-961a16ab3d50" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_6a75c878-dfaf-e368-936e-ce293fe86f6f" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/Cover" xlink:type="extended" />
  <link:calculationLink xlink:role="http://apyxmedical.com/role/EarningsPerShare" xlink:type="extended" />
  <link:calculationLink xlink:role="http://apyxmedical.com/role/EarningsPerShareDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://apyxmedical.com/role/EarningsPerShareTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://apyxmedical.com/role/GeographicAndSegmentInformation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://apyxmedical.com/role/GeographicAndSegmentInformationGeographicDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://apyxmedical.com/role/GeographicAndSegmentInformationNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://apyxmedical.com/role/GeographicAndSegmentInformationReportableSegmentDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://apyxmedical.com/role/GeographicAndSegmentInformationTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://apyxmedical.com/role/IncomeTaxes" xlink:type="extended" />
  <link:calculationLink xlink:role="http://apyxmedical.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://apyxmedical.com/role/IncomeTaxesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://apyxmedical.com/role/IncomeTaxesUnrecognizedTaxBenefitsRollForwardDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://apyxmedical.com/role/Inventories" xlink:type="extended" />
  <link:calculationLink xlink:role="http://apyxmedical.com/role/InventoriesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_aa7cc103-d668-cf3b-6875-81c99ffeac19" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryGross" xlink:label="loc_us-gaap_InventoryGross_94fef42f-79e8-6ba5-8b50-111a59f6360d" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_aa7cc103-d668-cf3b-6875-81c99ffeac19" xlink:to="loc_us-gaap_InventoryGross_94fef42f-79e8-6ba5-8b50-111a59f6360d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_us-gaap_InventoryRawMaterials_80b2cab3-30ae-20d1-0cea-6c990f5012bd" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_94fef42f-79e8-6ba5-8b50-111a59f6360d" xlink:to="loc_us-gaap_InventoryRawMaterials_80b2cab3-30ae-20d1-0cea-6c990f5012bd" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaap_InventoryWorkInProcess_c2b6624f-4172-33cb-87ca-3e23d17f2460" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_94fef42f-79e8-6ba5-8b50-111a59f6360d" xlink:to="loc_us-gaap_InventoryWorkInProcess_c2b6624f-4172-33cb-87ca-3e23d17f2460" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaap_InventoryFinishedGoods_b4994565-276e-19f8-ba9d-e3a584b51998" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_94fef42f-79e8-6ba5-8b50-111a59f6360d" xlink:to="loc_us-gaap_InventoryFinishedGoods_b4994565-276e-19f8-ba9d-e3a584b51998" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryValuationReserves" xlink:label="loc_us-gaap_InventoryValuationReserves_8ae06fed-5cf2-cf18-5f70-4f609a7c244e" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_aa7cc103-d668-cf3b-6875-81c99ffeac19" xlink:to="loc_us-gaap_InventoryValuationReserves_8ae06fed-5cf2-cf18-5f70-4f609a7c244e" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/InventoriesInventoriesNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://apyxmedical.com/role/InventoriesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://apyxmedical.com/role/RecentAccountingPronouncements" xlink:type="extended" />
  <link:calculationLink xlink:role="http://apyxmedical.com/role/RelatedPartyTransactions" xlink:type="extended" />
  <link:calculationLink xlink:role="http://apyxmedical.com/role/RelatedPartyTransactionsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://apyxmedical.com/role/StockBasedCompensation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://apyxmedical.com/role/StockBasedCompensationFairValueAssumptionsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://apyxmedical.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://apyxmedical.com/role/StockBasedCompensationSummaryOfStockOptionsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://apyxmedical.com/role/StockBasedCompensationTables" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>apyx-20200630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://apyxmedical.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:href="apyx-20200630.xsd#AccruedExpensesAndOtherCurrentLiabilities" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="apyx-20200630.xsd#AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:href="apyx-20200630.xsd#AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/BasisOfPresentation" xlink:href="apyx-20200630.xsd#BasisOfPresentation" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/BasisOfPresentationPolicies" xlink:href="apyx-20200630.xsd#BasisOfPresentationPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/ChangeInAccountingPolicy" xlink:href="apyx-20200630.xsd#ChangeInAccountingPolicy" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/CommitmentsAndContingencies" xlink:href="apyx-20200630.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:href="apyx-20200630.xsd#CommitmentsAndContingenciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/ConsolidatedBalanceSheets" xlink:href="apyx-20200630.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="apyx-20200630.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="apyx-20200630.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" xlink:href="apyx-20200630.xsd#ConsolidatedStatementsOfChangesInStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/ConsolidatedStatementsOfOperations" xlink:href="apyx-20200630.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/Cover" xlink:href="apyx-20200630.xsd#Cover" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/EarningsPerShare" xlink:href="apyx-20200630.xsd#EarningsPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/EarningsPerShareDetails" xlink:href="apyx-20200630.xsd#EarningsPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/EarningsPerShareTables" xlink:href="apyx-20200630.xsd#EarningsPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/GeographicAndSegmentInformation" xlink:href="apyx-20200630.xsd#GeographicAndSegmentInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/GeographicAndSegmentInformationGeographicDetails" xlink:href="apyx-20200630.xsd#GeographicAndSegmentInformationGeographicDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/GeographicAndSegmentInformationNarrativeDetails" xlink:href="apyx-20200630.xsd#GeographicAndSegmentInformationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/GeographicAndSegmentInformationReportableSegmentDetails" xlink:href="apyx-20200630.xsd#GeographicAndSegmentInformationReportableSegmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/GeographicAndSegmentInformationTables" xlink:href="apyx-20200630.xsd#GeographicAndSegmentInformationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/IncomeTaxes" xlink:href="apyx-20200630.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/IncomeTaxesNarrativeDetails" xlink:href="apyx-20200630.xsd#IncomeTaxesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/IncomeTaxesTables" xlink:href="apyx-20200630.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/IncomeTaxesUnrecognizedTaxBenefitsRollForwardDetails" xlink:href="apyx-20200630.xsd#IncomeTaxesUnrecognizedTaxBenefitsRollForwardDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/Inventories" xlink:href="apyx-20200630.xsd#Inventories" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/InventoriesDetails" xlink:href="apyx-20200630.xsd#InventoriesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/InventoriesInventoriesNarrativeDetails" xlink:href="apyx-20200630.xsd#InventoriesInventoriesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/InventoriesTables" xlink:href="apyx-20200630.xsd#InventoriesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/RecentAccountingPronouncements" xlink:href="apyx-20200630.xsd#RecentAccountingPronouncements" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/RelatedPartyTransactions" xlink:href="apyx-20200630.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/RelatedPartyTransactionsDetails" xlink:href="apyx-20200630.xsd#RelatedPartyTransactionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/StockBasedCompensation" xlink:href="apyx-20200630.xsd#StockBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/StockBasedCompensationFairValueAssumptionsDetails" xlink:href="apyx-20200630.xsd#StockBasedCompensationFairValueAssumptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/StockBasedCompensationNarrativeDetails" xlink:href="apyx-20200630.xsd#StockBasedCompensationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/StockBasedCompensationSummaryOfStockOptionsDetails" xlink:href="apyx-20200630.xsd#StockBasedCompensationSummaryOfStockOptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/StockBasedCompensationTables" xlink:href="apyx-20200630.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:definitionLink xlink:role="http://apyxmedical.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:type="extended" />
  <link:definitionLink xlink:role="http://apyxmedical.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://apyxmedical.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://apyxmedical.com/role/BasisOfPresentation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://apyxmedical.com/role/BasisOfPresentationPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://apyxmedical.com/role/ChangeInAccountingPolicy" xlink:type="extended" />
  <link:definitionLink xlink:role="http://apyxmedical.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://apyxmedical.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_B080252A18CB7D8737D3BFB854FC5A91" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsTable" xlink:label="loc_us-gaap_OtherCommitmentsTable_16D8463E9707F9217AE9BFB854FC6F13" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_B080252A18CB7D8737D3BFB854FC5A91" xlink:to="loc_us-gaap_OtherCommitmentsTable_16D8463E9707F9217AE9BFB854FC6F13" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_0EC59D5E1F2909CCC592BFB854FC0626" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_16D8463E9707F9217AE9BFB854FC6F13" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_0EC59D5E1F2909CCC592BFB854FC0626" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_F7601F4C1D9003F2DF81BFB854FCC85D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_0EC59D5E1F2909CCC592BFB854FC0626" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_F7601F4C1D9003F2DF81BFB854FCC85D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_F7601F4C1D9003F2DF81BFB854FCC85D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_0EC59D5E1F2909CCC592BFB854FC0626" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_F7601F4C1D9003F2DF81BFB854FCC85D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_5C91E5D9ECDD3B2D5127BFB854FC72AC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_F7601F4C1D9003F2DF81BFB854FCC85D" xlink:to="loc_us-gaap_SubsequentEventMember_5C91E5D9ECDD3B2D5127BFB854FC72AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_111B40AFDCE6995E68E1BFB854FC87BF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_16D8463E9707F9217AE9BFB854FC6F13" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_111B40AFDCE6995E68E1BFB854FC87BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="loc_us-gaap_LossContingencyNatureDomain_806B261CF0A034EF5383BFB854FC295E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_111B40AFDCE6995E68E1BFB854FC87BF" xlink:to="loc_us-gaap_LossContingencyNatureDomain_806B261CF0A034EF5383BFB854FC295E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="loc_us-gaap_LossContingencyNatureDomain_806B261CF0A034EF5383BFB854FC295E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_111B40AFDCE6995E68E1BFB854FC87BF" xlink:to="loc_us-gaap_LossContingencyNatureDomain_806B261CF0A034EF5383BFB854FC295E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnfavorableRegulatoryActionMember" xlink:label="loc_us-gaap_UnfavorableRegulatoryActionMember_5D6BBFBD0B5C957517F4BFB854FC5F5C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_806B261CF0A034EF5383BFB854FC295E" xlink:to="loc_us-gaap_UnfavorableRegulatoryActionMember_5D6BBFBD0B5C957517F4BFB854FC5F5C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusAxis" xlink:label="loc_us-gaap_LitigationStatusAxis_0129E62791E4A5EA2225BFB854FCCB33" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_16D8463E9707F9217AE9BFB854FC6F13" xlink:to="loc_us-gaap_LitigationStatusAxis_0129E62791E4A5EA2225BFB854FCCB33" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="loc_us-gaap_LitigationStatusDomain_A04A1D6F1B05483D14CCBFB854FC5D23_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_0129E62791E4A5EA2225BFB854FCCB33" xlink:to="loc_us-gaap_LitigationStatusDomain_A04A1D6F1B05483D14CCBFB854FC5D23_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="loc_us-gaap_LitigationStatusDomain_A04A1D6F1B05483D14CCBFB854FC5D23" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_0129E62791E4A5EA2225BFB854FCCB33" xlink:to="loc_us-gaap_LitigationStatusDomain_A04A1D6F1B05483D14CCBFB854FC5D23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PendingLitigationMember" xlink:label="loc_us-gaap_PendingLitigationMember_250ACA3EC6394E3D0755BFB854FC1572" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_A04A1D6F1B05483D14CCBFB854FC5D23" xlink:to="loc_us-gaap_PendingLitigationMember_250ACA3EC6394E3D0755BFB854FC1572" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_E16CB1CB071BFFBC165BBFB854FC5D8C" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_16D8463E9707F9217AE9BFB854FC6F13" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_E16CB1CB071BFFBC165BBFB854FC5D8C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_B5891504B184AD4553DABFB854FC8BEA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_E16CB1CB071BFFBC165BBFB854FC5D8C" xlink:to="loc_us-gaap_RelatedPartyDomain_B5891504B184AD4553DABFB854FC8BEA_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_B5891504B184AD4553DABFB854FC8BEA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_E16CB1CB071BFFBC165BBFB854FC5D8C" xlink:to="loc_us-gaap_RelatedPartyDomain_B5891504B184AD4553DABFB854FC8BEA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateJointVentureMember" xlink:label="loc_us-gaap_CorporateJointVentureMember_B6683DEF56C11D149A62BFB854FCF6E2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_B5891504B184AD4553DABFB854FC8BEA" xlink:to="loc_us-gaap_CorporateJointVentureMember_B6683DEF56C11D149A62BFB854FCF6E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_2C8402FFA33D78725CF3BFB854FCAE1B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_B080252A18CB7D8737D3BFB854FC5A91" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_2C8402FFA33D78725CF3BFB854FCAE1B" xlink:type="arc" />
    <link:loc xlink:href="apyx-20200630.xsd#apyx_LossContingencyAccrualTotalAccruedToDate" xlink:label="loc_apyx_LossContingencyAccrualTotalAccruedToDate_B20CA64750D61DADEB04BFB854FC11EA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_B080252A18CB7D8737D3BFB854FC5A91" xlink:to="loc_apyx_LossContingencyAccrualTotalAccruedToDate_B20CA64750D61DADEB04BFB854FC11EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseObligation" xlink:label="loc_us-gaap_PurchaseObligation_752F2D5B085034C9F22FBFB854FC1D57" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_B080252A18CB7D8737D3BFB854FC5A91" xlink:to="loc_us-gaap_PurchaseObligation_752F2D5B085034C9F22FBFB854FC1D57" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_4D880F0AEFFECEE9DABDBFB854FC573E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_B080252A18CB7D8737D3BFB854FC5A91" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_4D880F0AEFFECEE9DABDBFB854FC573E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInterestInJointVenture" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInJointVenture_CB49F4E6932EDD6D7169BFC1E3350193" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_B080252A18CB7D8737D3BFB854FC5A91" xlink:to="loc_us-gaap_PaymentsToAcquireInterestInJointVenture_CB49F4E6932EDD6D7169BFC1E3350193" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/ConsolidatedBalanceSheets" xlink:type="extended" />
  <link:definitionLink xlink:role="http://apyxmedical.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <link:definitionLink xlink:role="http://apyxmedical.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended" />
  <link:definitionLink xlink:role="http://apyxmedical.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_AADBAB236E0E6D442A8CD6069AC20EF2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_8526B04C1E4D8E5264DDD6069AC2742A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_AADBAB236E0E6D442A8CD6069AC20EF2" xlink:to="loc_us-gaap_StatementTable_8526B04C1E4D8E5264DDD6069AC2742A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_F449AE1669F26354E19DD6069AC213EF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_8526B04C1E4D8E5264DDD6069AC2742A" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_F449AE1669F26354E19DD6069AC213EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_6809CF8DA9057AD5719AD6069AC2F869_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_F449AE1669F26354E19DD6069AC213EF" xlink:to="loc_us-gaap_EquityComponentDomain_6809CF8DA9057AD5719AD6069AC2F869_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_6809CF8DA9057AD5719AD6069AC2F869" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_F449AE1669F26354E19DD6069AC213EF" xlink:to="loc_us-gaap_EquityComponentDomain_6809CF8DA9057AD5719AD6069AC2F869" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_0422BA68AD424DA0E8F2D6069AC26E0A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6809CF8DA9057AD5719AD6069AC2F869" xlink:to="loc_us-gaap_CommonStockMember_0422BA68AD424DA0E8F2D6069AC26E0A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_4715C9BD3D81C0F97FC0D6069AC25CE2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6809CF8DA9057AD5719AD6069AC2F869" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_4715C9BD3D81C0F97FC0D6069AC25CE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_AB9693376F2E74693A69D6069AC2A596" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6809CF8DA9057AD5719AD6069AC2F869" xlink:to="loc_us-gaap_RetainedEarningsMember_AB9693376F2E74693A69D6069AC2A596" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_86939D5C0B269DA2E2F2D6069AC2FC15" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_AADBAB236E0E6D442A8CD6069AC20EF2" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_86939D5C0B269DA2E2F2D6069AC2FC15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_AF298F00B6D3E6BD2861D6069AC228BA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_86939D5C0B269DA2E2F2D6069AC2FC15" xlink:to="loc_us-gaap_SharesIssued_AF298F00B6D3E6BD2861D6069AC228BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_C41DD87C48BE5BE023F4D6069AC2720A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_86939D5C0B269DA2E2F2D6069AC2FC15" xlink:to="loc_us-gaap_StockholdersEquity_C41DD87C48BE5BE023F4D6069AC2720A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_7ACA11283BE32C55FBB4D6069AC2D086" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_86939D5C0B269DA2E2F2D6069AC2FC15" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_7ACA11283BE32C55FBB4D6069AC2D086" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_C44D4A9726F11F2B7AEAD6069AC28067" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_86939D5C0B269DA2E2F2D6069AC2FC15" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_C44D4A9726F11F2B7AEAD6069AC28067" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_04C54C986730DC435FDCD6069AC24329" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_86939D5C0B269DA2E2F2D6069AC2FC15" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_04C54C986730DC435FDCD6069AC24329" xlink:type="arc" />
    <link:loc xlink:href="apyx-20200630.xsd#apyx_StockSwapToAcquireOptionsShares" xlink:label="loc_apyx_StockSwapToAcquireOptionsShares_9C5E056259485363517DD6069AC2F1BF" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_86939D5C0B269DA2E2F2D6069AC2FC15" xlink:to="loc_apyx_StockSwapToAcquireOptionsShares_9C5E056259485363517DD6069AC2F1BF" xlink:type="arc" />
    <link:loc xlink:href="apyx-20200630.xsd#apyx_StockSwapToAcquireOptionsAmount" xlink:label="loc_apyx_StockSwapToAcquireOptionsAmount_7139DD371C6934BABA58D6069AC289C7" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_86939D5C0B269DA2E2F2D6069AC2FC15" xlink:to="loc_apyx_StockSwapToAcquireOptionsAmount_7139DD371C6934BABA58D6069AC289C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_24A7C8BD6DA25D026834D6069AC2EF19" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_86939D5C0B269DA2E2F2D6069AC2FC15" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_24A7C8BD6DA25D026834D6069AC2EF19" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/ConsolidatedStatementsOfOperations" xlink:type="extended" />
  <link:definitionLink xlink:role="http://apyxmedical.com/role/Cover" xlink:type="extended" />
  <link:definitionLink xlink:role="http://apyxmedical.com/role/EarningsPerShare" xlink:type="extended" />
  <link:definitionLink xlink:role="http://apyxmedical.com/role/EarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_43B16F01DFC6E9D6ADD9D39D8867169F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9D84AE31716A9480B9DDD39D88670943" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_43B16F01DFC6E9D6ADD9D39D8867169F" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9D84AE31716A9480B9DDD39D88670943" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_86007F7BC842894300F7D39D8867F269" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9D84AE31716A9480B9DDD39D88670943" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_86007F7BC842894300F7D39D8867F269" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8AD585E05442BDE73E75D39D8867CBD5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_86007F7BC842894300F7D39D8867F269" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8AD585E05442BDE73E75D39D8867CBD5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8AD585E05442BDE73E75D39D8867CBD5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_86007F7BC842894300F7D39D8867F269" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8AD585E05442BDE73E75D39D8867CBD5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OptionOnSecuritiesMember" xlink:label="loc_us-gaap_OptionOnSecuritiesMember_E0B82190008726D7EDB7D39D88675C39" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8AD585E05442BDE73E75D39D8867CBD5" xlink:to="loc_us-gaap_OptionOnSecuritiesMember_E0B82190008726D7EDB7D39D88675C39" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareReconciliationAbstract" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract_0A58A37F9B28F4C44242D39D88678353" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_43B16F01DFC6E9D6ADD9D39D8867169F" xlink:to="loc_us-gaap_EarningsPerShareReconciliationAbstract_0A58A37F9B28F4C44242D39D88678353" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_39DB1A329815CFA54EC3D39D8867B02D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_0A58A37F9B28F4C44242D39D88678353" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_39DB1A329815CFA54EC3D39D8867B02D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_6E82C9428DD4F51D0E86D39D88674287" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_43B16F01DFC6E9D6ADD9D39D8867169F" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_6E82C9428DD4F51D0E86D39D88674287" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_7AF0FE5800629847DE2AD39D8867C082" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_6E82C9428DD4F51D0E86D39D88674287" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_7AF0FE5800629847DE2AD39D8867C082" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_0BA41D1F5FFFAB09D4FFD39D886785BE" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_43B16F01DFC6E9D6ADD9D39D8867169F" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_0BA41D1F5FFFAB09D4FFD39D886785BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_2001D84E3C041BE9B92ED39D886793AE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_0BA41D1F5FFFAB09D4FFD39D886785BE" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_2001D84E3C041BE9B92ED39D886793AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_DE6DAE6F76F98E91C50CD39D88671D0B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_43B16F01DFC6E9D6ADD9D39D8867169F" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_DE6DAE6F76F98E91C50CD39D88671D0B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_EC7CED9E97E31028EAEAD39D8867F803" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_DE6DAE6F76F98E91C50CD39D88671D0B" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_EC7CED9E97E31028EAEAD39D8867F803" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/EarningsPerShareTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://apyxmedical.com/role/GeographicAndSegmentInformation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://apyxmedical.com/role/GeographicAndSegmentInformationGeographicDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_A7477FD94E055464EE864986255CD0EB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1920097A1E3AE19650644986255AFF96" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_A7477FD94E055464EE864986255CD0EB" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1920097A1E3AE19650644986255AFF96" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_4569ADE50954DA92893B4986255A5E14" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1920097A1E3AE19650644986255AFF96" xlink:to="loc_srt_StatementGeographicalAxis_4569ADE50954DA92893B4986255A5E14" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_04A775BCCF5750C955834986255B1102_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_4569ADE50954DA92893B4986255A5E14" xlink:to="loc_srt_SegmentGeographicalDomain_04A775BCCF5750C955834986255B1102_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_04A775BCCF5750C955834986255B1102" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_4569ADE50954DA92893B4986255A5E14" xlink:to="loc_srt_SegmentGeographicalDomain_04A775BCCF5750C955834986255B1102" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US" xlink:label="loc_country_US_E444E02013089433CCC54986255B2981" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_04A775BCCF5750C955834986255B1102" xlink:to="loc_country_US_E444E02013089433CCC54986255B2981" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonUsMember" xlink:label="loc_us-gaap_NonUsMember_DD38742FB5A8C66902B54986255CDAAA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_04A775BCCF5750C955834986255B1102" xlink:to="loc_us-gaap_NonUsMember_DD38742FB5A8C66902B54986255CDAAA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_C244329DD7DF7B46EAAA4986255CA82C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_A7477FD94E055464EE864986255CD0EB" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_C244329DD7DF7B46EAAA4986255CA82C" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/GeographicAndSegmentInformationNarrativeDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://apyxmedical.com/role/GeographicAndSegmentInformationReportableSegmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_52EDD22D91B111D503C6D39D86DE474D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_A41E645B5320D2869554D39D86DE4FD5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_52EDD22D91B111D503C6D39D86DE474D" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_A41E645B5320D2869554D39D86DE4FD5" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis" xlink:label="loc_srt_ConsolidationItemsAxis_4B9581ACFDC4ED40C247D39D86DE2231" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_A41E645B5320D2869554D39D86DE4FD5" xlink:to="loc_srt_ConsolidationItemsAxis_4B9581ACFDC4ED40C247D39D86DE2231" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain" xlink:label="loc_srt_ConsolidationItemsDomain_094112CC4BED4B751CC0D39D86DEC8A3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_4B9581ACFDC4ED40C247D39D86DE2231" xlink:to="loc_srt_ConsolidationItemsDomain_094112CC4BED4B751CC0D39D86DEC8A3_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain" xlink:label="loc_srt_ConsolidationItemsDomain_094112CC4BED4B751CC0D39D86DEC8A3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_4B9581ACFDC4ED40C247D39D86DE2231" xlink:to="loc_srt_ConsolidationItemsDomain_094112CC4BED4B751CC0D39D86DEC8A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember" xlink:label="loc_us-gaap_OperatingSegmentsMember_FC6D081906EA7BAD9D6AD39D86DED80F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_094112CC4BED4B751CC0D39D86DEC8A3" xlink:to="loc_us-gaap_OperatingSegmentsMember_FC6D081906EA7BAD9D6AD39D86DED80F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateNonSegmentMember" xlink:label="loc_us-gaap_CorporateNonSegmentMember_8C8041654208CA1EE336D39D86DE4A8F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_094112CC4BED4B751CC0D39D86DEC8A3" xlink:to="loc_us-gaap_CorporateNonSegmentMember_8C8041654208CA1EE336D39D86DE4A8F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_16A996FB8F4DABC847F8D39D86DECE98" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_A41E645B5320D2869554D39D86DE4FD5" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_16A996FB8F4DABC847F8D39D86DECE98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_12B889E55E2B19E40670D39D86DEDF4D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_16A996FB8F4DABC847F8D39D86DECE98" xlink:to="loc_us-gaap_SegmentDomain_12B889E55E2B19E40670D39D86DEDF4D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_12B889E55E2B19E40670D39D86DEDF4D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_16A996FB8F4DABC847F8D39D86DECE98" xlink:to="loc_us-gaap_SegmentDomain_12B889E55E2B19E40670D39D86DEDF4D" xlink:type="arc" />
    <link:loc xlink:href="apyx-20200630.xsd#apyx_AdvancedEnergyMember" xlink:label="loc_apyx_AdvancedEnergyMember_249C7ED2494D95742FF5D39D86DEA3AF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_12B889E55E2B19E40670D39D86DEDF4D" xlink:to="loc_apyx_AdvancedEnergyMember_249C7ED2494D95742FF5D39D86DEA3AF" xlink:type="arc" />
    <link:loc xlink:href="apyx-20200630.xsd#apyx_OEMMember" xlink:label="loc_apyx_OEMMember_C6233E727596433CEDBED39D86DEC55B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_12B889E55E2B19E40670D39D86DEDF4D" xlink:to="loc_apyx_OEMMember_C6233E727596433CEDBED39D86DEC55B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_EF8BCBE8BB654339A33DD39D86E13AB3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_52EDD22D91B111D503C6D39D86DE474D" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_EF8BCBE8BB654339A33DD39D86E13AB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_7121565AE3747798149CD39D86E159A7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_52EDD22D91B111D503C6D39D86DE474D" xlink:to="loc_us-gaap_OperatingIncomeLoss_7121565AE3747798149CD39D86E159A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeOperating" xlink:label="loc_us-gaap_InterestIncomeOperating_457D5A463748DA14F3C4D39D86E137D4" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_52EDD22D91B111D503C6D39D86DE474D" xlink:to="loc_us-gaap_InterestIncomeOperating_457D5A463748DA14F3C4D39D86E137D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_98E4BE720EDCF00179D9D39D86E1139D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_52EDD22D91B111D503C6D39D86DE474D" xlink:to="loc_us-gaap_InterestExpense_98E4BE720EDCF00179D9D39D86E1139D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_672883FDDF17A51766AAD39D86E1066D" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_52EDD22D91B111D503C6D39D86DE474D" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_672883FDDF17A51766AAD39D86E1066D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_72554666F0A129B3ABD5D39D86E290A6" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_52EDD22D91B111D503C6D39D86DE474D" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_72554666F0A129B3ABD5D39D86E290A6" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/GeographicAndSegmentInformationTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://apyxmedical.com/role/IncomeTaxes" xlink:type="extended" />
  <link:definitionLink xlink:role="http://apyxmedical.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://apyxmedical.com/role/IncomeTaxesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://apyxmedical.com/role/IncomeTaxesUnrecognizedTaxBenefitsRollForwardDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://apyxmedical.com/role/Inventories" xlink:type="extended" />
  <link:definitionLink xlink:role="http://apyxmedical.com/role/InventoriesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://apyxmedical.com/role/InventoriesInventoriesNarrativeDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://apyxmedical.com/role/InventoriesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://apyxmedical.com/role/RecentAccountingPronouncements" xlink:type="extended" />
  <link:definitionLink xlink:role="http://apyxmedical.com/role/RelatedPartyTransactions" xlink:type="extended" />
  <link:definitionLink xlink:role="http://apyxmedical.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_6DAEF7B5862D9C5D402FBFB854ED5A3C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7EF22884742C08857396BFB854EDDF97" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6DAEF7B5862D9C5D402FBFB854ED5A3C" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7EF22884742C08857396BFB854EDDF97" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_B870C914B84619014D3FBFB854EDD603" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7EF22884742C08857396BFB854EDDF97" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_B870C914B84619014D3FBFB854EDD603" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_BA3AE2F22A6D20D6C9E6BFB854EDE21B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_B870C914B84619014D3FBFB854EDD603" xlink:to="loc_us-gaap_RelatedPartyDomain_BA3AE2F22A6D20D6C9E6BFB854EDE21B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_BA3AE2F22A6D20D6C9E6BFB854EDE21B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_B870C914B84619014D3FBFB854EDD603" xlink:to="loc_us-gaap_RelatedPartyDomain_BA3AE2F22A6D20D6C9E6BFB854EDE21B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember" xlink:label="loc_srt_DirectorMember_67237E412EB4C4F98CBABFB854EDF5A8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_BA3AE2F22A6D20D6C9E6BFB854EDE21B" xlink:to="loc_srt_DirectorMember_67237E412EB4C4F98CBABFB854EDF5A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CoVenturerMember" xlink:label="loc_us-gaap_CoVenturerMember_F81C827CB6C123332640BFC0237AFB0A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_BA3AE2F22A6D20D6C9E6BFB854EDE21B" xlink:to="loc_us-gaap_CoVenturerMember_F81C827CB6C123332640BFC0237AFB0A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_E03EF95CFB414AD43D28BFB854ED1BE8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7EF22884742C08857396BFB854EDDF97" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_E03EF95CFB414AD43D28BFB854ED1BE8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_6715047C82CEA5F2DAFABFB854EDEE1E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_E03EF95CFB414AD43D28BFB854ED1BE8" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_6715047C82CEA5F2DAFABFB854EDEE1E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_6715047C82CEA5F2DAFABFB854EDEE1E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_E03EF95CFB414AD43D28BFB854ED1BE8" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_6715047C82CEA5F2DAFABFB854EDEE1E" xlink:type="arc" />
    <link:loc xlink:href="apyx-20200630.xsd#apyx_BulgariaManufacturingPlantPurchaseMember" xlink:label="loc_apyx_BulgariaManufacturingPlantPurchaseMember_DBE958BA8BEC2213A00BBFB854EDA056" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_6715047C82CEA5F2DAFABFB854EDEE1E" xlink:to="loc_apyx_BulgariaManufacturingPlantPurchaseMember_DBE958BA8BEC2213A00BBFB854EDA056" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent_F1ED917A9B1DB51F9E6CBFB854EDD077" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6DAEF7B5862D9C5D402FBFB854ED5A3C" xlink:to="loc_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent_F1ED917A9B1DB51F9E6CBFB854EDD077" xlink:type="arc" />
    <link:loc xlink:href="apyx-20200630.xsd#apyx_TermOfPaymentDueNotesPayableRelatedParties" xlink:label="loc_apyx_TermOfPaymentDueNotesPayableRelatedParties_2333DE9F064FD5347799BFB854EDF8EF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6DAEF7B5862D9C5D402FBFB854ED5A3C" xlink:to="loc_apyx_TermOfPaymentDueNotesPayableRelatedParties_2333DE9F064FD5347799BFB854EDF8EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:label="loc_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_300AC56CE9F4E2C49D85BFB854EDEF97" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6DAEF7B5862D9C5D402FBFB854ED5A3C" xlink:to="loc_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_300AC56CE9F4E2C49D85BFB854EDEF97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_B7BD730538EEF4D12454BFB854EDE062" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6DAEF7B5862D9C5D402FBFB854ED5A3C" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_B7BD730538EEF4D12454BFB854EDE062" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/StockBasedCompensation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://apyxmedical.com/role/StockBasedCompensationFairValueAssumptionsDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://apyxmedical.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57B22A52C27FFE4C63CBC495293F7A1A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2C0462C637DC30D8E732C49529371BDA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57B22A52C27FFE4C63CBC495293F7A1A" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2C0462C637DC30D8E732C49529371BDA" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_A8BDC8C1821F342A2E36C4952937DCE6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2C0462C637DC30D8E732C49529371BDA" xlink:to="loc_us-gaap_StatementClassOfStockAxis_A8BDC8C1821F342A2E36C4952937DCE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2EDB080F685A8F4A5C69C4952937DE04_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_A8BDC8C1821F342A2E36C4952937DCE6" xlink:to="loc_us-gaap_ClassOfStockDomain_2EDB080F685A8F4A5C69C4952937DE04_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2EDB080F685A8F4A5C69C4952937DE04" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_A8BDC8C1821F342A2E36C4952937DCE6" xlink:to="loc_us-gaap_ClassOfStockDomain_2EDB080F685A8F4A5C69C4952937DE04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_A1A60A7E52571081A10FC4952937D6A5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_2EDB080F685A8F4A5C69C4952937DE04" xlink:to="loc_us-gaap_CommonStockMember_A1A60A7E52571081A10FC4952937D6A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_5A4C5108D3E50BF4C189C495293FE0C3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57B22A52C27FFE4C63CBC495293F7A1A" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_5A4C5108D3E50BF4C189C495293FE0C3" xlink:type="arc" />
    <link:loc xlink:href="apyx-20200630.xsd#apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived" xlink:label="loc_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived_082C903DA73DF4B5D6AFC495293F5168" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57B22A52C27FFE4C63CBC495293F7A1A" xlink:to="loc_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived_082C903DA73DF4B5D6AFC495293F5168" xlink:type="arc" />
    <link:loc xlink:href="apyx-20200630.xsd#apyx_StockIssuedDuringPeriodSharesStockSwaps" xlink:label="loc_apyx_StockIssuedDuringPeriodSharesStockSwaps_53733ECD8E2A5546D154C495293F9AD6" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57B22A52C27FFE4C63CBC495293F7A1A" xlink:to="loc_apyx_StockIssuedDuringPeriodSharesStockSwaps_53733ECD8E2A5546D154C495293F9AD6" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/StockBasedCompensationSummaryOfStockOptionsDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://apyxmedical.com/role/StockBasedCompensationTables" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>apyx-20200630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_9304E77B719B828889A349862501FE31_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract_9304E77B719B828889A349862501FE31" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_9304E77B719B828889A349862501FE31" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9304E77B719B828889A349862501FE31" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract_9304E77B719B828889A349862501FE31" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_12CDCC9593C2D88BC1EB498625026467_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_12CDCC9593C2D88BC1EB498625026467" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefits roll-forward</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_12CDCC9593C2D88BC1EB498625026467_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_12CDCC9593C2D88BC1EB498625026467" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_12CDCC9593C2D88BC1EB498625026467" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_12CDCC9593C2D88BC1EB498625026467" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_12CDCC9593C2D88BC1EB498625026467" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_FEF69DCBA3804FC6862549862545D2A4_label_en-US" xlink:label="lab_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_FEF69DCBA3804FC6862549862545D2A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Changes and Error Corrections [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_FEF69DCBA3804FC6862549862545D2A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_FEF69DCBA3804FC6862549862545D2A4" xlink:to="lab_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_FEF69DCBA3804FC6862549862545D2A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingChangesTextBlock_88AEFDD77A8B053B78D94986254556F0_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingChangesTextBlock_88AEFDD77A8B053B78D94986254556F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Accounting Policy</link:label>
    <link:label id="lab_us-gaap_AccountingChangesTextBlock_88AEFDD77A8B053B78D94986254556F0_label_en-US" xlink:label="lab_us-gaap_AccountingChangesTextBlock_88AEFDD77A8B053B78D94986254556F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Changes [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingChangesTextBlock" xlink:label="loc_us-gaap_AccountingChangesTextBlock_88AEFDD77A8B053B78D94986254556F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingChangesTextBlock_88AEFDD77A8B053B78D94986254556F0" xlink:to="lab_us-gaap_AccountingChangesTextBlock_88AEFDD77A8B053B78D94986254556F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_63A8DCB40FEE06326E4FC4952937E30F_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_63A8DCB40FEE06326E4FC4952937E30F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_63A8DCB40FEE06326E4FC4952937E30F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_63A8DCB40FEE06326E4FC4952937E30F" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_63A8DCB40FEE06326E4FC4952937E30F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2C0462C637DC30D8E732C49529371BDA_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2C0462C637DC30D8E732C49529371BDA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2C0462C637DC30D8E732C49529371BDA_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2C0462C637DC30D8E732C49529371BDA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2C0462C637DC30D8E732C49529371BDA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2C0462C637DC30D8E732C49529371BDA" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2C0462C637DC30D8E732C49529371BDA" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_A8BDC8C1821F342A2E36C4952937DCE6_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis_A8BDC8C1821F342A2E36C4952937DCE6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_A8BDC8C1821F342A2E36C4952937DCE6_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis_A8BDC8C1821F342A2E36C4952937DCE6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_A8BDC8C1821F342A2E36C4952937DCE6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis_A8BDC8C1821F342A2E36C4952937DCE6" xlink:to="lab_us-gaap_StatementClassOfStockAxis_A8BDC8C1821F342A2E36C4952937DCE6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfStockDomain_2EDB080F685A8F4A5C69C4952937DE04_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain_2EDB080F685A8F4A5C69C4952937DE04" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_2EDB080F685A8F4A5C69C4952937DE04_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain_2EDB080F685A8F4A5C69C4952937DE04" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2EDB080F685A8F4A5C69C4952937DE04" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain_2EDB080F685A8F4A5C69C4952937DE04" xlink:to="lab_us-gaap_ClassOfStockDomain_2EDB080F685A8F4A5C69C4952937DE04" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockMember_A1A60A7E52571081A10FC4952937D6A5_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember_A1A60A7E52571081A10FC4952937D6A5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_A1A60A7E52571081A10FC4952937D6A5_label_en-US" xlink:label="lab_us-gaap_CommonStockMember_A1A60A7E52571081A10FC4952937D6A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_A1A60A7E52571081A10FC4952937D6A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_A1A60A7E52571081A10FC4952937D6A5" xlink:to="lab_us-gaap_CommonStockMember_A1A60A7E52571081A10FC4952937D6A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57B22A52C27FFE4C63CBC495293F7A1A_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57B22A52C27FFE4C63CBC495293F7A1A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57B22A52C27FFE4C63CBC495293F7A1A_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57B22A52C27FFE4C63CBC495293F7A1A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57B22A52C27FFE4C63CBC495293F7A1A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57B22A52C27FFE4C63CBC495293F7A1A" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57B22A52C27FFE4C63CBC495293F7A1A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_5A4C5108D3E50BF4C189C495293FE0C3_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_5A4C5108D3E50BF4C189C495293FE0C3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_5A4C5108D3E50BF4C189C495293FE0C3_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_5A4C5108D3E50BF4C189C495293FE0C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_5A4C5108D3E50BF4C189C495293FE0C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_5A4C5108D3E50BF4C189C495293FE0C3" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_5A4C5108D3E50BF4C189C495293FE0C3" xlink:type="arc" />
    <link:label id="lab_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived_082C903DA73DF4B5D6AFC495293F5168_terseLabel_en-US" xlink:label="lab_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived_082C903DA73DF4B5D6AFC495293F5168" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock swaps equity instruments received (in shares)</link:label>
    <link:label id="lab_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived_082C903DA73DF4B5D6AFC495293F5168_label_en-US" xlink:label="lab_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived_082C903DA73DF4B5D6AFC495293F5168" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Stock Swaps Equity Instruments Received</link:label>
    <link:label id="lab_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived_082C903DA73DF4B5D6AFC495293F5168_documentation_en-US" xlink:label="lab_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived_082C903DA73DF4B5D6AFC495293F5168" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Stock Swaps Equity Instruments Received</link:label>
    <link:loc xlink:href="apyx-20200630.xsd#apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived" xlink:label="loc_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived_082C903DA73DF4B5D6AFC495293F5168" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived_082C903DA73DF4B5D6AFC495293F5168" xlink:to="lab_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived_082C903DA73DF4B5D6AFC495293F5168" xlink:type="arc" />
    <link:label id="lab_apyx_StockIssuedDuringPeriodSharesStockSwaps_53733ECD8E2A5546D154C495293F9AD6_terseLabel_en-US" xlink:label="lab_apyx_StockIssuedDuringPeriodSharesStockSwaps_53733ECD8E2A5546D154C495293F9AD6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock swaps (in shares)</link:label>
    <link:label id="lab_apyx_StockIssuedDuringPeriodSharesStockSwaps_53733ECD8E2A5546D154C495293F9AD6_label_en-US" xlink:label="lab_apyx_StockIssuedDuringPeriodSharesStockSwaps_53733ECD8E2A5546D154C495293F9AD6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Stock Swaps</link:label>
    <link:label id="lab_apyx_StockIssuedDuringPeriodSharesStockSwaps_53733ECD8E2A5546D154C495293F9AD6_documentation_en-US" xlink:label="lab_apyx_StockIssuedDuringPeriodSharesStockSwaps_53733ECD8E2A5546D154C495293F9AD6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Stock Swaps</link:label>
    <link:loc xlink:href="apyx-20200630.xsd#apyx_StockIssuedDuringPeriodSharesStockSwaps" xlink:label="loc_apyx_StockIssuedDuringPeriodSharesStockSwaps_53733ECD8E2A5546D154C495293F9AD6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_StockIssuedDuringPeriodSharesStockSwaps_53733ECD8E2A5546D154C495293F9AD6" xlink:to="lab_apyx_StockIssuedDuringPeriodSharesStockSwaps_53733ECD8E2A5546D154C495293F9AD6" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_327D43FD2ED4F6AFEA9FD6069AD2DA7D_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_327D43FD2ED4F6AFEA9FD6069AD2DA7D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_327D43FD2ED4F6AFEA9FD6069AD2DA7D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_327D43FD2ED4F6AFEA9FD6069AD2DA7D" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_327D43FD2ED4F6AFEA9FD6069AD2DA7D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsAbstract_D38363928204D19AF33DD6069AD28B82_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract_D38363928204D19AF33DD6069AD28B82" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_D38363928204D19AF33DD6069AD28B82_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract_D38363928204D19AF33DD6069AD28B82" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_D38363928204D19AF33DD6069AD28B82" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_D38363928204D19AF33DD6069AD28B82" xlink:to="lab_us-gaap_AssetsAbstract_D38363928204D19AF33DD6069AD28B82" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_0AAB457CA449EAFBEF3FD6069AD2678D_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_0AAB457CA449EAFBEF3FD6069AD2678D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_0AAB457CA449EAFBEF3FD6069AD2678D_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_0AAB457CA449EAFBEF3FD6069AD2678D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_0AAB457CA449EAFBEF3FD6069AD2678D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0AAB457CA449EAFBEF3FD6069AD2678D" xlink:to="lab_us-gaap_AssetsCurrentAbstract_0AAB457CA449EAFBEF3FD6069AD2678D" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_B4D83D6AED6A63E316B2D6069AD2B830_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_B4D83D6AED6A63E316B2D6069AD2B830" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_B4D83D6AED6A63E316B2D6069AD2B830_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_B4D83D6AED6A63E316B2D6069AD2B830" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_B4D83D6AED6A63E316B2D6069AD2B830" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_B4D83D6AED6A63E316B2D6069AD2B830" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_B4D83D6AED6A63E316B2D6069AD2B830" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_A3F51ED471340BBC97DBD6069AD21467_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_A3F51ED471340BBC97DBD6069AD21467" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade accounts receivable, net of allowance of $760 and $273</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_A3F51ED471340BBC97DBD6069AD21467_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_A3F51ED471340BBC97DBD6069AD21467" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_A3F51ED471340BBC97DBD6069AD21467" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_A3F51ED471340BBC97DBD6069AD21467" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent_A3F51ED471340BBC97DBD6069AD21467" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxesReceivable_44328DD25C5B534C894ED6069AD228BA_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesReceivable_44328DD25C5B534C894ED6069AD228BA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax receivables</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesReceivable_44328DD25C5B534C894ED6069AD228BA_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesReceivable_44328DD25C5B534C894ED6069AD228BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Receivable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="loc_us-gaap_IncomeTaxesReceivable_44328DD25C5B534C894ED6069AD228BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesReceivable_44328DD25C5B534C894ED6069AD228BA" xlink:to="lab_us-gaap_IncomeTaxesReceivable_44328DD25C5B534C894ED6069AD228BA" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_1B3D6BA8EA90C43E3812D6069AE17485_terseLabel_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent_1B3D6BA8EA90C43E3812D6069AE17485" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_1B3D6BA8EA90C43E3812D6069AE17485_label_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent_1B3D6BA8EA90C43E3812D6069AE17485" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Receivables, Net, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_1B3D6BA8EA90C43E3812D6069AE17485" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherReceivablesNetCurrent_1B3D6BA8EA90C43E3812D6069AE17485" xlink:to="lab_us-gaap_OtherReceivablesNetCurrent_1B3D6BA8EA90C43E3812D6069AE17485" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNet_B5BA46D1558F9FF49934D6069AE140F0_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet_B5BA46D1558F9FF49934D6069AE140F0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Inventories, net of provision for obsolescence of $685 and $392</link:label>
    <link:label id="lab_us-gaap_InventoryNet_B5BA46D1558F9FF49934D6069AE140F0_label_en-US" xlink:label="lab_us-gaap_InventoryNet_B5BA46D1558F9FF49934D6069AE140F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_B5BA46D1558F9FF49934D6069AE140F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet_B5BA46D1558F9FF49934D6069AE140F0" xlink:to="lab_us-gaap_InventoryNet_B5BA46D1558F9FF49934D6069AE140F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_A12D0730C9773EFF503ED6069AE198D5_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_A12D0730C9773EFF503ED6069AE198D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_A12D0730C9773EFF503ED6069AE198D5_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_A12D0730C9773EFF503ED6069AE198D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_A12D0730C9773EFF503ED6069AE198D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_A12D0730C9773EFF503ED6069AE198D5" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_A12D0730C9773EFF503ED6069AE198D5" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrent_130EF5287E7688BFCF58D6069AE16742_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent_130EF5287E7688BFCF58D6069AE16742" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_130EF5287E7688BFCF58D6069AE16742_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent_130EF5287E7688BFCF58D6069AE16742" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_130EF5287E7688BFCF58D6069AE16742" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_130EF5287E7688BFCF58D6069AE16742" xlink:to="lab_us-gaap_AssetsCurrent_130EF5287E7688BFCF58D6069AE16742" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_3288DB62C2B371BC8532D6069AE16427_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_3288DB62C2B371BC8532D6069AE16427" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net of accumulated depreciation and amortization of $4,702 and $4,403</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_3288DB62C2B371BC8532D6069AE16427_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_3288DB62C2B371BC8532D6069AE16427" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3288DB62C2B371BC8532D6069AE16427" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_3288DB62C2B371BC8532D6069AE16427" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_3288DB62C2B371BC8532D6069AE16427" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_87857D886BF6E12F0C66D6069AE155CA_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_87857D886BF6E12F0C66D6069AE155CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_87857D886BF6E12F0C66D6069AE155CA_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_87857D886BF6E12F0C66D6069AE155CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_87857D886BF6E12F0C66D6069AE155CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset_87857D886BF6E12F0C66D6069AE155CA" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset_87857D886BF6E12F0C66D6069AE155CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_BF2AC0A38CFF19D193B2D6069AE18157_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset_BF2AC0A38CFF19D193B2D6069AE18157" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_BF2AC0A38CFF19D193B2D6069AE18157_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset_BF2AC0A38CFF19D193B2D6069AE18157" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Right-of-Use Asset, after Accumulated Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_BF2AC0A38CFF19D193B2D6069AE18157" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAsset_BF2AC0A38CFF19D193B2D6069AE18157" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAsset_BF2AC0A38CFF19D193B2D6069AE18157" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_24395B11CEA202B7CE5DD6069AE11FB8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_24395B11CEA202B7CE5DD6069AE11FB8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_24395B11CEA202B7CE5DD6069AE11FB8_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_24395B11CEA202B7CE5DD6069AE11FB8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_24395B11CEA202B7CE5DD6069AE11FB8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_24395B11CEA202B7CE5DD6069AE11FB8" xlink:to="lab_us-gaap_OtherAssetsNoncurrent_24395B11CEA202B7CE5DD6069AE11FB8" xlink:type="arc" />
    <link:label id="lab_us-gaap_Assets_D57F646E1267CAD037C3D6069AE1839E_totalLabel_en-US" xlink:label="lab_us-gaap_Assets_D57F646E1267CAD037C3D6069AE1839E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_D57F646E1267CAD037C3D6069AE1839E_label_en-US" xlink:label="lab_us-gaap_Assets_D57F646E1267CAD037C3D6069AE1839E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_D57F646E1267CAD037C3D6069AE1839E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_D57F646E1267CAD037C3D6069AE1839E" xlink:to="lab_us-gaap_Assets_D57F646E1267CAD037C3D6069AE1839E" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1C6248826B9AA6F4F543D6069AE17532_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1C6248826B9AA6F4F543D6069AE17532" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1C6248826B9AA6F4F543D6069AE17532_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1C6248826B9AA6F4F543D6069AE17532" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1C6248826B9AA6F4F543D6069AE17532" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1C6248826B9AA6F4F543D6069AE17532" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1C6248826B9AA6F4F543D6069AE17532" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_782AB9E96E24DFA04DD1D6069AE1330D_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_782AB9E96E24DFA04DD1D6069AE1330D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_782AB9E96E24DFA04DD1D6069AE1330D_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_782AB9E96E24DFA04DD1D6069AE1330D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_782AB9E96E24DFA04DD1D6069AE1330D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_782AB9E96E24DFA04DD1D6069AE1330D" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_782AB9E96E24DFA04DD1D6069AE1330D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableCurrent_4691C64D430BD442E39AD6069AE1F978_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_4691C64D430BD442E39AD6069AE1F978" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_4691C64D430BD442E39AD6069AE1F978_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_4691C64D430BD442E39AD6069AE1F978" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_4691C64D430BD442E39AD6069AE1F978" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_4691C64D430BD442E39AD6069AE1F978" xlink:to="lab_us-gaap_AccountsPayableCurrent_4691C64D430BD442E39AD6069AE1F978" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_8A8396FD07E8E33D694ED6069AE1997D_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_8A8396FD07E8E33D694ED6069AE1997D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_8A8396FD07E8E33D694ED6069AE1997D_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_8A8396FD07E8E33D694ED6069AE1997D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_8A8396FD07E8E33D694ED6069AE1997D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8A8396FD07E8E33D694ED6069AE1997D" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_8A8396FD07E8E33D694ED6069AE1997D" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_E4A26D59D2081235023CD6069AE1E21E_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_E4A26D59D2081235023CD6069AE1E21E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_E4A26D59D2081235023CD6069AE1E21E_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_E4A26D59D2081235023CD6069AE1E21E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_E4A26D59D2081235023CD6069AE1E21E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent_E4A26D59D2081235023CD6069AE1E21E" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent_E4A26D59D2081235023CD6069AE1E21E" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_EC0DDD48112E3DC7502AD6069AE10AAF_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent_EC0DDD48112E3DC7502AD6069AE10AAF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion of finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_EC0DDD48112E3DC7502AD6069AE10AAF_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent_EC0DDD48112E3DC7502AD6069AE10AAF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_EC0DDD48112E3DC7502AD6069AE10AAF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent_EC0DDD48112E3DC7502AD6069AE10AAF" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent_EC0DDD48112E3DC7502AD6069AE10AAF" xlink:type="arc" />
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrent_780C970B86EE2E17EF67D6069AE13D9A_terseLabel_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrent_780C970B86EE2E17EF67D6069AE13D9A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related party note payable</link:label>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrent_780C970B86EE2E17EF67D6069AE13D9A_label_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrent_780C970B86EE2E17EF67D6069AE13D9A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Due to Related Parties, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_780C970B86EE2E17EF67D6069AE13D9A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrent_780C970B86EE2E17EF67D6069AE13D9A" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrent_780C970B86EE2E17EF67D6069AE13D9A" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrent_3D3BCE6206AFA1AE7808D6069AE16207_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_3D3BCE6206AFA1AE7808D6069AE16207" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_3D3BCE6206AFA1AE7808D6069AE16207_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_3D3BCE6206AFA1AE7808D6069AE16207" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_3D3BCE6206AFA1AE7808D6069AE16207" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_3D3BCE6206AFA1AE7808D6069AE16207" xlink:to="lab_us-gaap_LiabilitiesCurrent_3D3BCE6206AFA1AE7808D6069AE16207" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_A6F3529474B5985A1871D6069AE104DB_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_A6F3529474B5985A1871D6069AE104DB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_A6F3529474B5985A1871D6069AE104DB_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_A6F3529474B5985A1871D6069AE104DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_A6F3529474B5985A1871D6069AE104DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_A6F3529474B5985A1871D6069AE104DB" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_A6F3529474B5985A1871D6069AE104DB" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_2517EC961A31633D95E4D6069AE15B11_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_2517EC961A31633D95E4D6069AE15B11" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_2517EC961A31633D95E4D6069AE15B11_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_2517EC961A31633D95E4D6069AE15B11" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_2517EC961A31633D95E4D6069AE15B11" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_2517EC961A31633D95E4D6069AE15B11" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_2517EC961A31633D95E4D6069AE15B11" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_4CB10CB623C6A563974DD6069AE15B4F_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_4CB10CB623C6A563974DD6069AE15B4F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_4CB10CB623C6A563974DD6069AE15B4F_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_4CB10CB623C6A563974DD6069AE15B4F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_4CB10CB623C6A563974DD6069AE15B4F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_4CB10CB623C6A563974DD6069AE15B4F" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent_4CB10CB623C6A563974DD6069AE15B4F" xlink:type="arc" />
    <link:label id="lab_us-gaap_Liabilities_419833853B920F1C8E51D6069AE1EEE6_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities_419833853B920F1C8E51D6069AE1EEE6" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_419833853B920F1C8E51D6069AE1EEE6_label_en-US" xlink:label="lab_us-gaap_Liabilities_419833853B920F1C8E51D6069AE1EEE6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_419833853B920F1C8E51D6069AE1EEE6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_419833853B920F1C8E51D6069AE1EEE6" xlink:to="lab_us-gaap_Liabilities_419833853B920F1C8E51D6069AE1EEE6" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_BE07CA55C4478D33324AD6069AE1DB34_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_BE07CA55C4478D33324AD6069AE1DB34" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_BE07CA55C4478D33324AD6069AE1DB34_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_BE07CA55C4478D33324AD6069AE1DB34" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_BE07CA55C4478D33324AD6069AE1DB34" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_BE07CA55C4478D33324AD6069AE1DB34" xlink:to="lab_us-gaap_StockholdersEquityAbstract_BE07CA55C4478D33324AD6069AE1DB34" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockValue_1C4384B2EAF28142D59FD6069AE12CDF_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue_1C4384B2EAF28142D59FD6069AE12CDF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.001 par value; 75,000,000 shares authorized; 34,201,895 issued and outstanding as of June 30, 2020, and 34,312,527 issued and 34,169,952 outstanding as of December 31, 2019</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_1C4384B2EAF28142D59FD6069AE12CDF_label_en-US" xlink:label="lab_us-gaap_CommonStockValue_1C4384B2EAF28142D59FD6069AE12CDF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_1C4384B2EAF28142D59FD6069AE12CDF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_1C4384B2EAF28142D59FD6069AE12CDF" xlink:to="lab_us-gaap_CommonStockValue_1C4384B2EAF28142D59FD6069AE12CDF" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_EA78E9697A85B39845BCD6069AE1841E_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_EA78E9697A85B39845BCD6069AE1841E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_EA78E9697A85B39845BCD6069AE1841E_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_EA78E9697A85B39845BCD6069AE1841E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_EA78E9697A85B39845BCD6069AE1841E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital_EA78E9697A85B39845BCD6069AE1841E" xlink:to="lab_us-gaap_AdditionalPaidInCapital_EA78E9697A85B39845BCD6069AE1841E" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_BAFEF8B88D9BA9A4E1AAD6069AE188FF_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_BAFEF8B88D9BA9A4E1AAD6069AE188FF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_BAFEF8B88D9BA9A4E1AAD6069AE188FF_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_BAFEF8B88D9BA9A4E1AAD6069AE188FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_BAFEF8B88D9BA9A4E1AAD6069AE188FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_BAFEF8B88D9BA9A4E1AAD6069AE188FF" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_BAFEF8B88D9BA9A4E1AAD6069AE188FF" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_0104F96220D45D5E6B36D6069AE1D230_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_0104F96220D45D5E6B36D6069AE1D230" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_0104F96220D45D5E6B36D6069AE1D230_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity_0104F96220D45D5E6B36D6069AE1D230" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_0104F96220D45D5E6B36D6069AE1D230" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_0104F96220D45D5E6B36D6069AE1D230" xlink:to="lab_us-gaap_StockholdersEquity_0104F96220D45D5E6B36D6069AE1D230" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_1399C4FAA44C02200301D6069AE1CF6C_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_1399C4FAA44C02200301D6069AE1CF6C" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_1399C4FAA44C02200301D6069AE1CF6C_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_1399C4FAA44C02200301D6069AE1CF6C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_1399C4FAA44C02200301D6069AE1CF6C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_1399C4FAA44C02200301D6069AE1CF6C" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_1399C4FAA44C02200301D6069AE1CF6C" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_0A080C14A935E82E9CA2498625C3058E_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract_0A080C14A935E82E9CA2498625C3058E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_0A080C14A935E82E9CA2498625C3058E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_0A080C14A935E82E9CA2498625C3058E" xlink:to="lab_us-gaap_InventoryDisclosureAbstract_0A080C14A935E82E9CA2498625C3058E" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_B1008292689F2016F9B7498625C31442_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock_B1008292689F2016F9B7498625C31442" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">INVENTORIES</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_B1008292689F2016F9B7498625C31442_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock_B1008292689F2016F9B7498625C31442" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_B1008292689F2016F9B7498625C31442" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock_B1008292689F2016F9B7498625C31442" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock_B1008292689F2016F9B7498625C31442" xlink:type="arc" />
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_505765102C46161CB308C5334EC610B9_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract_505765102C46161CB308C5334EC610B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_505765102C46161CB308C5334EC610B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_505765102C46161CB308C5334EC610B9" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract_505765102C46161CB308C5334EC610B9" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedSalariesCurrent_0B7D34BE43B302F3A033C5334EC6DA03_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedSalariesCurrent_0B7D34BE43B302F3A033C5334EC6DA03" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued payroll</link:label>
    <link:label id="lab_us-gaap_AccruedSalariesCurrent_0B7D34BE43B302F3A033C5334EC6DA03_label_en-US" xlink:label="lab_us-gaap_AccruedSalariesCurrent_0B7D34BE43B302F3A033C5334EC6DA03" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Salaries, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="loc_us-gaap_AccruedSalariesCurrent_0B7D34BE43B302F3A033C5334EC6DA03" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedSalariesCurrent_0B7D34BE43B302F3A033C5334EC6DA03" xlink:to="lab_us-gaap_AccruedSalariesCurrent_0B7D34BE43B302F3A033C5334EC6DA03" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedBonusesCurrent_8B5CE7B8D58EB0486020C5334EC6D6C4_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedBonusesCurrent_8B5CE7B8D58EB0486020C5334EC6D6C4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued bonuses</link:label>
    <link:label id="lab_us-gaap_AccruedBonusesCurrent_8B5CE7B8D58EB0486020C5334EC6D6C4_label_en-US" xlink:label="lab_us-gaap_AccruedBonusesCurrent_8B5CE7B8D58EB0486020C5334EC6D6C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Bonuses, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="loc_us-gaap_AccruedBonusesCurrent_8B5CE7B8D58EB0486020C5334EC6D6C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedBonusesCurrent_8B5CE7B8D58EB0486020C5334EC6D6C4" xlink:to="lab_us-gaap_AccruedBonusesCurrent_8B5CE7B8D58EB0486020C5334EC6D6C4" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedSalesCommissionCurrent_310CED0C7FA0706FD6DFC5334EC6C472_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedSalesCommissionCurrent_310CED0C7FA0706FD6DFC5334EC6C472" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued commissions</link:label>
    <link:label id="lab_us-gaap_AccruedSalesCommissionCurrent_310CED0C7FA0706FD6DFC5334EC6C472_label_en-US" xlink:label="lab_us-gaap_AccruedSalesCommissionCurrent_310CED0C7FA0706FD6DFC5334EC6C472" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Sales Commission, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedSalesCommissionCurrent" xlink:label="loc_us-gaap_AccruedSalesCommissionCurrent_310CED0C7FA0706FD6DFC5334EC6C472" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedSalesCommissionCurrent_310CED0C7FA0706FD6DFC5334EC6C472" xlink:to="lab_us-gaap_AccruedSalesCommissionCurrent_310CED0C7FA0706FD6DFC5334EC6C472" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProductWarrantyAccrualClassifiedCurrent_F62B389387026D87524EC5334EC77488_terseLabel_en-US" xlink:label="lab_us-gaap_ProductWarrantyAccrualClassifiedCurrent_F62B389387026D87524EC5334EC77488" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued product warranties</link:label>
    <link:label id="lab_us-gaap_ProductWarrantyAccrualClassifiedCurrent_F62B389387026D87524EC5334EC77488_label_en-US" xlink:label="lab_us-gaap_ProductWarrantyAccrualClassifiedCurrent_F62B389387026D87524EC5334EC77488" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product Warranty Accrual, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:label="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent_F62B389387026D87524EC5334EC77488" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent_F62B389387026D87524EC5334EC77488" xlink:to="lab_us-gaap_ProductWarrantyAccrualClassifiedCurrent_F62B389387026D87524EC5334EC77488" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedInsuranceCurrent_8FBAD72EAD9D44217394C5334EC70152_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedInsuranceCurrent_8FBAD72EAD9D44217394C5334EC70152" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued insurance</link:label>
    <link:label id="lab_us-gaap_AccruedInsuranceCurrent_8FBAD72EAD9D44217394C5334EC70152_label_en-US" xlink:label="lab_us-gaap_AccruedInsuranceCurrent_8FBAD72EAD9D44217394C5334EC70152" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Insurance, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedInsuranceCurrent" xlink:label="loc_us-gaap_AccruedInsuranceCurrent_8FBAD72EAD9D44217394C5334EC70152" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedInsuranceCurrent_8FBAD72EAD9D44217394C5334EC70152" xlink:to="lab_us-gaap_AccruedInsuranceCurrent_8FBAD72EAD9D44217394C5334EC70152" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_A37BBEFB4B277218262DC5334EC7D83F_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent_A37BBEFB4B277218262DC5334EC7D83F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_A37BBEFB4B277218262DC5334EC7D83F_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent_A37BBEFB4B277218262DC5334EC7D83F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_A37BBEFB4B277218262DC5334EC7D83F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent_A37BBEFB4B277218262DC5334EC7D83F" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent_A37BBEFB4B277218262DC5334EC7D83F" xlink:type="arc" />
    <link:label id="lab_apyx_JointAndSeveralPayrollLiability_5A78D06EA891241DBFB6C5334EC714F6_terseLabel_en-US" xlink:label="lab_apyx_JointAndSeveralPayrollLiability_5A78D06EA891241DBFB6C5334EC714F6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Joint and several payroll liability</link:label>
    <link:label id="lab_apyx_JointAndSeveralPayrollLiability_5A78D06EA891241DBFB6C5334EC714F6_label_en-US" xlink:label="lab_apyx_JointAndSeveralPayrollLiability_5A78D06EA891241DBFB6C5334EC714F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Joint And Several Payroll Liability</link:label>
    <link:label id="lab_apyx_JointAndSeveralPayrollLiability_5A78D06EA891241DBFB6C5334EC714F6_documentation_en-US" xlink:label="lab_apyx_JointAndSeveralPayrollLiability_5A78D06EA891241DBFB6C5334EC714F6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Joint And Several Payroll Liability</link:label>
    <link:loc xlink:href="apyx-20200630.xsd#apyx_JointAndSeveralPayrollLiability" xlink:label="loc_apyx_JointAndSeveralPayrollLiability_5A78D06EA891241DBFB6C5334EC714F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_JointAndSeveralPayrollLiability_5A78D06EA891241DBFB6C5334EC714F6" xlink:to="lab_apyx_JointAndSeveralPayrollLiability_5A78D06EA891241DBFB6C5334EC714F6" xlink:type="arc" />
    <link:label id="lab_apyx_UncertainTaxPositionsLiability_AFF392B1F58784C34507C5334EC7F514_terseLabel_en-US" xlink:label="lab_apyx_UncertainTaxPositionsLiability_AFF392B1F58784C34507C5334EC7F514" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Uncertain tax positions</link:label>
    <link:label id="lab_apyx_UncertainTaxPositionsLiability_AFF392B1F58784C34507C5334EC7F514_label_en-US" xlink:label="lab_apyx_UncertainTaxPositionsLiability_AFF392B1F58784C34507C5334EC7F514" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Uncertain Tax Positions Liability</link:label>
    <link:label id="lab_apyx_UncertainTaxPositionsLiability_AFF392B1F58784C34507C5334EC7F514_documentation_en-US" xlink:label="lab_apyx_UncertainTaxPositionsLiability_AFF392B1F58784C34507C5334EC7F514" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Uncertain Tax Positions Liability</link:label>
    <link:loc xlink:href="apyx-20200630.xsd#apyx_UncertainTaxPositionsLiability" xlink:label="loc_apyx_UncertainTaxPositionsLiability_AFF392B1F58784C34507C5334EC7F514" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_UncertainTaxPositionsLiability_AFF392B1F58784C34507C5334EC7F514" xlink:to="lab_apyx_UncertainTaxPositionsLiability_AFF392B1F58784C34507C5334EC7F514" xlink:type="arc" />
    <link:label id="lab_apyx_OtherAccruedExpensesAndLiabilitiesCurrent_9ADA359301F7364C4D96C5334EC7A097_terseLabel_en-US" xlink:label="lab_apyx_OtherAccruedExpensesAndLiabilitiesCurrent_9ADA359301F7364C4D96C5334EC7A097" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other accrued expenses and current liabilities</link:label>
    <link:label id="lab_apyx_OtherAccruedExpensesAndLiabilitiesCurrent_9ADA359301F7364C4D96C5334EC7A097_label_en-US" xlink:label="lab_apyx_OtherAccruedExpensesAndLiabilitiesCurrent_9ADA359301F7364C4D96C5334EC7A097" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Expenses And Liabilities, Current</link:label>
    <link:label id="lab_apyx_OtherAccruedExpensesAndLiabilitiesCurrent_9ADA359301F7364C4D96C5334EC7A097_documentation_en-US" xlink:label="lab_apyx_OtherAccruedExpensesAndLiabilitiesCurrent_9ADA359301F7364C4D96C5334EC7A097" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Accrued Expenses And Liabilities, Current</link:label>
    <link:loc xlink:href="apyx-20200630.xsd#apyx_OtherAccruedExpensesAndLiabilitiesCurrent" xlink:label="loc_apyx_OtherAccruedExpensesAndLiabilitiesCurrent_9ADA359301F7364C4D96C5334EC7A097" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_OtherAccruedExpensesAndLiabilitiesCurrent_9ADA359301F7364C4D96C5334EC7A097" xlink:to="lab_apyx_OtherAccruedExpensesAndLiabilitiesCurrent_9ADA359301F7364C4D96C5334EC7A097" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_4C9792CAD9CAB380C9F2C5334EC7E844_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_4C9792CAD9CAB380C9F2C5334EC7E844" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total accrued expenses and other current liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_4C9792CAD9CAB380C9F2C5334EC7E844" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_4C9792CAD9CAB380C9F2C5334EC7E844" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_4C9792CAD9CAB380C9F2C5334EC7E844" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_D548B208E752067A273C498624E804A9_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_D548B208E752067A273C498624E804A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_D548B208E752067A273C498624E804A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_D548B208E752067A273C498624E804A9" xlink:to="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_D548B208E752067A273C498624E804A9" xlink:type="arc" />
    <link:label id="lab_us-gaap_DescriptionOfNewAccountingPronouncementsNotYetAdopted_7D6559BEC898DAD67774498624E90D5F_terseLabel_en-US" xlink:label="lab_us-gaap_DescriptionOfNewAccountingPronouncementsNotYetAdopted_7D6559BEC898DAD67774498624E90D5F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RECENT ACCOUNTING PRONOUNCEMENTS</link:label>
    <link:label id="lab_us-gaap_DescriptionOfNewAccountingPronouncementsNotYetAdopted_7D6559BEC898DAD67774498624E90D5F_label_en-US" xlink:label="lab_us-gaap_DescriptionOfNewAccountingPronouncementsNotYetAdopted_7D6559BEC898DAD67774498624E90D5F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of New Accounting Pronouncements Not yet Adopted [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DescriptionOfNewAccountingPronouncementsNotYetAdopted" xlink:label="loc_us-gaap_DescriptionOfNewAccountingPronouncementsNotYetAdopted_7D6559BEC898DAD67774498624E90D5F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DescriptionOfNewAccountingPronouncementsNotYetAdopted_7D6559BEC898DAD67774498624E90D5F" xlink:to="lab_us-gaap_DescriptionOfNewAccountingPronouncementsNotYetAdopted_7D6559BEC898DAD67774498624E90D5F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9E458903919331DC45FD4986251CFA5C_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9E458903919331DC45FD4986251CFA5C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9E458903919331DC45FD4986251CFA5C_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9E458903919331DC45FD4986251CFA5C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9E458903919331DC45FD4986251CFA5C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9E458903919331DC45FD4986251CFA5C" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9E458903919331DC45FD4986251CFA5C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_D6AA3B8B25C3431016834986251D9070_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_D6AA3B8B25C3431016834986251D9070" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_D6AA3B8B25C3431016834986251D9070_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_D6AA3B8B25C3431016834986251D9070" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_D6AA3B8B25C3431016834986251D9070" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_D6AA3B8B25C3431016834986251D9070" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_D6AA3B8B25C3431016834986251D9070" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_E12C26D0EDFA50A28C144986251D969A_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_E12C26D0EDFA50A28C144986251D969A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_E12C26D0EDFA50A28C144986251D969A_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_E12C26D0EDFA50A28C144986251D969A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_E12C26D0EDFA50A28C144986251D969A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_E12C26D0EDFA50A28C144986251D969A" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_E12C26D0EDFA50A28C144986251D969A" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0B2F5519915D52F525404986251D3953_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0B2F5519915D52F525404986251D3953" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0B2F5519915D52F525404986251D3953_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0B2F5519915D52F525404986251D3953" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0B2F5519915D52F525404986251D3953" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0B2F5519915D52F525404986251D3953" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0B2F5519915D52F525404986251D3953" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_A524E3AE98B06BA51BDF4986251DDC83_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_A524E3AE98B06BA51BDF4986251DDC83" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Canceled and forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_A524E3AE98B06BA51BDF4986251DDC83_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_A524E3AE98B06BA51BDF4986251DDC83" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_A524E3AE98B06BA51BDF4986251DDC83" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_A524E3AE98B06BA51BDF4986251DDC83" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_A524E3AE98B06BA51BDF4986251DDC83" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_A96F94ECC94FDC4F97B94986251D9172_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_A96F94ECC94FDC4F97B94986251D9172" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, end of period (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_A96F94ECC94FDC4F97B94986251D9172" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_A96F94ECC94FDC4F97B94986251D9172" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_A96F94ECC94FDC4F97B94986251D9172" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_93899BD1D5DBF8FBADF04986251EB0F2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_93899BD1D5DBF8FBADF04986251EB0F2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_93899BD1D5DBF8FBADF04986251EB0F2_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_93899BD1D5DBF8FBADF04986251EB0F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_93899BD1D5DBF8FBADF04986251EB0F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_93899BD1D5DBF8FBADF04986251EB0F2" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_93899BD1D5DBF8FBADF04986251EB0F2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_78BDFB0D2D179167CE2A4986251ED947_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_78BDFB0D2D179167CE2A4986251ED947" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_78BDFB0D2D179167CE2A4986251ED947_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_78BDFB0D2D179167CE2A4986251ED947" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_78BDFB0D2D179167CE2A4986251ED947" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_78BDFB0D2D179167CE2A4986251ED947" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_78BDFB0D2D179167CE2A4986251ED947" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_09538914603BABE549374986251EA0A0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_09538914603BABE549374986251EA0A0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_09538914603BABE549374986251EA0A0_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_09538914603BABE549374986251EA0A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_09538914603BABE549374986251EA0A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_09538914603BABE549374986251EA0A0" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_09538914603BABE549374986251EA0A0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_4E56E61A54730878EC634986251EDC19_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_4E56E61A54730878EC634986251EDC19" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_4E56E61A54730878EC634986251EDC19_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_4E56E61A54730878EC634986251EDC19" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_4E56E61A54730878EC634986251EDC19" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_4E56E61A54730878EC634986251EDC19" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_4E56E61A54730878EC634986251EDC19" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_1CEFDEA8EC7E54403D3E4986251ECF90_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_1CEFDEA8EC7E54403D3E4986251ECF90" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Canceled and forfeited (in dollars per shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_1CEFDEA8EC7E54403D3E4986251ECF90_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_1CEFDEA8EC7E54403D3E4986251ECF90" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_1CEFDEA8EC7E54403D3E4986251ECF90" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_1CEFDEA8EC7E54403D3E4986251ECF90" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_1CEFDEA8EC7E54403D3E4986251ECF90" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2E888B0692B39F6D2B364986251EDC06_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2E888B0692B39F6D2B364986251EDC06" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, end of period (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2E888B0692B39F6D2B364986251EDC06" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2E888B0692B39F6D2B364986251EDC06" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2E888B0692B39F6D2B364986251EDC06" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_B93D49DC1FB749B32ACC498624EB56C9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_B93D49DC1FB749B32ACC498624EB56C9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of stock options and stock awards</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_B93D49DC1FB749B32ACC498624EB56C9_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_B93D49DC1FB749B32ACC498624EB56C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_B93D49DC1FB749B32ACC498624EB56C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_B93D49DC1FB749B32ACC498624EB56C9" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_B93D49DC1FB749B32ACC498624EB56C9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_3649AADBB554C3A1FDD2498624EC0093_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_3649AADBB554C3A1FDD2498624EC0093" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of option fair value assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_3649AADBB554C3A1FDD2498624EC0093_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_3649AADBB554C3A1FDD2498624EC0093" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_3649AADBB554C3A1FDD2498624EC0093" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_3649AADBB554C3A1FDD2498624EC0093" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_3649AADBB554C3A1FDD2498624EC0093" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_BECCDA812911366EC69ED39D8888616D_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_BECCDA812911366EC69ED39D8888616D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_BECCDA812911366EC69ED39D8888616D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_BECCDA812911366EC69ED39D8888616D" xlink:to="lab_us-gaap_EarningsPerShareAbstract_BECCDA812911366EC69ED39D8888616D" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_46555E669833FE046A36D39D88886E75_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_46555E669833FE046A36D39D88886E75" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">EARNINGS PER SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_46555E669833FE046A36D39D88886E75_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_46555E669833FE046A36D39D88886E75" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_46555E669833FE046A36D39D88886E75" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock_46555E669833FE046A36D39D88886E75" xlink:to="lab_us-gaap_EarningsPerShareTextBlock_46555E669833FE046A36D39D88886E75" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_BEDCA3DBE8A1A93B19344986256E59CE_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_BEDCA3DBE8A1A93B19344986256E59CE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allowance for doubtful accounts receivable</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_BEDCA3DBE8A1A93B19344986256E59CE_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_BEDCA3DBE8A1A93B19344986256E59CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_BEDCA3DBE8A1A93B19344986256E59CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_BEDCA3DBE8A1A93B19344986256E59CE" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_BEDCA3DBE8A1A93B19344986256E59CE" xlink:type="arc" />
    <link:label id="lab_apyx_ProvisionForObsolescenceInventory_7C7830175666A220E1934986256F08A2_terseLabel_en-US" xlink:label="lab_apyx_ProvisionForObsolescenceInventory_7C7830175666A220E1934986256F08A2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories, provision for obsolescence</link:label>
    <link:label id="lab_apyx_ProvisionForObsolescenceInventory_7C7830175666A220E1934986256F08A2_label_en-US" xlink:label="lab_apyx_ProvisionForObsolescenceInventory_7C7830175666A220E1934986256F08A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provision For Obsolescence, Inventory</link:label>
    <link:label id="lab_apyx_ProvisionForObsolescenceInventory_7C7830175666A220E1934986256F08A2_documentation_en-US" xlink:label="lab_apyx_ProvisionForObsolescenceInventory_7C7830175666A220E1934986256F08A2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Provision For Obsolescence, Inventory</link:label>
    <link:loc xlink:href="apyx-20200630.xsd#apyx_ProvisionForObsolescenceInventory" xlink:label="loc_apyx_ProvisionForObsolescenceInventory_7C7830175666A220E1934986256F08A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_ProvisionForObsolescenceInventory_7C7830175666A220E1934986256F08A2" xlink:to="lab_apyx_ProvisionForObsolescenceInventory_7C7830175666A220E1934986256F08A2" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_B933032E1D55D235CF1B4986256FB243_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_B933032E1D55D235CF1B4986256FB243" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_B933032E1D55D235CF1B4986256FB243_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_B933032E1D55D235CF1B4986256FB243" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_B933032E1D55D235CF1B4986256FB243" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_B933032E1D55D235CF1B4986256FB243" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_B933032E1D55D235CF1B4986256FB243" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_91E2799C8B75B156EC734986256F9D84_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_91E2799C8B75B156EC734986256F9D84" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_91E2799C8B75B156EC734986256F9D84_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_91E2799C8B75B156EC734986256F9D84" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_91E2799C8B75B156EC734986256F9D84" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_91E2799C8B75B156EC734986256F9D84" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_91E2799C8B75B156EC734986256F9D84" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_A5915D145726FBC2E57D4986256F4D9F_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_A5915D145726FBC2E57D4986256F4D9F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_A5915D145726FBC2E57D4986256F4D9F_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_A5915D145726FBC2E57D4986256F4D9F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_A5915D145726FBC2E57D4986256F4D9F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_A5915D145726FBC2E57D4986256F4D9F" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_A5915D145726FBC2E57D4986256F4D9F" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesIssued_F205CFD81B7FEE8C8CAC4986256F9F04_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_F205CFD81B7FEE8C8CAC4986256F9F04" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_F205CFD81B7FEE8C8CAC4986256F9F04_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_F205CFD81B7FEE8C8CAC4986256F9F04" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_F205CFD81B7FEE8C8CAC4986256F9F04" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_F205CFD81B7FEE8C8CAC4986256F9F04" xlink:to="lab_us-gaap_CommonStockSharesIssued_F205CFD81B7FEE8C8CAC4986256F9F04" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_3B0E0A05EBA7A77D23124986256F2CF6_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_3B0E0A05EBA7A77D23124986256F2CF6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_3B0E0A05EBA7A77D23124986256F2CF6_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_3B0E0A05EBA7A77D23124986256F2CF6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_3B0E0A05EBA7A77D23124986256F2CF6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_3B0E0A05EBA7A77D23124986256F2CF6" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_3B0E0A05EBA7A77D23124986256F2CF6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_E5BC08CA1D394CBA6E04498624FDA9D3_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_E5BC08CA1D394CBA6E04498624FDA9D3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Option value (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_E5BC08CA1D394CBA6E04498624FDA9D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_E5BC08CA1D394CBA6E04498624FDA9D3" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_E5BC08CA1D394CBA6E04498624FDA9D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_77947CCC874266E0F3AB498624FE3432_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_77947CCC874266E0F3AB498624FE3432" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_77947CCC874266E0F3AB498624FE3432_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_77947CCC874266E0F3AB498624FE3432" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_77947CCC874266E0F3AB498624FE3432" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_77947CCC874266E0F3AB498624FE3432" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_77947CCC874266E0F3AB498624FE3432" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9C29B403A2099C5EA60C498624FEC06D_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9C29B403A2099C5EA60C498624FEC06D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9C29B403A2099C5EA60C498624FEC06D_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9C29B403A2099C5EA60C498624FEC06D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9C29B403A2099C5EA60C498624FEC06D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9C29B403A2099C5EA60C498624FEC06D" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9C29B403A2099C5EA60C498624FEC06D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_D8553F4677604F38D0A0498624FE2739_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_D8553F4677604F38D0A0498624FE2739" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_D8553F4677604F38D0A0498624FE2739_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_D8553F4677604F38D0A0498624FE2739" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_D8553F4677604F38D0A0498624FE2739" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_D8553F4677604F38D0A0498624FE2739" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_D8553F4677604F38D0A0498624FE2739" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_E75E45A9D9D883B318BC498624FE117F_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_E75E45A9D9D883B318BC498624FE117F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_E75E45A9D9D883B318BC498624FE117F_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_E75E45A9D9D883B318BC498624FE117F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_E75E45A9D9D883B318BC498624FE117F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_E75E45A9D9D883B318BC498624FE117F" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_E75E45A9D9D883B318BC498624FE117F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_925CB2CAEBC8211AAD5049862593694A_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_925CB2CAEBC8211AAD5049862593694A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued Expenses and Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_925CB2CAEBC8211AAD5049862593694A_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_925CB2CAEBC8211AAD5049862593694A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_925CB2CAEBC8211AAD5049862593694A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_925CB2CAEBC8211AAD5049862593694A" xlink:to="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_925CB2CAEBC8211AAD5049862593694A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9D84AE31716A9480B9DDD39D88670943_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9D84AE31716A9480B9DDD39D88670943" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9D84AE31716A9480B9DDD39D88670943_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9D84AE31716A9480B9DDD39D88670943" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9D84AE31716A9480B9DDD39D88670943" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9D84AE31716A9480B9DDD39D88670943" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9D84AE31716A9480B9DDD39D88670943" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_86007F7BC842894300F7D39D8867F269_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_86007F7BC842894300F7D39D8867F269" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_86007F7BC842894300F7D39D8867F269_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_86007F7BC842894300F7D39D8867F269" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_86007F7BC842894300F7D39D8867F269" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_86007F7BC842894300F7D39D8867F269" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_86007F7BC842894300F7D39D8867F269" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_8AD585E05442BDE73E75D39D8867CBD5_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_8AD585E05442BDE73E75D39D8867CBD5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_8AD585E05442BDE73E75D39D8867CBD5_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_8AD585E05442BDE73E75D39D8867CBD5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8AD585E05442BDE73E75D39D8867CBD5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8AD585E05442BDE73E75D39D8867CBD5" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain_8AD585E05442BDE73E75D39D8867CBD5" xlink:type="arc" />
    <link:label id="lab_us-gaap_OptionOnSecuritiesMember_E0B82190008726D7EDB7D39D88675C39_terseLabel_en-US" xlink:label="lab_us-gaap_OptionOnSecuritiesMember_E0B82190008726D7EDB7D39D88675C39" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options</link:label>
    <link:label id="lab_us-gaap_OptionOnSecuritiesMember_E0B82190008726D7EDB7D39D88675C39_label_en-US" xlink:label="lab_us-gaap_OptionOnSecuritiesMember_E0B82190008726D7EDB7D39D88675C39" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option on Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OptionOnSecuritiesMember" xlink:label="loc_us-gaap_OptionOnSecuritiesMember_E0B82190008726D7EDB7D39D88675C39" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OptionOnSecuritiesMember_E0B82190008726D7EDB7D39D88675C39" xlink:to="lab_us-gaap_OptionOnSecuritiesMember_E0B82190008726D7EDB7D39D88675C39" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_43B16F01DFC6E9D6ADD9D39D8867169F_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_43B16F01DFC6E9D6ADD9D39D8867169F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_43B16F01DFC6E9D6ADD9D39D8867169F_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_43B16F01DFC6E9D6ADD9D39D8867169F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_43B16F01DFC6E9D6ADD9D39D8867169F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_43B16F01DFC6E9D6ADD9D39D8867169F" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_43B16F01DFC6E9D6ADD9D39D8867169F" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_0A58A37F9B28F4C44242D39D88678353_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract_0A58A37F9B28F4C44242D39D88678353" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_0A58A37F9B28F4C44242D39D88678353_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract_0A58A37F9B28F4C44242D39D88678353" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share Reconciliation [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareReconciliationAbstract" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract_0A58A37F9B28F4C44242D39D88678353" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_0A58A37F9B28F4C44242D39D88678353" xlink:to="lab_us-gaap_EarningsPerShareReconciliationAbstract_0A58A37F9B28F4C44242D39D88678353" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_39DB1A329815CFA54EC3D39D8867B02D_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_39DB1A329815CFA54EC3D39D8867B02D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_39DB1A329815CFA54EC3D39D8867B02D_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_39DB1A329815CFA54EC3D39D8867B02D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_39DB1A329815CFA54EC3D39D8867B02D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_39DB1A329815CFA54EC3D39D8867B02D" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_39DB1A329815CFA54EC3D39D8867B02D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_6E82C9428DD4F51D0E86D39D88674287_terseLabel_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract_6E82C9428DD4F51D0E86D39D88674287" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_6E82C9428DD4F51D0E86D39D88674287_label_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract_6E82C9428DD4F51D0E86D39D88674287" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_6E82C9428DD4F51D0E86D39D88674287" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_6E82C9428DD4F51D0E86D39D88674287" xlink:to="lab_us-gaap_DilutiveSecuritiesAbstract_6E82C9428DD4F51D0E86D39D88674287" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_7AF0FE5800629847DE2AD39D8867C082_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_7AF0FE5800629847DE2AD39D8867C082" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average shares outstanding - basic and diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_7AF0FE5800629847DE2AD39D8867C082_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_7AF0FE5800629847DE2AD39D8867C082" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_7AF0FE5800629847DE2AD39D8867C082" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_7AF0FE5800629847DE2AD39D8867C082" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_7AF0FE5800629847DE2AD39D8867C082" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_0BA41D1F5FFFAB09D4FFD39D886785BE_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract_0BA41D1F5FFFAB09D4FFD39D886785BE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings (loss) per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_0BA41D1F5FFFAB09D4FFD39D886785BE_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract_0BA41D1F5FFFAB09D4FFD39D886785BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_0BA41D1F5FFFAB09D4FFD39D886785BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_0BA41D1F5FFFAB09D4FFD39D886785BE" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract_0BA41D1F5FFFAB09D4FFD39D886785BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_2001D84E3C041BE9B92ED39D886793AE_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_2001D84E3C041BE9B92ED39D886793AE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_2001D84E3C041BE9B92ED39D886793AE_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_2001D84E3C041BE9B92ED39D886793AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Basic and Diluted Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_2001D84E3C041BE9B92ED39D886793AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_2001D84E3C041BE9B92ED39D886793AE" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_2001D84E3C041BE9B92ED39D886793AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_DE6DAE6F76F98E91C50CD39D88671D0B_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract_DE6DAE6F76F98E91C50CD39D88671D0B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Anti-dilutive instruments excluded from diluted loss per common share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_DE6DAE6F76F98E91C50CD39D88671D0B_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract_DE6DAE6F76F98E91C50CD39D88671D0B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_DE6DAE6F76F98E91C50CD39D88671D0B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_DE6DAE6F76F98E91C50CD39D88671D0B" xlink:to="lab_us-gaap_EarningsPerShareDilutedAbstract_DE6DAE6F76F98E91C50CD39D88671D0B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_EC7CED9E97E31028EAEAD39D8867F803_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_EC7CED9E97E31028EAEAD39D8867F803" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_EC7CED9E97E31028EAEAD39D8867F803_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_EC7CED9E97E31028EAEAD39D8867F803" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_EC7CED9E97E31028EAEAD39D8867F803" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_EC7CED9E97E31028EAEAD39D8867F803" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_EC7CED9E97E31028EAEAD39D8867F803" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentReportingAbstract_0C4001687C954F3CD4E6498624F19BB9_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract_0C4001687C954F3CD4E6498624F19BB9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_0C4001687C954F3CD4E6498624F19BB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract_0C4001687C954F3CD4E6498624F19BB9" xlink:to="lab_us-gaap_SegmentReportingAbstract_0C4001687C954F3CD4E6498624F19BB9" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_4A56346FCA09245B660D498624F13F65_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock_4A56346FCA09245B660D498624F13F65" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GEOGRAPHIC AND SEGMENT INFORMATION</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_4A56346FCA09245B660D498624F13F65_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock_4A56346FCA09245B660D498624F13F65" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_4A56346FCA09245B660D498624F13F65" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock_4A56346FCA09245B660D498624F13F65" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock_4A56346FCA09245B660D498624F13F65" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_51739B3A8D313639C250498625C12CAB_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_51739B3A8D313639C250498625C12CAB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_51739B3A8D313639C250498625C12CAB_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_51739B3A8D313639C250498625C12CAB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_51739B3A8D313639C250498625C12CAB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_51739B3A8D313639C250498625C12CAB" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_51739B3A8D313639C250498625C12CAB" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_80A363A0A0A335568D2AD6069AC21882_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract_80A363A0A0A335568D2AD6069AC21882" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_80A363A0A0A335568D2AD6069AC21882" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_80A363A0A0A335568D2AD6069AC21882" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract_80A363A0A0A335568D2AD6069AC21882" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementTable_8526B04C1E4D8E5264DDD6069AC2742A_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable_8526B04C1E4D8E5264DDD6069AC2742A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_8526B04C1E4D8E5264DDD6069AC2742A_label_en-US" xlink:label="lab_us-gaap_StatementTable_8526B04C1E4D8E5264DDD6069AC2742A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_8526B04C1E4D8E5264DDD6069AC2742A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_8526B04C1E4D8E5264DDD6069AC2742A" xlink:to="lab_us-gaap_StatementTable_8526B04C1E4D8E5264DDD6069AC2742A" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_F449AE1669F26354E19DD6069AC213EF_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_F449AE1669F26354E19DD6069AC213EF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_F449AE1669F26354E19DD6069AC213EF_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_F449AE1669F26354E19DD6069AC213EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_F449AE1669F26354E19DD6069AC213EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_F449AE1669F26354E19DD6069AC213EF" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_F449AE1669F26354E19DD6069AC213EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityComponentDomain_6809CF8DA9057AD5719AD6069AC2F869_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_6809CF8DA9057AD5719AD6069AC2F869" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_6809CF8DA9057AD5719AD6069AC2F869_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_6809CF8DA9057AD5719AD6069AC2F869" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_6809CF8DA9057AD5719AD6069AC2F869" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain_6809CF8DA9057AD5719AD6069AC2F869" xlink:to="lab_us-gaap_EquityComponentDomain_6809CF8DA9057AD5719AD6069AC2F869" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_4715C9BD3D81C0F97FC0D6069AC25CE2_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_4715C9BD3D81C0F97FC0D6069AC25CE2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_4715C9BD3D81C0F97FC0D6069AC25CE2_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_4715C9BD3D81C0F97FC0D6069AC25CE2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_4715C9BD3D81C0F97FC0D6069AC25CE2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_4715C9BD3D81C0F97FC0D6069AC25CE2" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_4715C9BD3D81C0F97FC0D6069AC25CE2" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsMember_AB9693376F2E74693A69D6069AC2A596_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_AB9693376F2E74693A69D6069AC2A596" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_AB9693376F2E74693A69D6069AC2A596_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_AB9693376F2E74693A69D6069AC2A596" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_AB9693376F2E74693A69D6069AC2A596" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_AB9693376F2E74693A69D6069AC2A596" xlink:to="lab_us-gaap_RetainedEarningsMember_AB9693376F2E74693A69D6069AC2A596" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementLineItems_AADBAB236E0E6D442A8CD6069AC20EF2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems_AADBAB236E0E6D442A8CD6069AC20EF2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_AADBAB236E0E6D442A8CD6069AC20EF2_label_en-US" xlink:label="lab_us-gaap_StatementLineItems_AADBAB236E0E6D442A8CD6069AC20EF2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_AADBAB236E0E6D442A8CD6069AC20EF2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_AADBAB236E0E6D442A8CD6069AC20EF2" xlink:to="lab_us-gaap_StatementLineItems_AADBAB236E0E6D442A8CD6069AC20EF2" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_86939D5C0B269DA2E2F2D6069AC2FC15_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_86939D5C0B269DA2E2F2D6069AC2FC15" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_86939D5C0B269DA2E2F2D6069AC2FC15_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_86939D5C0B269DA2E2F2D6069AC2FC15" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_86939D5C0B269DA2E2F2D6069AC2FC15" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_86939D5C0B269DA2E2F2D6069AC2FC15" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_86939D5C0B269DA2E2F2D6069AC2FC15" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesIssued_AF298F00B6D3E6BD2861D6069AC228BA_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesIssued_AF298F00B6D3E6BD2861D6069AC228BA" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_AF298F00B6D3E6BD2861D6069AC228BA_label_en-US" xlink:label="lab_us-gaap_SharesIssued_AF298F00B6D3E6BD2861D6069AC228BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_AF298F00B6D3E6BD2861D6069AC228BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued_AF298F00B6D3E6BD2861D6069AC228BA" xlink:to="lab_us-gaap_SharesIssued_AF298F00B6D3E6BD2861D6069AC228BA" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_C41DD87C48BE5BE023F4D6069AC2720A_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_C41DD87C48BE5BE023F4D6069AC2720A" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_C41DD87C48BE5BE023F4D6069AC2720A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_C41DD87C48BE5BE023F4D6069AC2720A" xlink:to="lab_us-gaap_StockholdersEquity_C41DD87C48BE5BE023F4D6069AC2720A" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_7ACA11283BE32C55FBB4D6069AC2D086_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_7ACA11283BE32C55FBB4D6069AC2D086" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_7ACA11283BE32C55FBB4D6069AC2D086_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_7ACA11283BE32C55FBB4D6069AC2D086" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_7ACA11283BE32C55FBB4D6069AC2D086" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_7ACA11283BE32C55FBB4D6069AC2D086" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_7ACA11283BE32C55FBB4D6069AC2D086" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_C44D4A9726F11F2B7AEAD6069AC28067_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_C44D4A9726F11F2B7AEAD6069AC28067" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options exercised for cash</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_C44D4A9726F11F2B7AEAD6069AC28067_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_C44D4A9726F11F2B7AEAD6069AC28067" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_C44D4A9726F11F2B7AEAD6069AC28067" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_C44D4A9726F11F2B7AEAD6069AC28067" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_C44D4A9726F11F2B7AEAD6069AC28067" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_04C54C986730DC435FDCD6069AC24329_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_04C54C986730DC435FDCD6069AC24329" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_04C54C986730DC435FDCD6069AC24329_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_04C54C986730DC435FDCD6069AC24329" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_04C54C986730DC435FDCD6069AC24329" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_04C54C986730DC435FDCD6069AC24329" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_04C54C986730DC435FDCD6069AC24329" xlink:type="arc" />
    <link:label id="lab_apyx_StockSwapToAcquireOptionsShares_9C5E056259485363517DD6069AC2F1BF_terseLabel_en-US" xlink:label="lab_apyx_StockSwapToAcquireOptionsShares_9C5E056259485363517DD6069AC2F1BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued on net settlement of stock options (in shares)</link:label>
    <link:label id="lab_apyx_StockSwapToAcquireOptionsShares_9C5E056259485363517DD6069AC2F1BF_label_en-US" xlink:label="lab_apyx_StockSwapToAcquireOptionsShares_9C5E056259485363517DD6069AC2F1BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock swap to acquire options, Shares</link:label>
    <link:label id="lab_apyx_StockSwapToAcquireOptionsShares_9C5E056259485363517DD6069AC2F1BF_documentation_en-US" xlink:label="lab_apyx_StockSwapToAcquireOptionsShares_9C5E056259485363517DD6069AC2F1BF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock swap to acquire options shares.</link:label>
    <link:loc xlink:href="apyx-20200630.xsd#apyx_StockSwapToAcquireOptionsShares" xlink:label="loc_apyx_StockSwapToAcquireOptionsShares_9C5E056259485363517DD6069AC2F1BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_StockSwapToAcquireOptionsShares_9C5E056259485363517DD6069AC2F1BF" xlink:to="lab_apyx_StockSwapToAcquireOptionsShares_9C5E056259485363517DD6069AC2F1BF" xlink:type="arc" />
    <link:label id="lab_apyx_StockSwapToAcquireOptionsAmount_7139DD371C6934BABA58D6069AC289C7_terseLabel_en-US" xlink:label="lab_apyx_StockSwapToAcquireOptionsAmount_7139DD371C6934BABA58D6069AC289C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued on net settlement of stock options</link:label>
    <link:label id="lab_apyx_StockSwapToAcquireOptionsAmount_7139DD371C6934BABA58D6069AC289C7_label_en-US" xlink:label="lab_apyx_StockSwapToAcquireOptionsAmount_7139DD371C6934BABA58D6069AC289C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock swap to acquire options, Amount</link:label>
    <link:label id="lab_apyx_StockSwapToAcquireOptionsAmount_7139DD371C6934BABA58D6069AC289C7_documentation_en-US" xlink:label="lab_apyx_StockSwapToAcquireOptionsAmount_7139DD371C6934BABA58D6069AC289C7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock swap to acquire options amount.</link:label>
    <link:loc xlink:href="apyx-20200630.xsd#apyx_StockSwapToAcquireOptionsAmount" xlink:label="loc_apyx_StockSwapToAcquireOptionsAmount_7139DD371C6934BABA58D6069AC289C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_StockSwapToAcquireOptionsAmount_7139DD371C6934BABA58D6069AC289C7" xlink:to="lab_apyx_StockSwapToAcquireOptionsAmount_7139DD371C6934BABA58D6069AC289C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesIssued_0E0443D6E082DC16B135D6069AC26CCF_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesIssued_0E0443D6E082DC16B135D6069AC26CCF" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_0E0443D6E082DC16B135D6069AC26CCF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued_0E0443D6E082DC16B135D6069AC26CCF" xlink:to="lab_us-gaap_SharesIssued_0E0443D6E082DC16B135D6069AC26CCF" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_F6B4DE99E36E795FAE95D6069AC29151_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_F6B4DE99E36E795FAE95D6069AC29151" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_F6B4DE99E36E795FAE95D6069AC29151" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_F6B4DE99E36E795FAE95D6069AC29151" xlink:to="lab_us-gaap_StockholdersEquity_F6B4DE99E36E795FAE95D6069AC29151" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_A41E645B5320D2869554D39D86DE4FD5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_A41E645B5320D2869554D39D86DE4FD5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_A41E645B5320D2869554D39D86DE4FD5_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_A41E645B5320D2869554D39D86DE4FD5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_A41E645B5320D2869554D39D86DE4FD5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_A41E645B5320D2869554D39D86DE4FD5" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_A41E645B5320D2869554D39D86DE4FD5" xlink:type="arc" />
    <link:label id="lab_srt_ConsolidationItemsAxis_4B9581ACFDC4ED40C247D39D86DE2231_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis_4B9581ACFDC4ED40C247D39D86DE2231" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_4B9581ACFDC4ED40C247D39D86DE2231_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis_4B9581ACFDC4ED40C247D39D86DE2231" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis" xlink:label="loc_srt_ConsolidationItemsAxis_4B9581ACFDC4ED40C247D39D86DE2231" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis_4B9581ACFDC4ED40C247D39D86DE2231" xlink:to="lab_srt_ConsolidationItemsAxis_4B9581ACFDC4ED40C247D39D86DE2231" xlink:type="arc" />
    <link:label id="lab_srt_ConsolidationItemsDomain_094112CC4BED4B751CC0D39D86DEC8A3_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain_094112CC4BED4B751CC0D39D86DEC8A3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_094112CC4BED4B751CC0D39D86DEC8A3_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain_094112CC4BED4B751CC0D39D86DEC8A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain" xlink:label="loc_srt_ConsolidationItemsDomain_094112CC4BED4B751CC0D39D86DEC8A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain_094112CC4BED4B751CC0D39D86DEC8A3" xlink:to="lab_srt_ConsolidationItemsDomain_094112CC4BED4B751CC0D39D86DEC8A3" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingSegmentsMember_FC6D081906EA7BAD9D6AD39D86DED80F_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember_FC6D081906EA7BAD9D6AD39D86DED80F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Segments</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_FC6D081906EA7BAD9D6AD39D86DED80F_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember_FC6D081906EA7BAD9D6AD39D86DED80F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember" xlink:label="loc_us-gaap_OperatingSegmentsMember_FC6D081906EA7BAD9D6AD39D86DED80F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember_FC6D081906EA7BAD9D6AD39D86DED80F" xlink:to="lab_us-gaap_OperatingSegmentsMember_FC6D081906EA7BAD9D6AD39D86DED80F" xlink:type="arc" />
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_8C8041654208CA1EE336D39D86DE4A8F_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember_8C8041654208CA1EE336D39D86DE4A8F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate &amp; Other</link:label>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_8C8041654208CA1EE336D39D86DE4A8F_label_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember_8C8041654208CA1EE336D39D86DE4A8F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate, Non-Segment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateNonSegmentMember" xlink:label="loc_us-gaap_CorporateNonSegmentMember_8C8041654208CA1EE336D39D86DE4A8F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateNonSegmentMember_8C8041654208CA1EE336D39D86DE4A8F" xlink:to="lab_us-gaap_CorporateNonSegmentMember_8C8041654208CA1EE336D39D86DE4A8F" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_16A996FB8F4DABC847F8D39D86DECE98_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis_16A996FB8F4DABC847F8D39D86DECE98" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_16A996FB8F4DABC847F8D39D86DECE98_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis_16A996FB8F4DABC847F8D39D86DECE98" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_16A996FB8F4DABC847F8D39D86DECE98" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_16A996FB8F4DABC847F8D39D86DECE98" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis_16A996FB8F4DABC847F8D39D86DECE98" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentDomain_12B889E55E2B19E40670D39D86DEDF4D_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain_12B889E55E2B19E40670D39D86DEDF4D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_12B889E55E2B19E40670D39D86DEDF4D_label_en-US" xlink:label="lab_us-gaap_SegmentDomain_12B889E55E2B19E40670D39D86DEDF4D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_12B889E55E2B19E40670D39D86DEDF4D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain_12B889E55E2B19E40670D39D86DEDF4D" xlink:to="lab_us-gaap_SegmentDomain_12B889E55E2B19E40670D39D86DEDF4D" xlink:type="arc" />
    <link:label id="lab_apyx_AdvancedEnergyMember_249C7ED2494D95742FF5D39D86DEA3AF_terseLabel_en-US" xlink:label="lab_apyx_AdvancedEnergyMember_249C7ED2494D95742FF5D39D86DEA3AF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Advanced Energy</link:label>
    <link:label id="lab_apyx_AdvancedEnergyMember_249C7ED2494D95742FF5D39D86DEA3AF_label_en-US" xlink:label="lab_apyx_AdvancedEnergyMember_249C7ED2494D95742FF5D39D86DEA3AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advanced Energy [Member]</link:label>
    <link:label id="lab_apyx_AdvancedEnergyMember_249C7ED2494D95742FF5D39D86DEA3AF_documentation_en-US" xlink:label="lab_apyx_AdvancedEnergyMember_249C7ED2494D95742FF5D39D86DEA3AF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Advanced Energy [Member]</link:label>
    <link:loc xlink:href="apyx-20200630.xsd#apyx_AdvancedEnergyMember" xlink:label="loc_apyx_AdvancedEnergyMember_249C7ED2494D95742FF5D39D86DEA3AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_AdvancedEnergyMember_249C7ED2494D95742FF5D39D86DEA3AF" xlink:to="lab_apyx_AdvancedEnergyMember_249C7ED2494D95742FF5D39D86DEA3AF" xlink:type="arc" />
    <link:label id="lab_apyx_OEMMember_C6233E727596433CEDBED39D86DEC55B_terseLabel_en-US" xlink:label="lab_apyx_OEMMember_C6233E727596433CEDBED39D86DEC55B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">OEM</link:label>
    <link:label id="lab_apyx_OEMMember_C6233E727596433CEDBED39D86DEC55B_label_en-US" xlink:label="lab_apyx_OEMMember_C6233E727596433CEDBED39D86DEC55B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OEM [Member]</link:label>
    <link:label id="lab_apyx_OEMMember_C6233E727596433CEDBED39D86DEC55B_documentation_en-US" xlink:label="lab_apyx_OEMMember_C6233E727596433CEDBED39D86DEC55B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" />
    <link:loc xlink:href="apyx-20200630.xsd#apyx_OEMMember" xlink:label="loc_apyx_OEMMember_C6233E727596433CEDBED39D86DEC55B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_OEMMember_C6233E727596433CEDBED39D86DEC55B" xlink:to="lab_apyx_OEMMember_C6233E727596433CEDBED39D86DEC55B" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_52EDD22D91B111D503C6D39D86DE474D_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems_52EDD22D91B111D503C6D39D86DE474D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_52EDD22D91B111D503C6D39D86DE474D_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems_52EDD22D91B111D503C6D39D86DE474D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_52EDD22D91B111D503C6D39D86DE474D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_52EDD22D91B111D503C6D39D86DE474D" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems_52EDD22D91B111D503C6D39D86DE474D" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_EF8BCBE8BB654339A33DD39D86E13AB3_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_EF8BCBE8BB654339A33DD39D86E13AB3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_EF8BCBE8BB654339A33DD39D86E13AB3_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_EF8BCBE8BB654339A33DD39D86E13AB3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_EF8BCBE8BB654339A33DD39D86E13AB3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_EF8BCBE8BB654339A33DD39D86E13AB3" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_EF8BCBE8BB654339A33DD39D86E13AB3" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_7121565AE3747798149CD39D86E159A7_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_7121565AE3747798149CD39D86E159A7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income (loss) from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_7121565AE3747798149CD39D86E159A7_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_7121565AE3747798149CD39D86E159A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_7121565AE3747798149CD39D86E159A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_7121565AE3747798149CD39D86E159A7" xlink:to="lab_us-gaap_OperatingIncomeLoss_7121565AE3747798149CD39D86E159A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestIncomeOperating_457D5A463748DA14F3C4D39D86E137D4_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeOperating_457D5A463748DA14F3C4D39D86E137D4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InterestIncomeOperating_457D5A463748DA14F3C4D39D86E137D4_label_en-US" xlink:label="lab_us-gaap_InterestIncomeOperating_457D5A463748DA14F3C4D39D86E137D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Income, Operating</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeOperating" xlink:label="loc_us-gaap_InterestIncomeOperating_457D5A463748DA14F3C4D39D86E137D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeOperating_457D5A463748DA14F3C4D39D86E137D4" xlink:to="lab_us-gaap_InterestIncomeOperating_457D5A463748DA14F3C4D39D86E137D4" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestExpense_98E4BE720EDCF00179D9D39D86E1139D_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense_98E4BE720EDCF00179D9D39D86E1139D" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_98E4BE720EDCF00179D9D39D86E1139D_label_en-US" xlink:label="lab_us-gaap_InterestExpense_98E4BE720EDCF00179D9D39D86E1139D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_98E4BE720EDCF00179D9D39D86E1139D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense_98E4BE720EDCF00179D9D39D86E1139D" xlink:to="lab_us-gaap_InterestExpense_98E4BE720EDCF00179D9D39D86E1139D" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_672883FDDF17A51766AAD39D86E1066D_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet_672883FDDF17A51766AAD39D86E1066D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other income (losses), net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_672883FDDF17A51766AAD39D86E1066D_label_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet_672883FDDF17A51766AAD39D86E1066D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Operating Income (Expense), Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_672883FDDF17A51766AAD39D86E1066D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet_672883FDDF17A51766AAD39D86E1066D" xlink:to="lab_us-gaap_OtherOperatingIncomeExpenseNet_672883FDDF17A51766AAD39D86E1066D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_72554666F0A129B3ABD5D39D86E290A6_netLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_72554666F0A129B3ABD5D39D86E290A6" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Income tax (benefit) expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_72554666F0A129B3ABD5D39D86E290A6_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_72554666F0A129B3ABD5D39D86E290A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_72554666F0A129B3ABD5D39D86E290A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_72554666F0A129B3ABD5D39D86E290A6" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_72554666F0A129B3ABD5D39D86E290A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_BDA1E4B61325637D6174498625C530FB_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_BDA1E4B61325637D6174498625C530FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_BDA1E4B61325637D6174498625C530FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_BDA1E4B61325637D6174498625C530FB" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_BDA1E4B61325637D6174498625C530FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_D8C28C55FCD275EE192F498625C59A04_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_D8C28C55FCD275EE192F498625C59A04" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_D8C28C55FCD275EE192F498625C59A04_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_D8C28C55FCD275EE192F498625C59A04" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_D8C28C55FCD275EE192F498625C59A04" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_D8C28C55FCD275EE192F498625C59A04" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_D8C28C55FCD275EE192F498625C59A04" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_93BB02B5C9867BF1013B498625847E55_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_93BB02B5C9867BF1013B498625847E55" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_93BB02B5C9867BF1013B498625847E55" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_93BB02B5C9867BF1013B498625847E55" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_93BB02B5C9867BF1013B498625847E55" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_DE1753AF9743E04D0F32498625849022_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_DE1753AF9743E04D0F32498625849022" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BASIS OF PRESENTATION</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_DE1753AF9743E04D0F32498625849022_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_DE1753AF9743E04D0F32498625849022" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_DE1753AF9743E04D0F32498625849022" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_DE1753AF9743E04D0F32498625849022" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_DE1753AF9743E04D0F32498625849022" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_B6A1545BF572E057B6FED39D887FE60F_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_B6A1545BF572E057B6FED39D887FE60F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted loss per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_B6A1545BF572E057B6FED39D887FE60F_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_B6A1545BF572E057B6FED39D887FE60F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_B6A1545BF572E057B6FED39D887FE60F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_B6A1545BF572E057B6FED39D887FE60F" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_B6A1545BF572E057B6FED39D887FE60F" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_84EC5D4F10D5668967A8498625C84DC9_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract_84EC5D4F10D5668967A8498625C84DC9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_84EC5D4F10D5668967A8498625C84DC9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_84EC5D4F10D5668967A8498625C84DC9" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract_84EC5D4F10D5668967A8498625C84DC9" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_E970AB41AB66F17465B6498625C907C1_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_E970AB41AB66F17465B6498625C907C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RELATED PARTY TRANSACTIONS</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_E970AB41AB66F17465B6498625C907C1_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_E970AB41AB66F17465B6498625C907C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_E970AB41AB66F17465B6498625C907C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_E970AB41AB66F17465B6498625C907C1" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_E970AB41AB66F17465B6498625C907C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_C501159513615F2E60D54986257F46AD_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_C501159513615F2E60D54986257F46AD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">INCOME TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_C501159513615F2E60D54986257F46AD_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_C501159513615F2E60D54986257F46AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_C501159513615F2E60D54986257F46AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock_C501159513615F2E60D54986257F46AD" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock_C501159513615F2E60D54986257F46AD" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_C32E8A017D9C39AAE865498625CD6B80_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_C32E8A017D9C39AAE865498625CD6B80" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">STOCK-BASED COMPENSATION</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_C32E8A017D9C39AAE865498625CD6B80_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_C32E8A017D9C39AAE865498625CD6B80" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_C32E8A017D9C39AAE865498625CD6B80" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_C32E8A017D9C39AAE865498625CD6B80" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_C32E8A017D9C39AAE865498625CD6B80" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryWriteDown_F48C3F080A16E1489CC2BFC9BC01AD07_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWriteDown_F48C3F080A16E1489CC2BFC9BC01AD07" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of inventory</link:label>
    <link:label id="lab_us-gaap_InventoryWriteDown_F48C3F080A16E1489CC2BFC9BC01AD07_label_en-US" xlink:label="lab_us-gaap_InventoryWriteDown_F48C3F080A16E1489CC2BFC9BC01AD07" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Write-down</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="loc_us-gaap_InventoryWriteDown_F48C3F080A16E1489CC2BFC9BC01AD07" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWriteDown_F48C3F080A16E1489CC2BFC9BC01AD07" xlink:to="lab_us-gaap_InventoryWriteDown_F48C3F080A16E1489CC2BFC9BC01AD07" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_5EF8ED8B1F871BB8ABA9A686569D66BC_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_5EF8ED8B1F871BB8ABA9A686569D66BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_5EF8ED8B1F871BB8ABA9A686569D66BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_5EF8ED8B1F871BB8ABA9A686569D66BC" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_5EF8ED8B1F871BB8ABA9A686569D66BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2E6C42653EA7A3F6397AA68656A57204_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2E6C42653EA7A3F6397AA68656A57204" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2E6C42653EA7A3F6397AA68656A57204_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2E6C42653EA7A3F6397AA68656A57204" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2E6C42653EA7A3F6397AA68656A57204" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2E6C42653EA7A3F6397AA68656A57204" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2E6C42653EA7A3F6397AA68656A57204" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_953431EF7C52302926BDA68656A523A2_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_953431EF7C52302926BDA68656A523A2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_953431EF7C52302926BDA68656A523A2_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_953431EF7C52302926BDA68656A523A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_953431EF7C52302926BDA68656A523A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_953431EF7C52302926BDA68656A523A2" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_953431EF7C52302926BDA68656A523A2" xlink:type="arc" />
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_8FDB27305DF9DFF6E023A68656A63ADE_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_8FDB27305DF9DFF6E023A68656A63ADE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_8FDB27305DF9DFF6E023A68656A63ADE_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_8FDB27305DF9DFF6E023A68656A63ADE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_8FDB27305DF9DFF6E023A68656A63ADE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization_8FDB27305DF9DFF6E023A68656A63ADE" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization_8FDB27305DF9DFF6E023A68656A63ADE" xlink:type="arc" />
    <link:label id="lab_apyx_ProvisionForInventoryObsolescence_E05C5B34029D8753F762A68656A6173C_terseLabel_en-US" xlink:label="lab_apyx_ProvisionForInventoryObsolescence_E05C5B34029D8753F762A68656A6173C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provision for inventory obsolescence</link:label>
    <link:label id="lab_apyx_ProvisionForInventoryObsolescence_E05C5B34029D8753F762A68656A6173C_label_en-US" xlink:label="lab_apyx_ProvisionForInventoryObsolescence_E05C5B34029D8753F762A68656A6173C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provision For Inventory Obsolescence</link:label>
    <link:label id="lab_apyx_ProvisionForInventoryObsolescence_E05C5B34029D8753F762A68656A6173C_documentation_en-US" xlink:label="lab_apyx_ProvisionForInventoryObsolescence_E05C5B34029D8753F762A68656A6173C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Provision For Inventory Obsolescence</link:label>
    <link:loc xlink:href="apyx-20200630.xsd#apyx_ProvisionForInventoryObsolescence" xlink:label="loc_apyx_ProvisionForInventoryObsolescence_E05C5B34029D8753F762A68656A6173C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_ProvisionForInventoryObsolescence_E05C5B34029D8753F762A68656A6173C" xlink:to="lab_apyx_ProvisionForInventoryObsolescence_E05C5B34029D8753F762A68656A6173C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensation_5A22A64E9C7AC79AA8B4A68656A634AD_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_5A22A64E9C7AC79AA8B4A68656A634AD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_5A22A64E9C7AC79AA8B4A68656A634AD_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_5A22A64E9C7AC79AA8B4A68656A634AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_5A22A64E9C7AC79AA8B4A68656A634AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_5A22A64E9C7AC79AA8B4A68656A634AD" xlink:to="lab_us-gaap_ShareBasedCompensation_5A22A64E9C7AC79AA8B4A68656A634AD" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainLossOnInvestments_8B1A5B6AAE322FAF156BA68656A75D65_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnInvestments_8B1A5B6AAE322FAF156BA68656A75D65" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gain on short term investments</link:label>
    <link:label id="lab_us-gaap_GainLossOnInvestments_8B1A5B6AAE322FAF156BA68656A75D65_label_en-US" xlink:label="lab_us-gaap_GainLossOnInvestments_8B1A5B6AAE322FAF156BA68656A75D65" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnInvestments" xlink:label="loc_us-gaap_GainLossOnInvestments_8B1A5B6AAE322FAF156BA68656A75D65" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnInvestments_8B1A5B6AAE322FAF156BA68656A75D65" xlink:to="lab_us-gaap_GainLossOnInvestments_8B1A5B6AAE322FAF156BA68656A75D65" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_52F28E6DBDB3BD756669A68656A7357C_terseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts_52F28E6DBDB3BD756669A68656A7357C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provision (benefit) for allowance for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_52F28E6DBDB3BD756669A68656A7357C_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts_52F28E6DBDB3BD756669A68656A7357C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_52F28E6DBDB3BD756669A68656A7357C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts_52F28E6DBDB3BD756669A68656A7357C" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts_52F28E6DBDB3BD756669A68656A7357C" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5CDF18B161B4BF8FB199A68656A7DE67_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5CDF18B161B4BF8FB199A68656A7DE67" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5CDF18B161B4BF8FB199A68656A7DE67_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5CDF18B161B4BF8FB199A68656A7DE67" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5CDF18B161B4BF8FB199A68656A7DE67" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5CDF18B161B4BF8FB199A68656A7DE67" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5CDF18B161B4BF8FB199A68656A7DE67" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_DB22A31DAA27A1AFF2CFA68656A72C8D_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_DB22A31DAA27A1AFF2CFA68656A72C8D" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Trade receivables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_DB22A31DAA27A1AFF2CFA68656A72C8D_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_DB22A31DAA27A1AFF2CFA68656A72C8D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_DB22A31DAA27A1AFF2CFA68656A72C8D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_DB22A31DAA27A1AFF2CFA68656A72C8D" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_DB22A31DAA27A1AFF2CFA68656A72C8D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_D9643804B0092B46B8FBA68656A77F3C_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_D9643804B0092B46B8FBA68656A77F3C" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_D9643804B0092B46B8FBA68656A77F3C_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_D9643804B0092B46B8FBA68656A77F3C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_D9643804B0092B46B8FBA68656A77F3C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_D9643804B0092B46B8FBA68656A77F3C" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_D9643804B0092B46B8FBA68656A77F3C" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_CBC52D892965DFFB63ABA68656A7DCB0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_CBC52D892965DFFB63ABA68656A7DCB0" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_CBC52D892965DFFB63ABA68656A7DCB0_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_CBC52D892965DFFB63ABA68656A7DCB0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_CBC52D892965DFFB63ABA68656A7DCB0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories_CBC52D892965DFFB63ABA68656A7DCB0" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories_CBC52D892965DFFB63ABA68656A7DCB0" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_A7B7DF360BEA6B3CBF00A68656A7B5E2_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_A7B7DF360BEA6B3CBF00A68656A7B5E2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_A7B7DF360BEA6B3CBF00A68656A7B5E2_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_A7B7DF360BEA6B3CBF00A68656A7B5E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_A7B7DF360BEA6B3CBF00A68656A7B5E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable_A7B7DF360BEA6B3CBF00A68656A7B5E2" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable_A7B7DF360BEA6B3CBF00A68656A7B5E2" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_FFDA277908B0C1AFAA61A68656A73B95_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_FFDA277908B0C1AFAA61A68656A73B95" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_FFDA277908B0C1AFAA61A68656A73B95_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_FFDA277908B0C1AFAA61A68656A73B95" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_FFDA277908B0C1AFAA61A68656A73B95" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_FFDA277908B0C1AFAA61A68656A73B95" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_FFDA277908B0C1AFAA61A68656A73B95" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_BA8796A39A8636BBC815A68656A773A9_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_BA8796A39A8636BBC815A68656A773A9" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_BA8796A39A8636BBC815A68656A773A9_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_BA8796A39A8636BBC815A68656A773A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_BA8796A39A8636BBC815A68656A773A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_BA8796A39A8636BBC815A68656A773A9" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_BA8796A39A8636BBC815A68656A773A9" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_D42D3EE4B986AF419A78A68656A73B41_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_D42D3EE4B986AF419A78A68656A73B41" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_D42D3EE4B986AF419A78A68656A73B41_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_D42D3EE4B986AF419A78A68656A73B41" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_D42D3EE4B986AF419A78A68656A73B41" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_D42D3EE4B986AF419A78A68656A73B41" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_D42D3EE4B986AF419A78A68656A73B41" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_05555E11DD28C13C001CA68656A7107B_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_05555E11DD28C13C001CA68656A7107B" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_05555E11DD28C13C001CA68656A7107B_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_05555E11DD28C13C001CA68656A7107B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_05555E11DD28C13C001CA68656A7107B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_05555E11DD28C13C001CA68656A7107B" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_05555E11DD28C13C001CA68656A7107B" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_89E8372C00F2ADECFEAAA68656A730AB_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities_89E8372C00F2ADECFEAAA68656A730AB" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_89E8372C00F2ADECFEAAA68656A730AB_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities_89E8372C00F2ADECFEAAA68656A730AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_89E8372C00F2ADECFEAAA68656A730AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities_89E8372C00F2ADECFEAAA68656A730AB" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities_89E8372C00F2ADECFEAAA68656A730AB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_6597C958CF6059CA6C0BA68656A773EA_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_6597C958CF6059CA6C0BA68656A773EA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_6597C958CF6059CA6C0BA68656A773EA_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_6597C958CF6059CA6C0BA68656A773EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_6597C958CF6059CA6C0BA68656A773EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_6597C958CF6059CA6C0BA68656A773EA" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_6597C958CF6059CA6C0BA68656A773EA" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_B5E95BBE1D2F849662FEA68656A7FCFF_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_B5E95BBE1D2F849662FEA68656A7FCFF" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash (used in) provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_B5E95BBE1D2F849662FEA68656A7FCFF_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_B5E95BBE1D2F849662FEA68656A7FCFF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_B5E95BBE1D2F849662FEA68656A7FCFF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_B5E95BBE1D2F849662FEA68656A7FCFF" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_B5E95BBE1D2F849662FEA68656A7FCFF" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_E73A63282BE1631930CDA68656A732E2_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_E73A63282BE1631930CDA68656A732E2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_E73A63282BE1631930CDA68656A732E2_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_E73A63282BE1631930CDA68656A732E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_E73A63282BE1631930CDA68656A732E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_E73A63282BE1631930CDA68656A732E2" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_E73A63282BE1631930CDA68656A732E2" xlink:type="arc" />
    <link:label id="lab_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised_354942F2B86CB5FF988DA68656A75F62_terseLabel_en-US" xlink:label="lab_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised_354942F2B86CB5FF988DA68656A75F62" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from stock option exercises</link:label>
    <link:label id="lab_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised_354942F2B86CB5FF988DA68656A75F62_label_en-US" xlink:label="lab_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised_354942F2B86CB5FF988DA68656A75F62" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Stock Options Exercised And Warrants Exercised</link:label>
    <link:label id="lab_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised_354942F2B86CB5FF988DA68656A75F62_documentation_en-US" xlink:label="lab_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised_354942F2B86CB5FF988DA68656A75F62" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds From Stock Options Exercised And Warrants Exercised</link:label>
    <link:loc xlink:href="apyx-20200630.xsd#apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised" xlink:label="loc_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised_354942F2B86CB5FF988DA68656A75F62" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised_354942F2B86CB5FF988DA68656A75F62" xlink:to="lab_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised_354942F2B86CB5FF988DA68656A75F62" xlink:type="arc" />
    <link:label id="lab_apyx_RepaymentofFinanceLeaseLiabilities_802FEFFB3E7531835BADA68656A778B3_negatedTerseLabel_en-US" xlink:label="lab_apyx_RepaymentofFinanceLeaseLiabilities_802FEFFB3E7531835BADA68656A778B3" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repayment of finance lease liabilities</link:label>
    <link:label id="lab_apyx_RepaymentofFinanceLeaseLiabilities_802FEFFB3E7531835BADA68656A778B3_label_en-US" xlink:label="lab_apyx_RepaymentofFinanceLeaseLiabilities_802FEFFB3E7531835BADA68656A778B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayment of Finance Lease Liabilities</link:label>
    <link:label id="lab_apyx_RepaymentofFinanceLeaseLiabilities_802FEFFB3E7531835BADA68656A778B3_documentation_en-US" xlink:label="lab_apyx_RepaymentofFinanceLeaseLiabilities_802FEFFB3E7531835BADA68656A778B3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Repayment of Finance Lease Liabilities</link:label>
    <link:loc xlink:href="apyx-20200630.xsd#apyx_RepaymentofFinanceLeaseLiabilities" xlink:label="loc_apyx_RepaymentofFinanceLeaseLiabilities_802FEFFB3E7531835BADA68656A778B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_RepaymentofFinanceLeaseLiabilities_802FEFFB3E7531835BADA68656A778B3" xlink:to="lab_apyx_RepaymentofFinanceLeaseLiabilities_802FEFFB3E7531835BADA68656A778B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_EB633519B2B77F9B70FBA68656A72842_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_EB633519B2B77F9B70FBA68656A72842" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash (used in) provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_EB633519B2B77F9B70FBA68656A72842_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_EB633519B2B77F9B70FBA68656A72842" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_EB633519B2B77F9B70FBA68656A72842" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_EB633519B2B77F9B70FBA68656A72842" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_EB633519B2B77F9B70FBA68656A72842" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_CB09AC14999F01A138E5A68656A77520_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_CB09AC14999F01A138E5A68656A77520" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of exchange rates on cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_CB09AC14999F01A138E5A68656A77520_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_CB09AC14999F01A138E5A68656A77520" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_CB09AC14999F01A138E5A68656A77520" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_CB09AC14999F01A138E5A68656A77520" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_CB09AC14999F01A138E5A68656A77520" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_F32E6FE0A5C645C638D3A68656A701E8_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_F32E6FE0A5C645C638D3A68656A701E8" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net change in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_F32E6FE0A5C645C638D3A68656A701E8_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_F32E6FE0A5C645C638D3A68656A701E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_F32E6FE0A5C645C638D3A68656A701E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_F32E6FE0A5C645C638D3A68656A701E8" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_F32E6FE0A5C645C638D3A68656A701E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7E00AB911ED92802E39DA68656A7773C_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7E00AB911ED92802E39DA68656A7773C" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7E00AB911ED92802E39DA68656A7773C_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7E00AB911ED92802E39DA68656A7773C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7E00AB911ED92802E39DA68656A7773C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7E00AB911ED92802E39DA68656A7773C" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7E00AB911ED92802E39DA68656A7773C" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_D627D66C61DD1466C3C0A68656A7E4E3_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_D627D66C61DD1466C3C0A68656A7E4E3" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash, end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_D627D66C61DD1466C3C0A68656A7E4E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_D627D66C61DD1466C3C0A68656A7E4E3" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_D627D66C61DD1466C3C0A68656A7E4E3" xlink:type="arc" />
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_1A2091255B8B819BDECEA68EF8B44A80_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_1A2091255B8B819BDECEA68EF8B44A80" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_1A2091255B8B819BDECEA68EF8B44A80_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_1A2091255B8B819BDECEA68EF8B44A80" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_1A2091255B8B819BDECEA68EF8B44A80" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_1A2091255B8B819BDECEA68EF8B44A80" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract_1A2091255B8B819BDECEA68EF8B44A80" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestPaidNet_22BCF7B24A443600760FA69065BD7057_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet_22BCF7B24A443600760FA69065BD7057" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_22BCF7B24A443600760FA69065BD7057_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet_22BCF7B24A443600760FA69065BD7057" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_22BCF7B24A443600760FA69065BD7057" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet_22BCF7B24A443600760FA69065BD7057" xlink:to="lab_us-gaap_InterestPaidNet_22BCF7B24A443600760FA69065BD7057" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxesPaid_55783C1F2E716712D7AAA69345D0F4D4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid_55783C1F2E716712D7AAA69345D0F4D4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_55783C1F2E716712D7AAA69345D0F4D4_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid_55783C1F2E716712D7AAA69345D0F4D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaap_IncomeTaxesPaid_55783C1F2E716712D7AAA69345D0F4D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid_55783C1F2E716712D7AAA69345D0F4D4" xlink:to="lab_us-gaap_IncomeTaxesPaid_55783C1F2E716712D7AAA69345D0F4D4" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_2CE3898A3C712BB20295A6901C905DE3_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_2CE3898A3C712BB20295A6901C905DE3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_2CE3898A3C712BB20295A6901C905DE3_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_2CE3898A3C712BB20295A6901C905DE3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_2CE3898A3C712BB20295A6901C905DE3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_2CE3898A3C712BB20295A6901C905DE3" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_2CE3898A3C712BB20295A6901C905DE3" xlink:type="arc" />
    <link:label id="lab_apyx_NonCashProceedsFromStockOptionsAndWarrantsExercised_B63C4B00A296D01A741AA69065FCC2BA_terseLabel_en-US" xlink:label="lab_apyx_NonCashProceedsFromStockOptionsAndWarrantsExercised_B63C4B00A296D01A741AA69065FCC2BA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cashless exercise of stock options</link:label>
    <link:label id="lab_apyx_NonCashProceedsFromStockOptionsAndWarrantsExercised_B63C4B00A296D01A741AA69065FCC2BA_label_en-US" xlink:label="lab_apyx_NonCashProceedsFromStockOptionsAndWarrantsExercised_B63C4B00A296D01A741AA69065FCC2BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non Cash, Proceeds From Stock Options And Warrants Exercised</link:label>
    <link:label id="lab_apyx_NonCashProceedsFromStockOptionsAndWarrantsExercised_B63C4B00A296D01A741AA69065FCC2BA_documentation_en-US" xlink:label="lab_apyx_NonCashProceedsFromStockOptionsAndWarrantsExercised_B63C4B00A296D01A741AA69065FCC2BA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non Cash, Proceeds From Stock Options And Warrants Exercised</link:label>
    <link:loc xlink:href="apyx-20200630.xsd#apyx_NonCashProceedsFromStockOptionsAndWarrantsExercised" xlink:label="loc_apyx_NonCashProceedsFromStockOptionsAndWarrantsExercised_B63C4B00A296D01A741AA69065FCC2BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_NonCashProceedsFromStockOptionsAndWarrantsExercised_B63C4B00A296D01A741AA69065FCC2BA" xlink:to="lab_apyx_NonCashProceedsFromStockOptionsAndWarrantsExercised_B63C4B00A296D01A741AA69065FCC2BA" xlink:type="arc" />
    <link:label id="lab_apyx_LeaseAdoption_05406E8899D9FAE9A065A6906630DD2D_terseLabel_en-US" xlink:label="lab_apyx_LeaseAdoption_05406E8899D9FAE9A065A6906630DD2D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets capitalized and lease liabilities recognized upon adoption of Topic 842</link:label>
    <link:label id="lab_apyx_LeaseAdoption_05406E8899D9FAE9A065A6906630DD2D_label_en-US" xlink:label="lab_apyx_LeaseAdoption_05406E8899D9FAE9A065A6906630DD2D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Adoption</link:label>
    <link:label id="lab_apyx_LeaseAdoption_05406E8899D9FAE9A065A6906630DD2D_documentation_en-US" xlink:label="lab_apyx_LeaseAdoption_05406E8899D9FAE9A065A6906630DD2D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lease Adoption</link:label>
    <link:loc xlink:href="apyx-20200630.xsd#apyx_LeaseAdoption" xlink:label="loc_apyx_LeaseAdoption_05406E8899D9FAE9A065A6906630DD2D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_LeaseAdoption_05406E8899D9FAE9A065A6906630DD2D" xlink:to="lab_apyx_LeaseAdoption_05406E8899D9FAE9A065A6906630DD2D" xlink:type="arc" />
    <link:label id="lab_apyx_CapitalizationOfLeaseNonCash_A506D0A4006C632AA851A6906661E954_terseLabel_en-US" xlink:label="lab_apyx_CapitalizationOfLeaseNonCash_A506D0A4006C632AA851A6906661E954" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets capitalized and lease liabilities recognized upon lease remeasurement</link:label>
    <link:label id="lab_apyx_CapitalizationOfLeaseNonCash_A506D0A4006C632AA851A6906661E954_label_en-US" xlink:label="lab_apyx_CapitalizationOfLeaseNonCash_A506D0A4006C632AA851A6906661E954" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capitalization Of Lease, Non Cash</link:label>
    <link:label id="lab_apyx_CapitalizationOfLeaseNonCash_A506D0A4006C632AA851A6906661E954_documentation_en-US" xlink:label="lab_apyx_CapitalizationOfLeaseNonCash_A506D0A4006C632AA851A6906661E954" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Capitalization Of Lease, Non Cash</link:label>
    <link:loc xlink:href="apyx-20200630.xsd#apyx_CapitalizationOfLeaseNonCash" xlink:label="loc_apyx_CapitalizationOfLeaseNonCash_A506D0A4006C632AA851A6906661E954" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_CapitalizationOfLeaseNonCash_A506D0A4006C632AA851A6906661E954" xlink:to="lab_apyx_CapitalizationOfLeaseNonCash_A506D0A4006C632AA851A6906661E954" xlink:type="arc" />
    <link:label id="lab_apyx_CapitalizationOfLeaseExecution_D5CED33C82A533C76DF0A69E7AEDE3DD_terseLabel_en-US" xlink:label="lab_apyx_CapitalizationOfLeaseExecution_D5CED33C82A533C76DF0A69E7AEDE3DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets capitalized and lease liabilities recognized upon execution of lease</link:label>
    <link:label id="lab_apyx_CapitalizationOfLeaseExecution_D5CED33C82A533C76DF0A69E7AEDE3DD_label_en-US" xlink:label="lab_apyx_CapitalizationOfLeaseExecution_D5CED33C82A533C76DF0A69E7AEDE3DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capitalization Of Lease, Execution</link:label>
    <link:label id="lab_apyx_CapitalizationOfLeaseExecution_D5CED33C82A533C76DF0A69E7AEDE3DD_documentation_en-US" xlink:label="lab_apyx_CapitalizationOfLeaseExecution_D5CED33C82A533C76DF0A69E7AEDE3DD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Capitalization Of Lease, Execution</link:label>
    <link:loc xlink:href="apyx-20200630.xsd#apyx_CapitalizationOfLeaseExecution" xlink:label="loc_apyx_CapitalizationOfLeaseExecution_D5CED33C82A533C76DF0A69E7AEDE3DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_CapitalizationOfLeaseExecution_D5CED33C82A533C76DF0A69E7AEDE3DD" xlink:to="lab_apyx_CapitalizationOfLeaseExecution_D5CED33C82A533C76DF0A69E7AEDE3DD" xlink:type="arc" />
    <link:label id="lab_apyx_NonCashTransferOfOtherAssetsToFixedAssets_2E771E52B3380C9CF0DFA697BEBEDC4F_terseLabel_en-US" xlink:label="lab_apyx_NonCashTransferOfOtherAssetsToFixedAssets_2E771E52B3380C9CF0DFA697BEBEDC4F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transfer of other assets to fixed assets</link:label>
    <link:label id="lab_apyx_NonCashTransferOfOtherAssetsToFixedAssets_2E771E52B3380C9CF0DFA697BEBEDC4F_label_en-US" xlink:label="lab_apyx_NonCashTransferOfOtherAssetsToFixedAssets_2E771E52B3380C9CF0DFA697BEBEDC4F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non Cash, Transfer Of Other Assets To Fixed Assets</link:label>
    <link:label id="lab_apyx_NonCashTransferOfOtherAssetsToFixedAssets_2E771E52B3380C9CF0DFA697BEBEDC4F_documentation_en-US" xlink:label="lab_apyx_NonCashTransferOfOtherAssetsToFixedAssets_2E771E52B3380C9CF0DFA697BEBEDC4F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non Cash, Transfer Of Other Assets To Fixed Assets</link:label>
    <link:loc xlink:href="apyx-20200630.xsd#apyx_NonCashTransferOfOtherAssetsToFixedAssets" xlink:label="loc_apyx_NonCashTransferOfOtherAssetsToFixedAssets_2E771E52B3380C9CF0DFA697BEBEDC4F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_NonCashTransferOfOtherAssetsToFixedAssets_2E771E52B3380C9CF0DFA697BEBEDC4F" xlink:to="lab_apyx_NonCashTransferOfOtherAssetsToFixedAssets_2E771E52B3380C9CF0DFA697BEBEDC4F" xlink:type="arc" />
    <link:label id="lab_apyx_NonCashTransfersOfInventoryToFromFixedAssets_662C30719E3D2B2F3AC6A69854A172FD_terseLabel_en-US" xlink:label="lab_apyx_NonCashTransfersOfInventoryToFromFixedAssets_662C30719E3D2B2F3AC6A69854A172FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transfer of inventory (to) from fixed assets</link:label>
    <link:label id="lab_apyx_NonCashTransfersOfInventoryToFromFixedAssets_662C30719E3D2B2F3AC6A69854A172FD_label_en-US" xlink:label="lab_apyx_NonCashTransfersOfInventoryToFromFixedAssets_662C30719E3D2B2F3AC6A69854A172FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non Cash, Transfers Of Inventory To (From) Fixed Assets</link:label>
    <link:label id="lab_apyx_NonCashTransfersOfInventoryToFromFixedAssets_662C30719E3D2B2F3AC6A69854A172FD_documentation_en-US" xlink:label="lab_apyx_NonCashTransfersOfInventoryToFromFixedAssets_662C30719E3D2B2F3AC6A69854A172FD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non Cash, Transfers Of Inventory To (From) Fixed Assets</link:label>
    <link:loc xlink:href="apyx-20200630.xsd#apyx_NonCashTransfersOfInventoryToFromFixedAssets" xlink:label="loc_apyx_NonCashTransfersOfInventoryToFromFixedAssets_662C30719E3D2B2F3AC6A69854A172FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_NonCashTransfersOfInventoryToFromFixedAssets_662C30719E3D2B2F3AC6A69854A172FD" xlink:to="lab_apyx_NonCashTransfersOfInventoryToFromFixedAssets_662C30719E3D2B2F3AC6A69854A172FD" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementAbstract_B4691BAF6757CBAC9FAAD6069AC2544B_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract_B4691BAF6757CBAC9FAAD6069AC2544B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_B4691BAF6757CBAC9FAAD6069AC2544B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_B4691BAF6757CBAC9FAAD6069AC2544B" xlink:to="lab_us-gaap_IncomeStatementAbstract_B4691BAF6757CBAC9FAAD6069AC2544B" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_1F7BA58B788DF57AD02CD6069AC2196A_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold_1F7BA58B788DF57AD02CD6069AC2196A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_1F7BA58B788DF57AD02CD6069AC2196A_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold_1F7BA58B788DF57AD02CD6069AC2196A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_1F7BA58B788DF57AD02CD6069AC2196A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold_1F7BA58B788DF57AD02CD6069AC2196A" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold_1F7BA58B788DF57AD02CD6069AC2196A" xlink:type="arc" />
    <link:label id="lab_us-gaap_GrossProfit_8B6247739BCE18DD76DCD6069AC248A2_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit_8B6247739BCE18DD76DCD6069AC248A2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Gross profit</link:label>
    <link:label id="lab_us-gaap_GrossProfit_8B6247739BCE18DD76DCD6069AC248A2_label_en-US" xlink:label="lab_us-gaap_GrossProfit_8B6247739BCE18DD76DCD6069AC248A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_8B6247739BCE18DD76DCD6069AC248A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit_8B6247739BCE18DD76DCD6069AC248A2" xlink:to="lab_us-gaap_GrossProfit_8B6247739BCE18DD76DCD6069AC248A2" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_A50B895402E893C34E2FD6069AC28A04_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract_A50B895402E893C34E2FD6069AC28A04" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other costs and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_A50B895402E893C34E2FD6069AC28A04_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract_A50B895402E893C34E2FD6069AC28A04" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_A50B895402E893C34E2FD6069AC28A04" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_A50B895402E893C34E2FD6069AC28A04" xlink:to="lab_us-gaap_CostsAndExpensesAbstract_A50B895402E893C34E2FD6069AC28A04" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_6B0FB504ADAB0D874A44D6069AC26419_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_6B0FB504ADAB0D874A44D6069AC26419" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_6B0FB504ADAB0D874A44D6069AC26419_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_6B0FB504ADAB0D874A44D6069AC26419" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_6B0FB504ADAB0D874A44D6069AC26419" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_6B0FB504ADAB0D874A44D6069AC26419" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_6B0FB504ADAB0D874A44D6069AC26419" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProfessionalFees_A2A5C0F761150D29AFB2D6069AC22E44_terseLabel_en-US" xlink:label="lab_us-gaap_ProfessionalFees_A2A5C0F761150D29AFB2D6069AC22E44" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Professional services</link:label>
    <link:label id="lab_us-gaap_ProfessionalFees_A2A5C0F761150D29AFB2D6069AC22E44_label_en-US" xlink:label="lab_us-gaap_ProfessionalFees_A2A5C0F761150D29AFB2D6069AC22E44" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Professional Fees</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaap_ProfessionalFees_A2A5C0F761150D29AFB2D6069AC22E44" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfessionalFees_A2A5C0F761150D29AFB2D6069AC22E44" xlink:to="lab_us-gaap_ProfessionalFees_A2A5C0F761150D29AFB2D6069AC22E44" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalariesAndWages_D3CB4ED44325376FDEC0D6069AC287D1_terseLabel_en-US" xlink:label="lab_us-gaap_SalariesAndWages_D3CB4ED44325376FDEC0D6069AC287D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Salaries and related costs</link:label>
    <link:label id="lab_us-gaap_SalariesAndWages_D3CB4ED44325376FDEC0D6069AC287D1_label_en-US" xlink:label="lab_us-gaap_SalariesAndWages_D3CB4ED44325376FDEC0D6069AC287D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Salary and Wage, NonOfficer, Excluding Cost of Good and Service Sold</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalariesAndWages" xlink:label="loc_us-gaap_SalariesAndWages_D3CB4ED44325376FDEC0D6069AC287D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalariesAndWages_D3CB4ED44325376FDEC0D6069AC287D1" xlink:to="lab_us-gaap_SalariesAndWages_D3CB4ED44325376FDEC0D6069AC287D1" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_EBFEBE71D8D093AAB15ED6069AC2E6DF_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_EBFEBE71D8D093AAB15ED6069AC2E6DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_EBFEBE71D8D093AAB15ED6069AC2E6DF_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_EBFEBE71D8D093AAB15ED6069AC2E6DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_EBFEBE71D8D093AAB15ED6069AC2E6DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense_EBFEBE71D8D093AAB15ED6069AC2E6DF" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense_EBFEBE71D8D093AAB15ED6069AC2E6DF" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpenses_2321AB5C01A363D69585D6069AC2C259_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses_2321AB5C01A363D69585D6069AC2C259" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other costs and expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_2321AB5C01A363D69585D6069AC2C259_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses_2321AB5C01A363D69585D6069AC2C259" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_2321AB5C01A363D69585D6069AC2C259" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_2321AB5C01A363D69585D6069AC2C259" xlink:to="lab_us-gaap_OperatingExpenses_2321AB5C01A363D69585D6069AC2C259" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_27D9E8C77E20FB31B378D6069AC2E392_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_27D9E8C77E20FB31B378D6069AC2E392" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_27D9E8C77E20FB31B378D6069AC2E392" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_27D9E8C77E20FB31B378D6069AC2E392" xlink:to="lab_us-gaap_OperatingIncomeLoss_27D9E8C77E20FB31B378D6069AC2E392" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestIncomeOperating_0BBCD09974A868A6DA2CD6069AC2E90A_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeOperating_0BBCD09974A868A6DA2CD6069AC2E90A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeOperating" xlink:label="loc_us-gaap_InterestIncomeOperating_0BBCD09974A868A6DA2CD6069AC2E90A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeOperating_0BBCD09974A868A6DA2CD6069AC2E90A" xlink:to="lab_us-gaap_InterestIncomeOperating_0BBCD09974A868A6DA2CD6069AC2E90A" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_7963F78572AF7C105281D6069AC2754E_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet_7963F78572AF7C105281D6069AC2754E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other (loss) income, net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_7963F78572AF7C105281D6069AC2754E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet_7963F78572AF7C105281D6069AC2754E" xlink:to="lab_us-gaap_OtherOperatingIncomeExpenseNet_7963F78572AF7C105281D6069AC2754E" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_F743C26B277C04321C50D6069AC20C8A_totalLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_F743C26B277C04321C50D6069AC20C8A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other (loss) income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_F743C26B277C04321C50D6069AC20C8A_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_F743C26B277C04321C50D6069AC20C8A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_F743C26B277C04321C50D6069AC20C8A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_F743C26B277C04321C50D6069AC20C8A" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense_F743C26B277C04321C50D6069AC20C8A" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_D571AABA359763DE5E73D6069AC2DB5C_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_D571AABA359763DE5E73D6069AC2DB5C" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_D571AABA359763DE5E73D6069AC2DB5C_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_D571AABA359763DE5E73D6069AC2DB5C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_D571AABA359763DE5E73D6069AC2DB5C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_D571AABA359763DE5E73D6069AC2DB5C" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_D571AABA359763DE5E73D6069AC2DB5C" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_E0E1A8A7CB4495D6ED5BD6069AC206D5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_E0E1A8A7CB4495D6ED5BD6069AC206D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax (benefit) expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_E0E1A8A7CB4495D6ED5BD6069AC206D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_E0E1A8A7CB4495D6ED5BD6069AC206D5" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_E0E1A8A7CB4495D6ED5BD6069AC206D5" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_450DFAF7FEC4D7B85622D6069AC20C6A_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_450DFAF7FEC4D7B85622D6069AC20C6A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_450DFAF7FEC4D7B85622D6069AC20C6A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_450DFAF7FEC4D7B85622D6069AC20C6A" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_450DFAF7FEC4D7B85622D6069AC20C6A" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_547271CCE6FDA7FE8017D6069AC2BBD9_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_547271CCE6FDA7FE8017D6069AC2BBD9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings (loss) per Share:</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_547271CCE6FDA7FE8017D6069AC2BBD9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_547271CCE6FDA7FE8017D6069AC2BBD9" xlink:to="lab_us-gaap_EarningsPerShareAbstract_547271CCE6FDA7FE8017D6069AC2BBD9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_CCE88575D17BDF071DCE49862590AA51_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_CCE88575D17BDF071DCE49862590AA51" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_CCE88575D17BDF071DCE49862590AA51_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_CCE88575D17BDF071DCE49862590AA51" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_CCE88575D17BDF071DCE49862590AA51" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_CCE88575D17BDF071DCE49862590AA51" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_CCE88575D17BDF071DCE49862590AA51" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_309DB4AD83CBE5014E6349862590F0AD_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_309DB4AD83CBE5014E6349862590F0AD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_309DB4AD83CBE5014E6349862590F0AD_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_309DB4AD83CBE5014E6349862590F0AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_309DB4AD83CBE5014E6349862590F0AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_309DB4AD83CBE5014E6349862590F0AD" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_309DB4AD83CBE5014E6349862590F0AD" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_402392AAFF07DBBCFFC749862590C6A9_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock_402392AAFF07DBBCFFC749862590C6A9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_402392AAFF07DBBCFFC749862590C6A9_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock_402392AAFF07DBBCFFC749862590C6A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_402392AAFF07DBBCFFC749862590C6A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock_402392AAFF07DBBCFFC749862590C6A9" xlink:to="lab_us-gaap_InventoryPolicyTextBlock_402392AAFF07DBBCFFC749862590C6A9" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_D91FCE22366DEC055D4849862554E330_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_D91FCE22366DEC055D4849862554E330" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_D91FCE22366DEC055D4849862554E330_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_D91FCE22366DEC055D4849862554E330" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_D91FCE22366DEC055D4849862554E330" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_D91FCE22366DEC055D4849862554E330" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_D91FCE22366DEC055D4849862554E330" xlink:type="arc" />
    <link:label id="lab_dei_CoverAbstract_8424148013F205A841ABC974547D9BF5_label_en-US" xlink:label="lab_dei_CoverAbstract_8424148013F205A841ABC974547D9BF5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_8424148013F205A841ABC974547D9BF5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract_8424148013F205A841ABC974547D9BF5" xlink:to="lab_dei_CoverAbstract_8424148013F205A841ABC974547D9BF5" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_E5FB153A7BC92B533856C974547D5B19_terseLabel_en-US" xlink:label="lab_dei_DocumentType_E5FB153A7BC92B533856C974547D5B19" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_E5FB153A7BC92B533856C974547D5B19_label_en-US" xlink:label="lab_dei_DocumentType_E5FB153A7BC92B533856C974547D5B19" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_E5FB153A7BC92B533856C974547D5B19" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_E5FB153A7BC92B533856C974547D5B19" xlink:to="lab_dei_DocumentType_E5FB153A7BC92B533856C974547D5B19" xlink:type="arc" />
    <link:label id="lab_dei_DocumentQuarterlyReport_9612E130DA2921F496F6C974547E7C58_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport_9612E130DA2921F496F6C974547E7C58" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_9612E130DA2921F496F6C974547E7C58_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport_9612E130DA2921F496F6C974547E7C58" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_dei_DocumentQuarterlyReport_9612E130DA2921F496F6C974547E7C58" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport_9612E130DA2921F496F6C974547E7C58" xlink:to="lab_dei_DocumentQuarterlyReport_9612E130DA2921F496F6C974547E7C58" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_1E49874DC877A632A8ACC974547E3EF2_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_1E49874DC877A632A8ACC974547E3EF2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_1E49874DC877A632A8ACC974547E3EF2_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_1E49874DC877A632A8ACC974547E3EF2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_1E49874DC877A632A8ACC974547E3EF2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_1E49874DC877A632A8ACC974547E3EF2" xlink:to="lab_dei_DocumentPeriodEndDate_1E49874DC877A632A8ACC974547E3EF2" xlink:type="arc" />
    <link:label id="lab_dei_DocumentTransitionReport_DA65B4DECD96386EB8C5C974547E72DA_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport_DA65B4DECD96386EB8C5C974547E72DA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_DA65B4DECD96386EB8C5C974547E72DA_label_en-US" xlink:label="lab_dei_DocumentTransitionReport_DA65B4DECD96386EB8C5C974547E72DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_DA65B4DECD96386EB8C5C974547E72DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport_DA65B4DECD96386EB8C5C974547E72DA" xlink:to="lab_dei_DocumentTransitionReport_DA65B4DECD96386EB8C5C974547E72DA" xlink:type="arc" />
    <link:label id="lab_dei_EntityFileNumber_8FC902DD036CA558B7BBC974547E4A9C_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber_8FC902DD036CA558B7BBC974547E4A9C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_8FC902DD036CA558B7BBC974547E4A9C_label_en-US" xlink:label="lab_dei_EntityFileNumber_8FC902DD036CA558B7BBC974547E4A9C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_8FC902DD036CA558B7BBC974547E4A9C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber_8FC902DD036CA558B7BBC974547E4A9C" xlink:to="lab_dei_EntityFileNumber_8FC902DD036CA558B7BBC974547E4A9C" xlink:type="arc" />
    <link:label id="lab_dei_EntityRegistrantName_944C54941B786CEA96C8C974547E6319_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName_944C54941B786CEA96C8C974547E6319" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_944C54941B786CEA96C8C974547E6319_label_en-US" xlink:label="lab_dei_EntityRegistrantName_944C54941B786CEA96C8C974547E6319" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_944C54941B786CEA96C8C974547E6319" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_944C54941B786CEA96C8C974547E6319" xlink:to="lab_dei_EntityRegistrantName_944C54941B786CEA96C8C974547E6319" xlink:type="arc" />
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_E4248F32E22AC51E5441C974547EBE14_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode_E4248F32E22AC51E5441C974547EBE14" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_E4248F32E22AC51E5441C974547EBE14_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode_E4248F32E22AC51E5441C974547EBE14" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_E4248F32E22AC51E5441C974547EBE14" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode_E4248F32E22AC51E5441C974547EBE14" xlink:to="lab_dei_EntityIncorporationStateCountryCode_E4248F32E22AC51E5441C974547EBE14" xlink:type="arc" />
    <link:label id="lab_dei_EntityTaxIdentificationNumber_456367EBFF8C4872382CC974547EF5C3_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber_456367EBFF8C4872382CC974547EF5C3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_456367EBFF8C4872382CC974547EF5C3_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber_456367EBFF8C4872382CC974547EF5C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_456367EBFF8C4872382CC974547EF5C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber_456367EBFF8C4872382CC974547EF5C3" xlink:to="lab_dei_EntityTaxIdentificationNumber_456367EBFF8C4872382CC974547EF5C3" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressAddressLine1_809F7BD9C165856A0B05C974547FF9F3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1_809F7BD9C165856A0B05C974547FF9F3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_809F7BD9C165856A0B05C974547FF9F3_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1_809F7BD9C165856A0B05C974547FF9F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_809F7BD9C165856A0B05C974547FF9F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1_809F7BD9C165856A0B05C974547FF9F3" xlink:to="lab_dei_EntityAddressAddressLine1_809F7BD9C165856A0B05C974547FF9F3" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressCityOrTown_2CDEFA2CFBD5E2D632ABC974547FB47F_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown_2CDEFA2CFBD5E2D632ABC974547FB47F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_2CDEFA2CFBD5E2D632ABC974547FB47F_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown_2CDEFA2CFBD5E2D632ABC974547FB47F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_2CDEFA2CFBD5E2D632ABC974547FB47F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown_2CDEFA2CFBD5E2D632ABC974547FB47F" xlink:to="lab_dei_EntityAddressCityOrTown_2CDEFA2CFBD5E2D632ABC974547FB47F" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressStateOrProvince_6E68BC690B9F0C8567F6C9745484C53D_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince_6E68BC690B9F0C8567F6C9745484C53D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_6E68BC690B9F0C8567F6C9745484C53D_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince_6E68BC690B9F0C8567F6C9745484C53D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_6E68BC690B9F0C8567F6C9745484C53D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince_6E68BC690B9F0C8567F6C9745484C53D" xlink:to="lab_dei_EntityAddressStateOrProvince_6E68BC690B9F0C8567F6C9745484C53D" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressPostalZipCode_4A3B98BA40174A0F74DAC97454846CFB_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode_4A3B98BA40174A0F74DAC97454846CFB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_4A3B98BA40174A0F74DAC97454846CFB_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode_4A3B98BA40174A0F74DAC97454846CFB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_4A3B98BA40174A0F74DAC97454846CFB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode_4A3B98BA40174A0F74DAC97454846CFB" xlink:to="lab_dei_EntityAddressPostalZipCode_4A3B98BA40174A0F74DAC97454846CFB" xlink:type="arc" />
    <link:label id="lab_dei_CityAreaCode_09940B7FB8CFC47CB9B1C974548425AB_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode_09940B7FB8CFC47CB9B1C974548425AB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_09940B7FB8CFC47CB9B1C974548425AB_label_en-US" xlink:label="lab_dei_CityAreaCode_09940B7FB8CFC47CB9B1C974548425AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_09940B7FB8CFC47CB9B1C974548425AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode_09940B7FB8CFC47CB9B1C974548425AB" xlink:to="lab_dei_CityAreaCode_09940B7FB8CFC47CB9B1C974548425AB" xlink:type="arc" />
    <link:label id="lab_dei_LocalPhoneNumber_0564C326493F69A13DCEC97454856BE7_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber_0564C326493F69A13DCEC97454856BE7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_0564C326493F69A13DCEC97454856BE7_label_en-US" xlink:label="lab_dei_LocalPhoneNumber_0564C326493F69A13DCEC97454856BE7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_0564C326493F69A13DCEC97454856BE7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber_0564C326493F69A13DCEC97454856BE7" xlink:to="lab_dei_LocalPhoneNumber_0564C326493F69A13DCEC97454856BE7" xlink:type="arc" />
    <link:label id="lab_dei_Security12bTitle_BE1A7A105653DCEFFA47C97454850D55_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle_BE1A7A105653DCEFFA47C97454850D55" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_BE1A7A105653DCEFFA47C97454850D55_label_en-US" xlink:label="lab_dei_Security12bTitle_BE1A7A105653DCEFFA47C97454850D55" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_BE1A7A105653DCEFFA47C97454850D55" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle_BE1A7A105653DCEFFA47C97454850D55" xlink:to="lab_dei_Security12bTitle_BE1A7A105653DCEFFA47C97454850D55" xlink:type="arc" />
    <link:label id="lab_dei_TradingSymbol_DF7591953973B8DA94F4C9745485C904_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol_DF7591953973B8DA94F4C9745485C904" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_DF7591953973B8DA94F4C9745485C904_label_en-US" xlink:label="lab_dei_TradingSymbol_DF7591953973B8DA94F4C9745485C904" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_DF7591953973B8DA94F4C9745485C904" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol_DF7591953973B8DA94F4C9745485C904" xlink:to="lab_dei_TradingSymbol_DF7591953973B8DA94F4C9745485C904" xlink:type="arc" />
    <link:label id="lab_dei_SecurityExchangeName_61AC0582C5CCE85C0829C97454850FF6_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName_61AC0582C5CCE85C0829C97454850FF6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_61AC0582C5CCE85C0829C97454850FF6_label_en-US" xlink:label="lab_dei_SecurityExchangeName_61AC0582C5CCE85C0829C97454850FF6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_61AC0582C5CCE85C0829C97454850FF6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName_61AC0582C5CCE85C0829C97454850FF6" xlink:to="lab_dei_SecurityExchangeName_61AC0582C5CCE85C0829C97454850FF6" xlink:type="arc" />
    <link:label id="lab_dei_EntityCurrentReportingStatus_32E3BC357586EF7AEF3EC974548547A5_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_32E3BC357586EF7AEF3EC974548547A5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_32E3BC357586EF7AEF3EC974548547A5_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_32E3BC357586EF7AEF3EC974548547A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_32E3BC357586EF7AEF3EC974548547A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus_32E3BC357586EF7AEF3EC974548547A5" xlink:to="lab_dei_EntityCurrentReportingStatus_32E3BC357586EF7AEF3EC974548547A5" xlink:type="arc" />
    <link:label id="lab_dei_EntityInteractiveDataCurrent_A3DF952E8B16877C7BDCC9745485D7F9_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent_A3DF952E8B16877C7BDCC9745485D7F9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_A3DF952E8B16877C7BDCC9745485D7F9_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent_A3DF952E8B16877C7BDCC9745485D7F9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_A3DF952E8B16877C7BDCC9745485D7F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent_A3DF952E8B16877C7BDCC9745485D7F9" xlink:to="lab_dei_EntityInteractiveDataCurrent_A3DF952E8B16877C7BDCC9745485D7F9" xlink:type="arc" />
    <link:label id="lab_dei_EntityFilerCategory_0DC7320AB1CF94F4F653C974548604C9_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory_0DC7320AB1CF94F4F653C974548604C9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_0DC7320AB1CF94F4F653C974548604C9_label_en-US" xlink:label="lab_dei_EntityFilerCategory_0DC7320AB1CF94F4F653C974548604C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_0DC7320AB1CF94F4F653C974548604C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_0DC7320AB1CF94F4F653C974548604C9" xlink:to="lab_dei_EntityFilerCategory_0DC7320AB1CF94F4F653C974548604C9" xlink:type="arc" />
    <link:label id="lab_dei_EntitySmallBusiness_D27E3F7AB25C31962F32C97454864AA4_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness_D27E3F7AB25C31962F32C97454864AA4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_D27E3F7AB25C31962F32C97454864AA4_label_en-US" xlink:label="lab_dei_EntitySmallBusiness_D27E3F7AB25C31962F32C97454864AA4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_D27E3F7AB25C31962F32C97454864AA4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness_D27E3F7AB25C31962F32C97454864AA4" xlink:to="lab_dei_EntitySmallBusiness_D27E3F7AB25C31962F32C97454864AA4" xlink:type="arc" />
    <link:label id="lab_dei_EntityEmergingGrowthCompany_6D2070B02169A13022E3C97454863487_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_6D2070B02169A13022E3C97454863487" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_6D2070B02169A13022E3C97454863487_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_6D2070B02169A13022E3C97454863487" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_6D2070B02169A13022E3C97454863487" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany_6D2070B02169A13022E3C97454863487" xlink:to="lab_dei_EntityEmergingGrowthCompany_6D2070B02169A13022E3C97454863487" xlink:type="arc" />
    <link:label id="lab_dei_EntityShellCompany_CF1A5F8B2AFFCC9DAF04C9745486AD2C_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany_CF1A5F8B2AFFCC9DAF04C9745486AD2C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_CF1A5F8B2AFFCC9DAF04C9745486AD2C_label_en-US" xlink:label="lab_dei_EntityShellCompany_CF1A5F8B2AFFCC9DAF04C9745486AD2C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_CF1A5F8B2AFFCC9DAF04C9745486AD2C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany_CF1A5F8B2AFFCC9DAF04C9745486AD2C" xlink:to="lab_dei_EntityShellCompany_CF1A5F8B2AFFCC9DAF04C9745486AD2C" xlink:type="arc" />
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_CD447E107542C30427F6C9745486BC38_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_CD447E107542C30427F6C9745486BC38" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_CD447E107542C30427F6C9745486BC38_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_CD447E107542C30427F6C9745486BC38" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_CD447E107542C30427F6C9745486BC38" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_CD447E107542C30427F6C9745486BC38" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_CD447E107542C30427F6C9745486BC38" xlink:type="arc" />
    <link:label id="lab_dei_CurrentFiscalYearEndDate_FF9511E9647F42EB9D35C97454861391_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_FF9511E9647F42EB9D35C97454861391" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_FF9511E9647F42EB9D35C97454861391_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_FF9511E9647F42EB9D35C97454861391" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_FF9511E9647F42EB9D35C97454861391" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_FF9511E9647F42EB9D35C97454861391" xlink:to="lab_dei_CurrentFiscalYearEndDate_FF9511E9647F42EB9D35C97454861391" xlink:type="arc" />
    <link:label id="lab_dei_AmendmentFlag_B677154DE17F048A3778C9745487A9A9_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag_B677154DE17F048A3778C9745487A9A9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_B677154DE17F048A3778C9745487A9A9_label_en-US" xlink:label="lab_dei_AmendmentFlag_B677154DE17F048A3778C9745487A9A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_B677154DE17F048A3778C9745487A9A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_B677154DE17F048A3778C9745487A9A9" xlink:to="lab_dei_AmendmentFlag_B677154DE17F048A3778C9745487A9A9" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_19FA3E515209408F10DEC97454871472_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey_19FA3E515209408F10DEC97454871472" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_19FA3E515209408F10DEC97454871472_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_19FA3E515209408F10DEC97454871472" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_19FA3E515209408F10DEC97454871472" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_19FA3E515209408F10DEC97454871472" xlink:to="lab_dei_EntityCentralIndexKey_19FA3E515209408F10DEC97454871472" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_10D097D972EF00FE3156C974548788DD_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_10D097D972EF00FE3156C974548788DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_10D097D972EF00FE3156C974548788DD_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_10D097D972EF00FE3156C974548788DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_10D097D972EF00FE3156C974548788DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_10D097D972EF00FE3156C974548788DD" xlink:to="lab_dei_DocumentFiscalPeriodFocus_10D097D972EF00FE3156C974548788DD" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalYearFocus_7B620581260F3B97C1D7C9745487A1EB_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_7B620581260F3B97C1D7C9745487A1EB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_7B620581260F3B97C1D7C9745487A1EB_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_7B620581260F3B97C1D7C9745487A1EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_7B620581260F3B97C1D7C9745487A1EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_7B620581260F3B97C1D7C9745487A1EB" xlink:to="lab_dei_DocumentFiscalYearFocus_7B620581260F3B97C1D7C9745487A1EB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7EF22884742C08857396BFB854EDDF97_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7EF22884742C08857396BFB854EDDF97" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7EF22884742C08857396BFB854EDDF97_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7EF22884742C08857396BFB854EDDF97" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7EF22884742C08857396BFB854EDDF97" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7EF22884742C08857396BFB854EDDF97" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7EF22884742C08857396BFB854EDDF97" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_B870C914B84619014D3FBFB854EDD603_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_B870C914B84619014D3FBFB854EDD603" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_B870C914B84619014D3FBFB854EDD603_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_B870C914B84619014D3FBFB854EDD603" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_B870C914B84619014D3FBFB854EDD603" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_B870C914B84619014D3FBFB854EDD603" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_B870C914B84619014D3FBFB854EDD603" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyDomain_BA3AE2F22A6D20D6C9E6BFB854EDE21B_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain_BA3AE2F22A6D20D6C9E6BFB854EDE21B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_BA3AE2F22A6D20D6C9E6BFB854EDE21B_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain_BA3AE2F22A6D20D6C9E6BFB854EDE21B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_BA3AE2F22A6D20D6C9E6BFB854EDE21B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain_BA3AE2F22A6D20D6C9E6BFB854EDE21B" xlink:to="lab_us-gaap_RelatedPartyDomain_BA3AE2F22A6D20D6C9E6BFB854EDE21B" xlink:type="arc" />
    <link:label id="lab_srt_DirectorMember_67237E412EB4C4F98CBABFB854EDF5A8_terseLabel_en-US" xlink:label="lab_srt_DirectorMember_67237E412EB4C4F98CBABFB854EDF5A8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Director</link:label>
    <link:label id="lab_srt_DirectorMember_67237E412EB4C4F98CBABFB854EDF5A8_label_en-US" xlink:label="lab_srt_DirectorMember_67237E412EB4C4F98CBABFB854EDF5A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember" xlink:label="loc_srt_DirectorMember_67237E412EB4C4F98CBABFB854EDF5A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember_67237E412EB4C4F98CBABFB854EDF5A8" xlink:to="lab_srt_DirectorMember_67237E412EB4C4F98CBABFB854EDF5A8" xlink:type="arc" />
    <link:label id="lab_us-gaap_CoVenturerMember_F81C827CB6C123332640BFC0237AFB0A_terseLabel_en-US" xlink:label="lab_us-gaap_CoVenturerMember_F81C827CB6C123332640BFC0237AFB0A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Co-venturer</link:label>
    <link:label id="lab_us-gaap_CoVenturerMember_F81C827CB6C123332640BFC0237AFB0A_label_en-US" xlink:label="lab_us-gaap_CoVenturerMember_F81C827CB6C123332640BFC0237AFB0A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Co-venturer [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CoVenturerMember" xlink:label="loc_us-gaap_CoVenturerMember_F81C827CB6C123332640BFC0237AFB0A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CoVenturerMember_F81C827CB6C123332640BFC0237AFB0A" xlink:to="lab_us-gaap_CoVenturerMember_F81C827CB6C123332640BFC0237AFB0A" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_E03EF95CFB414AD43D28BFB854ED1BE8_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis_E03EF95CFB414AD43D28BFB854ED1BE8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_E03EF95CFB414AD43D28BFB854ED1BE8_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis_E03EF95CFB414AD43D28BFB854ED1BE8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_E03EF95CFB414AD43D28BFB854ED1BE8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_E03EF95CFB414AD43D28BFB854ED1BE8" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis_E03EF95CFB414AD43D28BFB854ED1BE8" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_6715047C82CEA5F2DAFABFB854EDEE1E_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain_6715047C82CEA5F2DAFABFB854EDEE1E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_6715047C82CEA5F2DAFABFB854EDEE1E_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain_6715047C82CEA5F2DAFABFB854EDEE1E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_6715047C82CEA5F2DAFABFB854EDEE1E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_6715047C82CEA5F2DAFABFB854EDEE1E" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain_6715047C82CEA5F2DAFABFB854EDEE1E" xlink:type="arc" />
    <link:label id="lab_apyx_BulgariaManufacturingPlantPurchaseMember_DBE958BA8BEC2213A00BBFB854EDA056_terseLabel_en-US" xlink:label="lab_apyx_BulgariaManufacturingPlantPurchaseMember_DBE958BA8BEC2213A00BBFB854EDA056" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bulgaria Manufacturing Plant Purchase</link:label>
    <link:label id="lab_apyx_BulgariaManufacturingPlantPurchaseMember_DBE958BA8BEC2213A00BBFB854EDA056_label_en-US" xlink:label="lab_apyx_BulgariaManufacturingPlantPurchaseMember_DBE958BA8BEC2213A00BBFB854EDA056" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bulgaria Manufacturing Plant Purchase [Member]</link:label>
    <link:label id="lab_apyx_BulgariaManufacturingPlantPurchaseMember_DBE958BA8BEC2213A00BBFB854EDA056_documentation_en-US" xlink:label="lab_apyx_BulgariaManufacturingPlantPurchaseMember_DBE958BA8BEC2213A00BBFB854EDA056" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Bulgaria Manufacturing Plant Purchase [Member]</link:label>
    <link:loc xlink:href="apyx-20200630.xsd#apyx_BulgariaManufacturingPlantPurchaseMember" xlink:label="loc_apyx_BulgariaManufacturingPlantPurchaseMember_DBE958BA8BEC2213A00BBFB854EDA056" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_BulgariaManufacturingPlantPurchaseMember_DBE958BA8BEC2213A00BBFB854EDA056" xlink:to="lab_apyx_BulgariaManufacturingPlantPurchaseMember_DBE958BA8BEC2213A00BBFB854EDA056" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_6DAEF7B5862D9C5D402FBFB854ED5A3C_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems_6DAEF7B5862D9C5D402FBFB854ED5A3C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_6DAEF7B5862D9C5D402FBFB854ED5A3C_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems_6DAEF7B5862D9C5D402FBFB854ED5A3C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_6DAEF7B5862D9C5D402FBFB854ED5A3C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6DAEF7B5862D9C5D402FBFB854ED5A3C" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems_6DAEF7B5862D9C5D402FBFB854ED5A3C" xlink:type="arc" />
    <link:label id="lab_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent_F1ED917A9B1DB51F9E6CBFB854EDD077_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent_F1ED917A9B1DB51F9E6CBFB854EDD077" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes payable</link:label>
    <link:label id="lab_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent_F1ED917A9B1DB51F9E6CBFB854EDD077_label_en-US" xlink:label="lab_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent_F1ED917A9B1DB51F9E6CBFB854EDD077" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable, Related Parties</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent_F1ED917A9B1DB51F9E6CBFB854EDD077" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent_F1ED917A9B1DB51F9E6CBFB854EDD077" xlink:to="lab_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent_F1ED917A9B1DB51F9E6CBFB854EDD077" xlink:type="arc" />
    <link:label id="lab_apyx_TermOfPaymentDueNotesPayableRelatedParties_2333DE9F064FD5347799BFB854EDF8EF_terseLabel_en-US" xlink:label="lab_apyx_TermOfPaymentDueNotesPayableRelatedParties_2333DE9F064FD5347799BFB854EDF8EF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term of payment due</link:label>
    <link:label id="lab_apyx_TermOfPaymentDueNotesPayableRelatedParties_2333DE9F064FD5347799BFB854EDF8EF_label_en-US" xlink:label="lab_apyx_TermOfPaymentDueNotesPayableRelatedParties_2333DE9F064FD5347799BFB854EDF8EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term Of Payment Due, Notes Payable, Related Parties</link:label>
    <link:label id="lab_apyx_TermOfPaymentDueNotesPayableRelatedParties_2333DE9F064FD5347799BFB854EDF8EF_documentation_en-US" xlink:label="lab_apyx_TermOfPaymentDueNotesPayableRelatedParties_2333DE9F064FD5347799BFB854EDF8EF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Term Of Payment Due, Notes Payable, Related Parties</link:label>
    <link:loc xlink:href="apyx-20200630.xsd#apyx_TermOfPaymentDueNotesPayableRelatedParties" xlink:label="loc_apyx_TermOfPaymentDueNotesPayableRelatedParties_2333DE9F064FD5347799BFB854EDF8EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_TermOfPaymentDueNotesPayableRelatedParties_2333DE9F064FD5347799BFB854EDF8EF" xlink:to="lab_apyx_TermOfPaymentDueNotesPayableRelatedParties_2333DE9F064FD5347799BFB854EDF8EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_300AC56CE9F4E2C49D85BFB854EDEF97_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_300AC56CE9F4E2C49D85BFB854EDEF97" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchases from related party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_300AC56CE9F4E2C49D85BFB854EDEF97_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_300AC56CE9F4E2C49D85BFB854EDEF97" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Purchases from Related Party</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:label="loc_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_300AC56CE9F4E2C49D85BFB854EDEF97" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_300AC56CE9F4E2C49D85BFB854EDEF97" xlink:to="lab_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_300AC56CE9F4E2C49D85BFB854EDEF97" xlink:type="arc" />
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_B7BD730538EEF4D12454BFB854EDE062_terseLabel_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_B7BD730538EEF4D12454BFB854EDE062" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due to related parties</link:label>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_B7BD730538EEF4D12454BFB854EDE062_label_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_B7BD730538EEF4D12454BFB854EDE062" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Due to Related Parties</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_B7BD730538EEF4D12454BFB854EDE062" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_B7BD730538EEF4D12454BFB854EDE062" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_B7BD730538EEF4D12454BFB854EDE062" xlink:type="arc" />
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_93B8A115C683AEB0BE1476CCC6A2B12E_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments_93B8A115C683AEB0BE1476CCC6A2B12E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_93B8A115C683AEB0BE1476CCC6A2B12E_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments_93B8A115C683AEB0BE1476CCC6A2B12E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_93B8A115C683AEB0BE1476CCC6A2B12E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments_93B8A115C683AEB0BE1476CCC6A2B12E" xlink:to="lab_us-gaap_NumberOfOperatingSegments_93B8A115C683AEB0BE1476CCC6A2B12E" xlink:type="arc" />
    <link:label id="lab_apyx_TotalRevenuePercent_84FC58BF36192A78246B76CCC6A27EE6_terseLabel_en-US" xlink:label="lab_apyx_TotalRevenuePercent_84FC58BF36192A78246B76CCC6A27EE6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">International sales, percent of total revenue</link:label>
    <link:label id="lab_apyx_TotalRevenuePercent_84FC58BF36192A78246B76CCC6A27EE6_label_en-US" xlink:label="lab_apyx_TotalRevenuePercent_84FC58BF36192A78246B76CCC6A27EE6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Revenue, Percent</link:label>
    <link:label id="lab_apyx_TotalRevenuePercent_84FC58BF36192A78246B76CCC6A27EE6_documentation_en-US" xlink:label="lab_apyx_TotalRevenuePercent_84FC58BF36192A78246B76CCC6A27EE6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total Revenue, Percent</link:label>
    <link:loc xlink:href="apyx-20200630.xsd#apyx_TotalRevenuePercent" xlink:label="loc_apyx_TotalRevenuePercent_84FC58BF36192A78246B76CCC6A27EE6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_TotalRevenuePercent_84FC58BF36192A78246B76CCC6A27EE6" xlink:to="lab_apyx_TotalRevenuePercent_84FC58BF36192A78246B76CCC6A27EE6" xlink:type="arc" />
    <link:label id="lab_apyx_CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards_D3444904B1D6F119400DC9632565B602_negatedTerseLabel_en-US" xlink:label="lab_apyx_CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards_D3444904B1D6F119400DC9632565B602" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Release of valuation allowance</link:label>
    <link:label id="lab_apyx_CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards_D3444904B1D6F119400DC9632565B602_label_en-US" xlink:label="lab_apyx_CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards_D3444904B1D6F119400DC9632565B602" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CARES Act, Income Tax Expense (Benefit), Release Of Valuation Allowance, Federal Net Operating Loss Carryforwards</link:label>
    <link:label id="lab_apyx_CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards_D3444904B1D6F119400DC9632565B602_documentation_en-US" xlink:label="lab_apyx_CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards_D3444904B1D6F119400DC9632565B602" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">CARES Act, Income Tax Expense (Benefit), Release Of Valuation Allowance, Federal Net Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="apyx-20200630.xsd#apyx_CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards" xlink:label="loc_apyx_CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards_D3444904B1D6F119400DC9632565B602" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards_D3444904B1D6F119400DC9632565B602" xlink:to="lab_apyx_CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards_D3444904B1D6F119400DC9632565B602" xlink:type="arc" />
    <link:label id="lab_apyx_CARESActIncomeTaxExpenseBenefitRelatedToCurrentPeriodNetIncomeLossBeforeIncomeTaxes_5D8EECF4AE8D882152C0C96325657FAB_terseLabel_en-US" xlink:label="lab_apyx_CARESActIncomeTaxExpenseBenefitRelatedToCurrentPeriodNetIncomeLossBeforeIncomeTaxes_5D8EECF4AE8D882152C0C96325657FAB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense (benefit), related to current period net loss before income taxes</link:label>
    <link:label id="lab_apyx_CARESActIncomeTaxExpenseBenefitRelatedToCurrentPeriodNetIncomeLossBeforeIncomeTaxes_5D8EECF4AE8D882152C0C96325657FAB_label_en-US" xlink:label="lab_apyx_CARESActIncomeTaxExpenseBenefitRelatedToCurrentPeriodNetIncomeLossBeforeIncomeTaxes_5D8EECF4AE8D882152C0C96325657FAB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CARES Act, Income Tax Expense (Benefit), Related To Current Period Net Income (Loss) Before Income Taxes</link:label>
    <link:label id="lab_apyx_CARESActIncomeTaxExpenseBenefitRelatedToCurrentPeriodNetIncomeLossBeforeIncomeTaxes_5D8EECF4AE8D882152C0C96325657FAB_documentation_en-US" xlink:label="lab_apyx_CARESActIncomeTaxExpenseBenefitRelatedToCurrentPeriodNetIncomeLossBeforeIncomeTaxes_5D8EECF4AE8D882152C0C96325657FAB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">CARES Act, Income Tax Expense (Benefit), Related To Current Period Net Income (Loss) Before Income Taxes</link:label>
    <link:loc xlink:href="apyx-20200630.xsd#apyx_CARESActIncomeTaxExpenseBenefitRelatedToCurrentPeriodNetIncomeLossBeforeIncomeTaxes" xlink:label="loc_apyx_CARESActIncomeTaxExpenseBenefitRelatedToCurrentPeriodNetIncomeLossBeforeIncomeTaxes_5D8EECF4AE8D882152C0C96325657FAB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_CARESActIncomeTaxExpenseBenefitRelatedToCurrentPeriodNetIncomeLossBeforeIncomeTaxes_5D8EECF4AE8D882152C0C96325657FAB" xlink:to="lab_apyx_CARESActIncomeTaxExpenseBenefitRelatedToCurrentPeriodNetIncomeLossBeforeIncomeTaxes_5D8EECF4AE8D882152C0C96325657FAB" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_5E56FD49F1E5B543DDEEC96325652108_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_5E56FD49F1E5B543DDEEC96325652108" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense (benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_5E56FD49F1E5B543DDEEC96325652108" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_5E56FD49F1E5B543DDEEC96325652108" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_5E56FD49F1E5B543DDEEC96325652108" xlink:type="arc" />
    <link:label id="lab_apyx_CARESActFederalIncomeTaxPaymentsAvailableToOffsetCurrentPeriodLosses_8CD0E468E0959E488872C9632566E728_terseLabel_en-US" xlink:label="lab_apyx_CARESActFederalIncomeTaxPaymentsAvailableToOffsetCurrentPeriodLosses_8CD0E468E0959E488872C9632566E728" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal income tax payments available to offset current period losses</link:label>
    <link:label id="lab_apyx_CARESActFederalIncomeTaxPaymentsAvailableToOffsetCurrentPeriodLosses_8CD0E468E0959E488872C9632566E728_label_en-US" xlink:label="lab_apyx_CARESActFederalIncomeTaxPaymentsAvailableToOffsetCurrentPeriodLosses_8CD0E468E0959E488872C9632566E728" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CARES Act, Federal Income Tax Payments Available To Offset Current Period Losses</link:label>
    <link:label id="lab_apyx_CARESActFederalIncomeTaxPaymentsAvailableToOffsetCurrentPeriodLosses_8CD0E468E0959E488872C9632566E728_documentation_en-US" xlink:label="lab_apyx_CARESActFederalIncomeTaxPaymentsAvailableToOffsetCurrentPeriodLosses_8CD0E468E0959E488872C9632566E728" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">CARES Act, Federal Income Tax Payments Available To Offset Current Period Losses</link:label>
    <link:loc xlink:href="apyx-20200630.xsd#apyx_CARESActFederalIncomeTaxPaymentsAvailableToOffsetCurrentPeriodLosses" xlink:label="loc_apyx_CARESActFederalIncomeTaxPaymentsAvailableToOffsetCurrentPeriodLosses_8CD0E468E0959E488872C9632566E728" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_CARESActFederalIncomeTaxPaymentsAvailableToOffsetCurrentPeriodLosses_8CD0E468E0959E488872C9632566E728" xlink:to="lab_apyx_CARESActFederalIncomeTaxPaymentsAvailableToOffsetCurrentPeriodLosses_8CD0E468E0959E488872C9632566E728" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1B847D785854FDEA3FFCC9632566C015_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1B847D785854FDEA3FFCC9632566C015" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective income tax rate, percent</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1B847D785854FDEA3FFCC9632566C015_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1B847D785854FDEA3FFCC9632566C015" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1B847D785854FDEA3FFCC9632566C015" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1B847D785854FDEA3FFCC9632566C015" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1B847D785854FDEA3FFCC9632566C015" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_530A3A29EBC6735394B3C96325661AC5_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_530A3A29EBC6735394B3C96325661AC5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued interest and penalties</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_530A3A29EBC6735394B3C96325661AC5_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_530A3A29EBC6735394B3C96325661AC5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_530A3A29EBC6735394B3C96325661AC5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_530A3A29EBC6735394B3C96325661AC5" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_530A3A29EBC6735394B3C96325661AC5" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_5CA95DB7EDBC7D031E89C963256628DF_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_5CA95DB7EDBC7D031E89C963256628DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest and penalties included in income tax expense</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_5CA95DB7EDBC7D031E89C963256628DF_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_5CA95DB7EDBC7D031E89C963256628DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_5CA95DB7EDBC7D031E89C963256628DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_5CA95DB7EDBC7D031E89C963256628DF" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_5CA95DB7EDBC7D031E89C963256628DF" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_9317083B106218A5C654C9632566926C_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_9317083B106218A5C654C9632566926C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Uncertain tax positions that would impact effective tax rate</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_9317083B106218A5C654C9632566926C_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_9317083B106218A5C654C9632566926C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_9317083B106218A5C654C9632566926C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_9317083B106218A5C654C9632566926C" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_9317083B106218A5C654C9632566926C" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherCommitmentsTable_16D8463E9707F9217AE9BFB854FC6F13_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable_16D8463E9707F9217AE9BFB854FC6F13" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_16D8463E9707F9217AE9BFB854FC6F13_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable_16D8463E9707F9217AE9BFB854FC6F13" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsTable" xlink:label="loc_us-gaap_OtherCommitmentsTable_16D8463E9707F9217AE9BFB854FC6F13" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsTable_16D8463E9707F9217AE9BFB854FC6F13" xlink:to="lab_us-gaap_OtherCommitmentsTable_16D8463E9707F9217AE9BFB854FC6F13" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_0EC59D5E1F2909CCC592BFB854FC0626_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_0EC59D5E1F2909CCC592BFB854FC0626" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_0EC59D5E1F2909CCC592BFB854FC0626_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_0EC59D5E1F2909CCC592BFB854FC0626" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_0EC59D5E1F2909CCC592BFB854FC0626" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_0EC59D5E1F2909CCC592BFB854FC0626" xlink:to="lab_us-gaap_SubsequentEventTypeAxis_0EC59D5E1F2909CCC592BFB854FC0626" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_F7601F4C1D9003F2DF81BFB854FCC85D_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_F7601F4C1D9003F2DF81BFB854FCC85D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_F7601F4C1D9003F2DF81BFB854FCC85D_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_F7601F4C1D9003F2DF81BFB854FCC85D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_F7601F4C1D9003F2DF81BFB854FCC85D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_F7601F4C1D9003F2DF81BFB854FCC85D" xlink:to="lab_us-gaap_SubsequentEventTypeDomain_F7601F4C1D9003F2DF81BFB854FCC85D" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventMember_5C91E5D9ECDD3B2D5127BFB854FC72AC_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_5C91E5D9ECDD3B2D5127BFB854FC72AC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_5C91E5D9ECDD3B2D5127BFB854FC72AC_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_5C91E5D9ECDD3B2D5127BFB854FC72AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_5C91E5D9ECDD3B2D5127BFB854FC72AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember_5C91E5D9ECDD3B2D5127BFB854FC72AC" xlink:to="lab_us-gaap_SubsequentEventMember_5C91E5D9ECDD3B2D5127BFB854FC72AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_111B40AFDCE6995E68E1BFB854FC87BF_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_111B40AFDCE6995E68E1BFB854FC87BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_111B40AFDCE6995E68E1BFB854FC87BF_label_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_111B40AFDCE6995E68E1BFB854FC87BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_111B40AFDCE6995E68E1BFB854FC87BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_111B40AFDCE6995E68E1BFB854FC87BF" xlink:to="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_111B40AFDCE6995E68E1BFB854FC87BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_806B261CF0A034EF5383BFB854FC295E_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain_806B261CF0A034EF5383BFB854FC295E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_806B261CF0A034EF5383BFB854FC295E_label_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain_806B261CF0A034EF5383BFB854FC295E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="loc_us-gaap_LossContingencyNatureDomain_806B261CF0A034EF5383BFB854FC295E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNatureDomain_806B261CF0A034EF5383BFB854FC295E" xlink:to="lab_us-gaap_LossContingencyNatureDomain_806B261CF0A034EF5383BFB854FC295E" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnfavorableRegulatoryActionMember_5D6BBFBD0B5C957517F4BFB854FC5F5C_terseLabel_en-US" xlink:label="lab_us-gaap_UnfavorableRegulatoryActionMember_5D6BBFBD0B5C957517F4BFB854FC5F5C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unfavorable Regulatory Action</link:label>
    <link:label id="lab_us-gaap_UnfavorableRegulatoryActionMember_5D6BBFBD0B5C957517F4BFB854FC5F5C_label_en-US" xlink:label="lab_us-gaap_UnfavorableRegulatoryActionMember_5D6BBFBD0B5C957517F4BFB854FC5F5C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unfavorable Regulatory Action [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnfavorableRegulatoryActionMember" xlink:label="loc_us-gaap_UnfavorableRegulatoryActionMember_5D6BBFBD0B5C957517F4BFB854FC5F5C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnfavorableRegulatoryActionMember_5D6BBFBD0B5C957517F4BFB854FC5F5C" xlink:to="lab_us-gaap_UnfavorableRegulatoryActionMember_5D6BBFBD0B5C957517F4BFB854FC5F5C" xlink:type="arc" />
    <link:label id="lab_us-gaap_LitigationStatusAxis_0129E62791E4A5EA2225BFB854FCCB33_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis_0129E62791E4A5EA2225BFB854FCCB33" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusAxis_0129E62791E4A5EA2225BFB854FCCB33_label_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis_0129E62791E4A5EA2225BFB854FCCB33" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusAxis" xlink:label="loc_us-gaap_LitigationStatusAxis_0129E62791E4A5EA2225BFB854FCCB33" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusAxis_0129E62791E4A5EA2225BFB854FCCB33" xlink:to="lab_us-gaap_LitigationStatusAxis_0129E62791E4A5EA2225BFB854FCCB33" xlink:type="arc" />
    <link:label id="lab_us-gaap_LitigationStatusDomain_A04A1D6F1B05483D14CCBFB854FC5D23_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain_A04A1D6F1B05483D14CCBFB854FC5D23" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusDomain_A04A1D6F1B05483D14CCBFB854FC5D23_label_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain_A04A1D6F1B05483D14CCBFB854FC5D23" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="loc_us-gaap_LitigationStatusDomain_A04A1D6F1B05483D14CCBFB854FC5D23" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusDomain_A04A1D6F1B05483D14CCBFB854FC5D23" xlink:to="lab_us-gaap_LitigationStatusDomain_A04A1D6F1B05483D14CCBFB854FC5D23" xlink:type="arc" />
    <link:label id="lab_us-gaap_PendingLitigationMember_250ACA3EC6394E3D0755BFB854FC1572_terseLabel_en-US" xlink:label="lab_us-gaap_PendingLitigationMember_250ACA3EC6394E3D0755BFB854FC1572" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pending Litigation</link:label>
    <link:label id="lab_us-gaap_PendingLitigationMember_250ACA3EC6394E3D0755BFB854FC1572_label_en-US" xlink:label="lab_us-gaap_PendingLitigationMember_250ACA3EC6394E3D0755BFB854FC1572" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pending Litigation [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PendingLitigationMember" xlink:label="loc_us-gaap_PendingLitigationMember_250ACA3EC6394E3D0755BFB854FC1572" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PendingLitigationMember_250ACA3EC6394E3D0755BFB854FC1572" xlink:to="lab_us-gaap_PendingLitigationMember_250ACA3EC6394E3D0755BFB854FC1572" xlink:type="arc" />
    <link:label id="lab_us-gaap_CorporateJointVentureMember_B6683DEF56C11D149A62BFB854FCF6E2_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateJointVentureMember_B6683DEF56C11D149A62BFB854FCF6E2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate Joint Venture</link:label>
    <link:label id="lab_us-gaap_CorporateJointVentureMember_B6683DEF56C11D149A62BFB854FCF6E2_label_en-US" xlink:label="lab_us-gaap_CorporateJointVentureMember_B6683DEF56C11D149A62BFB854FCF6E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Joint Venture [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateJointVentureMember" xlink:label="loc_us-gaap_CorporateJointVentureMember_B6683DEF56C11D149A62BFB854FCF6E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateJointVentureMember_B6683DEF56C11D149A62BFB854FCF6E2" xlink:to="lab_us-gaap_CorporateJointVentureMember_B6683DEF56C11D149A62BFB854FCF6E2" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_B080252A18CB7D8737D3BFB854FC5A91_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems_B080252A18CB7D8737D3BFB854FC5A91" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_B080252A18CB7D8737D3BFB854FC5A91_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems_B080252A18CB7D8737D3BFB854FC5A91" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_B080252A18CB7D8737D3BFB854FC5A91" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_B080252A18CB7D8737D3BFB854FC5A91" xlink:to="lab_us-gaap_OtherCommitmentsLineItems_B080252A18CB7D8737D3BFB854FC5A91" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_2C8402FFA33D78725CF3BFB854FCAE1B_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue_2C8402FFA33D78725CF3BFB854FCAE1B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Costs accrued</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_2C8402FFA33D78725CF3BFB854FCAE1B_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue_2C8402FFA33D78725CF3BFB854FCAE1B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_2C8402FFA33D78725CF3BFB854FCAE1B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue_2C8402FFA33D78725CF3BFB854FCAE1B" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue_2C8402FFA33D78725CF3BFB854FCAE1B" xlink:type="arc" />
    <link:label id="lab_apyx_LossContingencyAccrualTotalAccruedToDate_B20CA64750D61DADEB04BFB854FC11EA_terseLabel_en-US" xlink:label="lab_apyx_LossContingencyAccrualTotalAccruedToDate_B20CA64750D61DADEB04BFB854FC11EA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss contingency accrual, total accrued to date</link:label>
    <link:label id="lab_apyx_LossContingencyAccrualTotalAccruedToDate_B20CA64750D61DADEB04BFB854FC11EA_label_en-US" xlink:label="lab_apyx_LossContingencyAccrualTotalAccruedToDate_B20CA64750D61DADEB04BFB854FC11EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency Accrual, Total Accrued To Date</link:label>
    <link:label id="lab_apyx_LossContingencyAccrualTotalAccruedToDate_B20CA64750D61DADEB04BFB854FC11EA_documentation_en-US" xlink:label="lab_apyx_LossContingencyAccrualTotalAccruedToDate_B20CA64750D61DADEB04BFB854FC11EA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Loss Contingency Accrual, Total Accrued To Date</link:label>
    <link:loc xlink:href="apyx-20200630.xsd#apyx_LossContingencyAccrualTotalAccruedToDate" xlink:label="loc_apyx_LossContingencyAccrualTotalAccruedToDate_B20CA64750D61DADEB04BFB854FC11EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_LossContingencyAccrualTotalAccruedToDate_B20CA64750D61DADEB04BFB854FC11EA" xlink:to="lab_apyx_LossContingencyAccrualTotalAccruedToDate_B20CA64750D61DADEB04BFB854FC11EA" xlink:type="arc" />
    <link:label id="lab_us-gaap_PurchaseObligation_752F2D5B085034C9F22FBFB854FC1D57_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligation_752F2D5B085034C9F22FBFB854FC1D57" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase obligation</link:label>
    <link:label id="lab_us-gaap_PurchaseObligation_752F2D5B085034C9F22FBFB854FC1D57_label_en-US" xlink:label="lab_us-gaap_PurchaseObligation_752F2D5B085034C9F22FBFB854FC1D57" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Obligation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseObligation" xlink:label="loc_us-gaap_PurchaseObligation_752F2D5B085034C9F22FBFB854FC1D57" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligation_752F2D5B085034C9F22FBFB854FC1D57" xlink:to="lab_us-gaap_PurchaseObligation_752F2D5B085034C9F22FBFB854FC1D57" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireInterestInJointVenture_CB49F4E6932EDD6D7169BFC1E3350193_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInterestInJointVenture_CB49F4E6932EDD6D7169BFC1E3350193" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital commitment, funding</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInterestInJointVenture_CB49F4E6932EDD6D7169BFC1E3350193_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInterestInJointVenture_CB49F4E6932EDD6D7169BFC1E3350193" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Interest in Joint Venture</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInterestInJointVenture" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInJointVenture_CB49F4E6932EDD6D7169BFC1E3350193" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInterestInJointVenture_CB49F4E6932EDD6D7169BFC1E3350193" xlink:to="lab_us-gaap_PaymentsToAcquireInterestInJointVenture_CB49F4E6932EDD6D7169BFC1E3350193" xlink:type="arc" />
    <link:label id="lab_srt_StatementGeographicalAxis_4569ADE50954DA92893B4986255A5E14_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis_4569ADE50954DA92893B4986255A5E14" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_4569ADE50954DA92893B4986255A5E14_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis_4569ADE50954DA92893B4986255A5E14" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_4569ADE50954DA92893B4986255A5E14" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis_4569ADE50954DA92893B4986255A5E14" xlink:to="lab_srt_StatementGeographicalAxis_4569ADE50954DA92893B4986255A5E14" xlink:type="arc" />
    <link:label id="lab_srt_SegmentGeographicalDomain_04A775BCCF5750C955834986255B1102_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain_04A775BCCF5750C955834986255B1102" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_04A775BCCF5750C955834986255B1102_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain_04A775BCCF5750C955834986255B1102" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_04A775BCCF5750C955834986255B1102" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain_04A775BCCF5750C955834986255B1102" xlink:to="lab_srt_SegmentGeographicalDomain_04A775BCCF5750C955834986255B1102" xlink:type="arc" />
    <link:label id="lab_country_US_E444E02013089433CCC54986255B2981_terseLabel_en-US" xlink:label="lab_country_US_E444E02013089433CCC54986255B2981" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Domestic</link:label>
    <link:label id="lab_country_US_E444E02013089433CCC54986255B2981_label_en-US" xlink:label="lab_country_US_E444E02013089433CCC54986255B2981" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US" xlink:label="loc_country_US_E444E02013089433CCC54986255B2981" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US_E444E02013089433CCC54986255B2981" xlink:to="lab_country_US_E444E02013089433CCC54986255B2981" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonUsMember_DD38742FB5A8C66902B54986255CDAAA_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember_DD38742FB5A8C66902B54986255CDAAA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">International</link:label>
    <link:label id="lab_us-gaap_NonUsMember_DD38742FB5A8C66902B54986255CDAAA_label_en-US" xlink:label="lab_us-gaap_NonUsMember_DD38742FB5A8C66902B54986255CDAAA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonUsMember" xlink:label="loc_us-gaap_NonUsMember_DD38742FB5A8C66902B54986255CDAAA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember_DD38742FB5A8C66902B54986255CDAAA" xlink:to="lab_us-gaap_NonUsMember_DD38742FB5A8C66902B54986255CDAAA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_44F1FA90CE4031AB15AD76CCC6CAAB4A_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_44F1FA90CE4031AB15AD76CCC6CAAB4A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Tax Benefits</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_44F1FA90CE4031AB15AD76CCC6CAAB4A_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_44F1FA90CE4031AB15AD76CCC6CAAB4A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_44F1FA90CE4031AB15AD76CCC6CAAB4A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_44F1FA90CE4031AB15AD76CCC6CAAB4A" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_44F1FA90CE4031AB15AD76CCC6CAAB4A" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_B7FD4E79AAFBA15F54A176CCC6CA54D3_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_B7FD4E79AAFBA15F54A176CCC6CA54D3" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at January 1, 2020</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_B7FD4E79AAFBA15F54A176CCC6CA54D3_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_B7FD4E79AAFBA15F54A176CCC6CA54D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_B7FD4E79AAFBA15F54A176CCC6CA54D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits_B7FD4E79AAFBA15F54A176CCC6CA54D3" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits_B7FD4E79AAFBA15F54A176CCC6CA54D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_53272A7E64E06C815EB376CCC6CA58E3_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_53272A7E64E06C815EB376CCC6CA58E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions of tax positions related to the current year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_53272A7E64E06C815EB376CCC6CA58E3_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_53272A7E64E06C815EB376CCC6CA58E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_53272A7E64E06C815EB376CCC6CA58E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_53272A7E64E06C815EB376CCC6CA58E3" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_53272A7E64E06C815EB376CCC6CA58E3" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_CB3794BB8627ACFFFFD176CCC6CB24B3_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_CB3794BB8627ACFFFFD176CCC6CB24B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions of tax positions related to the prior year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_CB3794BB8627ACFFFFD176CCC6CB24B3_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_CB3794BB8627ACFFFFD176CCC6CB24B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_CB3794BB8627ACFFFFD176CCC6CB24B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_CB3794BB8627ACFFFFD176CCC6CB24B3" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_CB3794BB8627ACFFFFD176CCC6CB24B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_95A2FAFD5F36BF1F7B9976CCC6CB0728_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_95A2FAFD5F36BF1F7B9976CCC6CB0728" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Decreases for tax positions related to the prior year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_95A2FAFD5F36BF1F7B9976CCC6CB0728_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_95A2FAFD5F36BF1F7B9976CCC6CB0728" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_95A2FAFD5F36BF1F7B9976CCC6CB0728" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_95A2FAFD5F36BF1F7B9976CCC6CB0728" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_95A2FAFD5F36BF1F7B9976CCC6CB0728" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_3839066EC93AB9D2180B76CCC6CB4F4C_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_3839066EC93AB9D2180B76CCC6CB4F4C" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at June 30, 2020</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_3839066EC93AB9D2180B76CCC6CB4F4C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits_3839066EC93AB9D2180B76CCC6CB4F4C" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits_3839066EC93AB9D2180B76CCC6CB4F4C" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryRawMaterials_23CCB6E6AF4206A15318BFB8555144AD_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials_23CCB6E6AF4206A15318BFB8555144AD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterials_23CCB6E6AF4206A15318BFB8555144AD_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials_23CCB6E6AF4206A15318BFB8555144AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Raw Materials, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_us-gaap_InventoryRawMaterials_23CCB6E6AF4206A15318BFB8555144AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterials_23CCB6E6AF4206A15318BFB8555144AD" xlink:to="lab_us-gaap_InventoryRawMaterials_23CCB6E6AF4206A15318BFB8555144AD" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryWorkInProcess_393A87D13DF36403147EBFB855561DC1_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess_393A87D13DF36403147EBFB855561DC1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_393A87D13DF36403147EBFB855561DC1_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess_393A87D13DF36403147EBFB855561DC1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaap_InventoryWorkInProcess_393A87D13DF36403147EBFB855561DC1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcess_393A87D13DF36403147EBFB855561DC1" xlink:to="lab_us-gaap_InventoryWorkInProcess_393A87D13DF36403147EBFB855561DC1" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryFinishedGoods_B35E56830978166A11EBBFB855569448_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods_B35E56830978166A11EBBFB855569448" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_B35E56830978166A11EBBFB855569448_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods_B35E56830978166A11EBBFB855569448" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaap_InventoryFinishedGoods_B35E56830978166A11EBBFB855569448" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods_B35E56830978166A11EBBFB855569448" xlink:to="lab_us-gaap_InventoryFinishedGoods_B35E56830978166A11EBBFB855569448" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryGross_523F4EE78F16E340681BBFB855565C27_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryGross_523F4EE78F16E340681BBFB855565C27" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Gross inventories</link:label>
    <link:label id="lab_us-gaap_InventoryGross_523F4EE78F16E340681BBFB855565C27_label_en-US" xlink:label="lab_us-gaap_InventoryGross_523F4EE78F16E340681BBFB855565C27" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryGross" xlink:label="loc_us-gaap_InventoryGross_523F4EE78F16E340681BBFB855565C27" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryGross_523F4EE78F16E340681BBFB855565C27" xlink:to="lab_us-gaap_InventoryGross_523F4EE78F16E340681BBFB855565C27" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryValuationReserves_6C4497A3519795D3144CBFB855566E18_negatedLabel_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves_6C4497A3519795D3144CBFB855566E18" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: provision for obsolescence</link:label>
    <link:label id="lab_us-gaap_InventoryValuationReserves_6C4497A3519795D3144CBFB855566E18_label_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves_6C4497A3519795D3144CBFB855566E18" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Valuation Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryValuationReserves" xlink:label="loc_us-gaap_InventoryValuationReserves_6C4497A3519795D3144CBFB855566E18" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryValuationReserves_6C4497A3519795D3144CBFB855566E18" xlink:to="lab_us-gaap_InventoryValuationReserves_6C4497A3519795D3144CBFB855566E18" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNet_EA3748D14CF375F99461BFB855568B55_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet_EA3748D14CF375F99461BFB855568B55" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Inventories, net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_EA3748D14CF375F99461BFB855568B55" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet_EA3748D14CF375F99461BFB855568B55" xlink:to="lab_us-gaap_InventoryNet_EA3748D14CF375F99461BFB855568B55" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_AA536B9B047B80AFFBE4498625197FEC_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_AA536B9B047B80AFFBE4498625197FEC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of reporting information by segment</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_AA536B9B047B80AFFBE4498625197FEC_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_AA536B9B047B80AFFBE4498625197FEC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_AA536B9B047B80AFFBE4498625197FEC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_AA536B9B047B80AFFBE4498625197FEC" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_AA536B9B047B80AFFBE4498625197FEC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_24C0676AA2CAF4FFFC41498625193CB0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_24C0676AA2CAF4FFFC41498625193CB0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of revenue by geographic area</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_24C0676AA2CAF4FFFC41498625193CB0_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_24C0676AA2CAF4FFFC41498625193CB0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:label="loc_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_24C0676AA2CAF4FFFC41498625193CB0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_24C0676AA2CAF4FFFC41498625193CB0" xlink:to="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_24C0676AA2CAF4FFFC41498625193CB0" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>apyx-20200630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://apyxmedical.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:href="apyx-20200630.xsd#AccruedExpensesAndOtherCurrentLiabilities" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="apyx-20200630.xsd#AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:href="apyx-20200630.xsd#AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/BasisOfPresentation" xlink:href="apyx-20200630.xsd#BasisOfPresentation" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/BasisOfPresentationPolicies" xlink:href="apyx-20200630.xsd#BasisOfPresentationPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/ChangeInAccountingPolicy" xlink:href="apyx-20200630.xsd#ChangeInAccountingPolicy" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/CommitmentsAndContingencies" xlink:href="apyx-20200630.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:href="apyx-20200630.xsd#CommitmentsAndContingenciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/ConsolidatedBalanceSheets" xlink:href="apyx-20200630.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="apyx-20200630.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="apyx-20200630.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" xlink:href="apyx-20200630.xsd#ConsolidatedStatementsOfChangesInStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/ConsolidatedStatementsOfOperations" xlink:href="apyx-20200630.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/Cover" xlink:href="apyx-20200630.xsd#Cover" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/EarningsPerShare" xlink:href="apyx-20200630.xsd#EarningsPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/EarningsPerShareDetails" xlink:href="apyx-20200630.xsd#EarningsPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/EarningsPerShareTables" xlink:href="apyx-20200630.xsd#EarningsPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/GeographicAndSegmentInformation" xlink:href="apyx-20200630.xsd#GeographicAndSegmentInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/GeographicAndSegmentInformationGeographicDetails" xlink:href="apyx-20200630.xsd#GeographicAndSegmentInformationGeographicDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/GeographicAndSegmentInformationNarrativeDetails" xlink:href="apyx-20200630.xsd#GeographicAndSegmentInformationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/GeographicAndSegmentInformationReportableSegmentDetails" xlink:href="apyx-20200630.xsd#GeographicAndSegmentInformationReportableSegmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/GeographicAndSegmentInformationTables" xlink:href="apyx-20200630.xsd#GeographicAndSegmentInformationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/IncomeTaxes" xlink:href="apyx-20200630.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/IncomeTaxesNarrativeDetails" xlink:href="apyx-20200630.xsd#IncomeTaxesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/IncomeTaxesTables" xlink:href="apyx-20200630.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/IncomeTaxesUnrecognizedTaxBenefitsRollForwardDetails" xlink:href="apyx-20200630.xsd#IncomeTaxesUnrecognizedTaxBenefitsRollForwardDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/Inventories" xlink:href="apyx-20200630.xsd#Inventories" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/InventoriesDetails" xlink:href="apyx-20200630.xsd#InventoriesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/InventoriesInventoriesNarrativeDetails" xlink:href="apyx-20200630.xsd#InventoriesInventoriesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/InventoriesTables" xlink:href="apyx-20200630.xsd#InventoriesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/RecentAccountingPronouncements" xlink:href="apyx-20200630.xsd#RecentAccountingPronouncements" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/RelatedPartyTransactions" xlink:href="apyx-20200630.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/RelatedPartyTransactionsDetails" xlink:href="apyx-20200630.xsd#RelatedPartyTransactionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/StockBasedCompensation" xlink:href="apyx-20200630.xsd#StockBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/StockBasedCompensationFairValueAssumptionsDetails" xlink:href="apyx-20200630.xsd#StockBasedCompensationFairValueAssumptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/StockBasedCompensationNarrativeDetails" xlink:href="apyx-20200630.xsd#StockBasedCompensationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/StockBasedCompensationSummaryOfStockOptionsDetails" xlink:href="apyx-20200630.xsd#StockBasedCompensationSummaryOfStockOptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://apyxmedical.com/role/StockBasedCompensationTables" xlink:href="apyx-20200630.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:presentationLink xlink:role="http://apyxmedical.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_818CD21075EFCB2A6BF849862554F69A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_D91FCE22366DEC055D4849862554E330" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_818CD21075EFCB2A6BF849862554F69A" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_D91FCE22366DEC055D4849862554E330" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_505765102C46161CB308C5334EC610B9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="loc_us-gaap_AccruedSalariesCurrent_0B7D34BE43B302F3A033C5334EC6DA03" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_505765102C46161CB308C5334EC610B9" xlink:to="loc_us-gaap_AccruedSalariesCurrent_0B7D34BE43B302F3A033C5334EC6DA03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="loc_us-gaap_AccruedBonusesCurrent_8B5CE7B8D58EB0486020C5334EC6D6C4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_505765102C46161CB308C5334EC610B9" xlink:to="loc_us-gaap_AccruedBonusesCurrent_8B5CE7B8D58EB0486020C5334EC6D6C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedSalesCommissionCurrent" xlink:label="loc_us-gaap_AccruedSalesCommissionCurrent_310CED0C7FA0706FD6DFC5334EC6C472" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_505765102C46161CB308C5334EC610B9" xlink:to="loc_us-gaap_AccruedSalesCommissionCurrent_310CED0C7FA0706FD6DFC5334EC6C472" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:label="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent_F62B389387026D87524EC5334EC77488" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_505765102C46161CB308C5334EC610B9" xlink:to="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent_F62B389387026D87524EC5334EC77488" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedInsuranceCurrent" xlink:label="loc_us-gaap_AccruedInsuranceCurrent_8FBAD72EAD9D44217394C5334EC70152" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_505765102C46161CB308C5334EC610B9" xlink:to="loc_us-gaap_AccruedInsuranceCurrent_8FBAD72EAD9D44217394C5334EC70152" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_A37BBEFB4B277218262DC5334EC7D83F" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_505765102C46161CB308C5334EC610B9" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_A37BBEFB4B277218262DC5334EC7D83F" xlink:type="arc" />
    <link:loc xlink:href="apyx-20200630.xsd#apyx_JointAndSeveralPayrollLiability" xlink:label="loc_apyx_JointAndSeveralPayrollLiability_5A78D06EA891241DBFB6C5334EC714F6" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_505765102C46161CB308C5334EC610B9" xlink:to="loc_apyx_JointAndSeveralPayrollLiability_5A78D06EA891241DBFB6C5334EC714F6" xlink:type="arc" />
    <link:loc xlink:href="apyx-20200630.xsd#apyx_UncertainTaxPositionsLiability" xlink:label="loc_apyx_UncertainTaxPositionsLiability_AFF392B1F58784C34507C5334EC7F514" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_505765102C46161CB308C5334EC610B9" xlink:to="loc_apyx_UncertainTaxPositionsLiability_AFF392B1F58784C34507C5334EC7F514" xlink:type="arc" />
    <link:loc xlink:href="apyx-20200630.xsd#apyx_OtherAccruedExpensesAndLiabilitiesCurrent" xlink:label="loc_apyx_OtherAccruedExpensesAndLiabilitiesCurrent_9ADA359301F7364C4D96C5334EC7A097" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_505765102C46161CB308C5334EC610B9" xlink:to="loc_apyx_OtherAccruedExpensesAndLiabilitiesCurrent_9ADA359301F7364C4D96C5334EC7A097" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_4C9792CAD9CAB380C9F2C5334EC7E844" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_505765102C46161CB308C5334EC610B9" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_4C9792CAD9CAB380C9F2C5334EC7E844" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_D0F135B76178079F4C0149862593AB8B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_925CB2CAEBC8211AAD5049862593694A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_D0F135B76178079F4C0149862593AB8B" xlink:to="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_925CB2CAEBC8211AAD5049862593694A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/BasisOfPresentation" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_93BB02B5C9867BF1013B498625847E55" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_DE1753AF9743E04D0F32498625849022" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_93BB02B5C9867BF1013B498625847E55" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_DE1753AF9743E04D0F32498625849022" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/BasisOfPresentationPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_CD552EE3955FF8F2916149862590B649" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_CCE88575D17BDF071DCE49862590AA51" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_CD552EE3955FF8F2916149862590B649" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_CCE88575D17BDF071DCE49862590AA51" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_309DB4AD83CBE5014E6349862590F0AD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_CD552EE3955FF8F2916149862590B649" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_309DB4AD83CBE5014E6349862590F0AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_402392AAFF07DBBCFFC749862590C6A9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_CD552EE3955FF8F2916149862590B649" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_402392AAFF07DBBCFFC749862590C6A9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/ChangeInAccountingPolicy" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_FEF69DCBA3804FC6862549862545D2A4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingChangesTextBlock" xlink:label="loc_us-gaap_AccountingChangesTextBlock_88AEFDD77A8B053B78D94986254556F0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_FEF69DCBA3804FC6862549862545D2A4" xlink:to="loc_us-gaap_AccountingChangesTextBlock_88AEFDD77A8B053B78D94986254556F0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/CommitmentsAndContingencies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_BDA1E4B61325637D6174498625C530FB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_D8C28C55FCD275EE192F498625C59A04" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_BDA1E4B61325637D6174498625C530FB" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_D8C28C55FCD275EE192F498625C59A04" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_706452380C0D7385D86EBFB854F37A79" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsTable" xlink:label="loc_us-gaap_OtherCommitmentsTable_16D8463E9707F9217AE9BFB854FC6F13" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_706452380C0D7385D86EBFB854F37A79" xlink:to="loc_us-gaap_OtherCommitmentsTable_16D8463E9707F9217AE9BFB854FC6F13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_0EC59D5E1F2909CCC592BFB854FC0626" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_16D8463E9707F9217AE9BFB854FC6F13" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_0EC59D5E1F2909CCC592BFB854FC0626" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_F7601F4C1D9003F2DF81BFB854FCC85D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_0EC59D5E1F2909CCC592BFB854FC0626" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_F7601F4C1D9003F2DF81BFB854FCC85D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_5C91E5D9ECDD3B2D5127BFB854FC72AC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_F7601F4C1D9003F2DF81BFB854FCC85D" xlink:to="loc_us-gaap_SubsequentEventMember_5C91E5D9ECDD3B2D5127BFB854FC72AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_111B40AFDCE6995E68E1BFB854FC87BF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_16D8463E9707F9217AE9BFB854FC6F13" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_111B40AFDCE6995E68E1BFB854FC87BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="loc_us-gaap_LossContingencyNatureDomain_806B261CF0A034EF5383BFB854FC295E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_111B40AFDCE6995E68E1BFB854FC87BF" xlink:to="loc_us-gaap_LossContingencyNatureDomain_806B261CF0A034EF5383BFB854FC295E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnfavorableRegulatoryActionMember" xlink:label="loc_us-gaap_UnfavorableRegulatoryActionMember_5D6BBFBD0B5C957517F4BFB854FC5F5C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_806B261CF0A034EF5383BFB854FC295E" xlink:to="loc_us-gaap_UnfavorableRegulatoryActionMember_5D6BBFBD0B5C957517F4BFB854FC5F5C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusAxis" xlink:label="loc_us-gaap_LitigationStatusAxis_0129E62791E4A5EA2225BFB854FCCB33" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_16D8463E9707F9217AE9BFB854FC6F13" xlink:to="loc_us-gaap_LitigationStatusAxis_0129E62791E4A5EA2225BFB854FCCB33" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="loc_us-gaap_LitigationStatusDomain_A04A1D6F1B05483D14CCBFB854FC5D23" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_0129E62791E4A5EA2225BFB854FCCB33" xlink:to="loc_us-gaap_LitigationStatusDomain_A04A1D6F1B05483D14CCBFB854FC5D23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PendingLitigationMember" xlink:label="loc_us-gaap_PendingLitigationMember_250ACA3EC6394E3D0755BFB854FC1572" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_A04A1D6F1B05483D14CCBFB854FC5D23" xlink:to="loc_us-gaap_PendingLitigationMember_250ACA3EC6394E3D0755BFB854FC1572" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_E16CB1CB071BFFBC165BBFB854FC5D8C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_16D8463E9707F9217AE9BFB854FC6F13" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_E16CB1CB071BFFBC165BBFB854FC5D8C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_B5891504B184AD4553DABFB854FC8BEA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_E16CB1CB071BFFBC165BBFB854FC5D8C" xlink:to="loc_us-gaap_RelatedPartyDomain_B5891504B184AD4553DABFB854FC8BEA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateJointVentureMember" xlink:label="loc_us-gaap_CorporateJointVentureMember_B6683DEF56C11D149A62BFB854FCF6E2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_B5891504B184AD4553DABFB854FC8BEA" xlink:to="loc_us-gaap_CorporateJointVentureMember_B6683DEF56C11D149A62BFB854FCF6E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_B080252A18CB7D8737D3BFB854FC5A91" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_16D8463E9707F9217AE9BFB854FC6F13" xlink:to="loc_us-gaap_OtherCommitmentsLineItems_B080252A18CB7D8737D3BFB854FC5A91" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_2C8402FFA33D78725CF3BFB854FCAE1B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_B080252A18CB7D8737D3BFB854FC5A91" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_2C8402FFA33D78725CF3BFB854FCAE1B" xlink:type="arc" />
    <link:loc xlink:href="apyx-20200630.xsd#apyx_LossContingencyAccrualTotalAccruedToDate" xlink:label="loc_apyx_LossContingencyAccrualTotalAccruedToDate_B20CA64750D61DADEB04BFB854FC11EA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_B080252A18CB7D8737D3BFB854FC5A91" xlink:to="loc_apyx_LossContingencyAccrualTotalAccruedToDate_B20CA64750D61DADEB04BFB854FC11EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseObligation" xlink:label="loc_us-gaap_PurchaseObligation_752F2D5B085034C9F22FBFB854FC1D57" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_B080252A18CB7D8737D3BFB854FC5A91" xlink:to="loc_us-gaap_PurchaseObligation_752F2D5B085034C9F22FBFB854FC1D57" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_4D880F0AEFFECEE9DABDBFB854FC573E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_B080252A18CB7D8737D3BFB854FC5A91" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_4D880F0AEFFECEE9DABDBFB854FC573E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInterestInJointVenture" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInJointVenture_CB49F4E6932EDD6D7169BFC1E3350193" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_B080252A18CB7D8737D3BFB854FC5A91" xlink:to="loc_us-gaap_PaymentsToAcquireInterestInJointVenture_CB49F4E6932EDD6D7169BFC1E3350193" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_327D43FD2ED4F6AFEA9FD6069AD2DA7D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_D38363928204D19AF33DD6069AD28B82" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_327D43FD2ED4F6AFEA9FD6069AD2DA7D" xlink:to="loc_us-gaap_AssetsAbstract_D38363928204D19AF33DD6069AD28B82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_0AAB457CA449EAFBEF3FD6069AD2678D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_D38363928204D19AF33DD6069AD28B82" xlink:to="loc_us-gaap_AssetsCurrentAbstract_0AAB457CA449EAFBEF3FD6069AD2678D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_B4D83D6AED6A63E316B2D6069AD2B830" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0AAB457CA449EAFBEF3FD6069AD2678D" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_B4D83D6AED6A63E316B2D6069AD2B830" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_A3F51ED471340BBC97DBD6069AD21467" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0AAB457CA449EAFBEF3FD6069AD2678D" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_A3F51ED471340BBC97DBD6069AD21467" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="loc_us-gaap_IncomeTaxesReceivable_44328DD25C5B534C894ED6069AD228BA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0AAB457CA449EAFBEF3FD6069AD2678D" xlink:to="loc_us-gaap_IncomeTaxesReceivable_44328DD25C5B534C894ED6069AD228BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_1B3D6BA8EA90C43E3812D6069AE17485" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0AAB457CA449EAFBEF3FD6069AD2678D" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_1B3D6BA8EA90C43E3812D6069AE17485" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_B5BA46D1558F9FF49934D6069AE140F0" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0AAB457CA449EAFBEF3FD6069AD2678D" xlink:to="loc_us-gaap_InventoryNet_B5BA46D1558F9FF49934D6069AE140F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_A12D0730C9773EFF503ED6069AE198D5" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0AAB457CA449EAFBEF3FD6069AD2678D" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_A12D0730C9773EFF503ED6069AE198D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_130EF5287E7688BFCF58D6069AE16742" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0AAB457CA449EAFBEF3FD6069AD2678D" xlink:to="loc_us-gaap_AssetsCurrent_130EF5287E7688BFCF58D6069AE16742" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3288DB62C2B371BC8532D6069AE16427" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_D38363928204D19AF33DD6069AD28B82" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_3288DB62C2B371BC8532D6069AE16427" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_87857D886BF6E12F0C66D6069AE155CA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_D38363928204D19AF33DD6069AD28B82" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_87857D886BF6E12F0C66D6069AE155CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_BF2AC0A38CFF19D193B2D6069AE18157" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_D38363928204D19AF33DD6069AD28B82" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_BF2AC0A38CFF19D193B2D6069AE18157" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_24395B11CEA202B7CE5DD6069AE11FB8" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_D38363928204D19AF33DD6069AD28B82" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_24395B11CEA202B7CE5DD6069AE11FB8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_D57F646E1267CAD037C3D6069AE1839E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_D38363928204D19AF33DD6069AD28B82" xlink:to="loc_us-gaap_Assets_D57F646E1267CAD037C3D6069AE1839E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1C6248826B9AA6F4F543D6069AE17532" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_327D43FD2ED4F6AFEA9FD6069AD2DA7D" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1C6248826B9AA6F4F543D6069AE17532" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_782AB9E96E24DFA04DD1D6069AE1330D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1C6248826B9AA6F4F543D6069AE17532" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_782AB9E96E24DFA04DD1D6069AE1330D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_4691C64D430BD442E39AD6069AE1F978" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_782AB9E96E24DFA04DD1D6069AE1330D" xlink:to="loc_us-gaap_AccountsPayableCurrent_4691C64D430BD442E39AD6069AE1F978" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_8A8396FD07E8E33D694ED6069AE1997D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_782AB9E96E24DFA04DD1D6069AE1330D" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_8A8396FD07E8E33D694ED6069AE1997D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_E4A26D59D2081235023CD6069AE1E21E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_782AB9E96E24DFA04DD1D6069AE1330D" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_E4A26D59D2081235023CD6069AE1E21E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_EC0DDD48112E3DC7502AD6069AE10AAF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_782AB9E96E24DFA04DD1D6069AE1330D" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_EC0DDD48112E3DC7502AD6069AE10AAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_780C970B86EE2E17EF67D6069AE13D9A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_782AB9E96E24DFA04DD1D6069AE1330D" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_780C970B86EE2E17EF67D6069AE13D9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_3D3BCE6206AFA1AE7808D6069AE16207" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_782AB9E96E24DFA04DD1D6069AE1330D" xlink:to="loc_us-gaap_LiabilitiesCurrent_3D3BCE6206AFA1AE7808D6069AE16207" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_A6F3529474B5985A1871D6069AE104DB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1C6248826B9AA6F4F543D6069AE17532" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_A6F3529474B5985A1871D6069AE104DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_2517EC961A31633D95E4D6069AE15B11" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1C6248826B9AA6F4F543D6069AE17532" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_2517EC961A31633D95E4D6069AE15B11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_4CB10CB623C6A563974DD6069AE15B4F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1C6248826B9AA6F4F543D6069AE17532" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_4CB10CB623C6A563974DD6069AE15B4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_419833853B920F1C8E51D6069AE1EEE6" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1C6248826B9AA6F4F543D6069AE17532" xlink:to="loc_us-gaap_Liabilities_419833853B920F1C8E51D6069AE1EEE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_BE07CA55C4478D33324AD6069AE1DB34" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1C6248826B9AA6F4F543D6069AE17532" xlink:to="loc_us-gaap_StockholdersEquityAbstract_BE07CA55C4478D33324AD6069AE1DB34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_1C4384B2EAF28142D59FD6069AE12CDF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_BE07CA55C4478D33324AD6069AE1DB34" xlink:to="loc_us-gaap_CommonStockValue_1C4384B2EAF28142D59FD6069AE12CDF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_EA78E9697A85B39845BCD6069AE1841E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_BE07CA55C4478D33324AD6069AE1DB34" xlink:to="loc_us-gaap_AdditionalPaidInCapital_EA78E9697A85B39845BCD6069AE1841E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_BAFEF8B88D9BA9A4E1AAD6069AE188FF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_BE07CA55C4478D33324AD6069AE1DB34" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_BAFEF8B88D9BA9A4E1AAD6069AE188FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_0104F96220D45D5E6B36D6069AE1D230" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_BE07CA55C4478D33324AD6069AE1DB34" xlink:to="loc_us-gaap_StockholdersEquity_0104F96220D45D5E6B36D6069AE1D230" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_1399C4FAA44C02200301D6069AE1CF6C" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1C6248826B9AA6F4F543D6069AE17532" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_1399C4FAA44C02200301D6069AE1CF6C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_B81568AFE8E6A99A1D834986256EBEA2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_BEDCA3DBE8A1A93B19344986256E59CE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_B81568AFE8E6A99A1D834986256EBEA2" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_BEDCA3DBE8A1A93B19344986256E59CE" xlink:type="arc" />
    <link:loc xlink:href="apyx-20200630.xsd#apyx_ProvisionForObsolescenceInventory" xlink:label="loc_apyx_ProvisionForObsolescenceInventory_7C7830175666A220E1934986256F08A2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_B81568AFE8E6A99A1D834986256EBEA2" xlink:to="loc_apyx_ProvisionForObsolescenceInventory_7C7830175666A220E1934986256F08A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_B933032E1D55D235CF1B4986256FB243" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_B81568AFE8E6A99A1D834986256EBEA2" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_B933032E1D55D235CF1B4986256FB243" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_91E2799C8B75B156EC734986256F9D84" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_B81568AFE8E6A99A1D834986256EBEA2" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_91E2799C8B75B156EC734986256F9D84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_A5915D145726FBC2E57D4986256F4D9F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_B81568AFE8E6A99A1D834986256EBEA2" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_A5915D145726FBC2E57D4986256F4D9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_F205CFD81B7FEE8C8CAC4986256F9F04" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_B81568AFE8E6A99A1D834986256EBEA2" xlink:to="loc_us-gaap_CommonStockSharesIssued_F205CFD81B7FEE8C8CAC4986256F9F04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_3B0E0A05EBA7A77D23124986256F2CF6" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_B81568AFE8E6A99A1D834986256EBEA2" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_3B0E0A05EBA7A77D23124986256F2CF6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_5EF8ED8B1F871BB8ABA9A686569D66BC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_A60B21BBCEAE05F9764DA686569DC4DA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_5EF8ED8B1F871BB8ABA9A686569D66BC" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_A60B21BBCEAE05F9764DA686569DC4DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2E6C42653EA7A3F6397AA68656A57204" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_5EF8ED8B1F871BB8ABA9A686569D66BC" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2E6C42653EA7A3F6397AA68656A57204" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_953431EF7C52302926BDA68656A523A2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2E6C42653EA7A3F6397AA68656A57204" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_953431EF7C52302926BDA68656A523A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_8FDB27305DF9DFF6E023A68656A63ADE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_953431EF7C52302926BDA68656A523A2" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_8FDB27305DF9DFF6E023A68656A63ADE" xlink:type="arc" />
    <link:loc xlink:href="apyx-20200630.xsd#apyx_ProvisionForInventoryObsolescence" xlink:label="loc_apyx_ProvisionForInventoryObsolescence_E05C5B34029D8753F762A68656A6173C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_953431EF7C52302926BDA68656A523A2" xlink:to="loc_apyx_ProvisionForInventoryObsolescence_E05C5B34029D8753F762A68656A6173C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_5A22A64E9C7AC79AA8B4A68656A634AD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_953431EF7C52302926BDA68656A523A2" xlink:to="loc_us-gaap_ShareBasedCompensation_5A22A64E9C7AC79AA8B4A68656A634AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnInvestments" xlink:label="loc_us-gaap_GainLossOnInvestments_8B1A5B6AAE322FAF156BA68656A75D65" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_953431EF7C52302926BDA68656A523A2" xlink:to="loc_us-gaap_GainLossOnInvestments_8B1A5B6AAE322FAF156BA68656A75D65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_52F28E6DBDB3BD756669A68656A7357C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_953431EF7C52302926BDA68656A523A2" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_52F28E6DBDB3BD756669A68656A7357C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5CDF18B161B4BF8FB199A68656A7DE67" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_953431EF7C52302926BDA68656A523A2" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5CDF18B161B4BF8FB199A68656A7DE67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_DB22A31DAA27A1AFF2CFA68656A72C8D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5CDF18B161B4BF8FB199A68656A7DE67" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_DB22A31DAA27A1AFF2CFA68656A72C8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_D9643804B0092B46B8FBA68656A77F3C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5CDF18B161B4BF8FB199A68656A7DE67" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_D9643804B0092B46B8FBA68656A77F3C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_CBC52D892965DFFB63ABA68656A7DCB0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5CDF18B161B4BF8FB199A68656A7DE67" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_CBC52D892965DFFB63ABA68656A7DCB0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_A7B7DF360BEA6B3CBF00A68656A7B5E2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5CDF18B161B4BF8FB199A68656A7DE67" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_A7B7DF360BEA6B3CBF00A68656A7B5E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_FFDA277908B0C1AFAA61A68656A73B95" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5CDF18B161B4BF8FB199A68656A7DE67" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_FFDA277908B0C1AFAA61A68656A73B95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_BA8796A39A8636BBC815A68656A773A9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2E6C42653EA7A3F6397AA68656A57204" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_BA8796A39A8636BBC815A68656A773A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_D42D3EE4B986AF419A78A68656A73B41" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_5EF8ED8B1F871BB8ABA9A686569D66BC" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_D42D3EE4B986AF419A78A68656A73B41" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_05555E11DD28C13C001CA68656A7107B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_D42D3EE4B986AF419A78A68656A73B41" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_05555E11DD28C13C001CA68656A7107B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_89E8372C00F2ADECFEAAA68656A730AB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_D42D3EE4B986AF419A78A68656A73B41" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_89E8372C00F2ADECFEAAA68656A730AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_6597C958CF6059CA6C0BA68656A773EA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_D42D3EE4B986AF419A78A68656A73B41" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_6597C958CF6059CA6C0BA68656A773EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_B5E95BBE1D2F849662FEA68656A7FCFF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_D42D3EE4B986AF419A78A68656A73B41" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_B5E95BBE1D2F849662FEA68656A7FCFF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_E73A63282BE1631930CDA68656A732E2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_5EF8ED8B1F871BB8ABA9A686569D66BC" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_E73A63282BE1631930CDA68656A732E2" xlink:type="arc" />
    <link:loc xlink:href="apyx-20200630.xsd#apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised" xlink:label="loc_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised_354942F2B86CB5FF988DA68656A75F62" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_E73A63282BE1631930CDA68656A732E2" xlink:to="loc_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised_354942F2B86CB5FF988DA68656A75F62" xlink:type="arc" />
    <link:loc xlink:href="apyx-20200630.xsd#apyx_RepaymentofFinanceLeaseLiabilities" xlink:label="loc_apyx_RepaymentofFinanceLeaseLiabilities_802FEFFB3E7531835BADA68656A778B3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_E73A63282BE1631930CDA68656A732E2" xlink:to="loc_apyx_RepaymentofFinanceLeaseLiabilities_802FEFFB3E7531835BADA68656A778B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_EB633519B2B77F9B70FBA68656A72842" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_E73A63282BE1631930CDA68656A732E2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_EB633519B2B77F9B70FBA68656A72842" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_CB09AC14999F01A138E5A68656A77520" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_5EF8ED8B1F871BB8ABA9A686569D66BC" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_CB09AC14999F01A138E5A68656A77520" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_F32E6FE0A5C645C638D3A68656A701E8" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_5EF8ED8B1F871BB8ABA9A686569D66BC" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_F32E6FE0A5C645C638D3A68656A701E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7E00AB911ED92802E39DA68656A7773C" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_5EF8ED8B1F871BB8ABA9A686569D66BC" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7E00AB911ED92802E39DA68656A7773C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_D627D66C61DD1466C3C0A68656A7E4E3" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_5EF8ED8B1F871BB8ABA9A686569D66BC" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_D627D66C61DD1466C3C0A68656A7E4E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_1A2091255B8B819BDECEA68EF8B44A80" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_5EF8ED8B1F871BB8ABA9A686569D66BC" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_1A2091255B8B819BDECEA68EF8B44A80" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_22BCF7B24A443600760FA69065BD7057" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_1A2091255B8B819BDECEA68EF8B44A80" xlink:to="loc_us-gaap_InterestPaidNet_22BCF7B24A443600760FA69065BD7057" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaap_IncomeTaxesPaid_55783C1F2E716712D7AAA69345D0F4D4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_1A2091255B8B819BDECEA68EF8B44A80" xlink:to="loc_us-gaap_IncomeTaxesPaid_55783C1F2E716712D7AAA69345D0F4D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_2CE3898A3C712BB20295A6901C905DE3" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_5EF8ED8B1F871BB8ABA9A686569D66BC" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_2CE3898A3C712BB20295A6901C905DE3" xlink:type="arc" />
    <link:loc xlink:href="apyx-20200630.xsd#apyx_NonCashProceedsFromStockOptionsAndWarrantsExercised" xlink:label="loc_apyx_NonCashProceedsFromStockOptionsAndWarrantsExercised_B63C4B00A296D01A741AA69065FCC2BA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_2CE3898A3C712BB20295A6901C905DE3" xlink:to="loc_apyx_NonCashProceedsFromStockOptionsAndWarrantsExercised_B63C4B00A296D01A741AA69065FCC2BA" xlink:type="arc" />
    <link:loc xlink:href="apyx-20200630.xsd#apyx_LeaseAdoption" xlink:label="loc_apyx_LeaseAdoption_05406E8899D9FAE9A065A6906630DD2D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_2CE3898A3C712BB20295A6901C905DE3" xlink:to="loc_apyx_LeaseAdoption_05406E8899D9FAE9A065A6906630DD2D" xlink:type="arc" />
    <link:loc xlink:href="apyx-20200630.xsd#apyx_CapitalizationOfLeaseNonCash" xlink:label="loc_apyx_CapitalizationOfLeaseNonCash_A506D0A4006C632AA851A6906661E954" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_2CE3898A3C712BB20295A6901C905DE3" xlink:to="loc_apyx_CapitalizationOfLeaseNonCash_A506D0A4006C632AA851A6906661E954" xlink:type="arc" />
    <link:loc xlink:href="apyx-20200630.xsd#apyx_CapitalizationOfLeaseExecution" xlink:label="loc_apyx_CapitalizationOfLeaseExecution_D5CED33C82A533C76DF0A69E7AEDE3DD" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_2CE3898A3C712BB20295A6901C905DE3" xlink:to="loc_apyx_CapitalizationOfLeaseExecution_D5CED33C82A533C76DF0A69E7AEDE3DD" xlink:type="arc" />
    <link:loc xlink:href="apyx-20200630.xsd#apyx_NonCashTransferOfOtherAssetsToFixedAssets" xlink:label="loc_apyx_NonCashTransferOfOtherAssetsToFixedAssets_2E771E52B3380C9CF0DFA697BEBEDC4F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_2CE3898A3C712BB20295A6901C905DE3" xlink:to="loc_apyx_NonCashTransferOfOtherAssetsToFixedAssets_2E771E52B3380C9CF0DFA697BEBEDC4F" xlink:type="arc" />
    <link:loc xlink:href="apyx-20200630.xsd#apyx_NonCashTransfersOfInventoryToFromFixedAssets" xlink:label="loc_apyx_NonCashTransfersOfInventoryToFromFixedAssets_662C30719E3D2B2F3AC6A69854A172FD" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_2CE3898A3C712BB20295A6901C905DE3" xlink:to="loc_apyx_NonCashTransfersOfInventoryToFromFixedAssets_662C30719E3D2B2F3AC6A69854A172FD" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_80A363A0A0A335568D2AD6069AC21882" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_8526B04C1E4D8E5264DDD6069AC2742A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_80A363A0A0A335568D2AD6069AC21882" xlink:to="loc_us-gaap_StatementTable_8526B04C1E4D8E5264DDD6069AC2742A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_F449AE1669F26354E19DD6069AC213EF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8526B04C1E4D8E5264DDD6069AC2742A" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_F449AE1669F26354E19DD6069AC213EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_6809CF8DA9057AD5719AD6069AC2F869" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_F449AE1669F26354E19DD6069AC213EF" xlink:to="loc_us-gaap_EquityComponentDomain_6809CF8DA9057AD5719AD6069AC2F869" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_0422BA68AD424DA0E8F2D6069AC26E0A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6809CF8DA9057AD5719AD6069AC2F869" xlink:to="loc_us-gaap_CommonStockMember_0422BA68AD424DA0E8F2D6069AC26E0A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_4715C9BD3D81C0F97FC0D6069AC25CE2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6809CF8DA9057AD5719AD6069AC2F869" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_4715C9BD3D81C0F97FC0D6069AC25CE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_AB9693376F2E74693A69D6069AC2A596" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6809CF8DA9057AD5719AD6069AC2F869" xlink:to="loc_us-gaap_RetainedEarningsMember_AB9693376F2E74693A69D6069AC2A596" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_AADBAB236E0E6D442A8CD6069AC20EF2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8526B04C1E4D8E5264DDD6069AC2742A" xlink:to="loc_us-gaap_StatementLineItems_AADBAB236E0E6D442A8CD6069AC20EF2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_86939D5C0B269DA2E2F2D6069AC2FC15" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_AADBAB236E0E6D442A8CD6069AC20EF2" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_86939D5C0B269DA2E2F2D6069AC2FC15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_AF298F00B6D3E6BD2861D6069AC228BA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_86939D5C0B269DA2E2F2D6069AC2FC15" xlink:to="loc_us-gaap_SharesIssued_AF298F00B6D3E6BD2861D6069AC228BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_C41DD87C48BE5BE023F4D6069AC2720A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_86939D5C0B269DA2E2F2D6069AC2FC15" xlink:to="loc_us-gaap_StockholdersEquity_C41DD87C48BE5BE023F4D6069AC2720A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_7ACA11283BE32C55FBB4D6069AC2D086" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_86939D5C0B269DA2E2F2D6069AC2FC15" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_7ACA11283BE32C55FBB4D6069AC2D086" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_C44D4A9726F11F2B7AEAD6069AC28067" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_86939D5C0B269DA2E2F2D6069AC2FC15" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_C44D4A9726F11F2B7AEAD6069AC28067" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_04C54C986730DC435FDCD6069AC24329" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_86939D5C0B269DA2E2F2D6069AC2FC15" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_04C54C986730DC435FDCD6069AC24329" xlink:type="arc" />
    <link:loc xlink:href="apyx-20200630.xsd#apyx_StockSwapToAcquireOptionsShares" xlink:label="loc_apyx_StockSwapToAcquireOptionsShares_9C5E056259485363517DD6069AC2F1BF" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_86939D5C0B269DA2E2F2D6069AC2FC15" xlink:to="loc_apyx_StockSwapToAcquireOptionsShares_9C5E056259485363517DD6069AC2F1BF" xlink:type="arc" />
    <link:loc xlink:href="apyx-20200630.xsd#apyx_StockSwapToAcquireOptionsAmount" xlink:label="loc_apyx_StockSwapToAcquireOptionsAmount_7139DD371C6934BABA58D6069AC289C7" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_86939D5C0B269DA2E2F2D6069AC2FC15" xlink:to="loc_apyx_StockSwapToAcquireOptionsAmount_7139DD371C6934BABA58D6069AC289C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_24A7C8BD6DA25D026834D6069AC2EF19" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_86939D5C0B269DA2E2F2D6069AC2FC15" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_24A7C8BD6DA25D026834D6069AC2EF19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_0E0443D6E082DC16B135D6069AC26CCF" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_86939D5C0B269DA2E2F2D6069AC2FC15" xlink:to="loc_us-gaap_SharesIssued_0E0443D6E082DC16B135D6069AC26CCF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_F6B4DE99E36E795FAE95D6069AC29151" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_86939D5C0B269DA2E2F2D6069AC2FC15" xlink:to="loc_us-gaap_StockholdersEquity_F6B4DE99E36E795FAE95D6069AC29151" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/ConsolidatedStatementsOfOperations" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_B4691BAF6757CBAC9FAAD6069AC2544B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_EDDDAAD5EF978C81221ED6069AC27CA5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_B4691BAF6757CBAC9FAAD6069AC2544B" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_EDDDAAD5EF978C81221ED6069AC27CA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_1F7BA58B788DF57AD02CD6069AC2196A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_B4691BAF6757CBAC9FAAD6069AC2544B" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_1F7BA58B788DF57AD02CD6069AC2196A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_8B6247739BCE18DD76DCD6069AC248A2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_B4691BAF6757CBAC9FAAD6069AC2544B" xlink:to="loc_us-gaap_GrossProfit_8B6247739BCE18DD76DCD6069AC248A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_A50B895402E893C34E2FD6069AC28A04" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_B4691BAF6757CBAC9FAAD6069AC2544B" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_A50B895402E893C34E2FD6069AC28A04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_6B0FB504ADAB0D874A44D6069AC26419" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_A50B895402E893C34E2FD6069AC28A04" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_6B0FB504ADAB0D874A44D6069AC26419" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaap_ProfessionalFees_A2A5C0F761150D29AFB2D6069AC22E44" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_A50B895402E893C34E2FD6069AC28A04" xlink:to="loc_us-gaap_ProfessionalFees_A2A5C0F761150D29AFB2D6069AC22E44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalariesAndWages" xlink:label="loc_us-gaap_SalariesAndWages_D3CB4ED44325376FDEC0D6069AC287D1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_A50B895402E893C34E2FD6069AC28A04" xlink:to="loc_us-gaap_SalariesAndWages_D3CB4ED44325376FDEC0D6069AC287D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_EBFEBE71D8D093AAB15ED6069AC2E6DF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_A50B895402E893C34E2FD6069AC28A04" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_EBFEBE71D8D093AAB15ED6069AC2E6DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_2321AB5C01A363D69585D6069AC2C259" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_A50B895402E893C34E2FD6069AC28A04" xlink:to="loc_us-gaap_OperatingExpenses_2321AB5C01A363D69585D6069AC2C259" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_27D9E8C77E20FB31B378D6069AC2E392" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_B4691BAF6757CBAC9FAAD6069AC2544B" xlink:to="loc_us-gaap_OperatingIncomeLoss_27D9E8C77E20FB31B378D6069AC2E392" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeOperating" xlink:label="loc_us-gaap_InterestIncomeOperating_0BBCD09974A868A6DA2CD6069AC2E90A" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_B4691BAF6757CBAC9FAAD6069AC2544B" xlink:to="loc_us-gaap_InterestIncomeOperating_0BBCD09974A868A6DA2CD6069AC2E90A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_ECB74EDF3573B27C9ED3D6069AC26B0F" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_B4691BAF6757CBAC9FAAD6069AC2544B" xlink:to="loc_us-gaap_InterestExpense_ECB74EDF3573B27C9ED3D6069AC26B0F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_7963F78572AF7C105281D6069AC2754E" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_B4691BAF6757CBAC9FAAD6069AC2544B" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_7963F78572AF7C105281D6069AC2754E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_F743C26B277C04321C50D6069AC20C8A" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_B4691BAF6757CBAC9FAAD6069AC2544B" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_F743C26B277C04321C50D6069AC20C8A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_D571AABA359763DE5E73D6069AC2DB5C" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_B4691BAF6757CBAC9FAAD6069AC2544B" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_D571AABA359763DE5E73D6069AC2DB5C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_E0E1A8A7CB4495D6ED5BD6069AC206D5" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_B4691BAF6757CBAC9FAAD6069AC2544B" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_E0E1A8A7CB4495D6ED5BD6069AC206D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_450DFAF7FEC4D7B85622D6069AC20C6A" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_B4691BAF6757CBAC9FAAD6069AC2544B" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_450DFAF7FEC4D7B85622D6069AC20C6A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_547271CCE6FDA7FE8017D6069AC2BBD9" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_B4691BAF6757CBAC9FAAD6069AC2544B" xlink:to="loc_us-gaap_EarningsPerShareAbstract_547271CCE6FDA7FE8017D6069AC2BBD9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_71BF194896A4D2067E72D6069AC2F189" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_547271CCE6FDA7FE8017D6069AC2BBD9" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_71BF194896A4D2067E72D6069AC2F189" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/Cover" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_8424148013F205A841ABC974547D9BF5" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_E5FB153A7BC92B533856C974547D5B19" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8424148013F205A841ABC974547D9BF5" xlink:to="loc_dei_DocumentType_E5FB153A7BC92B533856C974547D5B19" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_dei_DocumentQuarterlyReport_9612E130DA2921F496F6C974547E7C58" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8424148013F205A841ABC974547D9BF5" xlink:to="loc_dei_DocumentQuarterlyReport_9612E130DA2921F496F6C974547E7C58" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_1E49874DC877A632A8ACC974547E3EF2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8424148013F205A841ABC974547D9BF5" xlink:to="loc_dei_DocumentPeriodEndDate_1E49874DC877A632A8ACC974547E3EF2" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_DA65B4DECD96386EB8C5C974547E72DA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8424148013F205A841ABC974547D9BF5" xlink:to="loc_dei_DocumentTransitionReport_DA65B4DECD96386EB8C5C974547E72DA" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_8FC902DD036CA558B7BBC974547E4A9C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8424148013F205A841ABC974547D9BF5" xlink:to="loc_dei_EntityFileNumber_8FC902DD036CA558B7BBC974547E4A9C" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_944C54941B786CEA96C8C974547E6319" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8424148013F205A841ABC974547D9BF5" xlink:to="loc_dei_EntityRegistrantName_944C54941B786CEA96C8C974547E6319" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_E4248F32E22AC51E5441C974547EBE14" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8424148013F205A841ABC974547D9BF5" xlink:to="loc_dei_EntityIncorporationStateCountryCode_E4248F32E22AC51E5441C974547EBE14" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_456367EBFF8C4872382CC974547EF5C3" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8424148013F205A841ABC974547D9BF5" xlink:to="loc_dei_EntityTaxIdentificationNumber_456367EBFF8C4872382CC974547EF5C3" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_809F7BD9C165856A0B05C974547FF9F3" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8424148013F205A841ABC974547D9BF5" xlink:to="loc_dei_EntityAddressAddressLine1_809F7BD9C165856A0B05C974547FF9F3" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_2CDEFA2CFBD5E2D632ABC974547FB47F" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8424148013F205A841ABC974547D9BF5" xlink:to="loc_dei_EntityAddressCityOrTown_2CDEFA2CFBD5E2D632ABC974547FB47F" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_6E68BC690B9F0C8567F6C9745484C53D" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8424148013F205A841ABC974547D9BF5" xlink:to="loc_dei_EntityAddressStateOrProvince_6E68BC690B9F0C8567F6C9745484C53D" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_4A3B98BA40174A0F74DAC97454846CFB" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8424148013F205A841ABC974547D9BF5" xlink:to="loc_dei_EntityAddressPostalZipCode_4A3B98BA40174A0F74DAC97454846CFB" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_09940B7FB8CFC47CB9B1C974548425AB" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8424148013F205A841ABC974547D9BF5" xlink:to="loc_dei_CityAreaCode_09940B7FB8CFC47CB9B1C974548425AB" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_0564C326493F69A13DCEC97454856BE7" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8424148013F205A841ABC974547D9BF5" xlink:to="loc_dei_LocalPhoneNumber_0564C326493F69A13DCEC97454856BE7" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_BE1A7A105653DCEFFA47C97454850D55" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8424148013F205A841ABC974547D9BF5" xlink:to="loc_dei_Security12bTitle_BE1A7A105653DCEFFA47C97454850D55" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_DF7591953973B8DA94F4C9745485C904" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8424148013F205A841ABC974547D9BF5" xlink:to="loc_dei_TradingSymbol_DF7591953973B8DA94F4C9745485C904" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_61AC0582C5CCE85C0829C97454850FF6" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8424148013F205A841ABC974547D9BF5" xlink:to="loc_dei_SecurityExchangeName_61AC0582C5CCE85C0829C97454850FF6" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_32E3BC357586EF7AEF3EC974548547A5" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8424148013F205A841ABC974547D9BF5" xlink:to="loc_dei_EntityCurrentReportingStatus_32E3BC357586EF7AEF3EC974548547A5" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_A3DF952E8B16877C7BDCC9745485D7F9" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8424148013F205A841ABC974547D9BF5" xlink:to="loc_dei_EntityInteractiveDataCurrent_A3DF952E8B16877C7BDCC9745485D7F9" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_0DC7320AB1CF94F4F653C974548604C9" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8424148013F205A841ABC974547D9BF5" xlink:to="loc_dei_EntityFilerCategory_0DC7320AB1CF94F4F653C974548604C9" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_D27E3F7AB25C31962F32C97454864AA4" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8424148013F205A841ABC974547D9BF5" xlink:to="loc_dei_EntitySmallBusiness_D27E3F7AB25C31962F32C97454864AA4" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_6D2070B02169A13022E3C97454863487" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8424148013F205A841ABC974547D9BF5" xlink:to="loc_dei_EntityEmergingGrowthCompany_6D2070B02169A13022E3C97454863487" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_CF1A5F8B2AFFCC9DAF04C9745486AD2C" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8424148013F205A841ABC974547D9BF5" xlink:to="loc_dei_EntityShellCompany_CF1A5F8B2AFFCC9DAF04C9745486AD2C" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_CD447E107542C30427F6C9745486BC38" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8424148013F205A841ABC974547D9BF5" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_CD447E107542C30427F6C9745486BC38" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_FF9511E9647F42EB9D35C97454861391" xlink:type="locator" />
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8424148013F205A841ABC974547D9BF5" xlink:to="loc_dei_CurrentFiscalYearEndDate_FF9511E9647F42EB9D35C97454861391" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_B677154DE17F048A3778C9745487A9A9" xlink:type="locator" />
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8424148013F205A841ABC974547D9BF5" xlink:to="loc_dei_AmendmentFlag_B677154DE17F048A3778C9745487A9A9" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_19FA3E515209408F10DEC97454871472" xlink:type="locator" />
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8424148013F205A841ABC974547D9BF5" xlink:to="loc_dei_EntityCentralIndexKey_19FA3E515209408F10DEC97454871472" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_10D097D972EF00FE3156C974548788DD" xlink:type="locator" />
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8424148013F205A841ABC974547D9BF5" xlink:to="loc_dei_DocumentFiscalPeriodFocus_10D097D972EF00FE3156C974548788DD" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_7B620581260F3B97C1D7C9745487A1EB" xlink:type="locator" />
    <link:presentationArc order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8424148013F205A841ABC974547D9BF5" xlink:to="loc_dei_DocumentFiscalYearFocus_7B620581260F3B97C1D7C9745487A1EB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/EarningsPerShare" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_BECCDA812911366EC69ED39D8888616D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_46555E669833FE046A36D39D88886E75" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_BECCDA812911366EC69ED39D8888616D" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_46555E669833FE046A36D39D88886E75" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/EarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_54F411C761DFC56CF4D3D39D8866D076" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9D84AE31716A9480B9DDD39D88670943" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_54F411C761DFC56CF4D3D39D8866D076" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9D84AE31716A9480B9DDD39D88670943" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_86007F7BC842894300F7D39D8867F269" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9D84AE31716A9480B9DDD39D88670943" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_86007F7BC842894300F7D39D8867F269" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8AD585E05442BDE73E75D39D8867CBD5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_86007F7BC842894300F7D39D8867F269" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8AD585E05442BDE73E75D39D8867CBD5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OptionOnSecuritiesMember" xlink:label="loc_us-gaap_OptionOnSecuritiesMember_E0B82190008726D7EDB7D39D88675C39" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8AD585E05442BDE73E75D39D8867CBD5" xlink:to="loc_us-gaap_OptionOnSecuritiesMember_E0B82190008726D7EDB7D39D88675C39" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_43B16F01DFC6E9D6ADD9D39D8867169F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9D84AE31716A9480B9DDD39D88670943" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_43B16F01DFC6E9D6ADD9D39D8867169F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareReconciliationAbstract" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract_0A58A37F9B28F4C44242D39D88678353" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_43B16F01DFC6E9D6ADD9D39D8867169F" xlink:to="loc_us-gaap_EarningsPerShareReconciliationAbstract_0A58A37F9B28F4C44242D39D88678353" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_39DB1A329815CFA54EC3D39D8867B02D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_0A58A37F9B28F4C44242D39D88678353" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_39DB1A329815CFA54EC3D39D8867B02D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_6E82C9428DD4F51D0E86D39D88674287" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_43B16F01DFC6E9D6ADD9D39D8867169F" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_6E82C9428DD4F51D0E86D39D88674287" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_7AF0FE5800629847DE2AD39D8867C082" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_6E82C9428DD4F51D0E86D39D88674287" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_7AF0FE5800629847DE2AD39D8867C082" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_0BA41D1F5FFFAB09D4FFD39D886785BE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_43B16F01DFC6E9D6ADD9D39D8867169F" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_0BA41D1F5FFFAB09D4FFD39D886785BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_2001D84E3C041BE9B92ED39D886793AE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_0BA41D1F5FFFAB09D4FFD39D886785BE" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_2001D84E3C041BE9B92ED39D886793AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_DE6DAE6F76F98E91C50CD39D88671D0B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_43B16F01DFC6E9D6ADD9D39D8867169F" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_DE6DAE6F76F98E91C50CD39D88671D0B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_EC7CED9E97E31028EAEAD39D8867F803" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_DE6DAE6F76F98E91C50CD39D88671D0B" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_EC7CED9E97E31028EAEAD39D8867F803" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/EarningsPerShareTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_8DD8194904535CFB99C0D39D8877AB31" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_B6A1545BF572E057B6FED39D887FE60F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8DD8194904535CFB99C0D39D8877AB31" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_B6A1545BF572E057B6FED39D887FE60F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/GeographicAndSegmentInformation" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_0C4001687C954F3CD4E6498624F19BB9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_4A56346FCA09245B660D498624F13F65" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_0C4001687C954F3CD4E6498624F19BB9" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_4A56346FCA09245B660D498624F13F65" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/GeographicAndSegmentInformationGeographicDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_E20FD5D2447B932932AE498625592B74" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1920097A1E3AE19650644986255AFF96" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_E20FD5D2447B932932AE498625592B74" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1920097A1E3AE19650644986255AFF96" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_4569ADE50954DA92893B4986255A5E14" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1920097A1E3AE19650644986255AFF96" xlink:to="loc_srt_StatementGeographicalAxis_4569ADE50954DA92893B4986255A5E14" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_04A775BCCF5750C955834986255B1102" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_4569ADE50954DA92893B4986255A5E14" xlink:to="loc_srt_SegmentGeographicalDomain_04A775BCCF5750C955834986255B1102" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US" xlink:label="loc_country_US_E444E02013089433CCC54986255B2981" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_04A775BCCF5750C955834986255B1102" xlink:to="loc_country_US_E444E02013089433CCC54986255B2981" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonUsMember" xlink:label="loc_us-gaap_NonUsMember_DD38742FB5A8C66902B54986255CDAAA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_04A775BCCF5750C955834986255B1102" xlink:to="loc_us-gaap_NonUsMember_DD38742FB5A8C66902B54986255CDAAA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_A7477FD94E055464EE864986255CD0EB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1920097A1E3AE19650644986255AFF96" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_A7477FD94E055464EE864986255CD0EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_C244329DD7DF7B46EAAA4986255CA82C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_A7477FD94E055464EE864986255CD0EB" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_C244329DD7DF7B46EAAA4986255CA82C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/GeographicAndSegmentInformationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_E7174F066DEC8463248576CCC6A296B5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_93B8A115C683AEB0BE1476CCC6A2B12E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_E7174F066DEC8463248576CCC6A296B5" xlink:to="loc_us-gaap_NumberOfOperatingSegments_93B8A115C683AEB0BE1476CCC6A2B12E" xlink:type="arc" />
    <link:loc xlink:href="apyx-20200630.xsd#apyx_TotalRevenuePercent" xlink:label="loc_apyx_TotalRevenuePercent_84FC58BF36192A78246B76CCC6A27EE6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_E7174F066DEC8463248576CCC6A296B5" xlink:to="loc_apyx_TotalRevenuePercent_84FC58BF36192A78246B76CCC6A27EE6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/GeographicAndSegmentInformationReportableSegmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_55FF93BD222B6E287215D39D86D61493" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_A41E645B5320D2869554D39D86DE4FD5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_55FF93BD222B6E287215D39D86D61493" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_A41E645B5320D2869554D39D86DE4FD5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis" xlink:label="loc_srt_ConsolidationItemsAxis_4B9581ACFDC4ED40C247D39D86DE2231" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_A41E645B5320D2869554D39D86DE4FD5" xlink:to="loc_srt_ConsolidationItemsAxis_4B9581ACFDC4ED40C247D39D86DE2231" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain" xlink:label="loc_srt_ConsolidationItemsDomain_094112CC4BED4B751CC0D39D86DEC8A3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_4B9581ACFDC4ED40C247D39D86DE2231" xlink:to="loc_srt_ConsolidationItemsDomain_094112CC4BED4B751CC0D39D86DEC8A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember" xlink:label="loc_us-gaap_OperatingSegmentsMember_FC6D081906EA7BAD9D6AD39D86DED80F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_094112CC4BED4B751CC0D39D86DEC8A3" xlink:to="loc_us-gaap_OperatingSegmentsMember_FC6D081906EA7BAD9D6AD39D86DED80F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateNonSegmentMember" xlink:label="loc_us-gaap_CorporateNonSegmentMember_8C8041654208CA1EE336D39D86DE4A8F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_094112CC4BED4B751CC0D39D86DEC8A3" xlink:to="loc_us-gaap_CorporateNonSegmentMember_8C8041654208CA1EE336D39D86DE4A8F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_16A996FB8F4DABC847F8D39D86DECE98" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_A41E645B5320D2869554D39D86DE4FD5" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_16A996FB8F4DABC847F8D39D86DECE98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_12B889E55E2B19E40670D39D86DEDF4D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_16A996FB8F4DABC847F8D39D86DECE98" xlink:to="loc_us-gaap_SegmentDomain_12B889E55E2B19E40670D39D86DEDF4D" xlink:type="arc" />
    <link:loc xlink:href="apyx-20200630.xsd#apyx_AdvancedEnergyMember" xlink:label="loc_apyx_AdvancedEnergyMember_249C7ED2494D95742FF5D39D86DEA3AF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_12B889E55E2B19E40670D39D86DEDF4D" xlink:to="loc_apyx_AdvancedEnergyMember_249C7ED2494D95742FF5D39D86DEA3AF" xlink:type="arc" />
    <link:loc xlink:href="apyx-20200630.xsd#apyx_OEMMember" xlink:label="loc_apyx_OEMMember_C6233E727596433CEDBED39D86DEC55B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_12B889E55E2B19E40670D39D86DEDF4D" xlink:to="loc_apyx_OEMMember_C6233E727596433CEDBED39D86DEC55B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_52EDD22D91B111D503C6D39D86DE474D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_A41E645B5320D2869554D39D86DE4FD5" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_52EDD22D91B111D503C6D39D86DE474D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_EF8BCBE8BB654339A33DD39D86E13AB3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_52EDD22D91B111D503C6D39D86DE474D" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_EF8BCBE8BB654339A33DD39D86E13AB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_7121565AE3747798149CD39D86E159A7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_52EDD22D91B111D503C6D39D86DE474D" xlink:to="loc_us-gaap_OperatingIncomeLoss_7121565AE3747798149CD39D86E159A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeOperating" xlink:label="loc_us-gaap_InterestIncomeOperating_457D5A463748DA14F3C4D39D86E137D4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_52EDD22D91B111D503C6D39D86DE474D" xlink:to="loc_us-gaap_InterestIncomeOperating_457D5A463748DA14F3C4D39D86E137D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_98E4BE720EDCF00179D9D39D86E1139D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_52EDD22D91B111D503C6D39D86DE474D" xlink:to="loc_us-gaap_InterestExpense_98E4BE720EDCF00179D9D39D86E1139D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_672883FDDF17A51766AAD39D86E1066D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_52EDD22D91B111D503C6D39D86DE474D" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_672883FDDF17A51766AAD39D86E1066D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_72554666F0A129B3ABD5D39D86E290A6" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/netLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_52EDD22D91B111D503C6D39D86DE474D" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_72554666F0A129B3ABD5D39D86E290A6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/GeographicAndSegmentInformationTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_95D91616589079C3B64849862518F22B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_AA536B9B047B80AFFBE4498625197FEC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_95D91616589079C3B64849862518F22B" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_AA536B9B047B80AFFBE4498625197FEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:label="loc_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_24C0676AA2CAF4FFFC41498625193CB0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_95D91616589079C3B64849862518F22B" xlink:to="loc_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_24C0676AA2CAF4FFFC41498625193CB0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_76E791946593A38DB43A4986257F13A5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_C501159513615F2E60D54986257F46AD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_76E791946593A38DB43A4986257F13A5" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_C501159513615F2E60D54986257F46AD" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_CE769D42C4D0717028ADC9632565D9E3" xlink:type="locator" />
    <link:loc xlink:href="apyx-20200630.xsd#apyx_CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards" xlink:label="loc_apyx_CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards_D3444904B1D6F119400DC9632565B602" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_CE769D42C4D0717028ADC9632565D9E3" xlink:to="loc_apyx_CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards_D3444904B1D6F119400DC9632565B602" xlink:type="arc" />
    <link:loc xlink:href="apyx-20200630.xsd#apyx_CARESActIncomeTaxExpenseBenefitRelatedToCurrentPeriodNetIncomeLossBeforeIncomeTaxes" xlink:label="loc_apyx_CARESActIncomeTaxExpenseBenefitRelatedToCurrentPeriodNetIncomeLossBeforeIncomeTaxes_5D8EECF4AE8D882152C0C96325657FAB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_CE769D42C4D0717028ADC9632565D9E3" xlink:to="loc_apyx_CARESActIncomeTaxExpenseBenefitRelatedToCurrentPeriodNetIncomeLossBeforeIncomeTaxes_5D8EECF4AE8D882152C0C96325657FAB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_5E56FD49F1E5B543DDEEC96325652108" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_CE769D42C4D0717028ADC9632565D9E3" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_5E56FD49F1E5B543DDEEC96325652108" xlink:type="arc" />
    <link:loc xlink:href="apyx-20200630.xsd#apyx_CARESActFederalIncomeTaxPaymentsAvailableToOffsetCurrentPeriodLosses" xlink:label="loc_apyx_CARESActFederalIncomeTaxPaymentsAvailableToOffsetCurrentPeriodLosses_8CD0E468E0959E488872C9632566E728" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_CE769D42C4D0717028ADC9632565D9E3" xlink:to="loc_apyx_CARESActFederalIncomeTaxPaymentsAvailableToOffsetCurrentPeriodLosses_8CD0E468E0959E488872C9632566E728" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1B847D785854FDEA3FFCC9632566C015" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_CE769D42C4D0717028ADC9632565D9E3" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1B847D785854FDEA3FFCC9632566C015" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_530A3A29EBC6735394B3C96325661AC5" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_CE769D42C4D0717028ADC9632565D9E3" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_530A3A29EBC6735394B3C96325661AC5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_5CA95DB7EDBC7D031E89C963256628DF" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_CE769D42C4D0717028ADC9632565D9E3" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_5CA95DB7EDBC7D031E89C963256628DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_9317083B106218A5C654C9632566926C" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_CE769D42C4D0717028ADC9632565D9E3" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_9317083B106218A5C654C9632566926C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_9304E77B719B828889A349862501FE31" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_12CDCC9593C2D88BC1EB498625026467" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9304E77B719B828889A349862501FE31" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_12CDCC9593C2D88BC1EB498625026467" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/IncomeTaxesUnrecognizedTaxBenefitsRollForwardDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_6C5F6BA51C3F4BB2671376CCC6CADA0B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_44F1FA90CE4031AB15AD76CCC6CAAB4A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6C5F6BA51C3F4BB2671376CCC6CADA0B" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_44F1FA90CE4031AB15AD76CCC6CAAB4A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_B7FD4E79AAFBA15F54A176CCC6CA54D3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_44F1FA90CE4031AB15AD76CCC6CAAB4A" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_B7FD4E79AAFBA15F54A176CCC6CA54D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_53272A7E64E06C815EB376CCC6CA58E3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_44F1FA90CE4031AB15AD76CCC6CAAB4A" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_53272A7E64E06C815EB376CCC6CA58E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_CB3794BB8627ACFFFFD176CCC6CB24B3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_44F1FA90CE4031AB15AD76CCC6CAAB4A" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_CB3794BB8627ACFFFFD176CCC6CB24B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_95A2FAFD5F36BF1F7B9976CCC6CB0728" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_44F1FA90CE4031AB15AD76CCC6CAAB4A" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_95A2FAFD5F36BF1F7B9976CCC6CB0728" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_3839066EC93AB9D2180B76CCC6CB4F4C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_44F1FA90CE4031AB15AD76CCC6CAAB4A" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_3839066EC93AB9D2180B76CCC6CB4F4C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/Inventories" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_0A080C14A935E82E9CA2498625C3058E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_B1008292689F2016F9B7498625C31442" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_0A080C14A935E82E9CA2498625C3058E" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_B1008292689F2016F9B7498625C31442" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/InventoriesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_DEE25ECFE13ACFA9B6D1BFB855515D2D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_us-gaap_InventoryRawMaterials_23CCB6E6AF4206A15318BFB8555144AD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_DEE25ECFE13ACFA9B6D1BFB855515D2D" xlink:to="loc_us-gaap_InventoryRawMaterials_23CCB6E6AF4206A15318BFB8555144AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaap_InventoryWorkInProcess_393A87D13DF36403147EBFB855561DC1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_DEE25ECFE13ACFA9B6D1BFB855515D2D" xlink:to="loc_us-gaap_InventoryWorkInProcess_393A87D13DF36403147EBFB855561DC1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaap_InventoryFinishedGoods_B35E56830978166A11EBBFB855569448" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_DEE25ECFE13ACFA9B6D1BFB855515D2D" xlink:to="loc_us-gaap_InventoryFinishedGoods_B35E56830978166A11EBBFB855569448" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryGross" xlink:label="loc_us-gaap_InventoryGross_523F4EE78F16E340681BBFB855565C27" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_DEE25ECFE13ACFA9B6D1BFB855515D2D" xlink:to="loc_us-gaap_InventoryGross_523F4EE78F16E340681BBFB855565C27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryValuationReserves" xlink:label="loc_us-gaap_InventoryValuationReserves_6C4497A3519795D3144CBFB855566E18" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_DEE25ECFE13ACFA9B6D1BFB855515D2D" xlink:to="loc_us-gaap_InventoryValuationReserves_6C4497A3519795D3144CBFB855566E18" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_EA3748D14CF375F99461BFB855568B55" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_DEE25ECFE13ACFA9B6D1BFB855515D2D" xlink:to="loc_us-gaap_InventoryNet_EA3748D14CF375F99461BFB855568B55" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/InventoriesInventoriesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_8AB5BB7E74DA856F8100BFB855513601" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="loc_us-gaap_InventoryWriteDown_F48C3F080A16E1489CC2BFC9BC01AD07" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_8AB5BB7E74DA856F8100BFB855513601" xlink:to="loc_us-gaap_InventoryWriteDown_F48C3F080A16E1489CC2BFC9BC01AD07" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/InventoriesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_11C485C4240C8BBC94E1498625C136E9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_51739B3A8D313639C250498625C12CAB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_11C485C4240C8BBC94E1498625C136E9" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_51739B3A8D313639C250498625C12CAB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/RecentAccountingPronouncements" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_D548B208E752067A273C498624E804A9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DescriptionOfNewAccountingPronouncementsNotYetAdopted" xlink:label="loc_us-gaap_DescriptionOfNewAccountingPronouncementsNotYetAdopted_7D6559BEC898DAD67774498624E90D5F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_D548B208E752067A273C498624E804A9" xlink:to="loc_us-gaap_DescriptionOfNewAccountingPronouncementsNotYetAdopted_7D6559BEC898DAD67774498624E90D5F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_84EC5D4F10D5668967A8498625C84DC9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_E970AB41AB66F17465B6498625C907C1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_84EC5D4F10D5668967A8498625C84DC9" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_E970AB41AB66F17465B6498625C907C1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_1CA4EC9EA3467798D86ABFB854ED03C5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7EF22884742C08857396BFB854EDDF97" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_1CA4EC9EA3467798D86ABFB854ED03C5" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7EF22884742C08857396BFB854EDDF97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_B870C914B84619014D3FBFB854EDD603" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7EF22884742C08857396BFB854EDDF97" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_B870C914B84619014D3FBFB854EDD603" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_BA3AE2F22A6D20D6C9E6BFB854EDE21B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_B870C914B84619014D3FBFB854EDD603" xlink:to="loc_us-gaap_RelatedPartyDomain_BA3AE2F22A6D20D6C9E6BFB854EDE21B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember" xlink:label="loc_srt_DirectorMember_67237E412EB4C4F98CBABFB854EDF5A8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_BA3AE2F22A6D20D6C9E6BFB854EDE21B" xlink:to="loc_srt_DirectorMember_67237E412EB4C4F98CBABFB854EDF5A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CoVenturerMember" xlink:label="loc_us-gaap_CoVenturerMember_F81C827CB6C123332640BFC0237AFB0A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_BA3AE2F22A6D20D6C9E6BFB854EDE21B" xlink:to="loc_us-gaap_CoVenturerMember_F81C827CB6C123332640BFC0237AFB0A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_E03EF95CFB414AD43D28BFB854ED1BE8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7EF22884742C08857396BFB854EDDF97" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_E03EF95CFB414AD43D28BFB854ED1BE8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_6715047C82CEA5F2DAFABFB854EDEE1E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_E03EF95CFB414AD43D28BFB854ED1BE8" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_6715047C82CEA5F2DAFABFB854EDEE1E" xlink:type="arc" />
    <link:loc xlink:href="apyx-20200630.xsd#apyx_BulgariaManufacturingPlantPurchaseMember" xlink:label="loc_apyx_BulgariaManufacturingPlantPurchaseMember_DBE958BA8BEC2213A00BBFB854EDA056" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_6715047C82CEA5F2DAFABFB854EDEE1E" xlink:to="loc_apyx_BulgariaManufacturingPlantPurchaseMember_DBE958BA8BEC2213A00BBFB854EDA056" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_6DAEF7B5862D9C5D402FBFB854ED5A3C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7EF22884742C08857396BFB854EDDF97" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_6DAEF7B5862D9C5D402FBFB854ED5A3C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent_F1ED917A9B1DB51F9E6CBFB854EDD077" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6DAEF7B5862D9C5D402FBFB854ED5A3C" xlink:to="loc_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent_F1ED917A9B1DB51F9E6CBFB854EDD077" xlink:type="arc" />
    <link:loc xlink:href="apyx-20200630.xsd#apyx_TermOfPaymentDueNotesPayableRelatedParties" xlink:label="loc_apyx_TermOfPaymentDueNotesPayableRelatedParties_2333DE9F064FD5347799BFB854EDF8EF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6DAEF7B5862D9C5D402FBFB854ED5A3C" xlink:to="loc_apyx_TermOfPaymentDueNotesPayableRelatedParties_2333DE9F064FD5347799BFB854EDF8EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:label="loc_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_300AC56CE9F4E2C49D85BFB854EDEF97" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6DAEF7B5862D9C5D402FBFB854ED5A3C" xlink:to="loc_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_300AC56CE9F4E2C49D85BFB854EDEF97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_B7BD730538EEF4D12454BFB854EDE062" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6DAEF7B5862D9C5D402FBFB854ED5A3C" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_B7BD730538EEF4D12454BFB854EDE062" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1B580709C6AEDF08A75A498625CD05D0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_C32E8A017D9C39AAE865498625CD6B80" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1B580709C6AEDF08A75A498625CD05D0" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_C32E8A017D9C39AAE865498625CD6B80" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/StockBasedCompensationFairValueAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B023799D2C54A7AAFA31498624FD7059" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_E5BC08CA1D394CBA6E04498624FDA9D3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B023799D2C54A7AAFA31498624FD7059" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_E5BC08CA1D394CBA6E04498624FDA9D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_77947CCC874266E0F3AB498624FE3432" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B023799D2C54A7AAFA31498624FD7059" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_77947CCC874266E0F3AB498624FE3432" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9C29B403A2099C5EA60C498624FEC06D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B023799D2C54A7AAFA31498624FD7059" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9C29B403A2099C5EA60C498624FEC06D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_D8553F4677604F38D0A0498624FE2739" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B023799D2C54A7AAFA31498624FD7059" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_D8553F4677604F38D0A0498624FE2739" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_E75E45A9D9D883B318BC498624FE117F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B023799D2C54A7AAFA31498624FD7059" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_E75E45A9D9D883B318BC498624FE117F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_63A8DCB40FEE06326E4FC4952937E30F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2C0462C637DC30D8E732C49529371BDA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_63A8DCB40FEE06326E4FC4952937E30F" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2C0462C637DC30D8E732C49529371BDA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_A8BDC8C1821F342A2E36C4952937DCE6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2C0462C637DC30D8E732C49529371BDA" xlink:to="loc_us-gaap_StatementClassOfStockAxis_A8BDC8C1821F342A2E36C4952937DCE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2EDB080F685A8F4A5C69C4952937DE04" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_A8BDC8C1821F342A2E36C4952937DCE6" xlink:to="loc_us-gaap_ClassOfStockDomain_2EDB080F685A8F4A5C69C4952937DE04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_A1A60A7E52571081A10FC4952937D6A5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_2EDB080F685A8F4A5C69C4952937DE04" xlink:to="loc_us-gaap_CommonStockMember_A1A60A7E52571081A10FC4952937D6A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57B22A52C27FFE4C63CBC495293F7A1A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2C0462C637DC30D8E732C49529371BDA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57B22A52C27FFE4C63CBC495293F7A1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_5A4C5108D3E50BF4C189C495293FE0C3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57B22A52C27FFE4C63CBC495293F7A1A" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_5A4C5108D3E50BF4C189C495293FE0C3" xlink:type="arc" />
    <link:loc xlink:href="apyx-20200630.xsd#apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived" xlink:label="loc_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived_082C903DA73DF4B5D6AFC495293F5168" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57B22A52C27FFE4C63CBC495293F7A1A" xlink:to="loc_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived_082C903DA73DF4B5D6AFC495293F5168" xlink:type="arc" />
    <link:loc xlink:href="apyx-20200630.xsd#apyx_StockIssuedDuringPeriodSharesStockSwaps" xlink:label="loc_apyx_StockIssuedDuringPeriodSharesStockSwaps_53733ECD8E2A5546D154C495293F9AD6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57B22A52C27FFE4C63CBC495293F7A1A" xlink:to="loc_apyx_StockIssuedDuringPeriodSharesStockSwaps_53733ECD8E2A5546D154C495293F9AD6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/StockBasedCompensationSummaryOfStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_AF6EFEE95DAC27C0C5E04986251CBEED" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9E458903919331DC45FD4986251CFA5C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_AF6EFEE95DAC27C0C5E04986251CBEED" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9E458903919331DC45FD4986251CFA5C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_D6AA3B8B25C3431016834986251D9070" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9E458903919331DC45FD4986251CFA5C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_D6AA3B8B25C3431016834986251D9070" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_E12C26D0EDFA50A28C144986251D969A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9E458903919331DC45FD4986251CFA5C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_E12C26D0EDFA50A28C144986251D969A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0B2F5519915D52F525404986251D3953" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9E458903919331DC45FD4986251CFA5C" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0B2F5519915D52F525404986251D3953" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_A524E3AE98B06BA51BDF4986251DDC83" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9E458903919331DC45FD4986251CFA5C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_A524E3AE98B06BA51BDF4986251DDC83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_A96F94ECC94FDC4F97B94986251D9172" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9E458903919331DC45FD4986251CFA5C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_A96F94ECC94FDC4F97B94986251D9172" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_93899BD1D5DBF8FBADF04986251EB0F2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_AF6EFEE95DAC27C0C5E04986251CBEED" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_93899BD1D5DBF8FBADF04986251EB0F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_78BDFB0D2D179167CE2A4986251ED947" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_93899BD1D5DBF8FBADF04986251EB0F2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_78BDFB0D2D179167CE2A4986251ED947" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_09538914603BABE549374986251EA0A0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_93899BD1D5DBF8FBADF04986251EB0F2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_09538914603BABE549374986251EA0A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_4E56E61A54730878EC634986251EDC19" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_93899BD1D5DBF8FBADF04986251EB0F2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_4E56E61A54730878EC634986251EDC19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_1CEFDEA8EC7E54403D3E4986251ECF90" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_93899BD1D5DBF8FBADF04986251EB0F2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_1CEFDEA8EC7E54403D3E4986251ECF90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2E888B0692B39F6D2B364986251EDC06" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_93899BD1D5DBF8FBADF04986251EB0F2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2E888B0692B39F6D2B364986251EDC06" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_62DA2FD9BC600926DD0F498624EBCA70" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_B93D49DC1FB749B32ACC498624EB56C9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_62DA2FD9BC600926DD0F498624EBCA70" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_B93D49DC1FB749B32ACC498624EB56C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_3649AADBB554C3A1FDD2498624EC0093" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_62DA2FD9BC600926DD0F498624EBCA70" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_3649AADBB554C3A1FDD2498624EC0093" xlink:type="arc" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>apyxmedicallogotagline.jpg
<DESCRIPTION>APYX LOGO
<TEXT>
begin 644 apyxmedicallogotagline.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" *0 _(# 2(  A$! Q$!_\0
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MG[CPEF'UO ^PD_>IZ?+I_E\AE%%%?&'VX5]*?LA^.-LFI^%+F3 ;_3;3<>_
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MVX9RCZ]6^LUE^[A^+[?+=_<?#<49S]0H?5J+_>3_  7?U>R^;->BBBOV<_$
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MK\\/$WA^Y\*^(-1TB['^D64[0L<8#8/##V(P1[&OR+B_ ^RQ$<7%:3T?JO\
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MR/R+C3'^TK0P47I'5^KV^Y?F%%%%?HI^:!1110 4444 %%%% !1110 4444
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M^G*+BY Z&9Q\H/\ NH?_ !\^E?3GB;Q!;>%?#^H:O>'%M9PM,PZ%L#A1[DX
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M\[****_FD_J **** /H[]C7_ )"7BG_KC;_^A25]15\N_L:_\A+Q3_UQM_\
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M6C7I.THO^OO.7%86GC*$\/65XR5OZ]#]+E99%5E(96&00<@BG5X+^R[\5/\
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MYJZ:L_F:4ZDJ,XU(.S3NO5'YJ7=K-8W4UM<1F*XA=HY(VZJP."#]"*BKV/\
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M<![#"O%36L]O1?YO]#\8XQS#ZQBHX2#]VGO_ (G_ )*WXA1117WI^?!1110
MUF"*68@*!DD]!7XE?M6_&)OCC\<?$/B**4R:3')]@TL9.!:Q$A&&>F\[I,=C
M(:_27]OCXR_\*F^ FI6EI/Y6N>)2=)M-K89(V7]_(._$>5R.C2(:_'ZOJ\EP
M]E*O+T7ZG@9E6NU27JPHHHKZ@\,**** "OV(_80^,O\ PMWX":7'>3^;KGAX
MC2;W<V6=44>3(<\G='M!)ZLCU^.]?3?_  3Y^,P^%GQVM=*O9_*T3Q0JZ9<;
MCA4GSFW<_P# R4]A*3VKR<SP_M\.[;QU._!5O95E?9Z'Z\4445\$?6!1110
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MC"/#3?O4_P GM]SO^!^+<89?]7Q:Q4%[M3?_ !+?[U9_>7****^Z/@ HHHH
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M/X/HG_H6?05X'7XYQ1FWUNO]4I/W(;^<O^!M]Y^U<*91]3H?6ZR]^:T\H_\
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M*^8/J0KW#]F/XJ?\(KX@_P"$<U&;;I.IR#R6<\0W!P ?8-PI]]OO7A]'2N_
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M,_9.#<O]CAI8R:UGHO1?YO\ )!1117Y^?H@5);V\EW<100HTLTC!$11DLQ.
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MK[B/[/H=F?EG_P .LOBO_P!#!X-_\#;O_P"1:/\ AUE\5_\ H8/!O_@;=_\
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M:<8'EN2=H]E;<O\ P&OO.O$?VJO W_"0>"8M;MTW7FCN6; Y:!\!_P CM;V
M:OD>)L#]<P+G%>]3U7IU_#7Y'V/"N8?4L>J<G[M3W7Z]']^GS/CVBBBOQ _=
MPHHHH ^V_P!G#QT?&7PYMH)Y-]_I1%G-D_,5 _=M^*\9[E37JM?$O[-OCC_A
M#_B-;VLTFRPU8"SER> Y/[IO^^OE^CFOMJOW;AW'_7L!'F?O0]U_+9_=^-S\
M!XER_P"H9A+E7NS]Y?/=?)_A8****^G/E3\]?B?_ ,E*\6_]A>[_ /1SUS-=
M-\3_ /DI7BW_ +"]W_Z.>N9K^:\5_O%3U?YG]/87_=Z?^%?D@HHHKF.H****
M "BBB@#J?!_Q0\3^!6']C:O<6T(.3:L?,A/K\C97\0 ?>O9O#/[8=U$J1Z_H
M,<_&&N-/D*'_ +X;()_X$*^<**]C"9OCL#I0JM+MNON9XV,R? 8_6O23?=:/
M[U^I]LZ-^TYX"U95\W4;C3)&Z)>VSC\RFY1^===8?%#PAJ2@VWB?27)_A:\C
M5O\ ODD'OZ5^?%%?34N,L9%6J4XR^]?JSY6MP5@I.]*I*/W/]$?I%#KFFW )
MBU"UE .#LF4X_6I/[4LO^?N#_OZO^-?FS17;_KK+KA__ ";_ (!P_P"H\.F(
M_P#)?_MC]&KGQ7HEGG[1K&GP8.#YETB\_B:P-1^-'@;2U+3>*--<#G_1YA/^
MB;J^!**QJ<:5W_#HI>K;_P C>GP1AU_$K2?HDO\ ,^Q=<_:R\&Z:&6PBO]7D
M_A,4/E(?J7((_P"^:\N\4_M;>)=55XM&L;71(VZ2-_I$P^A8!?\ QTUX717A
MXGB7,L0K<_*O[JM^._XGOX7A?*\*[^SYW_>=_P -OP-+7O$FJ^*+TW>K:A<:
MC<G_ ):7$A? ]!GH/8<5FT45\Q*4IMRD[MGU,8QA%1@K)!1114E!1110 ^&&
M2XF2*)&DE=@J(HR6).  /6ONSX(_#=?AKX)@M)U7^U;H_:+UASAR.$SZ*,#Z
MY/>O+/V:?@FUL;?QAKL&UR-^FVL@Y7/_ "V8?^@_GZ5]*5^M\+9.\/'Z[75I
M27NKLN_S_+U/Q[BS.HXF7U'#N\8OWGW?;T7Y^@4445^A'YP%%%% !1110 44
M44 %%%% 'R/^UIX)_L?Q;:>(;>/;;ZI'LFP.!.@ S_P)=O\ WRU>#U]Z_&SP
M5_PGGPYU2PCCWWL*_:K7CGS4YP/=AN7_ (%7P57XCQ1@?JF.=2*]VIK\^OXZ
M_,_=N%<?]<R]4Y/WJ>GRZ?AI\@HHHKY ^R"BBB@ KZY_9-\%_P!C^#[KQ!/'
MBYU63;$6'(A0D#\VW?DM?+'AK0;GQ1X@T[2+09N+V=84.,A<G!8^P&2?85^B
M&BZ3;Z#I-EIMHFRULX4@B7_94 #\>*_0.$,#[7$2Q<EI#1>K_P E^9^=\98[
MV.&AA(O6>K]%_F_R+U%%%?KI^-A1110 4444 %%%% !1110 4444 %%%<!\:
M/B9%\,_!TUVC*VJ7.8+&(\YDQRY']U1R?P'>N?$5Z>%I2K57:,5=G3AL/4Q=
M:-"DKRD[(\:_:H^*AO+H>#M-F_T>$K)J#H?OR=5B^B\,??']VOG.I+FXEO+B
M6>>1III6+O(YRS,3DDGN2:CK^?<RQU3,<3+$5.NR[+HC^B\MR^GEF%CAJ?3=
M]WU?]= HHHKS#U K;\%^$;[QSXFL=%T],SW+X+XRL:#EG/L!D_I6)7V/^S3\
M+/\ A#?#/]N7\.W6-4C#*&'S0P'E5]BW#'_@([5[N2Y;+-,4J7V5K)^7^;V/
M SO-(Y5A'5^V](KS_P EO^!ZEX5\-67@_P /6.CZ?'Y=I:1B-<]6/4L?<G)/
MN:UZ**_?80C3BH05DM$?SS.<JDG.;NWJPHHHJR HHHH **** /)/VB?A;_PG
MWA,WUC%OUK3%:6$*/FFCZO'[GN/<8[U\55^F%?&W[2WPM_X0SQ-_;=A#LT?5
M7+%5'RPS]67V#?>'_ AVK\RXLRFZ_M"DO*7Z/]'\C]3X/S>S_LZL_./ZK]5\
MSQBBBBOR\_50IT4KP2))&[1R(0RNIP5(Z$'L:;10!]U? WXG)\3/!\<L[J-8
MLML-['TRV/ED ]& )^H8=J]&KX ^%/Q"N/AIXPM=5CW26C?NKR!3_K8B>1]1
MPP]Q]:^]=-U"WU;3[:^LY5GM+B-98I4.0RL,@C\*_<N'<U_M+#<E1_O(:/S[
M/_/S/P7B3*/[,Q7/37[N>J\NZ_R\BU1117U9\B%%%% !1110 4444 %%%% !
M7Q+^TEXX_P"$P^(UQ:PR;[#20;.+!X+@_O6_[Z^7Z(*^J?BUXV7X?^ ]4U8,
M!=!/)M5/>9N%_+EC[*:^ G=I'9W8L[')9CDDU^;<88_EA#!0>^K].B^_7Y(_
M3^"\OYISQTUM[L?7J_NT^;&T445^5GZR%%%;W@/PI/XW\7Z5HD&0;N8([C^"
M,<NWX*"?PK2G3E5G&G!7;=E\S.I4C1A*I-V25WZ(^H_V5? __"/^")=<N(]M
MWK#[DW#!6!"0GYG<WN"M>WU7L;&#3;*WL[:,16]O&L44:]%50 !^ %6*_HK
M82.!PT,/'[*_'J_FS^:\PQDL?BJF)G]I_AT7R04445WGGA1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !5>^L8-2LKBSN8Q+;W$;12QMT96
M!!'X@U8HI-)JS&FXNZ/SM\>>%)_!'B_5=$GR3:3%$<_QQGE&_%2#^-8-?3G[
M7G@?S(--\5VZ?-'_ *%=D?W228V/T.X?BM?,=?SWF^!>7XV=#INO1[?Y']'9
M/CUF6!IXCKL_5;_Y_,****\<]D<CM&ZNC%74Y#*<$&OOWX2^-E^('@/2]6+
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M/#1J_"M?=EOUZ=SY>HKZA_X8UL_^AIG_ / )?_BZ/^&-;/\ Z&F?_P  E_\
MBZ\[_5C-?^?7_DT?\ST_]:LH_P"?O_DLO\CY>KZI_93^&,^CV=QXLU& Q37D
M?DV*.,,(<Y:3'^T0,>P)Z$5T_@O]F'PCX5NH[N[$VNW2'*_;<>2I]?+ P?\
M@1(KU_IP.!7UV1<-5,'66*Q;5ULEKKW?Z?>?&Y_Q/3QE!X3!IV>[>FG9?K?T
ML+1117Z*?FH4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% &/XN\-6WC#PSJ6BW?\ J+R%HBV,E#U5A[A@"/I7Y^^*O"^H>#=>
MN](U2 P7=NVUA_"P[,I[J1R#7Z-5R_CCX;>'_B)9I;ZW8K.T8(BN$.R:+/\
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MX'Z]CX1DO=C[S^7^;LCYKB+'_P!GY?.47[TO=7J_\E=GME%%%?O1_/@4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MHK[H^ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 ?GK\3_^2E>+?^PO=_\ HYZY
MFNF^)_\ R4KQ;_V%[O\ ]'/7,U_->*_WBIZO\S^GL+_N]/\ PK\D%%%%<QU'
MH7[/W_)8O#7_ %VD_P#13U]W5\(_L_?\EB\-?]=I/_13U]W5^P<&_P"XU/\
M&_R1^,\;?[_3_P "_-A1117WI^>A1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 5\-_M)?\EJ\1?\ ;M_Z315]R5\-_M)?\EJ\1?\
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MBBOK#Y **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /SU^
M)_\ R4KQ;_V%[O\ ]'/7,U^AUU\.O"E]=37%SX8T:XN)G,DDTNGQ,[L3DL25
MR23R2:B_X5AX._Z%+0__  6P_P#Q-?EE;@^O4J2FJJU;>S/UFCQIAZ=*--T7
MHDMUT/SVHK]"?^%8>#O^A2T/_P %L/\ \31_PK#P=_T*6A_^"V'_ .)K'_4S
M$?\ /Y?<S;_7?#_\^9?>CXX_9^_Y+%X:_P"NTG_HIZ^[JP-/\!>&-)O(KNQ\
M.:397<1S'/;V,4<B'&.&"@C@UOU]MD>5SRG#RHSDI-N^GHE^A\+GV;0SC$1K
M4XN*4;:^K?ZA1117T9\T%%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !7PW^TE_P EJ\1?]NW_ *315]R5@ZEX%\-:S>R7FH>'M*OK
MN3&^XN;**21\  98J2<  ?A7SV>99/-<-&A"2BU)/7T:_4^DR'-891B95ZD7
M).+6GJG^A^=M%?H9'\-O",#;X_"VBQM_>33H0?\ T&I_^$$\-#D>'M*'_;E%
M_P#$U\2N"ZW6LON9]R^-Z'2@_O1^=E36MC<7S[+:WEN&_NQ(6/Z5^C,/A[2K
M=MT6FV<;8QN2! ?Y5?55C554!548  P *WCP4_M5_P#R7_@F$N.%]C#_ /DW
M_P!J?GWI?PJ\8ZR5^R>&=4=6Z2/;-&A_X$P _6N\\/\ [*?C35F4W_V/1HOX
MO/F$CX]E3(S]2*^RJ*]2AP?@J;O5G*7X+_/\3R:_&F.J*U*$8_>W_E^!XIX,
M_95\+>'V2?5Y9O$%TO.V;]U #_N Y/XL1[5[+:6<&GVL=M:P1VUO$NU(H4"(
M@'0 #@"IJ*^MPN!PV!CRX>"C^?S>[/C\7F&*Q\N?$U'+\ODMD%%%%=YYX444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 ?FW\5O^"DGQ,\"_%'QCX;L-#\)S6.CZS>:=;R7-I<M*T<,
M[QJ7(N "Q"C)  SV%<O_ ,/3?BO_ -"_X-_\ KO_ .2:^>?VBO\ DX+XG?\
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MO':^]HX'#2I1;@KV1\I4Q593DE+J?8__  ]-^*__ $+_ (-_\ KO_P"2:/\
MAZ;\5_\ H7_!O_@%=_\ R37QQ16WU#"_\^T9?6Z_\[/L?_AZ;\5_^A?\&_\
M@%=__)-3V?\ P50^)L<V;OPSX3GC_NPV]U&?S,[?RKXQHH_L_"_\^T'UNO\
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MB5%,L3'WRC(/^NAKLS/#JM0<K:QU_P SGP-9TJJ71Z'ZVT445\&?5A7YZ_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 ?A;^T5_R<%\3O\ L9]4_P#2N6O/J]!_:*_Y."^)
MW_8SZI_Z5RUY]7Z;1_AQ]$?$5/CEZA0K%&#*2K Y!'45[S\1/@BMK^RK\*OB
MAID&%NC>Z7J^Q?XQ?7)@F/U4&,D_W8QWKP:G3J1JIN/1M?<*<'!I/R?WG[4_
MLA_&@?'+X':)K5S/Y^N6:_V=JN?O&XC !<_[ZE'^KD=J]JK\G?\ @G+\;/\
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MN<8RQ4$U=K.\._\ (OZ7_P!>L7_H K1K\Y>Y]DM@HHHI#/Q._;&_Y.<^(O\
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M_>:GJSZS"_P8>@4445Q'2?B=^V-_R<Y\1?\ L*-_Z"M>.U[%^V-_R<Y\1?\
ML*-_Z"M>.U^EX?\ @P]%^1\56_B2]6?IG^P/\"_A[X^_9[L]6\1^#-%UO4VU
M&ZC-W?6:2R%58;1DCH*^C/\ AE?X/_\ 1-?#/_@MC_PKRS_@FQ_R;#8_]A2[
M_P#0A7U/7PV,K5(XBHE)[OJ?48:G!T8-Q6QY7_PRO\'_ /HFOAG_ ,%L?^%'
M_#*_P?\ ^B:^&?\ P6Q_X5ZI17)[>K_._O9T>RI_RK[CRO\ X97^#_\ T37P
MS_X+8_\ "C_AE?X/_P#1-?#/_@MC_P *]4HH]O5_G?WL/94_Y5]PR&%+>%(H
MU"1HH5548  ' I]%%8&H4444 ?B=^V-_R<Y\1?\ L*-_Z"M>.U[%^V-_R<Y\
M1?\ L*-_Z"M>.U^EX?\ @P]%^1\56_B2]6?K9_P38_Y-AL?^PI=_^A"OJ>OE
MC_@FQ_R;#8_]A2[_ /0A7U/7P.-_WFIZL^LPO\&'H%%%%<1TA7!?'ZZ>P^!/
MQ'N8PIDA\-ZE(H;H2+60C/Y5WM>/?M?:RNA?LR_$:Y=MHDTF2USG',Q$('YR
M 5M17-5BO-&=1VA)^1^)M%%:?A72SKGBC1]."AS>7D-OM.<'>X7''/?M7Z8W
M97/B?(_?BQM%L;&WMD8LD,:QJS=2 ,<_E5BBBORT^Z"OSU_X*T_\TJ_[BO\
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M_!AZ+\CXJM_$EZL_6S_@FQ_R;#8_]A2[_P#0A7U/7RQ_P38_Y-AL?^PI=_\
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M*7D89X!VJ0,]R.O2OT>4HTH-O1(^,BG.5ENSSNBOTZ_X=4_#[_H;O$WYV_\
M\:H_X=4_#[_H;O$WYV__ ,:KRO[6PO=_<>A_9]?M^)^8M%?IU_PZI^'W_0W>
M)OSM_P#XU1_PZI^'W_0W>)OSM_\ XU1_:V%[O[@_L^OV_$_,6BOTZ_X=4_#[
M_H;O$WYV_P#\:KX]_;"_9M@_9K^(&G:5IM[=:GHFI6(NK:ZO OF;PQ62,[0
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MJ]!_:*_Y."^)W_8SZI_Z5RUY]7Z;1_AQ]$?$5/CEZG[&_P#!/_\ Y-&\!_\
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M,E9:16W^9]/A,*L/&[^)A1117E'>%?GK_P %:?\ FE7_ '%?_;.OT*K\]?\
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MOP-:I.LHRDVC[9HHHKXT^D"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M6*W\[^]A[&G_ "K[CQO_ (8[^"W_ $3K1O\ OVW_ ,51_P ,=_!;_HG6C?\
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M?C-XLC\-^%=9N+[5I(7G6*2PFA&Q!ECN90.]>T5^2/\ P39_Y.>L?^P7=_\
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MUYHHHKQ3TPHHHH XWXT?\D=\=_\ 8!O_ /TG>OP>K]X?C1_R1WQW_P!@&_\
M_2=Z_!ZOK<D^"?JCY_-/BB?L;_P3_P#^31O ?_;_ /\ I?<U]#5\\_\ !/\
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MPG5]E9IGVS1117DGH!17Y'_&#]N[XHWWQ0\42>$_&5QIOAI;^6/3K>&W@91
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MW8[_ '>7]=3Y(_8Y_P"3G/AU_P!A1?\ T%J_;&OQ._8Y_P"3G/AU_P!A1?\
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MY;:?BSBI<F)Q#G5>G]61[5I_["OP.L=)-A_P@MO<(R@--<7=PTS>^_S,J?\
M=P*^-?VT/V%[7X-Z$_C?P-+<S^&(Y%2_TVY?S)+'<0JR*_5HRQ"D'YE)!R03
MM^T/^&XO@;_T4"S_ / 6Y_\ C5<O\4/VN/@5XY^&_BGP])XZL;@:IIEQ:",V
MMP,L\;*N#Y?!R00>Q&:\+#U<=2J*4E)KK=,]2M3PM2#2<4^FQ^:7[.OQFO\
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M*G_DL7BW_L G_P!*(J^8_CK\3I/C)\7/%'C)HF@35+LO!"_WD@11'"K>XC1
M<=P:^G/^"5/_ "6+Q;_V 3_Z415]MB(.GE[@]U%?H?+T9*IC.9;-L_3VO*/V
MI/A;_P +A^!/BSPY%%YNH-:F[L /O?:8CYD8'IN*[#[.:]7HKXFG-TY*<=T?
M42BIQ<7LS^>^&:6SN(Y8G:&:)@Z.IPRL#D$>A!K]6?CG^TE%>_L)Q^,[6X5-
M4\5Z=%I2>6P&VZE!CNE7'0H$N,8_NCI7P=^V5\+?^%2_M#>*-,AB$.F7TO\
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M&T"-;A&UO0;>/2M2M=PWHT:[8Y"/1T56SC&=X_A-?0%<-7-,52J2IR2T\O\
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MGZ5^.=FL+7<"W+,EN742,G4+GDCWQFNG)J,.259K6]C#,JLN94UMN>P_"?\
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MJ<.(_P!]^:_0_9^BBBOBCZ8_&_\ ;^_Y.Y\>?]N'_I!;5[M_P2=_Y&#XC_\
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M^\T_5?F<V)_@S]&?D%7]"=?SV5_0G7NYY_R[^?Z'EY7]OY?J%?C1^W)\*_\
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ML1/$=TO^#^AX$J[J48T>W](_2_\ X)?_  L/AOX6ZUXVNX=EUXBNO(MF8?\
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M:XN/ %K'(3G;:7MU;)_WS%*J_I7:_#O]GOX;_"BX%UX4\'Z9I-X 5%X(S+<
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M/4_$;G6+C<,$(X A7Z>4J-]7-?2=06=G#I]G!:VT206\"+%%%&,*B@8"@=@
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MO4KGQ#K=S=ZE>:A.YEU&Z+.9I %+#<>I 9.!T!7H,5[=^P#_ ,G<^ _^W_\
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M=P=_D>-_9M5.RDK'Y$7?PC\3Z=\+8?B#>Z=)9>&KG48],M)[@%&NI'CED+1
MCYD41$%NF2 ,X;"?!?\ Y+%X$_[#UC_Z4)7Z&_\ !4[4;6S^"'A/25VQS3>(
M(YX8U  \N*VG5L#T!E3\Z_/WX!Z?)JWQS^'EG'G=-XAT]<@9VC[0F3CV&3^%
M>CA\0\3AY59*VYQUJ*HUE33OL?NQ1117Y^?7!1110!QOQH_Y([X[_P"P#?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !7RC^U]^V]8_ 2:/PWX7CM-
M;\:LR27$4^6M[&+(.)=I!+N.B @@'<<?*&^KJ^"?VI/^"<]SXNU[4_%_PVO(
MQJ%]*]U>:%J$Q42RL2S-#*W +$YV/@#)PP&!7H8&.'E57UAZ?A\SCQ3K*G^Y
M6IZ[\'_^"@'PL^)&D0'6=7C\%ZV$'GV.KMLBW8Y,<^-C+Z9*M[5W'BW]KSX.
M>#=/DN[OXA:'?!5R(=)NEOI7/.%"P[N3CO@#(R0*_(CQ1\!/B/X,NVM]9\#:
M_9.&VASI\CQL?]F105;H>A-86E?#_P 4Z],(M-\-:OJ,I.T1VMA+*Q.,XPJF
MO?>4X63YHST]4>2LPKQ7+*.IZA^UG^TI=?M*?$*/4X[:73O#NFQM;:78S$%U
M4G+ROCC>Y"Y . %49.,GTO\ X)N?!JZ\<?&<>,;F%AH?A9&E\Q@=LMW(A6)!
M_NAFD/IM7/WJS?@I_P $\/B3\2+^WN?$UHW@;P_N!EFU!?\ 3'7NL<&=P/O)
MM'.>>E?I_P#"WX7^'O@YX*L/"WABS^QZ7: G+MNDF<_>DD;^)V/4_0    3C
M<91P]#ZMAW=[>B_S'AL/4K5?;5EYG6T445\D?0A1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>a2020q210-q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:apyx="http://apyxmedical.com/20200630"
  xmlns:country="http://xbrl.sec.gov/country/2020-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="apyx-20200630.xsd" xlink:type="simple"/>
    <context id="FD2020Q2YTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="I2020Q3Aug6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
        </entity>
        <period>
            <instant>2020-08-06</instant>
        </period>
    </context>
    <context id="FI2020Q2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q2QTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FI2020Q1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2018Q4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_OptionOnSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:OptionOnSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_OptionOnSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:OptionOnSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_OptionOnSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:OptionOnSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_OptionOnSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:OptionOnSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="D2020Q3July2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_CorporateJointVentureMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_us-gaap_UnfavorableRegulatoryActionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:UnfavorableRegulatoryActionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_CorporateJointVentureMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_RelatedPartyTransactionAxis_apyx_BulgariaManufacturingPlantPurchaseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">apyx:BulgariaManufacturingPlantPurchaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_CoVenturerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CoVenturerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_CoVenturerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CoVenturerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_RelatedPartyTransactionAxis_apyx_BulgariaManufacturingPlantPurchaseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">apyx:BulgariaManufacturingPlantPurchaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_AdvancedEnergyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">apyx:AdvancedEnergyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_OEMMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">apyx:OEMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_AdvancedEnergyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">apyx:AdvancedEnergyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_OEMMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">apyx:OEMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_AdvancedEnergyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">apyx:AdvancedEnergyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_OEMMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">apyx:OEMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_OEMMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">apyx:OEMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_AdvancedEnergyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">apyx:AdvancedEnergyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="segment">
        <measure>apyx:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <apyx:ProvisionForObsolescenceInventory
      contextRef="FI2019Q4"
      decimals="-3"
      id="Fact-5ECD63DD2118AF18390B4985F0B07CC2-wk-Fact-5ECD63DD2118AF18390B4985F0B07CC2"
      unitRef="usd">392000</apyx:ProvisionForObsolescenceInventory>
    <apyx:ProvisionForObsolescenceInventory
      contextRef="FI2020Q2"
      decimals="-3"
      id="Fact-9B3CE0C950A00936F6194985F0AD89C3-wk-Fact-9B3CE0C950A00936F6194985F0AD89C3"
      unitRef="usd">685000</apyx:ProvisionForObsolescenceInventory>
    <dei:AmendmentFlag
      contextRef="FD2020Q2YTD"
      id="Fact-F0C70F9764034FC3DC504985F0DA06A1-wk-Fact-F0C70F9764034FC3DC504985F0DA06A1">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="FD2020Q2YTD"
      id="Fact-90E209854C62197BAEC44985F0DAD91F-wk-Fact-90E209854C62197BAEC44985F0DAD91F">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus
      contextRef="FD2020Q2YTD"
      id="Fact-8B1E51C3236E8F6E661E4985F0DCC3AC-wk-Fact-8B1E51C3236E8F6E661E4985F0DCC3AC">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus
      contextRef="FD2020Q2YTD"
      id="Fact-46F5AE107DEB829B9E884985F0DC91E8-wk-Fact-46F5AE107DEB829B9E884985F0DC91E8">2020</dei:DocumentFiscalYearFocus>
    <dei:EntityCentralIndexKey
      contextRef="FD2020Q2YTD"
      id="Fact-822DAC247BDEA6259BD14985F0DB5E1A-wk-Fact-822DAC247BDEA6259BD14985F0DB5E1A">0000719135</dei:EntityCentralIndexKey>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="FI2019Q4"
      decimals="-3"
      id="Fact-51DAD60546736DEB66984985F0AC4190-wk-Fact-51DAD60546736DEB66984985F0AC4190"
      unitRef="usd">4403000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="FI2020Q2"
      decimals="-3"
      id="Fact-11CA0366799B816F17A94985F0B687C7-wk-Fact-11CA0366799B816F17A94985F0B687C7"
      unitRef="usd">4702000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="FI2019Q4"
      decimals="-3"
      id="Fact-7460CD3B49194A842FB44985F0AFC046-wk-Fact-7460CD3B49194A842FB44985F0AFC046"
      unitRef="usd">273000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="FI2020Q2"
      decimals="-3"
      id="Fact-19EF9DA7BC975CD2C3D24985F0ADCC3E-wk-Fact-19EF9DA7BC975CD2C3D24985F0ADCC3E"
      unitRef="usd">760000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="FI2019Q4"
      decimals="INF"
      id="Fact-82790553536200EE48FA4985F0ADC041-wk-Fact-82790553536200EE48FA4985F0ADC041"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="FI2020Q2"
      decimals="INF"
      id="Fact-BF1E05C099789CF9865C4985F0ABECD2-wk-Fact-BF1E05C099789CF9865C4985F0ABECD2"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="FI2019Q4"
      decimals="INF"
      id="Fact-62775AC1D1638F990FF34985F0AF631A-wk-Fact-62775AC1D1638F990FF34985F0AF631A"
      unitRef="shares">75000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="FI2020Q2"
      decimals="INF"
      id="Fact-589B2297F1386F1DA1824985F0AF8C4D-wk-Fact-589B2297F1386F1DA1824985F0AF8C4D"
      unitRef="shares">75000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="FI2019Q4"
      decimals="INF"
      id="Fact-AE28C33B6FC7C733F3004985F0B7199F-wk-Fact-AE28C33B6FC7C733F3004985F0B7199F"
      unitRef="shares">34312257</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="FI2020Q2"
      decimals="INF"
      id="Fact-5C868BB1E9A90A464D4C4985F0AD5E5F-wk-Fact-5C868BB1E9A90A464D4C4985F0AD5E5F"
      unitRef="shares">34201895</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="FI2019Q4"
      decimals="INF"
      id="Fact-259C5ED017F87704646F4985F0B6ECEB-wk-Fact-259C5ED017F87704646F4985F0B6ECEB"
      unitRef="shares">34169952</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="FI2020Q2"
      decimals="INF"
      id="Fact-DF7CB262F9E35028F74F4985F0AC0FAD-wk-Fact-DF7CB262F9E35028F74F4985F0AC0FAD"
      unitRef="shares">34201895</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:InventoryWriteDown
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="Fact-A4241150829A98825E5DA6ABE23C29F1-wk-Fact-A4241150829A98825E5DA6ABE23C29F1"
      unitRef="usd">400000</us-gaap:InventoryWriteDown>
    <dei:DocumentType
      contextRef="FD2020Q2YTD"
      id="d5109e580-wk-Fact-9179CEA2955ADBF12F297728FE672348">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="FD2020Q2YTD"
      id="d5109e598-wk-Fact-4B27118DD5942D0825EFC48E2CB8787E">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="FD2020Q2YTD"
      id="d5109e624-wk-Fact-2145A9DEF0A353987D99C92B0FD78AFE">2020-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="FD2020Q2YTD"
      id="d5109e678-wk-Fact-9EF261A72565E3AEF6F4C48E5DE5D739">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="FD2020Q2YTD"
      id="d5109e720-wk-Fact-204720997DD4E56C574FC4900F74AA45">0-12183</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="FD2020Q2YTD"
      id="d5109e738-wk-Fact-122175ACAF03BC281D8AC969D865ADDD">APYX MEDICAL CORPORATION</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="FD2020Q2YTD"
      id="d5109e759-wk-Fact-CC8F16BD50B8227254B6772888AA314D">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="FD2020Q2YTD"
      id="d5109e769-wk-Fact-2F5C3F8A156F81099C9F7728BFB8D572">11-2644611</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="FD2020Q2YTD"
      id="d5109e794-wk-Fact-8F688F6E988D36978E6D7724B8E2B94A">5115 Ulmerton Road,</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="FD2020Q2YTD"
      id="d5109e799-wk-Fact-7BDA3497E63364457B537724FAAF6AAE">Clearwater</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="FD2020Q2YTD"
      id="d5109e804-wk-Fact-0E96182F7336F330688677253CC99136">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="FD2020Q2YTD"
      id="d5109e809-wk-Fact-7CD6D30472B4611A0D8C7725844E6658">33760</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="FD2020Q2YTD"
      id="d5109e820-wk-Fact-0D00A11A229F28C2FC597725D4E88365">727</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="FD2020Q2YTD"
      id="d5109e825-wk-Fact-9E63D00C81C464B797387726143FF4E4">384-2323</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="FD2020Q2YTD"
      id="d5109e866-wk-Fact-AE1794C98241BCE73EC977267EBB41DD">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="FD2020Q2YTD"
      id="d5109e871-wk-Fact-68364D9D96A01005D0077726C570AAAF">APYX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="FD2020Q2YTD"
      id="d5109e876-wk-Fact-A8933179D8AD0AAD8F0F772732FF3B1E">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="FD2020Q2YTD"
      id="d5109e883-wk-Fact-5CC8D06DA321AB9105C2772AEC1580D3">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="FD2020Q2YTD"
      id="d5109e897-wk-Fact-1AB592FFE6DC253CE9DD772B59D2A0B1">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="FD2020Q2YTD"
      id="d5109e941-wk-Fact-593FAF9851A22EA1778F772BC3724D9D">Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="FD2020Q2YTD"
      id="d5109e972-wk-Fact-3890BFBD93B5954A977377237B9827A6">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="FD2020Q2YTD"
      id="d5109e998-wk-Fact-F65ADC9CC0A11BD45E277723AE6C90C1">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="FD2020Q2YTD"
      id="d5109e1029-wk-Fact-B13D68557E584DD4C0597723EE507E18">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="I2020Q3Aug6"
      decimals="INF"
      id="d5109e1041-wk-Fact-88ED02F3F8152B3C62C6C63A082BDFE1"
      unitRef="shares">34216349</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2020Q2"
      decimals="-3"
      id="d33059e726-wk-Fact-02702598E6B173AB9753496B24B0061C"
      unitRef="usd">46156000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2019Q4"
      decimals="-3"
      id="d33059e745-wk-Fact-AF2FDE526FA8D3440A64496B24AB2685"
      unitRef="usd">58812000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="FI2020Q2"
      decimals="-3"
      id="d33059e760-wk-Fact-2FA617CD8C672D75113C496B24A7320C"
      unitRef="usd">6306000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d33059e779-wk-Fact-1CF40BA218015A80807E496B24AF5343"
      unitRef="usd">7987000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:IncomeTaxesReceivable
      contextRef="FI2020Q2"
      decimals="-3"
      id="d33059e799-wk-Fact-FE4318780EDE67A6C48C4985F0A988C1"
      unitRef="usd">6443000</us-gaap:IncomeTaxesReceivable>
    <us-gaap:IncomeTaxesReceivable
      contextRef="FI2019Q4"
      decimals="-3"
      id="d33059e818-wk-Fact-EFF263703BB25D312B834985F0AD2662"
      unitRef="usd">426000</us-gaap:IncomeTaxesReceivable>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="FI2020Q2"
      decimals="-3"
      id="d33059e838-wk-Fact-48D81FFD93457E05087D496B24ACC76E"
      unitRef="usd">1671000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d33059e857-wk-Fact-80488B4F378AD38DA903496B24AB5D70"
      unitRef="usd">1233000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:InventoryNet
      contextRef="FI2020Q2"
      decimals="-3"
      id="d33059e877-wk-Fact-2A22C0C0830CFBCD3D83496B24B26D14"
      unitRef="usd">5257000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="FI2019Q4"
      decimals="-3"
      id="d33059e896-wk-Fact-61A8AEC690F00F8AA7C1496B24A74F60"
      unitRef="usd">5068000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="FI2020Q2"
      decimals="-3"
      id="d33059e916-wk-Fact-CA59FE51CB032867F417496B24A6DE95"
      unitRef="usd">4008000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d33059e935-wk-Fact-B63FC252216E8273EB2F496B24B028D0"
      unitRef="usd">3207000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="FI2020Q2"
      decimals="-3"
      id="d33059e955-wk-Fact-4801B580ED3B3467CDAE496B24A9DA66"
      unitRef="usd">69841000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d33059e974-wk-Fact-1C99E09599A59806D00C496B24A1B620"
      unitRef="usd">76733000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2020Q2"
      decimals="-3"
      id="d33059e994-wk-Fact-979E84BC4453F65B4181496B24A8B0C7"
      unitRef="usd">6440000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2019Q4"
      decimals="-3"
      id="d33059e1013-wk-Fact-8797C551C22E1D8DDA41496B24A3A007"
      unitRef="usd">6618000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="FI2020Q2"
      decimals="-3"
      id="d33059e1034-wk-Fact-7DAEE34B0C9F713CDB0A496B24A4CD42"
      unitRef="usd">295000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="FI2019Q4"
      decimals="-3"
      id="d33059e1053-wk-Fact-EDFAF2D6D19F5E8B2C8F4985F0B82607"
      unitRef="usd">350000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="FI2020Q2"
      decimals="-3"
      id="d33059e1073-wk-Fact-811CF0FE9D3C195B98B0496B24A37B0E"
      unitRef="usd">691000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="FI2019Q4"
      decimals="-3"
      id="d33059e1092-wk-Fact-BF32F7AFE7C13B937D2C4985F0B6298B"
      unitRef="usd">653000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="FI2020Q2"
      decimals="-3"
      id="d33059e1112-wk-Fact-A35F4AFBAE67081420DE496B24B2A988"
      unitRef="usd">560000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d33059e1131-wk-Fact-57A46AB3892D183F3278496B24AC9DC7"
      unitRef="usd">391000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="FI2020Q2"
      decimals="-3"
      id="d33059e1156-wk-Fact-8C42496759915C5DA730496B24B2CC16"
      unitRef="usd">77827000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="FI2019Q4"
      decimals="-3"
      id="d33059e1175-wk-Fact-C8CDCCA60A61246FAA19496B24A43561"
      unitRef="usd">84745000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="FI2020Q2"
      decimals="-3"
      id="d33059e1318-wk-Fact-ACE7672888B76DDD62F1496B24AD0D39"
      unitRef="usd">2206000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d33059e1337-wk-Fact-DC10BD8ABD9CD75E4105496B24A6570A"
      unitRef="usd">2438000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="FI2020Q2"
      decimals="-3"
      id="d33059e1352-wk-Fact-E97C2C9BB55F7862D582496B24A591F2"
      unitRef="usd">6911000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d33059e1371-wk-Fact-AFAF8A0F159C9EA96842496B24A3652D"
      unitRef="usd">9396000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="FI2020Q2"
      decimals="-3"
      id="d33059e1391-wk-Fact-30A7CFE419C44D5FD56A496B24ABABA1"
      unitRef="usd">112000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d33059e1410-wk-Fact-A767E6C2003ED31BF5954985F0B66289"
      unitRef="usd">108000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="FI2020Q2"
      decimals="-3"
      id="d33059e1430-wk-Fact-A6BAFD688EEAE9B09570496B24ABBFEC"
      unitRef="usd">266000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d33059e1449-wk-Fact-A1D67908A1CE6BC2B5D34985F0BB223B"
      unitRef="usd">229000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="FI2020Q2"
      decimals="-3"
      id="d33059e1470-wk-Fact-48B2E4B51FF912FF1A474985F0B93F90"
      unitRef="usd">140000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d33059e1489-wk-Fact-78620A5CBC161809A70A4985F0BC526D"
      unitRef="usd">140000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="FI2020Q2"
      decimals="-3"
      id="d33059e1509-wk-Fact-3F3CED2C7E5A59BE718F4985F0AB87CB"
      unitRef="usd">9635000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d33059e1528-wk-Fact-A56BE3898FD4F2EA730B496B24AA5332"
      unitRef="usd">12311000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="FI2020Q2"
      decimals="-3"
      id="d33059e1548-wk-Fact-9CB200CF8683ECC7448B496B24A9D980"
      unitRef="usd">177000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d33059e1567-wk-Fact-77F78617A601E4EC5AD74985F0C33487"
      unitRef="usd">235000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="FI2020Q2"
      decimals="-3"
      id="d33059e1587-wk-Fact-DB1C2CE9B6526A550E07496B24B18BDA"
      unitRef="usd">414000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d33059e1606-wk-Fact-0041F9AE7410258270F14985F0B5F358"
      unitRef="usd">421000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="FI2020Q2"
      decimals="-3"
      id="d33059e1626-wk-Fact-C29E96B20CDD29BFF7F84985F0C043A7"
      unitRef="usd">765000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d33059e1645-wk-Fact-0A4EC0F3F9C9960AFAA14985F0BDC4C6"
      unitRef="usd">519000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="FI2020Q2"
      decimals="-3"
      id="d33059e1665-wk-Fact-C301B47BB7E9511C02D44985F0BABF80"
      unitRef="usd">10991000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="FI2019Q4"
      decimals="-3"
      id="d33059e1684-wk-Fact-041E06CD18644D34C57C4985F0B5E9FF"
      unitRef="usd">13486000</us-gaap:Liabilities>
    <us-gaap:CommonStockValue
      contextRef="FI2020Q2"
      decimals="-3"
      id="d33059e1745-wk-Fact-6FE995DD0EB32FBB27A3496B24A7327F"
      unitRef="usd">34000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="FI2019Q4"
      decimals="-3"
      id="d33059e1764-wk-Fact-143AAB9DC49A689E6EB7496B24ADBF29"
      unitRef="usd">34000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="FI2020Q2"
      decimals="-3"
      id="d33059e1784-wk-Fact-4DA6BCDC6F5D7593483E496B24A9E2CA"
      unitRef="usd">58926000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="FI2019Q4"
      decimals="-3"
      id="d33059e1803-wk-Fact-FC6ADB4EE9D33680920C496B24AE25C7"
      unitRef="usd">56708000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="FI2020Q2"
      decimals="-3"
      id="d33059e1823-wk-Fact-95D49C7D8DD0C809EF8C496B24AD5EEE"
      unitRef="usd">7876000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="FI2019Q4"
      decimals="-3"
      id="d33059e1842-wk-Fact-3BE633F8823CEAFD289B496B24AFD7D8"
      unitRef="usd">14517000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="FI2020Q2"
      decimals="-3"
      id="d33059e1862-wk-Fact-D1C436E250D6D86CF9D04985F0B6CF81"
      unitRef="usd">66836000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q4"
      decimals="-3"
      id="d33059e1881-wk-Fact-C94CE513F2192AF1C5CC4985F0BF3F35"
      unitRef="usd">71259000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="FI2020Q2"
      decimals="-3"
      id="d33059e1907-wk-Fact-9BAAAF0EFA3532B65DFD4985F0BA58F7"
      unitRef="usd">77827000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="FI2019Q4"
      decimals="-3"
      id="d33059e1926-wk-Fact-AB7967A703C16467D8F44985F0BD68F5"
      unitRef="usd">84745000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD"
      decimals="-3"
      id="d9871e772-wk-Fact-F2B9353892A9BBCB558E4985F0BD4A4E"
      unitRef="usd">4296000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d9871e791-wk-Fact-C4195FF56DAD7F05326E76D0BF59C9A4"
      unitRef="usd">6649000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d9871e810-wk-Fact-9BDD69852F22B2CE28FC496B254AFE05"
      unitRef="usd">9293000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d9871e830-wk-Fact-D8E04E1C126201AA5E924985F0D415DA"
      unitRef="usd">12278000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2020Q2QTD"
      decimals="-3"
      id="d9871e845-wk-Fact-13949BD7C40D35F039794985F0A8FB45"
      unitRef="usd">2202000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d9871e864-wk-Fact-FAFB259F9A77E77E137476D0BF216C98"
      unitRef="usd">1975000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d9871e883-wk-Fact-E0F7CB5DA114B3BAA245496B255992CE"
      unitRef="usd">4215000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d9871e903-wk-Fact-18242D1C00315F54ABF44985F0D6B253"
      unitRef="usd">4041000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="FD2020Q2QTD"
      decimals="-3"
      id="d9871e923-wk-Fact-E5FB9DF13C532438C2924985F0D3EA40"
      unitRef="usd">2094000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d9871e942-wk-Fact-0E157A89032C104AA31F76D0BF001948"
      unitRef="usd">4674000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d9871e961-wk-Fact-825D69C5A173FB997681496B25529520"
      unitRef="usd">5078000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d9871e981-wk-Fact-3222B037426F17C447DC4985F0DC4B60"
      unitRef="usd">8237000</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="FD2020Q2QTD"
      decimals="-3"
      id="d9871e1083-wk-Fact-34338D3A20A868A7A2B74985F0C776EC"
      unitRef="usd">975000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d9871e1102-wk-Fact-C0692A559A325D20173A76D0BF41A126"
      unitRef="usd">888000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d9871e1121-wk-Fact-248808F42544186D5BCB496B2550D3CF"
      unitRef="usd">1955000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d9871e1141-wk-Fact-25CF5287E4CB7C284DA84985F0D1A5BB"
      unitRef="usd">1618000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ProfessionalFees
      contextRef="FD2020Q2QTD"
      decimals="-3"
      id="d9871e1161-wk-Fact-8B14AECE3DC456392BC24985F0C38A2B"
      unitRef="usd">1658000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d9871e1180-wk-Fact-D565329A4105CC70C1A676D0BF53C8A3"
      unitRef="usd">1661000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d9871e1199-wk-Fact-DCE23DEFA4E2A4EFD2D2496B254FFA55"
      unitRef="usd">4047000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d9871e1219-wk-Fact-F8C9908017F14936F93C4985F0D5E913"
      unitRef="usd">3779000</us-gaap:ProfessionalFees>
    <us-gaap:SalariesAndWages
      contextRef="FD2020Q2QTD"
      decimals="-3"
      id="d9871e1239-wk-Fact-953192D65FF7BEFC43574985F0ED8175"
      unitRef="usd">3439000</us-gaap:SalariesAndWages>
    <us-gaap:SalariesAndWages
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d9871e1258-wk-Fact-02B779FF99179112C63976D0BF486791"
      unitRef="usd">3510000</us-gaap:SalariesAndWages>
    <us-gaap:SalariesAndWages
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d9871e1277-wk-Fact-4957373C43D2ED6AA41F496B2554FD44"
      unitRef="usd">6750000</us-gaap:SalariesAndWages>
    <us-gaap:SalariesAndWages
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d9871e1297-wk-Fact-DF93D491AFC4F0D9336B4985F0F960CB"
      unitRef="usd">6998000</us-gaap:SalariesAndWages>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="FD2020Q2QTD"
      decimals="-3"
      id="d9871e1317-wk-Fact-2872712017954F8BCA474985F0B50E35"
      unitRef="usd">2189000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d9871e1336-wk-Fact-9BF7D9A4E12173CA874F76D0BF4C3CE5"
      unitRef="usd">3037000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d9871e1355-wk-Fact-33489C5DA4CFA2333B15496B25526A56"
      unitRef="usd">5985000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d9871e1375-wk-Fact-324307BADF3204756D664985F0F8F4B1"
      unitRef="usd">5994000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="FD2020Q2QTD"
      decimals="-3"
      id="d9871e1395-wk-Fact-4A2BF40AEF11926075454985F0EF020A"
      unitRef="usd">8261000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d9871e1414-wk-Fact-A30CCF812AB2F075C19C76D0BF64EE60"
      unitRef="usd">9096000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d9871e1433-wk-Fact-00BE6571ABAFD386B4B7496B25438B98"
      unitRef="usd">18737000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d9871e1453-wk-Fact-A42421A70E68CDDFA7AB4985F0D55E98"
      unitRef="usd">18389000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2020Q2QTD"
      decimals="-3"
      id="d9871e1474-wk-Fact-6E4681D333F9B4FEF1B34985F0B9BDC1"
      unitRef="usd">-6167000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d9871e1494-wk-Fact-AC7AD5EC8AB2905C951C76D0BF2A7387"
      unitRef="usd">-4422000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d9871e1514-wk-Fact-5D65487F5B78F2E9304B496B254717EF"
      unitRef="usd">-13659000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d9871e1535-wk-Fact-7E20E27051E14A0D6F134985F0DA82C9"
      unitRef="usd">-10152000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeOperating
      contextRef="FD2020Q2QTD"
      decimals="-3"
      id="d9871e1556-wk-Fact-C227DBBE6CA87150FAD476D0BF5F3509"
      unitRef="usd">7000</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d9871e1575-wk-Fact-3B8FD60B29B0E0A1762F4985F0F80D00"
      unitRef="usd">403000</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d9871e1594-wk-Fact-E215DB812850C07E3CFAD6178E5F048A"
      unitRef="usd">223000</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d9871e1613-wk-Fact-6FCD05FE238ECD6069284985F0D3ADDC"
      unitRef="usd">826000</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestExpense
      contextRef="FD2020Q2QTD"
      decimals="-3"
      id="d9871e1633-wk-Fact-4935FB2E9F22EBA81F8376D0BF5C4BBA"
      unitRef="usd">8000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d9871e1653-wk-Fact-BA1C610CE519361C5AC34985F0DB0FCF"
      unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d9871e1672-wk-Fact-90E780016EE019A9EA93D6178E6C3B5B"
      unitRef="usd">14000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d9871e1693-wk-Fact-9B91CCF1131A4DAF67ED4985F0D58CED"
      unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="FD2020Q2QTD"
      decimals="-3"
      id="d9871e1713-wk-Fact-828CD9B42DC1F8EFA72276D0BF3B49AF"
      unitRef="usd">-14000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d9871e1733-wk-Fact-397B5DCDE56513731F094985F0C6DCEF"
      unitRef="usd">-200000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d9871e1753-wk-Fact-385DF51A61546F8417FCD6178E54A764"
      unitRef="usd">412000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d9871e1773-wk-Fact-D2C45063AEB20A37404A4985F0F80DE7"
      unitRef="usd">-495000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2020Q2QTD"
      decimals="-3"
      id="d9871e1794-wk-Fact-36859585850E626143FA4985F0C48B93"
      unitRef="usd">-15000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d9871e1814-wk-Fact-10ED1EC62F8C075BCA9376D0BF85B4E8"
      unitRef="usd">203000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d9871e1833-wk-Fact-2643E5884A32D19DB1D8496B254FD50A"
      unitRef="usd">621000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d9871e1853-wk-Fact-BB22CF791314B745B1934985F0D7CA8B"
      unitRef="usd">331000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2020Q2QTD"
      decimals="-3"
      id="d9871e1873-wk-Fact-AEF79181B1B1150A173F4985F0C513F8"
      unitRef="usd">-6182000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d9871e1893-wk-Fact-4EFB695BDD668292AB9B76D0BEFB3E72"
      unitRef="usd">-4219000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d9871e1913-wk-Fact-76DD743D1B2F774902F4496B254CDEB5"
      unitRef="usd">-13038000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d9871e1934-wk-Fact-57A2F849CC0910CEB30C4985F0D6CCCC"
      unitRef="usd">-9821000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2020Q2QTD"
      decimals="-3"
      id="d9871e1955-wk-Fact-E9BF97A1F660F7AF17B476D0BF378CF0"
      unitRef="usd">-1492000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d9871e1975-wk-Fact-697A31017246D2D682494985F0AB7C3C"
      unitRef="usd">76000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d9871e1994-wk-Fact-D787ABABBBA24B299E50C92CFBFFA215"
      unitRef="usd">-6397000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d9871e2015-wk-Fact-281575BA2D8E389065EB4985F0D51761"
      unitRef="usd">82000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="FD2020Q2QTD"
      decimals="-3"
      id="d9871e2040-wk-Fact-397B5F09FC560A26164C4985F0BC0BD5"
      unitRef="usd">-4690000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d9871e2060-wk-Fact-BCBB336E1C78F831CB4A4985F0E0D0DA"
      unitRef="usd">-4295000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d9871e2080-wk-Fact-B864AF01CE96AE141E184985F0DABD1D"
      unitRef="usd">-6641000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d9871e2100-wk-Fact-3FF03CC6BE82BB4D951C4985F0D79FDC"
      unitRef="usd">-9903000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
      contextRef="FD2020Q2QTD"
      decimals="2"
      id="d9871e2285-wk-Fact-41C4F6CFB4F80DCBFC6E76D0BF67B254"
      unitRef="usdPerShare">-0.14</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
      contextRef="FD2019Q2QTD"
      decimals="2"
      id="d9871e2305-wk-Fact-C38EA1DCCA208B27473C4985F0BECE0E"
      unitRef="usdPerShare">-0.13</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
      contextRef="FD2020Q2YTD"
      decimals="2"
      id="d9871e2325-wk-Fact-928250C9526DF248E575496B255746E3"
      unitRef="usdPerShare">-0.19</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
      contextRef="FD2019Q2YTD"
      decimals="2"
      id="d9871e2346-wk-Fact-EA9116B0A8E4B9421E734985F0DBF793"
      unitRef="usdPerShare">-0.30</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
    <us-gaap:SharesIssued
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d10848e902-wk-Fact-3E61C219A196ECF715464985F0B99DEC"
      unitRef="shares">33891000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d10848e921-wk-Fact-FDD4E76B0F3912BFB0AB4985F0C4DA27"
      unitRef="usd">34000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d10848e940-wk-Fact-0BF8CD6A14CE9DFCD96B4985F0AA1CAB"
      unitRef="usd">54182000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d10848e960-wk-Fact-A8DFCDC50248B35D73B54985F0A93B22"
      unitRef="usd">28615000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q1"
      decimals="-3"
      id="d10848e979-wk-Fact-328855CD6F52F68BA7E44985F0BD459A"
      unitRef="usd">82831000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d10848e994-wk-Fact-9B046A6128A2D09973154985F0A9315F"
      unitRef="shares">11000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d10848e1027-wk-Fact-A2827D4F89D14AB010AD4985F0BAE652"
      unitRef="usd">48000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d10848e1066-wk-Fact-CDAC796BA8A52078BB344985F0C83AE2"
      unitRef="usd">48000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d10848e1119-wk-Fact-6D0564721654AC4784324985F0CCECAD"
      unitRef="usd">856000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d10848e1158-wk-Fact-D32DED58334CB421199C4985F0BD521B"
      unitRef="usd">856000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <apyx:StockSwapToAcquireOptionsShares
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d10848e1178-wk-Fact-89A99B0D68E65D59610A4985F0A5A65C"
      unitRef="shares">17000</apyx:StockSwapToAcquireOptionsShares>
    <apyx:StockSwapToAcquireOptionsAmount
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d10848e1250-wk-Fact-87045BDE8CF9870114A64985F0BEAB66"
      unitRef="usd">0</apyx:StockSwapToAcquireOptionsAmount>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d10848e1323-wk-Fact-44D6DCE00CC5964928674985F0C76595"
      unitRef="usd">-4295000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d10848e1343-wk-Fact-BCBB336E1C78F831CB4A4985F0E0D0DA"
      unitRef="usd">-4295000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:SharesIssued
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d10848e1367-wk-Fact-FD0CC2743712FE54AA884985F0B6FF1B"
      unitRef="shares">33919000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d10848e1381-wk-Fact-B08CABE5DDD17F80178D4985F0CFDD2D"
      unitRef="usd">34000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d10848e1405-wk-Fact-DB19878C0AE7878EAFB94985F0D07D10"
      unitRef="usd">55086000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d10848e1425-wk-Fact-D1B6A04F02BD1944073D4985F0A98246"
      unitRef="usd">24320000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q2"
      decimals="-3"
      id="d10848e1444-wk-Fact-F743A1E39A1B7B19F4614985F0A6E10C"
      unitRef="usd">79440000</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d10848e1559-wk-Fact-C4D4A07964374AB6B5D276D28A687973"
      unitRef="shares">34184000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d10848e1578-wk-Fact-E144697B57FC77E61AE276D289B87827"
      unitRef="usd">34000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d10848e1597-wk-Fact-25A1E9BC0F5FA10F918576D288A1AA6D"
      unitRef="usd">57829000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d10848e1617-wk-Fact-550FDA73A96CE1C2ACA776D288A8ED22"
      unitRef="usd">12566000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2020Q1"
      decimals="-3"
      id="d10848e1636-wk-Fact-8D158F0138178224EEC876D28951EF5D"
      unitRef="usd">70429000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2020Q2QTD"
      decimals="-3"
      id="d10848e1685-wk-Fact-1FA21E17FBD44CD237EC76D2892FC0F7"
      unitRef="usd">1097000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2020Q2QTD"
      decimals="-3"
      id="d10848e1724-wk-Fact-1FA21E17FBD44CD237EC76D2892FC0F7"
      unitRef="usd">1097000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <apyx:StockSwapToAcquireOptionsShares
      contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d10848e1744-wk-Fact-A3DD9F2C5F9813A0486D76D28A596FE2"
      unitRef="shares">18000</apyx:StockSwapToAcquireOptionsShares>
    <apyx:StockSwapToAcquireOptionsAmount
      contextRef="FD2020Q2QTD"
      decimals="-3"
      id="d10848e1816-wk-Fact-A04794CA8C4E7AB7CF5476D28910ED4E"
      unitRef="usd">0</apyx:StockSwapToAcquireOptionsAmount>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d10848e1889-wk-Fact-2AA2AC602BF5E400F66776D28A4B9670"
      unitRef="usd">-4690000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="FD2020Q2QTD"
      decimals="-3"
      id="d10848e1909-wk-Fact-397B5F09FC560A26164C4985F0BC0BD5"
      unitRef="usd">-4690000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:SharesIssued
      contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d10848e1933-wk-Fact-0C5B0CCEF6B8E542B3344985F0BB5363"
      unitRef="shares">34202000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d10848e1952-wk-Fact-CC3BE3E5C0AFF40A096A76D28ABCC6B9"
      unitRef="usd">34000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d10848e1971-wk-Fact-8EA36CF8C8C15E03580A76D288C58682"
      unitRef="usd">58926000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d10848e1991-wk-Fact-84004FAEE5A39C6B528076D28978AD73"
      unitRef="usd">7876000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2020Q2"
      decimals="-3"
      id="d10848e2010-wk-Fact-D1C436E250D6D86CF9D04985F0B6CF81"
      unitRef="usd">66836000</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d10848e2412-wk-Fact-5B49065ABB21BC9C5AC84985F0D04F7B"
      unitRef="shares">33705000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d10848e2431-wk-Fact-12BD79913DF0373A92204985F0B62C66"
      unitRef="usd">34000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d10848e2450-wk-Fact-F3FDB1C2D9FD18FAD6264985F0C652A0"
      unitRef="usd">52920000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d10848e2470-wk-Fact-7D27A39B732FA0A3DA5E4985F0C6EA0B"
      unitRef="usd">34223000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4"
      decimals="-3"
      id="d10848e2489-wk-Fact-C26AB252431087F5B3E54985F0A79F6E"
      unitRef="usd">87177000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d10848e2504-wk-Fact-7233999634B56648C7E34985F0BEC02B"
      unitRef="shares">29000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d10848e2537-wk-Fact-89EEB737D0DC1FE2D3134985F0B9BDD0"
      unitRef="usd">115000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d10848e2576-wk-Fact-3351319196A9DD693C9D4985F0D0CDE7"
      unitRef="usd">115000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d10848e2629-wk-Fact-5776DBC247B0BA2FA5684985F0BFCE31"
      unitRef="usd">2051000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d10848e2668-wk-Fact-5776DBC247B0BA2FA5684985F0BFCE31"
      unitRef="usd">2051000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <apyx:StockSwapToAcquireOptionsShares
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d10848e2689-wk-Fact-20C5308DBE475167DAFF4985F0ACDDAC"
      unitRef="shares">185000</apyx:StockSwapToAcquireOptionsShares>
    <apyx:StockSwapToAcquireOptionsAmount
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d10848e2761-wk-Fact-3500A5FE7256EE29F9E44985F0CDB105"
      unitRef="usd">0</apyx:StockSwapToAcquireOptionsAmount>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d10848e2834-wk-Fact-A4BC828947F3466A81E14985F0AE9958"
      unitRef="usd">-9903000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d10848e2854-wk-Fact-3FF03CC6BE82BB4D951C4985F0D79FDC"
      unitRef="usd">-9903000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:SharesIssued
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d10848e2875-wk-Fact-FD0CC2743712FE54AA884985F0B6FF1B"
      unitRef="shares">33919000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d10848e2894-wk-Fact-B08CABE5DDD17F80178D4985F0CFDD2D"
      unitRef="usd">34000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d10848e2913-wk-Fact-DB19878C0AE7878EAFB94985F0D07D10"
      unitRef="usd">55086000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d10848e2933-wk-Fact-D1B6A04F02BD1944073D4985F0A98246"
      unitRef="usd">24320000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q2"
      decimals="-3"
      id="d10848e2952-wk-Fact-F743A1E39A1B7B19F4614985F0A6E10C"
      unitRef="usd">79440000</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d10848e3064-wk-Fact-232BEBACBBF823E62DA04985F0AB37AA"
      unitRef="shares">34170000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d10848e3083-wk-Fact-B3F69626EDD3937AAE7E4985F0A6C886"
      unitRef="usd">34000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d10848e3102-wk-Fact-E61121F7B359E08730754985F0C0089D"
      unitRef="usd">56708000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d10848e3122-wk-Fact-1D10998B85999E32B7694985F0AD5245"
      unitRef="usd">14517000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q4"
      decimals="-3"
      id="d10848e3141-wk-Fact-C94CE513F2192AF1C5CC4985F0BF3F35"
      unitRef="usd">71259000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d10848e3156-wk-Fact-1A236862BE568951FC3A4985F0ACCC9C"
      unitRef="shares">10000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d10848e3189-wk-Fact-751DB13003F58B8EE3EA4985F0B7043A"
      unitRef="usd">72000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d10848e3228-wk-Fact-813D88EEBF21DD99F65C4985F0C16C19"
      unitRef="usd">72000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d10848e3281-wk-Fact-D84C0C999FFF17FBC31A4985F0BC2397"
      unitRef="usd">2146000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d10848e3320-wk-Fact-F992FF3AC7F73ABDFEB34985F0C10D14"
      unitRef="usd">2146000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <apyx:StockSwapToAcquireOptionsShares
      contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d10848e3340-wk-Fact-3ADB7D22A67A50FCD4CF4985F0BB14A8"
      unitRef="shares">22000</apyx:StockSwapToAcquireOptionsShares>
    <apyx:StockSwapToAcquireOptionsAmount
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d10848e3412-wk-Fact-314CA07651F3BB5E5C644985F0B7B80F"
      unitRef="usd">0</apyx:StockSwapToAcquireOptionsAmount>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d10848e3485-wk-Fact-AF53225DA2AE8AD39A564985F0AFB30B"
      unitRef="usd">-6641000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d10848e3505-wk-Fact-B864AF01CE96AE141E184985F0DABD1D"
      unitRef="usd">-6641000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:SharesIssued
      contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d10848e3526-wk-Fact-0C5B0CCEF6B8E542B3344985F0BB5363"
      unitRef="shares">34202000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d10848e3545-wk-Fact-CC3BE3E5C0AFF40A096A76D28ABCC6B9"
      unitRef="usd">34000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d10848e3564-wk-Fact-8EA36CF8C8C15E03580A76D288C58682"
      unitRef="usd">58926000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d10848e3584-wk-Fact-84004FAEE5A39C6B528076D28978AD73"
      unitRef="usd">7876000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2020Q2"
      decimals="-3"
      id="d10848e3603-wk-Fact-D1C436E250D6D86CF9D04985F0B6CF81"
      unitRef="usd">66836000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d35337e723-wk-Fact-B864AF01CE96AE141E184985F0DABD1D"
      unitRef="usd">-6641000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d35337e743-wk-Fact-3FF03CC6BE82BB4D951C4985F0D79FDC"
      unitRef="usd">-9903000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d35337e800-wk-Fact-992575F2CEB1AB0DEEB5496B24C277EF"
      unitRef="usd">439000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d35337e819-wk-Fact-F13A63F99BFE66A198A64985F0A4C26F"
      unitRef="usd">316000</us-gaap:DepreciationDepletionAndAmortization>
    <apyx:ProvisionForInventoryObsolescence
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d35337e839-wk-Fact-7EA1C67920CECB3BD6DB496B24C26BC4"
      unitRef="usd">413000</apyx:ProvisionForInventoryObsolescence>
    <apyx:ProvisionForInventoryObsolescence
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d35337e858-wk-Fact-D0DDAD4364C310096DA676D6FDE594B8"
      unitRef="usd">36000</apyx:ProvisionForInventoryObsolescence>
    <us-gaap:ShareBasedCompensation
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d35337e878-wk-Fact-1E13275687914D0D788C496B253616CC"
      unitRef="usd">2146000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d35337e897-wk-Fact-2E7E719129609A16727E4985F0F49487"
      unitRef="usd">2051000</us-gaap:ShareBasedCompensation>
    <us-gaap:GainLossOnInvestments
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d35337e917-wk-Fact-FAB15C93DB0A5A48F724496B2493DD8B"
      unitRef="usd">0</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d35337e936-wk-Fact-0EA65CE40FE28EC1C44376D6FDF56060"
      unitRef="usd">164000</us-gaap:GainLossOnInvestments>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d35337e957-wk-Fact-8F4864F4CB3EB1454CBB496B24C3033C"
      unitRef="usd">486000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d35337e976-wk-Fact-774304EE0DAA49CE4F954985F0F2D670"
      unitRef="usd">-238000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d35337e1039-wk-Fact-BC4AD249EAF1188B36AD496B2542C306"
      unitRef="usd">-1195000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d35337e1058-wk-Fact-5408E91DE3E6C91C5B984985F0D5F39C"
      unitRef="usd">1333000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d35337e1079-wk-Fact-A72BD588AC9DA0337B22496B24B7ABED"
      unitRef="usd">7427000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d35337e1099-wk-Fact-2FAA61BB9A4F3629970E4985F0F7F436"
      unitRef="usd">879000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d35337e1120-wk-Fact-15B8A0BED265A5D464E9496B24C07A77"
      unitRef="usd">571000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d35337e1140-wk-Fact-105ED17B8A2BFECC67314985F0A451DB"
      unitRef="usd">1015000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d35337e1161-wk-Fact-3AA6104DD8298E67C444496B24E6638D"
      unitRef="usd">-232000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d35337e1181-wk-Fact-1C76EF043F7A630934174985F0F37BC0"
      unitRef="usd">218000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d35337e1201-wk-Fact-7A7D64EA36179DD4EC2E4985F0F47C2A"
      unitRef="usd">-2241000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d35337e1221-wk-Fact-126C15F89FD8276A96324985F0E0DBBE"
      unitRef="usd">236000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d35337e1241-wk-Fact-438C335908E2DA82CD49496B248CE208"
      unitRef="usd">-12433000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d35337e1261-wk-Fact-1D032740E753EC64FC974985F0D4630E"
      unitRef="usd">-10675000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d35337e1322-wk-Fact-CBC8069791C392261C24496B25404961"
      unitRef="usd">184000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d35337e1342-wk-Fact-00CF1C44698A482694F04985F0DD070F"
      unitRef="usd">518000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d35337e1363-wk-Fact-9D2B4369737A20E3EA4D496B248AE167"
      unitRef="usd">0</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d35337e1382-wk-Fact-B84583C5390ADC64D7A24985F0D8C6B1"
      unitRef="usd">18884000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d35337e1403-wk-Fact-BB6F47623A5FB27666A6496B24874DF0"
      unitRef="usd">0</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d35337e1422-wk-Fact-8F6BD59B7B409AD499824985F0F417BF"
      unitRef="usd">80726000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d35337e1442-wk-Fact-2E24ED1F3BCF54E9422F496B248891E4"
      unitRef="usd">-184000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d35337e1462-wk-Fact-93D5D7391E7AA66FCC224985F0D431A8"
      unitRef="usd">61324000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <apyx:ProceedsFromStockOptionsExercisedAndWarrantsExercised
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d35337e1522-wk-Fact-3F887D222C35EF18CAC3496B24BF13C9"
      unitRef="usd">72000</apyx:ProceedsFromStockOptionsExercisedAndWarrantsExercised>
    <apyx:ProceedsFromStockOptionsExercisedAndWarrantsExercised
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d35337e1541-wk-Fact-D469B7597F923A6D541276D6FDDBC630"
      unitRef="usd">115000</apyx:ProceedsFromStockOptionsExercisedAndWarrantsExercised>
    <apyx:RepaymentofFinanceLeaseLiabilities
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d35337e1561-wk-Fact-197696A34120D9B0AAD9496B24C1F8D2"
      unitRef="usd">120000</apyx:RepaymentofFinanceLeaseLiabilities>
    <apyx:RepaymentofFinanceLeaseLiabilities
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d35337e1581-wk-Fact-1638C4067E4E60F8C90476D6FD771C62"
      unitRef="usd">0</apyx:RepaymentofFinanceLeaseLiabilities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d35337e1601-wk-Fact-52EAC9B3B5DC368928E5496B2486D37B"
      unitRef="usd">-48000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d35337e1621-wk-Fact-B99587E7BD2A522D2B674985F0D47137"
      unitRef="usd">115000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d35337e1641-wk-Fact-AE68C0A8E66F02745FAC496B2542B221"
      unitRef="usd">9000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d35337e1660-wk-Fact-3BE6DB0FC0EABED8061876D6FD8D9184"
      unitRef="usd">0</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d35337e1680-wk-Fact-A4FE913805A5E4D9D637496B25350F76"
      unitRef="usd">-12656000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d35337e1700-wk-Fact-D09D6500F83A53C0DE3876D6FD61D69F"
      unitRef="usd">50764000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2019Q4"
      decimals="-3"
      id="d35337e1720-wk-Fact-F4CB43850573C5B66C11496B24BF52D4"
      unitRef="usd">58812000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2018Q4"
      decimals="-3"
      id="d35337e1739-wk-Fact-81B8FB49E350797C61C84985F0DCDD00"
      unitRef="usd">16596000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2020Q2"
      decimals="-3"
      id="d35337e1764-wk-Fact-0B73B5E8BFDA870FEF8D496B2538B9D1"
      unitRef="usd">46156000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2019Q2"
      decimals="-3"
      id="d35337e1783-wk-Fact-5A303D799F3853D3B00776D6FD9BEF5E"
      unitRef="usd">67360000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d35337e1885-wk-Fact-BE89B9B63E57CECA7D7B4985F0D9484F"
      unitRef="usd">8000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d35337e1904-wk-Fact-F400C96CB5D7A72F7E7B4985F0A5EE66"
      unitRef="usd">14000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaid
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d35337e1920-wk-Fact-4B9DFAFFE5B0CDB90A73A68AF2C37A2B"
      unitRef="usd">54000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d35337e1939-wk-Fact-1F8C0FDE9102AC97F558A68AF1F9FE96"
      unitRef="usd">248000</us-gaap:IncomeTaxesPaid>
    <apyx:NonCashProceedsFromStockOptionsAndWarrantsExercised
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d35337e2043-wk-Fact-E0D5F42D884658FD53B8496B24C2DED2"
      unitRef="usd">49000</apyx:NonCashProceedsFromStockOptionsAndWarrantsExercised>
    <apyx:NonCashProceedsFromStockOptionsAndWarrantsExercised
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d35337e2062-wk-Fact-90FE643917C03B4DCD914985F0F8F6C4"
      unitRef="usd">757000</apyx:NonCashProceedsFromStockOptionsAndWarrantsExercised>
    <apyx:LeaseAdoption
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d35337e2079-wk-Fact-5A332CC05E1E4DAD02684985F0F72B68"
      unitRef="usd">0</apyx:LeaseAdoption>
    <apyx:LeaseAdoption
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d35337e2098-wk-Fact-9F5775762CCB1E91B50A4985F0D83E0E"
      unitRef="usd">212000</apyx:LeaseAdoption>
    <apyx:CapitalizationOfLeaseNonCash
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d35337e2120-wk-Fact-E8411A31B4B6BD5A73D84985F0BC8002"
      unitRef="usd">0</apyx:CapitalizationOfLeaseNonCash>
    <apyx:CapitalizationOfLeaseNonCash
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d35337e2139-wk-Fact-6A42B812439D45CBFCFF4985F0DE1153"
      unitRef="usd">207000</apyx:CapitalizationOfLeaseNonCash>
    <apyx:CapitalizationOfLeaseExecution
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d35337e2161-wk-Fact-67500B84031C7D3C2739A69E7B553262"
      unitRef="usd">150000</apyx:CapitalizationOfLeaseExecution>
    <apyx:CapitalizationOfLeaseExecution
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d35337e2180-wk-Fact-5EA92C414819782F93B9A69E7B450CB4"
      unitRef="usd">0</apyx:CapitalizationOfLeaseExecution>
    <apyx:NonCashTransferOfOtherAssetsToFixedAssets
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d35337e2200-wk-Fact-8C22F4C998B857AD14FFA697BF2FC1C3"
      unitRef="usd">0</apyx:NonCashTransferOfOtherAssetsToFixedAssets>
    <apyx:NonCashTransferOfOtherAssetsToFixedAssets
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d35337e2219-wk-Fact-B3FD07FA5645A7A7F543A697BF41E326"
      unitRef="usd">42000</apyx:NonCashTransferOfOtherAssetsToFixedAssets>
    <apyx:NonCashTransfersOfInventoryToFromFixedAssets
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d35337e2239-wk-Fact-6D8BC42F8555F2DD9E38A698550B4058"
      unitRef="usd">-34000</apyx:NonCashTransfersOfInventoryToFromFixedAssets>
    <apyx:NonCashTransfersOfInventoryToFromFixedAssets
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d35337e2259-wk-Fact-5CF467B2D3555EFF7FF6A6985503F094"
      unitRef="usd">262000</apyx:NonCashTransfersOfInventoryToFromFixedAssets>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-BFADCCF3E0D79AE241244985F1012DB4-0-wk-Fact-8FB1C4F8F92982D444964985F0E197CE">BASIS OF PRESENTATION&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Unless the context otherwise indicates, the terms  &#x201c;Company,&#x201d; &#x201c;we,&#x201d; &#x201c;our,&#x201d; &#x201c;us,&#x201d; &#x201c;Apyx,&#x201d; and similar terms refer to Apyx Medical Corporation and its consolidated subsidiaries.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We are an advanced energy technology company with a passion for elevating people&#x2019;s lives through innovative products in the cosmetic and surgical markets. Known for our innovative Helium Plasma Technology, Apyx is solely focused on bringing transformative solutions to the physicians and patients it serves. Our Helium Plasma Technology is marketed and sold as Renuvion&#xae; in the cosmetic surgery market and J-Plasma&#xae; in the hospital surgical market. Renuvion&#xae; offers plastic surgeons, fascial plastic surgeons and cosmetic physicians a unique ability to provide controlled heat to the tissue to achieve their desired results. The J-Plasma&#xae; system allows surgeons to operate with a high level of precision and virtually eliminating unintended tissue trauma. We also leverage our deep expertise and decades of experience in unique waveforms through original equipment manufacturing (OEM) agreements with other medical device manufacturers.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In March 2020, the World Health Organization recognized the novel strain of coronavirus ("COVID-19"), as a pandemic. This pandemic has severely restricted the level of economic activity around the world. In response, the governments of many countries, states, cities and other geographic regions have taken preventative or protective actions, such as imposing restrictions on travel and business operations and advising or requiring individuals to limit or forego their time outside of their homes. The long-term impact of the COVID-19 pandemic on our business continues to be highly uncertain and difficult to predict as the environment created by the pandemic is rapidly changing. Starting in late February, the effects of the pandemic have been material and adverse on our business. While we experienced positive indications in our business late in the second quarter, we continue to expect that the severity of the impact of the COVID-19 pandemic on our business will depend on a number of factors, including, but not limited to, the duration and severity of the pandemic and the extent and severity of the impact on our customers and suppliers, all of which are uncertain and cannot be predicted. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Most of the procedures performed using our Helium Plasma Technology are elective, and as a result many of our customers have been affected by the actions taken by various governmental authorities requiring non-essential businesses to shut down temporarily.   As these shut-downs have begun to be reversed, we have started to see an increase in demand for elective cosmetic and plastic surgery procedures, resulting in higher than expected revenues in our Advanced Energy segment.  In international markets, a greater portion of these procedures are performed in a hospital, and it is less certain when elective procedures will fully return to normal.. While we  started to experience a significant decline in sales towards the end of our first fiscal quarter, we began to see an increase in sales towards the end of our second fiscal quarter as local jurisdictions started to re-open.  However, the full extent to which the COVID-19 pandemic may materially and adversely impact the Company's future financial position, liquidity, or results of operations remains uncertain. While we began to experience an improvement in sales, domestically and internationally, towards the end of our second fiscal quarter, the pace at which this continues into the third quarter and beyond is still highly uncertain.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The accompanying unaudited consolidated financial statements have been prepared based upon SEC rules that permit reduced disclosure for interim periods. For a more complete discussion of significant accounting policies and certain other information, please refer to the consolidated financial statements included in our Annual Report on Form 10-K for the year ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. These consolidated financial statements reflect all adjustments that are necessary for a fair presentation of results of consolidated operations and financial condition for the interim periods shown, including normal recurring accruals and other items. The results for the interim periods are not necessarily indicative of results for the full year.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:AccountingChangesTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-06A2A5F253A192C1E73C4985F10129FE-0-wk-Fact-1E05AB29AC688E0D10494985F0C31EF5">CHANGE IN ACCOUNTING POLICY&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;During 2019, we began granting stock option awards deeper within the organization. We do not have sufficient experience with grants to these employees and we have experienced challenges in developing reliable forfeiture estimates at the grant date. Accounting for revising the forfeiture estimates has been burdensome. Accounting Standards Codification 718, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Compensation-Stock Compensation,&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; prescribes two methods for accounting for forfeitures on stock option awards, either the estimation method utilized by the Company previously, or by accounting for forfeitures as they occur. On January 1, 2020 we made an accounting policy election change and began accounting for forfeitures on stock option awards using actual forfeitures. This accounting policy election change was made on a retrospective basis. However, the changes to the current and prior periods were determined to be immaterial and there have been no changes to previously reported results as a result of the change.&lt;/span&gt;&lt;/div&gt;</us-gaap:AccountingChangesTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="FD2020Q2YTD"
      id="TextSelection-3A0A103D5433867674BE4985F1010EF6-0-wk-Fact-FA581FEC39334BA9C6884985F0C5FB1A">&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;During 2019, we began granting stock option awards deeper within the organization. We do not have sufficient experience with grants to these employees and we have experienced challenges in developing reliable forfeiture estimates at the grant date. Accounting for revising the forfeiture estimates has been burdensome. Accounting Standards Codification 718, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Compensation-Stock Compensation,&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; prescribes two methods for accounting for forfeitures on stock option awards, either the estimation method utilized by the Company previously, or by accounting for forfeitures as they occur. On January 1, 2020 we made an accounting policy election change and began accounting for forfeitures on stock option awards using actual forfeitures. This accounting policy election change was made on a retrospective basis. However, the changes to the current and prior periods were determined to be immaterial and there have been no changes to previously reported results as a result of the change.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:DescriptionOfNewAccountingPronouncementsNotYetAdopted
      contextRef="FD2020Q2YTD"
      id="TextSelection-A316CB898EB03E2A8CC04985F1016884-0-wk-Fact-D3610EA111BAFDD2D5C04985F0E23888">RECENT ACCOUNTING PRONOUNCEMENTS &lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In June 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2016-13, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Financial Instruments&#x2014;Credit Losses (Topic 326).&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; The update changes the impairment model for most financial assets and certain other instruments, including trade and other receivables, contract assets, held-to-maturity debt securities and loans, and requires entities to use a new forward-looking expected loss model that will result in the earlier recognition of allowance for losses. This update, as originally issued, was effective for annual and interim periods beginning after December 15, 2019, with early adoption permitted. In November 2019, the FASB issued ASU 2019-10, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) Effective Dates&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, which deferred the effective dates of these standards for Smaller Reporting Companies until fiscal years beginning after December 15, 2022. The Company currently expects to continue to qualify as a Smaller Reporting Company, based upon the current SEC definition, and as a result, will be utilizing the deferred elective date. While we are in the process of determining the effects of the adoption of the standard on the consolidated financial statements,    we do not expect the impact to be material.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In January 2017, the FASB issued ASU 2017-04,&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt; Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. The purpose of this ASU is to reduce the cost and complexity of evaluating goodwill for impairment. It eliminates the need for entities to calculate the implied fair value of goodwill by assigning the fair value of a reporting unit to all of its assets and liabilities as if that reporting unit had been acquired in a business combination. Under this ASU, an entity will perform its goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An impairment charge is recognized for the amount by which the carrying value exceeds the reporting unit&#x2019;s fair value. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The Company adopted the ASU on January 1, 2020. The amendment did not have an impact on our consolidated financial condition or results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;No other new accounting pronouncement issued or effective during the fiscal year had or is expected to have a material impact on our consolidated financial statements or disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:DescriptionOfNewAccountingPronouncementsNotYetAdopted>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-499D2644D70F8E90618B4985F101DED7-0-wk-Fact-39A22F58977859F84F6E4985F0E33743">&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In June 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2016-13, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Financial Instruments&#x2014;Credit Losses (Topic 326).&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; The update changes the impairment model for most financial assets and certain other instruments, including trade and other receivables, contract assets, held-to-maturity debt securities and loans, and requires entities to use a new forward-looking expected loss model that will result in the earlier recognition of allowance for losses. This update, as originally issued, was effective for annual and interim periods beginning after December 15, 2019, with early adoption permitted. In November 2019, the FASB issued ASU 2019-10, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) Effective Dates&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, which deferred the effective dates of these standards for Smaller Reporting Companies until fiscal years beginning after December 15, 2022. The Company currently expects to continue to qualify as a Smaller Reporting Company, based upon the current SEC definition, and as a result, will be utilizing the deferred elective date. While we are in the process of determining the effects of the adoption of the standard on the consolidated financial statements,    we do not expect the impact to be material.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In January 2017, the FASB issued ASU 2017-04,&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt; Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. The purpose of this ASU is to reduce the cost and complexity of evaluating goodwill for impairment. It eliminates the need for entities to calculate the implied fair value of goodwill by assigning the fair value of a reporting unit to all of its assets and liabilities as if that reporting unit had been acquired in a business combination. Under this ASU, an entity will perform its goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An impairment charge is recognized for the amount by which the carrying value exceeds the reporting unit&#x2019;s fair value. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The Company adopted the ASU on January 1, 2020. The amendment did not have an impact on our consolidated financial condition or results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;No other new accounting pronouncement issued or effective during the fiscal year had or is expected to have a material impact on our consolidated financial statements or disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-6DCE98511C840D0861734985F101684D-0-wk-Fact-C1B056981BFABC27D47B4985F0C79565">INVENTORIES&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Inventories are stated at the lower of cost or net realizable values. Cost is determined on a first in, first out basis. Finished goods and work-in-process inventories include material, labor and overhead costs. Factory overhead costs are primarily allocated to inventory manufactured in-house based upon labor hours. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Inventories consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;June&#160;30, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December&#160;31, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Raw materials&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,441&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,935&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Work in process&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,504&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,209&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Finished goods &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,997&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,316&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Gross inventories&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,942&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,460&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Less: provision for obsolescence&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(685&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(392&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Inventories, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,257&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,068&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;During the second fiscal quarter, we reassessed our forecasted product mix due to COVID-19, increased availability of our newer handpiece designs and earlier than expected completion of product registrations in some of our foreign markets.&#160; As a result, certain products were reduced to a lower carrying value, and some components were also written off as it was determined to cease further production on these models. The total associated impairment was approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$400,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and is included in cost of sales in the accompanying consolidated statements of income for the three and six months ended June 30, 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-634C9313525AAAB8C1AD4985F1025198-0-wk-Fact-C55A14C816B3A62B85E94985F0C423E5">&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Inventories are stated at the lower of cost or net realizable values. Cost is determined on a first in, first out basis. Finished goods and work-in-process inventories include material, labor and overhead costs. Factory overhead costs are primarily allocated to inventory manufactured in-house based upon labor hours. &lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-9B391F5B2632162E3EBA4985F102214F-0-wk-Fact-D9BEC2D3E9BF0880F7794985F0C3EE24">&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Inventories consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;June&#160;30, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December&#160;31, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Raw materials&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,441&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,935&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Work in process&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,504&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,209&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Finished goods &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,997&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,316&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Gross inventories&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,942&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,460&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Less: provision for obsolescence&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(685&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(392&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Inventories, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,257&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,068&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials
      contextRef="FI2020Q2"
      decimals="-3"
      id="d5125e674-wk-Fact-3E2D532645559A8B749C496B24CF37DA"
      unitRef="usd">2441000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials
      contextRef="FI2019Q4"
      decimals="-3"
      id="d5125e693-wk-Fact-2D2531DAEB08A6687F09496B250D401C"
      unitRef="usd">2935000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess
      contextRef="FI2020Q2"
      decimals="-3"
      id="d5125e708-wk-Fact-3148CCA5105E5C41C952496B2519E016"
      unitRef="usd">1504000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess
      contextRef="FI2019Q4"
      decimals="-3"
      id="d5125e727-wk-Fact-EF5E5ECEC66A0CCE9F73496B250CAFD7"
      unitRef="usd">1209000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods
      contextRef="FI2020Q2"
      decimals="-3"
      id="d5125e747-wk-Fact-99AD4120FF17F9564D00496B249F06E3"
      unitRef="usd">1997000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="FI2019Q4"
      decimals="-3"
      id="d5125e766-wk-Fact-E32FC66014417BC83B49496B2511655A"
      unitRef="usd">1316000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryGross
      contextRef="FI2020Q2"
      decimals="-3"
      id="d5125e786-wk-Fact-BBDD3C0A6C1739FA08E7496B250EEA1E"
      unitRef="usd">5942000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="FI2019Q4"
      decimals="-3"
      id="d5125e805-wk-Fact-C697AFE4BB3E1300AEC2496B25167662"
      unitRef="usd">5460000</us-gaap:InventoryGross>
    <us-gaap:InventoryValuationReserves
      contextRef="FI2020Q2"
      decimals="-3"
      id="d5125e825-wk-Fact-02807CDC34044059A489496B250FF04D"
      unitRef="usd">685000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves
      contextRef="FI2019Q4"
      decimals="-3"
      id="d5125e845-wk-Fact-D35541FB151A5643E09C496B2520B6BC"
      unitRef="usd">392000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryNet
      contextRef="FI2020Q2"
      decimals="-3"
      id="d5125e871-wk-Fact-2A22C0C0830CFBCD3D83496B24B26D14"
      unitRef="usd">5257000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="FI2019Q4"
      decimals="-3"
      id="d5125e890-wk-Fact-61A8AEC690F00F8AA7C1496B24A74F60"
      unitRef="usd">5068000</us-gaap:InventoryNet>
    <us-gaap:InventoryWriteDown
      contextRef="FD2020Q2QTD"
      decimals="-3"
      id="d5125e906-wk-Fact-B0167297369722F645E9A6A7AA36566B"
      unitRef="usd">400000</us-gaap:InventoryWriteDown>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-EB858DD275A14525E73B4985F102B137-0-wk-Fact-2F250F983A7F4E08B00F4985F0A74D66">ACCRUED EXPENSES AND OTHER CURRENT LIABILTIES&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrued expenses and other current liabilities consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:94.53125%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:63%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:16%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:16%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;June 30, &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrued payroll&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;726&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;694&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrued bonuses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,306&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrued commissions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;531&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;877&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrued product warranties&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;439&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;452&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrued insurance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;626&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,170&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrued professional fees&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,043&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,383&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Joint and several payroll liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,045&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,045&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Uncertain tax positions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,573&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,491&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Other accrued expenses and current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;928&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;978&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,911&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9,396&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-9CADB143DF4F23B35BDE4985F102B83C-0-wk-Fact-1C3A650416C6484B56BF4985F0C28C41">&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrued expenses and other current liabilities consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:94.53125%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:63%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:16%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:16%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;June 30, &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrued payroll&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;726&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;694&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrued bonuses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,306&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrued commissions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;531&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;877&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrued product warranties&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;439&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;452&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrued insurance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;626&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,170&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrued professional fees&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,043&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,383&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Joint and several payroll liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,045&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,045&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Uncertain tax positions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,573&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,491&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Other accrued expenses and current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;928&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;978&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,911&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9,396&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:AccruedSalariesCurrent
      contextRef="FI2020Q2"
      decimals="-3"
      id="d11708e660-wk-Fact-CEA3F133FA7396C3ECDC496B24965466"
      unitRef="usd">726000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d11708e679-wk-Fact-676442E6E42472D06746496B2499061D"
      unitRef="usd">694000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedBonusesCurrent
      contextRef="FI2020Q2"
      decimals="-3"
      id="d11708e699-wk-Fact-FE82ADAC8DC47986C1C5496B2497C043"
      unitRef="usd">0</us-gaap:AccruedBonusesCurrent>
    <us-gaap:AccruedBonusesCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d11708e718-wk-Fact-C030734946A1502FDAA3496B24982660"
      unitRef="usd">1306000</us-gaap:AccruedBonusesCurrent>
    <us-gaap:AccruedSalesCommissionCurrent
      contextRef="FI2020Q2"
      decimals="-3"
      id="d11708e738-wk-Fact-E1C8C595EB9B1F0788A5496B2495E4D2"
      unitRef="usd">531000</us-gaap:AccruedSalesCommissionCurrent>
    <us-gaap:AccruedSalesCommissionCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d11708e757-wk-Fact-DE2E48CD7F3755979B1C496B24955F3F"
      unitRef="usd">877000</us-gaap:AccruedSalesCommissionCurrent>
    <us-gaap:ProductWarrantyAccrualClassifiedCurrent
      contextRef="FI2020Q2"
      decimals="-3"
      id="d11708e777-wk-Fact-D1AD6D3D4AE276AD13C7496B249653B2"
      unitRef="usd">439000</us-gaap:ProductWarrantyAccrualClassifiedCurrent>
    <us-gaap:ProductWarrantyAccrualClassifiedCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d11708e796-wk-Fact-4FA2049B56EFB7D8D8D4496B24980267"
      unitRef="usd">452000</us-gaap:ProductWarrantyAccrualClassifiedCurrent>
    <us-gaap:AccruedInsuranceCurrent
      contextRef="FI2020Q2"
      decimals="-3"
      id="d11708e816-wk-Fact-C896E8311E8F30DD69A2496B2494CEB2"
      unitRef="usd">626000</us-gaap:AccruedInsuranceCurrent>
    <us-gaap:AccruedInsuranceCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d11708e835-wk-Fact-129AB1E8E66E872C9DF3496B2496389F"
      unitRef="usd">1170000</us-gaap:AccruedInsuranceCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="FI2020Q2"
      decimals="-3"
      id="d11708e855-wk-Fact-6432DF3C051ED89642D2496B249A1371"
      unitRef="usd">1043000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d11708e874-wk-Fact-50D2672B8897D23A3330496B249AA869"
      unitRef="usd">1383000</us-gaap:AccruedProfessionalFeesCurrent>
    <apyx:JointAndSeveralPayrollLiability
      contextRef="FI2020Q2"
      decimals="-3"
      id="d11708e894-wk-Fact-5FD0BDC73BD953F25214496B249A882C"
      unitRef="usd">1045000</apyx:JointAndSeveralPayrollLiability>
    <apyx:JointAndSeveralPayrollLiability
      contextRef="FI2019Q4"
      decimals="-3"
      id="d11708e913-wk-Fact-DE469EF781FA15DFB532496B249B7F5B"
      unitRef="usd">1045000</apyx:JointAndSeveralPayrollLiability>
    <apyx:UncertainTaxPositionsLiability
      contextRef="FI2020Q2"
      decimals="-3"
      id="d11708e933-wk-Fact-2FBDD96BC4BF732480C4496B24970049"
      unitRef="usd">1573000</apyx:UncertainTaxPositionsLiability>
    <apyx:UncertainTaxPositionsLiability
      contextRef="FI2019Q4"
      decimals="-3"
      id="d11708e952-wk-Fact-D9C432933AB0C9ED1E12496B249903B5"
      unitRef="usd">1491000</apyx:UncertainTaxPositionsLiability>
    <apyx:OtherAccruedExpensesAndLiabilitiesCurrent
      contextRef="FI2020Q2"
      decimals="-3"
      id="d11708e972-wk-Fact-61B2BE49A9F0756F7D26496B249B606D"
      unitRef="usd">928000</apyx:OtherAccruedExpensesAndLiabilitiesCurrent>
    <apyx:OtherAccruedExpensesAndLiabilitiesCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d11708e991-wk-Fact-84E6A82F917B26447F9F496B2494FE18"
      unitRef="usd">978000</apyx:OtherAccruedExpensesAndLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="FI2020Q2"
      decimals="-3"
      id="d11708e1016-wk-Fact-E97C2C9BB55F7862D582496B24A591F2"
      unitRef="usd">6911000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d11708e1035-wk-Fact-AFAF8A0F159C9EA96842496B24A3652D"
      unitRef="usd">9396000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-BA7A558EA05BEDDED0214985F10235B3-0-wk-Fact-350D5EE60CC989A81BE24985F0AAE3B1"> PER SHARE &lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We compute basic earnings per share (&#x201c;basic EPS&#x201d;) by dividing the net income or loss by the weighted average number of common shares outstanding for the reporting period adjusted for other units required to be included in basic EPS. Diluted earnings per share (&#x201c;diluted EPS&#x201d;) gives effect to all dilutive potential shares outstanding. As we are in a net loss position for all periods presented, all potential shares outstanding are anti-dilutive. The following table provides the computation of basic and diluted earnings per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:48%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;(in thousands, except per share data)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;background-color:#cceeff;"&gt;Numerator:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(4,690&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(4,295&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(6,641&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(9,903&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Denominator:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Weighted average shares outstanding - basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;34,186&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;33,384&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;34,181&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;33,363&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Earnings (loss) per share:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(0.14&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(0.13&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(0.19&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(0.30&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Anti-dilutive instruments excluded from diluted loss per common share:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,986&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,882&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,986&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,882&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-DB283047A58D84CF12274985F1025E10-0-wk-Fact-5F77F1B8ED671F512D624985F0F37666">The following table provides the computation of basic and diluted earnings per share.&lt;div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:48%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;(in thousands, except per share data)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;background-color:#cceeff;"&gt;Numerator:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(4,690&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(4,295&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(6,641&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(9,903&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Denominator:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Weighted average shares outstanding - basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;34,186&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;33,384&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;34,181&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;33,363&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Earnings (loss) per share:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(0.14&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(0.13&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(0.19&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(0.30&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Anti-dilutive instruments excluded from diluted loss per common share:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,986&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,882&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,986&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,882&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="FD2020Q2QTD"
      decimals="-3"
      id="d12969e896-wk-Fact-397B5F09FC560A26164C4985F0BC0BD5"
      unitRef="usd">-4690000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d12969e916-wk-Fact-BCBB336E1C78F831CB4A4985F0E0D0DA"
      unitRef="usd">-4295000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d12969e937-wk-Fact-B864AF01CE96AE141E184985F0DABD1D"
      unitRef="usd">-6641000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d12969e957-wk-Fact-3FF03CC6BE82BB4D951C4985F0D79FDC"
      unitRef="usd">-9903000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="FD2020Q2QTD"
      decimals="-3"
      id="d12969e1154-wk-Fact-8ACC5EAA838F7814B44B76DF786A24D9"
      unitRef="shares">34186000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d12969e1173-wk-Fact-A8A5B09ECAFC04922F5A76DF787FE435"
      unitRef="shares">33384000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d12969e1192-wk-Fact-F5138C7D331A1C31A94C76DF785CBF13"
      unitRef="shares">34181000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d12969e1212-wk-Fact-50FA61C2CF58FA8149114985F0F963EB"
      unitRef="shares">33363000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
      contextRef="FD2020Q2QTD"
      decimals="2"
      id="d12969e1416-wk-Fact-41C4F6CFB4F80DCBFC6E76D0BF67B254"
      unitRef="usdPerShare">-0.14</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
      contextRef="FD2019Q2QTD"
      decimals="2"
      id="d12969e1436-wk-Fact-C38EA1DCCA208B27473C4985F0BECE0E"
      unitRef="usdPerShare">-0.13</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
      contextRef="FD2020Q2YTD"
      decimals="2"
      id="d12969e1457-wk-Fact-928250C9526DF248E575496B255746E3"
      unitRef="usdPerShare">-0.19</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
      contextRef="FD2019Q2YTD"
      decimals="2"
      id="d12969e1477-wk-Fact-EA9116B0A8E4B9421E734985F0DBF793"
      unitRef="usdPerShare">-0.30</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2020Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_OptionOnSecuritiesMember"
      decimals="-3"
      id="d12969e1673-wk-Fact-E628052F60F327AE23294985F0D2DD5C"
      unitRef="shares">4986000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2019Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_OptionOnSecuritiesMember"
      decimals="-3"
      id="d12969e1692-wk-Fact-927C9DA5CF5388E49DE54985F0CC053D"
      unitRef="shares">1882000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2020Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_OptionOnSecuritiesMember"
      decimals="-3"
      id="d12969e1711-wk-Fact-E41FD632A584A4B64BF04985F0A376E1"
      unitRef="shares">4986000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2019Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_OptionOnSecuritiesMember"
      decimals="-3"
      id="d12969e1731-wk-Fact-20FE28BD1DDA0175B7FA4985F0A7954E"
      unitRef="shares">1882000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-30B24434A4B89FDC59914985F10205AD-0-wk-Fact-0B68DA5EE73474BEB89A4985F0A4EA30">STOCK-BASED COMPENSATION &lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Under our stock option plans, our board of directors may grant restricted stock and options to purchase common shares to our employees, officers, directors and consultants. We account for stock options in accordance with FASB ASC Topic 718, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Compensation - Stock Compensation&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, with stock-based compensation expense amortized over the vesting period based on the fair value on the grant date utilizing a trinomial lattice model through 2018 and the Black Scholes model for grants in 2019 and 2020, both of which include a number of estimates that affect the amount of our expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We recognized approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1,097,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$2,146,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, in stock-based compensation expense during the three and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;six months ended June 30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, as compared with &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$856,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$2,051,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, for the three and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;six months ended June 30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The status of our stock options are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:4px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Number of options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Weighted average exercise price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Outstanding at December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,966,858&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4.67&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,274,900&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8.18&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(44,381&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3.23&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Canceled and forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(211,433&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7.51&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Outstanding at June 30, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,985,944&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5.46&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We allow stock option holders to exercise stock-based awards by surrendering  stock-based awards with a fair value of the stock-based awards exercised, referred to as net settlements. These surrenders are included in stock options exercised in the options rollforward above. For the three months ended June 30, 2020 and 2019, respectively, we received &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11,085&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,779&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; options as payment in the exercise of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;17,665&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;17,221&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; options. For the six months ended June 30, 2020 and 2019, respectively, we received  &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13,009&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;91,598&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; options as payment in the exercise of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;22,027&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;185,951&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; options. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Common shares required to be issued upon the exercise of stock options would be issued from our authorized and unissued shares. We calculated the fair value of issued options utilizing a Black Scholes model with an expected life calculated via the simplified method as we do not have sufficient history to determine actual expected life.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:54.97076023391813%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="2"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:72%;"/&gt;&lt;td style="width:28%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2020 Grants&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Option value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$8.18&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Risk-free rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.7%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Expected dividend yield&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Expected volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;65.9%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Expected term (in years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2020Q2QTD"
      decimals="-3"
      id="d14117e594-wk-Fact-EE18F3BEDA9343E1C21BC494595ED2D6"
      unitRef="usd">1097000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d14117e598-wk-Fact-E1AFAE8CF762AC3A6166C494C3DC05BE"
      unitRef="usd">2146000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d14117e606-wk-Fact-B7B9F290640DB342B13DC494870F9ABB"
      unitRef="usd">856000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d14117e610-wk-Fact-FA66117AF21B2F819EE7C494A70D2692"
      unitRef="usd">2051000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-E75E52DD9C5A9D8E1BDF4985F102DFBC-0-wk-Fact-16CEDA277DD61396A46A4985F0F1C608">&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The status of our stock options are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:4px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Number of options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Weighted average exercise price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Outstanding at December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,966,858&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4.67&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,274,900&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8.18&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(44,381&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3.23&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Canceled and forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(211,433&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7.51&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Outstanding at June 30, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,985,944&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5.46&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="FI2019Q4"
      decimals="INF"
      id="d14117e691-wk-Fact-766EEA3C457DF38363BF4985F0CFCDF5"
      unitRef="shares">3966858</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="FI2019Q4"
      decimals="2"
      id="d14117e710-wk-Fact-B5C7A7DC3BD81C70B1024985F0CE72CE"
      unitRef="usdPerShare">4.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="FD2020Q2YTD"
      decimals="INF"
      id="d14117e725-wk-Fact-0B63179B4A9CA7404D174985F0AA6CF0"
      unitRef="shares">1274900</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="FD2020Q2YTD"
      decimals="2"
      id="d14117e739-wk-Fact-CF0540108C0AA11387374985F0D483C4"
      unitRef="usdPerShare">8.18</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="FD2020Q2YTD"
      decimals="INF"
      id="d14117e759-wk-Fact-0CF4DE76482A440041DA4985F0D369F1"
      unitRef="shares">44381</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="FD2020Q2YTD"
      decimals="2"
      id="d14117e774-wk-Fact-D9C80AB1E3F48E10C8724985F0D652D4"
      unitRef="usdPerShare">3.23</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="FD2020Q2YTD"
      decimals="INF"
      id="d14117e794-wk-Fact-C39E2D8A1922F37C69E84985F0D0C4B5"
      unitRef="shares">211433</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="FD2020Q2YTD"
      decimals="2"
      id="d14117e809-wk-Fact-EBD70E122D3F036DEC2B4985F0CC7EC5"
      unitRef="usdPerShare">7.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="FI2020Q2"
      decimals="INF"
      id="d14117e829-wk-Fact-8F0159D8A9C9F6CF038D4985F0CEDD6C"
      unitRef="shares">4985944</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="FI2020Q2"
      decimals="2"
      id="d14117e848-wk-Fact-38D3971B058B8020210A4985F0A793E9"
      unitRef="usdPerShare">5.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <apyx:StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived
      contextRef="FD2020Q2QTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d14117e871-wk-Fact-1C70F173CBFFDE71D92176E57FEA5892"
      unitRef="shares">11085</apyx:StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived>
    <apyx:StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived
      contextRef="FD2019Q2QTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d14117e875-wk-Fact-D69B6AEEEAE2A68C6DC776E58DCFF4D9"
      unitRef="shares">7779</apyx:StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived>
    <apyx:StockIssuedDuringPeriodSharesStockSwaps
      contextRef="FD2020Q2QTD"
      decimals="INF"
      id="d14117e879-wk-Fact-CC06F9EE3248C378F58176E68FC69FDF"
      unitRef="shares">17665</apyx:StockIssuedDuringPeriodSharesStockSwaps>
    <apyx:StockIssuedDuringPeriodSharesStockSwaps
      contextRef="FD2019Q2QTD"
      decimals="INF"
      id="d14117e883-wk-Fact-534CEE3E0E4A6C468D9076E69AD661FF"
      unitRef="shares">17221</apyx:StockIssuedDuringPeriodSharesStockSwaps>
    <apyx:StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived
      contextRef="FD2020Q2YTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d14117e887-wk-Fact-7A40503985C924DA7EE276E6023BB984"
      unitRef="shares">13009</apyx:StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived>
    <apyx:StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived
      contextRef="FD2019Q2YTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d14117e892-wk-Fact-7ADE1B7E2CB0F492E62F76E60ECA0641"
      unitRef="shares">91598</apyx:StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived>
    <apyx:StockIssuedDuringPeriodSharesStockSwaps
      contextRef="FD2020Q2YTD"
      decimals="INF"
      id="d14117e896-wk-Fact-DD4FB7E4F9412A03D86776E6DA8FE3DF"
      unitRef="shares">22027</apyx:StockIssuedDuringPeriodSharesStockSwaps>
    <apyx:StockIssuedDuringPeriodSharesStockSwaps
      contextRef="FD2019Q2YTD"
      decimals="INF"
      id="d14117e900-wk-Fact-ADDD66734F1E51D7AF7976E6EDF3F1FF"
      unitRef="shares">185951</apyx:StockIssuedDuringPeriodSharesStockSwaps>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-CA8A7C25A9E687D8D2104985F1023248-0-wk-Fact-EE0A3F670C645BB457454985F0EF8ED5">We calculated the fair value of issued options utilizing a Black Scholes model with an expected life calculated via the simplified method as we do not have sufficient history to determine actual expected life.&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:54.97076023391813%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="2"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:72%;"/&gt;&lt;td style="width:28%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2020 Grants&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Option value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$8.18&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Risk-free rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.7%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Expected dividend yield&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Expected volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;65.9%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Expected term (in years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="FD2020Q2YTD"
      decimals="2"
      id="d14117e946-wk-Fact-CF0540108C0AA11387374985F0D483C4"
      unitRef="usdPerShare">8.18</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="FD2020Q2YTD"
      decimals="3"
      id="d14117e957-wk-Fact-752CB4C8F6AA654C86FE4985F0CFFE91"
      unitRef="number">0.017</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="FD2020Q2YTD"
      decimals="INF"
      id="d14117e968-wk-Fact-D9357CA47A0015AE93E74985F0D0F563"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="FD2020Q2YTD"
      decimals="3"
      id="d14117e979-wk-Fact-008893106CFCB699FAEB4985F0CEF201"
      unitRef="number">0.659</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="FD2020Q2YTD"
      id="d14117e990-wk-Fact-FE6E16031DE4FA33D3794985F0C99004">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-FF3ECC055B3B35888B864985F1036916-0-wk-Fact-580D5C1682BDCE9A9BA04985F0E48B3A">INCOME TAXES &lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;On March 27, 2020, the U.S. government enacted the CARES Act to provide relief from COVID-19. The CARES Act includes a provision that allows companies to carryback net operating losses (NOL&#x2019;s) generated in the period 2018 through 2020 to prior years. In conjunction with the disposition of the Core business in 2018, we generated a significant amount of taxable income in 2018. Subsequent to this, we generated net losses in 2019 and through the first half of 2020. For the net losses generated in 2019, we previously recorded a valuation allowance on the full value of the deferred tax assets associated with our NOL carryforwards due to realization of the NOL being improbable under then existing tax law. The CARES Act makes these assets realizable, and as of the date of the CARES Act, we have recognized an income tax benefit of approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$3.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; associated with the release of the valuation allowance on our Federal NOL carryforward related to 2019. We also recognized income tax benefits of &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, related to our net loss before income taxes for the three and six months ended June 30, 2020, respectively. There are approximately an additional &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$3.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of 2018 Federal income tax payments available to offset against any other 2020 losses that may be incurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Our income tax (benefit) expense was approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$(1,492,000)&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$76,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; with an effective tax rate of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;24.1%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1.8)%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the three months ended June 30, 2020 and 2019, respectively.  Our income tax (benefit) expense was approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$(6,397,000)&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$82,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; with an effective tax rate of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;49.1%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(0.8)%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the six months ended June 30, 2020 and 2019, respectively. The effective rate differs from the statutory rate primarily due to the release of the valuation allowance on our net operating loss carryforward from 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following is a roll-forward of the Company's total gross unrecognized tax benefits, not including interest and penalties, for the period ended June 30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:75.43859649122807%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:63%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:35%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Gross Unrealized Tax Benefits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Balance at January 1, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,313&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Additions of tax positions related to the current year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Additions of tax positions related to the prior year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Decreases for tax positions related to the prior year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Balance at June 30, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,313&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We recognize accrued interest and penalties related to unrecognized tax benefits in the provision for income taxes in our condensed consolidated financial statements. As of June 30, 2020, we had approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$260,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in accrued interest and penalties related to unrecognized tax benefits. Included in the income tax benefit for the three months and six ended June 30, 2020, respectively are approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$43,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$82,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of interest and penalties on the Company's uncertain tax positions. If the Company were to prevail on all uncertain tax positions, the resulting impact will be material as the Company will recognize approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1,573,000&lt;/span&gt;&lt;/span&gt; of tax benefits in the provision of income taxes. It is expected that all of the uncertain tax positions should be resolved by October 2022.</us-gaap:IncomeTaxDisclosureTextBlock>
    <apyx:CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d15041e596-wk-Fact-A379DB924AFF7956090F4985F0DFDCED"
      unitRef="usd">-3700000</apyx:CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards>
    <apyx:CARESActIncomeTaxExpenseBenefitRelatedToCurrentPeriodNetIncomeLossBeforeIncomeTaxes
      contextRef="FD2020Q2QTD"
      decimals="-5"
      id="d15041e603-wk-Fact-9ED1E11CBE0C09522215C4B866E92F8A"
      unitRef="usd">-1500000</apyx:CARESActIncomeTaxExpenseBenefitRelatedToCurrentPeriodNetIncomeLossBeforeIncomeTaxes>
    <apyx:CARESActIncomeTaxExpenseBenefitRelatedToCurrentPeriodNetIncomeLossBeforeIncomeTaxes
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d15041e607-wk-Fact-A675029181F753735F3D76EB6B0E403E"
      unitRef="usd">-1200000</apyx:CARESActIncomeTaxExpenseBenefitRelatedToCurrentPeriodNetIncomeLossBeforeIncomeTaxes>
    <apyx:CARESActFederalIncomeTaxPaymentsAvailableToOffsetCurrentPeriodLosses
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d15041e611-wk-Fact-8B842872D7F4E086044576EBD88B95E2"
      unitRef="usd">3200000</apyx:CARESActFederalIncomeTaxPaymentsAvailableToOffsetCurrentPeriodLosses>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2020Q2QTD"
      decimals="-3"
      id="d15041e620-wk-Fact-E9BF97A1F660F7AF17B476D0BF378CF0"
      unitRef="usd">-1492000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d15041e624-wk-Fact-697A31017246D2D682494985F0AB7C3C"
      unitRef="usd">76000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="FD2020Q2QTD"
      decimals="3"
      id="d15041e628-wk-Fact-30D9AC085D01697A372976EDCE634D61"
      unitRef="number">0.241</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="FD2019Q2QTD"
      decimals="3"
      id="d15041e632-wk-Fact-DF4B10EB2EC79FF1E13D76EDF02963C9"
      unitRef="number">-0.018</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2020Q2YTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember"
      decimals="-3"
      id="d15041e636-wk-Fact-8ECB3F441E3B836BA089496B25395465"
      unitRef="usd">-6397000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d15041e641-wk-Fact-281575BA2D8E389065EB4985F0D51761"
      unitRef="usd">82000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="FD2020Q2YTD"
      decimals="3"
      id="d15041e645-wk-Fact-656FD7B8908EB50979B876EE8C66D1F1"
      unitRef="number">0.491</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="FD2019Q2YTD"
      decimals="3"
      id="d15041e649-wk-Fact-7DDE18654DF9DC190B5776EE9818CA5A"
      unitRef="number">-0.008</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-C7DEDC9EBDE646917BCA4985F1037DCE-0-wk-Fact-8D75C7A491B70FA5C8E74985F0E40315">&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following is a roll-forward of the Company's total gross unrecognized tax benefits, not including interest and penalties, for the period ended June 30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:75.43859649122807%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:63%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:35%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Gross Unrealized Tax Benefits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Balance at January 1, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,313&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Additions of tax positions related to the current year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Additions of tax positions related to the prior year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Decreases for tax positions related to the prior year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Balance at June 30, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,313&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="FI2019Q4"
      decimals="-3"
      id="d15041e710-wk-Fact-D10A81D816CE1EA1DDC94985F0F8F8C8"
      unitRef="usd">1313000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d15041e725-wk-Fact-BCE9DEAED3314334BEAF4985F0ABA01E"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d15041e745-wk-Fact-E4FF5D2532FA277115D64985F0A4DF2E"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d15041e765-wk-Fact-1309016AF2373952DD034985F0A59E16"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="FI2020Q2"
      decimals="-3"
      id="d15041e790-wk-Fact-149570C000DE66340C344985F0A7B708"
      unitRef="usd">1313000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="FI2020Q2"
      decimals="-3"
      id="d15041e805-wk-Fact-566BD4B79D36005217C176EFF7C1FD73"
      unitRef="usd">260000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="FD2020Q2QTD"
      decimals="-3"
      id="d15041e809-wk-Fact-B3A2534934D1D7DD9C2E76F0571D87FC"
      unitRef="usd">43000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d15041e813-wk-Fact-DE17255186B40C05F7B376F08ED9C08E"
      unitRef="usd">82000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="FI2020Q2"
      decimals="-3"
      id="d15041e817-wk-Fact-62BE02B0E7D4EADEF082C497F9DFB2F2"
      unitRef="usd">1573000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-533AA3D0E29B30D261E44985F103182E-0-wk-Fact-3DC9E4BAA50E390E63704985F0ED5BFB">COMMITMENTS AND CONTINGENCIES&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Litigation &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The medical device industry is characterized by frequent claims and litigation, and we are and may become subject to various claims, lawsuits and proceedings in the ordinary course of our business. Such claims may include claims by current or former employees, distributors and competitors, claims concerning the marketing and promotion of our products and product liability claims.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We are involved in a number of legal actions relating to the use of our Helium Plasma technology. The outcomes of these legal actions are not within our complete control and may not be known for prolonged periods of time. We believe that such claims are adequately covered by insurance; however, in the case of one of our carriers, we are in a dispute regarding the total level of coverage available. Notwithstanding the foregoing, in the opinion of management, the Company has meritorious defenses and such claims are not expected, individually or in the aggregate, to result in a material, adverse effect on our financial condition. However, in the event that damages exceed the aggregate coverage limits of our policies or if our insurance carriers disclaim coverage, we believe it is possible that costs associated with these claims could have a material adverse impact on our consolidated results of operations, financial position or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;On April 17, 2019, a complaint (the &#x201c;Complaint&#x201d;) was filed in the United States District Court for the Middle District of Florida, against the Company and Charles D. Goodwin, the Company&#x2019;s President and Chief Executive Officer and a member of the Company&#x2019;s Board of Directors, alleging certain violations of the Securities Exchange Act of 1934, as amended.&#160; On July 16, 2019, the Court appointed lead plaintiff for the putative class and approved the lead plaintiff&#x2019;s selection of counsel. On September 3, 2019, lead plaintiff filed an amended complaint (the &#x201c;Amended Complaint&#x201d;) with the Court.&#160; &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Amended Complaint seeks class action status on behalf of all persons and entities that acquired the Company&#x2019;s securities between December 21, 2018 and April 1, 2019, and alleges violations by the Company and Goodwin of Sections 10(b) and 20(a) &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;of the Securities Exchange Act of 1934, as amended and Rule 10b-5 thereunder, primarily related to certain public statements concerning the Premarket Notification 510(k) submission made to the US Food and Drug Administration for a new indication for the Company&#x2019;s J-Plasma&#xae; technology for use in dermal resurfacing procedures. &#160;On October 3, 2019, defendants filed a motion to dismiss the Amended Complaint, and on March 11, 2020, the Court denied that motion.&#160; On July 10, 2020, the parties executed a settlement agreement, which is subject to Court approval. The Court preliminarily approved the settlement on July 21, 2020.&#160;The settlement agreement provides for the dismissal of the action with prejudice.&#160;At June 30, 2020,&#160;approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$670,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;of the&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1,000,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; insurance&#160;deductible is unpaid and is included in accrued expenses and other current liabilities in the accompanying consolidated balance sheets. During July 2020, substantially all of the unpaid deductible was paid.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We accrue a liability in our consolidated financial statements for these actions when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is recorded. If a loss is reasonably possible, but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed in the notes to the consolidated financial statements. In most cases, significant judgment is required to estimate the amount and timing of a loss to be recorded, actual results may differ from these estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Purchase Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;At &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, we had purchase commitments totaling approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$500,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; substantially all of which is expected to be purchased within the next six months.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;China Joint Venture&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In late 2019, we executed a joint venture agreement with our Chinese supplier. The agreement requires the Company to make a capital contribution into the newly formed entity of approximately&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$360,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. During July 2020, we funded approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$150,000&lt;/span&gt;&lt;/span&gt; of the commitment. As of the date of these consolidated financial statements, the joint venture has not commenced principal operations.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="FI2020Q2_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_us-gaap_UnfavorableRegulatoryActionMember"
      decimals="INF"
      id="d14031e619-wk-Fact-3FDB21E1BD1FBEC4BE2676F93A5AB122"
      unitRef="usd">670000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <apyx:LossContingencyAccrualTotalAccruedToDate
      contextRef="FI2020Q2_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_us-gaap_UnfavorableRegulatoryActionMember"
      decimals="-3"
      id="d14031e623-wk-Fact-FE92429057FF096BEC9176F96995C9C5"
      unitRef="usd">1000000</apyx:LossContingencyAccrualTotalAccruedToDate>
    <us-gaap:PurchaseObligation
      contextRef="FI2020Q2"
      decimals="-3"
      id="d14031e648-wk-Fact-C2DD7AF88F4CA841C10376FA469A0B27"
      unitRef="usd">500000</us-gaap:PurchaseObligation>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="FI2019Q4_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_CorporateJointVentureMember"
      decimals="-3"
      id="d14031e662-wk-Fact-DE42ADD9BBFF995EC90CA6B41E8E34D3"
      unitRef="usd">360000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:PaymentsToAcquireInterestInJointVenture
      contextRef="D2020Q3July2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_CorporateJointVentureMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember"
      decimals="0"
      id="d14031e666-wk-Fact-C916F0862D482C850CE6A6BAB1C364CD"
      unitRef="usd">150000</us-gaap:PaymentsToAcquireInterestInJointVenture>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-B3CCB92EE985A763A5864985F103897B-0-wk-Fact-D33F50D0DAB7A77C022F4985F0E34AF6">RELATED PARTY TRANSACTIONS&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Several relatives of Nikolay Shilev, Apyx Bulgaria&#x2019;s Managing Director, are considered related parties. Teodora Shileva, Mr. Shilev&#x2019;s spouse, is an employee of the Company working in the accounting department. Antoaneta Dimitrova Shileva-Toromanova, Mr. Shilev&#x2019;s sister, is the Manager of Production and Human Resources. Svetoslav Shilev, Mr. Shilev&#x2019;s son, is an engineer in the quality assurance department.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In addition, as part of the purchase of the Bulgaria manufacturing facility, Mr. Shilev was issued a note payable for &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$140,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; to be paid &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5 years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; after the original purchase date, which is in October 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The partner in our China joint venture is also a supplier of the Company. During the six months ended June 30, 2020, we made purchases from this supplier of approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$850,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. At June 30, 2020, we owed this supplier approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$4,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent
      contextRef="FI2020Q2_us-gaap_RelatedPartyTransactionAxis_apyx_BulgariaManufacturingPlantPurchaseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember"
      decimals="-3"
      id="d14503e591-wk-Fact-63CD81000BB91E59BEAE4985F0E3CEE6"
      unitRef="usd">140000</us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent>
    <apyx:TermOfPaymentDueNotesPayableRelatedParties
      contextRef="FD2020Q2YTD_us-gaap_RelatedPartyTransactionAxis_apyx_BulgariaManufacturingPlantPurchaseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember"
      id="d14503e595-wk-Fact-378714373A6EF6AD4EBD4985F0EE59CA">P5Y</apyx:TermOfPaymentDueNotesPayableRelatedParties>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty
      contextRef="FD2020Q2YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_CoVenturerMember"
      decimals="-3"
      id="d14503e604-wk-Fact-74A156DC4A85BCBA97A6A6C09D975764"
      unitRef="usd">850000</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="FI2020Q2_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_CoVenturerMember"
      decimals="-3"
      id="d14503e608-wk-Fact-70687A83995FC3D0E400A6C24FE2D711"
      unitRef="usd">4000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-BF9988144F6B6C9877814985F103A391-0-wk-Fact-CBACE21BDCE7DCED14CD4985F0D9D706">GEOGRAPHIC AND SEGMENT INFORMATION &lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating segments are aggregated into reportable segments only if they exhibit similar economic characteristics. In addition to similar economic characteristics, we also consider the following factors in determining the reportable segments: the nature of business activities, the management structure directly accountable to our chief operating decision maker for operating and administrative activities, availability of discrete financial information and information presented to the Board of Directors and investors. Asset information is not reviewed by the chief operating decision maker by segment and is not available by segment, accordingly, we have not presented a measure of assets by segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Our reportable segments are disclosed as principally organized and managed as&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;two&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;operating segments: Advanced Energy and OEM. "Corporate &amp;amp; Other" includes certain unallocated corporate and administrative costs which were not specifically attributed to any reportable segment. The OEM segment is primarily development and manufacturing contract and product driven, all related expenses are recorded as cost of sales, therefore no segment specific operating expenses are incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Summarized financial information with respect to reportable segments is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Three Months Ended June 30, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Advanced Energy&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;OEM&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Corporate &amp;amp; Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,867&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,429&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,296&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Income (loss) from operations&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(3,292&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;584&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(3,459&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(6,167&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Interest income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Interest expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Other losses, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(14&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(14&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Income tax benefit&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1,492&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1,492&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Three Months Ended June 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Advanced Energy&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;OEM&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Corporate &amp;amp; Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,350&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,299&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,649&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Income (loss) from operations&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(968&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;136&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(3,590&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(4,422&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Interest income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;403&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;403&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Other losses, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(200&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(200&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Income tax expense&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;76&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;76&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Six Months Ended June 30, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Advanced Energy&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;OEM&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Corporate &amp;amp; Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,853&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,440&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9,293&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Income (loss) from operations&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(7,276&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;831&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(7,214&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(13,659&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Interest income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;223&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;223&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Interest expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(14&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(14&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Other income, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;412&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;412&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Income tax benefit&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(6,397&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(6,397&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Six Months Ended June 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Advanced Energy&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;OEM&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Corporate &amp;amp; Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9,721&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,557&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12,278&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Income (loss) from operations&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(4,296&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;727&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(6,583&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(10,152&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Interest income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;826&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;826&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Other losses, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(495&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(495&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Income tax expense&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;82&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;82&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;International sales represented approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;21.0%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;24.6%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of total revenues for the three and six months ended June 30, 2020, respectively, as compared with &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;31.7%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;31.2%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of total revenues for the same prior year period. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Substantially all of these sales are denominated in U.S. dollars. Revenue by geographic region, based on the customer's &#x201c;ship to&#x201d; location on the invoice, are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Sales by Domestic and International&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Domestic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,393&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,540&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,011&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,450&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;International&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;903&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,109&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,282&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,828&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,296&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,649&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9,293&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12,278&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="FD2020Q2YTD"
      decimals="INF"
      id="d28910e590-wk-Fact-2A098727C94D24775FD54985F0D17D08"
      unitRef="segment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-B6D717FCD3B9498AA2784985F1034A94-0-wk-Fact-C02EF561DD8CB4CE10AB4985F0CF9456">&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Summarized financial information with respect to reportable segments is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Three Months Ended June 30, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Advanced Energy&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;OEM&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Corporate &amp;amp; Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,867&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,429&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,296&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Income (loss) from operations&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(3,292&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;584&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(3,459&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(6,167&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Interest income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Interest expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Other losses, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(14&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(14&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Income tax benefit&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1,492&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1,492&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Three Months Ended June 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Advanced Energy&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;OEM&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Corporate &amp;amp; Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,350&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,299&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,649&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Income (loss) from operations&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(968&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;136&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(3,590&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(4,422&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Interest income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;403&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;403&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Other losses, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(200&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(200&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Income tax expense&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;76&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;76&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Six Months Ended June 30, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Advanced Energy&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;OEM&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Corporate &amp;amp; Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,853&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,440&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9,293&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Income (loss) from operations&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(7,276&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;831&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(7,214&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(13,659&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Interest income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;223&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;223&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Interest expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(14&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(14&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Other income, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;412&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;412&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Income tax benefit&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(6,397&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(6,397&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Six Months Ended June 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Advanced Energy&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;OEM&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Corporate &amp;amp; Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9,721&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,557&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12,278&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Income (loss) from operations&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(4,296&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;727&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(6,583&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(10,152&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Interest income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;826&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;826&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Other losses, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(495&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(495&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Income tax expense&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;82&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;82&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_AdvancedEnergyMember"
      decimals="-3"
      id="d28910e807-wk-Fact-7519FBCB2DED681281A576FF7F680E99"
      unitRef="usd">2867000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_OEMMember"
      decimals="-3"
      id="d28910e826-wk-Fact-F7831D26858FE62D1AC476FF81DA703E"
      unitRef="usd">1429000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember"
      decimals="-3"
      id="d28910e845-wk-Fact-5DD55B3BD4CEBD5B84A076FF8445DA6E"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD"
      decimals="-3"
      id="d28910e865-wk-Fact-F2B9353892A9BBCB558E4985F0BD4A4E"
      unitRef="usd">4296000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2020Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_AdvancedEnergyMember"
      decimals="-3"
      id="d28910e962-wk-Fact-01771EC32019CF0D4CF64985F0EF9FFB"
      unitRef="usd">-3292000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2020Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_OEMMember"
      decimals="-3"
      id="d28910e982-wk-Fact-2F1DCC6317DDADE215CA76FFB7946DF9"
      unitRef="usd">584000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2020Q2QTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember"
      decimals="-3"
      id="d28910e1001-wk-Fact-358A757489759927403876FFBA2B1801"
      unitRef="usd">-3459000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2020Q2QTD"
      decimals="-3"
      id="d28910e1022-wk-Fact-6E4681D333F9B4FEF1B34985F0B9BDC1"
      unitRef="usd">-6167000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeOperating
      contextRef="FD2020Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_AdvancedEnergyMember"
      decimals="-3"
      id="d28910e1125-wk-Fact-8CFAFC52F132346BB79676FFDDCE6E62"
      unitRef="usd">0</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="FD2020Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_OEMMember"
      decimals="-3"
      id="d28910e1144-wk-Fact-B4C59B639A145C31ACEC76FFE0658ED6"
      unitRef="usd">0</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="FD2020Q2QTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember"
      decimals="-3"
      id="d28910e1163-wk-Fact-A0717C0DE726A0402E1E4985F0C643DE"
      unitRef="usd">7000</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="FD2020Q2QTD"
      decimals="-3"
      id="d28910e1183-wk-Fact-C227DBBE6CA87150FAD476D0BF5F3509"
      unitRef="usd">7000</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestExpense
      contextRef="FD2020Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_AdvancedEnergyMember"
      decimals="-3"
      id="d28910e1203-wk-Fact-3FC0411C46D8C7DDF3107700722CFDA3"
      unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="FD2020Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_OEMMember"
      decimals="-3"
      id="d28910e1222-wk-Fact-75554FA9137DF367D113770074C542EB"
      unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="FD2020Q2QTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember"
      decimals="-3"
      id="d28910e1241-wk-Fact-9321CA8176C640E83270770077404CB0"
      unitRef="usd">8000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="FD2020Q2QTD"
      decimals="-3"
      id="d28910e1262-wk-Fact-4935FB2E9F22EBA81F8376D0BF5C4BBA"
      unitRef="usd">8000</us-gaap:InterestExpense>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="FD2020Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_AdvancedEnergyMember"
      decimals="-3"
      id="d28910e1283-wk-Fact-2255372453A307ABBE7577000340DF1B"
      unitRef="usd">0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="FD2020Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_OEMMember"
      decimals="-3"
      id="d28910e1302-wk-Fact-A2BDC8C75A2EB61DEE1F770005813029"
      unitRef="usd">0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="FD2020Q2QTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember"
      decimals="-3"
      id="d28910e1321-wk-Fact-A088AA4D9C2335EDFBB64985F0D8EE3B"
      unitRef="usd">-14000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="FD2020Q2QTD"
      decimals="-3"
      id="d28910e1342-wk-Fact-828CD9B42DC1F8EFA72276D0BF3B49AF"
      unitRef="usd">-14000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2020Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_AdvancedEnergyMember"
      decimals="-3"
      id="d28910e1363-wk-Fact-5F333A32AF647FE0B9F2770036A7DC62"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2020Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_OEMMember"
      decimals="-3"
      id="d28910e1382-wk-Fact-67F9C3EE4C7C91B0ED927700391278E7"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2020Q2QTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember"
      decimals="-3"
      id="d28910e1401-wk-Fact-DAE407B701FC8E167C134985F0ADA564"
      unitRef="usd">-1492000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2020Q2QTD"
      decimals="-3"
      id="d28910e1422-wk-Fact-E9BF97A1F660F7AF17B476D0BF378CF0"
      unitRef="usd">-1492000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_AdvancedEnergyMember"
      decimals="-3"
      id="d28910e1637-wk-Fact-DFF395C9D97921FF84B076FE45E9EA82"
      unitRef="usd">5350000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_OEMMember"
      decimals="-3"
      id="d28910e1656-wk-Fact-B16372DC5FE1DCAAEAC576FE499E3FAE"
      unitRef="usd">1299000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember"
      decimals="-3"
      id="d28910e1675-wk-Fact-BDB53711C3A7D637DCDA76FE4D140863"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d28910e1695-wk-Fact-C4195FF56DAD7F05326E76D0BF59C9A4"
      unitRef="usd">6649000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2019Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_AdvancedEnergyMember"
      decimals="-3"
      id="d28910e1792-wk-Fact-D72CD5490897D81688A276FE7F269069"
      unitRef="usd">-968000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2019Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_OEMMember"
      decimals="-3"
      id="d28910e1812-wk-Fact-93F908F676EC020F4D9E76FE82DB6378"
      unitRef="usd">136000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2019Q2QTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember"
      decimals="-3"
      id="d28910e1831-wk-Fact-C1895E6BA780B07DC74A76FE86A24E37"
      unitRef="usd">-3590000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d28910e1852-wk-Fact-AC7AD5EC8AB2905C951C76D0BF2A7387"
      unitRef="usd">-4422000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeOperating
      contextRef="FD2019Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_AdvancedEnergyMember"
      decimals="-3"
      id="d28910e1955-wk-Fact-FECF995361E45CDAC81C76FEA9143826"
      unitRef="usd">0</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="FD2019Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_OEMMember"
      decimals="-3"
      id="d28910e1974-wk-Fact-50D501577F093A5DA80D76FEADD9DA18"
      unitRef="usd">0</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="FD2019Q2QTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember"
      decimals="-3"
      id="d28910e1993-wk-Fact-45FA6D22069933984C0676FEB168959E"
      unitRef="usd">403000</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d28910e2013-wk-Fact-3B8FD60B29B0E0A1762F4985F0F80D00"
      unitRef="usd">403000</us-gaap:InterestIncomeOperating>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="FD2019Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_AdvancedEnergyMember"
      decimals="-3"
      id="d28910e2033-wk-Fact-75375603BE1BF9AD854876FEFD374613"
      unitRef="usd">0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="FD2019Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_OEMMember"
      decimals="-3"
      id="d28910e2052-wk-Fact-E256B4DA4999E7D2E48376FF010FE4E7"
      unitRef="usd">0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="FD2019Q2QTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember"
      decimals="-3"
      id="d28910e2071-wk-Fact-9D9F767282B88E76243676FF049FDEBA"
      unitRef="usd">-200000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d28910e2092-wk-Fact-397B5DCDE56513731F094985F0C6DCEF"
      unitRef="usd">-200000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2019Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_AdvancedEnergyMember"
      decimals="-3"
      id="d28910e2113-wk-Fact-4A71523D0B490544AB3976FF307B1D3D"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2019Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_OEMMember"
      decimals="-3"
      id="d28910e2132-wk-Fact-A9CDAC4DC7947C9130E376FF33F6839B"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2019Q2QTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember"
      decimals="-3"
      id="d28910e2151-wk-Fact-0A9919C09E552445DA5676FF37BF6719"
      unitRef="usd">76000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d28910e2171-wk-Fact-697A31017246D2D682494985F0AB7C3C"
      unitRef="usd">76000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_AdvancedEnergyMember"
      decimals="-3"
      id="d28910e2386-wk-Fact-90AE8793C9648BCE5B214985F0B89FE9"
      unitRef="usd">6853000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_OEMMember"
      decimals="-3"
      id="d28910e2405-wk-Fact-2138248AEA74FBF678964985F0B5BA9D"
      unitRef="usd">2440000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember"
      decimals="-3"
      id="d28910e2424-wk-Fact-0A893C5EC4211E2BF5234985F0B0D2C6"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d28910e2444-wk-Fact-9BDD69852F22B2CE28FC496B254AFE05"
      unitRef="usd">9293000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2020Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_AdvancedEnergyMember"
      decimals="-3"
      id="d28910e2543-wk-Fact-FAFCFFB24DF51871B4EA496B247A9CEE"
      unitRef="usd">-7276000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2020Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_OEMMember"
      decimals="-3"
      id="d28910e2563-wk-Fact-D385D8B685CA7F794D534985F0AD87C2"
      unitRef="usd">831000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2020Q2YTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember"
      decimals="-3"
      id="d28910e2582-wk-Fact-69A7A9F22EBDFD910EFA4985F0F1183E"
      unitRef="usd">-7214000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d28910e2603-wk-Fact-5D65487F5B78F2E9304B496B254717EF"
      unitRef="usd">-13659000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeOperating
      contextRef="FD2020Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_AdvancedEnergyMember"
      decimals="-3"
      id="d28910e2706-wk-Fact-FE6A090190793B291D054985F0EE2948"
      unitRef="usd">0</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="FD2020Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_OEMMember"
      decimals="-3"
      id="d28910e2725-wk-Fact-CCE27D3C8B11326B83F94985F0ACB9EE"
      unitRef="usd">0</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="FD2020Q2YTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember"
      decimals="-3"
      id="d28910e2744-wk-Fact-BAE3D30E79D66CD1187F4985F0DDAB85"
      unitRef="usd">223000</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d28910e2764-wk-Fact-E215DB812850C07E3CFAD6178E5F048A"
      unitRef="usd">223000</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestExpense
      contextRef="FD2020Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_AdvancedEnergyMember"
      decimals="-3"
      id="d28910e2784-wk-Fact-EFBCB7C99EE31D8F567F4985F0ED60FD"
      unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="FD2020Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_OEMMember"
      decimals="-3"
      id="d28910e2803-wk-Fact-471C69656F243EB2C8704985F0AB5A70"
      unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="FD2020Q2YTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember"
      decimals="-3"
      id="d28910e2822-wk-Fact-541B7BA16260DDAD3AE8496B248160E4"
      unitRef="usd">14000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d28910e2843-wk-Fact-90E780016EE019A9EA93D6178E6C3B5B"
      unitRef="usd">14000</us-gaap:InterestExpense>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="FD2020Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_AdvancedEnergyMember"
      decimals="-3"
      id="d28910e2864-wk-Fact-F7186E311A061171670D4985F0AE8C04"
      unitRef="usd">0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="FD2020Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_OEMMember"
      decimals="-3"
      id="d28910e2883-wk-Fact-56D3BADAB9BA2A4D63AE4985F0A958B4"
      unitRef="usd">0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="FD2020Q2YTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember"
      decimals="-3"
      id="d28910e2902-wk-Fact-2CAF6360AB83B1F67901496B24F94508"
      unitRef="usd">412000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d28910e2922-wk-Fact-385DF51A61546F8417FCD6178E54A764"
      unitRef="usd">412000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2020Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_AdvancedEnergyMember"
      decimals="-3"
      id="d28910e2944-wk-Fact-605FD041AFE678778DDD4985F0F284CB"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2020Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_OEMMember"
      decimals="-3"
      id="d28910e2963-wk-Fact-48EAEB4B9D76D933914B4985F0EF35C3"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2020Q2YTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember"
      decimals="-3"
      id="d28910e2982-wk-Fact-8ECB3F441E3B836BA089496B25395465"
      unitRef="usd">-6397000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d28910e3003-wk-Fact-D787ABABBBA24B299E50C92CFBFFA215"
      unitRef="usd">-6397000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_AdvancedEnergyMember"
      decimals="-3"
      id="d28910e3224-wk-Fact-CF44D983D6F51B1755564985F0A8AF1D"
      unitRef="usd">9721000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_OEMMember"
      decimals="-3"
      id="d28910e3243-wk-Fact-C90F2EB637B4E9067DFB4985F0A474B6"
      unitRef="usd">2557000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember"
      decimals="-3"
      id="d28910e3262-wk-Fact-FB4BF43C049DFA6623AF4985F0BF995D"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d28910e3282-wk-Fact-D8E04E1C126201AA5E924985F0D415DA"
      unitRef="usd">12278000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2019Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_AdvancedEnergyMember"
      decimals="-3"
      id="d28910e3379-wk-Fact-F002544E81C2B3B6C3914985F0ACDCD1"
      unitRef="usd">-4296000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2019Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_OEMMember"
      decimals="-3"
      id="d28910e3399-wk-Fact-1521BB33CA335ED0149D4985F0AF6705"
      unitRef="usd">727000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2019Q2YTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember"
      decimals="-3"
      id="d28910e3418-wk-Fact-F4DB9144B623547AD8BA4985F0BFA746"
      unitRef="usd">-6583000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d28910e3439-wk-Fact-7E20E27051E14A0D6F134985F0DA82C9"
      unitRef="usd">-10152000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeOperating
      contextRef="FD2019Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_AdvancedEnergyMember"
      decimals="-3"
      id="d28910e3542-wk-Fact-6590C10A74EDBE35B1984985F0AAC649"
      unitRef="usd">0</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="FD2019Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_OEMMember"
      decimals="-3"
      id="d28910e3561-wk-Fact-264AA624159BA6C06AB04985F0C45E3A"
      unitRef="usd">0</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="FD2019Q2YTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember"
      decimals="-3"
      id="d28910e3580-wk-Fact-CDF1BC73E94640511E7E4985F0BA9AE2"
      unitRef="usd">826000</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d28910e3600-wk-Fact-6FCD05FE238ECD6069284985F0D3ADDC"
      unitRef="usd">826000</us-gaap:InterestIncomeOperating>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="FD2019Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_AdvancedEnergyMember"
      decimals="-3"
      id="d28910e3620-wk-Fact-8ECC999CD8F08AB4B1CC4985F0AFF543"
      unitRef="usd">0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="FD2019Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_OEMMember"
      decimals="-3"
      id="d28910e3639-wk-Fact-50B3C3E6D36A8B746C3F4985F0BCAE5E"
      unitRef="usd">0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="FD2019Q2YTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember"
      decimals="-3"
      id="d28910e3658-wk-Fact-848E7FC85E1472F505E14985F0BE7857"
      unitRef="usd">-495000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d28910e3679-wk-Fact-D2C45063AEB20A37404A4985F0F80DE7"
      unitRef="usd">-495000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2019Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_AdvancedEnergyMember"
      decimals="-3"
      id="d28910e3702-wk-Fact-7521982DBCFC17E8AB084985F0B735D8"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2019Q2YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_OEMMember"
      decimals="-3"
      id="d28910e3721-wk-Fact-1E471E616082E88D83FA4985F0A62198"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2019Q2YTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember"
      decimals="-3"
      id="d28910e3740-wk-Fact-63D1A137F55D80F5E2F74985F0E42D74"
      unitRef="usd">82000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d28910e3760-wk-Fact-281575BA2D8E389065EB4985F0D51761"
      unitRef="usd">82000</us-gaap:IncomeTaxExpenseBenefit>
    <apyx:TotalRevenuePercent
      contextRef="FD2020Q2QTD"
      decimals="3"
      id="d28910e3793-wk-Fact-8C7E4F3B0801D2C5111A7702A3ADE38C"
      unitRef="number">0.210</apyx:TotalRevenuePercent>
    <apyx:TotalRevenuePercent
      contextRef="FD2020Q2YTD"
      decimals="3"
      id="d28910e3797-wk-Fact-A0542E7839F890163FEE4985F0D1E264"
      unitRef="number">0.246</apyx:TotalRevenuePercent>
    <apyx:TotalRevenuePercent
      contextRef="FD2019Q2QTD"
      decimals="3"
      id="d28910e3801-wk-Fact-9C1CB00C7D6D681D966B7702B0746EF4"
      unitRef="number">0.317</apyx:TotalRevenuePercent>
    <apyx:TotalRevenuePercent
      contextRef="FD2019Q2YTD"
      decimals="3"
      id="d28910e3805-wk-Fact-93DF199A4285ED200C354985F0D13ED2"
      unitRef="number">0.312</apyx:TotalRevenuePercent>
    <us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-9FC547D087F611E1BC484985F103B558-0-wk-Fact-05C73EA0CA4912EC4CE84985F0CEB241">Revenue by geographic region, based on the customer's &#x201c;ship to&#x201d; location on the invoice, are as follows:&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Sales by Domestic and International&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Domestic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,393&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,540&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,011&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,450&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;International&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;903&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,109&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,282&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,828&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,296&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,649&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9,293&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12,278&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_srt_StatementGeographicalAxis_country_US"
      decimals="-3"
      id="d28910e4101-wk-Fact-E41056F015EF0B1880134985F0EE8203"
      unitRef="usd">3393000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_StatementGeographicalAxis_country_US"
      decimals="-3"
      id="d28910e4120-wk-Fact-5EA6A6F45969B745DBF84985F0EE5B3B"
      unitRef="usd">4540000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_srt_StatementGeographicalAxis_country_US"
      decimals="-3"
      id="d28910e4139-wk-Fact-4BF5AF72493A878B81C94985F0D361DE"
      unitRef="usd">7011000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_StatementGeographicalAxis_country_US"
      decimals="-3"
      id="d28910e4159-wk-Fact-4AAC858E92EBC74221724985F0E6FBB1"
      unitRef="usd">8450000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-3"
      id="d28910e4174-wk-Fact-F31E009617DA147503DB4985F0EEDAE0"
      unitRef="usd">903000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-3"
      id="d28910e4193-wk-Fact-81BBCCE0FFF736295B6F4985F0E20313"
      unitRef="usd">2109000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-3"
      id="d28910e4212-wk-Fact-F3EA3792C71B4BBD16044985F0E436D6"
      unitRef="usd">2282000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_StatementGeographicalAxis_us-gaap_NonUsMember"
      decimals="-3"
      id="d28910e4232-wk-Fact-71B5395672850F23CADF4985F0A9EFD6"
      unitRef="usd">3828000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD"
      decimals="-3"
      id="d28910e4257-wk-Fact-F2B9353892A9BBCB558E4985F0BD4A4E"
      unitRef="usd">4296000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d28910e4276-wk-Fact-C4195FF56DAD7F05326E76D0BF59C9A4"
      unitRef="usd">6649000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d28910e4295-wk-Fact-9BDD69852F22B2CE28FC496B254AFE05"
      unitRef="usd">9293000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d28910e4315-wk-Fact-D8E04E1C126201AA5E924985F0D415DA"
      unitRef="usd">12278000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140346917474344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Aug. 06, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-12183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">APYX MEDICAL CORPORATION<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">11-2644611<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">5115 Ulmerton Road,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Clearwater<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">FL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">33760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">384-2323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">APYX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,216,349<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000719135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140346842904696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 46,156<span></span>
</td>
<td class="nump">$ 58,812<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Trade accounts receivable, net of allowance of $760 and $273</a></td>
<td class="nump">6,306<span></span>
</td>
<td class="nump">7,987<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesReceivable', window );">Income tax receivables</a></td>
<td class="nump">6,443<span></span>
</td>
<td class="nump">426<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="nump">1,671<span></span>
</td>
<td class="nump">1,233<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories, net of provision for obsolescence of $685 and $392</a></td>
<td class="nump">5,257<span></span>
</td>
<td class="nump">5,068<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">4,008<span></span>
</td>
<td class="nump">3,207<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">69,841<span></span>
</td>
<td class="nump">76,733<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net of accumulated depreciation and amortization of $4,702 and $4,403</a></td>
<td class="nump">6,440<span></span>
</td>
<td class="nump">6,618<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">295<span></span>
</td>
<td class="nump">350<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease right-of-use assets</a></td>
<td class="nump">691<span></span>
</td>
<td class="nump">653<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">560<span></span>
</td>
<td class="nump">391<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">77,827<span></span>
</td>
<td class="nump">84,745<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,206<span></span>
</td>
<td class="nump">2,438<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other liabilities</a></td>
<td class="nump">6,911<span></span>
</td>
<td class="nump">9,396<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">112<span></span>
</td>
<td class="nump">108<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Current portion of finance lease liabilities</a></td>
<td class="nump">266<span></span>
</td>
<td class="nump">229<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Related party note payable</a></td>
<td class="nump">140<span></span>
</td>
<td class="nump">140<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">9,635<span></span>
</td>
<td class="nump">12,311<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">177<span></span>
</td>
<td class="nump">235<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Long-term finance lease liabilities</a></td>
<td class="nump">414<span></span>
</td>
<td class="nump">421<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">765<span></span>
</td>
<td class="nump">519<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">10,991<span></span>
</td>
<td class="nump">13,486<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS&#8217; EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 75,000,000 shares authorized; 34,201,895 issued and outstanding as of June 30, 2020, and 34,312,527 issued and 34,169,952 outstanding as of December 31, 2019</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">58,926<span></span>
</td>
<td class="nump">56,708<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">7,876<span></span>
</td>
<td class="nump">14,517<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">66,836<span></span>
</td>
<td class="nump">71,259<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 77,827<span></span>
</td>
<td class="nump">$ 84,745<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.5(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140346924021624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance for doubtful accounts receivable</a></td>
<td class="nump">$ 760<span></span>
</td>
<td class="nump">$ 273<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_ProvisionForObsolescenceInventory', window );">Inventories, provision for obsolescence</a></td>
<td class="nump">685<span></span>
</td>
<td class="nump">392<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation and amortization</a></td>
<td class="nump">$ 4,702<span></span>
</td>
<td class="nump">$ 4,403<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">75,000,000<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">34,201,895<span></span>
</td>
<td class="nump">34,312,257<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">34,201,895<span></span>
</td>
<td class="nump">34,169,952<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_ProvisionForObsolescenceInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Provision For Obsolescence, Inventory</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_ProvisionForObsolescenceInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121599878&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140346842916952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales</a></td>
<td class="nump">$ 4,296<span></span>
</td>
<td class="nump">$ 6,649<span></span>
</td>
<td class="nump">$ 9,293<span></span>
</td>
<td class="nump">$ 12,278<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">2,202<span></span>
</td>
<td class="nump">1,975<span></span>
</td>
<td class="nump">4,215<span></span>
</td>
<td class="nump">4,041<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">2,094<span></span>
</td>
<td class="nump">4,674<span></span>
</td>
<td class="nump">5,078<span></span>
</td>
<td class="nump">8,237<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Other costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">975<span></span>
</td>
<td class="nump">888<span></span>
</td>
<td class="nump">1,955<span></span>
</td>
<td class="nump">1,618<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Professional services</a></td>
<td class="nump">1,658<span></span>
</td>
<td class="nump">1,661<span></span>
</td>
<td class="nump">4,047<span></span>
</td>
<td class="nump">3,779<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalariesAndWages', window );">Salaries and related costs</a></td>
<td class="nump">3,439<span></span>
</td>
<td class="nump">3,510<span></span>
</td>
<td class="nump">6,750<span></span>
</td>
<td class="nump">6,998<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">2,189<span></span>
</td>
<td class="nump">3,037<span></span>
</td>
<td class="nump">5,985<span></span>
</td>
<td class="nump">5,994<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total other costs and expenses</a></td>
<td class="nump">8,261<span></span>
</td>
<td class="nump">9,096<span></span>
</td>
<td class="nump">18,737<span></span>
</td>
<td class="nump">18,389<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(6,167)<span></span>
</td>
<td class="num">(4,422)<span></span>
</td>
<td class="num">(13,659)<span></span>
</td>
<td class="num">(10,152)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeOperating', window );">Interest income</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">403<span></span>
</td>
<td class="nump">223<span></span>
</td>
<td class="nump">826<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(8)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(14)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other (loss) income, net</a></td>
<td class="num">(14)<span></span>
</td>
<td class="num">(200)<span></span>
</td>
<td class="nump">412<span></span>
</td>
<td class="num">(495)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total other (loss) income, net</a></td>
<td class="num">(15)<span></span>
</td>
<td class="nump">203<span></span>
</td>
<td class="nump">621<span></span>
</td>
<td class="nump">331<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(6,182)<span></span>
</td>
<td class="num">(4,219)<span></span>
</td>
<td class="num">(13,038)<span></span>
</td>
<td class="num">(9,821)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (benefit) expense</a></td>
<td class="num">(1,492)<span></span>
</td>
<td class="nump">76<span></span>
</td>
<td class="num">(6,397)<span></span>
</td>
<td class="nump">82<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss</a></td>
<td class="num">$ (4,690)<span></span>
</td>
<td class="num">$ (4,295)<span></span>
</td>
<td class="num">$ (6,641)<span></span>
</td>
<td class="num">$ (9,903)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings (loss) per Share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare', window );">Basic and diluted (in dollars per share)</a></td>
<td class="num">$ (0.14)<span></span>
</td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (0.19)<span></span>
</td>
<td class="num">$ (0.30)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each basic and diluted share of common stock or unit when the per share amount is the same for both basic and diluted shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.2(a),(b),(c),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874292-224272<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -URI http://asc.fasb.org/extlink&amp;oid=118262090&amp;loc=SL114874205-224268<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalariesAndWages">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalariesAndWages</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140346917721016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Retained Earnings</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="nump">$ 87,177<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">$ 52,920<span></span>
</td>
<td class="nump">$ 34,223<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Options exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Options exercised for cash</a></td>
<td class="nump">115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock based compensation</a></td>
<td class="nump">2,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_StockSwapToAcquireOptionsShares', window );">Shares issued on net settlement of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_StockSwapToAcquireOptionsAmount', window );">Shares issued on net settlement of stock options</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss</a></td>
<td class="num">(9,903)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,903)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Jun. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2019</a></td>
<td class="nump">79,440<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">55,086<span></span>
</td>
<td class="nump">24,320<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2019</a></td>
<td class="nump">82,831<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">54,182<span></span>
</td>
<td class="nump">28,615<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Options exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Options exercised for cash</a></td>
<td class="nump">48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock based compensation</a></td>
<td class="nump">856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_StockSwapToAcquireOptionsShares', window );">Shares issued on net settlement of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_StockSwapToAcquireOptionsAmount', window );">Shares issued on net settlement of stock options</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss</a></td>
<td class="num">(4,295)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,295)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Jun. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2019</a></td>
<td class="nump">79,440<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">55,086<span></span>
</td>
<td class="nump">24,320<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">71,259<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">56,708<span></span>
</td>
<td class="nump">14,517<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Options exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Options exercised for cash</a></td>
<td class="nump">72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock based compensation</a></td>
<td class="nump">2,146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_StockSwapToAcquireOptionsShares', window );">Shares issued on net settlement of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_StockSwapToAcquireOptionsAmount', window );">Shares issued on net settlement of stock options</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss</a></td>
<td class="num">(6,641)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,641)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2020</a></td>
<td class="nump">66,836<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">58,926<span></span>
</td>
<td class="nump">7,876<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2020</a></td>
<td class="nump">70,429<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">57,829<span></span>
</td>
<td class="nump">12,566<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock based compensation</a></td>
<td class="nump">1,097<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_StockSwapToAcquireOptionsShares', window );">Shares issued on net settlement of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_StockSwapToAcquireOptionsAmount', window );">Shares issued on net settlement of stock options</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss</a></td>
<td class="num">(4,690)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,690)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2020</a></td>
<td class="nump">$ 66,836<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">$ 58,926<span></span>
</td>
<td class="nump">$ 7,876<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_StockSwapToAcquireOptionsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock swap to acquire options amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_StockSwapToAcquireOptionsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_StockSwapToAcquireOptionsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock swap to acquire options shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_StockSwapToAcquireOptionsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140346843100552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfCashFlowsAbstract', window );"><strong>Statement of Cash Flows [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss</a></td>
<td class="num">$ (6,641)<span></span>
</td>
<td class="num">$ (9,903)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">439<span></span>
</td>
<td class="nump">316<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_ProvisionForInventoryObsolescence', window );">Provision for inventory obsolescence</a></td>
<td class="nump">413<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="nump">2,146<span></span>
</td>
<td class="nump">2,051<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Unrealized gain on short term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(164)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision (benefit) for allowance for doubtful accounts</a></td>
<td class="nump">486<span></span>
</td>
<td class="num">(238)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Trade receivables</a></td>
<td class="nump">1,195<span></span>
</td>
<td class="num">(1,333)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(7,427)<span></span>
</td>
<td class="num">(879)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(571)<span></span>
</td>
<td class="num">(1,015)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(232)<span></span>
</td>
<td class="nump">218<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued and other liabilities</a></td>
<td class="num">(2,241)<span></span>
</td>
<td class="nump">236<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(12,433)<span></span>
</td>
<td class="num">(10,675)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(184)<span></span>
</td>
<td class="num">(518)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(18,884)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from maturities of marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">80,726<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(184)<span></span>
</td>
<td class="nump">61,324<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised', window );">Proceeds from stock option exercises</a></td>
<td class="nump">72<span></span>
</td>
<td class="nump">115<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_RepaymentofFinanceLeaseLiabilities', window );">Repayment of finance lease liabilities</a></td>
<td class="num">(120)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="num">(48)<span></span>
</td>
<td class="nump">115<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rates on cash</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash, cash equivalents and restricted cash</a></td>
<td class="num">(12,656)<span></span>
</td>
<td class="nump">50,764<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, beginning of period</a></td>
<td class="nump">58,812<span></span>
</td>
<td class="nump">16,596<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of period</a></td>
<td class="nump">46,156<span></span>
</td>
<td class="nump">67,360<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Cash Flow Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Taxes</a></td>
<td class="nump">54<span></span>
</td>
<td class="nump">248<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_NonCashProceedsFromStockOptionsAndWarrantsExercised', window );">Cashless exercise of stock options</a></td>
<td class="nump">49<span></span>
</td>
<td class="nump">757<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_LeaseAdoption', window );">Right-of-use assets capitalized and lease liabilities recognized upon adoption of Topic 842</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">212<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_CapitalizationOfLeaseNonCash', window );">Right-of-use assets capitalized and lease liabilities recognized upon lease remeasurement</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">207<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_CapitalizationOfLeaseExecution', window );">Right-of-use assets capitalized and lease liabilities recognized upon execution of lease</a></td>
<td class="nump">150<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_NonCashTransferOfOtherAssetsToFixedAssets', window );">Transfer of other assets to fixed assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_NonCashTransfersOfInventoryToFromFixedAssets', window );">Transfer of inventory (to) from fixed assets</a></td>
<td class="num">$ (34)<span></span>
</td>
<td class="nump">$ 262<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_CapitalizationOfLeaseExecution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Capitalization Of Lease, Execution</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_CapitalizationOfLeaseExecution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_CapitalizationOfLeaseNonCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Capitalization Of Lease, Non Cash</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_CapitalizationOfLeaseNonCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_LeaseAdoption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease Adoption</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_LeaseAdoption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_NonCashProceedsFromStockOptionsAndWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non Cash, Proceeds From Stock Options And Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_NonCashProceedsFromStockOptionsAndWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_NonCashTransferOfOtherAssetsToFixedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non Cash, Transfer Of Other Assets To Fixed Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_NonCashTransferOfOtherAssetsToFixedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_NonCashTransfersOfInventoryToFromFixedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non Cash, Transfers Of Inventory To (From) Fixed Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_NonCashTransfersOfInventoryToFromFixedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Stock Options Exercised And Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_ProvisionForInventoryObsolescence">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Provision For Inventory Obsolescence</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_ProvisionForInventoryObsolescence</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_RepaymentofFinanceLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Repayment of Finance Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_RepaymentofFinanceLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27405-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(c),9(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140346842214552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">BASIS OF PRESENTATION</a></td>
<td class="text">BASIS OF PRESENTATION<div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unless the context otherwise indicates, the terms  &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us,&#8221; &#8220;Apyx,&#8221; and similar terms refer to Apyx Medical Corporation and its consolidated subsidiaries.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are an advanced energy technology company with a passion for elevating people&#8217;s lives through innovative products in the cosmetic and surgical markets. Known for our innovative Helium Plasma Technology, Apyx is solely focused on bringing transformative solutions to the physicians and patients it serves. Our Helium Plasma Technology is marketed and sold as Renuvion&#174; in the cosmetic surgery market and J-Plasma&#174; in the hospital surgical market. Renuvion&#174; offers plastic surgeons, fascial plastic surgeons and cosmetic physicians a unique ability to provide controlled heat to the tissue to achieve their desired results. The J-Plasma&#174; system allows surgeons to operate with a high level of precision and virtually eliminating unintended tissue trauma. We also leverage our deep expertise and decades of experience in unique waveforms through original equipment manufacturing (OEM) agreements with other medical device manufacturers.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In March 2020, the World Health Organization recognized the novel strain of coronavirus ("COVID-19"), as a pandemic. This pandemic has severely restricted the level of economic activity around the world. In response, the governments of many countries, states, cities and other geographic regions have taken preventative or protective actions, such as imposing restrictions on travel and business operations and advising or requiring individuals to limit or forego their time outside of their homes. The long-term impact of the COVID-19 pandemic on our business continues to be highly uncertain and difficult to predict as the environment created by the pandemic is rapidly changing. Starting in late February, the effects of the pandemic have been material and adverse on our business. While we experienced positive indications in our business late in the second quarter, we continue to expect that the severity of the impact of the COVID-19 pandemic on our business will depend on a number of factors, including, but not limited to, the duration and severity of the pandemic and the extent and severity of the impact on our customers and suppliers, all of which are uncertain and cannot be predicted. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Most of the procedures performed using our Helium Plasma Technology are elective, and as a result many of our customers have been affected by the actions taken by various governmental authorities requiring non-essential businesses to shut down temporarily.   As these shut-downs have begun to be reversed, we have started to see an increase in demand for elective cosmetic and plastic surgery procedures, resulting in higher than expected revenues in our Advanced Energy segment.  In international markets, a greater portion of these procedures are performed in a hospital, and it is less certain when elective procedures will fully return to normal.. While we  started to experience a significant decline in sales towards the end of our first fiscal quarter, we began to see an increase in sales towards the end of our second fiscal quarter as local jurisdictions started to re-open.  However, the full extent to which the COVID-19 pandemic may materially and adversely impact the Company's future financial position, liquidity, or results of operations remains uncertain. While we began to experience an improvement in sales, domestically and internationally, towards the end of our second fiscal quarter, the pace at which this continues into the third quarter and beyond is still highly uncertain.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accompanying unaudited consolidated financial statements have been prepared based upon SEC rules that permit reduced disclosure for interim periods. For a more complete discussion of significant accounting policies and certain other information, please refer to the consolidated financial statements included in our Annual Report on Form 10-K for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">. These consolidated financial statements reflect all adjustments that are necessary for a fair presentation of results of consolidated operations and financial condition for the interim periods shown, including normal recurring accruals and other items. The results for the interim periods are not necessarily indicative of results for the full year.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140346839107928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CHANGE IN ACCOUNTING POLICY<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract', window );"><strong>Accounting Changes and Error Corrections [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingChangesTextBlock', window );">Change in Accounting Policy</a></td>
<td class="text">CHANGE IN ACCOUNTING POLICY<div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During 2019, we began granting stock option awards deeper within the organization. We do not have sufficient experience with grants to these employees and we have experienced challenges in developing reliable forfeiture estimates at the grant date. Accounting for revising the forfeiture estimates has been burdensome. Accounting Standards Codification 718, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation-Stock Compensation,</span><span style="font-family:inherit;font-size:10pt;"> prescribes two methods for accounting for forfeitures on stock option awards, either the estimation method utilized by the Company previously, or by accounting for forfeitures as they occur. On January 1, 2020 we made an accounting policy election change and began accounting for forfeitures on stock option awards using actual forfeitures. This accounting policy election change was made on a retrospective basis. However, the changes to the current and prior periods were determined to be immaterial and there have been no changes to previously reported results as a result of the change.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingChangesAndErrorCorrectionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingChangesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting accounting changes, excludes error corrections information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI http://asc.fasb.org/topic&amp;trid=2122394<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingChangesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140346842329064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RECENT ACCOUNTING PRONOUNCEMENTS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract', window );"><strong>Accounting Standards Update and Change in Accounting Principle [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DescriptionOfNewAccountingPronouncementsNotYetAdopted', window );">RECENT ACCOUNTING PRONOUNCEMENTS</a></td>
<td class="text">RECENT ACCOUNTING PRONOUNCEMENTS <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2016-13, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments&#8212;Credit Losses (Topic 326).</span><span style="font-family:inherit;font-size:10pt;"> The update changes the impairment model for most financial assets and certain other instruments, including trade and other receivables, contract assets, held-to-maturity debt securities and loans, and requires entities to use a new forward-looking expected loss model that will result in the earlier recognition of allowance for losses. This update, as originally issued, was effective for annual and interim periods beginning after December 15, 2019, with early adoption permitted. In November 2019, the FASB issued ASU 2019-10, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) Effective Dates</span><span style="font-family:inherit;font-size:10pt;">, which deferred the effective dates of these standards for Smaller Reporting Companies until fiscal years beginning after December 15, 2022. The Company currently expects to continue to qualify as a Smaller Reporting Company, based upon the current SEC definition, and as a result, will be utilizing the deferred elective date. While we are in the process of determining the effects of the adoption of the standard on the consolidated financial statements,    we do not expect the impact to be material.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2017, the FASB issued ASU 2017-04,</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment</span><span style="font-family:inherit;font-size:10pt;">. The purpose of this ASU is to reduce the cost and complexity of evaluating goodwill for impairment. It eliminates the need for entities to calculate the implied fair value of goodwill by assigning the fair value of a reporting unit to all of its assets and liabilities as if that reporting unit had been acquired in a business combination. Under this ASU, an entity will perform its goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An impairment charge is recognized for the amount by which the carrying value exceeds the reporting unit&#8217;s fair value. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The Company adopted the ASU on January 1, 2020. The amendment did not have an impact on our consolidated financial condition or results of operations.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">No other new accounting pronouncement issued or effective during the fiscal year had or is expected to have a material impact on our consolidated financial statements or disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DescriptionOfNewAccountingPronouncementsNotYetAdopted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a new accounting pronouncement that has been issued but not yet adopted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI http://asc.fasb.org/topic&amp;trid=2122394<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DescriptionOfNewAccountingPronouncementsNotYetAdopted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140346839483560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORIES</a></td>
<td class="text">INVENTORIES<div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventories are stated at the lower of cost or net realizable values. Cost is determined on a first in, first out basis. Finished goods and work-in-process inventories include material, labor and overhead costs. Factory overhead costs are primarily allocated to inventory manufactured in-house based upon labor hours. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventories consisted of the following:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(In thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">June&#160;30, <br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, <br/>2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Raw materials</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,441</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,935</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Work in process</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,504</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,209</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finished goods </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,997</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,316</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross inventories</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,942</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,460</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: provision for obsolescence</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(685</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(392</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventories, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,257</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,068</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the second fiscal quarter, we reassessed our forecasted product mix due to COVID-19, increased availability of our newer handpiece designs and earlier than expected completion of product registrations in some of our foreign markets.&#160; As a result, certain products were reduced to a lower carrying value, and some components were also written off as it was determined to cease further production on these models. The total associated impairment was approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$400,000</span></span><span style="font-family:inherit;font-size:10pt;"> and is included in cost of sales in the accompanying consolidated statements of income for the three and six months ended June 30, 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140346839516952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</a></td>
<td class="text">ACCRUED EXPENSES AND OTHER CURRENT LIABILTIES<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued expenses and other current liabilities consisted of the following:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:94.53125%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:63%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30, </span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued payroll</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>726</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>694</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued bonuses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,306</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued commissions</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>531</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>877</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued product warranties</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>439</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>452</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued insurance</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>626</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,170</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued professional fees</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,043</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,383</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Joint and several payroll liability</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,045</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,045</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Uncertain tax positions</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,573</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,491</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other accrued expenses and current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>928</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>978</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total accrued expenses and other current liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,911</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,396</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140346839490872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS PER SHARE<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">EARNINGS PER SHARE</a></td>
<td class="text"> PER SHARE <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We compute basic earnings per share (&#8220;basic EPS&#8221;) by dividing the net income or loss by the weighted average number of common shares outstanding for the reporting period adjusted for other units required to be included in basic EPS. Diluted earnings per share (&#8220;diluted EPS&#8221;) gives effect to all dilutive potential shares outstanding. As we are in a net loss position for all periods presented, all potential shares outstanding are anti-dilutive. The following table provides the computation of basic and diluted earnings per share.</span></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:48%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended<br/>June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended<br/>June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in thousands, except per share data)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Numerator:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4,690</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4,295</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6,641</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(9,903</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Denominator:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average shares outstanding - basic and diluted</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34,186</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33,384</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34,181</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33,363</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Earnings (loss) per share:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic and diluted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.14</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.13</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.19</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.30</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Anti-dilutive instruments excluded from diluted loss per common share:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Options</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,986</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,882</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,986</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,882</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140346840731336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK-BASED COMPENSATION</a></td>
<td class="text">STOCK-BASED COMPENSATION <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under our stock option plans, our board of directors may grant restricted stock and options to purchase common shares to our employees, officers, directors and consultants. We account for stock options in accordance with FASB ASC Topic 718, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation - Stock Compensation</span><span style="font-family:inherit;font-size:10pt;">, with stock-based compensation expense amortized over the vesting period based on the fair value on the grant date utilizing a trinomial lattice model through 2018 and the Black Scholes model for grants in 2019 and 2020, both of which include a number of estimates that affect the amount of our expense.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We recognized approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$1,097,000</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$2,146,000</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, in stock-based compensation expense during the three and </span><span style="font-family:inherit;font-size:10pt;">six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;">, as compared with </span><span style="font-family:inherit;font-size:10pt;"><span>$856,000</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$2,051,000</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, for the three and </span><span style="font-family:inherit;font-size:10pt;">six months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The status of our stock options are summarized as follows:</span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:73%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Number of options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted average exercise price</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,966,858</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.67</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,274,900</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.18</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercised</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(44,381</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.23</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Canceled and forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(211,433</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.51</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding at June 30, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,985,944</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.46</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We allow stock option holders to exercise stock-based awards by surrendering  stock-based awards with a fair value of the stock-based awards exercised, referred to as net settlements. These surrenders are included in stock options exercised in the options rollforward above. For the three months ended June 30, 2020 and 2019, respectively, we received </span><span style="font-family:inherit;font-size:10pt;"><span>11,085</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>7,779</span></span><span style="font-family:inherit;font-size:10pt;"> options as payment in the exercise of </span><span style="font-family:inherit;font-size:10pt;"><span>17,665</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>17,221</span></span><span style="font-family:inherit;font-size:10pt;"> options. For the six months ended June 30, 2020 and 2019, respectively, we received  </span><span style="font-family:inherit;font-size:10pt;"><span>13,009</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>91,598</span></span><span style="font-family:inherit;font-size:10pt;"> options as payment in the exercise of </span><span style="font-family:inherit;font-size:10pt;"><span>22,027</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>185,951</span></span><span style="font-family:inherit;font-size:10pt;"> options. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Common shares required to be issued upon the exercise of stock options would be issued from our authorized and unissued shares. We calculated the fair value of issued options utilizing a Black Scholes model with an expected life calculated via the simplified method as we do not have sufficient history to determine actual expected life.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:54.97076023391813%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"/></tr><tr><td style="width:72%;"/><td style="width:28%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2020 Grants</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Option value</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$8.18</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Risk-free rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.7%</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected dividend yield</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected volatility</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>65.9%</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected term (in years)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140346840840024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text">INCOME TAXES <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On March 27, 2020, the U.S. government enacted the CARES Act to provide relief from COVID-19. The CARES Act includes a provision that allows companies to carryback net operating losses (NOL&#8217;s) generated in the period 2018 through 2020 to prior years. In conjunction with the disposition of the Core business in 2018, we generated a significant amount of taxable income in 2018. Subsequent to this, we generated net losses in 2019 and through the first half of 2020. For the net losses generated in 2019, we previously recorded a valuation allowance on the full value of the deferred tax assets associated with our NOL carryforwards due to realization of the NOL being improbable under then existing tax law. The CARES Act makes these assets realizable, and as of the date of the CARES Act, we have recognized an income tax benefit of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$3.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> associated with the release of the valuation allowance on our Federal NOL carryforward related to 2019. We also recognized income tax benefits of </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$1.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$1.2 million</span></span><span style="font-family:inherit;font-size:10pt;">, related to our net loss before income taxes for the three and six months ended June 30, 2020, respectively. There are approximately an additional </span><span style="font-family:inherit;font-size:10pt;"><span>$3.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> of 2018 Federal income tax payments available to offset against any other 2020 losses that may be incurred. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our income tax (benefit) expense was approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$(1,492,000)</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$76,000</span></span><span style="font-family:inherit;font-size:10pt;"> with an effective tax rate of </span><span style="font-family:inherit;font-size:10pt;"><span>24.1%</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>(1.8)%</span></span><span style="font-family:inherit;font-size:10pt;"> for the three months ended June 30, 2020 and 2019, respectively.  Our income tax (benefit) expense was approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$(6,397,000)</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$82,000</span></span><span style="font-family:inherit;font-size:10pt;"> with an effective tax rate of </span><span style="font-family:inherit;font-size:10pt;"><span>49.1%</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>(0.8)%</span></span><span style="font-family:inherit;font-size:10pt;"> for the six months ended June 30, 2020 and 2019, respectively. The effective rate differs from the statutory rate primarily due to the release of the valuation allowance on our net operating loss carryforward from 2019.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following is a roll-forward of the Company's total gross unrecognized tax benefits, not including interest and penalties, for the period ended June 30, 2020.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:75.43859649122807%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:63%;"/><td style="width:1%;"/><td style="width:35%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross Unrealized Tax Benefits</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at January 1, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,313</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additions of tax positions related to the current year</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additions of tax positions related to the prior year</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Decreases for tax positions related to the prior year</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at June 30, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,313</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:10pt;">We recognize accrued interest and penalties related to unrecognized tax benefits in the provision for income taxes in our condensed consolidated financial statements. As of June 30, 2020, we had approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$260,000</span></span><span style="font-family:inherit;font-size:10pt;"> in accrued interest and penalties related to unrecognized tax benefits. Included in the income tax benefit for the three months and six ended June 30, 2020, respectively are approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$43,000</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$82,000</span></span><span style="font-family:inherit;font-size:10pt;"> of interest and penalties on the Company's uncertain tax positions. If the Company were to prevail on all uncertain tax positions, the resulting impact will be material as the Company will recognize approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$1,573,000</span></span> of tax benefits in the provision of income taxes. It is expected that all of the uncertain tax positions should be resolved by October 2022.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140346839322584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Litigation </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The medical device industry is characterized by frequent claims and litigation, and we are and may become subject to various claims, lawsuits and proceedings in the ordinary course of our business. Such claims may include claims by current or former employees, distributors and competitors, claims concerning the marketing and promotion of our products and product liability claims.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are involved in a number of legal actions relating to the use of our Helium Plasma technology. The outcomes of these legal actions are not within our complete control and may not be known for prolonged periods of time. We believe that such claims are adequately covered by insurance; however, in the case of one of our carriers, we are in a dispute regarding the total level of coverage available. Notwithstanding the foregoing, in the opinion of management, the Company has meritorious defenses and such claims are not expected, individually or in the aggregate, to result in a material, adverse effect on our financial condition. However, in the event that damages exceed the aggregate coverage limits of our policies or if our insurance carriers disclaim coverage, we believe it is possible that costs associated with these claims could have a material adverse impact on our consolidated results of operations, financial position or cash flows.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On April 17, 2019, a complaint (the &#8220;Complaint&#8221;) was filed in the United States District Court for the Middle District of Florida, against the Company and Charles D. Goodwin, the Company&#8217;s President and Chief Executive Officer and a member of the Company&#8217;s Board of Directors, alleging certain violations of the Securities Exchange Act of 1934, as amended.&#160; On July 16, 2019, the Court appointed lead plaintiff for the putative class and approved the lead plaintiff&#8217;s selection of counsel. On September 3, 2019, lead plaintiff filed an amended complaint (the &#8220;Amended Complaint&#8221;) with the Court.&#160; </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Amended Complaint seeks class action status on behalf of all persons and entities that acquired the Company&#8217;s securities between December 21, 2018 and April 1, 2019, and alleges violations by the Company and Goodwin of Sections 10(b) and 20(a) </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">of the Securities Exchange Act of 1934, as amended and Rule 10b-5 thereunder, primarily related to certain public statements concerning the Premarket Notification 510(k) submission made to the US Food and Drug Administration for a new indication for the Company&#8217;s J-Plasma&#174; technology for use in dermal resurfacing procedures. &#160;On October 3, 2019, defendants filed a motion to dismiss the Amended Complaint, and on March 11, 2020, the Court denied that motion.&#160; On July 10, 2020, the parties executed a settlement agreement, which is subject to Court approval. The Court preliminarily approved the settlement on July 21, 2020.&#160;The settlement agreement provides for the dismissal of the action with prejudice.&#160;At June 30, 2020,&#160;approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$670,000</span></span><span style="font-family:inherit;font-size:10pt;">&#160;of the&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$1,000,000</span></span><span style="font-family:inherit;font-size:10pt;"> insurance&#160;deductible is unpaid and is included in accrued expenses and other current liabilities in the accompanying consolidated balance sheets. During July 2020, substantially all of the unpaid deductible was paid.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We accrue a liability in our consolidated financial statements for these actions when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is recorded. If a loss is reasonably possible, but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed in the notes to the consolidated financial statements. In most cases, significant judgment is required to estimate the amount and timing of a loss to be recorded, actual results may differ from these estimates.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Purchase Commitments</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;">, we had purchase commitments totaling approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$500,000</span></span><span style="font-family:inherit;font-size:10pt;"> substantially all of which is expected to be purchased within the next six months.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">China Joint Venture</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:10pt;">In late 2019, we executed a joint venture agreement with our Chinese supplier. The agreement requires the Company to make a capital contribution into the newly formed entity of approximately&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$360,000</span></span><span style="font-family:inherit;font-size:10pt;">. During July 2020, we funded approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$150,000</span></span> of the commitment. As of the date of these consolidated financial statements, the joint venture has not commenced principal operations.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140346842710648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text">RELATED PARTY TRANSACTIONS<div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Several relatives of Nikolay Shilev, Apyx Bulgaria&#8217;s Managing Director, are considered related parties. Teodora Shileva, Mr. Shilev&#8217;s spouse, is an employee of the Company working in the accounting department. Antoaneta Dimitrova Shileva-Toromanova, Mr. Shilev&#8217;s sister, is the Manager of Production and Human Resources. Svetoslav Shilev, Mr. Shilev&#8217;s son, is an engineer in the quality assurance department.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, as part of the purchase of the Bulgaria manufacturing facility, Mr. Shilev was issued a note payable for </span><span style="font-family:inherit;font-size:10pt;"><span>$140,000</span></span><span style="font-family:inherit;font-size:10pt;"> to be paid </span><span style="font-family:inherit;font-size:10pt;"><span>5 years</span></span><span style="font-family:inherit;font-size:10pt;"> after the original purchase date, which is in October 2020.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The partner in our China joint venture is also a supplier of the Company. During the six months ended June 30, 2020, we made purchases from this supplier of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$850,000</span></span><span style="font-family:inherit;font-size:10pt;">. At June 30, 2020, we owed this supplier approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$4,000</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140346842318056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GEOGRAPHIC AND SEGMENT INFORMATION<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">GEOGRAPHIC AND SEGMENT INFORMATION</a></td>
<td class="text">GEOGRAPHIC AND SEGMENT INFORMATION <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating segments are aggregated into reportable segments only if they exhibit similar economic characteristics. In addition to similar economic characteristics, we also consider the following factors in determining the reportable segments: the nature of business activities, the management structure directly accountable to our chief operating decision maker for operating and administrative activities, availability of discrete financial information and information presented to the Board of Directors and investors. Asset information is not reviewed by the chief operating decision maker by segment and is not available by segment, accordingly, we have not presented a measure of assets by segment.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our reportable segments are disclosed as principally organized and managed as&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;">&#160;operating segments: Advanced Energy and OEM. "Corporate &amp; Other" includes certain unallocated corporate and administrative costs which were not specifically attributed to any reportable segment. The OEM segment is primarily development and manufacturing contract and product driven, all related expenses are recorded as cost of sales, therefore no segment specific operating expenses are incurred.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Summarized financial information with respect to reportable segments is as follows:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended June 30, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(In thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Advanced Energy</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">OEM</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Corporate &amp; Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,867</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,429</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,296</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income (loss) from operations<br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,292</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>584</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,459</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6,167</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest income</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other losses, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(14</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(14</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax benefit<br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,492</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,492</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended June 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(In thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Advanced Energy</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">OEM</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Corporate &amp; Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,350</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,299</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,649</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income (loss) from operations<br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(968</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>136</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,590</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4,422</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest income</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>403</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>403</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other losses, net</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(200</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(200</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax expense<br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>76</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>76</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended June 30, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(In thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Advanced Energy</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">OEM</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Corporate &amp; Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,853</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,440</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,293</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income (loss) from operations</span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7,276</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>831</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7,214</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(13,659</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest income</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>223</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>223</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(14</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(14</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other income, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>412</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>412</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax benefit</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6,397</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6,397</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended June 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(In thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Advanced Energy</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">OEM</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Corporate &amp; Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,721</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,557</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,278</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income (loss) from operations<br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4,296</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>727</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6,583</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(10,152</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest income</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>826</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>826</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other losses, net</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(495</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(495</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax expense</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>82</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>82</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">International sales represented approximately </span><span style="font-family:inherit;font-size:10pt;"><span>21.0%</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>24.6%</span></span><span style="font-family:inherit;font-size:10pt;"> of total revenues for the three and six months ended June 30, 2020, respectively, as compared with </span><span style="font-family:inherit;font-size:10pt;"><span>31.7%</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>31.2%</span></span><span style="font-family:inherit;font-size:10pt;"> of total revenues for the same prior year period. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Substantially all of these sales are denominated in U.S. dollars. Revenue by geographic region, based on the customer's &#8220;ship to&#8221; location on the invoice, are as follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended<br/>June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended<br/>June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(In thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Sales by Domestic and International</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Domestic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,393</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,540</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,011</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,450</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">International</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>903</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,109</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,282</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,828</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,296</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,649</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,293</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,278</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140346842220936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share based compensation</a></td>
<td class="text"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During 2019, we began granting stock option awards deeper within the organization. We do not have sufficient experience with grants to these employees and we have experienced challenges in developing reliable forfeiture estimates at the grant date. Accounting for revising the forfeiture estimates has been burdensome. Accounting Standards Codification 718, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation-Stock Compensation,</span><span style="font-family:inherit;font-size:10pt;"> prescribes two methods for accounting for forfeitures on stock option awards, either the estimation method utilized by the Company previously, or by accounting for forfeitures as they occur. On January 1, 2020 we made an accounting policy election change and began accounting for forfeitures on stock option awards using actual forfeitures. This accounting policy election change was made on a retrospective basis. However, the changes to the current and prior periods were determined to be immaterial and there have been no changes to previously reported results as a result of the change.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2016-13, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments&#8212;Credit Losses (Topic 326).</span><span style="font-family:inherit;font-size:10pt;"> The update changes the impairment model for most financial assets and certain other instruments, including trade and other receivables, contract assets, held-to-maturity debt securities and loans, and requires entities to use a new forward-looking expected loss model that will result in the earlier recognition of allowance for losses. This update, as originally issued, was effective for annual and interim periods beginning after December 15, 2019, with early adoption permitted. In November 2019, the FASB issued ASU 2019-10, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) Effective Dates</span><span style="font-family:inherit;font-size:10pt;">, which deferred the effective dates of these standards for Smaller Reporting Companies until fiscal years beginning after December 15, 2022. The Company currently expects to continue to qualify as a Smaller Reporting Company, based upon the current SEC definition, and as a result, will be utilizing the deferred elective date. While we are in the process of determining the effects of the adoption of the standard on the consolidated financial statements,    we do not expect the impact to be material.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2017, the FASB issued ASU 2017-04,</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment</span><span style="font-family:inherit;font-size:10pt;">. The purpose of this ASU is to reduce the cost and complexity of evaluating goodwill for impairment. It eliminates the need for entities to calculate the implied fair value of goodwill by assigning the fair value of a reporting unit to all of its assets and liabilities as if that reporting unit had been acquired in a business combination. Under this ASU, an entity will perform its goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An impairment charge is recognized for the amount by which the carrying value exceeds the reporting unit&#8217;s fair value. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The Company adopted the ASU on January 1, 2020. The amendment did not have an impact on our consolidated financial condition or results of operations.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">No other new accounting pronouncement issued or effective during the fiscal year had or is expected to have a material impact on our consolidated financial statements or disclosures.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventories are stated at the lower of cost or net realizable values. Cost is determined on a first in, first out basis. Finished goods and work-in-process inventories include material, labor and overhead costs. Factory overhead costs are primarily allocated to inventory manufactured in-house based upon labor hours. </span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116846552&amp;loc=d3e543-108305<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140346839147352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of inventory</a></td>
<td class="text"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventories consisted of the following:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(In thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">June&#160;30, <br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, <br/>2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Raw materials</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,441</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,935</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Work in process</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,504</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,209</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finished goods </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,997</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,316</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross inventories</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,942</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,460</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: provision for obsolescence</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(685</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(392</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventories, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,257</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,068</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140346840811032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued expenses and other current liabilities consisted of the following:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:94.53125%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:63%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30, </span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued payroll</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>726</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>694</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued bonuses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,306</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued commissions</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>531</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>877</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued product warranties</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>439</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>452</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued insurance</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>626</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,170</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued professional fees</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,043</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,383</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Joint and several payroll liability</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,045</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,045</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Uncertain tax positions</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,573</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,491</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other accrued expenses and current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>928</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>978</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total accrued expenses and other current liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,911</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,396</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140346839126424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Basic and diluted loss per share</a></td>
<td class="text">The following table provides the computation of basic and diluted earnings per share.<div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:48%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended<br/>June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended<br/>June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in thousands, except per share data)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Numerator:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4,690</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4,295</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6,641</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(9,903</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Denominator:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average shares outstanding - basic and diluted</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34,186</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33,384</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34,181</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33,363</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Earnings (loss) per share:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic and diluted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.14</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.13</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.19</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.30</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Anti-dilutive instruments excluded from diluted loss per common share:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Options</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,986</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,882</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,986</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,882</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140346925626616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of stock options and stock awards</a></td>
<td class="text"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The status of our stock options are summarized as follows:</span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:73%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Number of options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted average exercise price</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,966,858</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.67</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,274,900</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.18</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercised</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(44,381</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.23</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Canceled and forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(211,433</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.51</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding at June 30, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,985,944</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.46</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of option fair value assumptions</a></td>
<td class="text">We calculated the fair value of issued options utilizing a Black Scholes model with an expected life calculated via the simplified method as we do not have sufficient history to determine actual expected life.<div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:54.97076023391813%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"/></tr><tr><td style="width:72%;"/><td style="width:28%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2020 Grants</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Option value</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$8.18</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Risk-free rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.7%</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected dividend yield</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected volatility</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>65.9%</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected term (in years)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140346839287784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Unrecognized tax benefits roll-forward</a></td>
<td class="text"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following is a roll-forward of the Company's total gross unrecognized tax benefits, not including interest and penalties, for the period ended June 30, 2020.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:75.43859649122807%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:63%;"/><td style="width:1%;"/><td style="width:35%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross Unrealized Tax Benefits</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at January 1, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,313</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additions of tax positions related to the current year</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additions of tax positions related to the prior year</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Decreases for tax positions related to the prior year</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at June 30, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,313</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI http://asc.fasb.org/extlink&amp;oid=121610041&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140346842273240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GEOGRAPHIC AND SEGMENT INFORMATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of reporting information by segment</a></td>
<td class="text"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Summarized financial information with respect to reportable segments is as follows:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended June 30, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(In thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Advanced Energy</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">OEM</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Corporate &amp; Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,867</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,429</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,296</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income (loss) from operations<br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,292</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>584</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,459</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6,167</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest income</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other losses, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(14</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(14</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax benefit<br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,492</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,492</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended June 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(In thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Advanced Energy</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">OEM</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Corporate &amp; Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,350</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,299</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,649</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income (loss) from operations<br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(968</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>136</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,590</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4,422</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest income</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>403</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>403</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other losses, net</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(200</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(200</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax expense<br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>76</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>76</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended June 30, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(In thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Advanced Energy</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">OEM</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Corporate &amp; Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,853</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,440</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,293</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income (loss) from operations</span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7,276</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>831</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7,214</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(13,659</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest income</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>223</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>223</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(14</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(14</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other income, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>412</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>412</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax benefit</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6,397</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6,397</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended June 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(In thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Advanced Energy</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">OEM</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Corporate &amp; Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,721</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,557</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,278</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income (loss) from operations<br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4,296</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>727</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6,583</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(10,152</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest income</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>826</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>826</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other losses, net</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(495</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(495</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax expense</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>82</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>82</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock', window );">Schedule of revenue by geographic area</a></td>
<td class="text">Revenue by geographic region, based on the customer's &#8220;ship to&#8221; location on the invoice, are as follows:<div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended<br/>June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended<br/>June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(In thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Sales by Domestic and International</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Domestic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,393</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,540</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,011</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,450</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">International</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>903</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,109</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,282</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,828</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,296</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,649</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,293</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,278</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the names of foreign countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140346843695176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INVENTORIES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 2,441<span></span>
</td>
<td class="nump">$ 2,935<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in process</a></td>
<td class="nump">1,504<span></span>
</td>
<td class="nump">1,209<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">1,997<span></span>
</td>
<td class="nump">1,316<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Gross inventories</a></td>
<td class="nump">5,942<span></span>
</td>
<td class="nump">5,460<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Less: provision for obsolescence</a></td>
<td class="num">(685)<span></span>
</td>
<td class="num">(392)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories, net</a></td>
<td class="nump">$ 5,257<span></span>
</td>
<td class="nump">$ 5,068<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140346839397112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES INVENTORIES - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Impairment of inventory</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140346919548968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued payroll</a></td>
<td class="nump">$ 726<span></span>
</td>
<td class="nump">$ 694<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrent', window );">Accrued bonuses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,306<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedSalesCommissionCurrent', window );">Accrued commissions</a></td>
<td class="nump">531<span></span>
</td>
<td class="nump">877<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductWarrantyAccrualClassifiedCurrent', window );">Accrued product warranties</a></td>
<td class="nump">439<span></span>
</td>
<td class="nump">452<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedInsuranceCurrent', window );">Accrued insurance</a></td>
<td class="nump">626<span></span>
</td>
<td class="nump">1,170<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">1,043<span></span>
</td>
<td class="nump">1,383<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_JointAndSeveralPayrollLiability', window );">Joint and several payroll liability</a></td>
<td class="nump">1,045<span></span>
</td>
<td class="nump">1,045<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_UncertainTaxPositionsLiability', window );">Uncertain tax positions</a></td>
<td class="nump">1,573<span></span>
</td>
<td class="nump">1,491<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_OtherAccruedExpensesAndLiabilitiesCurrent', window );">Other accrued expenses and current liabilities</a></td>
<td class="nump">928<span></span>
</td>
<td class="nump">978<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses and other current liabilities</a></td>
<td class="nump">$ 6,911<span></span>
</td>
<td class="nump">$ 9,396<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_JointAndSeveralPayrollLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Joint And Several Payroll Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_JointAndSeveralPayrollLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_OtherAccruedExpensesAndLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Accrued Expenses And Liabilities, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_OtherAccruedExpensesAndLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_UncertainTaxPositionsLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Uncertain Tax Positions Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_UncertainTaxPositionsLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedBonusesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedBonusesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedInsuranceCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable to insurance entities to mitigate potential loss from various risks or to satisfy a promise to provide certain coverage's to employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedInsuranceCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalesCommissionCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for sales commissions. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalesCommissionCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductWarrantyAccrualClassifiedCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers. For classified balance sheets, represents the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=68068213&amp;loc=d3e12524-110249<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 25<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68070138&amp;loc=d3e11281-110244<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductWarrantyAccrualClassifiedCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140346843254680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS PER SHARE (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareReconciliationAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss</a></td>
<td class="num">$ (4,690)<span></span>
</td>
<td class="num">$ (4,295)<span></span>
</td>
<td class="num">$ (6,641)<span></span>
</td>
<td class="num">$ (9,903)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average shares outstanding - basic and diluted (in shares)</a></td>
<td class="nump">34,186<span></span>
</td>
<td class="nump">33,384<span></span>
</td>
<td class="nump">34,181<span></span>
</td>
<td class="nump">33,363<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Earnings (loss) per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare', window );">Basic and diluted (in dollars per share)</a></td>
<td class="num">$ (0.14)<span></span>
</td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (0.19)<span></span>
</td>
<td class="num">$ (0.30)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_OptionOnSecuritiesMember', window );">Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Anti-dilutive instruments excluded from diluted loss per common share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Options (in shares)</a></td>
<td class="nump">4,986<span></span>
</td>
<td class="nump">1,882<span></span>
</td>
<td class="nump">4,986<span></span>
</td>
<td class="nump">1,882<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DilutiveSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DilutiveSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each basic and diluted share of common stock or unit when the per share amount is the same for both basic and diluted shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_OptionOnSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_OptionOnSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140346843483384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - NARRATIVE (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation</a></td>
<td class="nump">$ 1,097<span></span>
</td>
<td class="nump">$ 2,146<span></span>
</td>
<td class="nump">$ 856<span></span>
</td>
<td class="nump">$ 2,051<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_StockIssuedDuringPeriodSharesStockSwaps', window );">Stock swaps (in shares)</a></td>
<td class="nump">17,665<span></span>
</td>
<td class="nump">17,221<span></span>
</td>
<td class="nump">22,027<span></span>
</td>
<td class="nump">185,951<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived', window );">Stock swaps equity instruments received (in shares)</a></td>
<td class="nump">11,085<span></span>
</td>
<td class="nump">7,779<span></span>
</td>
<td class="nump">13,009<span></span>
</td>
<td class="nump">91,598<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_StockIssuedDuringPeriodSharesStockSwaps">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Stock Swaps</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_StockIssuedDuringPeriodSharesStockSwaps</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Stock Swaps Equity Instruments Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140346917465464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - SUMMARY OF STOCK OPTIONS (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, beginning of period (in shares) | shares</a></td>
<td class="nump">3,966,858<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">1,274,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares) | shares</a></td>
<td class="num">(44,381)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Canceled and forfeited (in shares) | shares</a></td>
<td class="num">(211,433)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, end of period (in shares) | shares</a></td>
<td class="nump">4,985,944<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, beginning of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 4.67<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">8.18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share) | $ / shares</a></td>
<td class="nump">3.23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Canceled and forfeited (in dollars per shares) | $ / shares</a></td>
<td class="nump">7.51<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, end of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 5.46<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140346839258536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - FAIR VALUE ASSUMPTIONS (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2020 </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Option value (in dollars per share)</a></td>
<td class="nump">$ 8.18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate</a></td>
<td class="nump">1.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">65.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140346843619816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - NARRATIVE (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards', window );">Release of valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_CARESActIncomeTaxExpenseBenefitRelatedToCurrentPeriodNetIncomeLossBeforeIncomeTaxes', window );">Income tax expense (benefit), related to current period net loss before income taxes</a></td>
<td class="num">$ (1,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="num">$ (1,492)<span></span>
</td>
<td class="nump">$ 76<span></span>
</td>
<td class="num">(6,397)<span></span>
</td>
<td class="nump">$ 82<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_CARESActFederalIncomeTaxPaymentsAvailableToOffsetCurrentPeriodLosses', window );">Federal income tax payments available to offset current period losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate, percent</a></td>
<td class="nump">24.10%<span></span>
</td>
<td class="num">(1.80%)<span></span>
</td>
<td class="nump">49.10%<span></span>
</td>
<td class="num">(0.80%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Accrued interest and penalties</a></td>
<td class="nump">$ 260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Interest and penalties included in income tax expense</a></td>
<td class="nump">43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Uncertain tax positions that would impact effective tax rate</a></td>
<td class="nump">$ 1,573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_CARESActFederalIncomeTaxPaymentsAvailableToOffsetCurrentPeriodLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>CARES Act, Federal Income Tax Payments Available To Offset Current Period Losses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_CARESActFederalIncomeTaxPaymentsAvailableToOffsetCurrentPeriodLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_CARESActIncomeTaxExpenseBenefitRelatedToCurrentPeriodNetIncomeLossBeforeIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>CARES Act, Income Tax Expense (Benefit), Related To Current Period Net Income (Loss) Before Income Taxes</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_CARESActIncomeTaxExpenseBenefitRelatedToCurrentPeriodNetIncomeLossBeforeIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>CARES Act, Income Tax Expense (Benefit), Release Of Valuation Allowance, Federal Net Operating Loss Carryforwards</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140346837946520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - UNRECOGNIZED TAX BENEFITS ROLL-FORWARD (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Gross Unrealized Tax Benefits</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at January 1, 2020</a></td>
<td class="nump">$ 1,313<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions of tax positions related to the current year</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Additions of tax positions related to the prior year</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Decreases for tax positions related to the prior year</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at June 30, 2020</a></td>
<td class="nump">$ 1,313<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140346843762152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES - NARRATIVE (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Purchase obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember', window );">Corporate Joint Venture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Due to related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 360,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_UnfavorableRegulatoryActionMember', window );">Unfavorable Regulatory Action | Pending Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Costs accrued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">670,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_LossContingencyAccrualTotalAccruedToDate', window );">Loss contingency accrual, total accrued to date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Corporate Joint Venture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInterestInJointVenture', window );">Capital commitment, funding</a></td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_LossContingencyAccrualTotalAccruedToDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency Accrual, Total Accrued To Date</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_LossContingencyAccrualTotalAccruedToDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3),(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInterestInJointVenture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the investment in or advances to an entity in which the reporting entity shares control of the entity with another party or group.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInterestInJointVenture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_UnfavorableRegulatoryActionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_UnfavorableRegulatoryActionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140346843766232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember', window );">Director | Bulgaria Manufacturing Plant Purchase</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent', window );">Notes payable</a></td>
<td class="nump">$ 140<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_TermOfPaymentDueNotesPayableRelatedParties', window );">Term of payment due</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CoVenturerMember', window );">Co-venturer</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty', window );">Purchases from related party</a></td>
<td class="nump">$ 850<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Due to related parties</a></td>
<td class="nump">$ 4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_TermOfPaymentDueNotesPayableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term Of Payment Due, Notes Payable, Related Parties</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_TermOfPaymentDueNotesPayableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3),(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount for notes payable (written promise to pay), due to related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=apyx_BulgariaManufacturingPlantPurchaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=apyx_BulgariaManufacturingPlantPurchaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CoVenturerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CoVenturerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140346837515992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GEOGRAPHIC AND SEGMENT INFORMATION - NARRATIVE (Details) - segment<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_TotalRevenuePercent', window );">International sales, percent of total revenue</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">31.70%<span></span>
</td>
<td class="nump">24.60%<span></span>
</td>
<td class="nump">31.20%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_TotalRevenuePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total Revenue, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_TotalRevenuePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140346843538808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GEOGRAPHIC AND SEGMENT INFORMATION - REPORTABLE SEGMENT (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales</a></td>
<td class="nump">$ 4,296<span></span>
</td>
<td class="nump">$ 6,649<span></span>
</td>
<td class="nump">$ 9,293<span></span>
</td>
<td class="nump">$ 12,278<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="num">(6,167)<span></span>
</td>
<td class="num">(4,422)<span></span>
</td>
<td class="num">(13,659)<span></span>
</td>
<td class="num">(10,152)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeOperating', window );">Interest income</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">403<span></span>
</td>
<td class="nump">223<span></span>
</td>
<td class="nump">826<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(8)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(14)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other income (losses), net</a></td>
<td class="num">(14)<span></span>
</td>
<td class="num">(200)<span></span>
</td>
<td class="nump">412<span></span>
</td>
<td class="num">(495)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (benefit) expense</a></td>
<td class="num">(1,492)<span></span>
</td>
<td class="nump">76<span></span>
</td>
<td class="num">(6,397)<span></span>
</td>
<td class="nump">82<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Advanced Energy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales</a></td>
<td class="nump">2,867<span></span>
</td>
<td class="nump">5,350<span></span>
</td>
<td class="nump">6,853<span></span>
</td>
<td class="nump">9,721<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="num">(3,292)<span></span>
</td>
<td class="num">(968)<span></span>
</td>
<td class="num">(7,276)<span></span>
</td>
<td class="num">(4,296)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeOperating', window );">Interest income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other income (losses), net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (benefit) expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | OEM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales</a></td>
<td class="nump">1,429<span></span>
</td>
<td class="nump">1,299<span></span>
</td>
<td class="nump">2,440<span></span>
</td>
<td class="nump">2,557<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="nump">584<span></span>
</td>
<td class="nump">136<span></span>
</td>
<td class="nump">831<span></span>
</td>
<td class="nump">727<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeOperating', window );">Interest income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other income (losses), net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (benefit) expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate &amp; Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="num">(3,459)<span></span>
</td>
<td class="num">(3,590)<span></span>
</td>
<td class="num">(7,214)<span></span>
</td>
<td class="num">(6,583)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeOperating', window );">Interest income</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">403<span></span>
</td>
<td class="nump">223<span></span>
</td>
<td class="nump">826<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other income (losses), net</a></td>
<td class="num">(14)<span></span>
</td>
<td class="num">(200)<span></span>
</td>
<td class="nump">412<span></span>
</td>
<td class="num">(495)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (benefit) expense</a></td>
<td class="num">$ (1,492)<span></span>
</td>
<td class="nump">$ 76<span></span>
</td>
<td class="num">$ (6,397)<span></span>
</td>
<td class="nump">$ 82<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=apyx_AdvancedEnergyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=apyx_AdvancedEnergyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=apyx_OEMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=apyx_OEMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140346956017128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GEOGRAPHIC AND SEGMENT INFORMATION - GEOGRAPHIC (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales</a></td>
<td class="nump">$ 4,296<span></span>
</td>
<td class="nump">$ 6,649<span></span>
</td>
<td class="nump">$ 9,293<span></span>
</td>
<td class="nump">$ 12,278<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">Domestic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales</a></td>
<td class="nump">3,393<span></span>
</td>
<td class="nump">4,540<span></span>
</td>
<td class="nump">7,011<span></span>
</td>
<td class="nump">8,450<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales</a></td>
<td class="nump">$ 903<span></span>
</td>
<td class="nump">$ 2,109<span></span>
</td>
<td class="nump">$ 2,282<span></span>
</td>
<td class="nump">$ 3,828<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>51
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MJ2&=BP,R@-V;&#SN8FXK23E5BWU>FR60V+?&MFAMB>]Z)JLM(L1T,X!(5=0
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M;/<.>W=2L'7UDO8S*PJ65(<K&O :4QKPZP^,%4\GY7O?YC\)QO\"4$L#!!0
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M80ST_]><J\,/,T#[DO7B/U!+ P04    "  @2 I1-QVA(DX)  #@%0  &
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ME(L(3D@73QU!R,E\0?A'A' >2V!J?P',M,O71HO1"!>/!+*7=BBSG[@X-LU
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M*=AJ"C\0<@/:>*C$#NGN%H7,)&H/^$! ^LHPH'LW#KQA%H> =:/,'H<4DYI
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MJZTT6,N7CK[4RN$YPJ8%P8K:(Z P$#3DOP*6NQJBQLG08P4Q(W;A?5-C*&2
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MF^C5^!6SRRE7K1+#$F#156)C/U%SCGE%)>IK'"F8=T"E[;G!:" ^%0H2N\(
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MPJ6S4;H)MHKGD;D-.-W$RP+'27*\ .\7UH;VA@-T!]2S?P%02P,$%     @
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M:=M9TEF[23QK!] W]W:,?V1Z3[4&@15!HYMA/P#=CL9V8]71CZ.=LC3<_/)
M?Q/4SH'.*Z7L9>,"=/^GZ7]02P,$%     @ ($@*450&=JBR P  20@  !D
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;*U7;6_;-A#^*P>OW1+
ME6W9>6N3 $[2;BG6IFCZ,F#8!UJB+"X2Z9)4'/?7[^XH*;(;9VNQ#XE%B7?W
MW,-[X_'2V!N72^GAKBRT.^GEWB^>#P8NR64I7&064N.7S-A2>%S:^< MK!0I
M"Y7%(!X.]P>E4+IW>LSOWMG38U/Y0FGYSH*KRE+8U9DLS/*D-^HU+]ZK>>[I
MQ>#T>"'F\EKZCXMW%E>#5DNJ2JF=,AJLS$YZT]'SLPGMYPV?E%RZSC.0)S-C
M;FAQF9[TA@1(%C+QI$'@SZT\ET5!BA#&EUIGKS5)@MWG1OLK]AU]F0DGSTWQ
M6:4^/^D=]B"5F:@*_]XL?Y.U/WND+S&%X_^P#'O'XQXDE?.FK(410:ET^!5W
M-0\=@</A%H&X%H@9=S#$*"^$%Z?'UBS!TF[41@_L*DLC.*7I4*Z]Q:\*Y?SI
MY=OSJS<OX</TCY?7QP./&NG](*FESX)TO$5Z']X8[7,'+W4JTW7Y 2)IX<0-
MG+/X486O*QW!>-B'>!@/']$W;MT;L[[Q-O=T8DH)'\0=7"B7%,955L*?TYGS
M%@/BKT=,3%H3$S8Q^4$&_[LT7&EX(VR20WP0&.B#SR5\C*XCF)M;:36F@P>I
M$;I,^=OY]#T*3A,/WL#"FEN52DR60LD,,FM*.+_Z='GQ;'04P8>U[4HG195*
M!R*(<9;Y7'@0!6:J R1N(;3"':@Y$=:N9B*Y 8V% DN"%5[I.2"A#G?LO+WZ
M_>>?#N/1P0NW"W.IZ3LB5)I!XG9E4O1H=(AK:ZIYSNX%S,I86$EA7027&LWJ
MORL=4G:I?,X*4N46QBE^:;+@N,&#G%4.^72.#)'V/BQEQ[P I^9:92H12)LH
M384_)"_NQ*R0Q %%1RT<P74U<_)+11PC,I\KMZ&0G*]=#D)'('3:^D2X,F6=
MAUP4&5DB+R/ ^L'?.N)K')$BMH1U]5:9RA4K/,/$V)2=N!5%)4(-HZ,1.I%@
M K-9513\73:\8$62UE)T8,P+M.4=_9A$L36FU%06\,3"J6)A7PJ;.DA1";J-
MI;U07T67:]H[DW3>JL1@F3%Y%:8\NZ5!WBG'X4 V"['<C+52W% 8Y=+)!E)M
M!17UF4+A6@<09WO(C0IF)Q>WDGG!,_U*S.CF!,GN#!G-%)^O6"#*.X4U6R*3
M3\;1 9;.HF &-Z@@*Y@N$@M[8W0+W43:*XD^B^(;\D@%ZT3^Z# C^(R>%LYT
MX7Z+U3T =A3MW8-%8O!%W+[H=PT1H":B4&-&"7%O PG/ZK##\)22E3EU!V6H
MV)(J-F"]E6V])>UN(;E/%BL^1%0IZ&\-(_(NTI2S$;E >N\!<LACEC=$=7Q>
MB!55+XS&6Z$*#B%R(LLP'D#,<7[ O!%Z!08QVU ?ZF3ALE2*%7I)&BN*[PBN
MT/^._IV:U%T,1QQ9\#R7&%0;[.Z,^I.CN#\<#G<#NP?[M BQ@'[)+ O^LTI;
MAV(\B49/>?_.*#K<?;K!['9&629D]SJU/X1]OS\^.NA@/XS_ _;)48M]N(;]
M\5C8BIPR^]X26TD5KJT+_895>^$K;^PJ?,<2CP.?0A_J$O-]2?=MQUG//38;
MLH[ 9884<+&BYF9Q^:S9VO8.:FVK7ZBU>8S2N26EE>XD:S=+^Z!-TS!9K_:8
M&!RM*?8V3 */;;+?,ENWNP=8C6"'6R*6>)3%5ODK6_ZH0SG$[32IG#75X4P4
M3 1&_VNA*QR:850?SQ-\&H_&,*T3T=5]#9H^Z;JE@E!QVF!GHU8+W*SC%]\A
M?M^G6^$+F5@ZP[K2?*=TU[FUR&M<^]PI]CB])[;B(OH0]UUS6X^QG4;:<8=@
MKU5,%2(.9Y"4LC"E)V<*E;+R3&E$K#!@*, E5[,(ILS=1B'E;I5N9G"\/^2,
M5?K_\(?&)9[AVCGK@6[X8*5J6L&_]H 'BO^3R9A]Z%8@]'^+'_68<I]P.-I)
MZP4![L8+^K*6FDB@E6$\E-0N(!2&;>+]NJ0XO(O58PJ.R%@9401[!D&W=&["
MK1NA[YT8V^C$_;T#]O6A2\*@<^4JI9WSQ9*&9APQP^VK?=O>7:?ARG:_/5Q\
M<>2?8_.#0F8H.HP.]GI@PV4R++Q9\ 5N9CQ>!_DQQ_NWM+0!OV?&^&9!!MH;
M_>D_4$L#!!0    ( "!("E'KL&\:4 D  + 5   9    >&PO=V]R:W-H965T
M<R]S:&5E=#$U+GAM;*U8VV[<.!+]%:)G,$@ C_MB.\E,; ..[4P2K"^(DYF'
MQ3Y0$M7-F"(5DNIVS]?OJ2*E[G:<++"[+W93(JM.G;I2QROG[\-"J2@>&F/#
MR6@18_O[>!S*A6IDV'>MLGA3.]_(B*6?CT/KE:SX4&/&L\GDQ;B1VHY.C_G9
MK3\]=ETTVJI;+T+7--*OWRCC5B>CZ:A_\%'/%Y$>C$^/6SE7=RI^;F\]5N-!
M2J4;98-V5GA5GXS.IK^_.:3]O.%/K59AZ[<@2PKG[FGQOCH930B0,JJ,)$'B
MWU*=*V-($&!\S3)'@THZN/V[E_Z6;8<MA0SJW)F_=!47)Z-7(U&I6G8F?G2K
M=RK;<T3R2F<"_Q6KM/=H-A)E%Z)K\F$@:+1-_^5#YF'KP*O)=P[,\H$9XTZ*
M&.6%C/+TV+N5\+0;TN@'F\JG 4Y;<LI=]'BK<2Z>GM]<7;W_='5Y_>E.G%U?
MB/.;ZT_OK_^XO#Y_?WEW/(Y001O'91;W)HF;?4?<"W'E;%P$<6DK5>V>'P/:
M@&_6XWLS^Z' #YW=%P>3/3&;S"8_D'<PV'O \@Z^9Z]K&AT153$(:2MQ#KC:
MSI4MM0KB0H?2N-!Y)?YY5H3H$33_^H'6PT'K(6L]_'^Q_#^($__04<\EQ_RG
MA1*-JG0I#4)UJ4LEM*T057XM=!#E0I*%RNN_526*M:B]^MJ!&U$:J9O$D!G$
M[?%ZI80$/_2SD6M1J-(U"DE=?$&BB>C$4GKMNI!E[ DC5Z'3F>_6NU(!D9T'
M0!$1 )W'$@5!E*[S >M:X(<HN@"S0]@7=UVYZ!&12FU+TU6J?P3<9><]P79>
M4)U27JBF-6ZM%/17&O;JHHO.)PP W*JH:;W7"RF=+96WP,684*#N%05&#[IQ
M3&C&A@=55VY,H@6(DH4&6^LL<U_\E:C2=NG,$@S#8"ELUQ0 "$E&S>$7R>4I
MH,(9R1I!(4'H-E2\4T9WC;@U,C121%4NK#-NOMYG!Z/4D@L"[<9!'-L53!"L
MBR@L<0$$)) 8,"HJ,CMZ%)W>F[2O4.+>NI4E*LDXXY ?,!-AXJJD!669K2L
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M=J-HD-Y#D,)3Q4JY8EVO+<_?+)0K&F]%L8UT7^EE(V]@#DHFNRXE"E60!A>
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M&^3[FN7TVTE(T#WNDW\ 4$L#!!0    ( "!("E'WV7.TNP8  &P1   9
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M?XR3NPEG^S!P>D7GZ9EV\!?=+@7':<8+X/U<:[<=^ 6Z'UC._@=02P,$%
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M3)X/X/W:N=C=L('^I\N+_P)02P,$%     @ ($@*48651/"> @  6 4  !D
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ML+HT*WGXA$T]7<N7R5*[)QR.L=W4@ZS61E8-F#*HN#B^V7/3AS- /[@"B!I
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MV7FWEX!KYE*S8:KB+)@0RV2)R[F,<G0A0-Y/B7BU"0G:/X?A/U!+ P04
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MN\-V477+UH:1I7OU&VFPA]PRQRD'RCK@^59*<S2L0#LWDW=02P,$%     @
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M.W2)[H:S&8R? G0^(0(G*;\ Z^-\@L[/+M 92G+T$-."XSSB/5U ,I)2#ZO
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MKCS(E97/@W(BZ$K=?\]4P&VJAC&\J B3#O!]0:G83F2 ^HTV^ 502P,$%
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M*;09>6Z9FG\,2AM@GJ^%T*>-%2C_6L._4$L#!!0    ( "!("E&U6<9TT ,
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M7.- #](8X/=$"+U_,0'J?Q'&_P-02P,$%     @ ($@*42$0@0"H @  S@8
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MMRRZ9S'1(G,=ZU5HT__<,#$?')1V@7F_%$+O)K9 ^0GK_ 902P,$%     @
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MA=(N,/.),!=CU[$"U7LX^ M02P,$%     @ ($@*4<T).<*K @  >P<  !D
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MN(,R'NO@2C!EG^10W.UT';+*E199"48/LI07;_I<YN$$@#SU +\$^"\!K3.
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M8@RR:/7%1HN=[65+H;$SVN46IR-(<P'/-T+HX\8(5/-V\!M02P,$%     @
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MLJDV$L_:B&PBV=K<DT],JEO7#"/5>A&N >K[DC&YFV@#13/7^P=02P,$%
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MZ]XVHL_:VM_M\J*Y*[A]<Z9_ %!+ P04    "  @2 I1EXJ[',     3 @
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MQ>$2';1795VEFO2+W8>/T[-^7K*^J^L(VI+V6I6K_;^'_7^3=[\ 4$L#!!0
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M<F]P<R]A<' N>&UL4$L! A0#%     @ ($@*42-/L6#N    *P(  !$
M         ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ ($@*
M49E<G",0!@  G"<  !,              ( !S $  'AL+W1H96UE+W1H96UE
M,2YX;6Q02P$"% ,4    "  @2 I162SJ7R4%  ! %0  &
M@($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ ($@*
M451]S, 6!@  JA<  !@              ("!: T  'AL+W=O<FMS:&5E=',O
M<VAE970R+GAM;%!+ 0(4 Q0    ( "!("E$'CH.6-P,  /4(   8
M      " @;03  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4
M"  @2 I1&RT7F88%  !?%@  &               @($A%P  >&PO=V]R:W-H
M965T<R]S:&5E=#0N>&UL4$L! A0#%     @ ($@*4<,D'TL/!@  52   !@
M             ("!W1P  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4
M Q0    ( "!("E&%_O--0@<  ' =   8              " @2(C  !X;"]W
M;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    "  @2 I1-QVA(DX)  #@
M%0  &               @(&:*@  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL
M4$L! A0#%     @ ($@*48^I#U"] P  6P@  !@              ("!'C0
M 'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( "!("E'B-$>-
M0P8  *P.   8              " @1$X  !X;"]W;W)K<VAE971S+W-H965T
M.2YX;6Q02P$"% ,4    "  @2 I14XD*NF8$  #U"   &0
M@(&*/@  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( "!(
M"E&F^( M P,  *L&   9              " @2=#  !X;"]W;W)K<VAE971S
M+W-H965T,3$N>&UL4$L! A0#%     @ ($@*450&=JBR P  20@  !D
M         ("!848  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4
M    "  @2 I1CM17Q[P%   1#0  &0              @(%*2@  >&PO=V]R
M:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( "!("E%28FRC. 8  -T/
M   9              " @3U0  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL
M4$L! A0#%     @ ($@*4>NP;QI0"0  L!4  !D              ("!K%8
M 'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    "  @2 I1N=;X
MUZH#  #H!P  &0              @($S8   >&PO=V]R:W-H965T<R]S:&5E
M=#$V+GAM;%!+ 0(4 Q0    ( "!("E'WV7.TNP8  &P1   9
M  " @11D  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @
M($@*43ALCC=^"   QA0  !D              ("!!FL  'AL+W=O<FMS:&5E
M=',O<VAE970Q."YX;6Q02P$"% ,4    "  @2 I1A95$\)X"  !8!0  &0
M            @(&[<P  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4
M Q0    ( "!("E&2C$5C$0,  (8&   9              " @9!V  !X;"]W
M;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ ($@*4978WLGV @
M:08  !D              ("!V'D  'AL+W=O<FMS:&5E=',O<VAE970R,2YX
M;6Q02P$"% ,4    "  @2 I1HJ__3)D#  "/!P  &0              @($%
M?0  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( "!("E&M
MD4.^P@(  "@&   9              " @=6   !X;"]W;W)K<VAE971S+W-H
M965T,C,N>&UL4$L! A0#%     @ ($@*4;_CS/)L!   +@P  !D
M     ("!SH,  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( "!("E$BV:P")0,  *\)   9              "
M@025  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ ($@*
M45DJP+TT P  6 H  !D              ("!8)@  'AL+W=O<FMS:&5E=',O
M<VAE970S,"YX;6Q02P$"% ,4    "  @2 I1'H$/#:0"  #!!@  &0
M        @('+FP  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0
M   ( "!("E&U6<9TT ,  "X,   9              " @::>  !X;"]W;W)K
M<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ ($@*42$0@0"H @  S@8
M !D              ("!K:(  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q0
M2P$"% ,4    "  @2 I1H'L"#$<#  #'"0  &0              @(&,I0
M>&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( "!("E%\R/^/
MN@(  !L'   9              " @0JI  !X;"]W;W)K<VAE971S+W-H965T
M,S4N>&UL4$L! A0#%     @ ($@*4<T).<*K @  >P<  !D
M ("!^ZL  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    "  @
M2 I1U=V9S[D%  !4'0  &0              @('=K@  >&PO=V]R:W-H965T
M<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( "!("E':E=XW  ,  -@)   9
M          " @<VT  !X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#
M%     @ ($@*45;!'[DX @  @ H   T              ( !!+@  'AL+W-T
M>6QE<RYX;6Q02P$"% ,4    "  @2 I1EXJ[',     3 @  "P
M    @ %GN@  7W)E;',O+G)E;'-02P$"% ,4    "  @2 I1BUL%TKT#  "[
M&0  #P              @ %0NP  >&PO=V]R:V)O;VLN>&UL4$L! A0#%
M  @ ($@*4;>]PDN! 0  *1<  !H              ( !.K\  'AL+U]R96QS
M+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ ($@*46/6BA2; 0  E!<
M !,              ( !\\   %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
/ "X +@!Y#   O\(

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>75</ContextCount>
  <ElementCount>256</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>18</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="a2020q210-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001000 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="a2020q210-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001000 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="a2020q210-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001501 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="a2020q210-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002000 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/ConsolidatedStatementsOfOperations</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="a2020q210-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003000 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="a2020q210-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1004000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="a2020q210-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101100 - Disclosure - BASIS OF PRESENTATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/BasisOfPresentation</Role>
      <ShortName>BASIS OF PRESENTATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="a2020q210-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2102100 - Disclosure - CHANGE IN ACCOUNTING POLICY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/ChangeInAccountingPolicy</Role>
      <ShortName>CHANGE IN ACCOUNTING POLICY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="a2020q210-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2107100 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/RecentAccountingPronouncements</Role>
      <ShortName>RECENT ACCOUNTING PRONOUNCEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="a2020q210-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2109100 - Disclosure - INVENTORIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/Inventories</Role>
      <ShortName>INVENTORIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="a2020q210-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2111100 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/AccruedExpensesAndOtherCurrentLiabilities</Role>
      <ShortName>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="a2020q210-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2113100 - Disclosure - EARNINGS PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/EarningsPerShare</Role>
      <ShortName>EARNINGS PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="a2020q210-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2115100 - Disclosure - STOCK-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/StockBasedCompensation</Role>
      <ShortName>STOCK-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="a2020q210-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2117100 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/IncomeTaxes</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="a2020q210-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2119100 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/CommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="a2020q210-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2120100 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/RelatedPartyTransactions</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="a2020q210-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2131100 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/GeographicAndSegmentInformation</Role>
      <ShortName>GEOGRAPHIC AND SEGMENT INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="a2020q210-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2201201 - Disclosure - BASIS OF PRESENTATION (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/BasisOfPresentationPolicies</Role>
      <ShortName>BASIS OF PRESENTATION (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="a2020q210-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2309301 - Disclosure - INVENTORIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/InventoriesTables</Role>
      <ShortName>INVENTORIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/Inventories</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="a2020q210-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2311301 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables</Role>
      <ShortName>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/AccruedExpensesAndOtherCurrentLiabilities</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="a2020q210-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2313301 - Disclosure - EARNINGS PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/EarningsPerShareTables</Role>
      <ShortName>EARNINGS PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/EarningsPerShare</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="a2020q210-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2315301 - Disclosure - STOCK-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/StockBasedCompensationTables</Role>
      <ShortName>STOCK-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/StockBasedCompensation</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="a2020q210-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2317301 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/IncomeTaxesTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/IncomeTaxes</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="a2020q210-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2331301 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/GeographicAndSegmentInformationTables</Role>
      <ShortName>GEOGRAPHIC AND SEGMENT INFORMATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/GeographicAndSegmentInformation</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="a2020q210-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2409402 - Disclosure - INVENTORIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/InventoriesDetails</Role>
      <ShortName>INVENTORIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/InventoriesTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="a2020q210-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2409403 - Disclosure - INVENTORIES INVENTORIES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/InventoriesInventoriesNarrativeDetails</Role>
      <ShortName>INVENTORIES INVENTORIES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="a2020q210-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2411402 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="a2020q210-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2413402 - Disclosure - EARNINGS PER SHARE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/EarningsPerShareDetails</Role>
      <ShortName>EARNINGS PER SHARE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/EarningsPerShareTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="a2020q210-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2415402 - Disclosure - STOCK-BASED COMPENSATION - NARRATIVE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/StockBasedCompensationNarrativeDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - NARRATIVE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="a2020q210-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2415403 - Disclosure - STOCK-BASED COMPENSATION - SUMMARY OF STOCK OPTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/StockBasedCompensationSummaryOfStockOptionsDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - SUMMARY OF STOCK OPTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="a2020q210-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2415404 - Disclosure - STOCK-BASED COMPENSATION - FAIR VALUE ASSUMPTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/StockBasedCompensationFairValueAssumptionsDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - FAIR VALUE ASSUMPTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="a2020q210-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2417402 - Disclosure - INCOME TAXES - NARRATIVE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>INCOME TAXES - NARRATIVE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="a2020q210-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2417403 - Disclosure - INCOME TAXES - UNRECOGNIZED TAX BENEFITS ROLL-FORWARD (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/IncomeTaxesUnrecognizedTaxBenefitsRollForwardDetails</Role>
      <ShortName>INCOME TAXES - UNRECOGNIZED TAX BENEFITS ROLL-FORWARD (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="a2020q210-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2419401 - Disclosure - COMMITMENTS AND CONTINGENCIES - NARRATIVE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/CommitmentsAndContingenciesNarrativeDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES - NARRATIVE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="a2020q210-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2420401 - Disclosure - RELATED PARTY TRANSACTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/RelatedPartyTransactions</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="a2020q210-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2431402 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION - NARRATIVE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/GeographicAndSegmentInformationNarrativeDetails</Role>
      <ShortName>GEOGRAPHIC AND SEGMENT INFORMATION - NARRATIVE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="a2020q210-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2431403 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION - REPORTABLE SEGMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/GeographicAndSegmentInformationReportableSegmentDetails</Role>
      <ShortName>GEOGRAPHIC AND SEGMENT INFORMATION - REPORTABLE SEGMENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="a2020q210-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2431404 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION - GEOGRAPHIC (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/GeographicAndSegmentInformationGeographicDetails</Role>
      <ShortName>GEOGRAPHIC AND SEGMENT INFORMATION - GEOGRAPHIC (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="a2020q210-q.htm">a2020q210-q.htm</File>
    <File>a2020q210-qexhibit311.htm</File>
    <File>a2020q210-qexhibit312.htm</File>
    <File>a2020q210-qexhibit321.htm</File>
    <File>a2020q210-qexhibit322.htm</File>
    <File>apyx-20200630.xsd</File>
    <File>apyx-20200630_cal.xml</File>
    <File>apyx-20200630_def.xml</File>
    <File>apyx-20200630_lab.xml</File>
    <File>apyx-20200630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>apyxmedicallogotagline.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>57
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "a2020q210-q.htm": {
   "axisCustom": 0,
   "axisStandard": 11,
   "contextCount": 75,
   "dts": {
    "calculationLink": {
     "local": [
      "apyx-20200630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "apyx-20200630_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "a2020q210-q.htm"
     ]
    },
    "labelLink": {
     "local": [
      "apyx-20200630_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "apyx-20200630_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "apyx-20200630.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd",
      "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd"
     ]
    }
   },
   "elementCount": 278,
   "entityCount": 1,
   "hidden": {
    "http://apyxmedical.com/20200630": 2,
    "http://fasb.org/us-gaap/2020-01-31": 13,
    "http://xbrl.sec.gov/dei/2020-01-31": 5,
    "total": 20
   },
   "keyCustom": 23,
   "keyStandard": 233,
   "memberCustom": 3,
   "memberStandard": 14,
   "nsprefix": "apyx",
   "nsuri": "http://apyxmedical.com/20200630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "a2020q210-q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001000 - Document - Cover",
     "role": "http://apyxmedical.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "a2020q210-q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "a2020q210-q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2109100 - Disclosure - INVENTORIES",
     "role": "http://apyxmedical.com/role/Inventories",
     "shortName": "INVENTORIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "a2020q210-q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "a2020q210-q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2111100 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES",
     "role": "http://apyxmedical.com/role/AccruedExpensesAndOtherCurrentLiabilities",
     "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "a2020q210-q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "a2020q210-q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2113100 - Disclosure - EARNINGS PER SHARE",
     "role": "http://apyxmedical.com/role/EarningsPerShare",
     "shortName": "EARNINGS PER SHARE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "a2020q210-q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "a2020q210-q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2115100 - Disclosure - STOCK-BASED COMPENSATION",
     "role": "http://apyxmedical.com/role/StockBasedCompensation",
     "shortName": "STOCK-BASED COMPENSATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "a2020q210-q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "a2020q210-q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2117100 - Disclosure - INCOME TAXES",
     "role": "http://apyxmedical.com/role/IncomeTaxes",
     "shortName": "INCOME TAXES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "a2020q210-q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "a2020q210-q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2119100 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "role": "http://apyxmedical.com/role/CommitmentsAndContingencies",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "a2020q210-q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "a2020q210-q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2120100 - Disclosure - RELATED PARTY TRANSACTIONS",
     "role": "http://apyxmedical.com/role/RelatedPartyTransactions",
     "shortName": "RELATED PARTY TRANSACTIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "a2020q210-q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "a2020q210-q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2131100 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION",
     "role": "http://apyxmedical.com/role/GeographicAndSegmentInformation",
     "shortName": "GEOGRAPHIC AND SEGMENT INFORMATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "a2020q210-q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "a2020q210-q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2201201 - Disclosure - BASIS OF PRESENTATION (Policies)",
     "role": "http://apyxmedical.com/role/BasisOfPresentationPolicies",
     "shortName": "BASIS OF PRESENTATION (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "a2020q210-q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "a2020q210-q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2309301 - Disclosure - INVENTORIES (Tables)",
     "role": "http://apyxmedical.com/role/InventoriesTables",
     "shortName": "INVENTORIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "a2020q210-q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "a2020q210-q.htm",
      "contextRef": "FI2020Q2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001000 - Statement - CONSOLIDATED BALANCE SHEETS",
     "role": "http://apyxmedical.com/role/ConsolidatedBalanceSheets",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "a2020q210-q.htm",
      "contextRef": "FI2020Q2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "a2020q210-q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2311301 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)",
     "role": "http://apyxmedical.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables",
     "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "a2020q210-q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "a2020q210-q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2313301 - Disclosure - EARNINGS PER SHARE (Tables)",
     "role": "http://apyxmedical.com/role/EarningsPerShareTables",
     "shortName": "EARNINGS PER SHARE (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "a2020q210-q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "a2020q210-q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2315301 - Disclosure - STOCK-BASED COMPENSATION (Tables)",
     "role": "http://apyxmedical.com/role/StockBasedCompensationTables",
     "shortName": "STOCK-BASED COMPENSATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "a2020q210-q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "a2020q210-q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2317301 - Disclosure - INCOME TAXES (Tables)",
     "role": "http://apyxmedical.com/role/IncomeTaxesTables",
     "shortName": "INCOME TAXES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "a2020q210-q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "a2020q210-q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2331301 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION (Tables)",
     "role": "http://apyxmedical.com/role/GeographicAndSegmentInformationTables",
     "shortName": "GEOGRAPHIC AND SEGMENT INFORMATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "a2020q210-q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "a2020q210-q.htm",
      "contextRef": "FI2020Q2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409402 - Disclosure - INVENTORIES (Details)",
     "role": "http://apyxmedical.com/role/InventoriesDetails",
     "shortName": "INVENTORIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "a2020q210-q.htm",
      "contextRef": "FI2020Q2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "a2020q210-q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryWriteDown",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409403 - Disclosure - INVENTORIES INVENTORIES - Narrative (Details)",
     "role": "http://apyxmedical.com/role/InventoriesInventoriesNarrativeDetails",
     "shortName": "INVENTORIES INVENTORIES - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "a2020q210-q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryWriteDown",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "a2020q210-q.htm",
      "contextRef": "FI2020Q2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedSalariesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411402 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)",
     "role": "http://apyxmedical.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails",
     "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "a2020q210-q.htm",
      "contextRef": "FI2020Q2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedSalariesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "a2020q210-q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413402 - Disclosure - EARNINGS PER SHARE (Details)",
     "role": "http://apyxmedical.com/role/EarningsPerShareDetails",
     "shortName": "EARNINGS PER SHARE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "a2020q210-q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "a2020q210-q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415402 - Disclosure - STOCK-BASED COMPENSATION - NARRATIVE (Details)",
     "role": "http://apyxmedical.com/role/StockBasedCompensationNarrativeDetails",
     "shortName": "STOCK-BASED COMPENSATION - NARRATIVE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "a2020q210-q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": null,
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001501 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://apyxmedical.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "a2020q210-q.htm",
      "contextRef": "FI2019Q4",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415403 - Disclosure - STOCK-BASED COMPENSATION - SUMMARY OF STOCK OPTIONS (Details)",
     "role": "http://apyxmedical.com/role/StockBasedCompensationSummaryOfStockOptionsDetails",
     "shortName": "STOCK-BASED COMPENSATION - SUMMARY OF STOCK OPTIONS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "a2020q210-q.htm",
      "contextRef": "FI2019Q4",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "a2020q210-q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415404 - Disclosure - STOCK-BASED COMPENSATION - FAIR VALUE ASSUMPTIONS (Details)",
     "role": "http://apyxmedical.com/role/StockBasedCompensationFairValueAssumptionsDetails",
     "shortName": "STOCK-BASED COMPENSATION - FAIR VALUE ASSUMPTIONS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "a2020q210-q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": "3",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "a2020q210-q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "apyx:CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417402 - Disclosure - INCOME TAXES - NARRATIVE (Details)",
     "role": "http://apyxmedical.com/role/IncomeTaxesNarrativeDetails",
     "shortName": "INCOME TAXES - NARRATIVE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "a2020q210-q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "apyx:CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "a2020q210-q.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417403 - Disclosure - INCOME TAXES - UNRECOGNIZED TAX BENEFITS ROLL-FORWARD (Details)",
     "role": "http://apyxmedical.com/role/IncomeTaxesUnrecognizedTaxBenefitsRollForwardDetails",
     "shortName": "INCOME TAXES - UNRECOGNIZED TAX BENEFITS ROLL-FORWARD (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "a2020q210-q.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "a2020q210-q.htm",
      "contextRef": "FI2020Q2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PurchaseObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419401 - Disclosure - COMMITMENTS AND CONTINGENCIES - NARRATIVE (Details)",
     "role": "http://apyxmedical.com/role/CommitmentsAndContingenciesNarrativeDetails",
     "shortName": "COMMITMENTS AND CONTINGENCIES - NARRATIVE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "a2020q210-q.htm",
      "contextRef": "FI2020Q2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PurchaseObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "a2020q210-q.htm",
      "contextRef": "FI2020Q2_us-gaap_RelatedPartyTransactionAxis_apyx_BulgariaManufacturingPlantPurchaseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420401 - Disclosure - RELATED PARTY TRANSACTIONS (Details)",
     "role": "http://apyxmedical.com/role/RelatedPartyTransactionsDetails",
     "shortName": "RELATED PARTY TRANSACTIONS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "a2020q210-q.htm",
      "contextRef": "FI2020Q2_us-gaap_RelatedPartyTransactionAxis_apyx_BulgariaManufacturingPlantPurchaseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "a2020q210-q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431402 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION - NARRATIVE (Details)",
     "role": "http://apyxmedical.com/role/GeographicAndSegmentInformationNarrativeDetails",
     "shortName": "GEOGRAPHIC AND SEGMENT INFORMATION - NARRATIVE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "a2020q210-q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "a2020q210-q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431403 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION - REPORTABLE SEGMENT (Details)",
     "role": "http://apyxmedical.com/role/GeographicAndSegmentInformationReportableSegmentDetails",
     "shortName": "GEOGRAPHIC AND SEGMENT INFORMATION - REPORTABLE SEGMENT (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "a2020q210-q.htm",
      "contextRef": "FD2020Q2QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_apyx_AdvancedEnergyMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "a2020q210-q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431404 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION - GEOGRAPHIC (Details)",
     "role": "http://apyxmedical.com/role/GeographicAndSegmentInformationGeographicDetails",
     "shortName": "GEOGRAPHIC AND SEGMENT INFORMATION - GEOGRAPHIC (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "a2020q210-q.htm",
      "contextRef": "FD2020Q2QTD_srt_StatementGeographicalAxis_country_US",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "a2020q210-q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002000 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS",
     "role": "http://apyxmedical.com/role/ConsolidatedStatementsOfOperations",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "a2020q210-q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "a2020q210-q.htm",
      "contextRef": "FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003000 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY",
     "role": "http://apyxmedical.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity",
     "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "a2020q210-q.htm",
      "contextRef": "FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "a2020q210-q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://apyxmedical.com/role/ConsolidatedStatementsOfCashFlows",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "a2020q210-q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "a2020q210-q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101100 - Disclosure - BASIS OF PRESENTATION",
     "role": "http://apyxmedical.com/role/BasisOfPresentation",
     "shortName": "BASIS OF PRESENTATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "a2020q210-q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "a2020q210-q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountingChangesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2102100 - Disclosure - CHANGE IN ACCOUNTING POLICY",
     "role": "http://apyxmedical.com/role/ChangeInAccountingPolicy",
     "shortName": "CHANGE IN ACCOUNTING POLICY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "a2020q210-q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountingChangesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "a2020q210-q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DescriptionOfNewAccountingPronouncementsNotYetAdopted",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2107100 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS",
     "role": "http://apyxmedical.com/role/RecentAccountingPronouncements",
     "shortName": "RECENT ACCOUNTING PRONOUNCEMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "a2020q210-q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DescriptionOfNewAccountingPronouncementsNotYetAdopted",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 18,
   "tag": {
    "apyx_AdvancedEnergyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Advanced Energy [Member]",
        "label": "Advanced Energy [Member]",
        "terseLabel": "Advanced Energy"
       }
      }
     },
     "localname": "AdvancedEnergyMember",
     "nsuri": "http://apyxmedical.com/20200630",
     "presentation": [
      "http://apyxmedical.com/role/GeographicAndSegmentInformationReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_BulgariaManufacturingPlantPurchaseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Bulgaria Manufacturing Plant Purchase [Member]",
        "label": "Bulgaria Manufacturing Plant Purchase [Member]",
        "terseLabel": "Bulgaria Manufacturing Plant Purchase"
       }
      }
     },
     "localname": "BulgariaManufacturingPlantPurchaseMember",
     "nsuri": "http://apyxmedical.com/20200630",
     "presentation": [
      "http://apyxmedical.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_CARESActFederalIncomeTaxPaymentsAvailableToOffsetCurrentPeriodLosses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "CARES Act, Federal Income Tax Payments Available To Offset Current Period Losses",
        "label": "CARES Act, Federal Income Tax Payments Available To Offset Current Period Losses",
        "terseLabel": "Federal income tax payments available to offset current period losses"
       }
      }
     },
     "localname": "CARESActFederalIncomeTaxPaymentsAvailableToOffsetCurrentPeriodLosses",
     "nsuri": "http://apyxmedical.com/20200630",
     "presentation": [
      "http://apyxmedical.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_CARESActIncomeTaxExpenseBenefitRelatedToCurrentPeriodNetIncomeLossBeforeIncomeTaxes": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "CARES Act, Income Tax Expense (Benefit), Related To Current Period Net Income (Loss) Before Income Taxes",
        "label": "CARES Act, Income Tax Expense (Benefit), Related To Current Period Net Income (Loss) Before Income Taxes",
        "terseLabel": "Income tax expense (benefit), related to current period net loss before income taxes"
       }
      }
     },
     "localname": "CARESActIncomeTaxExpenseBenefitRelatedToCurrentPeriodNetIncomeLossBeforeIncomeTaxes",
     "nsuri": "http://apyxmedical.com/20200630",
     "presentation": [
      "http://apyxmedical.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "CARES Act, Income Tax Expense (Benefit), Release Of Valuation Allowance, Federal Net Operating Loss Carryforwards",
        "label": "CARES Act, Income Tax Expense (Benefit), Release Of Valuation Allowance, Federal Net Operating Loss Carryforwards",
        "negatedTerseLabel": "Release of valuation allowance"
       }
      }
     },
     "localname": "CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards",
     "nsuri": "http://apyxmedical.com/20200630",
     "presentation": [
      "http://apyxmedical.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_CapitalizationOfLeaseExecution": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Capitalization Of Lease, Execution",
        "label": "Capitalization Of Lease, Execution",
        "terseLabel": "Right-of-use assets capitalized and lease liabilities recognized upon execution of lease"
       }
      }
     },
     "localname": "CapitalizationOfLeaseExecution",
     "nsuri": "http://apyxmedical.com/20200630",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_CapitalizationOfLeaseNonCash": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Capitalization Of Lease, Non Cash",
        "label": "Capitalization Of Lease, Non Cash",
        "terseLabel": "Right-of-use assets capitalized and lease liabilities recognized upon lease remeasurement"
       }
      }
     },
     "localname": "CapitalizationOfLeaseNonCash",
     "nsuri": "http://apyxmedical.com/20200630",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_JointAndSeveralPayrollLiability": {
     "auth_ref": [],
     "calculation": {
      "http://apyxmedical.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Joint And Several Payroll Liability",
        "label": "Joint And Several Payroll Liability",
        "terseLabel": "Joint and several payroll liability"
       }
      }
     },
     "localname": "JointAndSeveralPayrollLiability",
     "nsuri": "http://apyxmedical.com/20200630",
     "presentation": [
      "http://apyxmedical.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_LeaseAdoption": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lease Adoption",
        "label": "Lease Adoption",
        "terseLabel": "Right-of-use assets capitalized and lease liabilities recognized upon adoption of Topic 842"
       }
      }
     },
     "localname": "LeaseAdoption",
     "nsuri": "http://apyxmedical.com/20200630",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_LossContingencyAccrualTotalAccruedToDate": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Loss Contingency Accrual, Total Accrued To Date",
        "label": "Loss Contingency Accrual, Total Accrued To Date",
        "terseLabel": "Loss contingency accrual, total accrued to date"
       }
      }
     },
     "localname": "LossContingencyAccrualTotalAccruedToDate",
     "nsuri": "http://apyxmedical.com/20200630",
     "presentation": [
      "http://apyxmedical.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_NonCashProceedsFromStockOptionsAndWarrantsExercised": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Non Cash, Proceeds From Stock Options And Warrants Exercised",
        "label": "Non Cash, Proceeds From Stock Options And Warrants Exercised",
        "terseLabel": "Cashless exercise of stock options"
       }
      }
     },
     "localname": "NonCashProceedsFromStockOptionsAndWarrantsExercised",
     "nsuri": "http://apyxmedical.com/20200630",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_NonCashTransferOfOtherAssetsToFixedAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Non Cash, Transfer Of Other Assets To Fixed Assets",
        "label": "Non Cash, Transfer Of Other Assets To Fixed Assets",
        "terseLabel": "Transfer of other assets to fixed assets"
       }
      }
     },
     "localname": "NonCashTransferOfOtherAssetsToFixedAssets",
     "nsuri": "http://apyxmedical.com/20200630",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_NonCashTransfersOfInventoryToFromFixedAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Non Cash, Transfers Of Inventory To (From) Fixed Assets",
        "label": "Non Cash, Transfers Of Inventory To (From) Fixed Assets",
        "terseLabel": "Transfer of inventory (to) from fixed assets"
       }
      }
     },
     "localname": "NonCashTransfersOfInventoryToFromFixedAssets",
     "nsuri": "http://apyxmedical.com/20200630",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_OEMMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "OEM [Member]",
        "terseLabel": "OEM"
       }
      }
     },
     "localname": "OEMMember",
     "nsuri": "http://apyxmedical.com/20200630",
     "presentation": [
      "http://apyxmedical.com/role/GeographicAndSegmentInformationReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_OtherAccruedExpensesAndLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://apyxmedical.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Accrued Expenses And Liabilities, Current",
        "label": "Other Accrued Expenses And Liabilities, Current",
        "terseLabel": "Other accrued expenses and current liabilities"
       }
      }
     },
     "localname": "OtherAccruedExpensesAndLiabilitiesCurrent",
     "nsuri": "http://apyxmedical.com/20200630",
     "presentation": [
      "http://apyxmedical.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised": {
     "auth_ref": [],
     "calculation": {
      "http://apyxmedical.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Proceeds From Stock Options Exercised And Warrants Exercised",
        "label": "Proceeds From Stock Options Exercised And Warrants Exercised",
        "terseLabel": "Proceeds from stock option exercises"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercisedAndWarrantsExercised",
     "nsuri": "http://apyxmedical.com/20200630",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_ProvisionForInventoryObsolescence": {
     "auth_ref": [],
     "calculation": {
      "http://apyxmedical.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Provision For Inventory Obsolescence",
        "label": "Provision For Inventory Obsolescence",
        "terseLabel": "Provision for inventory obsolescence"
       }
      }
     },
     "localname": "ProvisionForInventoryObsolescence",
     "nsuri": "http://apyxmedical.com/20200630",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_ProvisionForObsolescenceInventory": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Provision For Obsolescence, Inventory",
        "label": "Provision For Obsolescence, Inventory",
        "terseLabel": "Inventories, provision for obsolescence"
       }
      }
     },
     "localname": "ProvisionForObsolescenceInventory",
     "nsuri": "http://apyxmedical.com/20200630",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_RepaymentofFinanceLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://apyxmedical.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Repayment of Finance Lease Liabilities",
        "label": "Repayment of Finance Lease Liabilities",
        "negatedTerseLabel": "Repayment of finance lease liabilities"
       }
      }
     },
     "localname": "RepaymentofFinanceLeaseLiabilities",
     "nsuri": "http://apyxmedical.com/20200630",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_StockIssuedDuringPeriodSharesStockSwaps": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Stock Swaps",
        "label": "Stock Issued During Period, Shares, Stock Swaps",
        "terseLabel": "Stock swaps (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockSwaps",
     "nsuri": "http://apyxmedical.com/20200630",
     "presentation": [
      "http://apyxmedical.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Stock Swaps Equity Instruments Received",
        "label": "Stock Issued During Period, Shares, Stock Swaps Equity Instruments Received",
        "terseLabel": "Stock swaps equity instruments received (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived",
     "nsuri": "http://apyxmedical.com/20200630",
     "presentation": [
      "http://apyxmedical.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "apyx_StockSwapToAcquireOptionsAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock swap to acquire options amount.",
        "label": "Stock swap to acquire options, Amount",
        "terseLabel": "Shares issued on net settlement of stock options"
       }
      }
     },
     "localname": "StockSwapToAcquireOptionsAmount",
     "nsuri": "http://apyxmedical.com/20200630",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_StockSwapToAcquireOptionsShares": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock swap to acquire options shares.",
        "label": "Stock swap to acquire options, Shares",
        "terseLabel": "Shares issued on net settlement of stock options (in shares)"
       }
      }
     },
     "localname": "StockSwapToAcquireOptionsShares",
     "nsuri": "http://apyxmedical.com/20200630",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "apyx_TermOfPaymentDueNotesPayableRelatedParties": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term Of Payment Due, Notes Payable, Related Parties",
        "label": "Term Of Payment Due, Notes Payable, Related Parties",
        "terseLabel": "Term of payment due"
       }
      }
     },
     "localname": "TermOfPaymentDueNotesPayableRelatedParties",
     "nsuri": "http://apyxmedical.com/20200630",
     "presentation": [
      "http://apyxmedical.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "apyx_TotalRevenuePercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total Revenue, Percent",
        "label": "Total Revenue, Percent",
        "terseLabel": "International sales, percent of total revenue"
       }
      }
     },
     "localname": "TotalRevenuePercent",
     "nsuri": "http://apyxmedical.com/20200630",
     "presentation": [
      "http://apyxmedical.com/role/GeographicAndSegmentInformationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "apyx_UncertainTaxPositionsLiability": {
     "auth_ref": [],
     "calculation": {
      "http://apyxmedical.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Uncertain Tax Positions Liability",
        "label": "Uncertain Tax Positions Liability",
        "terseLabel": "Uncertain tax positions"
       }
      }
     },
     "localname": "UncertainTaxPositionsLiability",
     "nsuri": "http://apyxmedical.com/20200630",
     "presentation": [
      "http://apyxmedical.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "Domestic"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/GeographicAndSegmentInformationGeographicDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r314"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r315"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r316"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r316"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r316"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r316"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r316"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r316"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r316"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r108",
      "r121",
      "r122",
      "r123",
      "r124",
      "r126",
      "r128",
      "r132"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Consolidation Items [Axis]",
        "terseLabel": "Consolidation Items [Axis]"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/GeographicAndSegmentInformationReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [
      "r108",
      "r121",
      "r122",
      "r123",
      "r124",
      "r126",
      "r128",
      "r132"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Consolidation Items [Domain]",
        "terseLabel": "Consolidation Items [Domain]"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/GeographicAndSegmentInformationReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r141"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Director"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r136",
      "r137",
      "r183",
      "r184",
      "r293",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/GeographicAndSegmentInformationGeographicDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r136",
      "r137",
      "r183",
      "r184",
      "r293",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/GeographicAndSegmentInformationGeographicDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingChangesAndErrorCorrectionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounting Changes and Error Corrections [Abstract]"
       }
      }
     },
     "localname": "AccountingChangesAndErrorCorrectionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingChangesTextBlock": {
     "auth_ref": [
      "r85"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for reporting accounting changes, excludes error corrections information.",
        "label": "Accounting Changes [Text Block]",
        "terseLabel": "Change in Accounting Policy"
       }
      }
     },
     "localname": "AccountingChangesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ChangeInAccountingPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.",
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "terseLabel": "Accrued Expenses and Other Current Liabilities"
       }
      }
     },
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/AccruedExpensesAndOtherCurrentLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r4",
      "r15",
      "r142",
      "r143"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Trade accounts receivable, net of allowance of $760 and $273"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedBonusesCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r32"
     ],
     "calculation": {
      "http://apyxmedical.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Bonuses, Current",
        "terseLabel": "Accrued bonuses"
       }
      }
     },
     "localname": "AccruedBonusesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedInsuranceCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r32"
     ],
     "calculation": {
      "http://apyxmedical.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable to insurance entities to mitigate potential loss from various risks or to satisfy a promise to provide certain coverage's to employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Insurance, Current",
        "terseLabel": "Accrued insurance"
       }
      }
     },
     "localname": "AccruedInsuranceCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://apyxmedical.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://apyxmedical.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "totalLabel": "Total accrued expenses and other current liabilities",
        "verboseLabel": "Accrued expenses and other liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails",
      "http://apyxmedical.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r32"
     ],
     "calculation": {
      "http://apyxmedical.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedSalariesCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r32"
     ],
     "calculation": {
      "http://apyxmedical.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Salaries, Current",
        "verboseLabel": "Accrued payroll"
       }
      }
     },
     "localname": "AccruedSalariesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedSalesCommissionCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r32"
     ],
     "calculation": {
      "http://apyxmedical.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for sales commissions. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Sales Commission, Current",
        "terseLabel": "Accrued commissions"
       }
      }
     },
     "localname": "AccruedSalesCommissionCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r27",
      "r160"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "terseLabel": "Accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r16",
      "r207"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r74",
      "r75",
      "r76",
      "r204",
      "r205",
      "r206"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r186",
      "r187",
      "r210",
      "r211"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "verboseLabel": "Stock based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r187",
      "r202",
      "r209"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Stock based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "auth_ref": [
      "r144",
      "r150",
      "r151",
      "r153"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable.",
        "label": "Accounts Receivable, Allowance for Credit Loss",
        "terseLabel": "Allowance for doubtful accounts receivable"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r94"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Options (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r94"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r94"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r69",
      "r116",
      "r123",
      "r130",
      "r148",
      "r236",
      "r238",
      "r241",
      "r277",
      "r284"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r5",
      "r6",
      "r42",
      "r69",
      "r148",
      "r236",
      "r238",
      "r241"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r26",
      "r64"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r57",
      "r64",
      "r66"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r57",
      "r242"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r68",
      "r69",
      "r88",
      "r89",
      "r90",
      "r92",
      "r93",
      "r100",
      "r101",
      "r102",
      "r148",
      "r241"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CoVenturerMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other venturer from the perspective of the entity in the corporate joint venture.",
        "label": "Co-venturer [Member]",
        "terseLabel": "Co-venturer"
       }
      }
     },
     "localname": "CoVenturerMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r165",
      "r166",
      "r167",
      "r175"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r74",
      "r75"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://apyxmedical.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r14",
      "r180"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value; 75,000,000 shares authorized; 34,201,895 issued and outstanding as of June 30, 2020, and 34,312,527 issued and 34,169,952 outstanding as of December 31, 2019"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateJointVentureMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Corporation owned and operated by a small group of ventures to accomplish a mutually beneficial venture or project.",
        "label": "Corporate Joint Venture [Member]",
        "terseLabel": "Corporate Joint Venture"
       }
      }
     },
     "localname": "CorporateJointVentureMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateNonSegmentMember": {
     "auth_ref": [
      "r121",
      "r122",
      "r123",
      "r124",
      "r126",
      "r132",
      "r134"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.",
        "label": "Corporate, Non-Segment [Member]",
        "terseLabel": "Corporate &amp; Other"
       }
      }
     },
     "localname": "CorporateNonSegmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/GeographicAndSegmentInformationReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r50",
      "r263"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of sales"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Other costs and expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r62",
      "r111"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DescriptionOfNewAccountingPronouncementsNotYetAdopted": {
     "auth_ref": [
      "r85"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for a new accounting pronouncement that has been issued but not yet adopted.",
        "label": "Description of New Accounting Pronouncements Not yet Adopted [Text Block]",
        "terseLabel": "RECENT ACCOUNTING PRONOUNCEMENTS"
       }
      }
     },
     "localname": "DescriptionOfNewAccountingPronouncementsNotYetAdopted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/RecentAccountingPronouncements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DilutiveSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "DilutiveSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "STOCK-BASED COMPENSATION"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrent": {
     "auth_ref": [
      "r29",
      "r72",
      "r257"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Due to Related Parties, Current",
        "terseLabel": "Related party note payable"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r72",
      "r257",
      "r280",
      "r288"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties.",
        "label": "Due to Related Parties",
        "terseLabel": "Due to related parties"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CommitmentsAndContingenciesNarrativeDetails",
      "http://apyxmedical.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings (loss) per Share:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share, Basic [Abstract]",
        "terseLabel": "Earnings (loss) per share:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share, Diluted [Abstract]",
        "terseLabel": "Anti-dilutive instruments excluded from diluted loss per common share:"
       }
      }
     },
     "localname": "EarningsPerShareDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share Reconciliation [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "EarningsPerShareReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r94",
      "r95",
      "r96",
      "r97"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "EARNINGS PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/EarningsPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r242"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of exchange rates on cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r216"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective income tax rate, percent"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r74",
      "r75",
      "r76",
      "r77",
      "r82",
      "r84",
      "r99",
      "r149",
      "r180",
      "r181",
      "r204",
      "r205",
      "r206",
      "r227",
      "r228",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r294",
      "r295",
      "r296"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r253"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease, Liability, Current",
        "terseLabel": "Current portion of finance lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r253"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance Lease, Liability, Noncurrent",
        "terseLabel": "Long-term finance lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "auth_ref": [
      "r252"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization",
        "terseLabel": "Finance lease right-of-use assets"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnInvestments": {
     "auth_ref": [
      "r52",
      "r62",
      "r147"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of realized and unrealized gain (loss) on investment.",
        "label": "Gain (Loss) on Investments",
        "negatedTerseLabel": "Unrealized gain on short term investments"
       }
      }
     },
     "localname": "GainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r49",
      "r69",
      "r116",
      "r122",
      "r126",
      "r129",
      "r132",
      "r148",
      "r241"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ConsolidatedStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r44",
      "r116",
      "r122",
      "r126",
      "r129",
      "r132",
      "r276",
      "r281",
      "r283",
      "r290"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) from continuing operations per each basic and diluted share of common stock or unit when the per share amount is the same for both basic and diluted shares.",
        "label": "Income (Loss) from Continuing Operations, Per Basic and Diluted Share",
        "terseLabel": "Basic and diluted (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerBasicAndDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedStatementsOfOperations",
      "http://apyxmedical.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r217",
      "r224",
      "r225",
      "r229",
      "r231",
      "r233",
      "r234",
      "r235"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r70",
      "r83",
      "r84",
      "r114",
      "r215",
      "r230",
      "r232",
      "r291"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "netLabel": "Income tax (benefit) expense",
        "terseLabel": "Income tax (benefit) expense",
        "verboseLabel": "Income tax expense (benefit)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedStatementsOfOperations",
      "http://apyxmedical.com/role/GeographicAndSegmentInformationReportableSegmentDetails",
      "http://apyxmedical.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r59",
      "r65"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesReceivable": {
     "auth_ref": [
      "r36",
      "r279",
      "r289"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.",
        "label": "Income Taxes Receivable, Current",
        "terseLabel": "Income tax receivables"
       }
      }
     },
     "localname": "IncomeTaxesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Trade receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedTerseLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r43",
      "r110",
      "r250",
      "r251",
      "r282"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedTerseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedStatementsOfOperations",
      "http://apyxmedical.com/role/GeographicAndSegmentInformationReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeOperating": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities.",
        "label": "Interest Income, Operating",
        "terseLabel": "Interest income",
        "verboseLabel": "Interest income"
       }
      }
     },
     "localname": "InterestIncomeOperating",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedStatementsOfOperations",
      "http://apyxmedical.com/role/GeographicAndSegmentInformationReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r56",
      "r58",
      "r65"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r158"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "INVENTORIES"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/Inventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://apyxmedical.com/role/InventoriesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryGross": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://apyxmedical.com/role/InventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Inventory, Gross",
        "totalLabel": "Gross inventories"
       }
      }
     },
     "localname": "InventoryGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r3",
      "r40"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://apyxmedical.com/role/InventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "totalLabel": "Inventories, net",
        "verboseLabel": "Inventories, net of provision for obsolescence of $685 and $392"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedBalanceSheets",
      "http://apyxmedical.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r9",
      "r41",
      "r67",
      "r98",
      "r154",
      "r156",
      "r158"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/BasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterials": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://apyxmedical.com/role/InventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Raw Materials, Gross",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryValuationReserves": {
     "auth_ref": [
      "r40",
      "r73",
      "r157"
     ],
     "calculation": {
      "http://apyxmedical.com/role/InventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of valuation reserve for inventory.",
        "label": "Inventory Valuation Reserves",
        "negatedLabel": "Less: provision for obsolescence"
       }
      }
     },
     "localname": "InventoryValuationReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://apyxmedical.com/role/InventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Inventory, Work in Process, Gross",
        "terseLabel": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWriteDown": {
     "auth_ref": [
      "r155"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.",
        "label": "Inventory Write-down",
        "terseLabel": "Impairment of inventory"
       }
      }
     },
     "localname": "InventoryWriteDown",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/InventoriesInventoriesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r31",
      "r69",
      "r124",
      "r148",
      "r237",
      "r238",
      "r239",
      "r241"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r20",
      "r69",
      "r148",
      "r241",
      "r278",
      "r286"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r33",
      "r69",
      "r148",
      "r237",
      "r238",
      "r239",
      "r241"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LitigationStatusAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Axis]",
        "terseLabel": "Litigation Status [Axis]"
       }
      }
     },
     "localname": "LitigationStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LitigationStatusDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Domain]",
        "terseLabel": "Litigation Status [Domain]"
       }
      }
     },
     "localname": "LitigationStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "auth_ref": [
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r177",
      "r178"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.",
        "label": "Loss Contingency Nature [Axis]",
        "terseLabel": "Loss Contingency Nature [Axis]"
       }
      }
     },
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "auth_ref": [
      "r168"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of loss contingency liability.",
        "label": "Loss Contingency Accrual",
        "terseLabel": "Costs accrued"
       }
      }
     },
     "localname": "LossContingencyAccrualAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyNatureDomain": {
     "auth_ref": [
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r177",
      "r178"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.",
        "label": "Loss Contingency, Nature [Domain]",
        "terseLabel": "Loss Contingency, Nature [Domain]"
       }
      }
     },
     "localname": "LossContingencyNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash (used in) provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash (used in) provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r57",
      "r60",
      "r63"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r78",
      "r79",
      "r80",
      "r81",
      "r86",
      "r87",
      "r91",
      "r93",
      "r116",
      "r122",
      "r126",
      "r129",
      "r132"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://apyxmedical.com/role/ConsolidatedStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedStatementsOfCashFlows",
      "http://apyxmedical.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://apyxmedical.com/role/ConsolidatedStatementsOfOperations",
      "http://apyxmedical.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounting Standards Update and Change in Accounting Principle [Abstract]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/BasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "International"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/GeographicAndSegmentInformationGeographicDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r72",
      "r257",
      "r288"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount for notes payable (written promise to pay), due to related parties.",
        "label": "Notes Payable, Related Parties",
        "terseLabel": "Notes payable"
       }
      }
     },
     "localname": "NotesPayableRelatedPartiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/GeographicAndSegmentInformationNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://apyxmedical.com/role/ConsolidatedStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total other costs and expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r116",
      "r122",
      "r126",
      "r129",
      "r132"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "terseLabel": "Loss from operations",
        "verboseLabel": "Income (loss) from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedStatementsOfOperations",
      "http://apyxmedical.com/role/GeographicAndSegmentInformationReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r253"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r253"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Long-term operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r252"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingSegmentsMember": {
     "auth_ref": [
      "r121",
      "r122",
      "r123",
      "r124",
      "r126",
      "r132"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Operating Segments [Member]",
        "terseLabel": "Operating Segments"
       }
      }
     },
     "localname": "OperatingSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/GeographicAndSegmentInformationReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OptionOnSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of a security at a specified price during a specified period or at a specified date.",
        "label": "Option on Securities [Member]",
        "terseLabel": "Options"
       }
      }
     },
     "localname": "OptionOnSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r1",
      "r240"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "BASIS OF PRESENTATION"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/BasisOfPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Other Commitments [Line Items]",
        "terseLabel": "Other Commitments [Line Items]"
       }
      }
     },
     "localname": "OtherCommitmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about obligations resulting from other commitments.",
        "label": "Other Commitments [Table]",
        "terseLabel": "Other Commitments [Table]"
       }
      }
     },
     "localname": "OtherCommitmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "totalLabel": "Total other (loss) income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingIncomeExpenseNet": {
     "auth_ref": [],
     "calculation": {
      "http://apyxmedical.com/role/ConsolidatedStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.",
        "label": "Other Operating Income (Expense), Net",
        "terseLabel": "Other (loss) income, net",
        "verboseLabel": "Other income (losses), net"
       }
      }
     },
     "localname": "OtherOperatingIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedStatementsOfOperations",
      "http://apyxmedical.com/role/GeographicAndSegmentInformationReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://apyxmedical.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.",
        "label": "Other Receivables, Net, Current",
        "terseLabel": "Other receivables"
       }
      }
     },
     "localname": "OtherReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsToAcquireInterestInJointVenture": {
     "auth_ref": [
      "r54"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the investment in or advances to an entity in which the reporting entity shares control of the entity with another party or group.",
        "label": "Payments to Acquire Interest in Joint Venture",
        "terseLabel": "Capital commitment, funding"
       }
      }
     },
     "localname": "PaymentsToAcquireInterestInJointVenture",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r146"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PendingLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Risk of loss associated with the outcome of pending litigation against the entity, for example, but not limited to, litigation in arbitration or within the trial process.",
        "label": "Pending Litigation [Member]",
        "terseLabel": "Pending Litigation"
       }
      }
     },
     "localname": "PendingLitigationMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r5",
      "r24",
      "r25"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://apyxmedical.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Proceeds from maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductWarrantyAccrualClassifiedCurrent": {
     "auth_ref": [
      "r32",
      "r176",
      "r179"
     ],
     "calculation": {
      "http://apyxmedical.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers. For classified balance sheets, represents the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Product Warranty Accrual, Current",
        "terseLabel": "Accrued product warranties"
       }
      }
     },
     "localname": "ProductWarrantyAccrualClassifiedCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfessionalFees": {
     "auth_ref": [
      "r299",
      "r300"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.",
        "label": "Professional Fees",
        "terseLabel": "Professional services"
       }
      }
     },
     "localname": "ProfessionalFees",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r10",
      "r11",
      "r161",
      "r287"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net of accumulated depreciation and amortization of $4,702 and $4,403"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r46",
      "r152"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "terseLabel": "Provision (benefit) for allowance for doubtful accounts"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PurchaseObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.",
        "label": "Purchase Obligation",
        "terseLabel": "Purchase obligation"
       }
      }
     },
     "localname": "PurchaseObligation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "terseLabel": "Gross Unrealized Tax Benefits"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/IncomeTaxesUnrecognizedTaxBenefitsRollForwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r185",
      "r256",
      "r257"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CommitmentsAndContingenciesNarrativeDetails",
      "http://apyxmedical.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r185",
      "r256",
      "r257",
      "r259"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r185"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction, Purchases from Related Party",
        "terseLabel": "Purchases from related party"
       }
      }
     },
     "localname": "RelatedPartyTransactionPurchasesFromRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r185",
      "r256",
      "r259",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CommitmentsAndContingenciesNarrativeDetails",
      "http://apyxmedical.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r254",
      "r255",
      "r257",
      "r260",
      "r261"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r213",
      "r311"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r17",
      "r181",
      "r207",
      "r285",
      "r297",
      "r298"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r74",
      "r75",
      "r76",
      "r77",
      "r82",
      "r84",
      "r149",
      "r204",
      "r205",
      "r206",
      "r227",
      "r228",
      "r294",
      "r296"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r107",
      "r108",
      "r121",
      "r127",
      "r128",
      "r135",
      "r136",
      "r139",
      "r182",
      "r183",
      "r263"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Sales"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedStatementsOfOperations",
      "http://apyxmedical.com/role/GeographicAndSegmentInformationGeographicDetails",
      "http://apyxmedical.com/role/GeographicAndSegmentInformationReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalariesAndWages": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ConsolidatedStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.",
        "label": "Salary and Wage, NonOfficer, Excluding Cost of Good and Service Sold",
        "terseLabel": "Salaries and related costs"
       }
      }
     },
     "localname": "SalariesAndWages",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r94"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Basic and diluted loss per share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/EarningsPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r9",
      "r21",
      "r22",
      "r23"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/InventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r71",
      "r258",
      "r259"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock": {
     "auth_ref": [
      "r48",
      "r136"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the names of foreign countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries.",
        "label": "Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]",
        "terseLabel": "Schedule of revenue by geographic area"
       }
      }
     },
     "localname": "ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/GeographicAndSegmentInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r116",
      "r119",
      "r125",
      "r159"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/GeographicAndSegmentInformationGeographicDetails",
      "http://apyxmedical.com/role/GeographicAndSegmentInformationReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "auth_ref": [
      "r116",
      "r119",
      "r125",
      "r159"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Schedule of reporting information by segment"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/GeographicAndSegmentInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r188",
      "r203"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r190",
      "r195",
      "r196"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of stock options and stock awards"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of option fair value assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r223",
      "r226"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Unrecognized tax benefits roll-forward"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r103",
      "r107",
      "r108",
      "r109",
      "r110",
      "r111",
      "r112",
      "r113",
      "r114",
      "r115",
      "r116",
      "r117",
      "r118",
      "r121",
      "r122",
      "r123",
      "r124",
      "r126",
      "r127",
      "r128",
      "r129",
      "r130",
      "r132",
      "r139",
      "r292"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/GeographicAndSegmentInformationReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r103",
      "r105",
      "r106",
      "r116",
      "r120",
      "r126",
      "r130",
      "r131",
      "r132",
      "r133",
      "r135",
      "r138",
      "r139",
      "r140"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "GEOGRAPHIC AND SEGMENT INFORMATION"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/GeographicAndSegmentInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/GeographicAndSegmentInformationGeographicDetails",
      "http://apyxmedical.com/role/GeographicAndSegmentInformationReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ConsolidatedStatementsOfOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/StockBasedCompensationFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/StockBasedCompensationFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/StockBasedCompensationFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r194"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedTerseLabel": "Canceled and forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/StockBasedCompensationSummaryOfStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r194"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Canceled and forfeited (in dollars per shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/StockBasedCompensationSummaryOfStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/StockBasedCompensationSummaryOfStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r192",
      "r203"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding, end of period (in shares)",
        "periodStartLabel": "Outstanding, beginning of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/StockBasedCompensationSummaryOfStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/StockBasedCompensationSummaryOfStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r191"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding, end of period (in dollars per share)",
        "periodStartLabel": "Outstanding, beginning of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/StockBasedCompensationSummaryOfStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted average exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/StockBasedCompensationSummaryOfStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/StockBasedCompensationSummaryOfStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)",
        "verboseLabel": "Option value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/StockBasedCompensationFairValueAssumptionsDetails",
      "http://apyxmedical.com/role/StockBasedCompensationSummaryOfStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r67",
      "r188",
      "r189"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Share based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/BasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r198",
      "r208"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/StockBasedCompensationFairValueAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r0",
      "r103",
      "r107",
      "r108",
      "r109",
      "r110",
      "r111",
      "r112",
      "r113",
      "r114",
      "r115",
      "r116",
      "r117",
      "r118",
      "r121",
      "r122",
      "r123",
      "r124",
      "r126",
      "r127",
      "r128",
      "r129",
      "r130",
      "r132",
      "r139",
      "r159",
      "r162",
      "r163",
      "r164",
      "r292"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/GeographicAndSegmentInformationReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r12",
      "r13",
      "r14",
      "r68",
      "r69",
      "r88",
      "r89",
      "r90",
      "r92",
      "r93",
      "r100",
      "r101",
      "r102",
      "r148",
      "r180",
      "r241"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r35",
      "r74",
      "r75",
      "r76",
      "r77",
      "r82",
      "r84",
      "r99",
      "r149",
      "r180",
      "r181",
      "r204",
      "r205",
      "r206",
      "r227",
      "r228",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r294",
      "r295",
      "r296"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r74",
      "r75",
      "r76",
      "r99",
      "r263"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r13",
      "r14",
      "r180",
      "r181"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Options exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r13",
      "r14",
      "r180",
      "r181",
      "r193"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/StockBasedCompensationSummaryOfStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r35",
      "r180",
      "r181"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Options exercised for cash"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r14",
      "r18",
      "r19",
      "r69",
      "r145",
      "r148",
      "r241"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedBalanceSheets",
      "http://apyxmedical.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r249",
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r249",
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r249",
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnfavorableRegulatoryActionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A enacted or proposed action, ruling or regulation that is likely to or possibly will have an adverse effect on the entity's financial position or results of operations, excluding tax matters.",
        "label": "Unfavorable Regulatory Action [Member]",
        "terseLabel": "Unfavorable Regulatory Action"
       }
      }
     },
     "localname": "UnfavorableRegulatoryActionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r214",
      "r219"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Balance at June 30, 2020",
        "periodStartLabel": "Balance at January 1, 2020"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/IncomeTaxesUnrecognizedTaxBenefitsRollForwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r220"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "negatedTerseLabel": "Decreases for tax positions related to the prior year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/IncomeTaxesUnrecognizedTaxBenefitsRollForwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r218"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Accrued interest and penalties"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "auth_ref": [
      "r218"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense",
        "terseLabel": "Interest and penalties included in income tax expense"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r221"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Additions of tax positions related to the current year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/IncomeTaxesUnrecognizedTaxBenefitsRollForwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r220"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Additions of tax positions related to the prior year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/IncomeTaxesUnrecognizedTaxBenefitsRollForwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "auth_ref": [
      "r222"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "terseLabel": "Uncertain tax positions that would impact effective tax rate"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Weighted average shares outstanding - basic and diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8475-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "http://asc.fasb.org/topic&trid=2134510"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4647-111522"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5074-111524"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27405-111563"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599878&loc=SL82895884-210446"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=68070138&loc=d3e11281-110244"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12021-110248"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12053-110248"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12524-110249"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)-(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=SL37586934-109318"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121610041&loc=d3e36027-109320"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(3),(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.17)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.5(c))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Subparagraph": "(k)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262090&loc=SL114874205-224268"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07.2(a),(b),(c),(d))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r312": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r313": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r314": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r315": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r316": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r317": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1(e))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(c),9(a))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "http://asc.fasb.org/topic&trid=2122394"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1377-109256"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e543-108305"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>58
<FILENAME>0000719135-20-000057-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000719135-20-000057-xbrl.zip
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M?"9)/Y]G>3ZDG_N3)^-O=K9)>GOD#>W:&_NN8QKJ@.$@0! *9:# $OA$"FJ
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MW'CTP4HDX%!"3!N&_6(TK93S.]6WZS =Y;HP*$H$AH7=;?\^BO._J/% Y94
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M0"\N :688F:9+0R),.IN_(# !?1:?:-%KS< P,W,LVY-GS=/W\ 04 VDY-8
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M&I8'K^T4;GNY@K9?9]5:'@FZ]"[3Y/OD:G;YC=77<3&V07PQ'!=[#XHP?AY
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M'UIW++/W?3)64UL4CXO,R6(7X/'T>I!,JEN//F#20Y#U<'[VQ/WY/;0-UA"
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MM)0$$8\F0?B*G,6J2VB]QS;YLD,Z#N1NA?'1ZKE6W%/-!-[\\(J#(;SB2!\
M7LT4?CFBY6<)E23*#Q0JT#H_5>@P(YN.'SX\Y<CN;H:IMF''JM/3)57_?.8Y
MN##" 4S<K?ZK&@[;$'X]35,+O%Z49?$D>_="/MCUY7;FP/[,M66%#KLJU%:&
M\^,U\WV$_?PO\3^GPV_1:#DHLC$.;R3@QF?^;YM0V"MFVCBA8K5;"2V5\QG^
MR*/Z)HWZQ8DH>5AI@#&@,N:('7__XSC?MG\,$ >(2A&R/+ZD?,DI)I+YB/@
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MLE20=D?NCSFUO^:#_GSQ>Q87-NG&E!J2=*\-T4X):5>5X/[)(9UKQS PRJ"
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MOW<[[V<-9KV;Z#9O7;0E'=?)F,2.Y%[P0A=%I4/..!)"^)P%0<"0F962!R#
MLJF?\)=RM3>]9Q'UD&O#O0NXYF2\8S*.Y\VM @V!'PCE!U('G(8$ CKKZ$$Y
M4.O*>$N11-0CV&T4V:E&=)9#TFE<VVYGP05P-0\/9)+.:XY"R372TO<I-5PP
M%%"!*IFD$IJES2(5Q3_.J;OY$S DW._*!^>)':04<KAP5)0R0@$#J=0R5)()
M,I-"S"@*7B"%+2E'V</2=1+?*8]X%@R[R;L E!T D@<[*]M3DCLKA7(NA1@H
MKHTU2Z4F)* FH&RV<=*W_RYEMN]OV)H)X^W&>XVW>DQ;9[7>(2FW794>Z\'-
M=1AG/&0: 8## $/?4$EG.T<8$DL1G.=*3UOMQEMMU-A];;7S/EZ-&KNXMP?2
M>7K-\HD7Y)/YR@1,B#!4H?2!I'RV*=+W3;ATW.'BSJZMZ3;$]MO(=*[>08HA
MF9_7IF# N 1"01TR7R.?!M5Q4;Z/$%ZYP7)K2A(AN==BN'>^WM>X[ %W$^6]
MXL;))%Z=!SWT)L>0<+#0)M5'(?$I-$9"9 Q4A%<B*;&12\T:@VE\EE04_V()
MOH4@*&RU 5QG6QL[G_  )$_,E6&><0"*:E]#!@60BN>MJ@K)TQ2QI;CG<R2O
M+7_Q,"3/-15?+AUT9NQ]R:5@+KG88!T&2/.0*BK]D,-9<ROE"ZZ7S-@M)@QE
MCV'76\YYD7LG?FBA7(XR/\1""A,0@\)\2[!?!7,4Q7@I;;_%3"%$/;SG"?O]
MVC9S].%CD@\I3J]=@G!9ZLA<ZJ3V$0#:""9PJ#4GUG.\.T]#BN735.M3'%MH
MU@-YFSOT.ZOH#DF?[:P L7D%*.=YD1GDB@$8DE!3%521%HTQ$8^T1'V2 +45
M 6W5A.R^IMKMK6"+*LPE!Y\JF&*A--N'&NE0^HPBIB@%(:@.6_2A\(.ETNS:
MK,06]!J!9*\MRTZ):5<UX=Y)(@/S;D\ $&BD"CF! %&!.,@W0A4A46HP76H"
M^6Q);$E!$N1\O%WR\3ZWO2MB3],3#"T<08QDF"M!H(, 2=\8;D1EK@*"57U#
MR(50RQ84(F>;ZWW4H?2$<P0/0/+(O,D84-8[! 8;J:5D0.5=QBHM&&BBEWH>
M/D?R6E* %+9:(]-5R3OXQ*#S()LEEBVT!<0 ^H3[/@\EA5 #%)!*8I5OEF.C
M"\*ZN2@HZ,D][YKL',:#%#PQ/^[-^HLA8#J @A$28*(IGYW804-IS+,$KZT<
M(.X1L=^5W/OF'[K.>*XSWMZOY:'LFEH!ESJYOD[R[TKZ?_2\?P-O (!YV;CW
M+1I-X_<>ISWK;^3_>]E5E.8]-::3JR2UWSUX[V'2LTJB)R3UAEF6M]XH.FY,
M)]G$_B6O&XBR?(?6?TS'L8=!S\MMN5YQDWT40]2CB"\^:C^%3/8D137?$L3]
M^/H\3CT,\V_*'2YG!RS: 7S!968FE)(& 0A]C(SO(ZYP59S ,>)+=D#)"*<Y
M'_Q7OO0;L\*Q2]DX"WSO)(_-+7!(L%*^#*S9K9B0(0M]/NM=YQNTM//Y<<EK
MZ\B@_9:\O=O%I>P;\U6*1E8C#P?'P['7CVZ&DVATH+5#?,'/)8%BO@XT,S3@
M5&(B<#@KO@N17NX>=T?,+Y:6)V-=4G)SY^.)GD2N1^2>*:Y=E1P!YL<A&\VL
M(B)A?AXR9@)(!'0E.2&BR^?:/5ERVLJDL!YW73EVR;_,-QQ/HN$X;[T8I6/[
M;I<;>2B :"Z UBTC4O- 6.],6_D+C9@)8$##<.D\\AEQPXJVJM^?7D^+78]!
M?#'L#S=83] 3?+\#M\Y?.TAQ)/.>I]@/&<9&6!'5H3(!$G*VC<,$5DK;$,?6
M=A_W*&SUL,7.R>.AG/M:1%RO["=QFLT2+/$_I\/)[2N8J)T_<5"PN;P&4!/,
MK*D* A8(IHT,P*RSG#9BJ2_CZ0*EPX+"FVM.S'H"MZHO.WFXH/,(]UW<Q+P-
MJI9$AQ1B@Z!$RD!-]:R@P&"#Z3KBUI(ZY+"'Z ;*[CHF;H=2<]<X_*<4XQ7I
MP^<JU6?48+9UHG'3'!=8#^W)4<>/LN/3(/(9Y-@B1$HPWRXG?:64 :%1F&+D
M,QJ88%;L2(59BJ@MU%RI\6"+]LDK'-;>37YWT0 'A@X,VP/#A5U2RN>2<<4!
MUI 1Q@-A9I7? 1-FR5Y\/ACN[E'QW>3WE7;GVTG>-O3N\^+GPG!&PW%\/#N?
M&H$_OU\87S^VZY:V,<*SJ]B+^OWDVCYXFQ>$Y2U-K<F7VH\M)]K77*9%ECR=
MY(5B$WN[99J"C$4?U+()P+ (N]@/KNW LC?W9US\* DQ_WWK$\4/EJ'X>97.
MON,FNHR/S],X^N,XNK"O?!>-OD>WF7W3VZNT&G-42&;FX\! +C$,.*!(^<(Z
M<0H(8R3B/F Z?R9Z\F27IQ8]9U[>59I+ZI\RQ97@"D-?$$11("3ABB$FB.'"
MB%"OQ1PY@^;+KG.<L"M[1\/HE1BVQE]17_[^-^_7,#C1ZJ.G/W_]\OFK.COY
M_&F)"1O'^4 O$*L7MC-T_?G3Z>>/)X$Z"_,3T^T?OX:?SDZ]S\;[_"4LIW%:
MQ[<U(K5=:?KI9&RQ()EFUC?,>E[\HQ_?3+R;."UK63T+#E'/^WT<30=#"Q,_
M/WTQE@>W</<]4PC,UFDXMC9<^?OBUXUS!36Z9P5 4)J"!?)Z_7@TJJ[^Y0@<
M%;_;8?9GO]<0Y&QX;='Q4_S=^YI<1TN&X_?A8'+U3HHW#%/".15($/;GF1*R
MFFD4W63QN]E?WC]4.4=WT8B[*!ED1\W!BO)]1/[Y_=&2)BVOP167P'J/N9>M
M\[)7W<;R6B%>WJ4=UAL$\C.KA6/O5WOA*O-""T># IUGQ?D''N@_%"XX'?YX
M%@]TLV=85[=$/<8EK]58;8,,E4<G72C-L<N3V:5IXY9C%\<N#ET<NVP 7?9N
M;]!I-&IJ0-.1<I77S,;L= V.%!S&G,\+W@SR):982*2D[VN?4A'.,BI$D9IZ
M\6_Q>!J;-+G.0Z+YE__W<'*EIYF=?)R&/_JC:4X.E66Q_6]P%OUXD&0)RHSS
M;V=!&ZTA>ZC=L\([6:1S *YRZ_/;5>SH #PLG%.N"934&,H"%7 #*$8LY"P
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M_QM?.K&.%L;(Y\*-K,?4,ZL08^_:7KC*O-ABP,#[C^DX]C#H>;E97:3R\FC
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M$E(B7*E"YBD@ITHN\I %#VNXCZ.C#E,P^8AWJM_NH/![YP:M;3(%"YY4;BI
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MP68TFG"Y!<[4GDJE$I40M7EF=;Z@\>Y;-!M9=:C,#C(*D-5 RR#/*J#9"A.
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MZKS_195O;S()?E29A\GW>+HL4]7/ZX797(35XH [+U8I[97LG25)E?'5DF3
M,L9+F]!9X2](I$D9"S<OL>M;O<-X%@J;O5"[?-:NBRM+MTJAMW1093ZFUNI=
MR?5V)TF3/7Q6RL@;MU_$DRH';VQE<)7?U4K1O3Q-9Y7_[+?9Q#I.2E :%E/N
M\[KD+56.F%W(:C\M;61A3OJTJF3)'[D_*R!M#5&<YQ9IXDNCZ>T[<M9^.&A
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MH8="07%)7$AH%[$[B<L \F#VM03CUD0T&E&WRW$FO97$.R!P=YUJL-\,>H^
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MC11^D+,]IE'3?>F@^\Q_#;[VMHC?R\%J6]CGGTW4[-5:=_>!@C%M9QP0Y(O
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MFR3TGR3/)G%Q8?14CA'^Y0.+D16=?,_ ^@7+>7']L65)*V#INIP+@EP61F'
MA(BDKK/*=83=[<J2^F#^MCJ75Y FC.YOAE8&<=(B$^/8<7Y*9\YU$N=%[^M
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M*>U2Q5FTE6S0T^V82,;IPL%E^%G<_8G>_5JKJ("&$X4&6A3JE!L!7Z$9_)W
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M-"+3*?_UKQ_D#_0S7,ZH_KSF;J^3&2FD"_(@?<UF\8J@^)",RPG\"5OC/3E
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M<<MQ-\_2& "M J3R+_]Q'ISANP^ [ G6E <)@2W)G\#]4^B9Q C0-P6  CP
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M^$,RQ1.@ ("J "!9#O?(^E$P\02$()R:35HKJJTF"S &IP)J4(KB^0T^$A=
M VZ0S7#!GFH/], 1-.AMU!I???8CJF/7_3]P+3!4 721ZA3 'P >@;X3/E\C
MFN2M[0*I7 >(X=QJQCM)<EPR.END?X," 5HK.X8,1+<;2G(>LU0TKF%O?*$-
M??C9%7-J]^A 4'NNOUW14TP6FL5Q497JA*TT0,\ZH2"%7.8,<>2,\IN[/'M
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MTJT-N+&!C7:7, :VA DU7X&9D8;488R#CN.UG&"$>4G#7.>@6]:O<ML-#39
M5H$\F0([<$P6=\P!OB5F25J -#BMW3-Q0P,*#%ZA%.Z!W"2@^Q4TB/\.?T/@
M Z9:E$NHMXAX##>!N7+RF2 ]0QQ&XC2'A9Q1\B$A^9":0'QF>QNSM]>=;[9D
M;>J@$.Z.ZJV .\E\V@ABU(15WWW+.@LF&=!C7,I%8"FC"QC7(35Y3FA^6%<<
M6A"86$9%8SYKUP-'S0\&"Z_.Z?DNCM.>'_V^8?@ <CE==7R#ED!<R#)):%%_
MWTC7#\QOC#P%N>-)?JBXW=WEY(YG;I893QRDBESS7)9B,. M,Q>2[Y/D!M.
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M!/V C/U<_HKQ[=0N_X>=AH_V\GWJ9#CQZS]EW!>$_X0O7Q#^D[W\)PG_BS+
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MJZOO3/##M[LK2+-\%D\75%=%9HHJU1>E$9E.^:]__2!_H)\+Y$/\\YH3NTZ
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M&^J 2>8A Y]JB#S0(P>^X]GKL>_OD F)K@U?50).$!(!?-L3H3:H'B6 KT?
M=V@ )Q+*#SH)]@?Q))UVX!OG.Z,SZ:>M973W*Y.[S=V.RS)/;BJ6BEMFS<%A
M/GZG!?<H2[%E.J"I=(N-Q3_^$4Y'@FFF< $_K6WO7O<&EXI)58ZSAY1U56]F
MD)*%8;,Y;<)>7R L!7/(YW%>IB1O5\*FUIJI!]BZ_ $N/,'^]:5TE\?8$7W.
M,LJ?'@4FQS,<2M<3TH$7'"LG](4DGL+Y9+>W!2FQUWF<-B4*\.UX1)NOX]+I
MOJIQLG@\>GL\=>MSVL =[2'2;9+&*:P$D^+A)UH) 5NK\[]9+_2Z>_Q8(K<
M327O #\C8SQJNK,$P]40 _#9/,.&[K>P0P)C$S;(#![%]NJPL?A;"AA#"I%&
M_P(*LH5R%-90V0+]Z%\=B*>IQVMQQ.HQCEQ/DK8HB?0 9&8=55B@EU-R!X/4
M$/0"&CF:PK=P3)3T3>.'HDI*/+6\@G&2E#YSF^1%*?V[@LF!A&6WM!)&+VGI
MOA&Z!U2%?<3'VWRYJW@*V,)!K0;S45:4FU7HZ,6!B3(AHDS(V^<294*V>U*B
M3,@1%Q4094*$\^2H]W=R&"W*A)PN/HLR(3W,"19E0OJ!'/V#C/U<OL@6/]G+
M%V5"3ASW!>$_X<L7A/]D+__$RX2L=9;4/0)$!N@!98!J UW;:JJ9R";KC=%1
M(-?>D<M0-A$0!7(=!G(=6*KF1_7U24@'EJLI"F\(SG (G,$<6(;@# *Y1.&-
MI3/8;^$-<^ XHO3AB>+LH4ES&V2"'H,T)TIO;)GO[!Y4;?GU16+Z"9$GFC=Z
MR,!GJ")I^<B![WCV>NS[.V1"8JFB@)0 OGUQ,4L4D#IRX#N2O?:^!$;]=?OY
MK>F4KUZ8NJP.T7\G>3W('/3!LYN<Q-_.XEN8\U,\?8@?"\P@F^0O6/3J$N/7
MK$^:Y.3VKQ_^4+B6:UNNIGBVKAIJ8#NZY9JJ:>N194=VZ&^R]VN:* K*K@^_
M8(9X<Q3Q*R%EA_$][I??_T_Z' ;GOONKY%]^_7+YU;T^O[S8;AKNV]?YV;UP
M?PD_AQ?7?[F2@O,K_[>K*UBFY%X$\)_[^Z]7YU?29=2W94?G%^Z%?T[/]B(X
MOZZ7_#6\^NW7:URQ=/DE9$=^)9U14*'U UZ^D1V93Y\B(N],V8(J!WK?J5R#
M@5@K-2@VKAZ!Z4V,P&,%BS<6HBB>"Q;KU "*Y_,\^YY@F8?IXQLJ JE#^2T5
M@7"5FT^N#8TW3#[ TAES,BJ3>SB#;@V/<0Y?I;3"S4(]"5J& @[O)DNK;EF4
MIFY.TA[QD^4Q)@"N!)E/-OJV7):"EK!8*A@"T@0:+"<D'M/2(4T5E#EL*QN+
M$A,]603[B(]WZER0*<Q]-Y#N2 K7.&47/)XE:5*4>8R0]T0DYUO91N?]!1E7
M%)T012=$T0E1=&+[JO:II*B+HA.G;' YI;L\%8P612=.%Y]%T8D>9IB*HA/]
M0([^0<9^+E_D'I_LY8NB$R>.^X+PG_#E"\)_LI=_ZD4G?OES/)O_[$HA<T^(
MA,<#2GA4!XHMZDP<.A$6R-5+Y-(&LF8)Y#I:Y#JTS$35&KZ*UA]+:J* 7L$:
M>L8:C(%CORI-6+"&TT4N46CBO0I- %HZNB@T<9HXN]5=[QF0L?_J?D6]_4*^
M*%'Q&A-MC_,K%9%?>=#D]I"!3S>&KS+?". [.. [GKT>^_X.F9"8^O!56H4@
M) +XML?%;%%HZ<B![TCVVOL2%>^\B)5L\CYFD;\\;[634_Z&+')KZ+PID_O'
MN=NP['O"-D*#ALHX26?P5[./CW^4AX8$$TV3+/UIL/1Z,<D>I%NRKF4]?5-M
MWF1GM?#R"* GFV'2=SR;@T9/WU Z;Q1%-DKHB ]).<&\]#)/1OBYL^SVH*E9
M0(HQ<STI'Z7;/)M)_N4_SH,SQ1E*^P;POF%97RLU;(1CVZK; !#;!X33MH!P
MRV^.LMDL*8IN787-,%3=%89>3TCG4@OI@>3DN5H1-S&.?;-X=&:[NOITRJPI
M'3&6JG3$#AWFSU**"9@KC_4NX&-V*V55#F^.2'*/O+F0I'%%< A\DHRR-)LE
M([BZ^R3/V,7!IJMIB6BUL)]U52N2M*CR&%8 @$)F235;H7ET"%K&(D^R7'HD
M<2Y(UQ,I7)<E0L%Y"I -=\\C,G_::)VB8(0H&/'VN43!B.V>E"@8<<3IY:)@
MQ"F;/T[I+D\%HT7!B-/%9U$PHH?9H:)@1#^0HW^0L9_+%WG#)WOYHF#$B>.^
M(/PG?/F"\)_LY9]XP8AS/%A2E.@&RF;[K1<A4JO>*R-EJXGP(JVJ;V3]G?#U
MN%#R'8(_94UD&1\M:AU: 0K''KX*'$4!BF.&7L$8]EGX2Q6,0:"60*T=H):M
MOJH?L4"M@T*M0Y.Y+.WU&?3'('.)8@];Y@^[A]4-:I;T$R 991'IB@<'@>9P
MN0.T@,!CA,#CV>NQ[^^0J8DJJCX(V-L;)SN2TD6"DYT")SN-R >6G9GP[,QI
M5A2D^&D@I:04!KX#,O!]5%[-UP_-HB+,@0(1#P 15?GH;9L"$X_4,.^<J&%>
M0*_@(SWC([KR*L>#\-@*U!*H]4(VISNOZG-SB%Q.8.*1BFB*K>V[C88(GA#!
M$R\#5OGUL=4'!)'"V-]OZ-M F170=UC0=SQ[/?;]'3(E$:TR!.SM3UD57.S8
MH>](]BIZ92R^<9V5\51*%DM+;*7C!":MOJ$ /JUYOOGLF+[QEMEOL[S30 37
MLM+DH"Y'N?DJW]C? &YLCL7F[\GT<2#%!=;EG\=Y74&?=F:(X3;G,$ V+FC+
M@*5R\->3I.B4Z2_J"O6Q!/A(<BD&U$3]_R:>8JUY.LL#F4[Q_^MG'A,R'0^P
M C[6NT_2>P DK&9/)_QM> 6SX/!5_BA=D5$%FTD(_C::5GB,V!L@+B;TC.D?
MY-]5<A]/<83AOM&C%SCZ=/A3IQG!(0#L6A!= <>FRP'"8Z<+1ML[@?94F)=H
ME<K);94";&/_!7CN]A9>B9/Q*JP/.DT?^!C979K4K1IBZ5\94$%V<.2>M@N9
M)O%-,J7=)6"0VSB95CE= ^_RP/MFS)(2YGS,X4M8PW> [4ZWB*+,1M^D;%ZR
M9ADD'R4%68>*^P:R'D Z^XB/MZ52>4N&:SQ7T8[A1^T8'&>H*X8JZZ9E:Z9J
M6*(Y@VC.T/^3$LT9CKB4NVC.<,KZ]BG=Y:E@M&C.<+KX+)HS]+ 2LVC.T _D
MZ!]D[.?R18WND[U\T9SAQ'%?$/X3OGQ!^$_V\D^^.0/U4Y3Q][:%^ U)R6U2
MOBK/023>[#N621GHSM$G+XC4&X&+_<=%2Q0$/E[,VNJN]]RDYZ,ZD,V]Y[SM
MM[N/*%H@F,HA,)6/YD!S7EWD3PAX A=_C(NB+=Y[<5Q[JY5'1%^\PT'8HY(;
MK8$C*T)NW-!HN'#C/2ZD$-[>LCP-:A_,X_()!]DAYP"J^K'T ! I@ <'?!^5
MH7T<P"<24(\\@$[<9:\IB>X(-B: ;U]L3!9L[-BA[TCVVOLZ"O77[>>W)HR^
M7B5:UNOIOY.\'F0>WY&SFYS$W\[B6YCS4SQ]B!\+S(J;Y"]8].H2X]>L3YKD
MY/:O'_Y0N)9K6ZZF>+:N&FI@.[KEFJIIZY%E1W;H;[+W:YH*F]U*/OR"J?S-
M4<2OA)0=QBRY7W[_/^ES&)S[[J^2?_GUR^57]_K\\F*[B<9O7^=G]\+])?P<
M7ES_Y4H*SJ_\WZZN8)F2>Q' ?^[OOUZ=7TF74=^6'9U?N!?^.3W;B^#\NE[R
MU_#JMU^O<<72Y9>0'?F5=$9!)4DK,G[Y1G9D?7V*B+PS9;NLFK(/:#AJ LJ:
M$+,'+,,QG^?9]V06EV3ZN'EIAS^RP*>!+,L_;3S(VXJV_-$R<?K-9Z<U)> E
MLF)O0TJT>=4+?:CLK9"-,K2W5\=F?3D0#-JFJ\0 WL6R,D-)>E\@I,[9O0*A
MK?82"%$QW1L0RML!PJ<KTCP/@M?P;GN<]"C'"7S."^DVSV9L[#(NJS++']GO
M3]2-F=+",G /^/$^GE8Q+<P23T%LQ@)'=14CK*V3S0D,!0*WA"5WI%&<YX^P
MDX<X'[-I<:U#Z3*5/L?Y:"*I%MO'@ Y."Q_=H4B>8C$DV' \HC5AX#??!18H
MN:,2%P:(<Y^,Z>(2<LM&]B__<1Z<X>C7"X_SHDE8>XF^5N#BRTE<LAWP\CHI
MUE?",C6X8G05K=D./'$'B)S3.C5U-1I:)PJW92.]R*J[";L8NLJZ4DTQE/[9
M'"7;SVTUG:X_S=LERO!';6A]K@\Y(F-:9^='AQT7139*Z$H[58/X]HOZ-IM3
M&DH;"4)'6$MG41S[-?EWE8RQG!$BFA_/,>55^DH*N(L1P(,X-2YR/63Y-X3$
M$3\B0*]%0K5-CF?*0U6"9Z8 RYM3V,6R6F]8C3[4W[X:.+" C,CLAN22I@PX
MH412UI::2U>.F5*^E?>0^*R>_EKRCG2$4@\@DU6.I\%K??F4*N*S.4Y(25:2
M%Z4TB:>W2#_HN'" 90*TZ[%3*2S-ZNITR'L0=Q@)QF%8::\;2@7Q_$$8BGF9
M+R88(9HAG6M)-3+"ECKBIW%6W91 /V&"45:)DG?\C>A%$@.K@4?OIRH8'VOY
M"+\QY(7;Q%=%W0*&#*2'20(B X!Q.DKF%.BPCAUA +/$#-\B-OY1 8Z[A?4N
M$IB7'?L*]W_#+N0M[*(>H)9W.L4Q*2XR,O5;F4R3_]1TXADY RZQ*2/X'SB&
M..WJ25Q-VN8AF-N@S7SOJ_0/"R1RL(1](0UC\BDMM@AB=\ST&%IO<;U@UYPO
M)[N$/8B#4YFQ'A/EU6KAE"\N?^U(JP\P#& ^'.MM,HK3$H:?D.D<AB^3.Q3N
M\95E[I$ ?,+@M>0LP=X*^&]<"YNT?0DCR0Q6X4H%K:6FV@45(YX66:U-5%2-
M&!/0M!@RQ(]4EX%+72QXV3)<4CX0LJP1T6-?XNP(<)26U##(%+2BFC+"U]3>
M1 8/=[C\.OR+H[*W9C$6:\R?>E8=2B[%WR5!@K"]X<*7H%D>*@O4@NZR"[.T
M-&EVE\>S!=#.)'Y<N#9TUR"< 73"@%HS(#P%GQM<EBJZ]NZ8B$$KYR6@%=]P
M4?EE<%)##4=]=#;4V,^1?@3S D'."TJK)_$]J<G96)HAI,VG^,V_*U*4!>4!
ML&:0W6A1V'09YMFKZ-A '7B2P+LP*G!%Y(Y G'C)UYHR4>A>6$6W=FQ3QY8-
MB+5Q$8@HQ%0%P"!*N<#]$_AU4+]5XP3;>+$X H#/+(/%5"!;YB5@! 7"SKXQ
MS+-F4[QJ\ ^$45;FF9WV4)(DEPO>6!$7=M48=FH!&^:DF#7BEGRZXQLB(7[B
MBJB @)@&PR AYV6EI6)"0**XG9+O"=OAH"-G4T$#;F,"VQETY?UVHVE<8FE>
MW&^5S@&?DQ&KQ5HF,QQB 5"*+J0(I,(W+I;E.5;%>XT8_<>.NCKH%CI>JON-
M=PR7PVP-6-%[CC\)TPRC8>7F4B"R,.:5K_G86[000D6D>07<&K5R1L?8)9;8
M&:!!V"YK-%H **J;H@01C>G-\$\K1"8%YXH,/H *U-,P)8(+HBF<<$?- RJS
M[]OI!8B(1?0_O&.Y;^ &X1VQE(S_^J'0 \TU/=_P[,@T?%VV;=_T#5.W%=U5
M0S7XL!0W(>)"1%R(B LYT;B0-2?JPV,88P@:/!7<D6V',!WR[,W:)AP;%SE'
MD93,X\8! "H*372C\NMMDH(> D(,=2.31HI%/2@?4Q6%N?7;X^6FVVGC2*4"
MT&A$YAV/ZF]I@I^N<%"J=KB@!L)%21^I>_@7U_WR4ZN:QN.,OGP/JP0=<&$V
M6.HH0;T3'52SK"B[!K)U3U*]=)P4HVG&9?J+##0NM5:>7K+_MD,/JK%?R3S+
M2]3$HBR?28I\]C^- HB.86ZAWU@<K0T>7+KE_I\W2+>WH*%W7,:=YD.HE(3?
M1[1D&2JOLZ2H=7YFN1(VEV4+(<.>N.Z7\V(4@H< 2&9HM: WT0 ^M;LD.:G-
MC+/X&Y%(3;28 :THJAEMG5/P* <:!$(GCV?,0I%3J&Q1[L>+HB./6*3$(Z),
M"HC!,>O)^;L&B7*24=/+@NZ;EED.H(7/@4)TAV8;?)^4\%6M#,-?TY@W&6IT
MXH$T)7>P0GAH1 A.4-  &$(!$1\=DWLRS?C##W&>PQB/4G8S16LX6QR\/*[@
M9!JSZ0#[%>4T* /66']-%\@LX3DIJSQE^T0R04]SP)R:9VN<FOA<Z][@]*6:
MLW.N_6O,K%-[M^!&**4:Q04S3\$-8M1(*?V[BN'.<@SN^2>A+E1*8=K31W-/
M4N"1(E=#/1(.ES8@R_*6/JZ !RSI!L-H[AN=$^U<64J%SMK,"C"2Y*-JAHKK
MB-]T:WRF1BT64@3K2IB-"V 3+_Y?U?B.P]!-5M4V/ Y_]*B9TXM?^\*IY[ H
M:A&CE\\\Q !T[JBL8(?UW+/X4<(3R)E"S:*<FB"GHH,@@C+A&V&+KSG#_00N
MN;G]42T7)91BP=FBG?$F0\,LHV&W&5I J9D1GL5S_R1]5'YB_BL^>$NINA#'
M0*"^+/RCI";>&A [9E@&*3 8<UUUN#596/\L'C,CYD?U)RFC7=]6@('&DC5O
MP4#3,9,>;M#OTH#[(QLL:T>0&+MK>H\M3MUY<9I\0T,/G& V H[)H(^[23$2
MC/[%R&5SOFNWQ 6(Q7/^M&^0Z0'<KI'@KSITU^_077%:\,9OE')3+VZWG1XR
M4Z"L6<T"LD5#)CQ13.*<M)Y[[J5 (@O$X0[Y*",59#:?9H\$Z71V"S(U(C)C
MC#G(&UF^,@3W<'L9QB?";T'](&5H'!LHZ^BN>*U.$;E7GN1>^=)U-D]&DJ78
M9\KF/1K91WR\[6C1A:<S"FAK06P3^S%N8'WLTPRX(@V+P!!8%F[+/0H- :D)
M:4YJ.:4J:O7,F\: #U>C28;"RBP;DRGS+BD.CQ/F;F5*64$7RV9(XT D X)$
M^'F?@3R";??:]SMAK(.&#]322A-;FU;4\0H_M<1LO?R)SU#)A6V;WCZEQF,"
M5'<&Z#%F;^(K3!BJ26;CPULDQ)0TUW;S:7++&,)]!CMCOK_:14,%F7@ZJJ8\
MF$$8SM>#?]@]37%&/+JN)GG/2/P8?,T\YXTDM J=*._2!Y=">JY"_R^%5"0P
M37*;H+^=@-XTIAC"GB0LY(%]3YO#TK@>CD"@E'54 )!':G+]@_4ND'/$DZ)"
MBIZ@W 185,T(#VKA^$G]VXV.T&R4T_O%+0[1\E'/TV$?*9":#@MY:!%S^;08
M@8MQX3>@F];:]!R5HKH[+/ F. &@4X-:H2WSF*D)N.9&@:"CLM@7*G<MORY<
M:4]1A'\TU%0<$+SQSPZ[8IRZY38@Z"SB=4<M[SS&V2 7=FJ.SY4&CDL<;Q80
M8BA])5-RCT:1NRIA4M%"\%FM0W1ZF)/OH+4W$AFP0XQ8H=@%6M[#XEX8YWUL
MDFQB%B+3P?A6R5_:>7=+H*<WL5S8:QW%-2:H+:X6EK:PVB8[J3-NK8K.N7:(
MK]U3HP*L8=$R0=?/K:^U[8$*"9@=A;9??+EBHBH;E@V%(P'- ,(XHA0&-HCD
MM*/C=3WS3,N+[W QG0CY]A$D.@MWV(HY.&QC)T;!N!/SQ@]A  _E:&+*R5V<
MU\\U/]+V[UR*P4@=6$I[6*\P<AP',JYS1M:Q6%^;6"],VB'Y_6M<.\=Q/)16
MU<%D+#(-SX&B;Y7R(#EF>JU/K8V0PY@] N2#)ZIQ,(_'Y-]5/'IL(/SYB#C*
MW6, [\?_=-"P2FD;>,26.MBOCFUCM.5;FCVDRU%\25%4*"^@;3 A#UW2>A.C
MV?>F7#!]-D./,,*MQ$!##*-!8DAE I 40 L"HI"3%%&KCO];LJPSHWQ*&&V@
M*AS\"">4%)/F5'YT"EUK."8 TOB[3GP=C0<&2L36,I3\UOBT;'BZG3(ZLYB%
M2&ED;10;2N?<7-<8]&$+C-+4A+J-LJ0,  0@G&/0B2FF$9'P;WW^M=.!AWC"
MLQWJU9Q 4=L+N!5PW%=%JP\A,;JH>"(B6T1DBXAL.5P98\VUGG/_[N,&@M?1
MGM-SLAA7T6BVU4V138$A-T[RQPY';O2C>88D$_GZ GLN"$84LQ1:]&]3%S(:
M=<F2)EB+&S2)C'KSLJ(L6,[Q+,Z_$1:,T*2WL1PPEKPQ@7,"E8C:DLH$2TP,
MZBS'A\[$L)>BRN^H>$9]]: KT664]!%",\UBC"&YRW %5+$<2E<5S,B6,)_&
M(%#5;CB4*D9QQ5W?S3S4<4G=[/7)46UK289CNM22^(4I'J!Z+R:)L)-HK<T+
M&V))(0O5)'YT?1@^PXQO3_GH%PU4?&VU' AR'+=EM2$+H+F/'D=3THEC&),9
MG3WG(55U-8G.E30GWWH1IKCJV_@>1#^:_ $GC4__BZWD!CT_*4@@+)"B(^NU
MH/F 3N"S,0CK*V)?'=7P0%VN55K/\UA[!?A.VU18[M07GOHGRE&4/'Z%L\$[
M )Y$D-8Z7'$E]K J)X!K94R+X-36LB8)F:)QFS7)K48_CH;BEB]TV7%,>D M
M.>:5% JNNF9Y-[H"D.J&HECM@>/>L!%L\V8AF* F6>-&A7O"VAZW$S6CUTL
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M<-8NA?[6"M[\M\%*Z9.25\^F&\>J#;!C5C^^C=EJ[K8%G"&PV0;:,(HMH;T
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M9RAU;0.E'^P(4H= [; #E4VBQ',O)UH*8KA'S8CK<]$#@+X:J2+&MR!Z*3J
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M<KY9E^]CJ\BV,*#]+4]9[5:%__\/]>$F&"Y_^<__.IDLIOXO_P]02P,$%
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M.;6<D=2(>$0^,6[NB4]JM;ED1R4S+4:A):?UTSKYI/2]&--"P@HK>;L[#<5
MV):7-6$R+Y^M-5!LUFXQ,2;&SB1_5QFJV-:&-!)RUNR+B!OR@4_(G8IH?.GZ
MC/B3-_UZ8B_1>AC9;E$2TPC&FIM&IW'QMO/ZS=NK[KE_T;UZ<]%Y?W%^<W-1
MO[FZ>7U=:;<\"K]N5/&GF%F*F-="CFMI^J?U;R\MG]H:E6(4-]T*LPLB9K Q
MS?.+9+IN4 NO;%J*B$.NA5T=X9J3;,Z!D@Q4=/_W8^]]KT\:_HG?\E"@9/!6
M6_^U)3!BH-O+$Y;VR?7MLV,!;!+7GV6'.EQ;,10! )-\3+5)*6BTBOS* V3
M=R_\U_7+1OUT]]U[&KO5D/Q*]8#& .KO7KPY]?U+<CN5?$:N DN@][3^]1G=
MZ=[U>S>]SE6_=_N!W-Z03O?V']GX>VK@KLT^#U*?WH9>E71"JB7<RVOR@U)L
M(F+2@ZLVY.2.CX2QX)/M]P;$!!^2[I0'J15C3FZ'@%VNJR1P.)[!"&J;7WH]
MZWMJZ4!R,%+*A#(&[O]=I5YQ;9/0H&CG<^0BM8&R5D5-OU%XQRVNG*P;8,$
MRPJ%$\%LV#Q[ WK0:UN&G?D'SXDNB8]Q+P,J\XVQ*JGLY3 +^R4?VF8]FW3O
M/?1/5OQG9O5V&R\?,/(S09>$%'"H^5CP"<1V&PI#_DBI!A\B9W ]41K\44QN
ME(Z(7Z_]@L[I*IE-R<^<X0H@ZFL0HNAN+S>LV=T@SP'HB*/];]#I8>#H/36
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MR5^YH?XYRUI94V"Y%6<,0OT$W7Z)6!G0T9:=)QHN332$B7"=JW0#"<S=FH=
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MV"D@\( M1DG!W.&B27TCF*!:X )$GLRY !JCIM1@@N7<AG'9F LPRG PR$)
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M@X$1_F(95WH&_D<JP'SG!=+8?:UNWCP?0_S?'D.<22@,0*=[[ +&XAE7(#A
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M>[=XU0=.M_;JYX*7F9LOR*[W0.QV[+.?CZJ!?3?]N&M?FO?^!U!+ P04
M"  @2 I1NX'BFF0+  #<9P  $0   &%P>7@M,C R,# V,S N>'-D[5Q?=ZI(
M$G^_GX+U96<?C!IOYFYR;NX<5$R857"!W#_[,J>%5CD7::<;DCB??JL;4%1$
M4&?C+#<G#PA=157]NJJKNIO^^,OKW).>,64N\>]KK:MF3<*^31S7G][7GLRZ
M;'95M?;+IW<?_U:O?^T8 ZE'['"._4#J4HP"[$@O;C"3OCB8?9<FE,RE+X1^
M=Y]1O1X12>+BE3EWS)[A.9)0$%!W' :X3^B\AR<H](+[6NC_'B+/G;C8 1$\
MS%^QT2#U.$!TB@,-S3%;(!O?UV9!L+AK--!B^3K'CFLC[\HF\\9U\[K9_+D-
M.H&6/KOCSPLW]ES_^ZKQR\O+U>N8>E>$3J%EL]W@C\>(X:2Y3WP_G&<3. %M
M!,L%;D"C.K3"U+57=(>)-@EX S=',-=G ?+ME6"O.XJ\M$7KUNWM;4,\735E
M3E9#8-MJ?!T.3(%?[=,[21)XNO,%H8'D[^ P06PL*!D-ZEP')JQ;;[;J[59-
MBOK!@-@H$+TNIA)JI$D%40-[ 5LSJJ\978$,-:E13IQS"'**""&K3Q%:E!<C
M31B)$M\Y51Q*O&/PR91'\#I5H",[3*9 1_>9/+_:(\XN"?]53^CJ_%:]=7V:
M%.NP4TZ*A.X<4MPV$+4YU ";'=3QZ\)#/@H(7?;A=S')/$HWN"AK)ES$6RYB
MZ^<31!2<?3SE0U1QD=)49Y6CA%D2BI/?GSWL%!$C3:E%A&>4YCA)CA<C#<B-
M^.44A"-%P%]\4^Z5#-M74_+<L$GH!W1Y,*2Q/,+DQS'!;)-I2"FD>,>(DZ9<
M_3I9( >[Y65)B/C%R1+@5WM67H05E;@Z60@?N38?]EH?B@Q[NU3197W-X#@Q
MF&N7-T5"Q"].-@0+%I1K],]R(B14XJJ^IM\6 OD^"00G?BNYN5BX_H1$=^ >
M'R[ODC'3P!-)Y,EW\8B5GTTW%I0L, U<R&)258)@,*-X<E_CI4<]J3=^XP4(
MY-])DYT7;([F8G0 $COTA!*#M9 )!QXO[VL,K.WA6//_N5(.GI15"DA<W[U@
MG3PT+JL3D&#O0M594%Q6'2!A4)<?U?$X PL:2"X4F;)MTQ [D/5AGV$F^XX>
MS##MBC$E&+AH['HNUZ0F<;HG0]U;MPO!BO-+A$K$6O>Z3]<M^&LVI;K4<YGM
M$192##_D;M=X4GJ2\G6D:*9B2K+6DW3K43&D[I-A*)HE#52YHPY42U7,CXUM
MMELO#!EV=/^3N-ZV9TP<-\DAW H A>DV?2R3++Z9P'4.$'LX0*YW=BP3MGF0
MOF^UWC>O3X-4^BE^TS]^@+N+@H7&WOG]-.::!VV[U6HW6Z="&[VH2LAV$'.9
M/AFEE"B(7A9E;CQM9L73CFRJIJ3WI9&AF("';*FZ5FW[CXCGVL5'NSP.>7A
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M\9@,.-U:QIL<&2232&WZ8XR[/'TPV5&S'L\8%#QRECFX<Z#D,':+MO; ZNK
MR>U?W"CY,;9U [;"MSG*>!.O_H>?9V?Y]:FW%WYYHO$0.OPVI>@W#<BRC%0J
M&FVQBT@0\'&)#A@)[A)RC$9OM1>^WW'E:;22MV=##S^VS7D-.'AU^:7+5XQ<
MQ730H9=^49]O6]3O7TF%K8HXIP@LL7E#<-1(4 &?-.?6RQ2U&F#JROA%3QE
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M]%$[7W \K6?@4S:#[>5!NOD(Q&,QLW6<KXQ=_L<!\;_^]G]02P,$%     @
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M,OF4PJU[PCO+!P +WR=2*4M\9VAP0IBWXDE"9P ,,^N@)3DEW2'T-J0_J#2
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MQ.;" 9:<,"B4U0H;C8&;DOTU! AY?1JMG8<B:HL[:1FV+CW1UP3N=$2W%0\
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M8UI ;#V%2]7V=?.TP,Z.GW6J NW U+<:F/O\\N+=1\6>E0PX,UBZQ1(8K2P
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M+->?FU..'$=9_?+^M_2EI/^U76Y>K]?EIJ@.MY9WV3Q;?LT6,SMR<6P# D-
M$@_Y;+S>CMT3WPDB$3$<!LD@&EERC%96@;26.Y16T<"T?EBNK;)RZD<Q^1RH
MG<ZKZO2:2%)LJ]:IL5LU>*M&?U4/=LNK)I50N6#5/EA[3EBM%Y-JM45SVKS2
MB>^H]=[@GE0K'D153ET5*^T V%6DU$+FD0 Z;".-&U<']C4?HQOHC\(S'X0
M4$PBRB8_OA<0Q_=:TS$D0FOT6@T.&%.-QLW+S.H+CUI)-1H%Q^!9?T#3RO<@
M<6N8V-0S! G3^OU$&G&7% **)%_2&[INGI+E.EW/E^GJ-B^754JMW<4,W)!X
M("$N)5["PA6%<4(".V!F71;'B.S.I#ZV3*I; X]O)>@ 6BW"T<X/B- FLHE)
M!^O32*?H=>G4UB9]? DGD,LRVSL\0$ $ A"[D6M[Q(EA @!IC40H<J42Q7*/
M-CPP@_?W].%>,OTK28Y@FM<<+W+J4P,9[U3T&Q[.Y6?5")N&<*B"/\RW]N%
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MI/^KPK$X*^/$8,E6TQ9X2ZF]%&<]L&.?#1X<+[ !@HCZ7@S"U@-H0UOK3'E
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M+G*$34Q%),&?D@L5#J1UH58AGF'-UWP=NZIQEWA>#*D3!''B!L#WJ!-W-AU
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M>MAMWM4_B@9-[G,5"NT V%4@%&'A2!#32MZX 4BO*[F!ETN'\#>% $,'Q(2
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MI]&!]+ARZAJ*_OR(=JI/V8:;NBWRK\M%MD"OO[(AP?6Z.R,)YYOEU^5FF>V
ML"D=]MS !Q2&$"0!B$-8 X%^Z,H=,3!@WO0Q ][[GJK>MU]U:OW92CNL<B'>
M1!.(J=W([,MI( -;2U\+EU_\_@-'S,96/^X=XMZA'DT?Y8D]HYH&6VD:6FK2
MP7RP-UY.=^'B_VS+^DS$0WZ7<::6*WX(?5?:ZR&7A1K[P ,.34+LN\!V8S=
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MGE7A$SK38(94B2@T,+EJ(:<GR6+!Y3(3IR*)1@XG$#9T>I.;>=-,Y9QF% 4
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M@ASIDX8W_I^5!C6FIB(-BNC?24,?%L2E@3YGQ6<V)_JYR'_;?.&W:Z7KUUE
M7#NTD>TZU<*L[;*I4FL->)'PIHD^-H:1BA:;58.S&G2RFJ%(HZAVF&=024-D
MR=,G)D<).2LJ_2B<BKCT].*=R.A@16(<\B5;K5HC.'&@GT3(A4G")D $)G:[
M-!1 XDK6&)-Z]$"C$ Y)55#DJ!(>@YAB26T((D20QA'(GO?G!R J-$U%(M3
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MB'B<F0>_U76L,YA/0[95Y_<N;CMJ!0&81@P:#Q3 Q'F*!:['B>*XSTM5=4&
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M?ESF;Z91"/EL_F;Z=)NP2TLU:R$83:0GCDF,G+7,<LBBZ6F@PY@"*%.\V:_
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MZ4#L^KM2^?1-D@_S8O3G33&)$IE55M7\H<'I9-,F C0,$2$0TU(IYHFG9(T
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M@D<@:F(KH.;>.6&$468]73PXL].T?FET%,0GH]#%_7PVSQ:OUQW"HR?5 M;
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M5!":(<(YEMHX**SE[(GK2:B4X)@!9LQMFR#'(]FG0JG(NWK\M\EK!=NJ5+>
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M(-GY879ILGE^792;\O-N*1F -1PCH.(NQU=KH(\6T&H(#,05,27<Z4Q]BRD
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M'7/2,F6MK!&$3*;<M1Q0V,-YK?3'2J\O_C_O[_M\5$Q'X\EXR9##][>;&PA
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MW9GJ\T'%X'E ]7"Y.A0OX1?35/A+ML15O5Y7W';851USSL>B:;;T\GRQH7Y
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M+H-WJ- 7?U\Y!>V8OCJ"*EXOUC1$_7E@>ZM4A\]52<!7!@!,'47_)OO-IK(
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MB!],9P4V<R]QKMC;)="TR3CFR9CW)#EEM!TR#_'-=E,3T/K4XZGJ= B/1<K
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MU!%'6A>3AXXU)6A?^ 5O@*U^@FW.$'<0\U6P2VS.V 2&<J-"[-T+K+O= CQ
M4Q6%5;><KRWC^O-GPDMUSL6;.QBV38&4I^3[=,O#^XPJ7K</:JY75T4Y1'GI
MJYL!CL49#0]?K7ZWVQ#RZ(&I8?EPH@!69*HQ[HV'V9\3P,&*)WDD3\]YM[M3
MW&;GLG^E-U#?WA^NJ--R^F6C=6.09TW_,GIZ425.M>F0H^7)Y]>@QN;+A9_N
M)Z2WMM^54UX?B!=\LZON< LWX$W&70,9N]\[S/&50TRVV!4"=32B6/QQVRA
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MS&3SE]-1QR(D+NN9".^_*_HM9^ :^"N,F^Z:#L7+)Q4]#LFX1:]+ +<HLE/
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MFA&ER$@$_A(YSGL/N*I-'_@H_/0AKL13R]5B"^DU:^?;8 :[Q 76P6-031:
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MU+[8)(U[;8V;@_MVL]&X#P$.^ALT7A_L!Y.087=4-PI:$4+22\(,;#!HQM2
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MVV8L0?@!*#\+L/" X,K<-\8";,C"/QM9L@#.4]7H2N0*]70BQ8$%.%),1K,
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MO:34.S>#^!8YO=%6"^O0\?-9.U5O:Y6$/%_=1B^G(Z7EI@*:=K\7^38];,G
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MTAK='"[RY$KNF7K "X!7S@5T2>,D@:RZ\7 RO08#J=8"\D<U3V=CWWZ9H;,
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M_](M!/\+!M>_1O>2B/]&]\#_+W1O#?T&X;!.D;$19@$*>Q +V>CJ/-*1PRR
M>PY3A2)&3+W" B#^HY@$C+W^+Q1__1EM!D])KLJ[$%B 5LO@5Q*O9)>'*+X?
MGUW?-R&,,<P6'(NJS1N1QF.&#9@&D%#,Z@@+H)^.?C]UVTM,KE&W4-@L-L9*
M,BMY>0&&X+$C!W0*757],BXENS90$;:XY)>"*K?^&O&>D-_%"(0"0""9?GW,
MTR$AA">>3Q<+Z3/@[?S.OVG-3\F;>MK/ G1.T.-!,_#42N@%Z,8\"R"10$%=
MLX$/)M%?,F*U>Q]HULS'@&?,OLEZD#X0UXKSW^;<^*P[RE]480H*O#('?(66
M2:_,G?>-LW/$)72,;!2-Z)WKO%#=^ ;NQ_2674HJ6ROSV?$+FMG!@7<^5[ZK
M1C6G]-^Z@#YY[[FWJ_&HOHXX_^\-'J0E:#/U..R\@K[87E.C&'U5 %SI.VE]
MR!M?1%0)PX:ZGON9G/GU2<61\Y5+&<S=6K;KY=4$5;7IHLM-O>/@-6MH^V3;
M],59LN.4DPO_3EWX'/:SEB!968-K$B:MNRN _&C,K9-NK-(UKTDYS_O@=[>9
MMQFWE"ZVON=_;YK0SGQ:8.:Y=*M SU>_G,&Y^" G]%^);/XO&/]KJYC_P8=^
MF-D#W;"LT6$!GDU0#?EA'7_]38"D(/LY-^C.[-T>3>7>BVAO14PBJ"9@1?;I
M(O:27O[G25_5$J&+XY@24!D_EZ+@%JL33B=>GT7B4%.N)#VM2I&!K2>FS28F
M7UJ^@],OHVWBA9/S+&_)6ULD3H*XEA!':W1<,QVCY_2/V"6^&N*!C2$_,>YP
M^]&P#77'OA) (3*E+FI71D8D5("U8J(6(Z.ISNIX3).U)#[JC1)#GB>F3GAJ
MXYI&QT@?==>0/TQ?L@ ]7"P2;?=B[%957SS3H)@!;O()U/0MT[D3_SZC(IF]
M!IS.X\N\[_Z57NS_6\8_B6E#TW#0(S4789[*+=A@)>?PMRD=YWL6B8K5)V*:
MXSK.;^A_P>#-?=290;*\+,#>KVSBHDRQ>\:+OI?Y.;? RE]Q.TG#,23[EM*8
M0+J!YR\Z*1US'?&7?U!"-'XE>#,.6@*9AQZRZ:TS<%OQ& L 2AC]@<$%@-C\
M;!P9!?JK2>8"$P2"E9+;"U<"U#*'K)L]1$@D>;US(K;!!_=/#C!@Y7IQV(M-
MWR-F,D?J4M_"0QKGATH5(_YP-@X/,RJO*V!RVOYUHY3^9;I F%AE<V_QO&8H
M:94%R.R&C,8%YO@(-%G^6$E("@DIS5O^)E\W-??]XOD P#[S'$G +C($ZY#X
M>/.^TI/KMV3U-6'"#'!FNX>YG6 B)$?@_-1 :@XS9-Z%GRH$;'+=7S\R32@/
M/X7P55K09K-4)P196T-)352T)X3QC7U6FG'-A8<*!HIIB3MRD0LO/C&WX%XF
M ^4J MCBX7&K8.;*37-F'%61E_T>7F,GDQU.V9Z*V<--,=TVC30UV6LJ". !
M2/L0C&FF+, &E"QQ?#J(=)D%H*BP $YPV"+B8(UM?AQ-,MA3SVQ1;$3I"6+R
M-H#A7,.&JI7L:4.+]Q,,I&XXN8;R!HFTNQW!N(DN_H*^%\(]F5/=GY)%EMND
M@R4PPK:YTO?>V.Y4,*&OIE)Y&'$!LGB2_K:O/7%OSV:YZ]@U7MK+&::,7IF_
M;%:*,"S?:^"KGHOK\=6;:=="7[X ' 'D?$$7-$ZZ#0INX"<S*/3Q%3+=YF%8
M6R?JA%'G!D66DP8Y[HO_5TW/_QW_=_PO&-QS$RVNY(N2S=C==",B,GA%"73@
MAVW&LDJ29TW"E019:3V>=>&$<Y.[FR]T 'A(_&PIV=0+Y^1[8R8GZ+LY^=Y)
ME'D26SC%OB9_9 %LM=C*,^LY#@69Z*W'IYP;/=G6 >:W_G_8>^^PIKIN7S16
M%%1$ 6D2%00$ 141D9(7$1 0$! B-2(J341Z"XF*B-0(""@(D6:D!J0) @%"
MD2XU$'KOD%!"(.TNWO?L<^_W^NU[OK/W<_?YX^X_UO/ ?-;*6G/,,<?X_<:8
M<TSM#!&*'.4*XZLX(T/Y9%9'CH79?1^T=AG7\*##W#S'K;$/C^XNU=DY91Y
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MYI^0Y;(7ELKO\E@V;2<J#9Y-K[_H=%&M1/>[MLA:1FH#)QFL0\_ ZC,^,B7
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M<<0E)A$BP-;0$4EL8R0UHC_/(\E2W>PEAA,1D?-LM!6KE\QY0R).BP5R'HT
MDS*8^Q:Z!]I_+1+[/'*O-_1[.'!O1T=./K)Y"QF14"),6@7HZP53LULZ$9C
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M*]=B4<GZTIN\XYZB*:<'KD2_MD2KK^$H[=1,%HC#B?*&K)JQ?\3K(Z:)$?/
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M9.9$)E8!]O/5)_ANV;?"R6-)8S2STG[J$\)6%N;,L#[/Z/7%MW7J_7$\Y+:
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M.^L\*'.+$SW5?L2;5E$%2X"H9"\AJ>?CZ9].O84L0;\#(/^'#G6BJA&0EQF
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M_^!9_U@OX/%>Y9-1)65;N-W*R%.H;#H@0D BM>HI!?4?2"8TCH.78\DB8^C
M-%+C&YFBN:*O,]&>%HGG8[<46^!U-*@#"\0I1@6\*X2HP.2 TIVFLR3/O\:W
ME>D<+IVZY\KS,"=]*4#W[S?%DL67!\CXNKY<9X6(F8*@-X>ZG<^4(.C;;U\V
MC@UGUTBDY_OX_,AR6F%[F[.52&OQJRK\ZA-HB+[;*YOG*;4]Z%$*C;GZ[6>
MV8=H@[XLDP@%W8H^E]3"[F7QJHH/RY$CQ&O16JHO_Q!E\FS"JG%4<0,44\3*
M D:M52!!@L,.>OZP'&VN"N$D"0_$[/<D#DLN$#*"(Q:4SEWH2K*SETJ6HZG"
M]Y YESDF6P+V:42D%*).+-SX%'K']/ELG/@/X9M84]47)R#V3&$JAQ85-I8K
M4DL\BALHRKVR9[]4P\Q*>YWGDX=F*+>Z7LX@V&'X91*L]AI3B/3E4WG :SMX
MI/[\,]'J@]JP;,7JV<_5(! HK[E*ZG1DW!53<PUGIEWW^*5L3D%<2!"WH;7A
MR/^9Q0UU9$S@!O:M,'<O7#'/@J--W.AE[LI9Y<>W%SB?L.T7KMM'+)G[DJ@_
MIV=EAGX++O)>VLICME=!T.H]G2L>96&Z7QQ?'HI<$=K9.%:V)[Y@\X#V6CEC
M@HHAH?%@_@H1U_$.GOFH!0$X[HK"<-S(']>CQ1<BK_B>5CLS=8)SYM3RGC]7
MLV[5^F?G:N%-NWT(M6-QVCFVP[Y[=W1!4Y.TIJB&V]:QE.]"[3RI*29$6*"J
M'<_+6+%I/6M(U'IIH++G!#C8;\J\\8UG8ANG$>JEZ^/+$6^9B[9OC(?UU5:D
MYD?9=Q?<5UV<\PH[B'$ C 47CV5 ZDK;Q >T\?0-+%,))M+&,=A,UHD0>EMO
M)O0@4^BXEJVV=8:EBL!.3ZC=T1N]%^@G"BB\ *<_<(N*R21>O>$5-5YYNM]V
MF<N\Y6)H@.:V#M/1:0;U=I17&49VN2^ #J.K^6.M\FXA'9##=9R&0HY[SZB&
M@O*,@HR6>-2>B(..?8F]*"\@LS'Q[EZNT9>8V-I*SC&M:@9R<K6.0_;(G.&'
M3M1'_Z]7>$.;00@',/B=943K'Y.Y?L'5L'Z%"?$&J43_8?UF@X/4QV_M>N1O
MA^YJ1C??,?Z0T_PEV+)YV%?(0<0AJO$8Y/7#7\K2#\Z$O2FKB#_J[GVFHT-J
M[)GRIV,OA$ '?/N'FI-/7^_VCI_R&L\WSNGYD@MN':2ZCQT%C[N\\D"QSQT/
M0.MTC1VORW%K==-5$EYJ-0M9N4_0UN AGXB)<5X)N*$C^5.*O,5D/[![E)'6
M,D_VP&#;C$.RH%I:]9[)UIMW9H6KG&[,=O+BC*JNP34#Q\5K4=P^Y0_+NI:2
M[YN4*\].!T'&C*YP-N#875S$>[#B/\IC,67)FG%FEM-)_5,%JNDQ,.WHSIE/
MV:H)PC)VIIT1\@0C2<9!8#J8P.6DQ<.5D:ZGV$]J?'-3\6J!,'_-#A%FVQ##
MS!;($:U:R(NJXZ2-=]NG)CJ?K;[D<REJHS7M\XN5+IQ[57EQI+00OR8]Y3J]
ML;WHKAJ<L[L!B>VO#4AP%##,%ZD/X'8D2? )"ZTJ6BTAS$W_"J+M E<S&YVC
MR7;I3=7W'"2?CW5'P\C)/KC*5YG%TZ;M3A>J%[_=DKB]53-1?FG3BKW@:[F<
M0 \C5U&]C'K8B@6JY@R)AH.I3>,&O-E7!N>WLBF?*^)*X.DM*&-!516R)2:L
M0BY@#,>]L',P QS[U<';;<!2/#VJS+2Q1.,Q86XMW%$-4ZAZ6>&PU3/4W(T1
MGY7/D?:/S&RBU-/?NN6D/SH><-F(T '.1]4;4,TAA7F!E)"*86.U]@CO[].H
M]VSO&Y4_U76N#[W9P*8LKIL7#0M$?]D!.^D[IG,3C*=0O\&A;/1OZT&J6L19
M(*_MPIEU\"0] O"-3.4^!!\5KT>&!*^<(-SO3DH><3AGQJ-MJA[[0&T<96B]
M^%MN>#LO=%/R;H;)2+HQPGX\R/Q];XH8ZE_RF%*0_Y%XCD+>SZ6OKOZKWCEM
MP0>Y3:F: O^[3P4TT@[0GY.]&UV"5<_T5M@B>5,"[+(2[UM+V8_OA8A=:S@.
M\K5M0]S:1<LG,,S;JV&X)67D1K+D6J&RBH"/G82:.$8=M\\\?5&B62]M.0%P
MOE=W_OC_JHQ.TR9VP& <_+8XC $U(@G'^'X=-3C?VU;W=C CMK^P;+L\3I0I
M;\#D6QTK99S,%60R 'GR6#=IN&R&MNA[;Q7*VAIL0X<>4B$UY;(OE)4</E/]
M]8.U.Y<5MGF]QEZCW M+Y!9:&\FY61(Y%L[#":+1W_[M_*?=%"ZG-%EV"4?*
M;A#87"G.]0'K]GA:#"@/AF5&A?T<P22TL4!OE*C2+-"M14T6".?, M5#OQE:
M9&T:?4ND#<1_^[+I"G/MH(I4JPI3G3]_"1N/D!S5[(K3C'5V5CO$7V;;D>O!
M;7B_9&JE[7\<4VH71XVGP*@FDT?]MLS[*C@S%F[D+B4[U_?\K)]R,6Y[P@+A
M3]-Y6:!4SS3DZ*ZF9 ](Y/;Z99KI,99:!HS]OF._DW%46]RKT0W](A<:991N
M B8U(@_@YI+L1[>6<=0LBLX%QL/2=5QE6'\WTV1+6($%.N)-LF"&] $JC@"4
M*#3M=V'^I4PV2X"?EJ2A!'_OM>%OOX)]E(K*,65Z;^53KK) L0&-$;]_>_^9
M(.GQ2(D>4=>O)H:_0)<.:&O82<9DDIN^31["C^\>Q%5X<6WT!+.%!6*OL,%:
M+YH37FY4:IE4QK1]+__(5Q&QX)LS^H^]]3_/4XXUD;J J_SH+^D"Y?D7.PCY
M\U,+_ 5V<T, <QB/9'(@.V]TXE8'D603E?BE*-*S6M@5V6"!?0KI?:F&VZH:
M?LO<57\N[FC\2RSA!D>I4OB1HR]JQAEL=WZ-BQQ4N=:NY-GXA4O#N5/CX>"S
MI4[1(H S&?'MLAHH/_GDV.HKIC32#N#3L/%!:20-TDJ3)?:@I5H'<7PB>?4L
M4)6&EX>)IE'83%CAR=#H0JU_(L(,$F<U+!C'X1E2##M,-3;X5<S_V<E,1OK>
M&_LP*6Y%\8B?&!+/:*>Y3K&9E.*URCN]DJ[>AK#=(U-"OOX;N\)3U\=0+U3%
MY2"ARF?3G>2257M='7'V^_BJWX,F2]7[H>\61DGZHR^),;S!>.\$!W'(7'E&
M#9A**PZ0UO!0YS)/*!(CM#;<<^@PTY";"9!E'NXE00S>71T1KNKQ;1_,-1H[
MEJ2J"<OUZWBINH=^@_KXBL$XZJ#]CA[Q>6G4H)0E)\UQ -GW8T<B^5RQAD,;
M[H-FQ'4GOHS=0QW*VG9/MCF&;&#N([% =1$'-F G'9X["1B7_Z3$\_>W8B1O
M[[<[6+'Z^X@Z"12?R>6_6GEG6O^$=_0=\B)R@&VLK;C.78NTKFDF\F !_N7Z
MF:GG>OY'N8UBM7NH@[;A(IQ!]R520UOS_\WVM%08TB[#I<A?*GUS%Q%L7<6G
M3<GTEK#,=ZM1^0?U.2WWF*'_/KFD/*VS3(V1_E<H]T;RI%:N ^87=X@.)J4*
MSL%%/IO/7;;^IE+GE?CJ9_,A(S7QJ.\$&PV>]^E3J^)>]JFI.5'M/HOCHV^8
MXO;9:52,5FG?1GVL'2_AC_?KW,<% WL.0I)\M^B71VM<=L3-%1@T%Z9D973H
M]][, _9-V(\G,(>5FB\D_TOZ#ON3APVH-J#7_@6+(;%3[S*+].?\TY3ZC/[C
M%Z#^/@&Y _ZT+\$%&'KVBK++WUYN1<"S0$%,;BKTR] \\\2O90\IJ9"*;9MB
M(YXIXBG7IL47;.-6)CPG<HT<NV*<>KYVO[::Y :4("?B7ZIF]M_7?U__/[@X
M$Y#C$[!]R+G'%;L8LN,O#*D[YL(X4HJF2N[N&Y5:8R^^BCNTF#!<\+V[R.HF
M<^BRNG1N3K3,>,]C-?XIA"<%)8Z7'J01ML%RC#18*HS0RG#818OPW0VJ<>L
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M9"B8='<US%JUXJ-'DC[DH,,=@WB[],]77@YZ+''$;5E]WH'&XVGZ<,M7I"%
M##S\G*0JK)(X@V3A,F^]=,6\"_H^6CGSB4?,-SUT&3=T&E*S2KT J8,=&%5S
MF905;RB7N?GS4<29BH@ HUM[[M.N*S:.G';:P(R[U$..P1^1G-$A=&F$;%'+
MJ[NOKC7M#Q1,C4(&-6AJI>Q_=-P@*;3&M'91'N/A=;?>N XN:]T(T_ 57S:$
MA!6MOD2(]<(YLSK2?<*T7SMRM>P5^7@N?.7C(<\'2.^*\"/3&@@ TN)=X:Z
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M$T +2@"M*:=:JCFHWA#_6HN55>64P&0QRPEM8,)MFRB2A:^S_:SG/,XZE*/
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M!GY"J'[+I7?+7F.GY_7Y\+L#/*+YOJ9],PIG_.S7O2G27P.+3JJ"O3-_/$\
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M^7@Y/I\_%ZEQQ3W@X2/6.451_'G*';QR29'I-0<WT4ZDE5"NU_5:OP+H'O1
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M^U(J =R;5F2L$<^8L6;IV=SJ[>$/$\TGA.DG=PQ)U1J*W[WN\I0W_B;CX@+
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M("@)I@VRA,\BJ(+E[<RY$T 5E93%JY$_\E<0_W95K ="; 7C03T']_XC16O
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MH@!&[;<>3=KZN+U#'/:\S*/$39#DR&D4;I+P+W8S%IQ?8N8,0-?L4D\5X&K
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M'/Q?-B7NO?L34$L! A0#%     @ ($@*4;CJ?9%M, $ RE40  \
M     ( !     &$R,#(P<3(Q,"UQ+FAT;5!+ 0(4 Q0    ( "!("E$)-&#0
M> @  #@V   9              "  9HP 0!A,C R,'$R,3 M<65X:&EB:70S
M,3$N:'1M4$L! A0#%     @ ($@*42%[ +YW"   @C8  !D
M ( !23D! &$R,#(P<3(Q,"UQ97AH:6)I=#,Q,BYH=&U02P$"% ,4    "  @
M2 I1G6;J%QP%  ""(   &0              @ 'W00$ 83(P,C!Q,C$P+7%E
M>&AI8FET,S(Q+FAT;5!+ 0(4 Q0    ( "!("E'9"K&S"P4  (\?   9
M          "  4I' 0!A,C R,'$R,3 M<65X:&EB:70S,C(N:'1M4$L! A0#
M%     @ ($@*4;N!XIID"P  W&<  !$              ( !C$P! &%P>7@M
M,C R,# V,S N>'-D4$L! A0#%     @ ($@*4?+F]KYQ%0  N](  !4
M         ( !'U@! &%P>7@M,C R,# V,S!?8V%L+GAM;%!+ 0(4 Q0    (
M "!("E&E^AJO<!<  +<' 0 5              "  <-M 0!A<'EX+3(P,C P
M-C,P7V1E9BYX;6Q02P$"% ,4    "  @2 I1V;/#P^IP  !XN04 %0
M        @ %FA0$ 87!Y>"TR,#(P,#8S,%]L86(N>&UL4$L! A0#%     @
M($@*48B]F8/20   -QL# !4              ( !@_8! &%P>7@M,C R,# V
M,S!?<')E+GAM;%!+ 0(4 Q0    ( "!("E%LMD@@9A$! $P\ 0 :
M      "  8@W @!A<'EX;65D:6-A;&QO9V]T86=L:6YE+FIP9U!+!08
.."P + .P"   F20,    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
